

SHAHROKH F. SHARIAT, M.D.



CITIZENSHIP: Austrian

LANGUAGES: Fluent in English, German, French, Spanish, and Farsi

CURRENT POSITIONS

Professor and Chairman 4/2013-present

Department of Urology

Comprehensive Cancer Center

Medical University of Vienna; Vienna General Hospital

Währinger Gürtel 18-20; A-1090 Vienna, Austria

Tel: +43 1 40400 26150; Cell: +43 664 8001651010; Fax: +43 1 40400 2332

Email: sfshariat@gmail.com or shahrokh.shariat@meduniwien.ac.at

Adjunct Professor of Urology 4/2013-present

Departments of Urology

Weill Cornell Medical College, New York, New York, USA

Adjunct Professor of Urology 5/2013-present

Department of Urology,

University of Texas Southwestern Medical Center, Dallas, Texas, USA

Adjunct Professor of Urology 5/2015-present

Department of Urology

Second Faculty of Medicine, Charles University, Prag, Czech Republic

Adjunct Professor of Urology 2/2019-present

Institute for Urology and Reproductive Health

I.M. Sechenov First Moscow State Medical University, Moscow, Russia

Honorary Professor of Urology 10/2019-present

Department of Urology, The University of Jordan, Amman, Jordan

Doctor Honoris Causa 10/2019

Carol Davila University of Medicine and Pharmacy, Bucarest, Romania

Doctor Honoris Causa 11/2021

Semmelweis University, Budapest, Hungary

ACADEMIC RESUME (status 7/2021)

>1570 peer-reviewed and >600 non-peer-reviewed research papers

Scopus h-index: 113; number of citations: 51593; www.scopus.com; accessed 10/2021

Google scholar h-index: 135; number of citations: 72198; www.google scholar.com; accessed 10/2021

26 book chapters; >2000 abstracts at national and international meetings (available on request)

Four patents; >80 national and international awards

Member of 25 academic societies; Editorial board of 26 scientific journals

EDUCATION & MEDICAL TRAINING

UNIVERSITY OF VIENNA MEDICAL SCHOOL, Vienna, Austria Doctor of Medicine <i>Thesis: "Impact of dialysis on serum total PSA, free PSA and free to total PSA ratio: is prostate cancer detection compromised in patients on chronic hemodialysis?"</i>	1993 – 1998
UNIVERSITY OF LA LAGUNA MEDICAL SCHOOL, La Laguna, Spain	1995 – 1996
SWISS FEDERAL INSTITUTE OF TECHNOLOGY, Lausanne, Switzerland Pre-diploma in mathematics, physics, chemistry with distinction	1992 – 1993
LYCEE FRANÇAIS DE VIENNE, Vienna, Austria French Baccalaureate and Austrian Matura with distinction	1979 – 1992

ACADEMIC TRACK

MEDICAL UNIVERSITY OF VIENNA, Vienna, Austria Professor and Chairman of Urology	4/2013 – present
WEILL CORNELL MEDICAL COLLEGE / NEW YORK-PRESBYTERIAN HOSPITAL, New York, NY, USA Adjunct Professor of Urology and Medical Oncology	4/2013 – present
Assistant Professor of Urology and Assistant Professor of Medical Oncology	2010 – 2011
Associate Professor of Urology and Associate Professor of Medical Oncology	2011 - 2013
Director, Bladder Cancer Outcomes and Translational Research	2011 - 2013
Director, Urologic Oncology Fellowship Program	2012 - 2013
MEMORIAL SLOAN-KETTERING CANCER CENTER, New York, NY, USA Fellow/Faculty Instructor, Urologic Oncology	6/2008 - 7/2010
UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER, Dallas, TX, USA Adjunct Professor of Urology	2013 - present
Chief Resident in Urology	2007 - 2008
Resident in Urology	2004 - 2007
Intern in Surgery	2003 - 2004
Faculty Instructor, Urologic Oncology	2002 - 2003
BAYLOR COLLEGE OF MEDICINE, Houston, TX, USA Faculty Instructor, Urologic Oncology	2001 - 2002
Postdoctoral Fellowship, Urologic Oncology	1999 - 2000
Postdoctoral Frost Fellowship in Gene Therapy for Urologic Diseases	1998 - 1999

PROFESSIONAL MEMBERSHIPS

• European Association of Urology (Europe)	1999
• Endourological Society (USA)	1999
• American Association for Cancer Research (USA)	1999
• American Society of Clinical Oncology (USA)	1999
• Society of Basic Urologic Research (USA)	2000
• Association of U.S. Trained European Physicians (USA); Founder	2000

• American Association of Clinical Urologists, Inc. (USA)	2001
• Bladder Cancer Research Consortium (International); Founder and Director	2002
• Texas Medical Association (USA)	2003
• American Urological Association (USA)	2004
• Society of Urologic Oncology (USA)	2004
• Bladder Cancer Early Detection Network (International); Founder and Director	2006
• American College of Surgeons (USA)	2008
• Upper Tract Urothelial Carcinoma Collaboration (International); Founder and Director	2008
• International Bladder Cancer Network (IBCN)	2008
• Bladder Cancer Advocacy Network (USA)	2010
• Österreichische Gesellschaft für Urologie und Andrologie (Austria)	2011
<i>Arbeitskreis: Geschlechtsspezifische Medizin in der Urologie</i>	
• Academic Men's Health Network (International)	2011
• Foundation for Men's Health (FMH); oncology-related advisory committee	2011
• American Society of Men's Health (ASMH); Executive committee and board of directors	2011
• Minimally Invasive Robotic Association (International)	2011
• Society of University Urologists (USA)	2011
• Iranian American Urological Society (North American); Co-founder and member	2012
• New York Academy of Sciences (USA)	2012
• New York Section of the American Urological Association (USA)	2012
• European Academy of Sciences and Arts (Europe)	2014
• Association of Academic European Urologists (Europe)	2014
• European Genito-Urinary Surgeons (Europe)	2015
• Central European Urological Society (CEUS; co-Founder and honorary member)	2017
• Deutsche Gesellschaft der Urologie (DE)	2018
• IVALKV (AUT; Schriftfuehrervertreter)	2021
• Korrespondierende Mitgliedschaft in der Deutschen Gesellschaft für Urologie	2022

ADMINISTRATIVE ACTIVITIES

Tissue Bank Steering Committee Urology, Weill Cornell Med College, NY, NY, USA	2010-2013
Bladder Cancer Team Leader, Weill Cornell Med College, NY, NY, USA	2010-2013
Lead of GU section of the Comprehensive Cancer Center, Med Uni Vienna, AUT	2014-present
Ambulatory operations council member, AKH Vienna, AUT	2016-present
Professorship title working group member, Med Uni Vienna, AUT	2016-present
Habilitations committee surgery member, Med Uni Vienna, AUT	2016-present
Privat medicine working group lead, Med Uni Vienna, AUT	2018-present
Senat member, Medical University of Vienna, AUT	2019-present
Appointment committee member, chair in general surgery, Med Uni Vienna, AUT	2019-2020
Renommee working group member, Med Uni Vienna, AUT	2020-present
Comprehensive cancer center governing body member, Med Uni Vienna, AUT	2020-present
Appointment committee lead, prof in bariatric surgery, Med Uni Vienna, AUT	2020-2021
Reviewer committee member, prof in palliative medicine, Med Uni Vienna, AUT	2021
Reviewer committee member, prof in obstetrics, Med Uni Vienna, AUT	2021
Appointment committee member, prof in translational oncology, Med Uni Vienna, AUT	2021
Reviewer committee member, prof in neuroradiology, Med Uni Vienna, AUT	2021
Member of the board of international patients, General Hospital Vienna, Vienna, AUT	2021
MD/PhD working group member, Med Uni Vienna, AUT	2021-present
Cooperation Med Uni Vienna/WIGEV working group member, Med Uni Vienna, AUT	2019-present

Further development comprehensive center working group member, Med Uni Vienna, AUT 2020-present
 Habilitation Fachbereich chirurgisch committee, Med Uni Vienna, AUT 2019-present

HONORS & AWARDS (selected)

- **Award for the First Term of Studies** 1995
Dean of the University of Vienna - Medical School (Austria)
- **“Matricula de Honor” Honorary Award for best student in 1995/1996** 1996
University of La Laguna - Medical School (Spain)
- **Award for the Second Term of Studies** 1997
Dean of the University of Vienna - Medical School (Austria)
- **Performance Grant for Outstanding Study Success in 1996/1997** 1997
Dean of the University of Vienna – Medical School (Austria)
- **Performance Grant for Outstanding Study Success in 1997/1998** 1998
Dean of the University of Vienna - Medical School (Austria)
- **Andlinger Educational Fellowship Grant, American-Austrian Foundation (USA)** 1998
- **Young Investigator Award, Hans und Rosa Blanca Foundation (Austria)** 1999
- **Performance Grant for Outstanding Achievements in Research** 1999
Dean of the University of Vienna - Medical School (Austria)
- **Grant, Methods in Clinical Cancer Research. Vail, Colorado** 1999
The American Association for Cancer Research and the American Society of Clinical Oncology
- **Travel Grant, Molecular Biology in Clinical Oncology. Aspen, Colorado** 2000
The American Association for Cancer Research
- **Glaxo SmithKline Scholar Award, for promising clinical/translational cancer research** 2001
American Association of Cancer Research
- **Pfizer Scholar in Urology Award** 2001
- **Winner of the Science Day 2001 Project – Baylor College of Medicine, Houston, TX** 2001
- **First Place Poster** 2001
2nd Alexander Research Symposium, Baylor College of Medicine, Houston, TX
Expression of TGF- β 1 and its receptors in transitional cell carcinoma of the bladder.
- **AUA / Praecis Gerald P. Murphy Scholar** 2002
- **American Cancer Society Institutional Research Grant (IRG#93-034-06)** 2002
Development of a nomogram for prediction of the development of distant prostate cancer metastases and mortality.
- **Best Poster** 2002
Society of Urologic Oncology Annual Meeting, National Cancer Institute, December 13 - 14, 2002, National Institutes of Health, Bethesda, MD
Preoperative serum levels of pro-PSA isoforms are associated with biologically aggressive prostate cancer.
- **2000 Outstanding Intellectuals of the 21st Century** 2003
International Biographical Center, Cambridge, England (Registration number 965274)
- **Best Poster** 2004
Society for Urodynamics and Female Urology 2004 Meeting. Scottsdale, Arizona.
February 26-29, 2004.
- **“Best Poster” in urothelial cancer** 2004
European Association of Urology Annual Meeting, Vienna, March 26, 2004.
Urine detection of survivin is a sensitive marker for the non-invasive diagnosis of bladder cancer.
- **“Best Poster” in urogenital trauma** 2005
21st European Association of Urology Annual Meeting, Paris, April 5-8, 2006.

Evidence-based validation of the predictive value of the American Association for the Surgery of Trauma kidney injury scale.

- **“Best Poster” in bladder cancer: diagnosis and staging III** 2006
21st European Association of Urology Annual Meeting, Paris, April 5-8, 2006. Survivin expression is associated with bladder cancer presence, stage, progression, metastasis, and mortality.
- **AUA / Threshold Pharmaceuticals Gerald P. Murphy Scholar** 2006
- **AUA / Novacea Gerald P. Murphy Scholar** 2007
- **Listed in the “Guide to America’s Top Urologists 2007”** – Consumers’ Research 2007
Council of America is an independent research company based in Washington, DC that evaluated professional services throughout America (www.consumerresearchcncl.org).
- **“Best Poster” in prostate cancer: staging I** 2007
22nd European Association of Urology Annual Meeting, Berlin, March 21-4, 2007. Caveolin-1 overexpression is associated with aggressive prostate cancer recurrence.
- **Best Poster** 2007
Society of Urologic Oncology Eight Annual Meeting, National Cancer Institute, November 29th - December 1st, 2007, National Institutes of Health, Bethesda, Maryland. Multiple bio-markers for the prediction of bladder cancer recurrence and mortality.
- **“Best Poster” in prostate cancer: prognostic factors and predictors of outcome** 2008
23rd European Association of Urology Annual Meeting, Milano, Italy. March 26-9, 2008. Early post-operative plasma transforming growth factor- β 1 is a powerful predictor of biochemical progression after radical prostatectomy.
- **“Best Poster” in diagnosis and staging of urothelial tumours II** 2008
23rd European Association of Urology Annual Meeting, Milano, Italy. March 26-9, 2008. Multiple bio-markers for the prediction of bladder cancer recurrence and mortality.
- **“Best Poster” in Prostate Cancer: Staging (I)** 2008
American Urological Association Annual Meeting, Orlando, FL, May 17-22, 2008. Improved prediction of disease relapse after radical prostatectomy using a panel of reoperative blood-based biomarkers.
- **“Best Poster” in Prostate Cancer: Advanced (I)** 2008
American Urological Association Annual Meeting, Orlando, FL, May 17-22, 2008. J.Urol 179(4): 186, 2008. The effect of androgen deprivation therapy on the rate of subsequent non-cancer morbidities.
- **“Best Poster” in Urothelial Cancer: Surgical Therapy** 2008
American Urological Association Annual Meeting, Orlando, FL, May 17-22, 2008. More extensive lymphadenectomy improves the prognosis of patients with upper tract urothelial carcinoma without nodal metastases.
- **Reviewer of the month January** – European Urology 2008
- **ASCO Cancer Foundation Merit Award** 2008
American Society of Clinical Oncology Cancer Foundation and the ASCO/National Cancer Institute/ EORTC Scientific Committee, Annual Meeting on Molecular Markers in Cancer, Hollywood, FL
- **Listed in the “Guide to America’s Top Urologists 2008”** 2008
- **Best Poster** 2008
*Society of Urologic Oncology Annual Meeting, National Cancer Institute, December 4-6th, 2008, National Institutes of Health, Bethesda, MD
 Multi-institutional validation of the predictive value of Ki-67 labeling index in patients with bladder cancer.*
- **Merit Award** 2009
*ASCO Cancer Foundation Board of Directors and the 2009 Genitourinary Cancers Symposium Program Committee, Genitourinary Cancers Symposium, Orlando, FL
 Use of pre-treatment biomarker levels to improve the accuracy of post-prostatectomy nomogram for*

- prediction of biochemical recurrence*
- **“Best Poster” in Transitional Cell Carcinoma Pathology** 2009
*24th European Association of Urology Meeting, Stockholm, Sweden. March 17-1,2009.
 Predictive value of the combination of immunohistochemical markers in patients with pT1 disease at radical cystectomy.*
 - **“Best Poster” in Management of Advanced Urothelial Pathology** 2009
*24th European Association of Urology Annual Meeting, Stockholm, Sweden. March 17-21, 2009.
 Improved prediction of clinical outcomes in patients with advanced bladder cancer using a panel of four cell cycle regulators.*
 - **“Best Poster” in Upper and Lower Urinary Tract Carcinoma** 2009
*24th European Association of Urology Annual Meeting, Stockholm, Sweden. March 17-21, 2009.
 Proposal for subclassification of pT3 urothelial cancer of the renal pelvis.*
 - **First Prize for the Best Abstract** 2009
*25th European Association of Urology Annual Meeting, Barcelona, Spain. April 16-20, 2010. Her2
 expression status provides independent prognostic information in patients with urothelial carcinoma
 of the bladder: a rationale for targeted therapy.*
 - **“Best Poster” in Urothelial Cancer: Natural history and pathophysiology/markers** 2010
*American Urological Association Annual Meeting, San Francisco, CA, May 29-June 3, 2010.
 J.Urol 183(4): 662-663, 2010.*
 - **BJU Int Reviewer of Year 2010** 2011
 - **Senior author of Merit award to Eugene Cha at 2011 Genitourinary Cancers** 2011
*Symposium from ASCO/ASTRO/SUO. February 2011. San Orlando, FL.
 Immunocytology is a strong predictor of bladder cancer presence in patients with painless
 hematuria: a multicentre study*
 - **“Best Poster” in Hematuria and Bladder Cancer Diagnosis session** 2011
*26th Annual EAU Congress. 18-22 March 2011, Vienna, Austria.
 Risk assessment of patients who present with asymptomatic hematuria: development and validation of
 a nomogram for prediction of bladder cancer presence. 3/19/2011. Abstract 149, page 128.*
 - **“Best Poster”** 2011
*26th Annual EAU Congress. 18-22 March 2011, Vienna, Austria.
 pT3 substaging is a prognostic indicator in lymph node negative urothelial carcinoma
 of the bladder 3/19/2011*
 - **Senior author of “Best Abstract”** 2011
*8th Men’s Health World Congress & 4th European Men’s Health Conference. 2-5 October 2011,
 Vienna, Austria
 Obesity adversely impacts disease-specific outcomes in urothelial carcinoma of the
 urinary bladder 10/3/2011*
 - **2011 Men’s Health World Congress outstanding contribution award** 2011
*8th Men’s Health World Congress & 4th European Men’s Health Conference. 2-5 October 2011,
 Vienna, Austria*
 - **BJU International Reviewer of Year 2011** 2012
 - **Senior author of Merit award to Eugene Cha at 2012 Genitourinary Cancers** 2012
*Symposium from ASCO/ASTRO/SUO. February 2-4, 2012. San Francisco, CA.
 Predicting clinical outcomes after radical nephroureterectomy for upper tract urothelial carcinoma*
 - **Senior author of Merit award to Michael Rink at 2012 Genitourinary Cancers** 2012
*Symposium from ASCO/ASTRO/SUO. February 2-4, 2012. San Francisco, CA.
 Prognostic role and HER2 expression of circulating tumor cells in peripheral blood of
 patients prior to radical cystectomy: a prospective study*
 - **Co-author of “Best Poster” in Session 75: Prognostic biomarkers in urothelial carcinoma** 2012
27th Annual EAU Congress. 24-28th February 2012

Circulating tumour cells can not predict clinical or nodal stage, but survival after radical cystectomy for urothelial carcinoma of the bladder.

- **Second author of Best Clinical Research Paper Published in European Urology** 2011
Salvage radical prostatectomy for radiation-recurrent prostate cancer: a multi-institutional collaboration
- **Co-author of “Best Poster”** in Radical prostatectomy: Pathological issues and surgical margins, 27th Annual EAU Congress. 24-28th February 2012 2012
Comparative analyses of surgical modalities for the management of prostate cancer: A multi-institutional study of positive surgical margin rates on 22,403 patients operated on in the new millennium
- Mentor of **Ferdinand C. Valentine Student Research Grant in Urology** to medical student Joseph J. Crivelli, New York, NY, USA 2012
Intravesical application of nanoparticle-mediated microwave thermotherapy for treatment of bladder cancer
- **Senior author of “Best Poster”** in Bladder Cancer: Metastatic Disease/Staging American Urological Association Association Annual Meeting, Atlanata, GA, USA 2012
Tuesday, May 22, 2012 3:30 PM-5:30 PM
Abstract 1904: Extranodal extension is a powerful prognostic factor in bladder cancer patients with lymph node metastasis
- **Senior author** of Dr. Johannes Ritschl Forschungspreis of the Österreichischen Krebshilfe Niederösterreich, Austria (recipient: Harun Fajkovic, MD) 2012
Prognostic value of extranodal extension and other lymph node parameters in bladder cancer patients
- **Leading Physician of the World & Top Urologic Oncologist in New York, NY, USA** 2012
bestowed by Doctors of Excellence, The Leading Physicians of the World, The International Association of Oncologists.
- Senior author of **Best Clinical Research Paper Published in European Urology in 2012** 2012
Michael Rink: *Stage-specific impact of tumor location on oncologic outcomes in patients with upper and lower tract urothelial carcinoma following radical surgery*
- **Compassionate Doctor Recognition** 2012-2013
by Vitals.com in conjunction with PatientsChoice.org
http://www.vitals.com/doctors/Dr_Shahrokh_Shariat/credentials#ixzz33bEiXwTM
- **Resident’s Corner Award for the Best Scientific Paper published in European Urology by a resident in 2012** 2013
Eugene Cha: *Immunocytology is a strong predictor of bladder cancer presence in patients with painless hematuria: a multicentre study*
European Urology, Volume 61, Issue 1, January 2012, Pages 185-192
- **European Association of Urology Best Paper published on Clinical Research in the Urological Literature Award.** EAU Scientific Congress Office. 2013
28th Annual EAU Congress, Milan, Italy. March 15-19th 2013
Pathologic nodal staging score for bladder cancer: a decision tool for adjuvant therapy after radical cystectomy
- **Senior author of “Best Poster”** in Poster Session 13: Bladder cancer: gene expression and molecular classification; 28th Annual EAU Congress. March 2013, Milan, Italy. 2013
Prediction and reversibility of cisplatin-resistance in bladder cancer: HOXA9 a novel epigenetic biomarker. Abstract number: 156
- **Senior author of “Best Poster”** in Poster Session 47: Urothelial cancer: Transurethral surgery and intravesical recurrence Hematuria and bladder cancer diagnosis session 2013
28th Annual EAU Congress. March 2013, Milan, Italy.
Prediction of cancer-specific survival after radical nephroureterectomy for upper tract urothelial

carcinoma: Development of an optimized post-operative nomogram using decision curve analysis
Abstract number: 576

- **Senior author of “Best Poster”** in Poster Session 62: Urothelial cancer treatment: 2013
Predicting outcomes; 28th Annual EAU Congress. March 2013, Milan, Italy.
Accuracy of the EORTC risk tables and of the CUETO scoring model to predict outcomes in non muscle-invasive urothelial carcinoma of the bladder. Abstract number: 754
- **Senior author of “Best Poster”** in Poster Session 62: Urothelial cancer treatment: 2013
Predicting outcomes; 28th Annual EAU Congress. March 2013, Milan, Italy.
Female gender is associated with higher risk of disease recurrence in patients with primary T1 high grade urothelial carcinoma of the bladder. Abstract number: 752
- **Senior author of “Best Poster”** in Poster Session 58: Urothelial cancer treatment: 2013
intravesical approaches; 28th Annual EAU Congress. March 2013, Milan, Italy.
Statin use is not associated with prognosis or BCG-response in patients with non-muscle invasive bladder cancer. Abstract number: 701
- **Senior author of Best Abstract in prostate cancer**, American Urological Association 2013
Annual Meeting ,San Diego, CA. May 4-8th 2013
Does increasing the nodal yield improve outcomes in patients without nodal metastasis at radical prostatectomy?
- **Senior author of Best Abstract in bladder cancer**, American Urological Association 2013
Annual Meeting ,San Diego, CA. May 4-8th 2013
Concordance in molecular marker status between bladder tumors at time of transurethral resection and subsequent radical cystectomy: results of a 5-year prospective study
- **Senior author of Best Abstract in bladder cancer**, American Urological Association 2013
Annual Meeting ,San Diego, CA. May 4-8th 2013
Concordance in molecular marker status between bladder tumors at time of transurethral resection and subsequent radical cystectomy: results of a 5-year prospective study
- **Patients' Choice Award** 2013
by Vitals.com in conjunction with PatientsChoice.org
http://www.vitals.com/doctors/Dr_Shahrokh_Shariat/credentials#ixzz33bEiXwTM
- Senior author of **Third Prize for the Best Abstract by a Resident** 2014
29th European Association of Urology Annual Meeting, Stockholm, Sweden
Malte Rieken: *Comparison of the EORTC tables and the newly introduced EAU categories for risk stratification of patients with no-muscle invasive bladder cancer*
- Senior author of **Best Poster Prize** in Upper Tract Urothelial Carcinoma poster session 2014
29th European Association of Urology Annual Meeting, Stockholm, Sweden
Malte Rieken: *Frequency and prognostic value of PTEN loss in patients with upper tract urothelial carcinoma*
- **Matula Award**, 29th European Association of Urology, Stockholm, Sweden 2014
- **Gold Cystosocpe Award**, American Urological Association, Boston, USA 2017
- Senior author of **Best Poster Prize** in Poster Session 46: Prostate cancer biomarkers: 2017
Technical advances and clinical implications at the 32nd European Association of Urology Annual Meeting, London, UK
Elevated preoperative neutrophil-lymphocyte ratio predicts upgrading at radical prostatectomy
- Senior author of **Best Poster Prize** in Poster Session 88: Upper urinary tract tumour: 2017
Outcomes after radical surgery & peri-operative chemotherapy at the 32nd European Association of Urology Annual Meeting, London, UK
Trends of lymphadenectomy in upper tract urothelial carcinoma patients treated with radical nephroureterectomy: The impact of surgical technique

- **Honorary member** of the Uro-oncologic Section, Congress of the Polish Urological Association, Katowice, PL 6/20/2017
- **Honorary member** of the Asutrian patient advocacy/selfhelp group prostate cancer 12/5/2017
- **Platinum award** of European Urology, Journal of the European Association of Urology 2018
- **Platinum award** of European Urology, Journal of the European Association of Urology 2019
- **Honorary member** of the Polish Urological Society 2021
- Co-author of **Best Poster Prize** by a YAU member at the European Association of Urology Annual Virtual Meeting 2021 2021
Survival outcomes after radical cystectomy versus conservative management for cT1 high grade non-muscle invasive micropapillary bladder cancer
- Senior-author of **best abstract poster** at EMUC21, Athens, GR 11/2021
P154: Preoperative plasma level of endoglin as a predictor for disease outcomes after radical cystectomy for non-metastatic urothelial carcinoma of the bladder"

GRANT FUNDING

- **Frost gene therapy for urologic diseases fellowship program** 1999
Frost Foundation, Inc. (USD 90,000)
Baylor College of Medicine, Principal Investigators: Lerner S., Slawin K., Shariat S.
- **Gene therapy for urologic diseases** 1999
Max Kade Foundation, Inc. (USD 53,350)
Baylor College of Medicine, Principal Investigator: Shariat S.
- **Gene therapy for urologic diseases fellowship** 2001
Prostate Cancer Research Initiative - PCRI (USD 90,000)
Baylor College of Medicine, Principal Investigators: Lerner S., Slawin K., Shariat S.
- **Identification of blood, urine, and tissue biomarkers associated with presence, pathologic features and/or clinical outcomes in patients with urologic cancers.** 2001
Erwin Schrödinger Scholarship from the Austrian Academy of Science. (USD 50,000)
Principal Investigator: Shariat S.
- **CTSC Pilot award** 6/2012
Metabolomic prognostication and prediction of response to therapy in non-muscle invasive bladder cancer (USD 45,000)
Principal Investigator: Shariat S.
- **Österreichische Nationalbank** 2013 - 2015
A non-invasive genetic and epigenetic biomarker panel for early diagnosis of bladder cancer
project number: 15362, 92,600 € Principal Investigator: Shariat S.
- **Medical-Scientific Fund** of the Mayor of the City of Vienna 2014 - 2015
Quality indicators for bladder cancer (project number: 14069/2014, 28,000 €)
Principal Investigator: Shariat S.
- **Jubiläumsfondsprojekt** Nr. 16702 2016 – 2018
Identifizierung von prädiktiven DNA-Methylierungsbiomarkern für BCG-Immuntherapie im Blasenkarzinom (Auftragsnummer: AP16702ONB / KP16702ONB; €74,000)
Principal Investigator: Hassler M. & Shariat S.

- **Sanofi grant** 2017-2019
Identifying men with low-risk prostate cancer who are unlikely to benefit from treatment.
120,000€ Principal Investigator: Shariat S.
- **Roche grant** 2019 **R**
Potentiation of Immune checkpoint inhibitors via a pre-stimulation with Azacitidine 47,000€
Investigators: M. Hassler, U. Lemberger Senior Investigator: Shariat S.
- **Österreichische Nationalbank** 2020 **Ö**
Functional relations of FGFR3 and TERT in urothelial carcinomas of the bladder and the upper urinary (#18329). 104,000 € Investigators: I. Ertl Senior Investigator: Shariat S.
- **Movember Golf trophy** 2018-2019
Research in prostate cancer 12,000€ Investigators: Shariat S.

PATENTS

- **Method to determine prognosis after therapy for prostate cancer** 2002
Inventors: Shahrokh Shariat, Kevin Slawin
A method for prognosis of patients with prostate cancer, e.g., clinically localized prostate cancer, is provided.
EP1373899 Patent record available from the European Patent Office
US20030054419 Patent record available from the US Patent Office
WO02068960 Patent record available from the World Intellectual Property Organization,
Granted 2002-09-06
- **Methods to determine prognosis after therapy for bladder cancer** 2003
Inventors: Shahrokh Shariat, Kevin Slawin, Seth Lerner
A method to diagnose, stage and predict prognosis of bladder cancer patients is provided, e.g., using TGF- β 1, IL-6, IL-6sR, uPA, uPAR and IGFBP-3.
US20030032074 Patent record available from the US Patent Office
WO02099114 Patent record available from the World Intellectual Property Organization,
Granted 2003-06-19
- **Prognostic methods for patients with prostatic disease** 2004
Inventors: Shahrokh Shariat, Kevin Slawin, Michael Kattan, Peter Scardino
A method to diagnose, stage and predict prognosis of prostate cancer patients is provided.
EP1540350 Patent record available from the European Patent Office
US20030235816 Patent record available from the US Patent Office
WO2004027432 Patent record available from the World Intellectual Property Organization,
Granted 2004-08-05
- **Soluble Fas urinary marker for the detection of bladder transitional cell carcinoma** 2010
Inventor: Shahrokh Shariat
The present invention is an apparatus, system and method for detecting bladder cancer are provided that includes a substrate including one or more sFas binding agents and one or more reagents that indicate the amount of sFas present in the sample.
US07759077 Patent record available from the US Patent Office,
Granted 2010-07-20

PROFESSIONAL RESPONSIBILITIES

EDITORIAL WORK

- Editorial Board Member, European Urology 1/2008 – present
- Editorial Board Member, Immunotherapy 3/2008 – present
- Contributor to Urology, Faculty of 1000 Medicine 5/2008 – 9/2010
- Editorial Board Member, Debates on Bladder Cancer 9/2009 – present
- Contributor, UpToDate 11/2009 – present
- Editorial Board Member, Oncology Reports 12/2009 – present
- Editorial Board Member, BJU Int 2/2010 – present
- Editorial Board, Journal of Men's Health 3/2010 – present
- Editorial Board Member, World Journal of Clinical Oncology 4/2010 – present
- Editorial Board Member, Journal of Molecular Biomarkers and Diagnosis 6/2010 – present
- Editorial Board Member, Journal of Molecular Imaging and Dynamics 8/2010 – present
- Editorial Board Member, World Journal of Clinical Urology 12/2010 – present
- International Scientific Board, Archivos Españoles De Urologia 1/2011 – present
- Consulting Editor, International Brazilian Journal of Urology 1/2011 – present
- Editorial Board Member, ISRN Oncology 2/2011 – present
- Editorial Board Member, Urology: Current Research (OMICS Publishing Group) 3/2011 – present
- Editorial Board Member, World Journal of Urology 7/2011 – present
- Editorial Board Member, Frontiers in Genitourinary Oncology 2/2012 – present
- Co-editor of book on Prostate cancer –original scientific reports and case studies Edited by Spiess P.E. 6/2012
- Scientific board of Spectrum Urologie - offizielle Organ des Berufsverbands der Österreichischen Urologen (BVU) 2/2013-present
- Bladder Cancer Advocacy Network's scientific advisory board 3/2013-present
- Editorial Board Member, Advances in Therapy (ISSN: 0741-238X) 3/2013-present
- Editorial Board Member, Journal of Tumor (ISSN 1819-6187) 4/2013-present
- Editorial Board Member, American Journal of Urology (ISSN 2162-9722) 5/2013-present
- Editorial Board Member, Bladder Cancer 8/2014-present
- *Editor in chief*, Urologie Scan 9/2014-12/2016
- Editorial Board Member, International Journal of Urology & Urological Practice (http://www.journalnetwork.org/journals/international-journal-of-urology-and-urological-practice) 9/2014-present
- Editorial board, Nature Reviews Urology 10/2014-present
- *Editor in chief*, Current Opinion in Urology (ISSN 0963-0643) 11/2014-present
- Editor Focused Issue: Urothelial Carcinoma 1/2013
- Editor Focused Issue: Immunotherapy 12/2017
- Editorial board, Minerva Urologica e Nefrologica (ISSN 0393-2249) 11/2014-present
- Journal Club report from MUW/AKH Wien, Spectrum Urologie 9/2013-present
- Editorial board, Der Urologe (ISSN: 0340-2592) 10/2014-present
- Editorial board, Bladder Cancer (ISSN print 2352-3727, ISSN online 2352-3735) 4/2015-present
- Editor, European Urology Focus 4/2015-12/2016
- Translational Andrology and Urology (ISSN 2223-4683) Vol 5, No 5, October 2016 8/2016
- Editor Focused Issue: Urothelial Carcinoma
- Editorial board, Journal für Urologie und Urogynäkologie 8/2017-present
- International advisory board, Jordan Medical Journal (ISSN: 0446-9283) 6/2021-present

- Clinical Surgery Research Communications (CSRC) 22022-present

MODERATED SESSIONS AT MEETINGS

- **Chair of Moderated Poster session:** Urothelial tumours: Basic research I (Poster session 33) at the 23rd European Association of Urology Annual Meeting, Milano, Italy. March 26-29, 2008. 2008
- **Chair of Moderated Poster session:** Genetics and basic research in urothelial tumours (Poster session 26) at the 24th European Association of Urology Annual Meeting, Stockholm, Sweden. March 17-21, 2009. 2009
- **Chair of Moderated Poster session II:** Basic research at the Northeastern Section AUA 61st Annual Meeting, Montreal, Quebec, Canada. October 7-11, 2009. 2009
- **Chair of Moderated Poster session 64:** Prostate cancer: markers II at the American Urological Association Annual Meeting, San Francisco, CA, May 29-June 3, 2010. 2010
- **Chair of Moderated Debate** on *Current Approaches to Bladder Cancer* at Seventh Annual Current Trends in Genitourinary Malignancies, New York, NY (10/16/2010). 2010
- **Chair of Session** – *Does it really matter to consider gender when managing male patients in primary care?* 7th Men's Health World Congress and 3rd European Men's Health Conference. 28-30 October 2010, Nice, France. 2010
- **Chair of Session** – *Comprehensive long term outcomes of male urogenital cancers.* 7th Men's Health World Congress and 3rd European Men's Health Conference. 28-30 October 2010, Nice, France (10/29/2010) 2010
- **Chair of Panel Discussion** – *Why and how to care for patients with advanced PCA in a multidisciplinary approach.* 7th Men's Health World Congress and 3rd European Men's Health Conference. 28-30 October 2010, Nice, France (10/30/2010) 2010
- **Chair of Panel Discussion** – *Developing a men's health curriculum: teaching men's health to medical students & health professionals.* 7th Men's Health World Congress and 3rd European Men's Health Conference. 28-30 October 2010, Nice, France (10/30/2010) 2010
- **Chair of Moderated Poster Session** at the 7th Men's Health World Congress and 3rd European Men's Health Conference. 28-30 October 2010, Nice, France (10/30/2010) 2010
- **Moderator of Prostate Cancer Clinical Case Discussion** at the 4th Journee d'onco-urologie of the Association Marocaine d'Urologie, Fes, Morocco (12/18/2010) 2010
- **Chair of Moderated Poster session 64:** Prostate cancer: markers II at the American Urological Association Annual Meeting, San Francisco, CA, May 29-June 3, 2010. 2010
- **Chair of Moderated Poster session 26:** Prostate cancer diagnosis at the 26th Annual European Association of Urology Congress. 18-22 March 2011, Vienna, Austria. 2011
- **Chair of Session:** Onkologie at the 44. Alpenländische Urologensymposium, Wolkenstein, Bozen, IT, March 30-April 2, 2011. 2011
- **Introduction session** at Young Urological Associates of the European Association of Urology. 9-10 April 2011, Lago Maggiore, Italy (4/9/11) 2011

- **Chair of Sessions** - The Inaugural International Prostate Cancer Symposium. 2011
May 10-12, 2011, New York, USA.
Prostate cancer complications and their management.
Surgical training mini-session.
- **Chair of Sessions** - 8th Men's Health World Congress & 4th European Men's 2011
Health Conference. 2-5 October 2011, Vienna, Austria
Urologic care for the elderly patient
Debate on PSA screening for prostate cancer
- **Chair of Session** – Menopause, Andropause, Anti-aging. 8-10 December, Vienna, Austria 2011
Urology and Andrology
- **Chair of moderated poster session 91: Prostate cancer: Active surveillance** 2012
at the 26th Annual European Association of Urology Congress. 24-28 February 2012, Paris, France.
- **Chair of Session** – Fortbildungstagung der Österreichischen Gesellschaft für Urologie 2012
und Andrologie. 9-10 November 2012, Linz, AUT.
Was sollte ich wissen? Leitlinien und Nomogramme
- **Chair of Session** - *Diagnostics, prognostic factors and risk stratification of upper tract* 2012
urothelial carcinoma at the Summit on Upper Tract Urothelial Carcinoma,
Society of Urologic Oncology Annual Meeting, November 28-30, 2012, Bethesda, MD, USA
- **Chair of session 2**, 19th St Lawrence Urological Group, 1/26/2013
McGill University Health Centre, Montreal, Quebec, Canada 1/25-27, 2013
- **Chair of moderated poster session 62: Urothelial cancer treatment: predicting outcomes** 3/19/2013
28th Annual EAU Congress. March 2013, Milan, Italy.
- **Chair of wissenschaftlichen Sitzung** Katheterismus, Wilhelimenspital, Vienna, Austria 7/3/2013
- **Chair of session, 33rd Congress of the Societe Internationale d'Urologie, Vancouver, Canada**
Surgical Tips 1: Endoscopic Management of Urothelial Cancer 9/9/2013
ICUD Consultation 2013: Upper Tract Urothelial Carcinoma 9/10/2013
- **Chair of local Lilly meeting on prostate cancer**, Hilton Hotel, Vienna, Austria 10/11/2013
- **Organizator/Chair** First Interdisciplinary Prostate Cancer Symposium, Vienna, AUT 11/29/2013
- **Chair** of Session VI at 23rd International Symposium of the Endourology and ESWL 3/8/2014
Section of the Polish Urological Association, Wroclaw, Poland
- **Chair of moderated poster session:** in Upper Tract Urothelial Carcinoma 4/2014
29th Annual EAU Congress. April 2013, Stockholm, Sweden
- **Chair of session, 34th Congress of the Societe Internationale d'Urologie, Glasgow, UK**
Debate: why do women have a worse prognosis from bladder cancer? 10/14/2014
- **Chair of session, 24. Jahrestagung der MKÖ, Linz, AUT** 10/18/2014
Kontinenz und Schmerz – Zukunftsperspektiven
- **Chair of local Lilly meeting on BPH/LUTS/ED**, Albertina, Vienna, Austria 10/24/2014
- **Chair of local Atellas meeting on castration-resistant prostate cancer** 10/25/2014
Aula der Wissenschaften, Vienna, Austria

- **Chair of Session** – Fortbildungstagung der Österreichischen Gesellschaft für Urologie und Andrologie. 7-8 November 2012, Linz, Austria 11/7/2014
Smoking kills- die Rolle der Urologie
- **Chair of Session** – 13th Meeting of the Association of Academic European Urologists (AAEU), 4-7 December 2014, Porto, Portugal 12/5/2014
Bladder cancer session
- **Chair of moderated poster session 62:** Urothelial cancer treatment: predicting outcomes 3/19/2014
28th Annual EAU Congress. March 2013, Milan, Italy.
- **Chair of moderated poster session 62:** Urothelial cancer treatment: predicting outcomes 3/19/2014
28th Annual EAU Congress. March 2013, Milan, Italy.
- **Chair of the poster session** MP68:Bladder Cancer: Basic Research IV at the American Urological Association Annual Meeting 2015, New Orleans, LA, USA 5/19/2015
- **Chair** of Inaugural Friends of Urology Austrian Polish meeting, Vienna, Austria 5/29/2015
- **Chair of Olympus Symposium**, Challenges in Endourology, Paris, France 6/29/2015
Clinical Innovations in Endourology
- **Chair of lecture session**, 7th European Multidisciplinary Meeting on Urological Cancers, Barcelona, Spain 11/14/2015
Management of upper urinary tract urothelial carcinoma
- **Chair of session**, 68. Deutsche Gesellschaft der Urologie Kongress, Leipzig, Germany 29/09/2016
Zystektomie
- **Chair of session**, 36th Congress of the Societe Internationale d'Urologie, Buenos Aires, Argentina 10/23/2016
Moderated Posters 16: Bladder Cancer
- **Chair of session**, Jahreshauptversammlung der ÖGU Fortbildungstagung der Österreichischen Gesellschaft für Urologie und Andrologie 11/5/2016
International Lectures
- **Chair of session** – 15th Meeting of the Association of Academic European Urologists (AAEU), 5-7 December 2016, Warsaw, Poland 12/5/2016
Endourology and more
- **Chair of session** – 2nd Michal J. Marberger Annual Symposium, Vienna, AUT 12/16/2016
Controversies and challenges in lymphadenectomy
- **Chair of moderated poster session:** Ongoing clinical trials 3/26/2017
29th Annual EAU Congress. March 2017, London, UK.
- **Chair of moderated poster session 64:** Prostate cancer: localized surgical therapy at the American Urological Association Annual Meeting, Bostom, MA, May 12-6, 2017. 5/14/2017
- **Chair of moderated poster session 64:** Prostate cancer: localized surgical therapy at the American Urological Association Annual Meeting, Bostom, MA, May 12-6, 2017. 5/14/2017
- **Chair of moderated session:** Urothelkarzinom 5/19/2017
43. Gemeinsame Tagung der Oesterreichischen Gesellschaft fuer Urologie und Andrologie und der Bayerischen Urologenvereinigung, Wien, AUT
- **Chair of moderated session:** Österreichisches Gesundheitssystem - Quo vadis? 5/31/2017

Gesellschaft der Ärzte in Wien – Billrothhaus, Wien, AUT

- **Chair of meeting:** Europa Uomo Seminar 360 Degree Perspectives on Prostate Cancer, 6/10/2017
Wien, AUT
- **Chair of the Uro-oncologic Section session, Congress of the Polish Urological Association, Katowice, PL** 6/20/2017 C
- **Chair of session** *Tumor development and promising biomarkers in prostate and renal cancers* of the EAU 17th Central European Meeting in conjunction with the national 63rd conference of the Czech Urological Society, Plzen, Czech Republic 10/19/2017 C
- **Chair of ESU session** of the EAU 17th Central European Meeting in conjunction with the national 63rd conference of the Czech Urological Society, Plzen, Czech Republic 10/19/2017 C
- **Chair of session, Jahreshauptversammlung der ÖGU Fortbildungstagung der Österreichischen Gesellschaft für Urologie und Andrologie, Linz, AUT**
International lectures 11/11/2017
- **Chair of session at 3rd Michal J. Marberger Annual Symposium, Vienna, AUT** 12/16/2017
Frontiers in Urology
- **Chair of session** at the 1st ESU/ESOU Masterclass on Non-Muscle Invasive Bladder Cancer, Prag, CZ; *Module 3- En Bloc resection* 1/12/2018
- **Chair of moderated poster session 75:** Urothelial carcinoma of the upper tract: New options, new strategies and personalised management. 32nd Annual EAU Congress. March 2018, Copenhagen, DK. 3/19/2018
- **Chair of moderated poster session 29:** Prostate cancer: localized surgical therapy at the American Urological Association Annual Meeting, San Francisco, CA, 2018. 5/19/2018
- **Chair of session, Young Scientist Association, Vienna, Austria** 6/7/2018
- **Chair of session** at EAU Update on Bladder Cancer, Munich, GE 6/8/2018
High risk non-muscle invasive bladder cancer: from guidelines to future approaches
- **Chair of session, Erster wissenschaftlicher Kongress iranischer Aerzte in Wien, AUT** 7/14/2018
Erkrankungen des Beckenbodens
- **Chair of Expert-Guided Poster Tour 14, 33rd Annual EAU Congress, Barcelona, SP** 3/18/2019
Mini invasive approaches for upper tract urothelial cancer treatment
- **Chair of session, Jahreshauptversammlung der ÖGU Fortbildungstagung der Österreichischen Gesellschaft für Urologie und Andrologie, Linz, AUT**
International lecture Axel Bex 11/9/2019
- **Chair of session** –Meeting of the Association of Academic European Urologists (AAEU), 29-30 November, Bratislava, Slovakia
Bladder cancer session 11/30/2019
- **Chair of meeting** –Dialog 2020 Prostatakarzinom, Vienna, AUT 11/13/2020

COMMITTEES AND GUIDELINE PANEL

- Member, Prognostic factors panel of **The International Consultation on Urological Diseases** and the EAU consensus meeting on Kidney Cancer. 2010
- Member of Biomarkers panel of **The WHO International Consultation on Prostate Cancer** 2010
- Chair of Early detection factors and Prognostic factors panel of **The International Consultation on Urological Diseases**, the AUA/EAU consensus meeting on Bladder Cancer. 2011
- Member of **EAU Guidelines panel on New Technologies** 2011-3
- Member of **EAU guidelines on Non-Muscle-invasive Carcinoma of the Bladder** 2011-present
- Guideline chair of **The International Consultation on Urological Diseases** on Upper tract urothelial carcinoma. Presentation at SIU 2013 in Vancouver, Canada 9/2013 2012
Panel chair of the Predictive and prognostic factors and pathology panel
- Member of **EAU guidelines on Upper Tract Urothelial Carcinoma** 2012-present
- Co-chair of **Summit on Upper Tract Urothelial Carcinoma** held under the auspices of the Society of Urologic Oncology at the annual meeting in Bethesda, MD, USA 12/2012 2012
- Chair of **The International Consultation on Urological Diseases** & the SIU consensus meeting on Upper Tract Urothelial Carcinoma. 2013
- Member of Senat of the **Christian Doppler Forschungsgesellschaft**, Vienna, AUT 3/2016-present
- Scientific committee member of the **Open Medical Institute of the Salzburg Foundation of the American Austrian Foundation** 3/2016-present
- Local organising committee and scientific committee member of the **Global Congress on Prostate Cancer 2016**, Vienna, AUT 6/29-7/1/2016
- Scientific organization committee member of the **Global Congress on Bladder Cancer 2016**, Brussels, BE 9/2016
- Wissenschaftlicher Beirat der **Österreichische Krebshilfe Wien**, AUT 11/2015 - present
- Chair of **Privatmedizin Arbeitsgruppe** of the Medical University of Vienna 2016-7 C
- Chair of scientific organization committee member of the **2nd Michal J. Marberger Annual Symposium**, Vienna, AUT *Controversies and challenges in lymphadenectomy* 12/16/2016
- Chair of Predictive and Prognostic Factors panel of **The International Consultation on Urological Diseases** consensus guidelines on Bladder Cancer. 2017 C
- Chair of **Europa Uomo Seminar 360 ° Perspectives on Prostate Cancer**, Wien, AUT 6/10/2017

- Chair of scientific organization committee member of the 3rd **Michal J. Marberger Annual Symposium**, Vienna, AUT *Frontiers of urology* 12/15/2017
- Chair of scientific organization committee member of the 2nd **B2B Bladder and Kidney Cancers**, Vienna, AUT 5/24-5/2018
- Member of scientific organization committee member of the **Erster wissenschaftlicher Kongress iranischer Aerzte** in Wien, AUT 7/13-5, 2018
- Chair of scientific organization committee of the 4th **Michal J. Marberger Annual Symposium**, Vienna, AUT 12/14/2018
- Chair of scientific organization committee of the **X-Change** meeting, Vienna, AUT 12/1/2019
- Chair of scientific organization committee member of the **Controversies in Urologic Oncology**, Vienna, AUT 3/30/2019
- Chair of scientific organization committee of the 5th **Michal J. Marberger Annual Symposium**, Vienna, AUT 12/13/2019

MEETING REVIEWER

- Abstract reviewer for **24th Annual European Association of Urology Congress** 17-21 March 2009, Stockholm, Sweden; Subject: Prostate cancer: PSA and markers 2008
- Abstract reviewer for **25th Annual European Association of Urology Congress** 16-20 April 2010, Barcelona, Spain; Subject: Prostate cancer: PSA and markers 2009
- Abstract reviewer for **7th Men's Health World Congress** "How To Overcome The Challenges?" 28-30 October 2010, Nice, France; Subject: Oncology 2010
- Abstract reviewer for **26th Annual European Association of Urology Congress** 18-22 March 2011, Vienna, Austria; Subject: Prostate cancer: PSA and markers 2010
- Abstract reviewer for the **8th Men's Health World Congress** and **4th European Men's Health Conference**. 2-5 October 2011, Vienna, Austria 2011
- Abstract reviewer for the **13th Annual Meeting of the Society of Urologic Oncology** November 28-30, 2012, Bethesda, MD, USA 2012
- Reviewer for the **National Agency for the Evaluation of Universities and Research Institutes** (ANVUR). Mission: assessment of research performed in the time frame 2004-2010 by researchers of all Italian universities and research institutes (eValuation of Quality of Research, VQR 2004-2010). 2012
- Member of **Bladder Cancer Advocacy Network – BCAN's Scientific Review Group** to review applications for the Young Investigator Awards program 2013
- Abstract reviewer for the **14th Annual Meeting of the Society of Urologic Oncology** December 4 - 6, 2013, Bethesda, MD, USA 2013
- Abstract reviewer for **29th Annual European Association of Urology Congress** 11-15 April 2014, Stockholm, Sweden; Subject: urothelial tumours: management of infiltrative/advanced tumors: surgical management 2014
- Abstract reviewer for **Deutsche Gesellschaft der Urologie** 2014

- Abstract reviewer for **30th Annual European Association of Urology Annual Congress** 2015
20-24 March, Madrid, Spain; Subject: urothelial tumours: management of infiltrative/advanced tumors: surgical management
- Abstract reviewer for **35th Societe International d'Urologie Annual Congress** 2015
15-18 October, Melbourne, Australia; Subjects: bladder and urothelial cancer
- Abstract reviewer for **31st Annual European Association of Urology Annual Congress** 2016
March, Munich, Germany; Subject: urothelial tumours: management of infiltrative/advanced tumors: surgical management
- Reviewer for the **National Agency for the Evaluation of Universities and Research Institutes (ANVUR)**. Mission: assessment of research performed in the time frame 2006-2012 by researchers of all Italian universities and research institutes (eValuation of Quality of Research, VQR 2006-2012) 2016
- Abstract reviewer for **Proscas: Global Prostate Cancer Meeting**, June, Vienna, Austria 2016
- Abstract reviewer for **36th Societe International d'Urologie Annual Congress** 2016
October, Argentina; Subjects: bladder and urothelial cancer
- Abstract reviewer for **32nd Annual European Association of Urology Annual Congress** 2017
March, London, UK; Subject: urothelial tumours: management of infiltrative/advanced tumors
- Abstract reviewer for **37th Societe International d'Urologie Annual Congress** 2017
October, Portugal Subjects: bladder and urothelial cancer
- Abstract reviewer for **33rd Annual European Association of Urology Annual Congress** 2018
March, Copenhagen, DK; Subject: urothelial tumours: management of infiltrative/advanced tumors
- Abstract reviewer for **38th Societe International d'Urologie Annual Congress** 2018
October, Seoul, South Korea; Subjects: bladder and urothelial cancer
- Abstract reviewer for **34rd Annual European Association of Urology Annual Congress** 2019
March, Barcelona, SP; Subject: urothelial tumours: management of infiltrative/advanced tumors
- Abstract reviewer for **39th Societe International d'Urologie Annual Congress** 2019
October, Athens, Greece; Subjects: bladder and urothelial cancer

SCIENTIFIC COMMITTEE MEMBER

- **Member of Scientific Committee** of the 7th Men's Health World Congress and 3rd European Men's Health Conference. A multidisciplinary approach to men's health: How to overcome the challenges? 28-30 October 2010, Nice, France 2010
- **Chair of Scientific Committee and Best Poster Award Committee** of the 8th Men's Health World Congress and 4th European Men's Health Conference. 2-5 October 2011, Vienna, Austria 2011
- **Guest Editor** of special issue on bladder cancer of the World Journal of Urology (ISSN: 0724-4983 and 1433-8726) 2011
- **Co-chair of the Best Presentation Award Committee** of 19th Association Marocaine d'Urologie Annual Meeting 2011
- **Chair of the Best Presentation Award Committee** of 20th Association Marocaine 2012

d'Urologie Annual Meeting

- **Member of Bladder Cancer Scientific Program Committee** for the 13th Annual Meeting of the Society of Urologic Oncology, November 28-30, Bethesda, MD, USA 2012
- **Co-chair of Summit on Upper Tract Urothelial Carcinoma Program** at the 13th Annual Meeting of the Society of Urologic Oncology, November 28, Bethesda, MD, USA 2012
- **Guest Editor** of special issue on "Prostatakazinom" in Spectrum Urologie 2012
- **Member of Best Presentation Award Committee** 2013
19th St Lawrence Urological Group, McGill University Health Centre, Montreal, Quebec, Canada 1/25-27, 2013
- **Member of Bladder Cancer Scientific Program Committee** for the 14th Annual Meeting of the Society of Urologic Oncology, December 4-6, Bethesda, MD, USA 2013
- **Guest Editor** of special issue on *Biomarkers in Uro-oncology* in Urologic Oncology 2013
- **Guest Editor** of special issue on "Das Harnblasenkarzinom" in Spectrum Urologie 2013
- **Scientific programme committee chair**, First Interdisciplinary Prostate Cancer Symposium, Vienna, AUT 11/29/2013
- **Scientific programme committee member** of the Societe International d'Urologie 11/2013-10/2015
- **Guest Editor** of special issue on "High risk non muscle invasive bladder cancer" Current Opinion in Urology 9/2014
- **Scientific advisory board**, Maennergesundheit verstehen 11/2014
- **Scientific advisory board**, Österreichisch-Iranische Ärztgesellschaft 8/2013-present
- **Scientific programme committee chair**, Inagural International Urothelial Carcinoma Meeting, Vienna, Austria 1/29/2016
- Member of the Scientific Advisory Board of the **Bladder Cancer Advocacy Network (BCAN)** 2016
- **Meeting and scientific program co-chair**, Friends of Urology Austrian Polish meeting, Krakow, Poland 5/2016
- **Local organising committee, 4th Global Congress on Prostate Cancer PROSCA 2016** (29 June- 01 July), Vienna, Austria. 6/2016
- **Scientific program committee chair**, Controversies and challenges in lymphadenectomy for urologic cancers meeting, Vienna, Austria 12/16/2016
- **Meeting & Scientific program chair**, Bench to Bedside Kidney and Urothelial Cancers meeting, Vienna, AUT 5/26-7/2017
- **Scientific program committee chair**, Europa Uomo Seminar 360 Degrees Perspectives on Prostate Cancer, Vienna, AUT 6/10/2017
- **President of the jury** for the PhD Defense of Dr Matthieu Romain, Rennes, FR 6/28/2017
- **Scientific program chair**, Frontiers in Urology, Vienna, AUT Meeting & 12/15/2017
- **Scientific program chair**, Bench to Bedside Bladder & Kidney Cancers Vienna, AUT Meeting & 5/25-6/2018

- **program chair**, Frontiers in Urology, Vienna, AUT **Scientific**
12/14/2018
- **& scientific program chair**, X-change your knowledge, Vienna, AUT **Meeting**
12/1/2019
- **Meeting & Scientific program chair**, Controversies in Urologic Oncology, Vienna, AUT 3/30/2019
- **Chair of Prostate cancer session**, 11th International Conference of the Jordanian Association of Urological Surgeons, Amman, Jordan 10/5/2019
- **Meeting & Scientific program chair**, 5th M.J.Marberger Meeting: Frontiers in Urology, Vienna, AUT 2/14/2019
- **Meeting & Scientific program co-chair**, International Conference “New Technologies in Urology: Pro et Contra”, Moscow, RU 2/7/2020
- **Chair of Young CCC session**, Trio meeting of the Comprehensive Cancer Center of the Medical University Vienna
- **Meeting & Scientific program chair**, 6th M.J.Marberger Virtual Meeting: Frontiers in Urology, Vienna, AUT 12/11/2020
- **Meeting & Scientific program chair**, 7th M.J.Marberger Virtual Meeting: Frontiers in Urology, Vienna, AUT 12/10/2021

JOURNAL REVIEWER

- Urology 1/2001 – present
- Journal of Clinical Oncology 3/2002 – present
- American Journal of Cancer 4/2002 – present
- European Urology 5/2003 – present
- Journal of Urology 1/2004 – present
- Cancer Chemotherapy and Pharmacology 2/2004 – present
- Expert Review of Molecular Diagnostics 4/2004 – present
- Biochimica et Biophysica Acta – Proteins and Proteomics 6/2004 – present
- BioMed Central Urology 7/2004 – present
- International Journal of Cancer 10/2004 – present
- BJU International 7/2005 – present
- European Journal of Cancer 9/2005 – present
- Artificial Intelligence in Medicine 2/2005 – present
- Urologic Oncology: Seminars and Original Investigations 1/2006 – present
- Medical Principles and Practice 2/2006 – present
- EAU – EBU Update Series 8/2006 – present
- International Brazilian Journal of Urology 8/2006 – present
- Cancer Letters 8/2006 – present
- Biomarker Insights 9/2006 – present
- The Scandinavian Journal of Clinical & Laboratory Investigation 10/2006 – present
- Human Pathology 11/2006 – present
- Clinical Cancer Research 12/2006 – present
- Experimental and Molecular Pathology 1/2007 – present
- Clinical Genetics: An International Journal of Genetics and Molecular Medicine 2/2007 – present

• Yonsei Medical Journal	2/2007 – present
• Apoptosis: An International Journal on Programmed Cell Death	3/2007 – present
• Biomarkers in Medicine	4/2007 – present
• European Journal of Surgical Oncology	7/2007 – present
• World Journal of Surgical Oncology	8/2007 – present
• Cleveland Clinic Journal of Medicine	9/2007 – present
• Pathology: The Official Journal of the Royal College of Pathologists of Australasia	9/2007 – present
• Cancer: Interdisciplinary International Journal of the American Cancer Society	9/2007 – present
• Expert Review of Anticancer Therapy	10/2007 – present
• Neoplasia: An International Journal for Oncology Research	10/2007 – present
• Nature Clinical Practice Oncology	11/2007 – present
• Expert Opinion on Therapeutic Targets	11/2007 – present
• Asian Journal of Andrology	11/2007 – present
• Current Opinion in Molecular Therapeutics	12/2007 – present
• Expert Review of Proteomics	1/2008 – present
• Expert Opinion on Medical Diagnostics	2/2008 – present
• World Journal of Urology	3/2008 – present
• Laboratory Investigation	4/2008 – present
• Radiotherapy and Oncology	6/2008 – present
• Cancer Treatment Review	8/2008 – present
• BioMed Central Cancer	1/2009 – present
• Annals of Oncology	3/2009 – present
• International Journal of Urology	3/2009 – present
• Lancet Oncology	7/2009 – present
• The Journal of Sexual Medicine	8/2009 – present
• The Prostate	9/2009 – present
• Molecular Cancer Therapeutics	10/2009 – present
• Nature Reviews Clinical Oncology	11/2009 – present
• Cancer Epidemiology, Biomarkers and Prevention	3/2010 – present
• International Journal of Surgery	3/2010 – present
• Expert Opinion on Investigational Drugs	4/2010 – present
• Tumor Biology - The International Society of Oncology and BioMarkers	5/2010 – present
• Critical Reviews in Oncology/Hematology	6/2010 – present
• The Journal of Proteome Research	6/2010 – present
• Cancer Treatment Reviews	9/2010 – present
• Molecular Medicine	11/2010 – present
• Journal of Endourology	11/2010 – present

VISITING PROFESSORSHIPS

- **Visiting Professor**, University of Montreal, Montreal, Quebec, Canada 9/2008
The benefits of early androgen blockade;
Urologic trauma: experience at Parkland Memorial Hospital;
Potential effect of testosterone supplements of prostate cancer biology
- **Visiting Professor**, XXV Jornadas Urológicas De La Filial Sur de la Sociedad Chilena de Urología. 13-15 Agosto 2010, Temuco, Chile 8/2010
Cancer Vesical Sin Invasión Muscular
Role of surgery in invasive and advanced bladder cancer

Perioperative chemotherapy for muscle invasive bladder cancer

Urine biomarkers for bladder cancer detection and surveillance

- **Visiting Professor**, Sociedad Chilena de Urologia, Santiago de Chile, Chile 8/2010
Update on non-muscle invasive bladder cancer
Cytoreductive nephrectomy in the era of targeted molecular agents: is it time to consider pre-surgical therapy?
- **Visiting Professor**, Department of Urology, University of Hamburg, Hamburg, Germany 11/2010
Evidence-based management of non-muscle invasive bladder cancer (11/3/2010)

Martini Prostate Klinik, University of Hamburg, Hamburg, Germany
Disease state-specific integration of biomarkers for prostate cancer (11/4/2010)
- **Visiting Professor**, Div. of Urology, Maimonides Medical Center, Brooklyn, NY, USA 4/16/2012
Optimal stage-specific management of prostate cancer
- **Visiting Professor**, Division of Urology, Instituto Do Cancer Do Estado De Sao Paulo (ICESP) and Department of Urology, University of Sao Paulo (USP), Sao Paulo, SP, Brazil 4/26-27/2012
How to integrate research in daily clinical setting
- **Visiting Professor**, Dept. of Urology, Universitaetsklinikum Aachen, Aachen, DL 11-12/12/2013
How to optimize outcomes in muscle-invasive bladder cancer: role of surgery and chemotherapy
- **Visiting Professor**, Div. of Urology, Dept. of Surgery, University of Oxford, Oxford, UK 7/2014
Personalized management of bladder cancer: where is the future
- **Visiting Professor**, Dept. of Urology, 2nd Medical Faculty, Charles University, Prag, CZ 4/2015
How to succeed as physician-scientist
- **Visiting Professor**, Dept. of Urology, European Center of Medicine Otwock, PL 2/24-5/2016
- **Visiting Professor**, Kantonspital Luzern, Luzern, Switzerland 1/12/2017
Upper tract urothelial carcinoma: research and progress
- **Visiting Professor**, University of Texas Southwestern Dallas, Dallas, TX, USA 5/10/2017
Upper tract urothelial carcinoma collaboration: a story that started in Dallas
- **Visiting Professor**, University of Tübingen, Tübingen, Germany 7/5/2017
Biomarkers for checkpoint therapy
- **Visiting Professor**, Northwestern University, Chicago, USA 3/29-31/2018
Upper tract urothelial carcinoma: what have learned in the last 10 years
Tips for a successful career in academia
- **Visiting Professor**, Fundación instituto valenciano de oncología, Valencia, SP 9/23-4/2021
Upper tract urothelial carcinoma: what have learned in the last 10 years
Tips for a successful career in academia
Role of local treatment in hormone naïve metastatic prostate cancer
Active surveillance 2021: From bench to bedside
Partial gland ablation (focal therapy) is the treatment of choice for some patients
Genetic Testing in Prostate Cancer
Metastatic bladder cancer
T1 bladder cancer
MRI/TRUS-Fusion Biopsy: Better than TRUS Biopsy?
Metastatic Castration-Sensitive Prostate Cancer – what is the best treatment sequence today?

Upper tract urothelial carcinoma: quality indicators

INVITED PRESENTATIONS AND COURSES

- **Invited Lecturer**, Austrian-Iranian Medical Society, Vienna, AUT 8/14/2007
Genitourinary Oncology: the US perspective
- **Invited Lecturer**, Association des Urologues du Quebec, Montebello, Canada 9/6/2008
Marqueurs urinaires; Déclenchement du hormono-therapy dans le cancer de la prostate non-avancé
- **Invited Lecturer**, Medizinische Universität Wien, Vienna, AUT 9/12/2008
Prostate cancer biomarkers: an update and future perspectives
- **Invited Lecturer**, The International Bladder Cancer Network Meeting, 10/16/2008
Barcelona, Spain. *Statistical needs in marker research*
- **Invited Lecturer**, Society of Urologic Oncology, Bethesda, MD, USA 12/3/2008
Multi-institutional validation of the predictive value of Ki-67 labeling index in patients with urinary bladder cancer.
- **Invited Lecturer**, Grand rounds of the Department of Urology at New York University, 6/17/2009
New York, NY, USA. *Molecular markers for bladder cancer*
- **Invited Lecturer**, Austrian-Iranian Medical Society, Vienna, AUT 8/23/2009
Trends in Prostate Cancer Management
- **Invited Lecturer**, Department of Urology at University of Texas Southwestern 9/15-16/2009
Medical Center, Dallas, TX, USA
*Integration of biomarkers in a programmatic approach to bladder cancer
Timing and duration of early androgen deprivation therapy*
- **Invited Panelist**, Northeastern Section AUA 61st Annual Meeting, Montreal, Canada 10/8/2009
Testosterone supplementation in prostate cancer and its risks.
- **Invited Lecturer**, Northeastern Section AUA 61st Annual Meeting, Montreal, Canada 10/8/2009
Residents' Breakfast: How to Select a Urology Fellowship Program
- **Invited Lecturer**, Glickman Urological Institute, Cleveland Clinic, Cleveland, OH, USA 10/29/2009
Molecular markers can improve the clinical decision-making in patients with bladder cancer
- **Invited Lecturer**, Society of Urologic Oncology, Bethesda, MD, USA 12/4/2009
Her2 expression status provides independent prognostic information in patients with urothelial carcinoma of the bladder
- **Invited Lecturer**, European School of Urology course at the time of the 26th Annual 4/18/2010
EAU Congress, Barcelona, Spain
How to write a manuscript and get it published in European Urology.
- **Invited Lecturer**, Resident Forum of the 2010 American Urological Association, 5/29/2010
San Francisco, CA, USA
Choosing a fellowship - Getting Started: A Blueprint for Post-Residency Life
- **Invited Lecturer**, 36 Gemeinsame Tagung der Bayerischen Urologenvereinigung und 6/10/2010
der Österreichischen Gesellschaft für Urologie, Munich, Germany
Blasenkarzinom: Grundlagen

- **Invited Lecturer**, Societed Chilena de Urologia, Santiago de Chile, Chile 8/19/2010
Update on non-muscle invasive bladder cancer
Cytoreductive nephrectomy in the era of targeted molecular agents: is it time to consider pre-surgical therapy?
- **Invited Lecturer**, Innovations in Urology First Annual Meeting, Milan, Italy 9/18/2010
Pelvic Lymph Node Dissection for Prostate Cancer: extended, limited, or not at all?
- **Invited Lecturer**, Seventh Annual Current Trends in Genitourinary Malignancies, 10/16/2010
 New York, NY, USA
Surgery for early-stage bladder cancer. Debate: radiation therapy is suboptimal for bladder cancer.
- **Invited Lecturer** at the session Prostate Cancer II of the 7th Men's Health World 10/29/2010
 Congress and 3rd European Men's Health Conference. 28-30 October 2010, Nice, France
Prostate cancer overview and recent advances - how can a common disease be so controversial
- **Invited Lecturer** at the 7th Men's Health World Congress and 3rd European Men's 10/29/2010
 Health Conference. *Update on the management of bladder cancer in 2010*
- **Invited Lecturer**, 4th Journee d' onco-urologie of the Association Marocaine 12/18/2010
 d'Urologie, Fes, Morocco
Recent advances in prostate cancer –a controversial common disease
Management of non-invasive bladder cancer
- **Lecturer**, ICUD-EAU International Consultation on Bladder cancer 2011 3/18/2011
Chapter 3: Markers
- **Lecturer**, European Society of Residents in Urology and Young Urologists Office 3/19/2011
 Vienna, AUT
How to make it in Urology
Panel discussion on career challenges in 2011
- **Lecturer**, ESU Course 20 How to write a manuscript and get it published in 3/21/2011
 European Urology, Vienna, AUT
Clinical research original article: how to write the best introduction section
Clinical research original article: how to write the results and discussion sections
Review article: the critical interpretation of the summarized evidence: why is the author's touch of class essential to write the perfect manuscript?
- **Lecturer**, Sub-plenary session 8: ICUD-EAU International Consultation Bladder Cancer 3/21/2011
 Vienna, AUT
Markers of early detection in bladder cancer
Prognostic/predictive markers in bladder cancer
- **Invited Lecturer**, 44. Alpenländische Urologensymposium, Wolkenstein, Bozen, IT 4/1/2011
Integration neuer Biomarker in der Diagnostik und Therapie von Blasenkarzinom
Optimales Management des invasiven Blasenkarzinoms- Wertigkeit der Chirurgie unter Integration der Chemotherapie
- **Panel** – *Management of the small renal mass.* EAU 4th leading light meeting. 4/9/2011
 7-9 April 2011, Lago Maggiore, Italy (4/9/11)
- **Invited Lecturer**, Tumor board at Columbia University College of Physicians 4/19/2011
 and Surgeons, NY, NY, AUT
Upper tract urothelial carcinoma: new data and old news

- **Invited Lecturer**, Association Marocaine d'Urologie Annual Meeting 2011 4/28-29/2011
Skhirat, Morocco
Biomarkers for early detection
Management of T1 high grade urothelial carcinoma of the bladder
Panel discussion on bladder cancer
Ablative therapy for small renal cortical tumors
- **Invited Lecturer**, Interactive Genitourinary Cancer Conference (IGUCC) 4/30/2011
Budapest, Hungary
Interpreting trends in prostate cancer
Panel discussion on prostate cancer biomarkers
- **Course lecturer**, American Urological Association Annual Meeting, Washington, DC, US 5/17/2011
Multidisciplinary management of urothelial carcinoma: stage- and site-specific discussions
upper tract urothelial carcinoma
- **Invited Lecturer**, Societa Italiana di Urologia Oncologica (SIUrO), Naples, Italy 6/23-24/11
Clinical utility of nuclear matrix protein 22 for the management of bladder cancer
Lymphadenectomy for prostate cancer: extended, standard, limited or not at all?
- **Course lecturer**, ESU-Weill Cornell Masterclass in General Urology, Salzburg, AUT 7/11-15/2011
Management of localized prostate cancer
Management of metastatic prostate cancer
Management of penile cancer
Management of upper tract urothelial carcinoma
- **Invited lecturer**, AUA Foundation/Society of Basic Urologic Research Conference 7/16-17/2011
AUA Headquarters, Linthicum, MD, USA
Aging and urothelial carcinoma: an oncogeriatric matter
- **Invited lecturer**, New York Section of the American Urological Association 9/11/2011
109th Annual Meeting, Paris, France
Bladder-sparing approaches to invasive bladder cancer
The role of early cystectomy in muscle invasive bladder cancer
- **Invited lecturer**, 8th Men's health world congress and 4th European men's 10/3-4/2011
health conference, Vienna, AUT
Early androgen deprivation- what is the evidence?
Integration of multidisciplinary care in the management of high-risk prostate cancer
- **Invited lecturer**, Andrologisch-Onkologisches Herbstseminar 10/8/2011
Arbeitskreise für Andrologie und Onkologie, Berufsverband der Österreichischen Urologen
Das Prostatakarzinom: warum bestehen bei einer so häufigen Erkrankung so viele Kontroversen?
- **Invited lecturer**, 5th Global Uro-Oncology Meeting under the auspices of the 10/15-16/2011
World Urological Oncology Federation, Berlin, Germany
Management of invasive bladder cancer in the elderly
- **Course lecturer**, 31st Congress of the Societe Internationale d'Urologie, Berlin, DE 10/19/2011
Updates on upper tract urothelial carcinoma: diagnosis, staging, and management
- **Invited lecturer**, Menopause, Andropause, Anti-aging. 8-10 December, Vienna, AUT 12/ 2011
Das Prostatakarzinom: eine paradoxe Krankheit
- **Invited lecturer**, 5th EAU Leading Lights in Urology Meeting. March 29-30, Madrid, SPA 3/2012
The risks of 5 α -reductase inhibitors for prostate cancer prevention
The role of neoadjuvant and adjuvant treatment in advanced bladder cancer

The future of urologic oncology research

- **Invited Lecturer**, 20th Association Marocaine d’Urologie (AMU) Annual Meeting 4/4-7/2012 and 20th Congres Fra
Traitement intravésical du cancer de vessie: thérapie de première ligne et algorithme de prise en charge
Cancer du rein de petite taille: place de la radiofréquence, de la cryothérapie
- **Invited Lecturer**, Department of Surgery, Maimonides Medical Center, Brooklyn, NY 4/16/2012
Lymphadenectomy for prostate cancer: extended, standard, limited, or not at all
- **Invited Lecturer**, III Simposio Internacional de Cancer Urologico, Sao Paulo, Brazil 4/20-21/2012
Intravesical therapy for T1high grade (T1G3)
Role of urinary and tissue markers in bladder cancer detection and prognosis
Bladder cancer in elderly: what is different?
Prognostic markers in upper tract urothelial carcinoma: what have we learned in the last 5 years
Upper tract urothelial carcinoma: when is conservative therapy indicated and safe?
Case Discussion: Bladder Cancer
Role of ablative therapy
Case Discussion: Kidney Cancer
The biologic and clinical importance of teratoma
Active surveillance: reasonable or risky?
Case Discussion: Prostate Cancer
- **Invited Lecturer**, Department of Urology, Albert Einstein College of Medicine, 5/7/2012
Montefiore Medical Center Center, Bronx, NY, USA
Upper tract urothelial carcinoma: what have we learned in the last 5 years?
- **Invited Lecturer**, Clinical Medicine, Weill Cornell Medical Associates-East Side 5/17/2012
New York, NY, USA
Prostate cancer: a thinking man’s approach
- **Course Director and Lecturer**, American Urological Association Association 5/22/2012
Annual Meeting, Atlanata, GA, USA
0511C: Contemporary Concepts and Controversies in the Diagnosis and Management of Upper Tract Urothelial Carcinoma (UTUC)
- **Invited Lecturer**, Sol and Margaret Berger Department of Urology, Beth Israel Medical 6/14/2012
Center, New York, NY, USA
Management of upper tract urothelial carcinoma
- **Course Director and Lecturer**, EAU/Weill Cornell Seminar in “ESU Master Class 7/9-14/2012
in Urology”, Salzburg, AUA
Non-muscle invasive bladder cancer: diagnosis & overview
Chemotherapy for bladder cancer
Workshop: why & how to publish in European Urology
Workshops: fellows’ case presentations
- **Invited Lecturer**, Australian and New Zealand Urogenital and Prostate Clinical 7/16-17/2012
Trials Group (ANZUP) Annual Scientific Meeting, Sydney, Australia.
State of the art in the diagnosis and treatment of upper tract urothelial carcinoma
Optimal management of bladder cancer- integrating surgery and systemic therapy
Role of surgery in the treatment of high-risk non-metastatic prostate cancer
Genitourinary carcinoma clinical trial concept development
- **Invited Lecturer**, Weill Cornell Medical College & Eli Lilly & Co 11/7/2012

2nd Men's Health Symposium: From Academic Research to New Drug Developments,
Weill Cornell Medical College, New York, NY, USA
Bladder cancer: opportunities for innovation

- **Invited Lecturer**, Fortbildungstagung der Österreichischen Gesellschaft 11/10/2012
für Urologie und Andrologie. 9-10 November 2012. Linz, AUT
Radikale Prostatektomie- state of the art surgery
13 Tipps für eine erfolgreiche Karriere in der urologischen Forschung
- **Invited Lecturer**, Society of Basic Urologic Research Annual Symposium, 11/17/2012
November 15-8, 2012. Miami, FL, USA
Biomolecular predictors of urothelial cancer behavior and treatment outcomes
- **Panelist**, Summit on Upper Tract Urothelial Carcinoma, Society of Urologic 11/ 28/2012
Oncology Annual Meeting, Bethesda, MD, USA
Achieving consensus on clinical risk stratification
Management of localized disease
- **Invited Lecturer**, 19th St Lawrence Urological Group, McGill University 1/25-27, 2013
Health Centre, Montreal, Quebec, Canada
My 15 tips for a successful career in academic urology
How to choose a fellowship – a primer for residents
Concepts and controversies in the management of upper tract urothelial carcinoma
Integration surgery and systemic therapy for invasive bladder cancer
- **Invited Lecturer**, Joint session of the European association of urology (EAU) and 3/15/2013
the Maghreb Union countries. 28th Annual EAU Congress. March 2013, Milan, Italy.
Management of non invasive bladder tumors
- **Invited Lecturer**, Plenary session 2 – Debate: How much surgery for upper tract 3/17/2013
urothelial cancer? 28th Annual EAU Congress. March 2013, Milan, Italy.
Radical nephroureterectomy or partial ureterectomy?
- **Course Director and Lecturer**, 28th Annual EAU Congress. March 2013, Milan, Italy. 3/18/2013
ESU course 31 Current concepts and controversy in the diagnosis and management of upper tract
urothelial carcinoma (UTUC)
Prognostic and predictive factors, pathology
Treatment of localized high risk (invasive) and metastatic cancer
- **Course Lecturer**, 28th Annual EAU Congress. March 2013, Milan, Italy. 3/19/2013
ESU course 20 How to write a manuscript and get it published in European Urology
How to write a clinical research article
- **Invited Lecturer**, National Urology Residents Preceptorship Program (NURPP), 5/5/ 2013
AUA 2013 Annual Meeting, May 4-8, San Diego, CA
Fellowships- a primer for residents
- **Invited Lecturer**, American Society for Men's Health, AUA 2013 Annual Meeting, 5/6/2013
May 4-8, San Diego, CA, USA
Localized Prostate Cancer: Active Surveillance versus Active Treatment?
- **Chair and lecturer**, Association of American-Iranian Urologists (AAIU), 5/6/2013
AUA 2013 Annual Meeting, May 4-8, San Diego, CA, USA
T1 bladder cancer: conservative therapy is the initial way to go
- **Course director and lecturer**, American Urological Association Association 5/7/2013

Annual Meeting 2013, San Diego, CA, USA

051IC: Contemporary Concepts and Controversies in the Diagnosis and Management of Upper Tract Urothelial Carcinoma (UTUC)

- **Invited lecturer**, 6th EAU Leading Lights in Urology Meeting. June 6-8th, Lisbon, Portugal 6/2013
Prostate cancer screening: pro
- **Invited lecturer**, 1st International uroanatomy congress. June 14th, Izmir, Turkey 6/14-15/2013
Anatomic steps of radical cystectomy and extended lymphadenectomy: rationale and video
Surgical approach to anatomic open prostatectomy- tips and tricks
Robotic urologic surgery and anatomy: against
Radiologic and sectional uroanatomy – challenger
- **Invited lecturer**, Open Medical Institute Satellite Symposium, Urothelial Cancer, 7/5/2013
Under the auspices of Weill Cornell Medical College and the American Austrian Foundation in collaboration with Postgraduate medical Education Center, European Health Center, Otwock, Poland
Non-muscle invasive bladder cancer: diagnosis, risk stratification, and management
Integrating surgery and systemic therapy for invasive bladder cancer
Modern management of upper tract urothelial carcinoma
Bladder cancer cases presentations and discussion
- **Course lecturer**, ESU-Weill Cornell Masterclass in General Urology, Salzburg, AUT 7/8-12/2013
Update on management of advanced and metastatic renal cancer
Testicular cancer: treatment stage by stage
- **Invited lecturer**, World Urologic Oncology Federation, Vancouver, Canada 9/8/2013
Variant histology in urothelial carcinoma: clinical impact
- **Invited lecturer**, International Young Urologists' Association, Vancouver, Canada 9/8/2013
Optimal integration of chemotherapy with surgery
- **Invited lecturer**, 33rd Congress of the Societe Internationale d'Urologie, Vancouver, Canada
Why Optimal Endoscopic Management Matters 9/9/2013
IC06: Management of urothelial carcinoma: stage- and site-specific discussions 9/11/2013
Diagnosis and management of upper tract urothelial carcinoma
IC10: Non-Muscle-Invasive Bladder Cancer Diagnosis and Treatment 9/12/2013
Risk-Based Clinical Decision Making in NMIBC
Intravesical Immunotherapy Today
- **Invited lecturer**, 30 Jahrestagung ACO ASSO 2013, St Wolfgang, AUT 10/3-5/2013
Primumresektion beim metastasierten Nierenzellkarzinom: der Standard?
- **Course lecturer**, ESU- Cornell Masterclass in Genitourinary Oncology, Salzburg, AUT 10/7/2013
Penis cancer: diagnosis, staging and treatment
Diagnosis, risk-stratification and management of bladder cancer
- **Invited lecturer**, Jahrestagung der Deutschen, Österreichischen und Schweizerischen 10/21/2013
Gesellschaften fuer Haematologie und Onkologie, Wien, AUT
Therapiestrategien beim Nicht-Urothelialkarzinom
- **Invited lecturer**, 8. Urologisch/Onkologisches Symposium, Interdisziplinäre Behandlung 11/9/2013
von urogenitalen Karzinomen, Barmherzige Brüder Krankenhaus, Wien, AUT
State of the Art der Diagnose und Therapie des nicht-muskelinvasiven Urothelkarzinoms

- **Invited lecturer**, Prag Urologic Society, Prag, CZ 11/14/2013
Optimal integration of surgery and chemotherapy for the management of muscle-invasive bladder cancer
- **Invited lecturer**, Fortbildungstagung der Oesterreichischen Gesellschaft fuer Urologie und Andrologie, Redoutensaele, Linz, AUT 11/16/2013
Konstante PDE-5-Hemmung—Welche Patienten profitieren?
- **Invited lecturer**, Update Blasenkarzinom, Landeskrankenhaus Hall i. Tirol, AUT 11/22/2013
Operative Therapiestrategien des muskelfiltrierenden Blasentumors
- **Invited lecturer**, First Interdisciplinary Prostate Cancer Symposium, Vienna, AUT 11/29/2013
Prostate cancer: a common disease with many faces
- **Invited lecturer**, Pediatric Surgery Postgraduate Seminars, Vienna, AUT 12/4/2013
Neuropathic Bladder, Bladder Reconstruction, Research in Regenerative Urology, and Pediatric Voiding Disorders
Primer for a successful career as a physician-scientist
- **Invited guest**, 12th Meeting of the Association of Academic European Urologists, Paris, FR 12/7/2013
Prediction of cisplatin-resistance in bladder cancer: HOXA- as a novel epigenetic biomarker
- **Invited lecturer**, Dept. of Urology, Universitätsklinikum Aachen, Aachen, DL
Upper tract urothelial carcinoma: from diagnosis to therapy 11/12/2013
How to obtain the best results in the management of muscle-invasive bladder cancer 12/12/2013
- **Invited lecturer**, Fun meeting, Semmelweis Klinik, Budapest, Hungary
T1 High Grade Bladder Cancer: How to Separate The Pussycat from the Tiger 2/21/2014
- **Invited lecturer**, State of the art and horizons in oncology, Medical Univ Vienna, Comprehensive Cancer Center, Vienna, Austria 3/4/2014
Surgical management of bladder cancer
- **Invited lecturer**, 23rd International Symposium of the Endourology and ESWL Section of the Polish Urological Association, Wroclaw, Poland 3/8/2014
Optimal endoscopic management of T1 bladder cancer
Upper tract urothelial carcinoma: role of endoscopy
- **Invited lecturer**, USANZ 67th Annual Scientific Meeting, Brisbane, AUS 3/17-9/2014
Clinical impact of histologic variants urothelial and non-urothelial cancer
Prostate cancer plenary: high-risk
Upper tract tumors: controversies revisited in 2014
Prostate cancer prevention: it is neither possible nor achievable
Prostate cancer and hormone therapy: treating biochemically relapsed prostate cancer
Meet the expert: bladder cancer
- **Invited lecturer**, 2.Fachtagung Prostatakarzinom, Vienna, AUT 3/21/2014
“Darf’s ein bisserl mehr sein”- Chirurgie beim fortgeschrittenen Prostatakarzinom
Interaktive Falldiskussion: Veteranen versus Jungstars
“Wer zuerst kommt...”- Enzalutamide versus Abiraterone
- **Course Director and Lecturer**, 29th Annual EAU Congress, Stockholm, Sweden. 4/13/2014
ESU course 31 Current concepts and controversy in the diagnosis and management of upper tract urothelial carcinoma (UTUC)
Prognostic and predictive factors, pathology

Treatment of localized high risk (invasive) and metastatic cancer

- **Course Lecturer**, 29th Annual EAU Congress, Stockholm, Sweden. 4/14/2014
ESU course 20 How to write a manuscript and get it published in European Urology
How to write a clinical research article
- **Invited lecturer**, 29th Annual EAU Congress, Stockholm, Sweden. 4/11/2014
Joint session of the EAU and the Iranian Urological Association (IUA)
Identifying high risk localized prostate cancer
- **Invited lecturer**, 29th Annual EAU Congress, Stockholm, Sweden 4/11/2014 Joint
session of the EAU and the Maghreb Union Countries
Biomarkers of prostate cancer aggressiveness
Bladder cancer session
Surgical quality indicators of radical cystectomy
- **Invited lecturer**, plenary session, 29th Annual EAU Congress, Stockholm, Sweden 4/13/2014
Diagnosis and treatment of non-muscl invasive bladder cancer
How to improve the outcome of transurethral resection of bladder tumors
- **Invited lecturer**, 29th Annual EAU Congress, Stockholm, Sweden. 4/11/2014
Innovation Approaches in Urological Cancers. Satellite Symposium Ipsen
“Think out of the box”: Target tumor microenvironment to improve prostate cancer management
- **Invited lecturer**, Frühjahrstagung des Berufsverbandes der Österreichischen 2/5/2014
Urologen 2014, Panhans Grand Hotel, NÖ, AUT
Festvortrag: Das Blasenkarzinom: aktuelle Therapieoptionen
- **Invited lecturer**, Wrap-Up EAU 2014, Museumsquartier, Vienna, AUT 9/5/2014
Das Blasenkarzinom
- **Co-chair** of Betmiga™ launch symposim, Sophiensäle, Vienna, AUT 10/5/2014
- **Invited lecture** at 40. Gemeinsame Tagung der Bayerischen Urologenvereinigung 15/5/2014
und der Österreichischen Gesellschaft Für Urologie and Andrologie, Erlangen, DE.
Diagnostik und Therapie des oberen Harntraktumors
- **Chair** at 40. Gemeinsame Tagung der Bayerischen Urologenvereinigung und der 15/5/2014
Österreichischen Gesellschaft Für Urologie and Andrologie, Erlangen, DE.
Kontroversen in der Urologie
- 2nd Challenges in Endourology, Paris, France
Chair of Workshop entitled Clinical Innovations in Endourology 2/6/2014
Chair of Live Surgery Session II: Upper and Lower Tract 3/6/2014
- The British Association of Urological Surgeons Annual Meeting, Liverpool, UK
Invited lecture: Personalised Therapeutic Strategies in Urothelial Cancer 6/23/2014
Course lecture: *How successful authors approach writing a clinical or surgical paper* 6/24/2014
at BJU International Course - *How to Get Published in a Modern Surgical Journal*
Invited lecture: *Contemporary concepts in upper tract urothelial carcinoma* 6/26/2014
- **Invited lectures**, Friends of Israel Urology, Tel Aviv, Israel 7/3/2014
Saturation biopsy of the prostate: con
Prostatic invasion of the urothelial carcinoma
- **Invited lecture**, Uroforum 2014, Barcelona, Spain 7/8/2014
Future of non-muscle invasive bladder cancer management

- **Course lectures**, ESU-Weill Cornell Masterclass in General Urology, Salzburg, AUT 7/10/2014
High risk prostate cancer: surgery or radiotherapy?
Treatment of biochemical progression after local therapy
Castrate resistant prostate cancer
- **Invited lecture**, FinnBladder 30 year Anniversary Meeting, Turku, Finland 9/1/2014
Unmet needs and objectives in bladder cancer care
- **Invited lecture**, 66.Kongress der Deutschen Gesellschaft für Urologie, Düsseldorf, GE 10/4/2014
Blasenkarzinom- was muss ich 2014 wissen?
- **Invited lectures**, 34th Congress of the Societe Internationale d'Urologie, Glasgow, UK
Major observations in upper tract urothelial carcinoma: aristolochia acid 10/12/2014
Oncologic outcomes of organ-sparing surgery for invasive penile cancer 10/13/2014
Disparate twins: biological and clinical differences between bladder and upper tract urothelial carcinoma 10/14/2014
- **Invited lecture**, 18. Österreich Tag-Wieviel Körper braucht der Mensch, Wien 10/16/2014
Wieviel Potenz macht den Mann zum Mann?
- **Invited lecture**, Urocyclicum 2014, St Wolfgang, Salzkammergut, Österreich 10/17/2014
Trends in der Urologie- die Zukunft
- **Invited lecture**, Czech Urological Society Annual Meeting 2014, Brno, Czech Rep 10/23/2014
Trends and novelties in upper tract urothelial carcinoma
- **Invited lecture** – Fortbildungstagung der Österreichischen Gesellschaft für Urologie und Andrologie. 7-8 November 2012, Linz, Austria 11/7/2014
Rauchen- der Einfluss in der Uro-Onkologie
- **Invited lecture** – 6. Symposium Urologische Forschung der Deutschen Gesellschaft für Urologie, Homburg/Saar, Germany 11/14/2014
15 Tips für eine erfolgreiche Karriere as Physician-scientist
- **Invited lecture** – 14th Belgian Association of Urology (BAU) Annual Meeting 12/12/2014
12-13 December 2014 in Spa, Belgium
Upper tract urothelial carcinoma – what are the standards and frontiers in 2014
- **Invited lecture** - Krebstag 2015, Rathaus Wien, Wien, AUT 2/10/2015
Der Prostatakrebs: Erkennen und Behandeln
- **Invited lecture** - 7 Interdisziplinäres Uro-Onkologisches Symposium am 30/1/2015
Universitätsspital Zürich, Zürich, Switzerland
Improving the quality of surgery for upper tract disease – lymphadenectomy, the bladder cuff and postoperative bladder instillations
- **Invited lecture** – SIU lecture at 30th Annual EAU Congress, Madrid, Spain 3/21/2015
Lymphadenectomy for upper tract urothelial carcinoma
- **Course Director and Lecturer**, 30th Annual EAU Congress, Madrid, Spain. 3/22/2015
ESU course 31 Current concepts and controversy in the diagnosis and management of upper tract urothelial carcinoma (UTUC)
Prognostic and predictive factors, pathology
Treatment of localized high risk (invasive) and metastatic cancer
- **Invited lecture** – Association Marocaine d'Urologie annual meeting, Rabat, Maroc 5/8/2015
Tumeurs T1 de haut grade refractaire a la BCG

Place de la biologie moleculaire dans le traitement des tumeurs de vessie
Therapie focales de la prostate

- **Course director and lecturer**, American Urological Association Association 5/19/2015
 Annual Meeting 2015, New Orleans, LA, USA
047IC: Contemporary Concepts and Controversies in the Diagnosis and Management of Upper Tract Urothelial Carcinoma (UTUC)
- **Invited lecturer**, Friends of Urology Austrian Polish inauguration meeting, Vienna, AUT 5/29/2015
Open prostatectomy: tips and tricks, 2015
Education & career
- **Invited lecturer**, LXXX Congreso Nacional de Urología, Salamanca, Spain
Marcadores de tumor urotelial. Limitaciones y aplicabilidad 6/11/2015
Es el tumor Gleason 6 cáncer o no? 6/12/2015
- **Invited lecturer**, 2015 Summer School in Oncology, Bucharest, Rumania 6/17/2015
Prostate cancer- how can such a common disease be so paradox?
Personalized surgery for bladder cancer in 2015
- **Invited lecturer**, Robotische Chirurgie im Landeskrankenhaus Wiener Neustadt 6/19/2015
 Festvortrag: Roboter Chirurgie- Notwendigkeit, Verbesserung, Luxus oder Humbug?
- **Invited lecturer**, 5. Urologischer Workshop der LMU am Tegernesse 6/21/2015
Blasenkarzinom bei der Frau – tatsächlich mit schlechterem Outcome assoziiert?
- **Invited lecturer**, 71. Jahresversammlung der Schweizerische Gesellschaft 9/4/2015
 für Urologie, St Gallen, Switzerland
State of the Art: Urothelkarzinom - Management des oberen Harntraktes
- **Invited lecturer**, 9th Uroforum, University of Barcelona, Barcelona, Spain 9/17/2015
Impact of new molecular classification in the management of muscle-invasive bladder cancer
- **Invited lecturer**, 67. Kongress der Deutschen Gesellschaft für Urologie Hamburg, Germany
Invasives Blasenkarzinom: Risiko- und Prognose-faktoren 9/25/2015
- **Invited lecturer**, Genitourinary Malignancies European Association of Urology (EAU) 9/29/2015
 Session, 18th European Cancer Congress & 40th European Society For Medical Oncology, Vienna, Austrian
Risk stratification of urothelial cancer in the lower and upper urinary tract
- **Invited lecturer**, Urology Robotic Oncology Paris, Paris, France 10/8/2015
Risk-stratification of urothelial carcinomas
- **Invited lecturer**, Going USA Weiterbildung, Fellowship, and Forschung, Wien, Austria 10/22/2015
Karrierewege in den USA
- **Invited lecturer**, 2015 Shanghai GU Oncology International Symposium, Shanghai, China 11/7/2015
Optimal multidisciplinary management of bladder cancer
- **Invited lecturer**, 7th European Multidisciplinary Meeting on Urological Cancers, Barcelona, Spain
Update on clinical trails in urothelial carcinoma 11/14/2015
- **Invited lecturer**, The 67th Annual Meeting of The Korean Urological Association, Seoul, Korea
Lymphadenectomy for upper tract urothelial carcinoma 11/19/2015
Risk stratification of high risk bladder cancer 11/20/2015

- **Invited lecturer**, Winter Meeting of Urology Section of the Royal Society of Medicine, Austria
Gleason 6 prostate lesions: cancer or not? 1/17/2016
UTUC: what have we learned in the last 5 years? 1/18/2016
- **Invited lecturer**, Inaugural International Urothelial Carcinoma Meeting, Vienna, Austria
Key concerns about the current state of bladder cancer 1/29/2016
- **Invited lecturer**, 4th National Bladder and Kidney Cancer Symposium, Melbourne, Australia
State of the art: Current standards and controversies in upper tract urothelial carcinoma 2/11/2016
Improving the quality of surgery for upper tract urothelial carcinoma 2/11/2016
Personalised therapeutic strategies in urothelial cancer 2/12/2016
State of the art lecture: Optimal management of T1G3 urothelial carcinoma 2/12/2016
Clinical impact of variant histology in urothelial carcinoma 2/12/2016
- **Invited lecturer**, Department of Urology, European Center of Medicine Otwock, PL
Upper tract urothelial carcinoma: standards and the future 2/25/2016
Tips for a successful career as surgeon-scientist 2/26/2016
- **Invited lecturer**, Postgraduate course of the Dept. of Urology, University of Istanbul, Istanbul, TK
Radical cystectomy: tips and tricks 2/27/2016
The shifting role of surgery in the management of prostate cancer 2/27/2016
New alternatives in the treatment of CRPC: what should be the optimal order? 2/27/2016
- **Invited lecturer**, 31st Annual EAU Congress, Munich, Germany.
When to perform radical cystectomy in T1HG bladder cancer at Joint Session of the EAU and Maghreb Union Countries 3/11/2016
Diagnosis and follow-up of upper tract urothelial carcinoma at Joint Session of the EAU and Korean Urological Association 3/11/2016
Exploring the limits of kidney sparing treatment of upper tract urothelial carcinoma 3/14/2016
State-of-the-art lecture at Non-muscle-invasive bladder cancer session
- **Course Director and Lecturer**, 31st Annual EAU Congress, Munich, Germany. 3/14/2016
ESU course: Current concepts and controversy in the diagnosis and management of upper tract urothelial carcinoma (UTUC)
Prognostic and predictive factors, pathology
Treatment of localized high risk (invasive) and metastatic cancer
- **Lecturer**, UROS 10 ans: Le cancer de la prostate: de A à Z, Oran, Algerie
Le Gleason 6 cancer est-il vraiment un cancer? 3/24/2016
Stratification des patients: comment choisir nos thérapies 3/24/2016
La surveillance active: qui et comment? 3/25/2016
Cas cliniques et discussions avec collègues algériens 3/25/2016
Traitement du recidive biochimique apres prostatectomy ou radiotherapie primaire 3/26/2016
Place de la chirurgie dans le cancer oligo-metastatique de la prostate 3/26/2016
Définition d'un cancer de la prostate résistant à la castration et traitement disponible 3/26/2016
Comment créer une base de donnée sur le cancer de la prostate 3/26/2016
- **Lecturer and panelist**, Novel Imaging Technique and Image-Guided Focal Therapy in Prostate Cancer, Istanbul, Turkey 4/9/2016
The drawbacks of multiparametric MRI in the diagnosis and treatment of prostate cancer
Multiparametric MRI in prostate cancer – Cases Discussions

- **Lecturer, 2nd Faculty of the Charles University**, Motol Hospital, Prague, CZ 4/20/2016
How to become a successful physician-scientist
- **Lecturer and panelist**, 104th Annual Meeting of the Japanese Urological Association, Sendai, Japan
 - The changing role of surgery in the management of prostate cancer* 4/23/2016
 - Maximizing success for muscle-invasive bladder cancer* 4/24/2016
 - Personalized medicine for bladder cancer in 2016: where are we going?* 4/24/2016
 - Risks and opportunities of kidney-sparing management of UTUC* 4/24/2016
 - Upper tract urothelial carcinoma: lessons learned in the last 10 years* 4/24/2016
- **Course director and lecturer**, American Urological Association Association 5/11/2016
Annual Meeting 2016, San Diego, CA, USA
083IC: Contemporary Concepts and Controversies in the Diagnosis and Management of Upper Tract Urothelial Carcinoma (UTUC)
- **Chair of session and invited lecturer**, Perioperative Medizin Symposium, AKH & MedUni Wien, Wien, AUT
 - High Tech I: Roboterchirurgie* 5/20/2016
 - Eras for major urological surgery: a step forward* 5/20/2016
- **Chair of session and lecturer**, 2nd Friends of Urology Austrian Polish meeting, 5/28-9/2016
Krakow, Poland
Surgery for very high risk prostate cancer
New concepts in the management of metastatic prostate cancer
- **Chair of session and lecturer**, 42. Gemeinsame Tagung der Bayerischen Urologen- 6/2-4/2016
vereinigung und der Österreichischen Gesellschaft für Urologie und Andrologie, Augsburg, DE
Invited Lecturer, *Die Rolle der Biomarker für individuelle Behandlungsstrategie für* 6/2/2016
Patienten mit metastasiertem Prostatakarzinom
Invited Lecturer, *Personalisierte Therapie des Harnblasenkarzinoms* 6/3/2016
Chair of session, *Palliativmedizin* 6/3/2016
Invited Lecturer, *TURB-Machen wir das was wir täglich tun auch wirklich richtig?* 6/3/2016
Invited Lecturer, *TURB: Können wir besser?* 6/3/2016
- **Chair of session and discussant**, 4th Global Congress on Prostate Cancer PROSCA 2016 6/30/2016
Chemotherapy for hormone-naïve metastatic patients: yes or no? Impact on clinical practice
- **Lecturer and live surgery**, Controversies in Urological Surgical Oncology, European Genito-
Urinary Surgeons, Molinette Hospital, Turin, IT
Extended lymphadenectomy live surgery 9/23/2016
Conservative versus radical treatment of upper tract urothelial carcinoma 9/23/2016
- **Lecturer**, EAU 16th Central European Meeting, Vienna, AUT 10/7/2016
Surgical management of prostate cancer in the modern era
- **Lecturer**, 36th Congress of the Societe Internationale d'Urologie, Buenos Aires, Argentina
 - Molecular medicine: shaping the future – bladder cancer* 10/21/2016
 - Follow-up after partial nephrectomy for localized RCC* 10/20/2016
- **Lecturer**, World Urological Oncology Federation Symposium (WUOF),
Innovation in Urology, Buenos Aires, Argentina
Unmet needs in upper tract urothelial carcinoma 10/20/2016
- **Invited lecturer**, Open Medical Institute Satellite Symposium, 12/7/2016
Under the auspices of Weill Cornell Medical College and the American Austrian Foundation in

collaboration with Postgraduate medical Education Center, European Health Center, Otwock, Poland
Penis cancer

Non-muscle invasive bladder cancer: diagnosis, risk stratification, and management

Optimal management of muscle-invasive bladder cancer

Upper tract urothelial carcinoma: what is new!

- **Invited lecturer**, Kantonspital Luzern, Luzern, Switzerland 1/12/2017
What is new and hot in upper tract urothelial carcinoma
- **Invited lecturer**, Young Scientist Association, Wien, Austria 3/16/2017
Wearing two hats: Bridging the gap between basic science and clinical practice
How to become a successful physician researcher
- **Invited lecturer**, 32nd Annual EAU Congress, London, UK. 3/26/2017
Biomarkers for immunotherapy treatment selection 3/25/2017
The future management of bladder cancer
- **Course Director and Lecturer**, 32nd Annual EAU Congress, London, UK. 3/26/2017
ESU course 31 Current concepts and controversy in the diagnosis and management of upper tract urothelial carcinoma (UTUC)
Prognostic and predictive factors, pathology
Treatment of localized high risk (invasive) and metastatic cancer
- **Invited lecturer**, 2nd Medical School, Motol Hospital, Charles University, Prag, CZ 4/15/2017
Residency training and excellence in medicine
Prostate cancer: diagnosis, risk stratification and management
- **Invited lecturer**, Taiwanese Urological Association, Taipei, Taiwan 4/29/2017
Changing role of radical prostatectomy today
Best of EAU 2017: what's hot and new in oncology
How androgen receptor inhibitors are reshaping the prostate cancer landscape
- **Invited lecturer**, UT Southwestern Dallas, Dallas, TX, USA 5/10/2017
Changing role of radical prostatectomy today
Tips for a successful career in medicine
UTUC Collaboration: an adventure that started at UT Southwestern
- **Invited lecturer**, 43 Gemeinsame Tagung der Oesterreichischen Gesellschaft fuer 5/18/2017
Urologie und Andrologie und der Bayerischen Urologenvereinigung, Wien, AUT
Organerhaltende Therapie beim UrothelKarzinom des oberen Harntrakts
- **Invited lecturer**, 24th Annual Meeting of the Slovak Urological Society, 6/8/2017
Trenčianskych Tepliciach, Slovakia
Upper tract urothelial carcinoma: diagnosis to therapy
Changing role of radical prostatectomy
- **Invited lecturer**, Europa Uomo Seminar 360° Perspectives Prostate Cancer, Wien, AUT 6/10/2017
Optimal treatment of high risk prostate cancer
- **Invited lecturer**, Session of the Uro-oncologic Section, Congress of the Polish 6/20/2017
Urological Association, Katowice, PL
Emerging novel therapies in systemic management of advanced bladder cancer
- **Invited lecturer**, University of Rennes, Rennes, FR 6/28/2017
T1 bladder cancer: tools for smart clinical decision making
- **Invited lecturer**, 15th European Urology Residents Education Programme, Prag, Cz 9/1-6/2017

Metastatic testicular cancer

Perioperative chemotherapy and systemic therapy for metastatic urothelial carcinoma

- **Invited lecturer**, Global Congress on Bladder Cancer, Edinburgh, UK 10/5/2017
Clinical aspects of immunotherapy in urothelial carcinoma
- **Invited lecturer**, 17th Congres Tunisien d'Urologie & 6th Congres Maghrebin d'Urologie, Tunis, TU
Prise en charge des T1 de haut grade: ce que je fais 10/13/2017
Surveillance active en cancer de prostate 10/14/2017
Curage etendu: technique, indications 10/14/2017
Prostatectomie de cyto-reduction dans les forms metastatiques 10/14/2017
- **Invited lecturer** at the EAU 17th Central European Meeting in conjunction with the national 63rd conference of the Czech Urological Society, Plzen, Czech Republic 10/19/2017
Tips for a successful career in research
- **Invited lecturer** at the Innere Medizin Compact 2017 of the Austrian Society of Internal Medicine (OGIM), Vienna, AUT 10/23/2017
Prostatakrebs im Überblick
- **Invited lecturer** at the Bleib gesund Mann! Event from the Medical University of Vienna, Vienna, AUT 11/4/2017
Prostatakrebs heute
- **Invited lecturer**, Sociedad Chilena de Urologia, Pucon, Chile
The changing role of surgery in prostate cancer 11/23/2017
Harnessing heterogeneity in advanced prostate cancer 11/23/2017
A roadmap to management of T1 high grade bladder cancer 11/24/2017
Round table on the management of prostate cancer: case presentations 11/24/2017
Upper tract urothelial carcinoma: an update 11/25/2017
The future of non-muscle invasive bladder cancer 11/25/2017
- **Invited lecturer** at the Selbsthilfegruppe Prostatakarzinom Austria, Vienna, AUT 12/5/2017
Prostatakrebs in 2017: was war neu?
- **Invited lecturer** at the 1st ESU/ESOU Masterclass on Non-Muscle Invasive Bladder Cancer, Prag, CZ
The future of NMIBC management 2/1/2018
Definition of GCG failure and treatment options 2/2/2018
Case presentations 2/2/2018
- **Invited lecturer**, 32nd Annual European Urologic Association Annual Congress, Copenhagen, DK. 3/19/2018
Can we rely on urinary markers?
- **Course director and lecturer**, 32nd Annual EAU Congress, Copenhagen, DE 3/26/2018
ESU course 25 New perspectives in the management of upper tract urothelial carcinoma (UTUC)
Prognostic and predictive factors, pathology

Treatment of localized high risk (invasive) and metastatic cancer

- **Invited lecturer**, Motol Hospital, Charles University, Prag, CZ 4/5-6/2018
Prostate cancer: all you need to know
Primer for a career in academia
- **Invited lecturer and panelist**, Curso de urologia - cancer de prostate, Madrid, Spain 4/26/2018
Por que hago linfadenectomia de rescate?
Tratamiento del paciente metastatico: casos clinicos
- **Invited lecturer**, American Urological Association Annual Meeting, San Francisco, CA 5/20/2018.
Statistical considerations for clinical utility of a bladder cancer biomarker
- **Course lecturer**, American Urological Association Annual Meeting, San Francisco, CA 5/20/2018.
053IC - Upper Tract Urothelial Carcinoma Tumor Board: A Case-Based Approach to Management
- **Invited lecturer**, 2 Interdisziplinäres Polytraumasymposium, Vienna, AUT 5/25/2018.
Verletzungen des Urogenitalsystems
- **Course lecturer**, EAU Update on Bladder Cancer, Munich, GE 6/9/2018
Histological variants in bladder cancer: how to deal with them? 3 x rotating course
- **Invited lecturer**, Fortbildungstag Schweizerische Gesellschaft für Urologie, Bern, SUI 6/14/2018.
Endourologische Behandlung der Urothelkarzinome des oberen Harntraktes
- **Course lecturer**, Updates on Onco-urology, Paris, FR
Decision-making for T1 bladder cancer 6/29/2018
Role for urinary marker and perspectives 6/29/2018
A role for PDL1-PD1 therapy in NMIBC 6/29/2018
Chemotherapy for metastatic urothelial carcinoma 6/30/2018
Clinical case discussions: urothelial carcinoma 6/30/2018
- **Course lecturer** 2018 Salzburg ESU/ Weill Cornell Master Class in Urology, Salzburg, AUT
Diagnosis and Pathology in NMIBC: What is the standard and what has to be changed? 7/3/2018
NMIBC Bladder Cancer: What is a TURBT in 2018? 7/3/2018
Immunotherapy in Metastatic Bladder Cancer: Is it really so good? 7/5/2018
Treatment of Invasive and Metastatic UTUC 7/5/2018
- **Invited lecturer**, Erster wissenschaftlicher Kongress der Österreichisch-Iranischen Ärzte, Wien, AUT 7/14/2018
Prostate cancer: current evidence and controversies
- **Invited lecturer**, 16th European Urology Residents Education Programme, Prag, Cz 8/31-9/5/2018
Metastatic testicular cancer
Perioperative chemotherapy and systemic therapy for metastatic urothelial carcinoma
Non-muscle invasive bladder cancer
- **Invited Lecturer**, 70ter Kongress der Deutschen Gesellschaft fuer Urologie, Dresden, GE
Role of molecular staging in the management of cT2c bladder urothelial carcinoma 9/27/2018
Die adäquate bildgebende Diagnostik fuer das Urothelkarzinom des oberen Harntraktes? 9/28/2018
- **Invited lecturer**, 18th Central European Meeting of the EAU, Cluj Napoca, Romania 10/12/2018
Genetic testing in prostate cancer

- **Invited lecturer**, 55th Urology Course of the Fundacio Puigvert,
Barcelona, Spain 10/17/2018
Quality criteria for radical nephroureterectomy
- **Invited lecturer**, European Society of Medical Oncology, Munich, DE 10/19/2018
Discussion of Keynote 057 -Efficacy of pembrolizumab in Bacillus Calmette Geurin–unresponsive bladder cancer with high risk for disease progression.
- **Invited lecturer** at the Innere Medizin Compact 2018 of the Austrian
Society of Internal Medicine (ÖGIM), Vienna, AUT 10/22/2018
Blasenkrebs im Überblick
- **Invited chair**, Nightmare session at the European Multidisciplinary
Congress on 11/10/2018
Urological Cancers, Amsterdam, NL
- **Invited lecturer**, 1. Onkologisch-Laparoskopischen und Roboterchirurgischen Herbstsymposium,
ÖGU Arbeitskreise, Stift Goettweig in Furth, Austria I
Keynote lecture: Genetik bei Prostatakrebs 11/23/2018
Kritisches Denken in der Medizin und darüber hinaus 11/23/2018
- **Invited lecturer**, 2nd ESU/ESOU Masterclass on Non-Muscle Invasive Bladder Cancer, Prag, CZ I
The future of NMIBC management 2/22/2019
Definition of BCG failure and treatment options 2/22/2019
Moderator of live surgery 2/22/2019
Case presentations 2/21/2019
- **Invited lecturer**, 33rd Annual European Urologic Association Annual Congress, Barcelona, SP I
European perspective on the management of pT1 high grade bladder tumors 3/15/2019
EAU Young Urologists Office (YUO) & European Society of Residents in Urology (ESRU)
What you need to know about the POUT trial for upper tract urothelial carcinoma 3/16/2019
Guidelines debate: perioperative chemotherapy will become the new standard 3/16/2019
Thematic Session 7: how much do you know about modern imaging 3/17/2019
- **Course director and lecturer**, 33rd Annual European Urologic Association, 3/17/2019
Annual Congress, Barcelona, SP
ESU course 25 New perspectives in the management of upper tract urothelial carcinoma (UTUC)
Prognostic and predictive factors, pathology
Treatment of localized high risk (invasive) and metastatic cancer
- **Invited lecturer** at the Institute for Urology and Reproductive Health
I.M. Sechenov, First Moscow State Medical University, Moscow, Russia
Novel standards in the management of prostate cancer 4/26/2019
- **Invited lecturer** at Central European Meeting of the European Association of Urology, Vienna, AUT
How to write a paper course x3 rotating course 5/9/2019
How to become a successful physician researcher 5/10/2019
- **Invited lecturer and chair**, Blasengesundheitstage Meine Blase und Ich, Netdoktor 5/17/2019
Therapiestrategien beim Blasenkarzinom: status quo und die Zukunft
- **Invited lecturer**, EAU Update on Bladder Cancer, Torino, IT 5/18/2019

Histological variants in bladder cancer in bladder cancer: how to deal with them? 3 x rotating course
Emerging role of immunotherapy in neoadjuvant and adjuvant setting

- **Invited lecturer**, ESU course at the 6th Baltic Meeting with the EAU, Tallinn, Estonia 5/24/2019
Prognostic and predictive factors, pathology
Treatment of localized high risk (invasive) and metastatic cancer
- **Invited lecturer**, Österreichische Gesellschaft für Orthopädie und Traumatologie (ÖGOuT), 6/5/2019
Urogenital Verletzungen bei Polytraumatisierten Patienten
- **Invited Skype lecturer**, 22nd Annual Meeting of the Iranian urological Association (IUA) 6/13/2019
T1 bladder cancer: a mysterious malignancy
- **Invited lecturer**, 17th European Urology Residents Education Programme, Prag, Cz 9/5-9/11/2019
Metastatic testicular cancer
Perioperative chemotherapy and systemic therapy for metastatic urothelial carcinoma
Non-muscle invasive bladder cancer
Upper tract urothelial carcinoma
- **Invited lecturer** at the Institute for Urology and Reproductive Health I.M. Sechenov, 18/9/2019
 First Moscow State Medical University, Moscow, Russia
Systemic therapy in the management of urothelial carcinoma
- **Invited lecturer** at Russian Urological Association, Rostov o Don, Russia 18/9/2019
T1 bladder cancer: how to differentiate the tiger from the pussycat
Emerging standards in the management of upper tract urothelial carcinoma
- **Invited lecturer**, ESMO Clinical Practice Guidelines, European Society of Medical Oncology, Barcelona, Spain 29/9/2019
Urothelial cancer: Bladder-preserving strategies followed by systemic relapse (ID 6211)
- **Invited lecturer**, 11th International Conference of the Jordanian Association of Urological Surgeons, Amman, Jordan 10/5/2019
Immunotherapy for bladder cancer
- **Invited lecturer**, King Hussein Cancer Center, Amman, Jordan 10/8/2019
Immunotherapy for GU Cancers
- **Invited lecturer**, The Congress of the University of Medicine and Pharmacy Carol Davila Bucharest 10/10/2019
The UTUC Collaboration: A Roadmap for an International Success Story
- **Invited lecturer**, Hungarian Urological Society, Eger, Hungary 10/13/2019
Tips for a successful career as physician-scientist
- **Invited chair**, International session, Austrian Urological Society, Linz, Austria 11/10/2019
- **Invited lecturer**, Young academic urologists autumn meeting, Vienna, AUT 11/14/2019
Establishing a professional career at a European level: motivation talk
- **Invited discussant**, EMUC 2019, Vienna, AUT 11/15/2019
Challenge the expert- response after neoadjuvant chemotherapy, histologic variant, upper tract

recurrence after cystectomy

- **Invited lecture and chair**, EAU Section of Oncological Urology 2020, Dublin, IE 18/1/2020
Urothelial cancer II
Perioperative systemic treatment in upper tract tumor
ESU ESOU session on immunotherapy for the treatment of urological cancers
Immunotherapy for non-muscle invasive bladder cancer
Game of thrones: Battle of nations
- **Invited lecture and chair**, International Conference “New Technologies in Urology: Pro et Contra”, Moscow, RU 2/7/2020
Quality criteria for a perfect TURBT
Robotic assisted radical cystectomy progress or gimmick?
New technologies in RCC management
- **Invited webinar lecture**, Association Marocaine d’Onco-Urologie 6/19/2020
Prise en charge de l’échec du BCG dans les tumeurs non invasives de la vessie
- **Invited webinar lecture**, European School of Urology/Weill Cornell Medical Center OMInar in Urology 7/9/2020
Bladder cancer
- **Invited lecture and chair at virtual congress**, 34th Annual EAU congress 18/7/2020
Pro – radical cystectomy for high risk non-muscle invasive bladder cancer
Medscape-live: treatment landscape for BCG unresponsive
Sequencing for urothelial carcinoma
- **Invited webinar lecture**, European School of Urology/Weill Cornell Medical Center OMInar in Urology 7/9/2020
Bladder cancer
- **Invited webinar lecture**, Algerian Urological Association 17/9/2020
Cancer de la prostate métastatique hormone-sensible
Cancer de la prostate métastatique résistant à la castration
Rôle de la thérapie locale dans le cancer métastatique
- **Invited webinar lecture**, Grand rounds at Division of Urology, University of Colorado, Denver, CO 10/2/2020
Modern Management of Upper Tract Urothelial Carcinoma
- **Invited webinar lecture**, EAU Urowebinar, 10/13/2020
BCG unresponsive non muscle invasive bladder cancer
- **Invited webinar lecture**, Semmelweis 250 online clinical conference, HU 11/10/2020
Tips for a successful career as a physician researcher
- **Invited webinar lecture**, Sechenov University, Moscow, RU 11/12/2020
Role local therapy for hormone sensitive metastatic prostate cancer
- **Invited webinar lecture**, Dialog 2020 Prostatakarzinom, Wien, AUT 11/13/2020
Lokale Therapie fuer metastatisches Prostatakarzinom
- **Invited webinar lecture**, European Multidisciplinary Urologic Congress 11/14/2020
Kidney Sparing in upper tract urothelial carcinoma
- **Invited webinar lecture**, Innere Medizin Compact Urogenitalsystem 11/16/2020

Prostatokarzinom

- **Invited webinar lecture**, EAU Section of Oncological Urology 2021
Open versus robotic radical nephroureterectomy 1/30/2021
- **Invited webinar lecturer**, ESU/ESOU Masterclass on Non-Muscle Invasive Bladder Cancer
The future of NMIBC management 2/5/2021
- **Invited webinar lecturer**, Joint Academic Meetings from Cambridge Urology Hospitals, University of Cambridge
Introducing Medical University of Vienna 2/11/2021
Quality indicators for UTUC care 2/11/2021
- **Invited webinar lecturer**, Phillipines Urological Association
Surgical management of prostate cancer: challenges and progress 4/22/2021
- **Invited webinar lecturer**, Trio meeting of the Comprehensive Cancer Center of the Medical University Vienna
Tip for becoming a surgeon scientist 4/16/2021
- **Invited webinar lecturer**, Iranian Urological Association Annual Meeting, Virtual.
Quality indicators for the management of upper tract urothelial carcinoma 5/21/2021
Therapeutic options for BCG unresponsive non muscle invasive bladder cancer 5/21/2021
- **Invited webinar lecturer**, North African Webinar from the Association Marocaine d'Urologie, Association Algerienne d'Urologie and Association Tunisienne d'Urologie, Virtual
Quand et comment faire un traitement local pour le cancer de la prostate metastatique 5/21/2021
- **Invited webinar lecturer**, SPIEF 2021 Medical Science. How To Expedite Introduction Into Practical Healthcare, St Petersburg, RU
How can we get more health care workers involved in science 5/21/2021
- **Invited lecture and chair at virtual congress**, 35th Annual EAU congress
Chair: Steering through new treatment landscapes for patients with locally advanced or metastatic urothelial carcinoma 10/7/2021
Lecture: Looking to the horizon: Treatment goals and requirements in LA/mUC 7/10/2021
Chair: Current concepts & controversy in the diagnosis & management of UTUC 7/11/2021
Accurate risk stratification and pathology 7/11/2021
Treatment of metastatic disease 7/11/2021
UTUC: molecular characterisation and modern management; Poster Session 27 7/11/2021
Active surveillance is the best choice, patients can enjoy life before treatment! 7/12/2021
- **Invited lecture**, ESTPU TEACHING, NHS FIFE, UK- online
UTUC: Quality indicators in 2021 9/17/2021
- **Invited lecture**, Algerian community of endourology & lap surgery (ACELAS)- online
Genetic of prostate cancer 9/29/2021
- **Invited lecture**, Interdisciplinary TUMOR Tage, Wien, AUT
Management of locally advanced and metastatic urothelial carcinoma in 2021/2022 10/15/2021
- **Invited lecture**, Turkish Society of Urology - 30th National Urology Congress- online
BCG unresponsive: diagnosis and management 10/20/2021
- **Invited lecture**, 7th Croatian Urology Congress, Pula, Croatia
Changing role of surgery in prostate cancer 10/22/2021

- **Invited lecture, CHUK** Urology Symposium, Hong Kong, China-online
Early cystectomy in high-risk NMIBC: is it justified? 10/30/2021
- **Invited chair**, International session, Austrian Urological Society, Linz, Austria 11/9/2021
- **Invited lecturer**, 15.CCIV Symposium, Vienna, Austria 11/14/2021
Value base health care als Loesungsansatz; Sicht eines Klinikers
- **Invited lecturer**, 18th Symposium Urology Arena, Controversies in urothelial cancer 12/3/2021
What is the standard and what is new in therapy of metastatic urothelial carcinoma
- **Invited lecturer**, Slovak urological society oncurological symposium 11/17/2021
Perioperative systemic therapy: what is new
- **Invited lecturer**, Algerian Urological Association Annual meeting 12/3/2021
Cystectomie precoce: qui et quand?
- **Invited lecturer**, 7th M.J.Marberger Virtual Meeting: Frontiers in Urology, Vienna, AUT 12/10/2021
Neo-adjuvant and adjuvant systemic therapy for muscle invasive bladder cancer
- **Invited lecturer**, Tabriz University of Medical Sciences, Tabriz Iran 12/14/2021
Tips how to become a successful physician-scientist
- **Invited lecturer**, Philadelphia University, Philadelphia, Pennsylvania 2/17/2022
Quality indicators in UTUC

PEER-REVIEWED PUBLICATIONS

1. Würnschimmel C, Wenzel M, Chierigo F, Flammia RS, Horlemann B, Tian Z, Saad F, Briganti A, **Shariat SF**, Gallucci M, Suardi N, Chun FKH, Tilki D, Graefen M, Karakiewicz PI. Radiation therapy after radical prostatectomy is associated with higher other-cause mortality. *Cancer Causes Control*. 2022 Mar 1. PMID: 35230576
2. Chierigo F, Borghesi M, Würnschimmel C, Flammia RS, Horlemann B, Sorce G, Hoeh B, Tian Z, Saad F, Graefen M, Gallucci M, Briganti A, Montorsi F, Chun FKH, **Shariat SF**, Mantica G, Suardi N, Terrone C, Karakiewicz PI. Survival after radical prostatectomy versus radiation therapy in clinical node-positive prostate cancer. *Prostate*. 2022 Feb 28. PMID: 35226380
3. Würnschimmel C, Chandrasekar T, Hahn L, Esen T, **Shariat SF**, Tilki D. MRI as a screening tool for prostate cancer: current evidence and future challenges. *World J Urol*. 2022 Feb 28. PMID: 35226140
4. Lonati C, Afferi L, Mari A, Minervini A, Krajewski W, Borghesi M, Schulz GB, Rink M, Montorsi F, Briganti A, Colombo R, Martini A, Necchi A, Contieri R, Hurle R, Umari P, Zamboni S, Simeone C, Soria F, Marra G, Gontero P, Teoh JY, Klatte T, Bajaj AS, Roumiguié M, Rouprêt M, Masson-Lecomte A, Laukhtina E, Valiquette AS, Mir MC, Antonelli A, Einerhand SMH, Hendricksen K, Carando R, Fankhauser CD, Baumeister P, Mattei A, **Shariat SF**, Moschini M; European Association of Urology—Young Academic Urologists (EAU-YAU): Urothelial Carcinoma Working Group. Immediate radical cystectomy versus BCG immunotherapy for T1 high-grade non-muscle-invasive

- squamous bladder cancer: an international multi-centre collaboration. *World J Urol.* 2022 Feb 26. PMID: 35218372
5. Cimagli A, Lonati C, Di Trapani E, De Cobelli O, Rink M, Zamboni S, Simeone C, Soria F, Briganti A, Montorsi F, Afferi L, Mattei A, Carando R, Ornaghi PI, Tafuri A, Antonelli A, Karnes RJ, Colomer A, Sanchez-Salas R, Contieri R, Hurle R, Poyet C, Simone G, D'Andrea D, **Shariat SF**, Galfano A, Umari P, Francavilla S, Roumiguie M, Terrone C, Hendricksen K, Krajewski W, Buisan O, Laukhtina E, Xylinas E, Alvarez-Maestro M, Rouprêt M, Montironi R, Moschini M; European Association of Urology - Young Academic Urologists (EAU-YAU): Urothelial Carcinoma Working Group. Variant histologies in bladder cancer: Does the centre have an impact in detection accuracy? *Urol Oncol.* 2022 Feb 22:S1078-1439(22)00026-6. PMID: 35216892
6. Califano G, Ouzaid I, Laine-Caroff P, Peyrottes A, Collà Ruvolo C, Pradère B, Elalouf V, Misrai V, Hermieu JF, **Shariat SF**, Xylinas E. Current Advances in Immune Checkpoint Inhibition and Clinical Genomics in Upper Tract Urothelial Carcinoma: State of the Art. *Curr Oncol.* 2022 Jan 29;29(2):687-697. PMID: 35200559
7. Hoeh B, Flammia RS, Hohenhorst L, Sorce G, Chierigo F, Tian Z, Saad F, Gallucci M, Briganti A, Terrone C, **Shariat SF**, Graefen M, Tilki D, Kluth LA, Mandel P, Becker A, Chun FKH, Karakiewicz PI. Non-organ confined stage and upgrading rates in exclusive PSA high-risk prostate cancer patients. *Prostate.* 2022 Feb 21. PMID: 35188982
8. Hoeh B, Würnschimmel C, Flammia RS, Horlemann B, Sorce G, Chierigo F, Tian Z, Saad F, Graefen M, Gallucci M, Briganti A, Terrone C, **Shariat SF**, Tilki D, Kluth LA, Mandel P, Chun FKH, Karakiewicz PI. Effect of chemotherapy in metastatic prostate cancer according to race/ethnicity groups. *Prostate.* 2022 Feb 21..PMID: 35188981
9. Würnschimmel C, Nocera L, Wenzel M, Ruvolo CC, Tian Z, Saad F, Briganti A, **Shariat SF**, Mirone V, Chun FKH, Tilki D, Graefen M, Karakiewicz PI. J Race/Ethnicity may be an Important Predictor of Life Expectancy in Localized Prostate Cancer Patients: Novel Analyses Using Social Security Administration Life Tables. *Racial Ethn Health Disparities.* 2022 Feb 18. PMID: 35182370
10. Vartolomei L, Cotruş A, Tătaru SO, Vartolomei MD, Man A, Ferro M, Stanciu C, Sin AI, **Shariat SF**. Lower urinary tract symptoms are associated with clinically relevant depression, anxiety, and stress symptoms. *Aging Male.* 2022 Dec;25(1):62-66. PMID: 35179090
11. Afferi L, Lonati C, Montorsi F, Briganti A, Necchi A, Mari A, Minervini A, Campi R, di Trapani E, de Cobelli O, Karnes RJ, Ahmed M, Mir MC, Algarra MA, Rink M, Zamboni S, Simeone C, Krajewski W, Xylinas E, Soria F, Hendricksen K, Einerhand S, Mattei A, Carando R, Roumiguie M, Bajeot AS, Black PC, **Shariat SF**, Moschini M; European Association of Urology-Young Academic Urologists (EAU-YAU), Urothelial carcinoma working group. Carboplatin-based adjuvant chemotherapy versus observation after radical cystectomy in patients with pN1-3 urothelial bladder cancer. *World J Urol.* 2022 Feb 10. PMID: 35142865
12. Katayama S, Mori K, Pradere B, Mostafaei H, Schuettfort VM, Quhal F, Motlagh RS, Laukhtina E, Grossmann NC, Rajwa P, Aydh A, König F, Mathieu R, Nyirady P, Karakiewicz PI, Nasu Y, **Shariat SF**. Comparison of short-term and long-term neoadjuvant hormone therapy prior to radical prostatectomy: a systematic review and meta-analysis. *Scand J Urol.* 2022 Feb 10;1-9.PMID: 35142251
13. Grossmann NC, Pradere B, D'Andrea D, Schuettfort VM, Mori K, Rajwa P, Quhal F, Laukhtina E, Katayama S, Fankhauser CD, Xylinas E, Margulis V, Moschini M, Abufaraj M, Bandini M, Lonati

- C, Nyirady P, Karakiewicz PI, Fajkovic H, **Shariat SF**. Neoadjuvant Chemotherapy in Elderly Patients With Upper Tract Urothelial Cancer: Oncologic Outcomes From a Multicenter Study. Clin Genitourin Cancer. 2022 Jan 11: PMID: 35125303
14. Enikeev D, Taratkin M, Morozov A, Petov V, Korolev D, Shpikina A, Spivak L, Kharlamova S, Shchedrina I, Mestnikov O, Fiev D, Ganzha T, Geladze M, Mambetova A, Kogan E, Zharkov N, Demyashkin G, **Shariat SF**, Glybochko P. Prospective two-arm study of testicular function in patients with COVID-19. Andrology. 2022 Feb 6. PMID: 35124885
15. Martini A, Lonati C, Montorsi F, Briganti A, Colombo R, Necchi A, Simeone C, Zamboni S, Afferi L, Mattei A, Carando R, Ploussard G, Soria F, Marra G, Rouprêt M, Xylinas E, Pradere B, Abufaraj M, D'Andrea D, **Shariat SF**, Moschini M. The Role of Prior Bladder Cancer on Recurrence in Patients Treated with Radical Nephroureterectomy. Clin Genitourin Cancer. 2021 Dec 11: PMID: 35105509
16. Sorce G, Flammia RS, Hoeh B, Chierigo F, Horlemann B, Würmschimmel C, Tian Z, Graefen M, Terrone C, Gallucci M, Chun FKH, Saad F, **Shariat SF**, Montorsi F, Briganti A, Karakiewicz PI. Plasmacytoid variant urothelial carcinoma of the bladder: effect of radical cystectomy and chemotherapy in non-metastatic and metastatic patients. World J Urol. 2022 Jan 27. PMID: 35084543
17. Aydh A, Motlagh RS, Alshyarba M, Mori K, Katayama S, Grossmann N, Rajwa P, Mostafai H, Laukhtina E, Pradere B, Quhal F, König F, Nyirady P, Karakiewicz PI, Haydter M, **Shariat SF**. Association of statins use and mortality outcomes in prostate cancer patients who received androgen deprivation therapy: a systematic review and meta-analysis. Cent European J Urol. 2021;74(4):484-490. PMID: 35083066
18. Brönimann S, Talhammer F, Springer A, Tonnhofer U, **Shariat SF**, D'Andrea D. Ischemic priapism in a 12-year old patient associated with coronavirus disease 2019 (COVID-19): a case report. Urology. 2022 Jan 23: PMID: 35081397
19. Yanagisawa T, Mori K, Motlagh RS, Kawada T, Mostafaei H, Quhal F, Laukhtina E, Rajwa P, Aydh A, König F, Pallauf M, Pradere B, D'Andrea D, Compérat E, Miki J, Kimura T, Egawa S, **Shariat SF**. En bloc Resection for Bladder Tumors: An Updated Systematic Review and Meta-Analysis of Its Differential Effect on Its Safety, Recurrence, and Histopathology. J Urol. 2022 PMID: 35060770
20. Arnoldner MA, Polanec SH, Lazar M, Kadhjavi S, Clauser P, Pötsch N, Schwarz-Nemec U, Korn S, Hübner N, **Shariat SF**, Helbich TH, Baltzer PAT. Rectal preparation significantly improves prostate imaging quality: Assessment of the PI-QUAL score with visual grading characteristics. Eur J Radiol. 2022. PMID: 35007983
21. Katayama S, Schuettfort VM, Pradere B, Mori K, Mostafaei H, Quhal F, Sari Motlagh R, Laukhtina E, Grossmann NC, Aydh A, Rajwa P, König F, Karakiewicz PI, Haydter M, Moschini M, Abufaraj M, Lotan Y, Lee RK, Trinh QD, Compérat E, Teoh J, Nasu Y, **Shariat SF**. Prognostic value of hepatocyte growth factor for muscle-invasive bladder cancer. J Cancer Res Clin Oncol. 2022 Jan 8. PMID: 34997350
22. Laukhtina E, Quhal F, Mori K, Sari Motlagh R, Rajwa P, Yanagisawa T, Mostafaei H, König F, Aydh A, Pradere B, Enikeev D, Karakiewicz PI, Schmidinger M, **Shariat SF**. Pembrolizumab outperforms tyrosine kinase inhibitors as adjuvant treatment in patients with high-risk renal cell carcinoma after nephrectomy. Eur Urol Oncol. 2022 Jan 3:S2588-9311(21)00223-6. PMID: 34992006

23. Dillinger T, Sheibani-Tezerji R, Pulverer W, Stelzer I, Hassler MR, Scheibelreiter J, Pérez Malla CU, Kuroll M, Domazet S, Redl E, Ely S, Brezina S, Tiefenbacher A, Rebhan K, Hübner N, Grubmüller B, Mitterhauser M, Hacker M, Weinhaeusel A, Simon J, Zeitlinger M, Gsur A, Kramer G, **Shariat SF**, Kenner L, Egger G. Identification of tumor tissue-derived DNA methylation biomarkers for the detection and therapy response evaluation of metastatic castration resistant prostate cancer in liquid biopsies. *Mol Cancer*. 2022 Jan 3;21(1):7 .PMID: 34980142
24. Katayama S, Mori K, Pradere B, Yanagisawa T, Mostafaei H, Quhal F, Motlagh RS, Laukhtina E, Grossmann NC, Rajwa P, Aydh A, König F, Karakiewicz PI, Araki M, Nasu Y, **Shariat SF**. Influence of steep Trendelenburg position on postoperative complications: a systematic review and meta-analysis. *J Robot Surg*. 2021 Dec 31. PMID: 34972981
25. Keresztes D, Csizmarik A, Nagy N, Módos O, Fazekas T, Bracht T, Sitek B, Witzke K, Pühr M, Sevcenco S, Kramer G, **Shariat S**, Küronya Z, Takács L, Tornyi I, Lázár J, Hadaschik B, Lászik A, Szűcs M, Nyirády P, Szarvas T. Comparative proteome analysis identified CD44 as a possible serum marker for docetaxel resistance in castration-resistant prostate cancer. *J Cell Mol Med*. 2021 Dec 30. PMID: 34970839
26. Enikeev D, Babjuk M, Shpikina A, **Shariat S**, Glybochko P. En bloc resection for nonmuscle-invasive bladder cancer: selecting a proper laser. *Curr Opin Urol*. 2021 Dec 24. PMID: 34954702
27. Mostafaei H, Jilch S, Carlin GL, Mori K, Quhal F, Pradere B, Laukhtina E, Schuettfort VM, Aydh A, Sari Motlagh R, Roehrborn CG, **Shariat SF**, Hajebrami S. The placebo and nocebo effects in functional urology. *Nat Rev Urol*. 2021 Dec 23. PMID: 34949831
28. Kosiba M, Stolzenbach LF, Collà Ruvolo C, Nocera L, Mansour M, Tian Z, Roos FC, Becker A, Kluth LA, Tilki D, **Shariat SF**, Saad F, Chun FKH, Karakiewicz PI. Contemporary Trends and Efficacy of Pelvic Lymph Node Dissection at Radical Cystectomy for Urothelial and Variant Histology Carcinoma of the Urinary Bladder. *Clin Genitourin Cancer*. 2021.PMID: 34906434
29. Mertens LS, Claps F, Mayr R, Bostrom PJ, **Shariat SF**, Zwarthoff EC, Boormans JL, Abas C, van Leenders GJLH, Götz S, Hippe K, Bertz S, Neuzillet Y, Sanders J, Broeks A, Peters D, van der Heijden MS, Jewett MAS, Stöhr R, Zlotta AR, Eckstein M, Soorojebally Y, van der Schoot DKE, Wullich B, Burger M, Otto W, Radvanyi F, Sirab N, Pouessel D, van der Kwast TH, Hartmann A, Lotan Y, Allory Y, Zuiverloon TCM, van Rhijn BWG. Prognostic markers in invasive bladder cancer: FGFR3 mutation status versus P53 and KI-67 expression: a multi-center, multi-laboratory analysis in 1058 radical cystectomy patients. *Urol Oncol*. 2021.PMID: 34906411
30. Laukhtina E, Sari Motlagh R, Mori K, Katayama S, Rajwa P, Yanagisawa T, Quhal F, Mostafaei H, Grossmann NC, König F, Aydh A, Pradere B, Resch I, Merseburger AS, Enikeev D, **Shariat SF**. Chemotherapy is superior to checkpoint inhibitors after radical surgery for urothelial carcinoma: a systematic review and network meta-analysis of oncologic and toxicity outcomes. *Crit Rev Oncol Hematol*. 2021 PMID: 34902554 Review.
31. Lonati C, Necchi A, Gómez Rivas J, Afferi L, Laukhtina E, Martini A, Ventimiglia E, Colombo R, Gandaglia G, Salonia A, Briganti A, Montorsi F, Mattei A, Simeone C, Carlo MI, **Shariat SF**, Spiess PE, Moschini M; European Association of Urology Young Academic Urologists EAU-YAU: Urothelial Carcinoma Working Group, the Global Society of Rare Genitourinary Tumors GSRGT. Upper Tract Urothelial Carcinoma in the Lynch Syndrome Tumour Spectrum: A Comprehensive Overview from the European Association of Urology - Young Academic Urologists and the Global Society of Rare Genitourinary Tumors. *Eur Urol Oncol*. 2021.PMID: 34896051 Review.
32. Zhao H, Chan VW, Castellani D, Chan EO, Ong WLK, Peng Q, Moschini M, Krajewski W, Pradere B, Ng CF, Enikeev D, Vasdev N, Ekin G, Sousa A, Leon J, Guerrero-Ramos F, Tan WS,

- Kelly J, **Shariat SF**, Witjes JA, Teoh JY. Intravesical Chemohyperthermia vs. Bacillus Calmette-Guerin Instillation for Intermediate- and High-Risk Non-muscle Invasive Bladder Cancer: A Systematic Review and Meta-Analysis. *Front Surg*. 2021 Nov 23;8:775527. PMID: 34888347 Free PMC article.
33. Hoeh B, Würnschimmel C, Flammia RS, Horlemann B, Sorce G, Chierigo F, Tian Z, Saad F, Graefen M, Gallucci M, Briganti A, Terrone C, **Shariat SF**, Tilki D, Kluth LA, Mandel P, Chun FKH, Karakiewicz PI. Effect of Chemotherapy on Overall Survival in Contemporary Metastatic Prostate Cancer Patients. *Front Oncol*. 2021.PMID: 34888250
34. Janisch F, Kienapfel C, Fühner C, Klotzbücher T, Marks P, Hillemacher T, Meyer CP, Iwata T, Parizi MK, Sauter G, Fisch M, **Shariat SF**, Dahlem R, Rink M. Treatment and Outcome of Metastatic Renal Cell Carcinoma With Sarcomatoid Differentiation: A Single-Center, Real-World Analysis of Retrospective Data. *Front Surg*. 2021 Nov 18;8:763271. PMID: 34869564
35. Powles T, Bellmunt J, Comperat E, De Santis M, Huddart R, Loriot Y, Necchi A, Valderrama BP, Ravaud A, **Shariat SF**, Szabados B, van der Heijden MS, Gillessen S; ESMO Guidelines Committee. Bladder cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. *Ann Oncol*. 2021 Nov 27:S0923-7534(21)04827-4. PMID: 34861372
36. Rajwa P, Huebner NA, Hostermann DI, Grossmann NC, Schuettfort VM, Korn S, Quhal F, König F, Mostafaei H, Laukhtina E, Mori K, Motlagh RS, Yanagisawa T, Aydh A, Bryniarski P, Pradere B, Paradysz A, Baltzer PA, Grubmüller B, **Shariat SF**. Evaluation of the predictive role of blood-based biomarkers in the context of suspicious prostate mri in patients undergoing prostate biopsy. *J Pers Med*. 2021 Nov 19;11(11):1231. PMID: 34834583
37. Laukhtina E, Lemberger U, Bruchbacher A, Ilijazi D, Korn S, Berndl F, D'Andrea D, Susani M, Enikeev D, Compérat E, **Shariat SF**, Hassler MR. Expression analysis and mutational status of histone methyltransferase KMT2D at different upper tract urothelial carcinoma locations. *J Pers Med*. 2021 Nov 4;11(11):1147. PMID: 34834500
38. Chierigo F, Wenzel M, Würnschimmel C, Flammia RS, Horlemann B, Tian Z, Saad F, Chun FKH, Tilki D, **Shariat SF**, Gallucci M, Borghesi M, Suardi N, Terrone C, Karakiewicz PI. Immuno-oncology therapy in metastatic bladder cancer: a systematic review and network meta-analysis. *Crit Rev Oncol Hematol*. 2021 Nov 22:103534. doi: 10.1016/j.critrevonc.2021.103534. PMID: 34823022
39. Grossmann NC, Schuettfort VM, Pradere B, Rajwa P, Quhal F, Mostafaei H, Laukhtina E, Mori K, Motlagh RS, Aydh A, Katayama S, Moschini M, Fankhauser CD, Hermanns T, Abufaraj M, Mun DH, Zimmermann K, Fajkovic H, Haydter M, **Shariat SF**. Impact of preoperative systemic immune-inflammation Index on oncologic outcomes in bladder cancer patients treated with radical cystectomy. *Urol Oncol*. 2021 PMID: 34810077
40. Gust KM, Resch I, D'Andrea D, **Shariat SF**. Update on systemic treatment of upper tract urothelial carcinoma: a narrative review of the literature. *Transl Androl Urol*. 2021 PMID: 34804847
41. Chierigo F, Borghesi M, Würnschimmel C, Flammia RS, Horlemann B, Sorce G, Höh B, Tian Z, Saad F, Graefen M, Gallucci M, Briganti A, Montorsi F, Chun FKH, **Shariat SF**, Mantica G, Suardi N, Terrone C, Karakiewicz PI. Survival after radical prostatectomy vs. radiation therapy in ductal carcinoma of the prostate. *Int Urol Nephrol*. 2021 Nov 19. PMID: 34797483
42. Würnschimmel C, Wenzel M, Chierigo F, Simone Flammia R, Tian Z, Saad F, Briganti A, **Shariat SF**, Suardi N, Terrone C, Gallucci M, Chun FK, Tilki D, Graefen M, Karakiewicz PI. Response to Re: External beam radiotherapy and radical prostatectomy are associated with better survival in Asian prostate cancer patients. *Int J Urol*. 2021 Nov 17. PMID: 34788899

43. Hoeh B, Hohenhorst JL, Flammia R, Horlemann B, Sorce G, Chierigo F, Tian Z, Saad F, Graefen M, Gallucci M, Briganti A, Terrone C, **Shariat SF**, Kluth LA, Becker A, Chun FKH, Karakiewicz PI. Cancer-specific mortality after radical prostatectomy vs external beam radiotherapy in high-risk Hispanic/Latino prostate cancer patients. *Int Urol Nephrol*. 2021 Nov 16. PMID: 34783982
44. Tulchiner G, Staudacher N, Fritz J, Hackl M, Pichler M, Seles M, **Shariat SF**, D'Andrea D, Gust K, Albrecht W, Grubmüller K, Madersbacher S, Graf S, Lusuadi L, Augustin H, Berger A, Loidl W, Horninger W, Pichler R. Seasonal Variations in the Diagnosis of Testicular Germ Cell Tumors: A National Cancer Registry Study in Austria. *Cancers (Basel)*. 2021 Oct 27;13(21):5377. PMID: 34771540
45. Mori K, Katayama S, Laukhtina E, Schuettfort VM, Pradere B, Quhal F, Sari Motlagh R, Mostafaei H, Grossmann NC, Rajwa P, Zimmermann K, Karakiewicz PI, Abufaraj M, Fajkovic H, Roupřet M, Margulis V, Enikeev DV, Egawa S, **Shariat SF**. Discordance Between Clinical and Pathological Staging and Grading in Upper Tract Urothelial Carcinoma. *Clin Genitourin Cancer*. 2021 Oct 10:S1558-7673(21)00192-0. PMID: 34764007
46. Yanagisawa T, Mori K, Katayama S, Mostafaei H, Quhal F, Laukhtina E, Rajwa P, Motlagh RS, Aydh A, König F, Grossmann NC, Pradere B, Miki J, Kimura T, Egawa S, **Shariat SF**. Pretreatment clinical and hematologic prognostic factors of metastatic urothelial carcinoma treated with pembrolizumab: a systematic review and meta-analysis. *Int J Clin Oncol*. 2021 Nov 10. PMID: 34757531
47. Laukhtina E, Shim SR, Mori K, D'Andrea D, Soria F, Rajwa P, Mostafaei H, Compérat E, Cimadamore A, Moschini M, Teoh JY, Enikeev D, Xylinas E, Lotan Y, Palou J, Gontero P, Babjuk M, Witjes JA, Kamat AM, Roupřet M, **Shariat SF**, Pradere B; European Association of Urology–Young Academic Urologists (EAU-YAU): Urothelial Carcinoma Working Group. Diagnostic Accuracy of Novel Urinary Biomarker Tests in Non-muscle-invasive Bladder Cancer: A Systematic Review and Network Meta-analysis. *Eur Urol Oncol*. 2021 Nov 6:S2588-9311(21)00183-8. PMID: 34753702
48. Laukhtina E, Mori K, Mostafaei H, Merseburger AS, Nyirady P, Moschini M, Quhal F, Pradere B, Motlagh RS, Enikeev D, **Shariat SF**. Adverse events of different chemotherapy regimens in the first-line treatment of patients with advanced or metastatic urothelial cancer: A systematic review and network meta-analysis of randomized controlled trials. *Semin Oncol*. 2021 Jun;48(3):181-192. PMID: 34749886
49. Winkler D, Grohmann R, Friedrich ME, Toto S, Bleich S, Seifert J, Konstantinidis A, **Shariat SF**, Kasper S, Pjrek E. Urological adverse drug reactions of psychotropic medication in psychiatric inpatients - A drug surveillance report from German-speaking countries. *J Psychiatr Res*. 2021 Oct 27;144:412-420. PMID: 34741839
50. Quhal F, Mori K, Fajkovic H, Remzi M, **Shariat SF**, Schmidinger M. Immunotherapy-based combinations in the first-line treatment of metastatic renal cell carcinoma with sarcomatoid features: a systematic review and network meta-analysis. *Curr Opin Urol*. 2021 Oct 29. PMID: 34720102
51. Sari Motlagh R, Rajwa P, Mori K, Laukhtina E, Aydh A, Katayama S, Yanagisawa T, König F, Grossmann NC, Pradere B, Mostafai H, Quhal F, Karakiewicz PI, Babjuk M, **Shariat SF**. Comparison of Clinicopathologic and Oncological Outcomes Between Transurethral En Bloc Resection and Conventional Transurethral Resection of Bladder Tumor: A Systematic Review, Meta-Analysis and Network Meta-Analysis with Focus on Different Energy Sources. *J Endourol*. 2021 Nov 16. PMID: 34693740

52. Luzzago S, Piccinelli ML, Marvaso G, Laukhtina E, Miura N, Schuettfort VM, Mori K, Aydh A, Ferro M, Mistretta FA, Fusco N, Petralia G, Jereczek-Fossa BA, **Shariat SF**, Karakiewicz PI, de Cobelli O, Musi G. Active surveillance for prostate cancer: comparison between incidental tumors vs. tumors diagnosed at prostate biopsies. *World J Urol.* 2021 Oct 23. doi: 10.1007/s00345-021-03864-6. Online ahead of print. PMID: 34687344
53. Flammia RS, Chierigo F, Würnschimmel C, Horlemann B, Hoeh B, Sorce G, Tian Z, Leonardo C, Tilki D, Terrone C, Saad F, **Shariat SF**, Montorsi F, Chun FK, Gallucci M, Karakiewicz PI. Survival benefit of chemotherapy in a contemporary cohort of metastatic urachal carcinoma. *Urol Oncol.* 2021 Oct 19:S1078-1439(21)00432-4. PMID: 34686429
54. Laukhtina E, Schuettfort VM, D'Andrea D, Pradere B, Quhal F, Mori K, Sari Motlagh R, Mostafaei H, Katayama S, Grossmann NC, Rajwa P, Karakiewicz PI, Schmidinger M, Fajkovic H, Enikeev D, **Shariat SF**. Selection and evaluation of preoperative systemic inflammatory response biomarkers model prior to cytoreductive nephrectomy using a machine-learning approach. *World J Urol.* 2021 Oct 20. doi: 10.1007/s00345-021-03844-w. Online ahead of print. PMID: 34671856
55. Hoeh B, Würnschimmel C, Flammia RS, Horlemann B, Sorce G, Chierigo F, Tian Z, Saad F, Graefen M, Gallucci M, Briganti A, Terrone C, **Shariat SF**, Kluth LA, Mandel P, Chun FKH, Karakiewicz PI. Cancer-specific survival after radical prostatectomy versus external beam radiotherapy in high-risk and very high-risk African American prostate cancer patients. *Prostate.* 2021 Oct 18. PMID: 34662443
56. Cacciamani GE, Matulewicz RS, Kumar R, Teoh JY, Mari A, Pradere B, Gomez Rivas J, Necchi A, Kumar Pal S, Ribal MJ, **Shariat S**, Rink M; SMART (Stop sMoking for Advance Rehabilitation Treatments) Urology Working Group. Fighting the 'tobacco epidemic' - A call to action to identify Targeted Intervention Points (TIPs) for better counseling patients with urothelial cancer. *Urol Oncol.* 2021 Oct 7:S1078-1439(21)00407-5. PMID: 34629283
57. Horlemann B, Würnschimmel C, Hoeh B, Sorce G, Chierigo F, Flammia RS, Tian Z, Saad F, Briganti A, **Shariat SF**, Galucci M, Chun FKH, Graefen M, Karakiewicz PI. Radical Cystectomy vs. Radiotherapy in Urothelial Bladder Cancer in Elderly and Very Elderly Patients. *Clin Genitourin Cancer.* 2021 Sep 1:S1558-7673(21)00160-9. PMID: 34620567
58. Wollenweber T, Zisser L, Kretschmer-Chott E, Weber M, Grubmüller B, Kramer G, **Shariat SF**, Mitterhauser M, Schmitl S, Vranka C, Haug AR, Hacker M, Hartenbach M, Rasul S. Renal and Salivary Gland Functions after Three Cycles of PSMA-617 Therapy Every Four Weeks in Patients with Metastatic Castration-Resistant Prostate Cancer. *Curr Oncol.* 2021 Sep 23;28(5):3692-3704. PMID: 34590608
59. Laukhtina E, Schuettfort VM, D'Andrea D, Pradere B, Mori K, Quhal F, Sari Motlagh R, Mostafaei H, Katayama S, Grossmann NC, Rajwa P, Zeinler F, Abufaraj M, Moschini M, Zimmermann K, Karakiewicz PI, Fajkovic H, Scherr D, Compérat E, Nyirady P, Rink M, Enikeev D, **Shariat SF**. Preoperative plasma level of endoglin as a predictor for disease outcomes after radical cystectomy for nonmetastatic urothelial carcinoma of the bladder. *Mol Carcinog.* 2021 Sep 29. PMID: 34587660
60. Reichl F, Muhr D, Rebhan K, Kramer G, **Shariat SF**, Singer CF, Tan YY. Cancer Spectrum, Family History of Cancer and Overall Survival in Men with Germline *BRCA1* or *BRCA2* Mutations. *J Pers Med.* 2021 Sep 15;11(9):917. PMID: 34575694
61. Mostafaei H, Salehi-Pourmehr H, Jilch S, Carlin GL, Mori K, Quhal F, Pradere B, Grossmann NC, Laukhtina E, Schuettfort VM, Aydh A, Sari Motlagh R, König F, Roehrborn CG, Katayama S, Rajwa P, Hajebrabimi S, **Shariat SF**. Choosing the Most Efficacious and Safe Oral Treatment for

- Idiopathic Overactive Bladder: A Systematic Review and Network Meta-analysis. *Eur Urol Focus*. 2021 Sep 22:S2405-4569(21)00226-1. PMID: 34563481
62. Chierigo F, Wenzel M, Würnschimmel C, Flammia RS, Horlemann B, Tian Z, Saad F, Chun FKH, Graefen M, Gallucci M, **Shariat SF**, Mantica G, Borghesi M, Suardi N, Terrone C, Karakiewicz PI. Survival after Radical Prostatectomy vs. Radiation Therapy in High-Risk and Very High-Risk Prostate Cancer. *Urol*. 2021 Sep 24. PMID: 34555930
63. Würnschimmel C, Wenzel M, Chierigo F, Flammia RS, Tian Z, Saad F, Briganti A, **Shariat SF**, Suardi N, Terrone C, Gallucci M, Chun FK, Tilki D, Graefen M, Karakiewicz PI. External beam radiotherapy and radical prostatectomy are associated with better survival in Asian prostate cancer patients. *Int J Urol*. 2021 Sep 22. PMID: 34553428
64. Nocera L, Karakiewicz PI, Wenzel M, Tian Z, **Shariat SF**, Saad F, Chun FKH, Briganti A, Kapoor A, Lalani AK. Clinical Outcomes and Adverse Events after First-Line Treatment in Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-Analysis. *J Urol*. 2021 PMID: 34546767
65. Hoeh B, Würnschimmel C, Flammia RS, Horlemann B, Sorce G, Chierigo F, Tian Z, Saad F, Graefen M, Gallucci M, Briganti A, Terrone C, **Shariat SF**, Tilki D, Kluth LA, Mandel P, Chun FKH, Karakiewicz PI. Improvement in overall and cancer-specific survival in contemporary, metastatic prostate cancer chemotherapy exposed patients. *Prostate*. 2021 Sep 15. PMID: 34523162
66. Wenzel M, Würnschimmel C, Chierigo F, Tian Z, **Shariat SF**, Terrone C, Saad F, Tilki D, Graefen M, Banek S, Kluth LA, Mandel P, Chun FKH, Karakiewicz PI. Increased risk of postoperative in-hospital complications after radical prostatectomy in patients with prior organ transplant. *Prostate*. 2021 Sep 13. PMID: 34516668
67. Babjuk M, Burger M, Capoun O, Cohen D, Comp  rat EM, Dominguez Escrig JL, Gontero P, Liedberg F, Masson-Lecomte A, Mostafid AH, Palou J, van Rhijn BWG, Roupr  t M, **Shariat SF**, Seisen T, Soukup V, Sylvester RJ. European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (Ta, T1, and Carcinoma in Situ). *Eur Urol*. 2021 Sep 9:S0302-2838(21)01978-3. PMID: 34511303.
68. Coll   Ruvolo C, W  rnschimmel C, Nocera L, Wenzel M, Tian Z, **Shariat SF**, Saad F, Verze P, Imbimbo C, Briganti A, Mirone V, Karakiewicz PI. Stage and cancer-specific mortality differ within specific Asian ethnic groups for upper tract urothelial carcinoma: North American population-based study. *Int J Urol*. 2021 Sep 3. PMID: 34480378
69. Sari Motlagh R, Abufaraj M, Karakiewicz PI, Rajwa P, Mori K, Mun DH, **Shariat SF**. Association between SARS-CoV-2 infection and disease severity among prostate cancer patients on androgen deprivation therapy: a systematic review and meta-analysis. *World J Urol*. 2021 Sep 3:1-8. doi: 10.1007/s00345-021-03810-6. PMID: 34477955 .
70. Wenzel M, Siron N, Coll   Ruvolo C, Nocera L, W  rnschimmel C, Tian Z, **Shariat SF**, Saad F, Briganti A, Tilki D, Banek S, Kluth LA, Roos FC, Chun FKH, Karakiewicz PI. Temporal trends, tumor characteristics and stage-specific survival in penile non-squamous cell carcinoma vs. squamous cell carcinoma. *Cancer Causes Control*. 2021 Sep 2 PMID: 34476653
71. Mori K, Schuettfort VM, Katayama S, Laukhtina E, Pradere B, Qahal F, Sari Motlagh R, Mostafaei H, Grossmann NC, Rajwa P, K  nig F, Aydh A, Soria F, Moschini M, Karakiewicz PI, Lotan Y, Scherr D, Haydter M, Nyirady P, Teoh JYC, Egawa S, Comp  rat E, **Shariat SF**. The Value of Preoperative Plasma VEGF Levels in Urothelial Carcinoma of the Bladder Treated with Radical Cystectomy. *Eur Urol Focus*. 2021 Aug 25:S2405-4569(21)00221-2. PMID: 34454852

72. D'Andrea D, Black PC, Zargar H, Dinney CP, Soria F, Cookson MS, Montgomery JS, Kassouf W, Dall'Era MA, Sridhar SS, McGrath JS, Wright JL, Thorpe AC, Holzbeierlein JM, Carrión DM, Di Trapani E, Bivalacqua TJ, North S, Barocas DA, Lotan Y, Grivas P, Stephenson AJ, van Rhijn BW, Daneshmand S, Spiess PE, **Shariat SF**, Zargar-Shoshtar K, Mertens LS, Fairey AS, Mir MC, Krabbe LM, Jacobsen NE, Vasdev N, Yu EY, Xylinas E, Pradere B, Pichler R, Campain NJ, Seah JA, Ercole CE, Horenblas S, Aning J, Morgan TM, Shah JB, Moschini M. Identifying the Optimal Number of Neoadjuvant Chemotherapy Cycles in Patients with Muscle-Invasive Bladder Cancer. *J Urol*. 2021 Aug 27. PMID: 34445891
73. Nocera L, Wenzel M, Collà Ruvolo C, Würnschimmel C, Tian Z, Gandaglia G, Fossati N, Chun FKH, Mirone V, Graefen M, Saad F, **Shariat SF**, Montorsi F, Briganti A, Karakiewicz PI. The impact of race/ethnicity on upstaging and/or upgrading rates among intermediate risk prostate cancer patients treated with radical prostatectomy. *World J Urol*. 2021 Aug 26. PMID: 34436637
74. Grubmüller B, Jahrreiss V, Brönimann S, Quhal F, Mori K, Heidenreich A, Briganti A, Tilki D, **Shariat SF**. Salvage Radical Prostatectomy for Radio-Recurrent Prostate Cancer: An Updated Systematic Review of Oncologic, Histopathologic and Functional Outcomes and Predictors of Good Response. *Curr Oncol*. 2021 Jul 29;28(4):2881-2892. PMID: 34436018
75. Lonati C, Baumeister P, Afferi L, Mari A, Minervini A, Krajewski W, Azizi S, Hendricksen K, Martini A, Necchi A, Montorsi F, Briganti A, Colombo R, Tafuri A, Antonelli A, Cerruto MA, Rouprêt M, Masson-Lecomte A, Laukhtina E, D'Andrea D, **Shariat SF**, Soria F, Marra G, Gontero P, Contieri R, Hurle R, Valiquette AS, Mir MC, Zamboni S, Simeone C, Klatte T, Teoh JY, Yoshida S, Fujii Y, Carando R, Schulz GB, Mordasini L, Mattei A, Moschini M; European Association of Urology Young Academic Urologists (EAU-YAU): Urothelial Carcinoma Working Group. Survival Outcomes After Immediate Radical Cystectomy Versus Conservative Management with Bacillus Calmette-Guérin Among T1 High-grade Micropapillary Bladder Cancer Patients: Results from a Multicentre Collaboration. *Eur Urol Focus*. 2021. PMID: 34419381
76. Laukhtina E, Quhal F, Mori K, Sari Motlagh R, Pradere B, Schuettfort VM, Mostafaei H, Katayama S, Grossmann NC, Rajwa P, Resch I, Enikeev D, Karakiewicz PI, **Shariat SF**, Schmidinger M. Adjuvant therapy with tyrosine kinase inhibitors for localized and locally advanced renal cell carcinoma: an updated systematic review and meta-analysis. *Urol Oncol*. 2021 Aug 14:S1078-1439(21)00340-9. PMID: 34400065
77. Enikeev D, Misrai V, **Shariat S**. Lower urinary tract symptoms, benign prostate hyperplasia and beyond. *Curr Opin Urol*. 2021 Sep 1;31(5):437. PMID: 34397504
78. Wenzel M, Deuker M, Nocera L, Collà Ruvolo C, Würnschimmel C, Tian Z, **Shariat SF**, Saad F, Briganti A, Tilki D, Graefen M, Kluth LA, Becker A, Roos FC, Chun FKH, Karakiewicz PI. Median time to progression with TKI-based therapy after failure of immuno-oncology therapy in metastatic kidney cancer: A systematic review and meta-analysis. *Eur J Cancer*. 2021 Aug 12;155:245-255. PMID: 34392067.
79. D'Andrea D, Black PC, Zargar H, Zargar-Shoshtari K, Soria F, Fairey AS, Mertens LS, Dinney CP, Mir MC, Krabbe LM, Cookson MS, Jacobsen NE, Montgomery JS, Vasdev N, Yu EY, Xylinas E, Campain NJ, Kassouf W, Dall'Era MA, Seah JA, Ercole CE, Horenblas S, Sridhar SS, McGrath JS, Aning J, Wright JL, Thorpe AC, Morgan TM, Holzbeierlein JM, Bivalacqua TJ, North S, Barocas DA, Lotan Y, Grivas P, Stephenson AJ, Shah JB, van Rhijn BW, Daneshmand S, Spiess PE, **Shariat SF**. Association of age with response to preoperative chemotherapy in patients with muscle-invasive bladder cancer. *World J Urol*. 2021 Aug 9. PMID: 34370078
80. Wenzel M, Collà Ruvolo C, Nocera L, Würnschimmel C, Tian Z, **Shariat SF**, Saad F, Briganti A, Graefen M, Becker A, Mandel P, Chun FKH, Karakiewicz PI. Regional differences in patient age

- and prostate cancer characteristics and rates of treatment modalities in favorable and unfavorable intermediate risk prostate cancer across United States SEER registries. *Cancer Epidemiol.* 2021 Aug 5;74:101994. PMID: 34364187
81. Khene ZE, Kokorian R, Mathieu R, Gasmi A, Nathalie RL, Solène-Florence KJ, **Shariat S**, de Crevoisier R, Laguerre B, Bensalah K. Metastatic clear cell renal cell carcinoma: computed tomography texture analysis as predictive biomarkers of survival in patients treated with nivolumab. *Int J Clin Oncol.* 2021 Aug 2. PMID: 34338919
82. Stangl-Kremser J, Rasul S, Tosoian JJ, Salami SS, Zaslavsky A, Udager A, Mazal P, Kain R, Comperat E, Hacker M, Haug A, Mitterhauser M, Pozo-Salido C, Steinbach C, Hassler MR, Kramer G, **Shariat SF**, Palapattu GS. Single-lesion Prostate-specific Membrane Antigen Protein Expression (PSMA) and Response to [177Lu]-PSMA-ligand Therapy in Patients with Castration-resistant Prostate Cancer. *Eur Urol Open Sci.* 2021 Jun 30;30:63-66. PMID: 34337549
83. Wenzel M, Würnschimmel C, Chierigo F, Flammia RS, Tian Z, **Shariat SF**, Gallucci M, Terrone C, Saad F, Tilki D, Graefen M, Becker A, Kluth LA, Mandel P, Chun FKH, Karakiewicz PI. Nomogram Predicting Downgrading in National Comprehensive Cancer Network High-risk Prostate Cancer Patients Treated with Radical Prostatectomy. *Eur Urol Focus.* 2021 Jul 29:S2405-4569(21)00188-7. PMID: 34334344
84. Collà Ruvolo C, Wenzel M, Nocera L, Würnschimmel C, Tian Z, **Shariat SF**, Saad F, Longo N, Imbimbo C, Briganti A, Mirone V, Karakiewicz PI. The effect of race on stage at presentation and survival in upper tract urothelial carcinoma. *Urol Oncol.* 2021 Jul 27:S1078-1439(21)00303-3. PMID: 34330651
85. Wenzel M, Würnschimmel C, Chierigo F, Tian Z, **Shariat SF**, Terrone C, Saad F, Tilki D, Graefen M, Roos FC, A Kluth L, Mandel P, Chun FKH, Karakiewicz PI. Assessment of the optimal number of positive biopsy cores to discriminate between cancer-specific mortality in high-risk versus very high-risk prostate cancer patients. *Prostate.* 2021 Oct;81(14):1055-1063. PMID: 34312910
86. Mori K, Quhal F, Katayama S, Mostafaei H, Laukhtina E, Schuettfort VM, Sari Motlagh R, Grossmann NC, Rajwa P, Ploussard G, Briganti A, Kimura T, Egawa S, Papalia R, Carrion DM, Fiori C, **Shariat SF**, Esperto F, Pradere B. Androgen receptor axis-targeted agents for non-metastatic castration-resistant prostate cancer impact on overall survival and safety profile: an updated systematic review and meta-analysis. *Minerva Urol Nephrol.* 2021 Jul 26. doi: 10.23736/S2724-6051.21.04431-1. PMID: 34308608
87. Sari Motlagh R, Abufaraj M, Mori K, Aydh A, Rajwa P, Katayama S, Grossmann NC, Laukhtina E, Mostafai H, Pradere B, Quhal F, Karakiewicz PI, Enikeev DV, **Shariat SF**. The Efficacy and Safety of Relugolix Compared with Degarelix in Advanced Prostate Cancer Patients: A Network Meta-analysis of Randomized Trials. *Eur Urol Oncol.* 2021 Jul 20:S2588-9311(21)00122-X. PMID: 34301529.
88. Laukhtina E, Mori K, D Andrea D, Moschini M, Abufaraj M, Soria F, Mari A, Krajewski W, Albisinni S, Teoh JY, Quhal F, Sari Motlagh R, Mostafaei H, Katayama S, Grossmann NC, Rajwa P, Enikeev D, Zimmermann K, Fajkovic H, Glybochko P, **Shariat SF**, Pradere B; European Association of Urology–Young Academic Urologists Urothelial Carcinoma Working Group (EAU-YAU). Incidence, risk factors and outcomes of urethral recurrence after radical cystectomy for bladder cancer: A systematic review and meta-analysis. *Urol Oncol.* 2021 PMID: 34266740
89. Gmeiner J, Garstka N, Helbich TH, **Shariat SF**, Baltzer PA. Vesical Imaging Reporting and Data System (VI-RADS): Are the individual MRI sequences equivalent in diagnostic performance of high grade NMIBC and MIBC? *Eur J Radiol.* 2021 PMID: 34252867

90. Resch I, Bruchbacher A, Franke J, Fajkovic H, Remzi M, **Shariat SF**, Schmidinger M. Outcome of immune checkpoint inhibitors in metastatic renal cell carcinoma across different treatment lines. *ESMO Open*. 2021 Jul 1;6(4):100122. PMID: 34217917
91. Chan VW, Tan WS, Asif A, Ng A, Gbolahan O, Dinneen E, To W, Kadhim H, Premchand M, Burton O, Koe JS, Wang N, Leow JJ, Giannarini G, Vasdev N, **Shariat SF**, Enikeev D, Ng CF, Teoh JY. Effects of Delayed Radical Prostatectomy and Active Surveillance on Localised Prostate Cancer-A Systematic Review and Meta-Analysis. *Cancers (Basel)*. 2021 Jun 30;13(13):3274. PMID: 34208888
92. Mun DH, Yang L, **Shariat SF**, Reitter-Pfoertner S, Gredinger G, Waldhoer T. Difference in Incontinence Pad Use between Patients after Radical Prostatectomy and Cancer-Free Population with Subgroup Analysis for Open vs. Minimally Invasive Radical Prostatectomy: A Descriptive Analysis of Insurance Claims-Based Data. *Int J Environ Res Public Health*. 2021 PMID: 34199008
93. Claps F, van de Kamp MW, Mayr R, Bostrom PJ, Boormans JL, Eckstein M, Mertens LS, Boevé ER, Neuzillet Y, Burger M, Pouessel D, Trombetta C, Wullich B, van der Kwast TH, Hartmann A, Allory Y, Lotan Y, **Shariat SF**, Zuiverloon TCM, Mir MC, van Rhijn BWG. Risk factors associated with positive surgical margins' location at radical cystectomy and their impact on bladder cancer survival. *World J Urol*. 2021 Jul 1. PMID: 34196758
94. Aydh A, Mori K, D'Andrea D, Motlagh RS, Abufaraj M, Pradere B, Mostafaei H, Laukhtina E, Quhal F, Karakiewicz PI, Luzzago S, Briganti A, Trinh QD, Parizi MK, Tilki D, Enikeev DV, **Shariat SF**. Prognostic value of the pre-operative serum albumin to globulin ratio in patients with non-metastatic prostate cancer undergoing radical prostatectomy. *Int J Clin Oncol*. 2021 Jun 28. PMID: 34184136
95. Schuettfort VM, Pradere B, D'Andrea D, Grossmann NC, Quhal F, Mostafaei H, Laukhtina E, Mori K, Rink M, Karakiewicz PI, Motlagh RS, Katayama S, Lotan Y, Scherr D, Abufaraj M, Fajkovic H, Compérat E, Enikeev D, **Shariat SF**. Prognostic Impact of Preoperative Plasma Levels of Urokinase Plasminogen Activator Proteins on Disease Outcomes After Radical Cystectomy. *J Urol*. 2021 Online ahead of print. PMID: 34181469
96. Bravi CA, Droghetti M, Fossati N, Gandaglia G, Suardi N, Mazzone E, Cucchiara V, Scuderi S, Barletta F, Schiavina R, Osmonov D, Juenemann KP, Boeri L, Karnes RJ, Kretschmer A, Buchner A, Stief C, Hiester A, Nini A, Albers P, Devos G, Joniau S, Van Poppel H, Grubmüller B, **Shariat SF**, Heidenreich A, Pfister D, Tilki D, Graefen M, Gill IS, Motttrie A, Karakiewicz PI, Montorsi F, Briganti A. Definition and Impact on Oncologic Outcomes of Persistently Elevated Prostate-specific Antigen After Salvage Lymph Node Dissection for Node-only Recurrent Prostate Cancer After Radical Prostatectomy: Clinical Implications for Multimodal Therapy. *Eur Urol Oncol*. 2021 Jun. PMID: 34176768
97. Mori K, Mostafaei H, Sari Motlagh R, Pradere B, Quhal F, Laukhtina E, Schuettfort VM, Kramer G, Abufaraj M, Karakiewicz PI, Kimura T, Egawa S, **Shariat SF**. Systemic Therapies for Metastatic Hormone-Sensitive Prostate Cancer: Network Meta-Analysis. *BJU Int*. 2021 Jun 25.
98. Mori K, Pradere B, Quhal F, Katayama S, Mostafaei H, Laukhtina E, Schuettfort VM, D'Andrea D, Egawa S, Bensalah K, Schmidinger M, Powles T, **Shariat SF**. Differences in oncological and toxicity outcomes between programmed cell death-1 and programmed cell death ligand-1 inhibitors in metastatic renal cell carcinoma: A systematic review and meta-analysis. *Cancer Treat Rev*. 2021 Jun 12;99:102242. PMID: 34153830
99. Mori K, Sharma V, Egawa S, Tilki D, Boorjian SA, **Shariat SF**. ASO Author Reflections: Is There Any Difference Among Various Gleason Scores Classified as Grade Group 4 Prostate Cancer? *Ann Surg Oncol*. 2021 Jun 21. PMID: 34152524

100. Pisano F, Gontero P, Sylvester R, Joniau S, Serretta V, Larré S, Di Stasi S, van Rhijn B, Witjes A, Grotenhuis A, Colombo R, Briganti A, Babjuk M, Soukup V, Malmstrom PU, Irani J, Malats N, Baniel J, Mano R, Cai T, Cha E, Ardelt P, Varkarakis J, Bartoletti R, Dalbagni G, **Shariat SF**, Xylinas E, Karnes RJ, Palou J. Risk factors for residual disease at re-TUR in a large cohort of T1G3 patients. *Actas Urol Esp (Engl Ed)*. 2021 Jun 16:S2173-5786(21)00071-8. PMID: 34147426
101. Katayama S, Mori K, Pradere B, Mostafaei H, Schuettfort VM, Quhal F, Motlagh RS, Laukhtina E, Moschini M, Grossmann NC, Nasu Y, **Shariat SF**, Fajkovic H. Intracorporeal versus extracorporeal urinary diversion in robot-assisted radical cystectomy: a systematic review and meta-analysis. *Int J Clin Oncol*. 2021 Jun 19. PMID: 34146185 Review.
102. Katayama S, Mori K, Pradere B, Laukhtina E, Schuettfort VM, Quhal F, Motlagh RS, Mostafaei H, Grossmann NC, Rajwa P, Moschini M, Mathieu R, Abufaraj M, D'Andrea D, Compérat E, Haydter M, Egawa S, Nasu Y, **Shariat SF**; European Association of Urology–Young Academic Urologists Urothelial Carcinoma Working Group (EAU-YAU). Prognostic value of the systemic immune-inflammation index in non-muscle invasive bladder cancer. *World J Urol*. 2021 Jun 18. doi: 10.1007/s00345-021-03740-3. Online ahead of print. PMID: 34143284
103. Compérat E, Amin MB, Epstein JI, Hansel DE, Paner G, Al-Ahmadie H, True L, Bayder D, Bivalacqua T, Brimo F, Cheng L, Cheville J, Dalbagni G, Falzarano S, Gordetsky J, Guo C, Gupta S, Hes O, Iyer G, Kaushal S, Kunju L, Magi-Galluzzi C, Matoso A, McKenney J, Netto GJ, Osunkoya AO, Pan CC, Pivovarcikova K, Raspollini MR, Reis H, Rosenberg J, Roupert M, Shah RB, **Shariat SF**, Trpkov K, Weyerer V, Zhou M, Reuter V. The Genitourinary Pathology Society Update on Classification of Variant Histologies, T1 Substaging, Molecular Taxonomy, and Immunotherapy and PD-L1 Testing Implications of Urothelial Cancers. *Adv Anat Pathol*. 2021 Jul 1;28(4):196-208. PMID: 34128484
104. Amin MB, Comperat E, Epstein JI, True LD, Hansel D, Paner GP, Al-Ahmadie H, Baydar D, Bivalacqua T, Brimo F, Cheng L, Cheville J, Dalbagni G, Falzarano S, Gordetsky J, Guo CC, Gupta S, Hes O, Iyer G, Kaushal S, Kunju L, Magi-Galluzzi C, Matoso A, Netto G, Osunkoya AO, Pan CC, Pivovarcikova K, Raspollini MR, Reis H, Rosenberg J, Roupert M, Shah RB, **Shariat SF**, Trpkov K, Weyerer V, Zhou M, McKenney J, Reuter VE. The Genitourinary Pathology Society Update on Classification and Grading of Flat and Papillary Urothelial Neoplasia With New Reporting Recommendations and Approach to Lesions With Mixed and Early Patterns of Neoplasia. *Adv Anat Pathol*. 2021 Jul 1;28(4):179-195. PMID: 34128483
105. Laukhtina E, Rajwa P, Mori K, Moschini M, D'Andrea D, Abufaraj M, Soria F, Mari A, Krajewski W, Albisinni S, Teoh JY, Quhal F, Sari Motlagh R, Mostafaei H, Katayama S, Grossmann NC, Enikeev D, Zimmermann K, Fajkovic H, Glybochko P, **Shariat SF**, Pradere B; European Association of Urology Young Academic Urologists Urothelial Carcinoma Working Group (EAU YAU). Accuracy of Frozen Section Analysis of Urethral and Ureteral Margins During Radical Cystectomy for Bladder Cancer: A Systematic Review and Diagnostic Meta-Analysis. *Eur Urol Focus*. 2021 Jun 11:S2405-4569(21)00162-0. PMID: 34127436 Review.
106. Mori K, Sharma V, Comperat EM, Sato S, Laukhtina E, Schuettfort VM, Pradere B, Sari Motlagh R, Mostafaei H, Quhal F, Kardoust Parizi M, Abufaraj M, Karakiewicz PI, Egawa S, Tilki D, Boorjian SA, **Shariat SF**. Prognostic Impact of Different Gleason Patterns on Biopsy Within Grade Group 4 Prostate Cancer. *Ann Surg Oncol*. 2021 Jun 11. PMID: 34117577
107. Rajwa P, Schuettfort VM, D'Andrea D, Quhal F, Mori K, Katayama S, Laukhtina E, Pradere B, Motlagh RS, Mostafaei H, Grossmann NC, Huebner N, Aulitzky A, Mun DH, Briganti A, Karakiewicz PI, Fajkovic H, **Shariat SF**. Impact of systemic Immune-inflammation Index on oncologic outcomes in patients treated with radical prostatectomy for clinically nonmetastatic prostate cancer. *Urol Oncol*. 2021 Jun 8:S1078-1439(21)00208-8. PMID: 34116934

108. Schuettfort VM, Gust K, D'Andrea D, Quhal F, Mostafaei H, Laukhtina E, Mori K, Rink M, Abufaraj M, Karakiewicz PI, Luzzago S, Rouprêt M, Enikeev D, Zimmermann K, Deuker M, Moschini M, Sari Motlagh R, Grossmann NC, Katayama S, Pradere B, **Shariat SF**. Impact of the preoperative modified glasgow prognostic score on disease outcome after radical cystectomy for urothelial carcinoma of the bladder. *Minerva Urol Nephrol*. 2021 Jun 11. PMID: 34114784
109. Kozikowski M, Suarez-Ibarrola R, Osiecki R, Bilski K, Gratzke C, **Shariat SF**, Miernik A, Dobruch J. Role of Radiomics in the Prediction of Muscle-invasive Bladder Cancer: A Systematic Review and Meta-analysis. *Eur Urol Focus*. 2021 Jun 4:S2405-4569(21)00157-7. PMID: 34099417
110. Jobczyk M, Stawiski K, Kaszkowiak M, Rajwa P, Róžański W, Soria F, **Shariat SF**, Fendler W. Deep Learning-based Recalibration of the CUETO and EORTC Prediction Tools for Recurrence and Progression of Non-muscle-invasive Bladder Cancer. *Eur Urol Oncol*. 2021 Jun 3:S2588-9311(21)00112-7. PMID: 34092528
111. Ruvolo CC, Nocera L, Stolzenbach FL, Wenzel M, Würnschimmel C, Fusco F, Palmieri A, Tian Z, **Shariat SF**, Saad F, Briganti A, Imbimbo C, Mirone V, Karakiewicz PI. Contemporary analysis of the effect of marital status on survival in upper tract urothelial carcinoma patients treated with radical nephroureterectomy: A population-based study. *Urol Oncol*. 2021 Jun 4:S1078-1439(21)00197-6. PMID: 34092481
112. Collà Ruvolo C, Würnschimmel C, Wenzel M, Nocera L, Celentano G, Mangiapia F, Tian Z, **Shariat SF**, Saad F, Chun FHC, Briganti A, Longo N, Mirone V, Karakiewicz PI. Comparison between 1973 and 2004/2016 World Health Organization grading in upper tract urothelial carcinoma treated with radical nephroureterectomy. *Int J Clin Oncol*. 2021 Jun 6. PMID: 34091795
113. Laukhtina E, Mori K, Mostafaei H, Merseburger AS, Nyirady P, Moschini M, Quhal F, Schuettfort VM, Pradere B, Motlagh RS, Enikeev D, **Shariat SF**, Of Urology-Young Academic Urologists Eau-Yau Urothelial Carcinoma Working Group EA. Adverse events of the second-line treatment for patients with locally advanced or metastatic urothelial carcinoma of the bladder: network meta-analysis. *Immunotherapy*. 2021 Jun 3. PMID: 34078134
114. Bajorin DF, Witjes JA, Gschwend JE, Schenker M, Valderrama BP, Tomita Y, Bamias A, Lebre T, **Shariat SF**, Park SH, Ye D, Agerbaek M, Enting D, McDermott R, Gajate P, Peer A, Milowsky MI, Nosov A, Neif Antonio J Jr, Tupikowski K, Toms L, Fischer BS, Qureshi A, Collette S, Unsal-Kacmaz K, Broughton E, Zardavas D, Koon HB, Galsky MD. Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial Carcinoma. *N Engl J Med*. 2021 Jun 3;384(22):2102-2114. PMID: 34077643
115. Pones M, D'Andrea D, Mori K, Abufraj M, Moschini M, Comperat E, **Shariat SF**. Differential Prognosis and Response of Denovo vs. Secondary Muscle-Invasive Bladder Cancer: An Updated Systematic Review and Meta-Analysis. *Cancers (Basel)*. 2021 May 20;13(10):2496. PMID: 34065365
116. Rasul S, Wollenweber T, Zisser L, Kretschmer-Chott E, Grubmüller B, Kramer G, **Shariat SF**, Eidherr H, Mitterhauser M, Vranka C, Langsteger W, Hacker M, Haug AR. Response and Toxicity to the Second Course of 3 Cycles of 177Lu-PSMA Therapy Every 4 Weeks in Patients with Metastatic Castration-Resistant Prostate Cancer. *Cancers (Basel)*. 2021 May 20;13(10):2489. PMID: 34065303
117. Quhal F, Rajwa P, Mori K, Laukhtina E, Grossmann NC, Schuettfort VM, König F, Aydh A, Motlagh RS, Katayama S, Mostafai H, Pradere B, Marra G, Gontero P, Mathieu R, Karakiewicz PI, Briganti A, **Shariat SF**, Heidenreich A. The role of lymph node dissection in salvage radical prostatectomy for patients with radiation recurrent prostate cancer. *Prostate*. 2021 May 31. PMID: 34057227

118. Würnschimmel C, Wenzel M, Chierigo F, Flammia RS, Mori K, Tian Z, **Shariat SF**, Saad F, Briganti A, Suardi N, Terrone C, Gallucci M, Chun FKH, Tilki D, Graefen M, Karakiewicz PI. Presence of biopsy Gleason pattern 5 + 3 is associated with higher mortality after radical prostatectomy but not after external beam radiotherapy compared to other Gleason Grade Group IV patterns. *Prostate*. 2021 May 31. PMID: 34057220
119. Wenzel M, Nocera L, Collà Ruvolo C, Würnschimmel C, Tian Z, **Shariat SF**, Saad F, Tilki D, Graefen M, Kluth LA, Briganti A, Mandel P, Montorsi F, Chun FKH, Karakiewicz PI. Overall survival and adverse events after treatment with darolutamide vs. apalutamide vs. enzalutamide for high-risk non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis. *Prostate Cancer Prostatic Dis*. 2021 May 30. PMID: 34054128.
120. Katayama S, Mori K, Schuettfort VM, Pradere B, Mostafaei H, Quhal F, Rajwa P, Motlagh RS, Laukhtina E, Moschini M, Grossmann NC, Araki M, Teoh JY, Rouprêt M, Margulis V, Enikeev D, Karakiewicz PI, Abufaraj M, Compérat E, Nasu Y, **Shariat SF**. Accuracy and Clinical Utility of a Tumor Grade- and Stage-based Predictive Model in Localized Upper Tract Urothelial Carcinoma. *Eur Urol Focus*. 2021 May 27:S2405-4569(21)00154-1. PMID: 34053904 .
121. Laukhtina E, Sari Motlagh R, Mori K, Quhal F, Schuettfort VM, Mostafaei H, Katayama S, Grossmann NC, Ploussard G, Karakiewicz PI, Briganti A, Abufaraj M, Enikeev D, Pradere B, **Shariat SF**. Oncologic impact of delaying radical prostatectomy in men with intermediate- and high-risk prostate cancer: a systematic review. *World J Urol*. 2021 May 28:1-15PMID: 34047825
122. Martini A, Afferi L, Zamboni S, Schultz JG, Lonati C, Mattei A, Karnes RJ, Soligo M, Stabile A, Di Trapani E, De Cobelli O, Simone G, Simeone C, Alvarez-Maestro M, Gandaglia G, Gallina A, Colombo R, Briganti A, Montorsi F, Xylinas E, Shariat SF, Moschini M: Oncologic Surveillance for Variant Histology Bladder Cancer after Radical Cystectomy. *J Urol*. 2021 PMID: 34032498
123. Stangl-Kremser J, Mari A, Lai LY, Lee CT, Vince R, Zaslavsky A, Salami SS, Fajkovic H, **Shariat SF**, Palapattu GS. Sarcopenic Obesity and Its Prognostic Impact on Urologic Cancers: A Systematic Review. *J Urol*. 2021 May 25: PMID: 34032495
124. Schuettfort VM, Pradere B, Trinh QD, D'Andrea D, Quhal F, Mostafaei H, Laukhtina E, Mori K, Sari Motlagh R, Rink M, Karakiewicz PI, Chlosta P, Yuen-Chun Teoh J, Lotan Y, Scherr D, Abufaraj M, Moschini M, **Shariat SF**. Impact of preoperative plasma levels of interleukin 6 and interleukin 6 soluble receptor on disease outcomes after radical cystectomy for bladder cancer. *Cancer Immunol Immunother*. 2021 May 23. PMID: 34023914
125. Foerster B, Abufaraj M, Matin SF, Azizi M, Gupta M, Li WM, Seisen T, Clinton T, Xylinas E, Mir MC, Schweitzer D, Mari A, Kimura S, Bandini M, Mathieu R, Ku JH, Marcq G, Guruli G, Grabbert M, Czech AK, Muilwijk T, Pycha A, D'Andrea D, Petros FG, Spiess PE, Bivalacqua T, Wu WJ, Rouprêt M, Krabbe LM, Hendricksen K, Egawa S, Briganti A, Moschini M, Graffelle V, Kassouf W, Autorino R, Heidenreich A, Chlosta P, Joniau S, Soria F, Pierorazio PM, **Shariat SF**. Pretreatment Risk Stratification for Endoscopic Kidney-sparing Surgery in Upper Tract Urothelial Carcinoma: An International Collaborative Study. *Eur Urol*. 2021 May 19:S0302-2838(21)00328-6. PMID: 34023164
126. Rajwa P, Pradere B, Quhal F, Mori K, Laukhtina E, Huebner NA, D'Andrea D, Krzywon A, Shim SR, Baltzer PA, Renard-Penna R, Leapman MS, **Shariat SF**, Ploussard G. Reliability of Serial Prostate Magnetic Resonance Imaging to Detect Prostate Cancer Progression During Active Surveillance: A Systematic Review and Meta-analysis. *Eur Urol*. 2021 May 18:S0302-2838(21)00325-0. PMID: 34020828
127. Wenzel M, Würnschimmel C, Chierigo F, Tian Z, **Shariat SF**, Terrone C, Saad F, Tilki D, Graefen M, Mandel P, Kluth LA, Chun FKH, Karakiewicz PI. Non-cancer mortality in elderly prostate

- cancer patients treated with combination of radical prostatectomy and external beam radiation therapy. *Prostate*. 2021 May 19. PMID: 34010465
128. Baard J, Cormio L, Cavadas V, Alcaraz A, **Shariat SF**, de la Rosette J, Laguna MP. Contemporary patterns of presentation, diagnostics and management of upper tract urothelial cancer in 101 centres: the Clinical Research Office of the Endourological Society Global upper tract urothelial carcinoma registry. *Curr Opin Urol*. 2021 Jul 1;31(4):354-362. PMID: 34009177
 129. Rajwa P, Schuettfort VM, Quhal F, Mori K, Katayama S, Laukhtina E, Pradere B, Motlagh RS, Mostafaei H, Grossmann NC, Aulitzky A, Paradysz A, Karakiewicz PI, Fajkovic H, Zimmermann K, Heidenreich A, Gontero P, **Shariat SF**. Role of systemic immune-inflammation index in patients treated with salvage radical prostatectomy. *World J Urol*. 2021 May 17. PMID: 33997919
 130. Würnschimmel C, Wenzel M, Collà Ruvolo C, Nocera L, Tian Z, Saad F, Briganti A, **Shariat SF**, Mirone V, Chun FK, Tilki D, Graefen M, Karakiewicz PI. Life expectancy in metastatic prostate cancer patients according to racial/ethnic groups. *Int J Urol*. 2021 May 15. PMID: 33993551
 131. Nocera L, Wenzel M, Collà Ruvolo C, Würnschimmel C, Tian Z, Gandaglia G, Fossati N, Chun FKH, Mirone V, Graefen M, **Shariat SF**, Saad F, Montorsi F, Briganti A, Karakiewicz PI. The effect of race/ethnicity on active treatment rates among septuagenarian or older low risk prostate cancer patients. *Urol Oncol*. 2021 May 12:S1078-1439(21)00161-7. PMID: 33992522
 132. Pisano F, Gontero P, Sylvester R, Joniau S, Serretta V, Larré S, Di Stasi S, van Rhijn B, Witjes A, Grotenhuis A, Colombo R, Briganti A, Babjuk M, Soukup V, Malmstrom PU, Irani J, Malats N, Baniel J, Mano R, Cai T, Cha E, Ardelt P, Varkarakis J, Bartoletti R, Dalbagni G, **Shariat SF**, Xylinas E, Karnes RJ, Palou J. Risk factors for residual disease at re-TUR in a large cohort of T1G3 patients. *Actas Urol Esp*. 2021 May 12:S0210-4806(21)00012-7. PMID: 33992448 .
 133. Enikeev D, Taratkin M, Efetov S, Shlomina A, Boldyreva M, Galkina I, Spivak L, Gitel E, Kuchieva A, Mikhailov V, Teoh JY, Herrmann TRW, Kikic Ž, Fomin V, **Shariat SF**, Glybochko P. Acute kidney injury in COVID-19: are kidneys the target or just collateral damage? A comprehensive assessment of viral RNA and AKI rate in patients with COVID-19. *Curr Opin Urol*. 2021 May 14 PMID: 33989230
 134. Würnschimmel C, Wenzel M, Collà Ruvolo C, Nocera L, Tian Z, Saad F, Briganti A, **Shariat SF**, Mandel P, Chun FKH, Tilki D, Graefen M, Karakiewicz PI. Survival advantage of Asian metastatic prostate cancer patients treated with external beam radiotherapy over other races/ethnicities. *World J Urol*. 2021 May 12. PMID: 33978812
 135. König F, **Shariat SF**, Karakiewicz PI, Mun DH, Rink M, Pradere B. Quality indicators for the management of high-risk upper tract urothelial carcinoma requiring radical nephroureterectomy. *Curr Opin Urol*. 2021 PMID: 33973537
 136. Zimmermann K, Mostafaei H, Heidenreich A, Schmelz HU, **Shariat SF**, Mori K. Health-related quality of life in bladder cancer patients: bladder cancer-specific instruments and domains. Part 2. *Curr Opin Urol*. 2021 PMID: 33973536
 137. Schuettfort VM, Pradere B, Compérat E, Abufaraj M, Shariat SF. Novel transurethral resection technologies and training modalities in the management of nonmuscle invasive bladder cancer: a comprehensive review. *Curr Opin Urol*. 2021 PMID: 33973535
 138. Deuker M, Krimphove MJ, Stolzenbach LF, Collà Ruvolo C, Nocera L, Mansour M, Tian Z, Roos FC, Becker A, Kluth LA, **Shariat SF**, Black PC, Kassouf W, Tilki D, Saad F, Chun FKH, Karakiewicz PI. Radical Cystectomy vs. Multimodality Treatment in T2N0M0 Bladder Cancer: A Population-based, Age-matched Analysis. *Clin Genitourin Cancer*. 2021 PMID: 33972185

139. Jahrreiss V, Laukhtina E, D'Andrea D, **Shariat SF**. The prognostic value of sarcopenia in patients with prostate cancer: a systematic review. *Curr Opin Urol*. 2021 May 6. PMID: 33965982
140. Mun DH, Pradere B, **Shariat SF**, Yurdakul O, Remzi M. COVID-19 crisis and minimally invasive surgery: a narrative review on intraoperative aerosol viral transmission and their impact on guidelines and clinical practice in Austria. *Curr Opin Urol*. 2021 PMID: 33965981
141. Zimmermann K, Mostafaei H, Heidenreich A, Schmelz HU, **Shariat SF**, Mori K. Part I. Health-related quality of life in bladder cancer patients: general and cancer-specific instruments. *Curr Opin Urol*. 2021 May 6 PMID: 33965980
142. Laukhtina E, Mori K, Pradere B, **Shariat SF**. Association between male infertility and prostate cancer: a systematic review and meta-analysis. *Curr Opin Urol*. 2021 May 6. PMID: 33965979
143. Quhal F, Mori K, Remzi M, Fajkovic H, **Shariat SF**, Schmidinger M. Adverse events of systemic immune-based combination therapies in the first-line treatment of patients with metastatic renal cell carcinoma: systematic review and network meta-analysis. *Curr Opin Urol*. 2021 PMID: 33965978
144. Oszwald A, Wasinger G, Pradere B, **Shariat SF**, Comp  rat EM. Artificial intelligence in prostate histopathology: where are we in 2021? *Curr Opin Urol*. 2021 PMID: 33965977
145. Mori K, Pradere B, Moschini M, Mostafaei H, Laukhtina E, Schuettfort VM, Sari Motlagh R, Soria F, Teoh JYC, Egawa S, Powles T, **Shariat SF**; European Association of Urology–Young Academic Urologists Urothelial Carcinoma Working Group (EAU-YAU). First-line immune-checkpoint inhibitor combination therapy for chemotherapy-eligible patients with metastatic urothelial carcinoma: A systematic review and meta-analysis. *Eur J Cancer*. 2021 May 4;151:35-48. PMID: 33962359 Review.
146. Rosiello G, Palumbo C, Deuker M, Stolzenbach LF, Martin T, Tian Z, Larcher A, Capitanio U, Montorsi F, **Shariat SF**, Kapoor A, Saad F, Briganti A, Karakiewicz PI. Partial nephrectomy in frail patients: Benefits of robot-assisted surgery *Surg Oncol*. 2021 Apr 22;38:101588. PMID: 33945961
147. Wenzel M, W  rnschimmel C, Chierigo F, Mori K, Tian Z, Terrone C, **Shariat SF**, Saad F, Tilki D, Graefen M, Mandel P, Roos FC, Chun FKH, Karakiewicz PI. Pattern of Biopsy Gleason Grade Group 5 (4 + 5 vs 5 + 4 vs 5 + 5) Predicts Survival After Radical Prostatectomy or External Beam Radiation Therapy. *Eur Urol Focus*. 2021 Apr 28:S2405-4569(21)00117-6. PMID: 33933420
148. Mori K, Sasaki H, Tsutsumi Y, Sato S, Takiguchi Y, Saito S, Nishi E, Ishii G, Yamamoto T, Koike Y, Miki J, Shimomura T, Kimura T, Miki K, **Shariat SF**, Takahashi H, Aoki M, Egawa S. Trimodal therapy with high-dose-rate brachytherapy and hypofractionated external beam radiation combined with long-term androgen deprivation for unfavorable-risk prostate cancer. *Strahlenther Onkol*. 2021 Apr 28. PMID: 33909100
149. Rajwa P, Mori K, Huebner NA, Martin DT, Sprenkle PC, Weinreb JC, Ploussard G, Pradere B, **Shariat SF**, Leapman MS. The Prognostic Association of Prostate MRI PI-RADS v2 Assessment Category and Risk of Biochemical Recurrence after Definitive Local Therapy for Prostate Cancer: A Systematic Review and Meta-analysis. *J Urol*. 2021 PMID: 33904755
150. Laukhtina E, Pradere B, Mori K, Schuettfort VM, Quhal F, Mostafaei H, Sari Motlagh R, Aydh A, Moschini M, Enikeev D, Karakiewicz PI, Abufaraj M, **Shariat SF**; European Association of Urology-Young Academic Urologists (EAU-YAU): Urothelial carcinoma working group. Prognostic blood-based biomarkers in patients treated with neoadjuvant chemotherapy for urothelial carcinoma of the bladder: A systematic review. *Urol Oncol*. 2021 Apr 19:S1078-1439(21)00115-0. PMID: 33888424

151. Wenzel M, Würnschimmel C, Nocera L, Collà Ruvolo C, Tian Z, **Shariat SF**, Saad F, Briganti A, Tilki D, Graefen M, Kluth LA, Roos FC, Mandel P, Chun FKH, Karakiewicz PI. Overall Survival After Systemic Treatment in High-volume Versus Low-volume Metastatic Hormone-sensitive Prostate Cancer: Systematic Review and Network Meta-analysis. *Eur Urol Focus*. 2021 Apr 11:S2405-4569(21)00109-7. PMID: 33853754
152. Wenzel M, Würnschimmel C, Nocera L, Collà Ruvolo C, Tian Z, **Shariat SF**, Saad F, Briganti A, Graefen M, Becker A, Kluth LA, Mandel P, Chun FKH, Karakiewicz PI. Salvage Radical Prostatectomy: Baseline Prostate Cancer Characteristics and Survival Across SEER Registries. *Clin Genitourin Cancer*. 2021 Mar 19:S1558-7673(21)00078-1. PMID: 33849813
153. Glukhov A, Potoldykova N, Taratkin M, Gordeev S, Polyakovsky K, Laukhtina E, Moschini M, Abufaraj M, **Shariat SF**, Sekacheva M, Enikeev D, Glybochko P. Detection of Urothelial Bladder Cancer Based on Urine and Tissue Telomerase Activity Measured by Novel RT-TRAP-2PCR Method. *J Clin Med*. 2021 Mar 4;10(5):1055. PMID: 33806392
154. Marcq G, Foerster B, Abufaraj M, Matin SF, Azizi M, Gupta M, Li WM, Seisen T, Clinton T, Xylinas E, Mir MC, Schweitzer D, Mari A, Kimura S, Bandini M, Mathieu R, Ku JH, Guruli G, Grabbert M, Czech AK, Muilwijk T, Pycha A, D'Andrea D, Petros FG, Spiess PE, Bivalacqua T, Wu WJ, Rouprêt M, Krabbe LM, Hendricksen K, Egawa S, Briganti A, Moschini M, Graffelle V, Autorino R, John P, Heidenreich A, Chlosta P, Joniau S, Soria F, Pierorazio PM, **Shariat SF**, Kassouf W. Novel Classification for Upper Tract Urothelial Carcinoma to Better Risk-stratify Patients Eligible for Kidney-sparing Strategies: An International Collaborative Study. *Eur Urol Focus*. 2021 Mar 24:S2405-4569(21)00097-3. PMID: 33773965
155. Laukhtina E, Pradere B, D'Andrea D, Rosiello G, Luzzago S, Pecoraro A, Palumbo C, Knipper S, Karakiewicz PI, Margulis V, Quhal F, Sari Motlagh R, Mostafaei H, Mori K, Schuettfort VM, Enikeev D, **Shariat SF**. Prognostic effect of preoperative systemic immune-inflammation index in patients treated with cytoreductive nephrectomy for metastatic renal cell carcinoma. *Minerva Urol Nephrol*. 2021 Mar 26. PMID: 33769012
156. Awamlh BAHA, Shoag JE, Basourakos SP, Lewicki PJ, Posada L, Ma X, Raman JD, **Shariat SF**, Scherr D. The consequences of inadvertent radical nephrectomy in the treatment of upper tract urothelial carcinoma. *Urology*. 2021 Mar 22:S0090-4295(21)00255-7. doi:
157. Aydh A, Abufaraj M, Mori K, Quhal F, Pradere B, Motlagh RS, Mostafaei H, Karakiewicz PI, **Shariat SF**. Performance of fluoro-2-deoxy-D-glucose positron emission tomography-computed tomography imaging for lymph node staging in bladder and upper tract urothelial carcinoma: a systematic review. *Arab J Urol*. 2020 Dec 10;19(1):59-66. PMID: 33763249
158. Moschini M, Zamboni S, Afferi L, Pradere B, Abufaraj M, Soria F, D'Andrea D, Roupret M, De la Taille A, Simeone C, Mattei A, Mathieu R, Bensalah K, Wirth MP, Montorsi F, Briganti A, Gallina A, Simone G, Gallucci M, Di Bona C, Marra G, Mari A, Di Trapani E, Alvarez Maestro M, Krajewski W, **Shariat SF**, Xylinas E, Baumeister P. Comparing oncological outcomes of laparoscopic vs open radical nephroureterectomy for the treatment of upper tract urothelial carcinoma: A propensity score-matched analysis. *rab J Urol*. 2020 Sep 4;19(1):31-36. PMID: 33763246
159. Laukhtina E, Abufaraj M, Al-Ani A, Ali MR, Mori K, Moschini M, Quhal F, Sari Motlagh R, Pradere B, Schuettfort VM, Mostafaei H, Katayama S, Grossmann NC, Fajkovic H, Soria F, Enikeev D, **Shariat SF**; European Association of Urology-Young Academic Urologists (EAU-YAU): Urothelial carcinoma working group. Intravesical Therapy in Patients with Intermediate-risk Non-muscle-invasive Bladder Cancer: A Systematic Review and Network Meta-analysis of Disease Recurrence. *Eur Urol Focus*. 2021 Mar 21:S2405-4569(21)00095-X. PMID: 33762203

160. Quhal F, Mori K, Bruchbacher A, Resch I, Mostafaei H, Pradere B, Schuettfort VM, Laukhtina E, Egawa S, Fajkovic H, Remzi M, **Shariat SF**, Schmidinger M. First-line Immunotherapy-based Combinations for Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-analysis. *Eur Urol Oncol*. 2021 Mar 20:S2588-9311(21)00045-6. PMID: 33757737
161. Wenzel M, Nocera L, Collà Ruvolo C, Würnschimmel C, Tian Z, **Shariat SF**, Saad F, Briganti A, Tilki D, Mandel P, Becker A, Kluth LA, Chun FKH, Karakiewicz PI. Incidence rates and contemporary trends in primary urethral cancer. *Cancer Causes Control*. 2021 Mar 22. PMID: 33751293
162. Schmidinger M, Resch I, Fajkovic H, Remzi M, **Shariat SF**, Bedke J. Dual immune check point blockade or immune check point-tyrosine kinase inhibitor combination: as a first-line treatment in metastatic renal cell carcinoma? *Curr Opin Urol*. 2021 May 1;31(3):270-275. PMID: 33742987
163. Mori K, Schmidinger M, Quhal F, Egawa S, **Shariat SF**, Grünwald V. What is next in second- and later-line treatment of metastatic renal cell carcinoma? review of the recent literature. *Curr Opin Urol*. 2021 May 1;31(3):276-284. PMID: 33742984
164. Abufaraj M, Al-Ani A, AlQudah A, **Shariat SF**. Surgical intervention in patients with urothelial carcinoma of the bladder and lymph node metastasis. *Curr Opin Urol*. 2021 May 1;31(3):220-225. PMID: 33742983
165. Collà Ruvolo C, Nocera L, Stolzenbach LF, Wenzel M, Califano G, Tian Z, Verze P, **Shariat SF**, Saad F, Briganti A, Mirone V, Karakiewicz PI. Tumor Size Predicts Muscle-invasive and Non-organ-confined Disease in Upper Tract Urothelial Carcinoma at Radical Nephroureterectomy. *Eur Urol Focus*. 2021 Mar 15:S2405-4569(21)00060-2. PMID: 33737024
166. Abufaraj M, Siyam A, Xu T, Imm K, Cao C, Waldoer T, Schernhammer E, **Shariat SF**, Yang L. Association Between Body Fat Mass and Kidney Stones in US Adults: Analysis of the National Health and Nutrition Examination Survey 2011-2018. *Eur Urol Focus*. 2021 Mar 15:S2405-4569(21)00067-5. PMID: 33737023
167. Abufaraj M, Xu T, Cao C, Siyam A, Isleem U, Massad A, Soria F, **Shariat SF**, Sutcliffe S, Yang L. Prevalence and trends in urinary incontinence among women in the United States 2005-2018. *Am J Obstet Gynecol*. 2021 Mar 13:S0002-9378(21)00168-X. PMID: 33727114
168. Laukhtina E, Pradere B, D'Andrea D, Rosiello G, Luzzago S, Pecoraro A, Palumbo C, Knipper S, Karakiewicz PI, Margulis V, Quhal F, Motlagh RS, Mostafaei H, Mori K, Schuettfort VM, Enikeev D, **Shariat SF**. Prognostic effect of preoperative serum albumin to globulin ratio in patients treated with cytoreductive nephrectomy for metastatic renal cell carcinoma. *Transl Androl Urol*. 2021 Feb;10(2):609-619. PMID: 33718063
169. D'Andrea D, Soria F, Grotenhuis AJ, Cha EK, Malats N, Di Stasi S, Joniau S, Cai T, van Rhijn BWG, Irani J, Karnes J, Varkarakis J, Baniel J, Palou J, Babjuk M, Spahn M, Ardelt P, Colombo R, Serretta V, Dalbagni G, Gontero P, Bartoletti R, Larré S, Malmstrom PU, Sylvester R, **Shariat SF**. Association of patients' sex with treatment outcomes after intravesical bacillus Calmette-Guérin immunotherapy for T1G3/HG bladder cancer. *World J Urol*. 2021 Mar 13. PMID: 33713162
170. Collà Ruvolo C, Stolzenbach LF, Nocera L, Deuker M, Wenzel M, Tian Z, La Rocca R, Creta M, Capece M, Saad F, **Shariat SF**, Tilki D, Briganti A, Mirone V, Karakiewicz PI. Higher Cancer Mortality in Rural Upper Urinary Tract Urothelial Carcinoma Patients. *Urol Int*. 2021 Mar 12:1-7. PMID: 33709970
171. Rajwa P, Pradere B, Mori K, Ploussard G, Leapman MS, **Shariat SF**. Association of Negative Follow-Up Biopsy and Reclassification during Active Surveillance of Prostate Cancer: A Systematic Review and meta-Analysis. *J Urol*. 2021 PMID: 33683937

172. Wenzel M, Nocera L, Ruvolo CC, Würnschimmel C, Tian Z, **Shariat SF**, Saad F, Briganti A, Tilki D, Graefen M, Kluth LA, Mandel P, Chun FKH, Karakiewicz PI. Racial/Ethnic Disparities in Tumor Characteristics and Treatments in Favorable and Unfavorable Intermediate Risk Prostate Cancer. *J Urol*. 2021 PMID: 33683934
173. Sari Motlagh R, Mori K, Laukhtina E, Aydh A, Katayama S, Grossmann NC, Mostafai H, Pradere B, Quhal F, Schuettfort VM, Roshandel MR, Karakiewicz PI, Teoh J, **Shariat SF**, Fajkovic H. Impact of enhanced optical techniques at time of TURBT with or without single immediate intravesical chemotherapy on recurrence rate of NMIBC, a systematic review and network meta-analysis of randomized trials. *BJU Int*. 2021 Mar 8.PMID: 33683778
174. Mostafaei H, Janisch F, Mori K, Quhal F, Pradere B, Hajebrahimi S, Roehrborn CG, **Shariat SF**. Placebo Response in Patients with Oral Therapy for Overactive Bladder: A Systematic Review and Meta-analysis. *Eur Urol Focus*. 2021 Mar 2:S2405-4569(21)00048-1. PMID: 33674256
175. Miura N, Mori K, Laukhtina E, Schuettfort VM, Abufaraj M, Teoh JYC, Luzzago S, Stolzenbach F, Deuker M, Karakiewicz PI, Briganti A, Enikeev DV, Rouprêt M, Margulis V, Chlosta P, Nyirady P, Babjuk M, Egawa S, Saika T, **Shariat SF**. Prognostic value of the preoperative albumin-globulin ratio in patients with upper urinary tract urothelial carcinoma treated with radical nephroureterectomy: results from a large multicenter international collaboration. *Jpn J Clin Oncol*. 2021 Feb 27.PMID: 33667307
176. Wenzel M, Würnschimmel C, Nocera L, Collà Ruvolo C, Tian Z, **Shariat SF**, Saad F, Briganti A, Graefen M, Kluth LA, Mandel P, Chun FKH, Karakiewicz PI. The effect of lymph node dissection on cancer-specific survival in salvage radical prostatectomy patients. *Prostate*. 2021 Mar 5. PMID: 33666271
177. Nocera L, Collà Ruvolo C, Stolzenbach LF, Wenzel M, Tian Z, Larcher A, Capitanio U, Mirone V, Tilki D, Chun FKH, Kapoor A, **Shariat SF**, Saad F, Montorsi F, Briganti A, Karakiewicz PI. Tumor stage and substage predict cancer-specific mortality after nephrectomy for nonmetastatic renal cancer: histological subtype-specific validation. *Eur Urol Focus*. 2021 Feb 27:S2405-4569(21)00052-3. PMID: 33653677
178. Schuettfort VM, Andrea DD, Quhal F, Mostafaei H, Laukhtina E, Mori K, König F, Rink M, Abufaraj M, Karakiewicz PI, Luzzago S, Rouprêt M, Enikeev D, Zimmermann K, Deuker M, Moschini M, Sari Motlagh R, Grossmann NC, Katayama S, Pradere B, **Shariat SF**. A Panel of systemic inflammatory response biomarkers for outcome prediction in patients treated with radical cystectomy for urothelial carcinoma. *BJU Int*. 2021 Mar 1. PMID: 33650265
179. Janisch F, Klotzbücher T, Marks P, Kienapfel C, Meyer CP, Yu H, Fühner C, Hillemacher T, Mori K, Mostafei H, **Shariat SF**, Fisch M, Dahlem R, Rink M. Predictive value of De Ritis ratio in metastatic renal cell carcinoma treated with tyrosine-kinase inhibitors. *World J Urol*. 2021 Mar 1. PMID: 33649869
180. Kardoust Parizi M, Margulis V, Lotan Y, Mori K, **Shariat SF**. Fibroblast growth factor receptor: A systematic review and meta-analysis of prognostic value and therapeutic options in patients with urothelial bladder carcinoma. *Urol Oncol*. 2021 Feb 25:S1078-1439(21)00048-X. PMID: 33642228.
181. Collà Ruvolo C, Würnschimmel C, Wenzel M, Nocera L, Califano G, Tian Z, **Shariat SF**, Saad F, Chun FKH, Briganti A, Verze P, Imbimbo C, Mirone V, Karakiewicz PI. Comparison between 1973 and 2004/2016 WHO grading systems in patients with Ta urothelial carcinoma of urinary bladder. *J Clin Pathol*. 2021 Feb 23.PMID: 33622681

182. Würnschimmel C, Ruvolo CC, Nocera L, Wenzel M, Tian Z, Saad F, Briganti A, **Shariat SF**, Mirone V, Chun FKH, Tilki D, Graefen M, Karakiewicz PI. Race/Ethnicity Determines Life Expectancy in Surgically Treated T1aN0M0 Renal Cell Carcinoma Patients. *Eur Urol Focus*. 2021. PMID: 33610487
183. Pecoraro A, Deuker M, Rosiello G, Stolzenbach F, Luzzago S, Tian Z, **Shariat SF**, Saad F, Briganti A, Kapoor A, Fiori C, Porpiglia F, Karakiewicz PI. Comparison between small renal masses 0-2 cm vs. 2.1-4 cm in size: A population-based study. *Urol Oncol*. 2021 Apr;39(4):239. PMID: 33602621
184. Wenzel M, Deuker M, Nocera L, Collà Ruvolo C, Tian Z, **Shariat SF**, Saad F, Briganti A, Becker A, Kluth LA, Chun FKH, Karakiewicz PI. Comparison between urothelial and non-urothelial urethral cancer. *Front Oncol*. 2021 Jan 29;10:629692. PMID: 33585257
185. Mori K, Resch I, Miura N, Laukhtina E, Schuettfort VM, Pradere B, Katayama S, D'Andrea D, Kardoust Parizi M, Abufaraj M, Fukuokaya W, Collà Ruvolo C, Luzzago S, Knipper S, Palumbo C, Karakiewicz PI, Briganti A, Enikeev DV, Rouprêt M, Margulis V, Egawa S, **Shariat SF**. Prognostic role of the systemic immune-inflammation index in upper tract urothelial carcinoma treated with radical nephroureterectomy: results from a large multicenter international collaboration. *Cancer Immunol Immunother*. 2021 Feb 16. PMID: 33591412
186. Zhao C, Bjurlin MA, Roberts T, Rink M, **Shariat SF**, Matulewicz RS. A Systematic Review and Scoping Analysis of Smoking Cessation after a Urological Cancer Diagnosis. *J Urol*. 2021 Feb 12. PMID: 33577364
187. Deuker M, Rosiello G, Stolzenbach LF, Martin T, Collà Ruvolo C, Nocera L, Tian Z, Roos FC, Becker A, Kluth LA, Tilki D, **Shariat SF**, Saad F, Chun FKH, Karakiewicz PI. Sex- and age-related differences in the distribution of metastases in patients with upper urinary tract urothelial carcinoma. *J Natl Compr Canc Netw*. 2021 Feb 11:1-7. PMID: 33571954
188. Krajewski W, Nowak Ł, Moschini M, Poletajew S, Chorbińska J, Necchi A, Montorsi F, Briganti A, Sanchez-Salas R, **Shariat SF**, Palou J, Babjuk M, Teoh JY, Soria F, Pradere B, Ornaghi PI, Pawlak A, Dembowski J, Zdrojowy R. Impact of adjuvant chemotherapy on survival of patients with advanced residual disease at radical cystectomy following neoadjuvant chemotherapy: systematic review and meta-analysis. *J Clin Med*. 2021 Feb 8;10(4):651. PMID: 33567656
189. Rosiello G, Palumbo C, Deuker M, Stolzenbach LF, Martin T, Tian Z, Gallina A, Montorsi F, Black P, Kassouf W, **Shariat SF**, Saad F, Briganti A, Karakiewicz PI. Sex- and age-related differences in the distribution of bladder cancer metastases. *Jpn J Clin Oncol*. 2021. PMID: 33558890
190. Rosiello G, Palumbo C, Deuker M, Stolzenbach LF, Martin T, Tian Z, Gallina A, Montorsi F, Black P, Kassouf W, **Shariat SF**, Saad F, Briganti A, Karakiewicz PI. Racial differences in the distribution of bladder cancer metastases: a population-based analysis. *Cent European J Urol*. 2020;73(4):407-415. PMID: 33552564
191. Wenzel M, Nocera L, Collà Ruvolo C, Würnschimmel C, Tian Z, **Shariat SF**, Saad F, Briganti A, Tilki D, Mandel P, Kluth LA, Chun FKH, Karakiewicz PI. Sex-Related Differences Include Stage, Histology, and Survival in Urethral Cancer Patients. *Clin Genitourin Cancer*. 2021 PMID: 33526327
192. Rosiello G, Pecoraro A, Deuker M, Stolzenbach LF, Martin T, Tian Z, Larcher A, Capitanio U, Montorsi F, **Shariat SF**, Kapoor A, Saad F, Briganti A, Karakiewicz PI. The impact of sex and age on distribution of metastases in patients with renal cell carcinoma. *Int J Clin Oncol*. 2021 Jan 30. PMID: 33515351

193. Khene ZE, Dosin G, Peyronnet B, Gasmi A, Doumerc N, Ouzaid I, Pradere B, Brassier M, Roumiguié M, Mathieu R, Rioux-Leclercq N, Raman JD, **Shariat S**, Bensalah K. Adherent perinephric fat affects perioperative outcomes after partial nephrectomy: a systematic review and meta-analysis. *Int J Clin Oncol*. 2021 Jan 27. PMID: 33502646
194. Quhal F, Pradere B, Laukhtina E, Sari Motlagh R, Mostafaei H, Mori K, Schuettfort VM, Karakiewicz PI, Rouprêt M, Enikeev D, Rink M, Abufaraj M, **Shariat SF**. Prognostic value of albumin to globulin ratio in non-muscle-invasive bladder cancer. *World J Urol*. 2021 Jan 26. PMID: 33496841
195. Grossmann NC, Schuettfort VM, Pradere B, Moschini M, Quhal F, Mostafaei H, Soria F, Katayama S, Laukhtina E, Mori K, Sari Motlagh R, Poyet C, Abufaraj M, Karakiewicz PI, **Shariat SF**, D'Andrea D. Further understanding of urokinase plasminogen activator overexpression in urothelial bladder cancer progression, clinical outcomes and potential therapeutic targets. *Onco Targets Ther*. 2021 Jan 13;14:315-324. PMID: 33488094
196. Lemberger U, Quhal F, Bruchbacher A, **Shariat SF**, Hiess M. The microbiome in urinary tract infections in children - an update. *Eur Urol*. 2021 Jan 21:S0302-2838(21)00017-8. PMID: 33487477
Curr Opin Urol. 2021 Mar 1;31(2):147-154. PMID: 33449574
197. Motlagh RS, Abufaraj M, Yang L, Mori K, Pradere B, Laukhtina E, Mostafaei H, Schuettfort V, Quhal F, Montorsi F, Amjadi M, Gratzke C, **Shariat SF**. Penile Rehabilitation Strategy after Nerve Sparing Radical Prostatectomy: A Systematic Review and Network Meta-Analysis of Randomized Trials. *J Urol*. 2021 Jan 14;. PMID: 33443457
198. Abufaraj M, Siyam A, Ali MR, Suarez-Ibarrola R, Yang L, Foerster B, **Shariat SF**. Functional Outcomes after Local Salvage Therapies for Radiation-Recurrent Prostate Cancer Patients: A Systematic Review. *Cancers (Basel)*. 2021 Jan 11;13(2):244. PMID: 33440752
199. Afferi L, Abufaraj M, Soria F, D'Andrea D, Xylinas E, Seisen T, Roupret M, Lonati C, De la Taille A, Peyronnet B, Laukhtina E, Pradere B, Mari A, Krajewski W, Alvarez-Maestro M, Kikuchi E, Shigeta K, Chlosta P, Montorsi F, Briganti A, Simone G, Ornaghi PI, Cerruto MA, Antonelli A, Matsumoto K, Karakiewicz PI, Mordasini L, Mattei A, **Shariat SF**, Moschini M. A comparison of perioperative outcomes of laparoscopic versus open nephroureterectomy for upper tract urothelial carcinoma: a propensity score matching analysis. *Minerva Urol Nefrol*. 2021 Jan 13. PMID: 33439575
200. Luzzago S, Palumbo C, Rosiello G, Pecoraro A, Deuker M, Stolzenbach F, Mistretta FA, Tian Z, Musi G, Montanari E, **Shariat SF**, Saad F, Briganti A, de Cobelli O, Karakiewicz PI. Metabolic syndrome predicts worse perioperative outcomes in patients treated with radical prostatectomy for non-metastatic prostate cancer. *Surg Oncol*. 2021 Jan 3;37:101519. PMID: 33429324
201. van Rhijn BWG, Hentschel AE, Bründl J, Compérat EM, Hernández V, Čapoun O, Bruins HM, Cohen D, Rouprêt M, **Shariat SF**, Mostafid AH, Zigeuner R, Dominguez-Escrig JL, Burger M, Soukup V, Gontero P, Palou J, van der Kwast TH, Babjuk M, Sylvester RJ; Prognostic Value of the WHO1973 and WHO2004/2016 Classification Systems for Grade in Primary Ta/T1 Non-muscle-invasive Bladder Cancer: A Multicenter European Association of Urology Non-muscle-invasive Bladder Cancer Guidelines Panel Study. *Eur Urol Oncol*. 2021 Jan 8:S2588-9311(20)30210-8. PMID: 33423944
202. Laukhtina E, Pradere B, Mori K, Schuettfort VM, Quhal F, Mostafaei H, Sari Motlagh R, Katayama S, Grossmann NC, Moschini M, Enikeev D, **Shariat SF**. Catalog of prognostic tissue-based biomarkers in patients treated with neoadjuvant systemic therapy for urothelial carcinoma of the bladder: a systematic review. *Urol Oncol*. 2021 Jan 7:S1078-1439(20)30647-5. PMID: 33423937.

203. Schmidinger M, **Shariat SF**, Fajkovic H. Dual immune checkpoint inhibition in metastatic renal cell carcinoma: Editorial re.: Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced RCC: extended 4-year follow-up of the phase III CheckMate 214 trial. *ESMO Open*. 2021 Jan 6;6(1):100035. PMID: 33421736
204. Sylvester RJ, Rodríguez O, Hernández V, Turturica D, Bauerová L, Bruins HM, Bründl J, van der Kwast TH, Brisuda A, Rubio-Briones J, Seles M, Hentschel AE, Kusuma VRM, Huebner N, Cotte J, Mertens LS, Volanis D, Cussenot O, Subiela Henríquez JD, de la Peña E, Pisano F, Pešl M, van der Heijden AG, Herdegen S, Zlotta AR, Hacek J, Calatrava A, Mannweiler S, Bosschieter J, Ashabere D, Haitel A, Côté JF, El Sheikh S, Lunelli L, Algaba F, Alemany I, Soria F, Runneboom W, Breyer J, Nieuwenhuijzen JA, Llorente C, Molinaro L, Hulsbergen-van de Kaa CA, Evert M, Kiemeny LALM, N'Dow J, Plass K, Čapoun O, Soukup V, Dominguez-Escrig JL, Cohen D, Palou J, Gontero P, Burger M, Zigeuner R, Mostafid AH, **Shariat SF**, Roupřet M, Compérat EM, Babjuk M, van Rhijn BWG. European Association of Urology (EAU) Prognostic Factor Risk Groups for Non-muscle-invasive Bladder Cancer (NMIBC) Incorporating the WHO 2004/2016 and WHO 1973 Classification Systems for Grade: An Update from the EAU NMIBC Guidelines Panel. *Eur Urol*. 2021 Jan 6:S0302-2838(20)31019-8. PMID: 33419683
205. Luzzago S, Rosiello G, Pecoraro A, Deuker M, Stolzenbach F, Mistretta FA, Tian Z, Musi G, Montanari E, **Shariat SF**, Saad F, Briganti A, de Cobelli O, Karakiewicz PI. Contemporary rates and predictors of open conversion during minimally invasive partial nephrectomy for kidney cancer. *Surg Oncol*. 2021 Mar;36:131-137. PMID: 33401103
206. Sfakianos JP, Gul Z, **Shariat SF**, Matin SF, Daneshmand S, Plimack E, Lerner S, Roupřet M, Pal S. Genetic Differences Between Bladder and Upper Urinary Tract Carcinoma: Implications for Therapy. *Eur Urol Oncol*. 2020 Dec 30:S2588-9311(20)30215-7. PMID: 33386276
207. Mori K, Sharma V, Comperat EM, Sato S, Laukhtina E, Schuettfort VM, Pradere B, Parizi MK, Karakiewicz PI, Egawa S, Tilki D, Boorjian SA, **Shariat SF**. Differential prognostic impact of different Gleason patterns in grade group 4 in radical prostatectomy specimens. *Eur J Surg Oncol*. 2020 Dec 24:S0748-7983(20)31235-X. PMID: 33371950
208. Deuker M, Stolzenbach LF, Collà Ruvolo C, Nocera L, Tian Z, Roos FC, Becker A, Kluth LA, Tilki D, **Shariat SF**, Saad F, Chun FKH, Karakiewicz PI. Upper Urinary Tract Tumors: Variant Histology Versus Urothelial Carcinoma. *Clin Genitourin Cancer*. 2020 Dec 2:S1558-7673(20)30265-2. PMID: 33358490
209. Woldu SL, Ng CK, Loo RK, Slezak JM, Jacobsen SJ, Tan WS, Kelly JD, Lough T, Darling D, van Kessel KEM, de Jong JJ, van Criekinge W, **Shariat SF**, Hiar A, Brown S, Boorjian SA, Barocas DA, Svatek RS, Lotan Y. Evaluation of the New American Urological Association Guidelines Risk Classification for Hematuria. *J Urol*. 2020 Dec 24: PMID: 33356483
210. Papp L, Spielvogel CP, Grubmüller B, Grahovac M, Krajnc D, Ecsedi B, Sareshgi RAM, Mohamad D, Hamboeck M, Rausch I, Mitterhauser M, Wadsak W, Haug AR, Kenner L, Mazal P, Susani M, Hartenbach S, Baltzer P, Helbich TH, Kramer G, **Shariat SF**, Beyer T, Hartenbach M, Hacker M. Supervised machine learning enables non-invasive lesion characterization in primary prostate cancer with [68Ga]Ga-PSMA-11 PET/MRI. *Eur J Nucl Med Mol Imaging*. 2020 Dec 19. PMID: 33341915
211. Wenzel M, Deuker M, Stolzenbach F, Nocera L, Collà Ruvolo C, Tian Z, **Shariat SF**, Saad F, Briganti A, Kluth LA, Chun FKH, Karakiewicz PI. The effect of race/ethnicity on histological subtype distribution, stage at presentation and cancer specific survival in urethral cancer. *Urol Oncol*. 2020 Dec 10:S1078-1439(20)30618-9. PMID: 33309509

212. Ziouziou I, **Shariat SF**, Ajdi F, Khabbal Y.: Association of Processed Meats and Alcohol Consumption with Renal Cell Carcinoma: A Worldwide Population-Based Study. *Nutr Cancer*. 2020.PMID: 33283531
213. Huebner NA, Korn S, Resch I, Grubmüller B, Gross T, Gale R, Kramer G, Poetsch N, Clauser P, Haitel A, Fajkovic H, **Shariat SF**, Baltzer PA.: Visibility of significant prostate cancer on multiparametric magnetic resonance imaging (MRI)-do we still need contrast media? *Eur Radiol*. 2020.PMID: 33263793
214. Mostafaei H, Mori K, Hajebrاهيمi S, Abufaraj M, Karakiewicz PI, **Shariat SF.**: Association of erectile dysfunction and cardiovascular diseases: an umbrella review of systematic reviews and meta-analyses. *BJU Int*. 2020.PMID: 33260254.
215. Huebner NA, **Shariat SF.**: Clinical Impact and Statistical Significance of Multiparametric Magnetic Resonance Imaging for Local Staging of Prostate Cancer. *Eur Urol*. 2020.PMID: 33246667.
216. Deuker M, Stolzenbach LF, Collà Ruvolo C, Nocera L, Tian Z, Roos FC, Becker A, Kluth LA, Tilki D, **Shariat SF**, Saad F, Chun FKH, Karakiewicz PI.: Bladder cancer stage and mortality: urban vs. rural residency. *Cancer Causes Control*. 2020.PMID: 33230694
217. Schuettfort VM, D Andrea D, Quhal F, Mostafaei H, Laukhtina E, Mori K, Sari Motlagh R, Rink M, Abufaraj M, Karakiewicz PI, Luzzago S, Rouprêt M, Chlosta P, Babjuk M, Deuker M, Moschini M, **Shariat SF**, Pradere B. Impact of Preoperative Serum Albumin-Globulin Ratio on Disease Outcome After Radical Cystectomy for Urothelial Carcinoma of the Bladder. *Urol Oncol*. 2020.PMID: 33189530
218. Mori K, Abufaraj M, Mostafaei H, Quhal F, Fajkovic H, Remzi M, Karakiewicz PI, Egawa S, Schmidinger M, **Shariat SF**, Gust KM. The Predictive Value of Programmed Death Ligand 1 in Patients with Metastatic Renal Cell Carcinoma Treated with Immune-checkpoint Inhibitors: A Systematic Review and Meta-analysis.*Eur Urol*. 2020 Nov 7:S0302-2838(20)30783-1. PMID: 33172722
219. Rosiello G, Pecoraro A, Luzzago S, Deuker M, Stolzenbach LF, Tian Z, Larcher A, Capitanio U, Montorsi F, **Shariat SF**, Kapoor A, Saad F, Briganti A, Karakiewicz PI. Prognostic factors in patients with small renal masses: a comparison between <2 vs. 2.1-4 cm renal cell carcinomas. *Cancer Causes Control*. 2020 Nov 9. PMID: 33169306
220. Nocera L, Stolzenbach LF, Ruvolo CC, Wenzel M, Tian Z, Rosiello G, Bravi CA, Candela L, Basile G, Larcher A, **Shariat SF**, Bertini R, Capitanio U, Salonia A, Montorsi F, Briganti A, Karakiewicz PI. Predicting the risk of pT3a stage in cT1 clear cell renal cell carcinoma. *Eur J Surg Oncol*. 2020 Nov 5:S0748-7983(20)30877-5. PMID: 33168336
221. Tellini R, Mari A, Muto G, Cacciamani GE, Ferro M, Stangl-Kremser J, Campi R, Soria F, Rink M, Xylinas E, Minervini A, Briganti A, Montorsi F, Roupret M, **Shariat SF**, Moschini M; European Association of Urology–Young Academic Urologists Urothelial Carcinoma Working Group (EAU-YAU). Impact of Smoking Habit on Perioperative Morbidity in Patients Treated with Radical Cystectomy for Urothelial Bladder Cancer: A Systematic Review and Meta-analysis. *Eur Urol Oncol*. 2020 Nov 4:S2588-9311(20)30171-1. PMID: 33160975
222. Roumiguie M, Brisuda A, Burger M, Escrig J, Hammerer P, Mccracken S, Mostafid H, Muto G, Redorta J, de Reijke T, **Shariat S**, Ströck V, Malavaud B. Un patient sur quatre ressent un inconfort significatif lors des cystoscopies de surveillance (TVNIM) dans une étude observationnelle européenne.*Prog Urol*. 2020 Nov;30(13):830-831. PMID: 33157794

223. Khene Z, Brassier M, Kokorian R, Mathieu R, Peyronnet B, Gasmi A, Rioux-Leclercq N, Kammerer-Jacquet S, **Shariat S**, Pradere B, Laguerre B, Bensalah K. Carcinome à cellules claires métastatique : la radiomique comme biomarqueur prédictif de la survie des patients traités par nivolumab. *Prog Urol*. 2020 Nov;30(13):818. PMID: 33157774
224. Khene Z, Brassier M, Mathieu R, Kokorian R, Gasmi A, Peyronnet B, Khene F, Rioux-Leclercq N, **Shariat S**, Laguerre B, Bensalah K. L'apprentissage machine peut prédire la réponse tumorale chez les patients traités par nivolumab pour un carcinome rénal métastatique – Un concept d'intelligence artificielle. *Prog Urol*. 2020 Nov;30(13):787-788. PMID: 33157724
225. Mazouin C, Khene Z, Peyronnet B, Gasmi A, Dosin G, Brassier M, Thi Dang V, Ouzaid I, Larcher A, Roumiguié M, Verhoest G, Pradère B, **Shariat S**, Mathieu R, Bigot P, Doumerc N, Bensalah K. Prédire la morbidité de la néphrectomie partielle : retour à la simplicité. *Prog Urol*. 2020 Nov;30(13):748-749. PMID: 33157662
226. Mostafaei H, Mori K, Quhal F, Miura N, Motlagh RS, Pradere B, Laukhtina E, Lysenko I, Ghaffari S, Hajebrahimi S, **Shariat SF**. Nocebo Response in the Pharmacological Management of Overactive Bladder: A Systematic Review and Meta-analysis. *Eur Urol Focus*. 2020 Nov 2:S2405-4569(20)30294-7. PMID: 33153953
227. Stolzenbach LF, Rosiello G, Pecoraro A, Palumbo C, Luzzago S, Deuker M, Tian Z, Knipper AS, Pompe R, Zorn KC, **Shariat SF**, Chun FKH, Graefen M, Saad F, Karakiewicz PI. Prostate Cancer Grade and Stage Misclassification in Active Surveillance Candidates: Black Versus White Patients. *J Natl Compr Canc Netw*. 2020 Nov 2;18(11):1492-1499. PMID: 33152695
228. Soria F, Black PC, Fairey AS, Cookson MS, Yu EY, Kassouf W, Dall'Era MA, Sridhar SS, McGrath JS, Wright JL, Thorpe AC, Morgan TM, Daneshmand S, Holzbeierlein JM, Bivalacqua TJ, North S, Barocas DA, Lotan Y, Grivas P, Stephenson AJ, Shah JB, van Rhijn BW, Spiess PE, **Shariat SF**, Gontero P. Neoadjuvant chemotherapy plus radical cystectomy versus radical cystectomy alone in clinical T2 bladder cancer without hydronephrosis. *BJU Int*. 2020 Nov 5. PMID: 33152179
229. Ziouziou I, Touzani AM, Lahlou L, **Shariat SF**, Sanguedolce F, Neuzillet Y, Ajdi F, Khabbal Y. Association of Prostate Cancer with Nuts, Seeds, Alcohol and Processed Meats: A Worldwide Population-Based Study. *Nutr Cancer*. 2020 Nov 5:1-8. PMID: 33148052
230. Rasul S, Hartenbach M, Wollenweber T, Kretschmer-Chott E, Grubmüller B, Kramer G, **Shariat S**, Wadsak W, Mitterhauser M, Pichler V, Vranka C, Hacker M, Haug AR. Prediction of response and survival after standardized treatment with 7400 MBq ¹⁷⁷Lu-PSMA-617 every 4 weeks in patients with metastatic castration-resistant prostate cancer. *Eur J Nucl Med Mol Imaging*. 2020 Oct 30. PMID: 33128131
231. Kardoust Parizi M, **Shariat SF**, Margulis V, Mori K, Lotan Y. Value of tumour-infiltrating immune cells in predicting response to intravesical BCG in patients with non-muscle-invasive bladder cancer: a systematic review and meta-analysis. *BJU Int*. 2020 Oct 18. PMID: 33073457.
232. Schuettfort VM, Pradere B, Quhal F, Mostafaei H, Laukhtina E, Mori K, Motlagh RS, Rink M, D'Andrea D, Abufaraj M, Karakiewicz PI, **Shariat SF**. Diagnostic challenges and treatment strategies in the management of upper-tract urothelial carcinoma. *Turk J Urol*. 2020 Oct 9. PMID: 33052841
233. Foerster B, Abufaraj M, Mari A, Seisen T, Bandini M, Schweitzer D, Czech AK, Moschini M, D'Andrea D, Bianchi M, Hendricksen K, Rouprêt M, Briganti A, van Rhijn BWG, Chłosta P, Colin P, John H, **Shariat SF**. The Performance of Tumor Size as Risk Stratification Parameter in Upper

- Tract Urothelial Carcinoma (UTUC). Clin Genitourin Cancer. 2020 Sep 18:S1558-7673(20)30218-4. PMID: 33046411
234. Szarvas T, Csizmarik A, Váradi M, Fazekas T, Hüttl A, Nyirády P, Hadaschik B, Grünwald V, Tschirdewahn S, **Shariat SF**, Sevcenco S, Maj-Hes A, Kramer G. The prognostic value of serum MMP-7 levels in prostate cancer patients who received docetaxel, abiraterone, or enzalutamide therapy. Urol Oncol. 2020 Oct 9:S1078-1439(20)30436-1. PMID: 33046366
235. Rosiello G, Palumbo C, Pecoraro A, Luzzago S, Deuker M, Stolzenbach LF, Tian Z, Gallina A, Gandaglia G, Montorsi F, **Shariat SF**, Saad F, Briganti A, Karakiewicz PI. The effect of sex on disease stage and survival after radical cystectomy: a population-based analysis. Urol Oncol. 2020 Oct 6:S1078-1439(20)30435-X. PMID: 33036900
236. Aksoy O, Pencik J, Hartenbach M, Moazzami AA, Schleder M, Balber T, Varady A, Philippe C, Baltzer PA, Mazumder B, Whitchurch JB, Roberts CJ, Haitel A, Herac M, Susani M, Mitterhauser M, Marculescu R, Stangl-Kremser J, Hassler MR, Kramer G, **Shariat SF**, Turner SD, Tichy B, Oppelt J, Pospisilova S, Hartenbach S, Tangermann S, Egger G, Neubauer HA, Moriggl R, Culig Z, Greiner G, Hoermann G, Hacker M, Heery DM, Merkel O, Kenner L. Thyroid and androgen receptor signaling are antagonized by μ -Crystallin in prostate cancer. Int J Cancer. 2020 Oct 9. PMID: 33034050
237. Pecoraro A, Rosiello G, Luzzago S, Deuker M, Stolzenbach F, Tian Z, **Shariat SF**, Saad F, Briganti A, Kapoor A, Fiori C, Porpiglia F, Karakiewicz PI. Small Renal Masses With Tumor Size 0 to 2 cm: A SEER-Based Study and Validation of NCCN Guidelines. J Natl Compr Canc Netw. 2020 Oct 1;18(10):1340-1347. PMID: 33022641
238. Moschini M, Afferi L, Gandaglia G, D'Andrea D, Zamboni S, Di Bona C, Mordasini L, Mattei A, Baumeister P, Martini A, Burgio G, **Shariat SF**, Sanchez-Salas R, Cathelineau X, Stabile A, Zaffuto E, Salonia A, Colombo R, Necchi A, Montorsi F, Briganti A, Gallina A. Prediction of the Need for an Extended Lymphadenectomy at the Time of Radical Cystectomy in Patients with Bladder Cancer. Eur Urol Focus. 2020 Oct 2:S2405-4569(20)30268-6. PMID: 33020030
239. Schuettfort VM, Pradere B, Quhal F, Mostafaei H, Laukhtina E, Mori K, Sari Motlagh R, Fisch M, D'Andrea D, Rink M, Gontero P, Soria F, **Shariat SF**. Incidence and outcome of salvage cystectomy after bladder sparing therapy for muscle invasive bladder cancer: a systematic review and meta-analysis. World J Urol. 2020 Sep 29. PMID: 32995918
240. Palumbo C, Mazzone E, Mistretta FA, Knipper S, Tian Z, Perrotte P, Montorsi F, **Shariat SF**, Saad F, Simeone C, Briganti A, Antonelli A, Karakiewicz PI. Primary lymphomas of the genitourinary tract: A population-based study. Asian J Urol. 2020 Oct;7(4):332-339. PMID: 32995277
241. Grubmüller B, Jahrreiss V, Huebner N, Mitterhauser M, Stangl-Kremser J, Grubmüller KH, Baltzer P, Hacker M, Goldner G, **Shariat SF**, Rasul S. Differential impact of radiation therapy after radical prostatectomy on recurrence patterns: an assessment using [68Ga]Ga-PSMA ligand PET/CT(MRI). Prostate Cancer Prostatic Dis. 2020 Sep 29. PMID: 32994534
242. Quhal F, Pradere B, Sari Motlagh R, Mori K, Laukhtina E, Aydh A, Mostafaei H, Lysenko I, Schuettfort VM, Stolzenbach F, Palumbo C, Heidenreich A, Briganti A, Karakiewicz PI, Chlosta P, **Shariat SF**. Prognostic value of preoperative albumin to globulin ratio in patients treated with salvage radical prostatectomy for radiation recurrent prostate cancer. Minerva Urol Nefrol. 2020 Sep 29. doi: 10.23736/S0393-2249.20.03938-7. PMID: 32993278

243. D'Andrea D, Pradere B, **Shariat SF**. Re: Adjuvant Chemotherapy in Upper Tract Urothelial Carcinoma (the POUT Trial): A Phase 3, Open-label, Randomised Controlled Trial. *Eur Urol*. 2020 Sep 24:S0302-2838(20)30632-1. PMID: 32981804.
244. D'Andrea D, Matin S, Black PC, Petros FG, Zargar H, Dinney CP, Cookson MS, Kassouf W, Dall'Era MA, McGrath JS, Wright JL, Thorpe AC, Morgan TM, Holzbeierlein JM, Bivalacqua TJ, Sridhar SS, North S, Barocas DA, Lotan Y, Stephenson AJ, van Rhijn BW, Spiess PE, Daneshmand S, **Shariat SF**. Comparative effectiveness of neoadjuvant chemotherapy in bladder and upper urinary tract urothelial carcinoma. *BJU Int*. 2020 Sep 27. PMID: 32981193
245. Luzzago S, Knipper S, Palumbo C, Rosiello G, Pecoraro A, Deuker M, Mistretta FA, Tian Z, Musi G, Montanari E, **Shariat SF**, Saad F, Briganti A, de Cobelli O, Karakiewicz PI. Effect of Age on Cancer-specific Mortality in Patients With Urothelial Carcinoma of the Urinary Bladder: A Population-based Competing-risks Analysis Across Disease Stages. *Am J Clin Oncol*. 2020 Sep 23. PMID: 32976177
246. Teoh JY, Huang J, Ko WY, Lok V, Choi P, Ng CF, Sengupta S, Mostafid H, Kamat AM, Black PC, **Shariat S**, Babjuk M, Wong MC. Global Trends of Bladder Cancer Incidence and Mortality, and Their Associations with Tobacco Use and Gross Domestic Product Per Capita. *Eur Urol*. 2020 Sep 21:S0302-2838(20)30697-7. PMID: 32972792.
247. Powles T, van der Heijden MS, Castellano D, Galsky MD, Loriot Y, Petrylak DP, Ogawa O, Park SH, Lee JL, De Giorgi U, Bögemann M, Bamias A, Eigl BJ, Gurney H, Mukherjee SD, Fradet Y, Skoneczna I, Tsiatas M, Novikov A, Suárez C, Fay AP, Duran I, Necchi A, Wildsmith S, He P, Angra N, Gupta AK, Levin W, Bellmunt J; DANUBE study investigators. Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial. *Lancet Oncol*. 2020 Sep 21:S1470-2045(20)30541-6. PMID: 32971005.
248. Deuker M, Stolzenbach LF, Collà Ruvolo C, Nocera L, Mansour M, Tian Z, Roos FC, Becker A, Kluth LA, Tilki D, **Shariat SF**, Saad F, Chun FKH, Karakiewicz PI. Micropapillary Versus Urothelial Carcinoma of the Urinary Bladder: Stage at Presentation and Efficacy of Chemotherapy Across All Stages-A SEER-based Study. *Eur Urol Focus*. 2020 Sep 19:S2405-4569(20)30223-6. PMID: 32962961.
249. Laukhina E, Pradere B, D Andrea D, Rosiello G, Luzzago S, Pecoraro A, Palumbo C, Knipper S, Karakiewicz PI, Margulis V, Quhal F, Sari Motlagh R, Mostafaei H, Mori K, Kimura S, Enikeev D, **Shariat SF**. Association of preoperative serum De Ritis ratio with oncological outcomes in patients treated with cytoreductive nephrectomy for metastatic renal cell carcinoma. *Urol Oncol*. 2020 Sep 19:S1078-1439(20)30380-X. PMID: 32962909.
250. Benamran D, Seisen T, Naoum E, Vaessen C, Parra J, Mozer P, **Shariat SF**, Rouprêt M. Risk stratification for upper tract urinary carcinoma. *Transl Androl Urol*. 2020 Aug;9(4):1799-1808. PMID: 32944543; PMCID: PMC7475669.
251. Kocher NJ, Canes D, Bensalah K, Roupert M, Lallas C, Margulis V, **Shariat S**, Colin P, Matin S, Tracy C, Xylinas E, Wagner A, Roumiguie M, Kassouf W, Klatte T, Raman JD. Incidence and preoperative predictors for major complications following radical nephroureterectomy. *Transl Androl Urol*. 2020 Aug;9(4):1786-1793. PMID: 32944541
252. Mun DH, Pradere B, **Shariat SF**, Remzi M. Intraoperative aerosol viral transmission in minimally invasive surgery: A scoping review and impact on clinical guidelines and practice during the onset of the COVID-19 pandemic. *BJU Int*. 2020 Sep 16. PMID: 32937006.

253. Baboudjian M, Ploussard G, **Shariat SF**, Ost P, Briganti A, Roupret M, Pradere B. How to deal with steroids use in the management of metastatic prostate cancer during pandemic. *Transl Androl Urol*. 2020 Aug;9(4):1546-1549. PMID: 32944516; PMCID: PMC7475678.
254. Enikeev D, Traxer O, Taratkin M, Okhunov Z, **Shariat S**. A review of thulium-fiber laser in stone lithotripsy and soft tissue surgery. *Curr Opin Urol*. 2020 Sep 10. PMID: 32925311.
255. Mori K, Mostafaei H, Pradere B, Motlagh RS, Quhal F, Laukhtina E, Schuettfort VM, Abufaraj M, Karakiewicz PI, Kimura T, Egawa S, **Shariat SF**. Apalutamide, enzalutamide, and darolutamide for non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis. *Int J Clin Oncol*. 2020 Sep 14. PMID: 32924096.
256. Fizazi K, Shore N, Tammela TL, Ulys A, Vjaters E, Polyakov S, Jievaltas M, Luz M, Alekseev B, Kuss I, Le Berre MA, Petrenciuc O, Snapir A, Sarapohja T, Smith MR; ARAMIS Investigators. Nonmetastatic, castration-resistant prostate cancer and survival with darolutamide. *N Engl J Med*. 2020 Sep 10;383(11):1040-1049. PMID: 32905676.
257. Abufaraj M, Xu T, Cao C, Waldhoer T, Seitz C, D'andrea D, Siyam A, Tarawneh R, Fajkovic H, Schernhammer E, Yang L, **Shariat SF**. Prevalence and trends in kidney stone among adults in the usa: analyses of national health and nutrition examination survey 2007-2018 Data. *Eur Urol Focus*. 2020 Sep 5:S2405-4569(20)30224-8. PMID: 32900675.
258. Kardoust Parizi M, Margulis V, Compe Rat E, **Shariat SF**. The value and limitations of urothelial bladder carcinoma molecular classifications to predict oncological outcomes and cancer treatment response: A systematic review and meta-analysis. *Urol Oncol*. 2020 Sep 5:S1078-1439(20)30389-6. PMID: 32900624.
259. Gild P, Vetterlein MW, Seiler R, Necchi A, Hendricksen K, Mertens LS, Roghmann F, Landenberg NV, Gontero P, Cumberbatch M, Dobruch J, Seisen T, Grande P, D'Andrea D, Anract J, Comploj E, Pycha A, Saba K, Poyet C, van Rhijn BW, Noon AP, Roupret M, **Shariat SF**, Fisch M, Xylinas E, Rink M. The association of cigarette smoking and pathological response to neoadjuvant platinum-based chemotherapy in patients undergoing treatment for urinary bladder cancer – A prospective European multicenter observational study of the EAU Young Academic Urologists (YAU) urothelial carcinoma working group. *Surg Oncol*. 2020 Sep;34:312-317. PMID: 32891350.
260. Schuettfort VM, Pradere B, Rink M, Comperat E, **Shariat SF**. Pathomics in urology. *Curr Opin Urol*. 2020 Sep 15. PMID: 32881725.
261. Sari Motlagh R, Quhal F, Mori K, Miura N, Aydh A, Laukhtina E, Pradere B, Karakiewicz PI, Enikeev DV, Deuker M, **Shariat SF**. The risk of new onset dementia and/or alzheimer's disease among prostate cancer patients treated with androgen deprivation therapy: a systematic review and meta-analysis. *J Urol*. 2020 Aug 28: PMID: 32856962.
262. Pecoraro A, Knipper S, Palumbo C, Rosiello G, Luzzago S, Tian Z, **Shariat SF**, Saad F, Briganti A, Fiori C, Porpiglia F, Karakiewicz PI. Assessment of other-cause mortality in localized renal cell carcinoma patients within 15 years: A population-based analysis. *J Surg Oncol*. 2020 Aug 18. PMID: 32812284.
263. Laukhtina E, Mostafaei H, D'Andrea D, Pradere B, Quhal F, Mori K, Miura N, Schuettfort VM, Sari Motlagh R, Aydh A, Abufaraj M, Karakiewicz PI, Enikeev D, Kimura S, **Shariat SF**. Association of De Ritis ratio with oncological outcomes in patients with non-muscle invasive bladder cancer (NMIBC). *World J Urol*. 2020 Aug 17. PMID: 32808107.
264. Palumbo C, Mistretta FA, Knipper S, Pecoraro A, Tian Z, Dzyuba-Negrean C, **Shariat SF**, Saad F, Simeone C, Berruti A, Briganti A, Kapoor A, Antonelli A, Karakiewicz PI. Contemporary

- cytoreductive nephrectomy provides survival benefit in clear-cell metastatic renal cell carcinoma. Clin Genitourin Cancer. 2020 May 20:S1558-7673(20)30117-8. PMID: 32800473.
265. Deuker M, Martin T, Stolzenbach F, Rosiello G, Collà Ruvolo C, Nocera L, Tian Z, Becker A, Kluth L, Roos FC, Tilki D, **Shariat SF**, Black PC, Kassouf W, Saad F, Chun F, Karakiewicz PI. Bladder Cancer: A comparison between non-urothelial variant histology and urothelial carcinoma across all stages and treatment modalities. Clin Genitourin Cancer. 2020 Jul 18:S1558-7673(20)30171-3. PMID: 32782133.
266. Quhal F, D'Andrea D, Soria F, Moschini M, Abufaraj M, Rouprêt M, Karakiewicz PI, Yang L, Mostafaei H, Laukhtina E, Mori K, Sari Motlagh R, Rink M, **Shariat SF**. Primary Ta high grade bladder tumors: Determination of the risk of progression. Urol Oncol. 2020 Aug 6:S1078-1439(20)30339-2. PMID: 32773232.
267. Mir MC, Marchioni M, Zargar H, Zargar-Shoshtari K, Fairey AS, Mertens LS, Dinney CP, Krabbe LM, Cookson MS, Jacobsen NE, Griffin J, Montgomery JS, Vasdev N, Yu EY, Xylinas E, McGrath JS, Kassouf W, Dall'Era MA, Sridhar SS, Aning J, **Shariat SF**, Wright JL, Thorpe AC, Morgan TM, Holzbeierlein JM, Bivalacqua TJ, North S, Barocas DA, Lotan Y, Grivas P, Stephenson AJ, Shah JB, van Rhijn BW, Spiess PE, Daneshmand D, Black PC. Nomogram predicting bladder cancer-specific mortality after neoadjuvant chemotherapy and radical cystectomy for muscle-invasive bladder cancer: results of an international consortium. Eur Urol Focus. 2020 Aug 5:S2405-4569(20)30208-X. PMID: 32771446.
268. Ilijazi D, Pulverer W, Ertl IE, Lemberger U, Kimura S, Abufaraj M, D'Andrea D, Pradere B, Bruchbacher A, Graf A, Soria F, Susani M, Haitel A, Molinaro L, Pycha A, Comploj E, Pabinger S, Weinhäusel A, Egger G, **Shariat SF**, Hassler MR. Discovery of Molecular DNA Methylation-Based Biomarkers through Genome-Wide Analysis of Response Patterns to BCG for Bladder Cancer. Cells. 2020 Aug 5;9(8):1839. PMCID: PMC7464079.
269. Mori K, Mostafaei H, Miura N, Karakiewicz PI, Luzzago S, Schmidinger M, Bruchbacher A, Pradere B, Egawa S, **Shariat SF**. Systemic therapy for metastatic renal cell carcinoma in the first-line setting: a systematic review and network meta-analysis. Cancer Immunol Immunother. 2020 Aug 5. PMID: 32757054.
270. Quhal F, Pradere B, Mori K, **Shariat SF**. Volume outcome relationship in penile cancer: a systematic review. Curr Opin Urol. 2020 Sep;30(5):696-700. PMID: 32740139.
271. Tully KH, Moschini M, von Rundstedt FE, Aziz A, Kluth LA, Necchi A, Rink M, Hendricksen K, Sargos P, Vetterlein MW, Seiler R, Poyet C, Krajewski W, Fajkovic H, **Shariat SF**, Xylinas E, Roghmann F. Impact of tumor size on the oncological outcome of high-grade nonmuscle invasive bladder cancer - examining the utility of classifying Ta bladder cancer based on size. Urol Oncol. 2020 Jul 29:S1078-1439(20)30321-5. PMID: 32739227.
272. Sari Motlagh R, Mori K, Aydh A, Karakiewicz PI, Trinh QD, **Shariat SF**. Impact of hospital and surgeon volumes on short-term and long-term outcomes of radical cystectomy. Curr Opin Urol. 2020 Sep;30(5):701-710. PMID: 32732625.
273. Mori K, Abufaraj M, Mostafaei H, Quhal F, Karakiewicz PI, Briganti A, Kimura S, Egawa S, **Shariat SF**. A Systematic Review and Meta-Analysis of Variant Histology in Urothelial Carcinoma of the Bladder Treated with Radical Cystectomy. J Urol. 2020 Jul 275. PMID: 32716694.
274. Zamboni S, Afferi L, Soria F, Aziz A, Abufaraj M, Poyet C, Necchi A, D'Andrea D, Simone G, Ferriero M, Di Trapani E, Simeone C, Antonelli A, Gallina A, Montorsi F, Briganti A, Colombo R, Gandaglia G, Mattei A, Baumeister P, Mordasini L, Hendricksen K, Voskuilen CS, Rink M, **Shariat SF**, Xylinas E, Moschini M. Adjuvant chemotherapy is ineffective in patients with bladder

- cancer and variant histology treated with radical cystectomy with curative intent. *World J Urol.* 2020 Jul 25. PMID: 32712850.
275. Brönimann S, Rebhan K, Lemberger U, Misrai V, **Shariat SF**, Pradere B. Secretion of severe acute respiratory syndrome coronavirus 2 in urine. *Curr Opin Urol.* 2020 Sep;30(5):735-739. PMID: 32701726; PMCID: PMC7386676.
276. Brönimann S, Pradere B, Karakiewicz P, Huebner NA, Briganti A, **Shariat SF**. An up-to-date catalogue of urinary markers for the management of prostate cancer. *Curr Opin Urol.* 2020 Sep;30(5):684-688. PMID: 32701725.
277. Rebhan K, Ertl IE, **Shariat SF**, Grollman AP, Rosenquist T. Aristolochic acid and its effect on different cancers in uro-oncology. *Curr Opin Urol.* 2020 Sep;30(5):689-695. PMID: 32701724.
278. Mori K, Mostafaei H, Abufaraj M, Yang L, Egawa S, **Shariat SF**. Smoking and bladder cancer: review of the recent literature. *Curr Opin Urol.* 2020 Sep;30(5):720-725. PMID: 32701723.
279. Miura N, Mori K, Mostafaei H, Quhal F, Motlagh RS, Pradere B, Laukhtina E, D'Andrea D, Saika T, **Shariat SF**. The Prognostic Impact of Intraductal Carcinoma of the Prostate: A Systematic Review and Meta-Analysis. *J Urol.* 2020 Jul 23; PMID: 32698712.
280. Deuker M, Stolzenbach LF, Collà Ruvolo C, Nocera L, Mansour M, Tian Z, Roos FC, Becker A, Kluth LA, Tilki D, **Shariat SF**, Saad F, Chun FKH, Karakiewicz PI. Obesity is associated with adverse short-term perioperative outcomes in patients treated with open and robot-assisted radical cystectomy for bladder cancer. *Urol Oncol.* 2020 Jul 16:S1078-1439(20)30291-X. doi: 10.1016/j.urolonc.2020.06.020. PMID: 32684511.
281. Miura N, Mori K, Mostafaei H, Quhal F, Sari Motlagh R, Abufaraj M, Pradere B, Aydh A, Laukhtina E, D'Andrea D, Saika T, **Shariat SF**. Prognostic value of testosterone for the castration-resistant prostate cancer patients: a systematic review and meta-analysis. *Int J Clin Oncol.* 2020 Jul 17. PMID: 32681382.
282. Cao C, Yang L, Xu T, Cavazos-Rehg PA, Liu Q, McDermott D, Veronese N, Waldhoer T, Ilie PC, **Shariat SF**, Smith L. Trends in Sexual Activity and Associations With All-Cause and Cause-Specific Mortality Among US Adults. *J Sex Med.* 2020 Jul 11; PMID: 32665214.
283. Mori K, Miura N, Babjuk M, Karakiewicz PI, Mostafaei H, Laukhtina E, Quhal F, Motlagh RS, Pradere B, Kimura S, Egawa S, **Shariat SF**. Low compliance to guidelines in nonmuscle-invasive bladder carcinoma: A systematic review. *Urol Oncol.* 2020 Jul 9:S1078-1439(20)30281-7. PMID: 32654948.
284. Palumbo C, Pecoraro A, Rosiello G, Luzzago S, Deuker M, Stolzenbach F, Tian Z, **Shariat SF**, Simeone C, Briganti A, Saad F, Berruti A, Antonelli A, Karakiewicz PI. Bladder cancer incidence rates and trends in young adults aged 20-39 years. *Urol Oncol.* 2020 Jul 8:S1078-1439(20)30280-5. PMID: 32653412.
285. Khene ZE, Mathieu R, Peyronnet B, Kokorian R, Gasmi A, Khene F, Rioux- Leclercq N, Kammerer-Jacquet SF, **Shariat S**, Laguerre B, Bensalah K. Radiomics can predict tumour response in patients treated with Nivolumab for a metastatic renal cell carcinoma: an artificial intelligence concept. *World J Urol.* 2020 Jul 6. PMID: 32632555.
286. Bravi CA, Fossati N, Gandaglia G, Suardi N, Mazzone E, Robesti D, Osmonov D, Juenemann KP, Boeri L, Jeffrey Karnes R, Kretschmer A, Buchner A, Stief C, Hiester A, Nini A, Albers P, Devos G, Joniau S, Van Poppel H, **Shariat SF**, Heidenreich A, Pfister D, Tilki D, Graefen M, Gill IS, Mottrie A, Karakiewicz PI, Montorsi F, Briganti A. Long-term Outcomes of Salvage Lymph Node

- Dissection for Nodal Recurrence of Prostate Cancer After Radical Prostatectomy: Not as Good as Previously Thought. *Eur Urol.* 2020 Jul 2:S0302-2838(20)30472-3. PMID: 32624288.
287. Bravi CA, Fossati N, Gandaglia G, Suardi N, Mazzone E, Robesti D, Osmonov D, Juenemann KP, Boeri L, Jeffrey Karnes R, Kretschmer A, Buchner A, Stief C, Hiester A, Nini A, Albers P, Devos G, Joniau S, Van Poppel H, **Shariat SF**, Heidenreich A, Pfister D, Tilki D, Graefen M, Gill IS, Mottrie A, Karakiewicz PI, Montorsi F, Briganti A. Assessing the Best Surgical Template at Salvage Pelvic Lymph Node Dissection for Nodal Recurrence of Prostate Cancer After Radical Prostatectomy: When Can Bilateral Dissection be Omitted? Results from a Multi-institutional Series. *Eur Urol.* 2020 Jul 2:S0302-2838(20)30507-8. PMID: 32624281.
288. Abufaraj M, Iwata T, Kimura S, Haddad A, Al-Ani H, Abusubaih L, Moschini M, Briganti A, Karakiewicz PI, **Shariat SF**. Differential Impact of Gonadotropin-releasing Hormone Antagonist Versus Agonist on Clinical Safety and Oncologic Outcomes on Patients with Metastatic Prostate Cancer: A Meta-analysis of Randomized Controlled Trials. *Eur Urol.* 2020 Jun 27:S0302-2838(20)30429-2. PMID: 32605859.
289. Rouprêt M, Babjuk M, Burger M, Capoun O, Cohen D, Compérat EM, Cowan NC, Dominguez-Escrig JL, Gontero P, Hugh Mostafid A, Palou J, Peyronnet B, Seisen T, Soukup V, Sylvester RJ, Rhijn BWGV, Zigeuner R, **Shariat SF**. European Association of Urology Guidelines on Upper Urinary Tract Urothelial Carcinoma: 2020 Update. *Eur Urol.* 2020 Jun 24:S0302-2838(20)30427-9. PMID: 32593530.
290. Palumbo C, Pecoraro A, Rosiello G, Luzzago S, Deuker M, Stolzenbach F, Tian Z, **Shariat SF**, Simeone C, Briganti A, Saad F, Berruti A, Antonelli A, Karakiewicz PI. Renal cell carcinoma incidence rates and trends in young adults aged 20-39 years. *Cancer Epidemiol.* 2020 Jun 22;67:101762. PMID: 32585430.
291. Janisch F, Hillemacher T, Fuehner C, D'Andrea D, Meyer CP, Klotzbücher T, Kienapfel C, Vetterlein MW, Kimura S, Abufaraj M, Dahlem R, **Shariat SF**, Fisch M, Rink M. The impact of cytoreductive nephrectomy on survival outcomes in patients treated with tyrosine kinase inhibitors for metastatic renal cell carcinoma in a real-world cohort. *Urol Oncol.* 2020 Jun 21:S1078-1439(20)30192-7. PMID: 32576526.
292. Hassler MR, Bray F, Catto JWF, Grollman AP, Hartmann A, Margulis V, Matin SF, Roupert M, Sfakianos JP, **Shariat SF**, Faltas BM. Molecular Characterization of Upper Tract Urothelial Carcinoma in the Era of Next-generation Sequencing: A Systematic Review of the Current Literature. *Eur Urol.* 2020 Jun 20:S0302-2838(20)30417-6. PMID: 32571725.
293. Sari Motlagh R, Mori K, Miura N, Quhal F, Aydh A, Laukhtina E, Pradere B, Karakiewicz PI, Enikeev DV, Deuker M, **Shariat SF** The recurrence and progression risk after simultaneous endoscopic surgery of urothelial bladder tumor and benign prostatic hyperplasia; a systematic review and meta-analysis. *BJU Int.* 2020 Jun 21. PMID: 32564458
294. Brönimann S, Pradere B, Karakiewicz P, Abufaraj M, Briganti A, **Shariat SF**. An overview of current and emerging diagnostic, staging and prognostic markers for prostate cancer. *Expert Rev Mol Diagn.* 2020 Jun 18. PMID: 32552088
295. Miura N, Pradere B, Mori K, Mostafaei H, Quhal F, Misrai V, D'andrea D, Albisinni S, Papalia R, Saika T, Scarpa RM, **Shariat SF**, Esperto F. Metastasis-directed therapy and prostate-targeted therapy in oligometastatic prostate cancer: a systematic review. *Minerva Urol Nefrol.* 2020 Jun 16. PMID: 32550632.
296. Soria F, D'Andrea D, Abufaraj M, Moschini M, Giordano A, Gust KM, Karakiewicz PI, Babjuk M, Gontero P, **Shariat SF**. Stratification of Intermediate-risk Non-muscle-invasive Bladder Cancer

- Patients: Implications for Adjuvant Therapies. *Eur Urol Focus*. 2020 Jun 9:S2405-4569(20)30115-2. PMID: 32532704.
297. Gontero P, Marra G, Teber D, **Shariat S**, Albayrak S, Coelho R, Tanguay S, Konety B. Making a case "against" focal therapy for intermediate-risk prostate cancer. *World J Urol*. 2020 Jun 11. PMID: 32529451.
298. Mostafaei H, **Shariat SF**, Salehi-Pourmehr H, Janisch F, Mori K, Quhal F, Hajebrاهيمi S. The clinical pharmacology of the medical treatment for overactive bladder in adults. *Expert Rev Clin Pharmacol*. 2020 Jun 16:1-13. PMID: 32500759.
299. Palumbo C, Mazzone E, Mistretta FA, Knipper S, Perrotte P, **Shariat SF**, Saad F, Kapoor A, Lattouf JB, Simeone C, Briganti A, Antonelli A, Karakiewicz PI. A plea for optimizing selection in current adjuvant immunotherapy trials for high-risk nonmetastatic renal cell carcinoma according to expected cancer-specific mortality. *Clin Genitourin Cancer*. 2019 Dec 5:S1558-7673(19)30361-1. PMID: 32482565.
300. Luzzago S, Palumbo C, Rosiello G, Pecoraro A, Deuker M, Mistretta FA, Tian Z, Musi G, Montanari E, **Shariat SF**, Saad F, Briganti A, de Cobelli O, Karakiewicz PI. The Effect of systemic chemotherapy on survival in patients with localized, regional, or metastatic adenocarcinoma of the urinary bladder. *Am J Clin Oncol*. 2020 May 27. PMID: 32467527.
301. Deuker M, Franziska Stolzenbach L, Rosiello G, Luzzago S, Martin T, Tian Z, Tilki D, **Shariat SF**, Saad F, Kassouf W, Black PC, Chun FKH, Karakiewicz PI. Radical cystectomy improves survival in patients with stage T1 squamous cell carcinoma and neuroendocrine carcinoma of the urinary bladder. *Eur J Surg Oncol*. 2020 May 12:S0748-7983(20)30459-5. PMID: 32457017.
302. Palumbo C, Pecoraro A, Knipper S, Rosiello G, Luzzago S, Deuker M, Tian Z, **Shariat SF**, Simeone C, Briganti A, Saad F, Berruti A, Antonelli A, Karakiewicz PI. Contemporary Age-adjusted Incidence and Mortality Rates of Renal Cell Carcinoma: Analysis According to Gender, Race, Stage, Grade, and Histology. *Eur Urol Focus*. 2020 May 23:S2405-4569(20)30114-0. PMID: 32456993.
303. Huebner NA, **Shariat SF**, Resch I, Gust K, Kramer G. The role of taxane-based chemotherapy in the treatment of prostate cancer. *Curr Opin Urol*. 2020 Jul;30(4):527-533. PMID: 32453003.
304. Gust KM, Rebhan K, Resch I, Shariat SF, Necchi A. Immune checkpoint inhibition in muscle-invasive and locally advanced bladder cancer. *Curr Opin Urol*. 2020 Jul;30(4):547-556. PMID: 32453001.
305. Ertl IE, **Shariat SF**, Mostafaei H, Ilijazi D, Loriot Y. Fibroblast growth factor receptors across urothelial carcinoma landscape. *Curr Opin Urol*. 2020 Jul;30(4):557-565. PMID: 32452999.
306. Mori K, Miura N, Mostafaei H, Quhal F, Motlagh RS, Lysenko I, Kimura S, Egawa S, Karakiewicz PI, **Shariat SF**. Prognostic value of preoperative hematologic biomarkers in urothelial carcinoma of the bladder treated with radical cystectomy: a systematic review and meta-analysis. *Int J Clin Oncol*. 2020 May 26. PMID: 32451768.
307. Pradere B, **Shariat SF**. Exploring the molecular basis of sexual dimorphism in bladder cancer. *Nat Rev Urol*. 2020 May 22. PMID: 32444779.
308. Luzzago S, Palumbo C, Rosiello G, Knipper S, Pecoraro A, Mistretta FA, Tian Z, Musi G, Montanari E, Soulières D, **Shariat SF**, Saad F, Briganti A, de Cobelli O, Karakiewicz PI. Association Between Systemic Therapy and/or Cytoreductive Nephrectomy and Survival in Contemporary Metastatic Non-clear Cell Renal Cell Carcinoma Patients. *Eur Urol Focus*. 2020 May 19:S2405-4569(20)30108-5. PMID: 32444303.

309. Mori K, Miura N, Comperat E, Nikles S, Pang KH, Misrai V, Gomez Rivas J, Papalia R, **Shariat SF**, Esperto F, Pradere B. A systematic review and meta-analysis of prognostic impact of different Gleason patterns in ISUP grade group 4. *Minerva Urol Nefrol.* 2020 May 20. PMID: 32432435.
310. Soria F, Giordano A, **Shariat SF**, Gontero P. Bladder sparing landscape for bacillus Calmette-Guérin unresponsive bladder cancer. *Curr Opin Urol.* 2020 May 13. PMID: 32427633.
311. Hughes T, Ho HC, **Shariat SF**, Somani BK. Where do urologists stand in the era of novel coronavirus-2019 disease. *Curr Opin Urol.* 2020 May 13. PMID: 32427632.
312. Brönimann S, Lemberger U, Bruchbacher A, **Shariat SF**, Hassler MR. Poly(ADP-ribose) polymerase inhibitors in prostate and urothelial cancer. *Curr Opin Urol.* 2020 May 13. PMID: 32427631.
313. Rosiello G, Pecoraro A, Palumbo C, Knipper S, Luzzago S, Deuker M, Tian Z, Gandaglia G, Fossati N, Montorsi F, **Shariat SF**, Saad F, Briganti A, Karakiewicz PI. Radical cystectomy plus chemotherapy in patients with pure squamous cell bladder carcinoma: a population-based study. *World J Urol.* 2020 May 18. PMID: 32424515.
314. Abufaraj M, Kimura S, Haitel A, Iwata T, Isleem U, D'Andrea D, Soria F, Mori K, Rink M, Bensalah K, Rouprêt M, Margulis V, Briganti A, Karakiewicz PI, **Shariat SF**. The expression of urokinase-type plasminogen activator system in upper tract urothelial carcinoma and its prognostic value after radical nephroureterectomy. *Urol Oncol.* 2020 May 4:S1078-1439(20)30136-8. PMID: 32381392.
315. Cao C, Liu Q, Abufaraj M, Han Y, Xu T, Waldhoer T, **Shariat SF**, Li S, Yang L, Smith L. Regular Coffee Consumption Is Associated with Lower Regional Adiposity Measured by DXA among US Women. *J Nutr.* 2020 May 3:nxaa121. PMID: 32361729.
316. Afferi L, Zamboni S, Karnes RJ, Roghmann F, Sargos P, Montorsi F, Briganti A, Gallina A, Mattei A, Schulz GB, Hendricksen K, Voskuilen CS, Rink M, Poyet C, De Cobelli O, di Trapani E, Simeone C, Soligo M, Simone G, Tuderti G, Alvarez- Maestro M, Martínez-Piñeiro L, Aziz A, **Shariat SF**, Abufaraj M, Xylinas E, Moschini M; European Association of Urology-Young Academic Urologists (EAU-YAU), Urothelial Carcinoma Working Group. The impact of treatment modality on survival in patients with clinical node-positive bladder cancer: results from a multicenter collaboration. *World J Urol.* 2020 Apr 30. PMID: 32356226.
317. Teoh JYC, Roupret M, **Shariat SF**, Herrmann T. Intravesical therapy for bladder cancer in the pandemic of Covid-19. *World J Urol.* 2020 Apr 30:1–2. PMID: 32356225; PMCID: PMC7191133.
318. Szarvas T, Csizmarik A, Fazekas T, Hüttl A, Nyirády P, Hadaschik B, Grünwald V, Püllen L, Jurányi Z, Kocsis ZS, **Shariat SF**, Sevcenco S, Maj-Hes A, Kramer G. Comprehensive analysis of serum chromogranin A and neuron-specific enolase levels in localized and castration-resistant prostate cancer. *BJU Int.* 2020 Apr 20. PMID: 32314509
319. Sari Motlagh R, Pradere B, Mori K, Miura N, Abufaraj M, **Shariat SF**. Bladder-preserving strategies for Bacillus Calmette-Guérin unresponsive non-muscle invasive bladder cancer; where are we and what will be expected? *Curr Opin Urol.* 2020 Apr 16. PMID: 32304379
320. Schuettfort V, **Shariat SF**, Rink M. Surgery only? Multimodal treatment for urothelial carcinoma of the bladder. *Aktuelle Urol.* 2020 Apr 14. PMID: 32289833
321. Rosiello G, Palumbo C, Knipper S, Pecoraro A, Luzzago S, St-Hilaire PA, Tian Z, Capitanio U, Montorsi F, **Shariat SF**, Saad F, Briganti A, Karakiewicz PI. Comparison of survival outcomes in patients with metastatic papillary vs. clear-cell renal cell carcinoma: a propensity-score analysis. *World J Urol.* 2020 Apr 6. PMID: 32253579

322. Deuker M, Stolzenbach F, Rosiello G, Palumbo C, Martin T, Tian Z, Chun FK, Saad F, **Shariat SF**, Kapoor A, Karakiewicz PI. Renal Cell Carcinoma: Comparison Between Variant Histology and Clear Cell Carcinoma Across all Stages and Treatment Modalities. *J Urol*. 2020 Apr 6; PMID: 32250728
323. Rosiello G, Knipper S, Palumbo C, Pecoraro A, Luzzago S, Deuker M, Stolzenbach LF, Tian Z, Gallina A, Gandaglia G, Montorsi F, **Shariat SF**, Saad F, Briganti A, Karakiewicz PI. Rates of other-cause mortality after radical cystectomy are decreasing over time-A population-based analysis over two decades. *J Surg Oncol*. 2020 Apr 4. PMID: 32246846
324. Enikeev D, **Shariat SF**. Novel technologies that change the diagnostic and treatment paradigm in urology: En-bloc as the new treatment standard. *Curr Opin Urol*. 2020 May;30(3):475-476. PMID: 32235286
325. Rebhan K, Laukhtina E, **Shariat SF**, Gust KM. Frontiers in combining immune checkpoint inhibitors for advanced urothelial cancer management. *Curr Opin Urol*. 2020 May;30(3):457-466. PMID: 32235284
326. Jahrreiss V, Pradere B, Laukhtina E, Mori K, **Shariat SF**. Catalog of exogenous risk factors for bladder carcinogenesis. *Curr Opin Urol*. 2020 May;30(3):449-456. PMID: 32235283
327. Carando R, **Shariat SF**, Moschini M, D'Andrea D. Ureteral and urethral recurrence after radical cystectomy: a systematic review. *Curr Opin Urol*. 2020 May;30(3):441-448. PMID: 32235282
328. Lysenko I, Mori K, Mostafaei H, Enikeev DV, Karakiewicz PI, Briganti A, Quhal F, Janisch F, **Shariat SF**. Prognostic Value of Gleason Score at Positive Surgical Margin in Prostate Cancer: A Systematic Review and Meta-analysis. *Clin Genitourin Cancer*. 2020 Mar 4. PMID: 32229268
329. Palumbo C, Knipper S, Pecoraro A, Rosiello G, Luzzago S, Deuker M, Tian Z, **Shariat SF**, Simeone C, Briganti A, Saad F, Berruti A, Antonelli A, Karakiewicz PI. Differences in short-term outcomes between open versus robot-assisted radical cystectomy in frail malnourished patients. *Eur J Surg Oncol*. 2020 Mar 14. PMID: 32220544
330. Jilch S, Sel R, **Shariat SF**. Medical practice and placebo response: an inseparable bond? *Wien Klin Wochenschr*. 2020 Mar 24. PMID: 32211987
331. Misrai V, Taille A, Zorn KC, Marrauld L, Pon D, **Shariat SF**, Rouprêt M. A Plea for the Evaluation of the Carbon Footprint of New Mini-invasive Surgical Technologies in Urology. *Eur Urol*. 2020 Mar 21. PMID: 32209285
332. Mori K, Egawa S, **Shariat SF**. Re: Cabazitaxel Versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer. *Eur Urol*. 2020 Mar 21. PMID: 32209284
333. Janisch F, D'Andrea D, Iwata T, Kimura S, Abufaraj M, Enikeev D, Glybochko PV, Karakiewicz PI, Nyirady P, Fajkovic H, Haitel A, Seebacher V, Rink M, **Shariat SF**. The prognostic value of the urokinase-plasminogen activator system (uPA) in bladder cancer patients treated with radical cystectomy. *Urol Oncol*. 2020 Mar 21. PMID: 32209281
334. Quhal F, Mori K, Sari Motlagh R, Laukhtina E, Pradere B, Rouprêt M, Necchi A, Moschini M, **Shariat SF**. Efficacy of neoadjuvant and adjuvant chemotherapy for localized and locally advanced upper tract urothelial carcinoma: a systematic review and meta-analysis. *Int J Clin Oncol*. 2020 Mar 23. PMID: 32206939
335. Rosiello G, Palumbo C, Knipper S, Deuker M, Stolzenbach LF, Tian Z, Gandaglia G, Fossati N, Montorsi F, **Shariat SF**, Saad F, Briganti A, Karakiewicz PI. Preoperative frailty predicts adverse short-term postoperative outcomes in patients treated with radical prostatectomy. *Prostate Cancer Prostatic Dis*. 2020 Mar 18. PMID: 32203071

336. Mostafid H, Babjuk M, Bochner B, Lerner SP, Witjes F, Palou J, Roupert M, **Shariat S**, Gontero P, van Rhijn B, Zigeuner R, Sylvester R, Comperat E, Burger M, Malavaud B, Soloway M, Williams S, Black P, Daneshmand S, Steinberg G, Brausi M, Catto J, Kamat AM. Transurethral Resection of Bladder Tumour: The Neglected Procedure in the Technology Race in Bladder Cancer. *Eur Urol*. 2020 Mar 16. PMID: 32192815
337. Luzzago S, Rosiello G, Pecoraro A, Deuker M, Stolzenbach F, Mistretta FA, Tian Z, Musi G, Montanari E, **Shariat SF**, Saad F, Briganti A, de Cobelli O, Karakiewicz PI. Contemporary Rates and Predictors of Open Conversion During Minimally Invasive Radical Prostatectomy for Nonmetastatic Prostate Cancer. *J Endourol*. 2020 Apr 14. PMID: 32178532
338. Pecoraro A, Palumbo C, Knipper S, Rosiello G, Luzzago S, Tian Z, **Shariat SF**, Saad F, Lavallée L, Briganti A, Kapoor A, Fiori C, Porpiglia F, Karakiewicz PI. Histologic Subtype, Tumor Grade, Tumor Size, and Race Can Accurately Predict the Probability of Synchronous Metastases in T2 Renal Cell Carcinoma. *Clin Genitourin Cancer*. 2020 Feb 8. PMID: 32173357
339. Mistretta FA, Negrean-Dzyuba C, Palumbo C, Pecoraro A, Knipper S, Tian Z, Musi G, Montanari E, Perrotte P, Briganti A, **Shariat SF**, Saad F, de Cobelli O, Karakiewicz PI. Adherence to guideline recommendations for multimodality treatment of patients with pT2-3 M0 non-urothelial carcinoma of the urinary bladder: Temporal trends and survival outcomes. *Int J Urol*. 2020 Mar 14. PMID: 32172530
340. Pecoraro A, Palumbo C, Knipper S, Mistretta FA, Rosiello G, Tian Z, St-Hilaire PA, **Shariat SF**, Saad F, Lavallée L, Briganti A, Kapoor A, Fiori C, Porpiglia F, Karakiewicz PI. Synchronous Metastasis Rates in T1 Renal Cell Carcinoma: A Surveillance, Epidemiology, and End Results Database-based Study. *Eur Urol Focus*. 2020 Mar 10. PMID: 32169361
341. Kamat AM, Shore N, Hahn N, Alanee S, Nishiyama H, **Shariat S**, Nam K, Kapadia E, Frenkl T, Steinberg G. KEYNOTE-676: Phase III study of BCG and pembrolizumab for persistent/recurrent high-risk NMIBC. *Future Oncol*. 2020 Apr;16(10):507-516. PMID: 32162533
342. Mori K, Miura N, Mostafaei H, Quhal F, Sari Motlagh R, Pradere B, Kimura S, Kimura T, Egawa S, Briganti A, Karakiewicz PI, **Shariat SF**. Sequential therapy of abiraterone and enzalutamide in castration-resistant prostate cancer: a systematic review and meta-analysis. *Prostate Cancer Prostatic Dis*. 2020 Mar 9. PMID: 32152435
343. Luzzago S, Palumbo C, Rosiello G, Pecoraro A, Deuker M, Stolzenbach F, Mistretta FA, Tian Z, Musi G, Montanari E, **Shariat SF**, Saad F, Briganti A, de Cobelli O, Karakiewicz PI. Metabolic syndrome predicts worse perioperative outcomes in patients treated with partial nephrectomy for renal cell carcinoma. *Urology*. 2020 Mar 6. PMID: 32151650
344. Luzzago S, Palumbo C, Rosiello G, Knipper S, Pecoraro A, Nazzani S, Tian Z, Musi G, Montanari E, **Shariat SF**, Saad F, Briganti A, de Cobelli O, Karakiewicz PI. survival of contemporary patients with non-metastatic small-cell carcinoma of urinary bladder, according to alternative treatment modalities. *Clin Genitourin Cancer*. 2019 Dec 13. PMID: 32146153
345. Luzzago S, Palumbo C, Rosiello G, Knipper S, Pecoraro A, Mistretta FA, Tian Z, Musi G, Montanari E, **Shariat SF**, Saad F, Briganti A, de Cobelli O, Karakiewicz PI. Effect of stage and grade migration on cancer specific mortality in renal cell carcinoma patients, according to clear cell vs. non-clear cell histology: A contemporary population-based analysis. *Urol Oncol*. 2020 Mar 2. PMID: 32139292
346. Mori K, Janisch F, Mostafaei H, Kimura S, Lysenko I, Karakiewicz PI, Briganti A, Enikeev DV, Roupert M, Margulis V, Chlosta P, Nyirady P, Babjuk M, Egawa S, **Shariat SF**. Prognostic role of

- preoperative De Ritis ratio in upper tract urothelial carcinoma treated with nephroureterectomy. *Urol Oncol*. 2020 Feb 29. PMID: 32127252
347. Rosiello G, Palumbo C, Knipper S, Pecoraro A, Luzzago S, Tian Z, Larcher A, Capitanio U, Montorsi F, **Shariat SF**, Saad F, Briganti A, Karakiewicz PI. Histotype predicts the rate of lymph node invasion at nephrectomy in patients with nonmetastatic renal cell carcinoma. *Urol Oncol*. 2020 Feb 28. PMID: 32122729
 348. Hupe MC, Offermann A, Tharun L, Fürschke A, Frydrychowicz A, Garstka N, **Shariat SF**, Barkhausen J, Merseburger AS, Kramer MW, Perner S. Histomorphological analysis of false positive PI-RADS 4 and 5 lesions. *Urol Oncol*. 2020 Feb 27. PMID: 32113858
 349. Rosiello G, Palumbo C, Knipper S, Pecoraro A, Luzzago S, Deuker M, Mistretta FA, Tian Z, Fossati N, Gallina A, Montorsi F, **Shariat SF**, Saad F, Briganti A, Karakiewicz PI. Contemporary conditional cancer-specific survival after radical nephroureterectomy in patients with nonmetastatic urothelial carcinoma of upper urinary tract. *J Surg Oncol*. 2020 Feb 27. PMID: 32107785
 350. Cacciamani GE, Ghodoussipour S, Mari A, Gill KS, Desai M, Artibani W, Gill PS, **Shariat SF**, Gill IS, Djaladat H. Association Between Smoking Exposure, Neoadjuvant Chemotherapy Response and Survival Outcomes Following Radical Cystectomy: Systematic Review and Meta-Analysis. *J Urol*. 2020 Feb 27. PMID: 32105187
 351. Stangl-Kremser J, Lemberger U, Hassler MR, Garstka N, Grubmüller B, Haitel A, Enikeev DV, Glybochko PV, Kramer G, Susani M, **Shariat SF**. The prognostic impact of tumour NSD2 expression in advanced prostate cancer. *Biomarkers*. 2020 Mar 2:1-6. PMID: 32091270
 352. Mori K, Janisch F, Mostafaei H, Lysenko I, Kimura S, Egawa S, **Shariat SF**. Prognostic value of preoperative blood-based biomarkers in upper tract urothelial carcinoma treated with nephroureterectomy: A systematic review and meta-analysis. *Urol Oncol*. 2020 Feb 19. PMID: 32088103
 353. Fossati N, Scarcella S, Gandaglia G, Suardi N, Robesti D, Boeri L, Karnes RJ, Heidenreich A, Pfister D, Kretschmer A, Buchner A, Stief C, Battaglia A, Joniau S, Van Poppel H, Osmonov D, Juenemann KP, **Shariat SF**, Hiester A, Nini A, Albers P, Tilki D, Graefen M, Gill IS, Motttrie A, Galosi AB, Montorsi F, Briganti A. Underestimation of PET/CT Scan in Assessing Tumour Burden of Men With Nodal Recurrence From Prostate Cancer: Head-to-Head Comparison OF 68Ga-PSMA and 11C-Choline in a Large, Multi-Institutional Series of Extended Salvage Lymph Node Dissections. *J Urol*. 2020 Feb 18. PMID: 32068488
 354. Mottet N, Ribal MJ, Boyle H, De Santis M, Caillet P, Choudhury A, Garg T, Nielsen M, Wüthrich P, Gust KM, **Shariat SF**, Gakis G. Management of bladder cancer in older patients: Position paper of a SIOG Task Force. *J Geriatr Oncol*. 2020 Feb 10. PMID: 32057720
 355. D'Andrea D, Black PC, Zargar H, Zargar-Shoshtari K, Zehetmayer S, Fairey AS, Mertens LS, Dinney CP, Mir MC, Krabbe LM, Cookson MS, Jacobsen NE, Montgomery JS, Vasdev N, Yu EY, Xylinas E, Campain NJ, Kassouf W, Dall'Era MA, Seah JA, Ercole CE, Horenblas S, Sridhar SS, McGrath JS, Aning J, Wright JL, Thorpe AC, Morgan TM, Holzbeierlein JM, Bivalacqua TJ, North S, Barocas DA, Lotan Y, Grivas P, Stephenson AJ, Shah JB, van Rhijn BW, Daneshmand S, Spiess PE, **Shariat SF**. Impact of sex on response to neoadjuvant chemotherapy in patients with bladder cancer. *Urol Oncol*. 2020 Feb 11. PMID: 32057595
 356. Soria F, Giordano A, D'Andrea D, Moschini M, Roupřet M, Margulis V, Karakiewicz PI, Briganti A, Bensalah K, Mathieu R, Chlosta P, Babjuk M, Glybochko PV, Enikeev DV, Remzi M, Gust K, Gontero P, **Shariat SF**. Prognostic value of the systemic inflammation modified Glasgow prognostic score in patients with upper tract urothelial carcinoma (UTUC) treated with radical

- nephroureterectomy: Results from a large multicenter international collaboration. *Urol Oncol*. 2020 Feb 6. PMID: 32037197
357. Luzzago S, Palumbo C, Rosiello G, Knipper S, Pecoraro A, Deuker M, Mistretta FA, Tian Z, Musi G, Montanari E, **Shariat SF**, Saad F, Briganti A, de Cobelli O, Karakiewicz PI. Survival After Partial Cystectomy for Variant Histology Bladder Cancer Compared With Urothelial Carcinoma: A Population-based Study. *Clin Genitourin Cancer*. 2019 Oct 16. pii: S1558-7673(19)30320-9. PMID: 32035800
358. Baard J, Celebi M, de la Rosette J, Alcaraz A, **Shariat SF**, Cormio L, Cavadas V, Laguna MP. Evaluation of Patterns of Presentation, Practice, and Outcomes of Upper Tract Urothelial Cancer: Protocol for an Observational, International, Multicenter, Cohort Study by the Clinical Research Office of the Endourology Society. *JMIR Res Protoc*. 2020 Jan 24;9(1):e15363. PMID:32012106
359. Janisch F, Rink M, **Shariat SF**. The promise and challenges of neoadjuvant immunotherapy in the management of non-metastatic muscle-invasive bladder cancer. *BJU Int*. 2020 Feb 3. PMID: 32011069
360. Mori K, Janisch F, Mostafaei H, Lysenko I, Karakiewicz PI, Enikeev DV, Briganti A, Kimura S, Egawa S, **Shariat SF**. Prognostic Value of Hemoglobin in Metastatic Hormone-sensitive Prostate Cancer: A Systematic Review and Meta-analysis. *Clin Genitourin Cancer*. 2019 Dec 13. PMID: 32007439
361. Mistretta FA, Cyr SJ, Luzzago S, Mazzone E, Knipper S, Palumbo C, Tian Z, Nazzani S, Saad F, Montanari E, Tilki D, Briganti A, **Shariat SF**, de Cobelli O, Karakiewicz PI. Partial Cystectomy With Pelvic Lymph Node Dissection for Patients With Nonmetastatic Stage pT2-T3 Urothelial Carcinoma of Urinary Bladder: Temporal Trends and Survival Outcomes. *Clin Genitourin Cancer*. 2019 Sep 26. PMID: 32001182
362. Mori K, Mostafaei H, Enikeev DV, Lysenko I, Quhal F, Kimura S, Karakiewicz PI, Egawa S, **Shariat SF**. Differential Effect of Sex on Outcomes After Radical Surgery for Upper Tract and Bladder Urothelial Carcinoma: A Systematic Review and Meta-Analysis. *J Urol*. 2020 Jan 29; PMID: 31995432
363. Luzzago S, Palumbo C, Rosiello G, Knipper S, Pecoraro A, Nazzani S, Tian Z, Musi G, Montanari E, **Shariat SF**, Saad F, Briganti A, de Cobelli O, Karakiewicz PI. Racial and ethnic differences in survival in contemporary metastatic renal cell carcinoma patients, according to alternative treatment modalities. *Cancer Causes Control*. 2020 Mar;31(3):263-272. PMID: 31993859
364. D'Andrea D, Soria F, Zehetmayer S, Stangl-Kremser J, Grubmüller B, Abufaraj M, Gust K, Kimura S, Babjuk M, Goldner GM, **Shariat SF**. Comparative effectiveness of radical cystectomy and radiotherapy without chemotherapy in frail patients with bladder cancer. *Scand J Urol*. 2020 Jan 24;1-6. PMID: 31975654
365. Resch I, Abufaraj M, Hübner NA, **Shariat SF**. An update on systemic therapy for penile cancer. *Curr Opin Urol*. 2020 Mar;30(2):229-233. PMID: 31972637
366. Ilijazi D, **Shariat SF**, Hassler MR, Lemberger U, Ertl IE. Epigenetic alterations of testicular germ cell tumours. *Curr Opin Urol*. 2020 Mar;30(2):264-270. PMID: 31905176
367. Rasul S, Hacker M, Kretschmer-Chott E, Leisser A, Grubmüller B, Kramer G, **Shariat S**, Wadsak W, Mitterhauser M, Hartenbach M, Haug AR. Clinical outcome of standardized 177Lu-PSMA-617 therapy in metastatic prostate cancer patients receiving 7400 MBq every 4 weeks. *Eur J Nucl Med Mol Imaging*. 2020 Mar;47(3):713-720. PMID: 31781834

368. Palumbo C, Knipper S, Pecoraro A, Rosiello G, Luzzago S, Deuker M, Tian Z, **Shariat SF**, Simeone C, Briganti A, Saad F, Berruti A, Antonelli A, Karakiewicz PI. Patient frailty predicts worse perioperative outcomes and higher cost after radical cystectomy. *Surg Oncol*. 2020 Mar;32:8-13. PMID: 31683158
369. Knipper S, Pecoraro A, Palumbo C, Rosiello G, Luzzago S, Deuker M, Tian Z, **Shariat SF**, Saad F, Tilki D, Graefen M, Karakiewicz PI. The effect of age on cancer-specific mortality in patients with prostate cancer: a population-based study across all stages. *Cancer Causes Control*. 2020 Feb 7. PMID: 32034540
370. Janisch F, Rink M, **Shariat SF**. The promise and challenges of neoadjuvant immunotherapy in the management of non-metastatic muscle-invasive bladder cancer. *BJU Int*. 2020 Feb 3. PMID: 32011069
371. D'Andrea D, Soria F, Abufaraj M, Pones M, Gontero P, Machado AT, Waksman R, Enikeev DV, Glybochko PV, Adonias SP, Nahas WC, **Shariat SF**, Chade DC. Comparative Effectiveness of Intravesical BCG-Tice and BCG-Moreau in Patients With Non-muscle-invasive Bladder Cancer. *Clin Genitourin Cancer*. 2020 Feb;18(1):20-25. PMID: 31786120
372. Rosiello G, Knipper S, Palumbo C, Pecoraro A, Luzzago S, Deuker M, Tian Z, Gandaglia G, Gallina A, Montorsi F, **Shariat SF**, Saad F, Briganti A, Karakiewicz PI. Increasing Rates of Perioperative Chemotherapy are Associated With Improved Survival in Men With Urothelial Bladder Cancer With Prostatic Stromal Invasion. *Clin Genitourin Cancer*. 2020 Feb;18(1):35-44. PMID: 31711842
373. Polanec SH, Bickel H, Wengert GJ, Arnoldner M, Clauser P, Susani M, **Shariat SF**, Pinker K, Helbich TH, Baltzer PAT. Can the addition of clinical information improve the accuracy of PI-RADS version 2 for the diagnosis of clinically significant prostate cancer in positive MRI? *Clin Radiol*. 2020 Feb;75(2):157.e1-157.e7. PMID: 31690449
374. Vartolomei MD, Kimura S, Vartolomei L, **Shariat SF**. Systematic Review of the Impact of Testosterone Replacement Therapy on Depression in Patients with Late-onset Testosterone Deficiency. *Eur Urol Focus*. 2020 Jan 15;6(1):170-177. PMID: 30017901
375. Stangl-Kremser J, Mari A, Suarez-Ibarrola R, D'Andrea D, Korn SM, Pones M, Kramer G, Karakiewicz P, Enikeev DV, Glybochko PV, Briganti A, **Shariat SF**. Development of a prognostic model for survival time prediction in castration-resistant prostate cancer patients. *Urol Oncol*. 2020 Jan 14. PMID: 31953003
376. Rosiello G, Palumbo C, Deuker M, Stolzenbach LF, Tian Z, Larcher A, Capitanio U, Montorsi F, **Shariat SF**, Kapoor A, Saad F, Briganti A, Karakiewicz PI. Preoperative frailty predicts adverse short-term postoperative outcomes in patients treated with radical nephroureterectomy. *J Surg Oncol*. 2020 Jan 12. PMID: 31930511
377. Ilijazi D, **Shariat SF**, Hassler MR, Lemberger U, Ertl IE. Epigenetic alterations of testicular germ cell tumours. *Curr Opin Urol*. 2020 Jan 3. PMID: 31905176
378. Foerster B, Abufaraj M, Petros F, Azizi M, Gupta M, Schweitzer D, Margulis V, Iwata T, Kimura S, Shabsigh A, Briganti A, Ku JH, Muilwijk T, Kassouf W, Matin SF, Spiess PE, Pierorazio PM, Hendricksen K, **Shariat SF**; UTUC collaboration. Efficacy of Preoperative Chemotherapy in High-Risk Upper Tract Urothelial Carcinoma (UTUC). *J Urol*. 2020 PMID: 31898919
379. Mori K, D'Andrea D, Enikeev DV, Egawa S, Shariat SF. En bloc resection for nonmuscle invasive bladder cancer: review of the recent literature. *Curr Opin Urol*. 2020 Jan;30(1):41-47. PMID: 31724997

380. Moschini M, **Shariat SF**, Black P, Kamat AM, Stabile A, Cathelineau X, Kassouf W, Bochner BH, Xylinas E, Roupert M, Boorjian SA, Catto JW, Sanchez-Salas R. Do Not Learn a Technique, Learn the Biology Underlying the Disease: Techniques Evolve, Biology Prevails. *Eur Urol*. 2020 Jan;77(1):1-2. PMID: 31506227
381. Palumbo C, Mistretta FA, Knipper S, Pecoraro A, Tian Z, **Shariat SF**, Saad F, Simeone C, Briganti A, Antonelli A, Karakiewicz PI. Conditional Survival of Patients With Nonmetastatic Renal Cell Carcinoma: How Cancer-Specific Mortality Changes After Nephrectomy. *J Natl Compr Canc Netw*. 2020 Jan;18(1):44-51. PMID: 31910387
382. Grubmüller B, Rasul S, Baltzer P, Fajkovic H, D'Andrea D, Berndt F, Maj-Hes A, Grubmüller KH, Mitterhauser M, Wadsak W, Pfaff S, **Shariat SF**, Hacker M, Kramer G, Hartenbach M. Response assessment using [68 Ga]Ga-PSMA ligand PET in patients undergoing systemic therapy for metastatic castration-resistant prostate cancer. *Prostate*. 2020 Jan;80(1):74-82. PMID: 31614001
383. Black AJ, Zargar H, Zargar-Shoshtari K, Fairey AS, Mertens LS, Dinney CP, Mir MC, Krabbe LM, Cookson MS, Jacobsen NE, Griffin J, Montgomery JS, Vasdev N, Yu EY, Xylinas E, Campain NJ, Kassouf W, Dall'Era MA, Seah JA, Ercole CE, Horenblas S, McGrath JS, Aning J, **Shariat SF**, Wright JL, Thorpe AC, Morgan TM, Holzbeierlein JM, Bivalacqua TJ, North S, Barocas DA, Lotan Y, Grivas P, Stephenson AJ, Shah JB, van Rhijn BW, Spiess PE, Daneshmand S, Sridhar SS, Black PC. The prognostic value of the neutrophil-to-lymphocyte ratio in patients with muscle-invasive bladder cancer treated with neoadjuvant chemotherapy and radical cystectomy. *Urol Oncol*. 2020 Jan;38(1):3.e17-3.e27. PMID: 31676278
384. D'Andrea D, Abufaraj M, Soria F, Gust K, Haitel A, Krakiewicz PI, **Shariat SF**. Association of super-extended lymphadenectomy at radical cystectomy with perioperative complications and re-hospitalization. *World J Urol*. 2020 Jan;38(1):121-128. PMID: 31006052
385. Ferro M, Di Lorenzo G, Vartolomei MD, Bruzzese D, Cantiello F, Lucarelli G, Musi G, Di Stasi S, Hurle R, Guazzoni G, Busetto GM, Gabriele A, Del Giudice F, Damiano R, Perri F, Perdona S, Verze P, Borghesi M, Schiavina R, Almeida GL, Bove P, Lima E, Autorino R, Crisan N, Farhan ARA, Battaglia M, Russo GI, Ieluzzi V, Morgia G, De Placido P, Terracciano D, Cimmino A, Scafuri L, Mirone V, De Cobelli O, **Shariat S**, Sonpavde G, Buonerba C. Absolute basophil count is associated with time to recurrence in patients with high-grade T1 bladder cancer receiving bacillus Calmette-Guérin after transurethral resection of the bladder tumor. *World J Urol*. 2020 Jan;38(1):143-150. PMID: 30993426
386. Beer L, Polanec SH, Baltzer PAT, Schatzl G, Georg D, Schestak C, Dutschke A, Herrmann H, Mazal P, Brendel AK, **Shariat SF**, Ringl H, Helbich TH, Apfalter P. 4D perfusion CT of prostate cancer for image-guided radiotherapy planning: A proof of concept study. *PLoS One*. 2019 Dec 19;14(12):e0225673. PMID: 31856177
387. Yeh HC, Margulis V, Singla N, Hernandez E, Panwar V, Woldu SL, Karam JA, Wood CG, Weizer AZ, Raman JD, Remzi M, Rioux-Leclercq N, Haitel A, Roscigno M, Bolenz C, Bensalah K, Li CC, Ke HL, Li WM, Lee HY, Rapoport LM, Lotan Y, Kapur P, **Shariat SF**, Hsieh JT, Wu WJ. PTRF independently predicts progression and survival in multiracial upper tract urothelial carcinoma following radical nephroureterectomy. *Urol Oncol*. 2019 Dec 17. pii: S1078-1439(19)30483-1. PMID: 31862213
388. Vartolomei L, Vartolomei MD, **Shariat SF**. Bladder Cancer: Depression, Anxiety, and Suicidality Among the Highest-risk Oncology Patients. *Eur Urol Focus*. 2019 Dec 10. PMID: 31836463
389. Kimura S, Iwata T, Abufaraj M, Janisch F, D'Andrea D, Moschini M, Al-Rawashdeh B, Fajkovic H, Seebacher V, Egawa S, **Shariat SF**. Impact of Gender on Chemotherapeutic Response and Oncologic Outcomes in Patients Treated With Radical Cystectomy and Perioperative

- Chemotherapy for Bladder Cancer: A Systematic Review and Meta-Analysis. Clin Genitourin Cancer. 2019 Dec 5. PMID: 31889669
390. Kimura S, D'Andrea D, Iwata T, Foerster B, Janisch F, Parizi MK, Moschini M, Briganti A, Babjuk M, Chlosta P, Karakiewicz PI, Enikeev D, Rapoport LM, Seebacher V, Egawa S, Abufaraj M, **Shariat SF**. Expression of urokinase-type plasminogen activator system in non-metastatic prostate cancer. World J Urol. 2019 Dec 4. PMID: 31797075
 391. Mazzone E, Mistretta FA, Knipper S, Tian Z, Palumbo C, Gandaglia G, Soulieres D, Tilki D, Montorsi F, **Shariat SF**, Saad F, Briganti A, Karakiewicz PI. Contemporary Assessment of Long-Term Survival Rates in Patients With Stage I Nonseminoma Germ-Cell Tumor of the Testis: Population-Based Comparison Between Surveillance and Active Treatment After Initial Orchiectomy. Clin Genitourin Cancer. 2019 Dec;17(6):e1153-e1162. PMID: 31515197
 392. Rasul S, Hacker M, Kretschmer-Chott E, Leisser A, Grubmüller B, Kramer G, **Shariat SF**, Wadsak W, Mitterhauser M, Hartenbach M, Haug AR. Clinical outcome of standardized 177Lu-PSMA-617 therapy in metastatic prostate cancer patients receiving 7400 MBq every 4 weeks. Eur J Nucl Med Mol Imaging. 2019 Nov 28. PMID: 31781834
 393. Mori K, Janisch F, Parizi MK, Mostafaei H, Lysenko I, Enikeev DV, Kimura S, Egawa S, **Shariat SF**. Prognostic value of alkaline phosphatase in hormone-sensitive prostate cancer: a systematic review and meta-analysis. Int J Clin Oncol. 2019 Nov 25. PMID: 31768692
 394. Rosiello G, Palumbo C, Knipper S, Pecoraro A, Dzyuba-Negrean C, Luzzago S, Tian Z, Gallina A, Montorsi F, **Shariat SF**, Saad F, Briganti A, Karakiewicz PI. Unmarried men have worse oncologic outcomes after radical cystectomy for nonmetastatic urothelial bladder cancer. Urol Oncol. 2019 Nov 21. PMID: 31761614
 395. Witjes JA, Babjuk M, Bellmunt J, Bruins HM, De Reijke TM, De Santis M, Gillessen S, James N, MacLennan S, Palou J, Powles T, Ribal MJ, **Shariat SF**, Der Kwast TV, Xylinas E, EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer-An International Collaborative Multistakeholder Effort†: Under the Auspices of the EAU-ESMO Guidelines Committees. Eur Urol. 2019 Nov 16. pii: S0302-2838(19)30763-8. doi: 10.1016/j.eururo.2019.09.035. PMID: 31753752
 396. Lebentrau S, Wolff I, Hempel MC, Haccius M, Kluth LA, Pycha A, Brookman-May S, Schneider TR, Hermanns T, Distler FA, Boegemann M, Kübler H, **Shariat SF**, Burger M, May M. Knowledge of German-speaking urologists regarding the association between penile cancer and human papilloma virus: results of a survey of the European PROspective Penile Cancer Study (E-PROPS). Aktuelle Urol. 2019 Nov 19. PMID: 31745963
 397. Stangl-Kremser J, Suarez-Ibarrola R, Andrea D, Korn SM, Pones M, Kramer G, Marhold M, Krainer M, Enikeev DV, Glybochko PV, Tamandl D, **Shariat SF**, Baltzer P. Assessment of body composition in the advanced stage of castration-resistant prostate cancer: special focus on sarcopenia. Prostate Cancer Prostatic Dis. 2019 Nov 19. PMID: 31745255
 398. Horwich A, Babjuk M, Bellmunt J, Bruins HM, Reijke TM, Santis M, Gillessen S, James N, MacLennan S, Palou J, Powles T, Ribal MJ, **Shariat SF**, Kwast TV, Xylinas E,. EAU-ESMO consensus statements on the management of advanced and variant bladder cancer-an international collaborative multi-stakeholder effort: under the auspices of the EAU and ESMO Guidelines Committees†. Ann Oncol. 2019 Nov 19. PMID: 31740927
 399. Enikeev D, **Shariat SF**, Taratkin M, Glybochko P. The changing role of lasers in urologic surgery. Curr Opin Urol. 2019 Nov 12. PMID: 31724998

400. Rosiello G, Knipper S, Palumbo C, Pecoraro A, Luzzago S, Deuker M, Tian Z, Gandaglia G, Gallina A, Montorsi F, **Shariat SF**, Saad F, Briganti A, Karakiewicz PI. Increasing Rates of Perioperative Chemotherapy are Associated With Improved Survival in Men With Urothelial Bladder Cancer With Prostatic Stromal Invasion. *Clin Genitourin Cancer*. 2019 Oct 17. PMID: 31711842
401. Mistretta FA, Cyr SJ, Palumbo C, Mazzone E, Knipper S, Tian Z, Nazzani S, Montanari E, Tilki D, Briganti A, **Shariat SF**, Perrotte P, Saad F, de Cobelli O, Karakiewicz PI. Adherence to Guideline Recommendations for Perioperative Chemotherapy in Patients with pN2-3 M0 Squamous Cell Carcinoma of the Penis: Temporal Trends and Survival Outcomes. *Clin Oncol (R Coll Radiol)*. 2019 Nov 6. PMID: 31706712
402. Hentschel AE, van Rhijn BWG, Bründl J, Compérat EM, Plass K, Rodríguez O, Henríquez JDS, Hernández V, de la Peña E, Alemany I, Turturica D, Pisano F, Soria F, Čapoun O, Bauerová L, Pešl M, Bruins HM, Runneboom W, Herdegen S, Breyer J, Brisuda A, Scavarda-Lamberti A, Calatrava A, Rubio-Briones J, Seles M, Mannweiler S, Bosschieter J, Kusuma VRM, Ashabere D, Huebner N, Cotte J, Mertens LS, Cohen D, Lunelli L, Cussenot O, Sheikh SE, Volanis D, Côté JF, Rouprêt M, Haitel A, **Shariat SF**, Mostafid AH, Nieuwenhuijzen JA, Zigeuner R, Dominguez-Escrig JL, Hacek J, Zlotta AR, Burger M, Evert M, Hulsbergen-van de Kaa CA, van der Heijden AG, Kiemeny LALM, Soukup V, Molinaro L, Gontero P, Llorente C, Algaba F, Palou J, N'Dow J, Babjuk M, van der Kwast TH, Sylvester RJ. Papillary urothelial neoplasm of low malignant potential (PUN-LMP): Still a meaningful histo-pathological grade category for Ta, noninvasive bladder tumors in 2019? *Urol Oncol*. 2019 Nov 5. PMID: 31704141
403. Mazzone E, Knipper S, Mistretta FA, Palumbo C, Tian Z, Gallina A, Tilki D, **Shariat SF**, Montorsi F, Saad F, Briganti A, Karakiewicz PI. Trends and social barriers for inpatient palliative care in patients with metastatic bladder cancer receiving critical care therapies. *J Natl Compr Canc Netw*. 2019 Nov 1;17(11):1344-1352. PMID: 31693981
404. Gontero P, Pisano F, Palou J, Joniau S, Albersen M, Colombo R, Briganti A, Pellucchi F, Faba OR, van Rhijn BW, van de Putte EF, Babjuk M, Fritsche HM, Mayr R, Albers P, Niegisch G, Anract J, Masson-Lecomte A, De la Taille A, Roupret M, Peyronnet B, Cai T, Witjes AJ, Bruins M, Baniel J, Mano R, Lapini A, Sessa F, Irani J, Brausi M, Stenzl A, Karnes JR, Scherr D, O'Malley P, Taylor B, **Shariat SF**, Black P, Abdi H, Matveev VB, Samuseva O, Parekh D, Gonzalgo M, Vetterlein MW, Aziz A, Fisch M, Catto J, Pang KH, Xylinas E, Rink M; Young Academic Urologists Urothelial Carcinoma Group of the European Association of Urology. Complication rate after cystectomy following pelvic radiotherapy: an international, multicenter, retrospective series of 682 cases. *World J Urol*. 2019 Nov 6. PMID: 31691084
405. Polanec SH, Bickel H, Wengert GJ, Arnoldner M, Clauser P, Susani M, **Shariat SF**, Pinker K, Helbich TH, Baltzer PAT. Can the addition of clinical information improve the accuracy of PI-RADS version 2 for the diagnosis of clinically significant prostate cancer in positive MRI? *Clin Radiol*. 2019 Nov 2. PMID: 31690449
406. Mazzone E, Mistretta FA, Knipper S, Tian Z, Palumbo C, Gandaglia G, Fossati N, **Shariat SF**, Saad F, Montorsi F, Graefen M, Briganti A, Karakiewicz PI. Temporal trends and social barriers for inpatient palliative care delivery in metastatic prostate cancer patients receiving critical care therapies. *Prostate Cancer Prostatic Dis*. 2019 Nov 4. PMID: 31685982
407. Palumbo C, Knipper S, Pecoraro A, Rosiello G, Luzzago S, Deuker M, Tian Z, **Shariat SF**, Simeone C, Briganti A, Saad F, Berruti A, Antonelli A, Karakiewicz PI. Patient frailty predicts worse perioperative outcomes and higher cost after radical cystectomy. *Surg Oncol*. 2019 Oct 25;32:8-13. PMID: 31683158

408. Black AJ, Zargar H, Zargar-Shoshtari K, Fairey AS, Mertens LS, Dinney CP, Mir MC, Krabbe LM, Cookson MS, Jacobsen NE, Griffin J, Montgomery JS, Vasdev N, Yu EY, Xylinas E, Campain NJ, Kassouf W, Dall'Era MA, Seah JA, Ercole CE, Horenblas S, McGrath JS, Aning J, **Shariat SF**, Wright JL, Thorpe AC, Morgan TM, Holzbeierlein JM, Bivalacqua TJ, North S, Barocas DA, Lotan Y, Grivas P, Stephenson AJ, Shah JB, van Rhijn BW, Spiess PE, Daneshmand S, Sridhar SS, Black PC. The prognostic value of the neutrophil-to-lymphocyte ratio in patients with muscle-invasive bladder cancer treated with neoadjuvant chemotherapy and radical cystectomy. *Urol Oncol*. 2019 Oct 29. PMID: 31676278
409. Hassler MR, Abufaraj M, Kimura S, Stangl-Kremser J, Gust K, Glybochko PV, Schmidinger M, Karakiewicz PI, **Shariat SF**. Impact of Patients' Gender on Efficacy of Immunotherapy in Patients With Metastatic Kidney Cancer: A Systematic Review and Meta-analysis. *Clin Genitourin Cancer*. 2019 Sep 27. PMID: 31668768
410. Stangl-Kremser J, Kramer G, **Shariat SF**. Association of Hyponatremia With Survival in Patients With Castration-resistant Prostate Cancer: A Clinical Commentary. *Clin Genitourin Cancer*. 2019 Aug 20. PMID:31623929
411. Grubmüller B, Rasul S, Baltzer P, Fajkovic H, D'Andrea D, Berndt F, Maj-Hes A, Grubmüller KH, Mitterhauser M, Wadsak W, Pfaff S, **Shariat SF**, Hacker M, Kramer G, Hartenbach M. Response assessment using [68 Ga]Ga-PSMA ligand PET in patients undergoing systemic therapy for metastatic castration-resistant prostate cancer. *Prostate*. 2019 Oct 15. PMID: 31614001
412. Veskimäe E, Espinos EL, Bruins HM, Yuan Y, Sylvester R, Kamat AM, **Shariat SF**, Witjes JA, Compérat EM. What Is the Prognostic and Clinical Importance of Urothelial and Nonurothelial Histological Variants of Bladder Cancer in Predicting Oncological Outcomes in Patients with Muscle-invasive and Metastatic Bladder Cancer? A European Association of Urology Muscle Invasive and Metastatic Bladder Cancer Guidelines Panel Systematic Review. *Eur Urol Oncol*. 2019 Oct 7. PMID: 31601522
413. Bandini M, Marchioni M, Preisser F, Nazzani S, Tian Z, Graefen M, Montorsi F, Saad F, **Shariat SF**, Schips L, Briganti A, Karakiewicz PI. Comprehensive analysis of in-hospital delirium after major surgical oncology procedures. *Can Urol Assoc J*. 2019 Sep 27. PMID: 31599720
414. Voskuilen CS, Schweitzer D, Jensen JB, Nielsen AM, Joniau S, Muilwijk T, Necchi A, Azizi M, Spiess PE, Briganti A, Bandini M, Goffin K, Bouchelouche K, van Werkhoven E, **Shariat SF**, Xylinas E, Azawi NH, Ku JH, Foerster B, van Rhijn BWG, Vegt E, Hendricksen K. Diagnostic Value of 18F-fluorodeoxyglucose Positron Emission Tomography with Computed Tomography for Lymph Node Staging in Patients with Upper Tract Urothelial Carcinoma. *Eur Urol Oncol*. 2019 Oct 4. PMID: 31591037
415. Leow JJ, Catto JWF, Efsthathiou JA, Gore JL, Hussein AA, **Shariat SF**, Smith AB, Weizer AZ, Wirth M, Witjes JA, Trinh QD. Quality Indicators for Bladder Cancer Services: A Collaborative Review. *Eur Urol*. 2019 Sep 25. PMID: 31563501
416. Luzzago S, Palumbo C, Rosiello G, Pecoraro A, Deuker M, Tian Z, **Shariat SF**, Saad F, de Cobelli O, Karakiewicz PI. The effect of radical cystectomy on survival in patients with metastatic urothelial carcinoma of the urinary bladder. *J Surg Oncol*. 2019 Sep 28. PMID: 31562831
417. Mori K, Kimura S, Parizi MK, Enikeev DV, Glybochko PV, Seebacher V, Fajkovic H, Mostafaei H, Lysenko I, Janisch F, Egawa S, **Shariat SF**. Prognostic Value of Lactate Dehydrogenase in Metastatic Prostate Cancer: A Systematic Review and Meta-analysis. *Clin Genitourin Cancer*. 2019 Jul 19. PMID: 31558410

418. Janisch F, Yu H, Vetterlein MW, Dahlem R, Engel O, Fisch M, **Shariat SF**, Soave A, Rink M. Do Younger Patients with Muscle-Invasive Bladder Cancer have Better Outcomes? *J Clin Med*. 2019 Sep 13;8(9). PMID: 31540247
419. Lobo N, **Shariat SF**, Guo CC, Fernandez MA, Kassouf W, Choudhury A, Gao J, Williams SB, Galsky MD, Taylor JA 3rd, Roupert M, Kamat AM. What Is the Significance of Variant Histology in Urothelial Carcinoma? *Eur Urol Focus*. 2019 Sep 14. PMID: 31530497
420. Soria F, D'Andrea D, Moschini M, Giordano A, Mazzoli S, Pizzuto G, Hurle R, Colombo R, Briganti A, Altieri V, **Shariat SF**, Gontero P. Predictive factors of the absence of residual disease at repeated transurethral resection of the bladder. Is there a possibility to avoid it in well-selected patients? *Urol Oncol*. 2019 Sep 14. PMID: 31526650
421. Heide J, Ribback S, Klatte T, **Shariat S**, Burchardt M, Dombrowski F, Belldegrun AS, Drakaki A, Pantuck AJ, Kroeger N. Evaluation of the prognostic role of co-morbidities on disease outcome in renal cell carcinoma patients. *World J Urol*. 2019 Sep 13. PMID: 31520111
422. Mazzone E, Mistretta FA, Knipper S, Tian Z, Palumbo C, Gandaglia G, Soulieres D, Tilki D, Montorsi F, **Shariat SF**, Saad F, Briganti A, Karakiewicz PI. Contemporary Assessment of Long-Term Survival Rates in Patients With Stage I Nonseminoma Germ-Cell Tumor of the Testis: Population-Based Comparison Between Surveillance and Active Treatment After Initial Orchiectomy. *Clin Genitourin Cancer*. 2019 Aug 21. PMID: 31515197
423. Moschini M, **Shariat SF**, Black P, Kamat AM, Stabile A, Cathelineau X, Kassouf W, Bochner BH, Xylinas E, Roupert M, Boorjian SA, Catto JW, Sanchez-Salas R. Do Not Learn a Technique, Learn the Biology Underlying the Disease: Techniques Evolve, Biology Prevails. *Eur Urol*. 2019 Sep 7. PMID: 31506227
424. Kardoust Parizi M, Enikeev D, Glybochko PV, Seebacher V, Janisch F, Fajkovic H, Chłosta PL, **Shariat SF**. Prognostic value of T1 substaging on oncological outcomes in patients with non-muscle-invasive bladder urothelial carcinoma: a systematic literature review and meta-analysis. *World J Urol*. 2019 Sep 6. PMID: 31493109
425. Palumbo C, Mistretta FA, Knipper S, Mazzone E, Pecoraro A, Tian Z, Perrotte P, Antonelli A, Montorsi F, **Shariat SF**, Saad F, Simeone C, Briganti A, Lavallee LT, Karakiewicz PI. Assessment of local tumor ablation and non-interventional management versus partial nephrectomy in T1a renal cell carcinoma. *Minerva Urol Nefrol*. 2019 Sep 4. PMID: 31487976
426. **Shariat S**, Gontero P, Catto JWF. How to Treat a Patient with T1 High-grade Disease and No Tumour on Repeat Transurethral Resection of the Bladder? *Eur Urol Oncol*. 2019 Aug 31. pii: S2588-9311(19)30109-9. PMID: 31481345
427. Mori K, Janisch F, Parizi MK, Mostafaei H, Lysenko I, Kimura S, Enikeev DV, Egawa S, **Shariat SF**. Prognostic Value of Variant Histology in Upper Tract Urothelial Carcinoma Treated with Nephroureterectomy: A Systematic Review and Meta-Analysis. *J Urol*. 2019 PMID:31479406
428. Rosiello G, Knipper S, Palumbo C, Dzyuba-Negrean C, Pecoraro A, Mazzone E, Mistretta FA, Tian Z, Capitano U, Montorsi F, **Shariat SF**, Saad F, Briganti A, Karakiewicz PI. Unmarried status is a barrier for access to treatment in patients with metastatic renal cell carcinoma. *Int Urol Nephrol*. 2019 Aug 29. PMID: 1468289
429. Mazzone E, Knipper S, Mistretta FA, Tian Z, Palumbo C, Soulieres D, De Cobelli O, Montorsi F, **Shariat SF**, Saad F, Briganti A, Karakiewicz PI. Contemporary North-American population-based validation of the International Germ Cell Consensus Classification for metastatic germ cell tumors of the testis. *World J Urol*. 2019 Aug 28. PMID31463562

430. Babjuk M, Burger M, Compérat EM, Gontero P, Mostafid AH, Palou J, van Rhijn BWG, Roupřet M, **Shariat SF**, Sylvester R, Zigeuner R, Capoun O, Cohen D, Escrig JLD, Hernández V, Peyronnet B, Seisen T, Soukup V. European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (TaT1 and Carcinoma In Situ) - 2019 Update. *Eur Urol.* 2019 Aug 20.PMID: 31443960
431. Mazzone E, Preisser F, Nazzani S, Tian Z, Bandini M, Gandaglia G, Fossati N, Montorsi F, Graefen M, **Shariat SF**, Saad F, Briganti A, Karakiewicz PI. The Effect of Lymph Node Dissection in Metastatic Prostate Cancer Patients Treated with Radical Prostatectomy: A Contemporary Analysis of Survival and Early Postoperative Outcomes. *Eur Urol Oncol.* 2019 Sep;2(5):541-548. PMID: 31411992
432. Moschini M, Zamboni S, Soria F, Mathieu R, Xylinas E, Tan WS, Kelly JD, Simone G, Meraney A, Krishna S, Konety B, Mattei A, Baumeister P, Mordasini L, Montorsi F, Briganti A, Gallina A, Stabile A, Sanchez-Salas R, Cathelineau X, Rink M, Necchi A, Karakiewicz PI, Roupřet M, Koupparis A, Kassouf W, Scherr DS, Ploussard G, Boorjian SA, Lotan Y, Sooriakumaran P, **Shariat SF**. Open Versus Robotic Cystectomy: A Propensity Score Matched Analysis Comparing Survival Outcomes. *J Clin Med.* 2019 Aug 9;8(8). PMID: 31395826
433. **Shariat SF**, Enikeev DV, Mostafaei H. Six essential conditions for bladder-sparing strategies in bacillus Calmette-Guérin unresponsive bladder cancer. *Immunotherapy.* 2019 Sep;11(13):1083-1086. doi: 10.2217/imt-2019-0083. Epub 2019 Aug 6. No abstract available. MID: 31385744
434. Sevcenco S, Grubmüller B, Sonneck-Koenne C, Ahmadi Y, Knoll P, Floth A, Pokieser W, Zandieh S, Christoph Klingler H, **Shariat S**, Mirzaei S. Bone Scintigraphy in Staging of Newly Diagnosed Prostate Cancer in Regard of Different Risk Groups. *Asia Ocean J Nucl Med Biol.* 2019 Spring;7(2):149-152PMID: 31380454
435. Palumbo C, Mistretta FA, Mazzone E, Knipper S, Tian Z, Perrotte P, Antonelli A, Montorsi F, **Shariat SF**, Saad F, Simeone C, Briganti A, Lattouf JB, Karakiewicz PI. Contemporary Incidence and Mortality Rates in Patients With Testicular Germ Cell Tumors. *Clin Genitourin Cancer.* 2019 Jun 13. pii: PMID: 31378580
436. Preisser F, Nazzani S, Mazzone E, Marchioni M, Bandini M, Tian Z, Haese A, Saad F, Zorn K, Montorsi F, **Shariat SF**, Graefen M, Tilki D, Karakiewicz PI. Comparison of Open Versus Robotically Assisted Cytoreductive Radical Prostatectomy for Metastatic Prostate Cancer. *Clin Genitourin Cancer.* 2019 May 27. PMID: 31375352
437. Palumbo C, Pecoraro A, Knipper S, Rosiello G, Tian Z, **Shariat SF**, Simeone C, Briganti A, Saad F, Berruti A, Antonelli A, Karakiewicz PI. Survival and Complication Rates of Metastasectomy in Patients With Metastatic Renal Cell Carcinoma Treated Exclusively With Targeted Therapy: A Combined Population-based Analysis. *Anticancer Res.* 2019 Aug;39(8):4357-4361. PMID: 31366530
438. Pecoraro A, Palumbo C, Knipper S, Mistretta FA, Tian Z, **Shariat SF**, Saad F, Briganti A, Fiori C, Porpiglia F, Karakiewicz PI. In Patients with Nonmetastatic pT1b Kidney Cancer Cryoablation Predisposes to Higher Cancer Specific Mortality Relative to Partial Nephrectomy. *J Urol.* 2019 Jul 26;PMID: 31347950
439. Loriot Y, Necchi A, Park SH, Garcia-Donas J, Huddart R, Burgess E, Fleming M, Rezazadeh A, Mellado B, Varlamov S, Joshi M, Duran I, Tagawa ST, Zakharia Y, Zhong B, Stuyckens K, Santiago-Walker A, De Porre P, O'Hagan A, Avadhani A, Siefker-Radtke AO; BLC2001 Study Group. Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma. *N Engl J Med* 2019 Jul 25;381(4):338-348. PMID:31340094

440. Stangl-Kremser J, Lemberger U, Hassler MR, Bruchbacher A, Ilijazi D, Garstka N, Kramer G, Haitel A, Abufaraj M, **Shariat SF**. Prevalence and Prognostic Value of the Polymorphic Variant 1245A>C of HSD3B1 in Castration-resistant Prostate Cancer. *Clin Genitourin Cancer*. 2019 Jun 26. PMID 31331867
441. Janisch F, **Shariat SF**, Baltzer P, Fajkovic H, Kimura S, Iwata T, Korn P, Yang L, Glybochko PV, Rink M, Abufaraj M. Diagnostic performance of multidetector computed tomographic (MDCTU) in upper tract urothelial carcinoma (UTUC): a systematic review and meta-analysis. *World J Urol*. 2019 Jul 18. PMID: 31321509
442. Janisch F, Abufaraj M, Fajkovic H, Kimura S, Iwata T, Nyirady P, Rink M, **Shariat SF**. Current Disease Management of Primary Urethral Carcinoma. *Eur Urol Focus*. 2019 Jul 12. PMID:31307949
443. Mistretta FA, Palumbo C, Knipper S, Mazzone E, Pecoraro A, Tian Z, Musi G, Perrotte P, Montanari E, Shariat SF, Saad F, Briganti A, de Cobelli O, Karakiewicz PI. Conditional survival of patients with stage I-III squamous cell carcinoma of the penis: temporal changes in cancer-specific mortality. *World J Urol*. 2019 Jul 11. PMID: 31297629
444. Palumbo C, Mistretta FA, Knipper S, Pecoraro A, Tian Z, Shariat SF, Saad F, Simeone C, Briganti A, Antonelli A, Karakiewicz PI. How cancer-specific mortality changes over time after radical cystectomy: Conditional survival of patients with nonmetastatic urothelial carcinoma of the urinary bladder. *Urol Oncol*. 2019 Jul 8. PMID: 31296422
445. Kardoust Parizi M, Abufaraj M, Fajkovic H, Kimura S, Iwata T, D'Andrea D, Karakiewicz PI, Shariat SF. Oncological safety of testosterone replacement therapy in prostate cancer survivors after definitive local therapy: A systematic literature review and meta-analysis. *Urol Oncol*. 2019 Jul 8. PMID: 31296421
446. Mistretta FA, Mazzone E, Palumbo C, Knipper S, Tian Z, Nazzani S, Tilki D, Musi G, Perrotte P, Montanari E, Shariat SF, Saad F, Briganti A, de Cobelli O, Karakiewicz PI. Adherence to guideline recommendations for lymph node dissection in squamous cell carcinoma of the penis: Effect on survival and complication rates. *Urol Oncol*. 2019 Jul 8. PMID: 31296420
447. Lucca I, Hofbauer SL, Haitel A, Susani M, Shariat SF, Klatte T, De Martino M. Urinary expression of genes involved in DNA methylation and histone modification for diagnosis of bladder cancer in patients with asymptomatic microscopic haematuria. *Oncol Lett*. 2019 Jul;18(1):57-62. PMID: 31289472
448. Robinson BD, Vlachostergios PJ, Bhinder B, Liu W, Li K, Moss TJ, Bareja R, Park K, Tavassoli P, Cyrta J, Tagawa ST, Nanus DM, Beltran H, Molina AM, Khani F, Miguel Mosquera J, Xylinas E, Shariat SF, Scherr DS, Rubin MA, Lerner SP, Matin SF, Elemento O, Faltas BM. Upper tract urothelial carcinoma has a luminal-papillary T-cell depleted contexture and activated FGFR3 signaling. *Nat Commun*. 2019 Jul 5;10(1):2977. PMID: 31278255
449. Pignot G, Lorient Y, Kamat AM, Shariat SF, Plimack ER. Effect of Immunotherapy on Local Treatment of Genitourinary Malignancies. *Eur Urol Oncol*. 2019 Jul;2(4):355-364. PMID: 31277773
450. Palumbo C, Knipper S, Dzyuba-Negrean C, Pecoraro A, Rosiello G, Tian Z, Shariat SF, Simeone C, Briganti A, Saad F, Berruti A, Antonelli A, Karakiewicz PI. Complication rates, failure to rescue and in-hospital mortality after cytoreductive nephrectomy in the older patients. *J Geriatr Oncol*. 2019 Jun 27. PMID: 31257163
451. Iwata T, Kimura S, Abufaraj M, Janisch F, Parizi MK, Haitel A, Rink M, Rouprêt M, Fajkovic H, Seebacher V, Nyirady P, Karakiewicz PI, Enikeev D, Rapoport LM, Nasu Y, Shariat SF. Prognostic

- role of the urokinase plasminogen activator (uPA) system in patients with nonmuscle invasive bladder cancer. *Urol Oncol*. 2019 Jun 26. PMID: 31255543
452. Iwata T, Kimura S, Abufaraj M, Janisch F, Karakiewicz PI, Seebacher V, Rouprêt M, Nasu Y, Shariat SF. The role of adjuvant radiotherapy after surgery for upper and lower urinary tract urothelial carcinoma: A systematic review. *Urol Oncol*. 2019 Jun 26. PMID: 31255542
453. Abufaraj M, Grubmüller B, Zeitlinger M, Kramer G, Seitz C, Haitel A, Baltzer P, Hacker M, Wadsak W, Pfaff S, Wiatr T, Mitterhauser M, Shariat SF, Hartenbach M. Prospective evaluation of the performance of [68Ga]Ga-PSMA-11 PET/CT(MRI) for lymph node staging in patients undergoing superextended salvage lymph node dissection after radical prostatectomy. *Eur J Nucl Med Mol Imaging*. 2019 Jun 29. PMID: 31254037
454. Krimphove MJ, Szymaniak J, Marchese M, Tully KH, D'Andrea D, Mossanen M, Lipsitz SR, Kilbridge K, Kibel AS, Kluth LA, Shariat SF, Trinh QD. Sex-specific Differences in the Quality of Treatment of Muscle-invasive Bladder Cancer Do Not Explain the Overall Survival Discrepancy. *Eur Urol Focus*. 2019 Jun 18. PMID: 31227463
455. Khene ZE, Peyronnet B, Bernhard JC, Kocher NJ, Vaessen C, Doumerc N, Pradere B, Seisen T, Beauval JB, Verhoest G, Roumiguié M, De la Taille A, Bruyere F, Roupert M, Mejean A, Mathieu R, Shariat S, Raman JD, Bensalah K; members of the French Committee of Urologic Oncology (CCAFU). A preoperative nomogram to predict major complications after robot assisted partial nephrectomy (UroCCR-57 study). *Urol Oncol*. 2019 Jun 8. PMID: 31186143
456. Mistretta FA, Mazzone E, Palumbo C, Knipper S, Tian Z, Nazzani S, Lattouf JB, Musi G, Perrotte P, Montanari E, Shariat SF, Montorsi F, Saad F, de Cobelli O, Karakiewicz PI. Contemporary Assessment of Survival Rates in Stage I Testicular Seminoma: A Population-Based Comparison Between Surveillance and Active Treatment After Orchiectomy. *Clin Genitourin Cancer*. 2019 Apr 30. PMID: 31182339
457. Vartolomei MD, Iwata T, Roth B, Kimura S, Mathieu R, Ferro M, Shariat SF, Seitz C. Impact of alcohol consumption on the risk of developing bladder cancer: a systematic review and meta-analysis. *World J Urol*. 2019 Jun 6. PMID: 31172281
458. Cantiello F, Russo GI, Vartolomei MD, Farhan ARA, Terracciano D, Musi G, Lucarelli G, Di Stasi SM, Hurle R, Serretta V, Busetto GM, Scafuro C, Perdonà S, Borghesi M, Schiavina R, Cioffi A, De Berardinis E, Almeida GL, Bove P, Lima E, Ucciero G, Matei DV, Crisan N, Verze P, Battaglia M, Guazzoni G, Autorino R, Morgia G, Damiano R, de Cobelli O, Mirone V, Shariat SF, Ferro M. Systemic Inflammatory Markers and Oncologic Outcomes in Patients with High-risk Non-muscle-invasive Urothelial Bladder Cancer. *Eur Urol Oncol*. 2018 Oct;1(5):403-410. PMID: 31158079
459. González J, Gaynor JJ, Martínez-Salamanca JJ, Capitanio U, Tilki D, Carballido JA, Chantada V, Daneshmand S, Evans CP, Gasch C, Gontero P, Haferkamp A, Huang WC, Espinós EL, Master VA, McKiernan JM, Montorsi F, Pahernik S, Palou J, Pruthi RS, Rodriguez-Faba O, Russo P, Scherr DS, Shariat SF, Spahn M, Terrone C, Vera-Donoso C, Zigeuner R, Hohenfellner M, Libertino JA, Ciancio G. Association of an organ transplant-based approach with a dramatic reduction in postoperative complications following radical nephrectomy and tumor thrombectomy in renal cell carcinoma. *Eur J Surg Oncol*. 2019 May 15. PMID: 31155470
460. Kimura S, Abufaraj M, Janisch F, Iwata T, Parizi MK, Foerster B, Fossati N, Briganti A, Egawa S, Hartenbach M, Shariat SF. Performance of [68Ga] Ga-PSMA 11 PET for detecting prostate cancer in the lymph nodes before salvage lymph node dissection: a systematic review and meta-analysis. *Prostate Cancer Prostatic Dis*. 2019 May 30. PMID: 31147628

461. Mazzone E, Mistretta FA, Knipper S, Palumbo C, Tian Z, Pecoraro A, Preisser F, Gallina A, Shariat SF, Saad F, Graefen M, Montorsi F, Briganti A, Karakiewicz PI. Long-Term Incidence of Secondary Bladder, Rectal Cancer in Patients Treated with Brachytherapy for Localized Prostate Cancer: A Large-Scale Population-Based Analysis. *BJU Int.* 2019 May 30. PMID: 31144770
462. Kardoust Parizi M, Glybochko PV, Enikeev D, Rouprêt M, Fajkovic H, Seebacher V, **Shariat SF**. Risk stratification of upper tract urothelial carcinoma: A Review of the Current Literature. *Expert Rev Anticancer Ther.* 2019 Jun;19(6):503-513. PMID: 31131643
463. Knipper S, Preisser F, Mazzone E, Mistretta FA, Palumbo C, Tian Z, Briganti A, **Shariat SF**, Saad F, Tilki D, Graefen M, Karakiewicz PI. Contemporary analysis of the effect of marital status on survival of prostate cancer patients across all stages: A population-based study. *Urol Oncol.* 2019 May 15. PMID: 31103337
464. Bandini M, Preisser F, Nazzani S, Marchioni M, Tian Z, Mazzone E, Graefen M, Montorsi F, **Shariat SF**, Saad F, Briganti A, Karakiewicz PI. The Effect of Other-cause Mortality Adjustment on Access to Alternative Treatment Modalities for Localized Prostate Cancer Among African American Patients. *Eur Urol Oncol.* 2018 Aug;1(3):215-222. PMID: 31102624
465. Nazzani S, Preisser F, Bandini M, Marchioni M, Tian Z, Soulières D, Montanari E, Ratti D, Acquati P, Briganti A, **Shariat SF**, Abdollah F, Carmignani L, Karakiewicz PI. Surgically Treated Retroperitoneal Sarcoma: A Population-based Competing Risks Analysis. *Eur Urol Oncol.* 2018 Sep;1(4):346-351. PMID: 31100257
466. Bandini M, Mazzone E, Preisser F, Nazzani S, Zaffuto E, Marchioni M, Tian Z, Pompe RS, Tilki D, Graefen M, **Shariat SF**, Montorsi F, Saad F, Briganti A, Karakiewicz P. Increase in the Annual Rate of Newly Diagnosed Metastatic Prostate Cancer: A Contemporary Analysis of the Surveillance, Epidemiology and End Results Database. *Eur Urol Oncol.* 2018 Sep;1(4):314-320. PMID: 31100253
467. Vartolomei L, **Shariat SF**, Vartolomei MD. Psychotherapeutic Interventions Targeting Prostate Cancer Patients: A Systematic Review of the Literature. *Eur Urol Oncol.* 2018 Sep;1(4):283-291. PMID: 31100249
468. Zaffuto E, Bandini M, Moschini M, Leyh-Bannurah SR, Gazdovich S, Dell'Oglio P, Gallina A, **Shariat SF**, Briganti A, Montorsi F, Saad F, Karakiewicz PI. Location of Metastatic Bladder Cancer as a Determinant of In-hospital Mortality After Radical Cystectomy. *Eur Urol Oncol.* 2018 Jun;1(2):169-175. PMID: 31100242
469. Heidenreich A, Fossati N, Pfister D, Suardi N, Montorsi F, **Shariat S**, Grubmüller B, Gandaglia G, Briganti A, Karnes RJ. Cyto-reductive Radical Prostatectomy in Men with Prostate Cancer and Skeletal Metastases. *Eur Urol Oncol.* 2018 May ;1(1):46-53. PMID: 31100228
470. Kimura S, Iwata T, Foerster B, Fossati N, Briganti A, Nasu Y, Egawa S, Abufaraj M, **Shariat SF**. Comparison of perioperative complications and health-related quality of life between robot-assisted and open radical cystectomy: A systematic review and meta-analysis. *Int J Urol.* 2019 May 13. PMID: 31083783
471. Zamboni S, Soria F, Mathieu R, Xylinas E, Abufaraj M, D'Andrea D, Tan WS, Kelly JD, Simone G, Gallucci M, Meraney A, Krishna S, Konety BR, Antonelli A, Simeone C, Baumeister P, Mattei A, Briganti A, Gallina A, Montorsi F, Rink M, Aziz A, Karakiewicz PI, Rouprêt M, Koupparis A, Scherr DS, Ploussard G, Sooriakumaran P, **Shariat SF**, Moschini M: Differences in utilization-trend and time changes of peri-operative outcomes of robotic and open radical cystectomy between American and European selected centers: an international multicenter collaboration. *BJU Int.* 2019 May 4. PMID: 31055865

472. Mazzone E, Preisser F, Nazzani S, Tian Z, Zaffuto E, Gallina A, Tilki D, Montorsi F, **Shariat SF**, Saad F, Briganti A, Karakiewicz PI. The effect of age and comorbidities on early postoperative complications after radical cystectomy: A contemporary population-based analysis. *J Geriatr Oncol.* 2019 Apr 19. PMID: 31010691
473. Abufaraj M, Tabung FK, **Shariat SF**, Moschini M, Devore E, Papantoniou K, Yang L, Strohmaier S, Rohrer F, Markt SC, Zhang X, Giovannucci E, Schernhammer E. Association between inflammatory potential of diet and bladder cancer risk: Results from three US prospective cohort studies. *J Urol.* 2019 Apr 22; PMID: 31009297
474. D'Andrea D, Abufaraj M, Soria F, Gust K, Haitel A, Krakiewicz PI, **Shariat SF**. Association of super-extended lymphadenectomy at radical cystectomy with perioperative complications and re-hospitalization. *World J Urol.* 2019 Apr 20. PMID: 31006052
475. Nazzani S, Preisser F, Mazzone E, Marchioni M, Bandini M, Tian Z, Mistretta FA, **Shariat SF**, Soulières D, Saad F, Montanari E, Luzzago S, Briganti A, Carmignani L, Karakiewicz PI. Survival effect of nephroureterectomy in metastatic upper urinary tract urothelial carcinoma. *Clin Genitourin Cancer.* 2019 Mar 29. PMID: 31005472
476. Ferro M, Di Lorenzo G, Vartolomei MD, Bruzzese D, Cantiello F, Lucarelli G, Musi G, Di Stasi S, Hurle R, Guazzoni G, Busetto GM, Gabriele A, Del Giudice F, Damiano R, Perri F, Perdona S, Verze P, Borghesi M, Schiavina R, Almeida GL, Bove P, Lima E, Autorino R, Crisan N, Farhan ARA, Battaglia M, Russo GI, Ieluzzi V, Morgia G, De Placido P, Terracciano D, Cimmino A, Scafuri L, Mirone V, De Cobelli O, **Shariat S**, Sonpavde G, Buonerba C. Absolute basophil count is associated with time to recurrence in patients with high-grade T1 bladder cancer receiving bacillus Calmette-Guérin after transurethral resection of the bladder tumor. *World J Urol.* 2019 Apr 16. PMID: 30993426
477. Palumbo C, Cyr SJ, Mazzone E, Mistretta FA, Knipper S, Pecoraro A, Tian Z, **Shariat SF**, Saad F, Simeone C, Briganti A, Kapoor A, Antonelli A, Karakiewicz PI. Impact of tumor size on cancer specific mortality after local tumor ablation in T1a renal cell carcinoma. *J Endourol.* 2019 Apr 16. PMID: 30990074
478. Iwata T, Kimura S, Foerster B, Fossati N, Briganti A, Karakiewicz PI, Gust KM, Egawa S, Nasu Y, Abufaraj M, **Shariat SF**. Oncologic outcomes after robot-assisted versus open radical cystectomy: a systematic review and meta-analysis. *World J Urol.* 2019 Apr 11. PMID: 30976902
479. D'Andrea D, Gontero P, **Shariat SF**, Soria F. Intravesical bacillus Calmette-Guérin for bladder cancer: are all the strains equal? *Transl Androl Urol.* 2019 Feb;8(1):85-93. PMID: 30976572
480. Soria F, Marra G, D'Andrea D, Gontero P, **Shariat SF**. The rational and benefits of the second look transurethral resection of the bladder for T1 high grade bladder cancer. *Transl Androl Urol.* 2019 Feb;8(1):46-53. PMID: 30976568
481. Pozo C, **Shariat SF**, D'Andrea D, Fajkovic H, Abufaraj M. Enhanced Recovery after Radical Cystectomy. *Curr Opin Urol.* 2019 May;29(3):227-238. PMID: 30950886
482. Azizi M, Cheriyan SK, Peyton CC, Foerster B, **Shariat SF**, Spiess PE. Optimal Management of Upper Tract Urothelial Carcinoma: an Unmet Need. *Curr Treat Options Oncol.* 2019 Apr 1;20(5):40. PMID: 30937554
483. Mazzone E, Mistretta FA, Knipper S, Tian Z, Larcher A, Widmer H, Zorn KC, Capitanio U, Graefen M, Montorsi F, **Shariat SF**, Saad F, Briganti A, Karakiewicz PI. Contemporary North-American Assessment of Robot-assisted Surgery Rates and Total Hospital Charges for Major Surgical Uro-oncological Procedures. *J Endourol.* 2019 Mar 30. PMID: 30931607

484. Zamboni S, Foerster B, Abufaraj M, Seisen T, Roupret M, Colin P, De la Taille A, Di Bona C, Peyronnet B, Bensalah K, Herout R, Wirth MP, Novotny V, Soria F, Chlosta P, Antonelli A, Simeone C, Baumeister P, Mattei A, Montorsi F, Simone G, Gallucci M, Matsumoto K, Karakiewicz PI, Briganti A, Xylinas E, **Shariat SF**, Moschini M. Incidence and survival outcomes of upper urinary tract urothelial carcinoma (UTUC) patients diagnosed with variant histology treated with nephroureterectomy. *BJU Int.* 2019 Mar 25. PMID: 30908835
485. Kardoust Parizi M, Iwata T, Kimura S, Janisch F, Abufaraj M, Karakiewicz PI, Enikeev D, Rapoport LM, Hutterer G, **Shariat SF**. Focal Neuroendocrine Differentiation of Conventional Prostate Adenocarcinoma as a Prognostic Factor after Radical Prostatectomy: A Systematic Review and Meta-Analysis. *Int J Mol Sci.* 2019 Mar 19;20(6). PMID: 30893781
486. Janisch F, **Shariat SF**, Schernhammer E, Rink M, Fajkovic H. The interaction of gender and smoking on bladder cancer risks. *Curr Opin Urol.* 2019 May;29(3):249-255. PMID: 30888973
487. Mun DH, Kimura S, **Shariat SF**, Abufaraj M. The impact of gender on oncologic outcomes of bladder cancer. *Curr Opin Urol.* 2019 Mar 6. PMID: 30855378
488. Marks P, Gild P, Soave A, Janisch F, Minner S, Engel O, Vetterlein MW, **Shariat SF**, Sauter G, Dahlem R, Fisch M, Rink M. The impact of variant histological differentiation on extranodal extension and survival in node positive bladder cancer treated with radical cystectomy. *Surg Oncol.* 2019 Mar;28:208-213. PMID: 30851902
489. Nazzani S, Bandini M, Preisser F, Mazzone E, Marchioni M, Tian Z, Stubinski R, Clementi MC, Saad F, **Shariat SF**, Montanari E, Briganti A, Carmignani L, Karakiewicz PI. Postoperative paralytic ileus after major oncological procedures in the enhanced recovery after surgery era: A population based analysis. *Surg Oncol.* 2019 Mar;28:201-207. PMID: 30851901
490. Moschini M, Martini A, Zamboni S, Mattei A, Baumeister P, Di Bona C, Dell'Oglio P, Zaffuto E, Burgio G, **Shariat SF**, Sanchez-Salas R, Cathelineau X, Salonia A, Montorsi F, Briganti A, Gallina A, Colombo R. Evaluation of Cause of Death After Radical Cystectomy for Patients With Bladder Cancer: The Impact of Age at the Time of Surgery. *Clin Genitourin Cancer.* 2019 Feb 13. PMID: 30850337
491. Foerster B, D'Andrea D, Abufaraj M, Broenimann S, Karakiewicz PI, Rouprêt M, Gontero P, Lerner SP, **Shariat SF**, Soria F. Endocavitary treatment for upper tract urothelial carcinoma: A meta-analysis of the current literature. *Urol Oncol.* 2019 Mar 4. PMID: 30846387
492. Fossati N, Robesti D, Karnes RJ, Soligo M, Boorjian SA, Bossi A, Coraggio G, Di Muzio N, Cozzarini C, Noris Chiorda B, Gandaglia G, Scarcella S, Bartkowiak D, Böhmer D, **Shariat S**, Goldner G, Battaglia A, Joniau S, Haustermans K, De Meerleer G, Fonteyne V, Ost P, Van Poppel H, Montorsi F, Wiegel T, Briganti A. Assessing the Role and Optimal Duration of Hormonal Treatment in Association with Salvage Radiation Therapy After Radical Prostatectomy: Results from a Multi-Institutional Study. *Eur Urol.* 2019 Feb 21. PMID: 3079918
493. Mistretta FA, Mazzone E, Knipper S, Palumbo C, Tian Z, Nazzani S, Saad F, Montanari E, Tilki D, Briganti A, **Shariat SF**, de Cobelli O, Karakiewicz PI. Contemporary trends of pelvic lymph node dissection at radical cystectomy for urothelial carcinoma of urinary bladder and associated cancer specific mortality and complications: comparison between octogenarian versus younger patients. *Cancer Epidemiol.* 2019 Feb 13;59:135-142. PMID: 30771698
494. Hassler MR, **Shariat SF**, Soria F. Salvage therapeutic strategies for bacillus Calmette-Guerin failure. *Curr Opin Urol.* 2019 Feb 11. PMID: 30762670
495. Aydin AM, Singla N, Panwar V, Woldu SL, Freifeld Y, Wood CG, Karam JA, Weizer AZ, Raman JD, Remzi M, Rioux-Leclercq N, Haitel A, Roscigno M, Bolenz C, Bensalah K, Westerman ME,

- Sagalowsky AI, **Shariat SF**, Lotan Y, Bagrodia A, Kapur P, Margulis V, Krabbe LM. Prognostic significance of BAP1 expression in high-grade upper tract urothelial carcinoma: a multi-institutional study. *World J Urol*. 2019 Feb 13. PMID: 30759271
496. Nazzani S, Bazinet A, Preisser F, Mazzone E, Tian Z, Mistretta FA, **Shariat SF**, Saad F, Zorn KC, Montanari E, Briganti A, Carmignani L, Karakiewicz PI. Comparison of perioperative outcomes between open and minimally invasive nephroureterectomy: A population-based analysis. *Int J Urol*. 2019 Feb 12. PMID: 30756440
497. Mazzone E, Nazzani S, Knipper S, Tian Z, Preisser F, Gallina A, Soulières D, Tilki D, Montorsi F, **Shariat SF**, Saad F, Briganti A, Wisnivesky J, Karakiewicz PI. Contemporary use and survival after perioperative systemic chemotherapy in patients with locally advanced non-metastatic urothelial carcinoma of the bladder treated with radical cystectomy. *Eur J Surg Oncol*. 2019 Feb 3. PMID: 30755341
498. Iwata T, Kimura S, Foerster B, Abufaraj M, Karakiewicz PI, Preisser F, Nasu Y, **Shariat SF**: Perioperative blood transfusion affects oncologic outcomes after nephrectomy for renal cell carcinoma: A systematic review and meta-analysis. *Urol Oncol*. 2019 Feb 5. PMID: 30737159
499. Moschini M, Zamboni S, Mattei A, Baumeister P, Di Bona C, Cornelius J, **Shariat SF**, Freschi M, Zaffuto E, Salonia A, Montorsi F, Briganti A, Colombo R, Gallina A: Radical Cystectomy in Pathological T4a and T4b Bladder Cancer Patients: Is There Any Space for Sub Stratification? *Urol Int*. 2019 Jan 29:1-8. PMID: 30695782
500. Soria F, **Shariat SF**. Biomarkers for the prediction of oncologic outcomes in non-muscle invasive bladder cancer: state of affairs and new frontiers. *Transl Androl Urol*. 2018 Dec;7(Suppl 6):S753-S755. PMID: 30687617
501. D'Andrea D, Soria F, Zehetmayer S, Gust KM, Korn S, Witjes JA, **Shariat SF**. Diagnostic accuracy, clinical utility and influence on decision making of a methylation urine biomarker test in the surveillance of non-muscle-invasive bladder cancer. *BJU Int*. 2019 Jan 17. PMID: 30653818
502. Korn SM, Hübner NA, Seitz C, **Shariat SF**, Fajkovic H. Role of lasers in urology. *Photochem Photobiol Sci*. 2019 Jan 14. PMID: 30640321
503. Berg S, D'Andrea D, Vetterlein MW, Cole AP, Fletcher SA, Krimphove MJ, Marchese M, Lipsitz SR, Sonpavde G, Noldus J, **Shariat SF**, Kibel AS, Trinh QD, Mossanen M. Impact of adjuvant chemotherapy in patients with adverse features and variant histology at radical cystectomy for muscle-invasive carcinoma of the bladder: Does histologic subtype matter? *Cancer*. 2019 Jan 8. PMID: 30620387
504. Foerster B, **Shariat SF**, Klein JT, Bolenz C. Biopsy techniques in the upper urinary tract for the diagnosis of urothelial carcinoma: systematic review. *Urologe A*. 2019 Jan 7. PMID: 30617531
505. Preisser F, Mazzone E, Nazzani S, Knipper S, Tian Z, Mandel P, Pompe R, Saad F, Montorsi F, **Shariat SF**, Huland H, Graefen M, Tilki D, Karakiewicz PI. Impact of age on perioperative outcomes at radical prostatectomy: a population-based study. *Eur Urol Focus*. 2018 Dec 26. PMID: 30594487
506. Kimura S, D'Andrea D, Soria F, Foerster B, Abufaraj M, Vartolomei MD, Iwata T, Karakiewicz PI, Rink M, Gust KM, Egawa S, **Shariat SF**. Prognostic value of modified Glasgow Prognostic Score in non-muscle-invasive bladder cancer. *Urol Oncol*. 2018 Dec 20. PMID: 30580906
507. Stangl-Kremser J, D'Andrea D, Vartolomei M, Abufaraj M, Goldner G, Baltzer P, **Shariat SF**, Tamandl D. Prognostic value of nutritional indices and body composition parameters including

- sarcopenia in patients treated with radiotherapy for urothelial carcinoma of the bladder. *Urol Oncol*. 2018 Dec 18. PMID: 30578161
508. Grubmüller B, Senn D, Kramer G, Baltzer P, D'Andrea D, Grubmüller KH, Mitterhauser M, Eidherr H, Haug AR, Wadsak W, Pfaff S, **Shariat SF**, Hacker M, Hartenbach M. Response assessment using 68Ga-PSMA ligand PET in patients undergoing 177Lu-PSMA radioligand therapy for metastatic castration-resistant prostate cancer. *Eur J Nucl Med Mol Imaging*. 2018 Dec 19. PMID: 30569186
509. Nazzani S, Mazzone E, Preisser F, Tian Z, Mistretta FA, **Shariat SF**, Montanari E, Acquati P, Briganti A, Saad F, Carmignani L, Karakiewicz PI. Rates of lymph node invasion and their impact on cancer specific mortality in upper urinary tract urothelial carcinoma. *Eur J Surg Oncol*. 2018 Dec 11. PMID: 30563773
510. Abufaraj M, Foerster B, Schernhammer E, Moschini M, Kimura S, Hassler MR, Preston MA, Karakiewicz PI, Remzi M, **Shariat SF**. Micropapillary Urothelial Carcinoma of the Bladder: A Systematic Review and Meta-analysis of Disease Characteristics and Treatment Outcomes. *Eur Urol*. 2018 Dec 12. PMID: 30553613
511. Vartolomei MD, D'Andrea D, Chade DC, Soria F, Kimura S, Foerster B, Abufaraj M, Mathieu R, Moschini M, Rouprêt M, Briganti A, Karakiewicz PI, **Shariat SF**. Role of serum cholinesterase in patients treated with salvage radical prostatectomy. *Urol Oncol*. 2018 Dec 3. PMID: 30522902
512. Mazzone E, Knipper S, Mistretta FA, Tian Z, Preisser F, Gallina A, Soulieres D, Tilki D, Montorsi F, **Shariat SF**, Saad F, Briganti A, Wisnivesky J, Karakiewicz PI. Is neoadjuvant chemotherapy for pT2 bladder cancer associated with a survival benefit in a population-based analysis? *Cancer Epidemiol*. 2018 Dec 5;58:83-88. PMID: 30528834
513. Mazzone E, Preisser F, Nazzani S, Tian Z, Fossati N, Gandaglia G, Gallina A, Soulieres D, Tilki D, Montorsi F, **Shariat SF**, Saad F, Briganti A, Karakiewicz PI. More Extensive Lymph Node Dissection Improves Survival Benefit of Radical Cystectomy in Metastatic Urothelial Carcinoma of the Bladder. *Clin Genitourin Cancer*. 2018 Nov 17. PMID: 30527745
514. Soukup V, Čapoun O, Cohen D, Hernández V, Burger M, Compérat E, Gontero P, Lam T, Mostafid AH, Palou J, van Rhijn BWG, Rouprêt M, **Shariat SF**, Sylvester R, Yuan Y, Zigeuner R, Babjuk M. Risk Stratification Tools and Prognostic Models in Non-muscle-invasive Bladder Cancer: A Critical Assessment from the European Association of Urology Non-muscle-invasive Bladder Cancer Guidelines Panel. *Eur Urol Focus*. 2018 Nov 20. PMID: 30470647
515. Soria F, Moschini M, D'andrea D, Abufaraj M, Foerster B, Mathieu R, Gust KM, Gontero P, Simone G, Meraney A, Krishna S, Konety B, Rouprêt M, Perry M, Rowe E, Ploussard G, Boorjian SA, Wiklund P, Sooriakumaran P, **Shariat SF**. Comparative Effectiveness in Perioperative Outcomes of Robotic versus Open Radical Cystectomy: Results from a Multicenter Contemporary Retrospective Cohort Study. *Eur Urol Focus*. 2018 Nov 16. PMID: 30455153
516. D'Andrea D, Soria F, Abufaraj M, Gust K, Foerster B, Vartolomei MD, Kimura S, Mari A, Briganti A, Remzi M, Seitz CK, Mathieu R, Karakiewicz PI, **Shariat SF**. Clinical value of cholinesterase in the prediction of biochemical recurrence after radical prostatectomy. *Urol Oncol*. 2018 Nov 13. PMID: 30446461
517. Moschini M, Soria F, Mathieu R, Xylinas E, D'Andrea D, Tan WS, Kelly JD, Simone G, Tuderti G, Meraney A, Krishna S, Konety B, Zamboni S, Baumeister P, Mattei A, Briganti A, Montorsi F, Galucci M, Rink M, Karakiewicz PI, Rouprêt M, Aziz A, Perry M, Rowe E, Koupparis A, Kassouf W, Scherr DS, Ploussard G, Boorjian SA, Sooriakumaran P, **Shariat SF**: Propensity-score-matched

- comparison of soft tissue surgical margins status between open and robotic-assisted radical cystectomy. *Urol Oncol*. 2018 Nov 13. PMID: 30446442
518. Khene ZE, Peyronnet B, Freton L, Graffelle V, Pradere B, Robert C, Kammerer-Jacquet SF, Verhoest G, Rioux-Leclercq N, **Shariat S**, Mathieu R, Bensalah K. What Is Better for Predicting Morbidity of Robotic Partial Nephrectomy-A Score or Your Clinical Judgement? *Eur Urol Focus*. 2018 Nov 12. PMID: 30442584
519. Preisser F, Mazzone E, Nazzani S, Marchioni M, Bandini M, Tian Z, Saad F, Soulières D, **Shariat SF**, Montorsi F, Huland H, Graefen M, Tilki D, Karakiewicz PI. North American population-based validation of the National Comprehensive Cancer Network Practice Guideline Recommendations for locoregional lymph node and bone imaging in prostate cancer patients. *Br J Cancer*. 2018 Nov 14. PMID: 30425350
520. Rieken M, Boorjian SA, Kluth LA, Capitanio U, Briganti A, Thompson RH, Leibovich BC, Krabbe LM, Margulis V, Raman JD, Regelman M, Karakiewicz PI, Rouprêt M, Abufaraj M, Foerster B, Gönen M, **Shariat SF**. Development and external validation of a pathological nodal staging score for patients with clear cell renal cell carcinoma. *World J Urol*. 2018 Nov 7. PMID: 30406477
521. Salami SS, Hovelson DH, Kaplan JB, Mathieu R, Udager AM, Curci NE, Lee M, Plouffe KR, de la Vega LL, Susani M, Rioux-Leclercq N, Spratt DE, Morgan TM, Davenport MS, Chinnaiyan AM, Cyrta J, Rubin MA, **Shariat SF**, Tomlins SA, Palapattu GS. Transcriptomic heterogeneity in multifocal prostate cancer. *JCI Insight*. 2018 Nov 2;3(21). PMID: 30385730
522. Preisser F, Mazzone E, Knipper S, Nazzani S, Bandini M, **Shariat SF**, Tian Z, Saad F, Montorsi F, Zorn KC, Graefen M, Tilki D, Karakiewicz PI. Rates of Positive Surgical Margins and Their Effect on Cancer-specific Mortality at Radical Prostatectomy for Patients With Clinically Localized Prostate Cancer. *Clin Genitourin Cancer*. 2018 Oct 4. PMID: 30366880
523. Williams SB, Kamat AM, Chamie K, Froehner M, Wirth MP, Wiklund PN, Black PC, Steinberg GD, Boorjian SA, Daneshmand S, Goebell PJ, Pohar KS, **Shariat SF**, Thalmann GN. Systematic Review of Comorbidity and Competing-risks Assessments for Bladder Cancer Patients. *Eur Urol Oncol*. 2018 Jun;1(2):91-100. PMID: 30345422
524. Bandini M, Nazzani S, Marchioni M, Preisser F, Tian Z, Moschini M, Abdollah F, Suardi N, Graefen M, Montorsi F, **Shariat SF**, Saad F, Briganti A, Karakiewicz PI. Increasing Rate of Noninterventional Treatment Management in Localized Prostate Cancer Candidates for Active Surveillance: A North American Population-Based Study. *Clin Genitourin Cancer*. 2018 Sep 22. PMID: 30342845
525. Nazzani S, Preisser F, Mazzone E, Marchioni M, Bandini M, Tian Z, Mistretta FA, **Shariat SF**, Soulières D, Montanari E, Acquati P, Briganti A, Carmignani L, Karakiewicz PI. Survival Effect of Chemotherapy in Metastatic Upper Urinary Tract Urothelial Carcinoma. *Clin Genitourin Cancer*. 2018 Sep 27. PMID: 30337106
526. Mazzone E, Bandini M, Preisser F, Nazzani S, Tian Z, Abdollah F, Soulières D, Graefen M, Montorsi F, **Shariat S**, Saad F, Briganti A, Karakiewicz P. The effect of race on survival after local therapy in metastatic prostate cancer patients. *Can Urol Assoc J*. 2018 Oct 15. PMID: 30332592
527. Hofbauer SL, de Martino M, Lucca I, Haitel A, Susani M, **Shariat SF**, Klatte T. A urinary microRNA (miR) signature for diagnosis of bladder cancer. *Urol Oncol*. 2018 Oct 12. PMID: 30322728
528. Preisser F, Nazzani S, Mazzone E, Knipper S, Bandini M, Tian Z, Haese A, Saad F, Zorn KC, Montorsi F, **Shariat SF**, Graefen M, Tilki D, Karakiewicz PI. Regional differences in total hospital

- charges between open and robotically assisted radical prostatectomy in the United States. *World J Urol.* 2018 Oct 12. PMID: 30315358
529. Fossati N, Suardi N, Gandaglia G, Bravi CA, Soligo M, Karnes RJ, **Shariat S**, Battaglia A, Everaerts W, Joniau S, Van Poppel H, Rajarubendra N, Gill IS, Larcher A, Mottrie A, Schmautz M, Heidenreich A, Kalz A, Osmonov D, Juenemann KP, Herlemann A, Gratzke C, Stief C, Montorsi F, Briganti A. Identifying the Optimal Candidate for Salvage Lymph Node Dissection for Nodal Recurrence of Prostate Cancer: Results from a Large, Multi-institutional Analysis. *Eur Urol.* 2018 Oct 6. PMID: 30301694
530. Nazzani S, Preisser F, Mazzone E, Tian Z, Mistretta FA, **Shariat SF**, Soulières D, Saad F, Montanari E, Luzzago S, Briganti A, Carmignani L, Karakiewicz PI. Survival effect of perioperative systemic chemotherapy on overall mortality in locally advanced and/or positive regional lymph node non-metastatic urothelial carcinoma of the upper urinary tract. *World J Urol.* 2018 Oct 8. PMID: 30298285
531. Moschini M, Zaffuto E, Karakiewicz PI, Andrea DD, Foerster B, Abufaraj M, Soria F, Mattei A, Montorsi F, Briganti A, **Shariat SF**. External Beam Radiotherapy Increases the Risk of Bladder Cancer When Compared with Radical Prostatectomy in Patients Affected by Prostate Cancer: A Population-based Analysis. *Eur Urol.* 2018 Oct 4. PMID: 30293908
532. Moschini M, Zaffuto E, Karakiewicz P, Mattei A, Gandaglia G, Fossati N, Montorsi F, Briganti A, **Shariat SF**. The effect of androgen deprivation treatment on subsequent risk of bladder cancer diagnosis in male patients treated for prostate cancer. *World J Urol.* 2018 Oct 1. PMID: 30276543
533. Nazzani S, Preisser F, Mazzone E, Tian Z, Mistretta FA, Soulières D, Montanari E, Acquati P, Briganti A, **Shariat SF**, Abdollah F, Carmignani L, Karakiewicz PI. Nephroureterectomy with or without Bladder Cuff Excision for Localized Urothelial Carcinoma of the Renal Pelvis. *Eur Urol Focus.* 2018 Sep 25. PMID: 30266210
534. Soria F, Krabbe LM, Todenhöfer T, Dobruch J, Mitra AP, Inman BA, Gust KM, Lotan Y, **Shariat SF**. Molecular markers in bladder cancer. *World J Urol.* 2018 Sep 26. PMID: 30259123
535. Suarez-Ibarrola R, Soria F, Abufaraj M, D'Andrea D, Preto M, Gust KM, Briganti A, **Shariat SF**, Gontero P. Surgical checklist impact on recurrence-free survival of non-muscle invasive bladder cancer patients undergoing transurethral resection of bladder tumor. *BJU Int.* 2018 PMID: 30248235
536. Hübner N, **Shariat SF**, Remzi M. Focal therapy of prostate cancer. *Curr Opin Urol.* 2018 Nov;28(6):550-554. PMID: 30239415
537. Bruchbacher A, Soria F, Hassler M, **Shariat SF**, D'Andrea D. Tissue biomarkers in nonmuscle-invasive bladder cancer: any role in clinical practice? *Curr Opin Urol.* 2018 Nov;28(6):584-590. PMID: 30188332
538. Hübner N, **Shariat SF**. Palliative surgery for metastatic urothelial cancer. *Aktuelle Urol.* 2018 Sep;49(5):412-416. PMID: 30184599
539. Gächter A, Halling T, **Shariat SF**, Moll FH: Transfer of Knowledge in Urology: A Case Study of Jacob Eduard Polak (1818-1891) and the Introduction of Contemporary Techniques of Lithotomy and Lithotripsy from Vienna to Persia in the Mid-19th Century: A New Analysis of Scientific Papers from the 19th Century. *Urol Int.* 2018 Sep 3:1-12. PMID: 30176666
540. Mazzone E, Nazzani S, Preisser F, Tian Z, Marchioni M, Bandini M, Capitanio U, Kapoor A, Tilki D, Montorsi F, **Shariat SF**, Saad F, Briganti A, I Karakiewicz P. Partial nephrectomy seems to

- confer a survival benefit relative to radical nephrectomy in metastatic renal cell carcinoma. *Cancer Epidemiol.* 2018 Aug 30;56:118-125. PMID: 30173050
541. Soria F, Pisano F, Gontero P, Palou J, Joniau S, Serretta V, Larré S, Di Stasi S, van Rhijn B, Witjes JA, Grotenhuis A, Colombo R, Briganti A, Babjuk M, Soukup V, Malmstrom PU, Irani J, Malats N, Baniel J, Mano R, Cai T, Cha E, Ardelt P, Varkarakis J, Bartoletti R, Dalbagni G, **Shariat SF**, Xylinas E, Karnes RJ, Sylvester R. Predictors of oncological outcomes in T1G3 patients treated with BCG who undergo radical cystectomy. *World J Urol.* 2018 Aug 31. PMID: 30171454
542. Soria F, D'Andrea D, Pohar K, **Shariat SF**, Lotan Y. Diagnostic, prognostic and surveillance urinary markers in nonmuscle invasive bladder cancer: any role in clinical practice? *Curr Opin Urol.* 2018 Aug 27. PMID: 30157039
543. Preisser F, Nazzani S, Bandini M, Marchioni M, Tian Z, Saad F, Chun FK, **Shariat SF**, Montorsi F, Huland H, Graefen M, Tilki D, Karakiewicz PI. Racial disparities in lymph node dissection at radical prostatectomy: A Surveillance, Epidemiology and End Results database analysis. *Int J Urol.* 2018 Aug 26. PMID: 30146729
544. Grubmüller B, Baltzer PA, Hartenbach S, D'Andrea D, Helbich TH, Haug A, Goldner G, Wadsak W, Pfaff S, Mitterhauser M, Balber T, Berroterán-Infante N, Grahovac M, Babich JW, Seitz C, Kramer G, Susani M, Mazal P, Kenner L, **Shariat SF**, Hacker M, Hartenbach M. PSMA ligand PET/MRI for primary prostate cancer: Staging performance and clinical impact. *Clin Cancer Res.* 2018 Aug 23. PMID: 30139879
545. Abufaraj M, Mostafid H, **Shariat SF**, Babjuk M. What to do during Bacillus Calmette-Guérin shortage? Valid strategies based on evidence. *Curr Opin Urol.* 2018 Aug 21. PMID: 30138122
546. Vartolomei L, Ferro M, Mirone V, **Shariat SF**, Vartolomei MD. Systematic Review: Depression and Anxiety Prevalence in Bladder Cancer Patients. *Bladder Cancer.* 2018 Jul 30;4(3):319-326. PMID: 30112443
547. Stangl-Kremser, Mari A, D'Andrea D, Kimura S, Resch I, **Shariat SF**, Klatte T. Sarcopenia as a Predictive Factor for Response to Upfront Cisplatin-Based Chemotherapy in Patients with Muscle-Invasive Urothelial Bladder Cancer. *Urol Int.* 2018;101(2):197-200. PMID: 30089304
548. Kimura S, Mari A, Foerster B, Abufaraj M, Vartolomei MD, Stangl-Kremser J, Karakiewicz PI, Egawa S, **Shariat SF**. Prognostic value of concomitant carcinoma in situ in the radical cystectomy specimen: A systematic review and meta-analysis. *J Urol.* 2018 Aug 2. PMID: 30077559
549. Vartolomei MD, Ferro M, Cantiello F, Lucarelli G, Di Stasi S, Hurle R, Guazzoni G, Busetto GM, De Berardinis E, Damiano R, Perdoni S, Verze P, La Rocca R, Borghesi M, Schiavina R, Brunocilla E, Almeida GL, Bove P, Lima E, Grimaldi G, Autorino R, Crisan N, Abu Farhan AR, Battaglia M, Serretta V, Russo GI, Morgia G, Terracciano D, Musi G, de Cobelli O, Mirone V, **Shariat SF**. Validation of Neutrophil-to-lymphocyte Ratio in a Multi-institutional Cohort of Patients With T1G3 Non-muscle-invasive Bladder Cancer. *Clin Genitourin Cancer.* 2018 Jul 6. PMID: 30077463
550. Babjuk M, Burger M, Compérat EM, Gontero P, Mostafid HA, Palou J, van Rhijn BWG, Roupřet M, **Shariat SF**, Sylvester R, Zigeuner R, Capoun O, Cohen D, Dominguez-Escrig JL, Hernández V, Peyronnet B, Seisen T, Soukup V; European Association of Urology Guidelines Panel on Non-muscle-invasive Bladder Cancer. Indication for a Single Postoperative Instillation of Chemotherapy in Non-muscle-invasive Bladder Cancer: What Factors Should Be Considered? *Eur Urol Focus.* 2018 Jul 27. PMID: 30061076

551. Kimura S, Soria F, D'Andrea D, Foerster B, Abufaraj M, Vartolomei MD, Karakiewicz PI, Mathieu R, Moschini M, Rink M, Egawa S, **Shariat SF**, Gust KM. Prognostic Value of Serum Cholinesterase in Non-muscle-invasive Bladder Cancer. *Clin Genitourin Cancer*. 2018 Jul 6. PMID: 30061034
552. Suarez-Ibarrola R, Abufaraj M, **Shariat SF**. Intermediate and long-term complications associated with adjuvant chemotherapy for stage I germ cell tumor patients. *Curr Opin Urol*. 2018 Sep;28(5):485-490. PMID: 30044319
553. Preisser F, Mazzone E, Nazzani S, Bandini M, Tian Z, Marchioni M, Steuber T, Saad F, Montorsi F, **Shariat SF**, Huland H, Graefen M, Tilki D, Karakiewicz PI. Comparison of Perioperative Outcomes Between Cytoreductive Radical Prostatectomy and Radical Prostatectomy for Nonmetastatic Prostate Cancer. *Eur Urol*. 2018 Jul 20. PMID: 30037529
554. Vartolomei MD, Kimura S, Vartolomei L, **Shariat SF**. Systematic Review of the Impact of Testosterone Replacement Therapy on Depression in Patients with Late-onset Testosterone Deficiency. *Eur Urol Focus*. 2018 Jul 14. PMID: 30017901
555. Ferro M, Vartolomei MD, Russo GI, Cantiello F, Farhan ARA, Terracciano D, Cimmino A, Di Stasi S, Musi G, Hurle R, Serretta V, Busetto GM, De Berardinis E, Cioffi A, Perdonà S, Borghesi M, Schiavina R, Cozzi G, Almeida GL, Bove P, Lima E, Grimaldi G, Matei DV, Crisan N, Muto M, Verze P, Battaglia M, Guazzoni G, Autorino R, Morgia G, Damiano R, de Cobelli O, **Shariat S**, Mirone V, Lucarelli G. An increased body mass index is associated with a worse prognosis in patients administered BCG immunotherapy for T1 bladder cancer. *World J Urol*. 2018 Jul 10. PMID: 29992381
556. Polanec SH, Helbich TH, Bickel H, Wengert GJ, Pinker K, Spick C, Clauser P, Susani M, **Shariat S**, Baltzer PAT. Quantitative Apparent Diffusion Coefficient Derived From Diffusion-Weighted Imaging Has the Potential to Avoid Unnecessary MRI-Guided Biopsies of mpMRI-Detected PI-RADS 4 and 5 Lesions. *Invest Radiol*. 2018 Jul 6. PMID: 29985792
557. Mathieu R, Castelli C, Fardoun T, Peyronnet B, **Shariat SF**, Bensalah K, Vincendeau S. Cost analysis of prostate cancer detection including the prostate health index (phi). *World J Urol*. 2018 Jul 6. PMID: 29980838
558. Ferro M, Vartolomei MD, Cantiello F, Lucarelli G, Di Stasi SM, Hurle R, Guazzoni G, Busetto GM, De Berardinis E, Damiano R, Perdonà S, Borghesi M, Schiavina R, Almeida GL, Bove P, Lima E, Grimaldi G, Autorino R, Crisan N, Abu Farhan AR, Verze P, Battaglia M, Serretta V, Russo GI, Morgia G, Musi G, de Cobelli O, Mirone V, **Shariat SF**. High-Grade T1 on Re-Transurethral Resection after Initial High-Grade T1 Confers Worse Oncological Outcomes: Results of a Multi-Institutional Study. *Urol Int*. 2018;101(1):7-15. PMID: 29975950
559. Mazzone E, Preisser F, Nazzani S, Tian Z, Bandini M, Gandaglia G, Fossati N, Soulières D, Graefen M, Montorsi F, **Shariat SF**, Saad F, Briganti A, Karakiewicz PI. Location of Metastases in Contemporary Prostate Cancer Patients Affects Cancer-Specific Mortality. *Clin Genitourin Cancer*. 2018 Jun 5. PMID: 29954690
560. Darr C, Krafft U, Hadaschik B, Tschirdewahn S, Sevcenco S, Csizmarik A, Nyirady P, Küronya Z, Reis H, Maj-Hes A, **Shariat SF**, Kramer G, Szarvas T. The Role of YKL-40 in Predicting Resistance to Docetaxel Chemotherapy in Prostate Cancer. *Urol Int*. 2018;101(1):65-73. PMID: 29949801
561. Krabbe LM, Margulis V, Schrader AJ, **Shariat SF**, Gust KM, Boegemann M. Molecularly-driven precision medicine for advanced bladder cancer. *World J Urol*. 2018 Jun 8. PMID: 29948043

562. Soria F, Droller MJ, Lotan Y, Gontero P, D'Andrea D, Gust KM, Rouprêt M, Babjuk M, Palou J, **Shariat SF**. An up-to-date catalog of available urinary biomarkers for the surveillance of non-muscle invasive bladder cancer. *World J Urol*. 2018 Jun 21. PMID: 29931526
563. Vartolomei MD, Porav-Hodade D, Ferro M, Mathieu R, Abufaraj M, Foerster B, Kimura S, **Shariat SF**. Prognostic role of pretreatment neutrophil-to-lymphocyte ratio (NLR) in patients with non-muscle-invasive bladder cancer (NMIBC): A systematic review and meta-analysis. *Urol Oncol*. 2018 Jun 5. PMID: 29884342
564. Vasdev N, Zargar H, Noël JP, Veeratterapillay R, Fairey AS, Mertens LS, Dinney CP, Mir MC, Krabbe LM, Cookson MS, Jacobsen NE, Gandhi NM, Griffin J, Montgomery JS, Yu EY, Xylinas E, Campain NJ, Kassouf W, Dall'Era MA, Seah JA, Ercole CE, Horenblas S, Sridhar SS, McGrath JS, Aning J, **Shariat SF**, Wright JL, Morgan TM, Bivalacqua TJ, North S, Barocas DA, Lotan Y, Grivas P, Stephenson AJ, Shah JB, van Rhijn BW, Daneshmand S, Spiess PE, Holzbeierlein JM, Thorpe A, Black PC. Concomitant CIS on TURBT does not impact oncological outcomes in patients treated with neoadjuvant or induction chemotherapy followed by radical cystectomy. *World J Urol*. 2018 Jun 7. PMID: 29882105
565. Garstka N, **Shariat SF**, Remzi M. The evolving role of percutaneous biopsy in renal masses. *Curr Opin Urol*. 2018 Jul;28(4):364-368. PMID: 29847524
566. Hübner N, **Shariat S**, Remzi M. Prostate biopsy: guidelines and evidence. *Curr Opin Urol*. 2018 Jul;28(4):354-359. PMID: 29847523
567. Nazzani S, Mazzone E, Preisser F, Bandini M, Tian Z, Marchioni M, Ratti D, Motta G, Zorn KC, Briganti A, **Shariat SF**, Montanari E, Carmignani L, Karakiewicz PI. Comparison of Perioperative Outcomes Between Open and Robotic Radical Cystectomy: A Population-Based Analysis. *J Endourol*. 2018 Aug;32(8):701-709. PMID: 29845866
568. Mari A, Kimura S, Foerster B, Abufaraj M, D'Andrea D, Hassler M, Minervini A, Rouprêt M, Babjuk M, **Shariat SF**. A systematic review and meta-analysis of the impact of lymphovascular invasion in bladder cancer transurethral resection specimens. *BJU Int*. 2018 May 28. doi: 10.1111/bju.14417. PMID: 29807387
569. Szarvas T, Sevcenco S, Módos O, Keresztes D, Nyirády P, Csizmarik A, Ristl R, Pühr M, Hoffmann MJ, Niedworok C, Hadaschik B, Maj-Hes A, **Shariat SF**, Kramer G. Matrix metalloproteinase 7, soluble Fas and Fas ligand serum levels for predicting docetaxel resistance and survival in castration-resistant prostate cancer. *BJU Int*. 2018 May 26. PMID: 29802777
570. Preisser F, Bandini M, Mazzone E, Nazzani S, Marchioni M, Tian Z, Saad F, Pompe RS, **Shariat SF**, Heinzer H, Montorsi F, Huland H, Graefen M, Tilki D, Karakiewicz PI. Validation of the Social Security Administration Life Tables (2004-2014) in Localized Prostate Cancer Patients within the Surveillance, Epidemiology, and End Results database. *Eur Urol Focus*. 2018 May 22. PMID: 29802052
571. Foerster B, Pozo C, Abufaraj M, Mari A, Kimura S, D'Andrea D, John H, **Shariat SF**. Association of Smoking Status With Recurrence, Metastasis, and Mortality Among Patients With Localized Prostate Cancer Undergoing Prostatectomy or Radiotherapy: A Systematic Review and Meta-analysis. *JAMA Oncol*. 2018 Jul 1;4(7):953-961. PMID: 29800115
572. Nazzani S, Preisser F, Mazzone E, Tian Z, Mistretta FA, **Shariat SF**, Saad F, Graefen M, Tilki D, Montanari E, Luzzago S, Briganti A, Carmignani L, Karakiewicz PI. In-hospital length of stay after major surgical oncological procedures. *Eur J Surg Oncol*. 2018 Jul;44(7):969-974. PMID: 29784507

573. Singla N, Krabbe LM, Aydin AM, Panwar V, Woldu SL, Freifeld Y, Wood CG, Karam JA, Weizer AZ, Raman JD, Remzi M, Rioux-Leclercq N, Haitel A, Roscigno M, Bolenz C, Bensalah K, Sagalowsky AI, **Shariat SF**, Lotan Y, Bagrodia A, Kapur P, Margulis V. Multi-institutional evaluation of the prognostic significance of EZH2 expression in high-grade upper tract urothelial carcinoma. *Urol Oncol*. 2018 Jul;36(7):343.e1-343.e8. PMID: 29748098
574. Marchioni M, Nazzani S, Preisser F, Bandini M, Tian Z, Kapoor A, Cindolo L, Primiceri G, Carmignani L, Briganti A, Montorsi F, **Shariat SF**, Schips L, Karakiewicz PI. The Effect of Institution Teaching Status on Perioperative Outcomes After Robotic Partial or Radical Nephrectomy. *J Endourol*. 2018 Jul;32(7):621-629. PMID: 29739253
575. D'Andrea D, Hassler MR, Abufaraj M, Soria F, Ertl IE, Ilijazi D, Mari A, Foerster B, Egger G, **Shariat SF**. Progressive tissue biomarker profiling in non-muscle-invasive bladder cancer. *Expert Rev Anticancer Ther*. 2018 Jul;18(7):695-703. PMID: 29737231
576. Palou J, Pisano F, Sylvester R, Joniau S, Serretta V, Larré S, Di Stasi S, van Rhijn B, Witjes AJ, Grotenhuis A, Colombo R, Briganti A, Babjuk M, Soukup V, Malmstrom PU, Irani J, Malats N, Baniel J, Mano R, Cai T, Cha EK, Ardelt P, Varkarakis J, Bartoletti R, Dalbagni G, **Shariat SF**, Xylinas E, Karnes RJ, Gontero P. Recurrence, progression and cancer-specific mortality according to stage at re-TUR in T1G3 bladder cancer patients treated with BCG: not as bad as previously thought. *World J Urol*. 2018 May 2. PMID: 29721611
577. Bandini M, Marchioni M, Preisser F, Zaffuto E, Tian Z, Tilki D, Montorsi F, **Shariat SF**, Saad F, Briganti A, Karakiewicz PI. Survival after radical prostatectomy or radiotherapy for locally advanced (cT3) prostate cancer. *World J Urol*. 2018 Sep;36(9):1399-1407. PMID: 29717358
578. Marchioni M, Harmouch SS, Nazzani S, Bandini M, Preisser F, Tian Z, Kapoor A, Cindolo L, Briganti A, **Shariat SF**, Schips L, Karakiewicz PI. Effect of African-American race on cancer specific mortality differs according to clear cell vs. non-clear cell histologic subtype in metastatic renal cell carcinoma. *Cancer Epidemiol*. 2018 Jun;54:112-118. PMID: 29715680
579. Vartolomei MD, Kimura S, Ferro M, Foerster B, Abufaraj M, Briganti A, Karakiewicz PI, **Shariat SF**. The impact of moderate wine consumption on the risk of developing prostate cancer. *Clin Epidemiol*. 2018 Apr 17;10:431-444. PMID: 29713200
580. Ferro M, Vartolomei MD, Russo GI, Cantiello F, Farhan ARA, Terracciano D, Cimmino A, Di Stasi S, Musi G, Hurle R, Serretta V, Busetto GM, De Berardinis E, Cioffi A, Perdonà S, Borghesi M, Schiavina R, Cozzi G, Almeida GL, Bove P, Lima E, Grimaldi G, Matei DV, Crisan N, Muto M, Verze P, Battaglia M, Guazzoni G, Autorino R, Morgia G, Damiano R, de Cobelli O, **Shariat S**, Mirone V, Lucarelli G. An increased body mass index is associated with a worse prognosis in patients administered BCG immunotherapy for T1 bladder cancer. *World J Urol*. 2018 Jul 10. PMID: 29992381
581. Polanec SH, Helbich TH, Bickel H, Wengert GJ, Pinker K, Spick C, Clauser P, Susani M, **Shariat S**, Baltzer PAT. Quantitative apparent diffusion coefficient derived from diffusion-weighted imaging has the potential to avoid unnecessary mri-guided biopsies of mpMRI-detected PI-RADS 4 and 5 lesions. *Invest Radiol*. 2018 Jul 6. PMID: 29985792
582. Mathieu R, Castelli C, Fardoun T, Peyronnet B, **Shariat SF**, Bensalah K, Vincendeau S. Cost analysis of prostate cancer detection including the prostate health index (phi). *World J Urol*. 2018 Jul 6. PMID: 29980838
583. Ferro M, Vartolomei MD, Cantiello F, Lucarelli G, Di Stasi SM, Hurle R, Guazzoni G, Busetto GM, De Berardinis E, Damiano R, Perdonà S, Borghesi M, Schiavina R, Almeida GL, Bove P, Lima E, Grimaldi G, Autorino R, Crisan N, Abu Farhan AR, Verze P, Battaglia M, Serretta V,

- Russo GI, Morgia G, Musi G, de Cobelli O, Mirone V, **Shariat SF**. High-Grade T1 on re-transurethral resection after initial high-grade T1 Confers Worse Oncological Outcomes: Results of a Multi-Institutional Study. *Urol Int*. 2018 Jul 4;101(1):1-9. PMID: 29975950
584. Mazzone E, Preisser F, Nazzani S, Tian Z, Bandini M, Gandaglia G, Fossati N, Soulières D, Graefen M, Montorsi F, **Shariat SF**, Saad F, Briganti A, Karakiewicz PI. Location of Metastases in Contemporary Prostate Cancer Patients Affects Cancer-Specific Mortality. *Clin Genitourin Cancer*. 2018 Jun 5. PMID: 29954690
585. Darr C, Krafft U, Hadaschik B, Tschirdewahn S, Sevcenco S, Csizmarik A, Nyirady P, Küronya Z, Reis H, Maj-Hes A, **Shariat SF**, Kramer G, Szarvas T. The Role of YKL-40 in Predicting Resistance to Docetaxel Chemotherapy in Prostate Cancer. *Urol Int*. 2018 Jun 27;1-9. PMID: 29949801
586. Krabbe LM, Margulis V, Schrader AJ, **Shariat SF**, Gust KM, Boegemann M. Molecularly-driven precision medicine for advanced bladder cancer. *World J Urol*. 2018 Jun 8. PMID: 29948043
587. Soria F, Droller MJ, Lotan Y, Gontero P, D'Andrea D, Gust KM, Rouprêt M, Babjuk M, Palou J, **Shariat SF**. An up-to-date catalog of available urinary biomarkers for the surveillance of non-muscle invasive bladder cancer. *World J Urol*. 2018 Jun 21. PMID: 29931526
588. Vartolomei MD, Porav-Hodade D, Ferro M, Mathieu R, Abufaraj M, Foerster B, Kimura S, **Shariat SF**. Prognostic role of pretreatment neutrophil-to-lymphocyte ratio (NLR) in patients with non-muscle-invasive bladder cancer (NMIBC): A systematic review and meta-analysis. *Urol Oncol*. 2018 Jun 5. PMID: 29884342
589. Vasdev N, Zargar H, Noël JP, Veeratterapillay R, Fairey AS, Mertens LS, Dinney CP, Mir MC, Krabbe LM, Cookson MS, Jacobsen NE, Gandhi NM, Griffin J, Montgomery JS, Yu EY, Xylinas E, Campaign NJ, Kassouf W, Dall'Era MA, Seah JA, Ercole CE, Horenblas S, Sridhar SS, McGrath JS, Aning J, **Shariat SF**, Wright JL, Morgan TM, Bivalacqua TJ, North S, Barocas DA, Lotan Y, Grivas P, Stephenson AJ, Shah JB, van Rhijn BW, Daneshmand S, Spiess PE, Holzbeierlein JM, Thorpe A, Black PC. Concomitant CIS on TURBT does not impact oncological outcomes in patients treated with neoadjuvant or induction chemotherapy followed by radical cystectomy. *World J Urol*. 2018 Jun 7. PMID: 29882105
590. Garstka N, **Shariat SF**, Remzi M. The evolving role of percutaneous biopsy in renal masses. *Curr Opin Urol*. 2018 Jul;28(4):364-368. PMID: 29847524
591. Hübner N, **Shariat S**, Remzi M. Prostate biopsy: guidelines and evidence. *Curr Opin Urol*. 2018 Jul;28(4):354-359. PMID: 29847523
592. Nazzani S, Mazzone E, Preisser F, Bandini M, Tian Z, Marchioni M, Ratti D, Motta G, Zorn KC, Briganti A, **Shariat SF**, Montanari E, Carmignani L, Karakiewicz PI. Comparison of perioperative outcomes between open and robotic radical cystectomy: a population based analysis. *J Endourol*. 2018 May 30. PMID: 29845866
593. Mari A, Kimura S, Foerster B, Abufaraj M, D'Andrea D, Hassler M, Minervini A, Rouprêt M, Babjuk M, **Shariat SF**. A Systematic Review and Meta-Analysis of the impact of Lymphovascular Invasion in Bladder Cancer Transurethral Resection Specimens. *BJU Int*. 2018 May 28. PMID: 29807387
594. Szarvas T, Sevcenco S, Módos O, Keresztes D, Nyirady P, Csizmarik A, Ristl R, Pühr M, Hoffmann MJ, Niedworok C, Hadaschik B, Maj-Hes A, **Shariat SF**, Kramer G. MMP-7, sFas and FasL serum levels for predicting docetaxel resistance and survival in castration-resistant prostate cancer. *BJU Int*. 2018 May 26. PMID: 29802777

595. Preisser F, Bandini M, Mazzone E, Nazzani S, Marchioni M, Tian Z, Saad F, Pompe RS, **Shariat SF**, Heinzer H, Montorsi F, Huland H, Graefen M, Tilki D, Karakiewicz PI. Validation of the Social Security Administration Life Tables (2004-2014) in Localized Prostate Cancer Patients within the Surveillance, Epidemiology, and End Results database. *Eur Urol Focus*. 2018 May 22. PMID: 29802052
596. Foerster B, Pozo C, Abufaraj M, Mari A, Kimura S, D'Andrea D, John H, **Shariat SF**. Association of Smoking Status With Recurrence, Metastasis, and Mortality Among Patients With Localized Prostate Cancer Undergoing Prostatectomy or Radiotherapy: A Systematic Review and Meta-analysis. *JAMA Oncol*. 2018 May 24. PMID: 29800115
597. Nazzani S, Preisser F, Mazzone E, Tian Z, Mistretta FA, **Shariat SF**, Saad F, Graefen M, Tilki D, Montanari E, Luzzago S, Briganti A, Carmignani L, Karakiewicz PI. In-hospital length of stay after major surgical oncological procedures. *Eur J Surg Oncol*. 2018 May 9. PMID: 29784507
598. Singla N, Krabbe LM, Aydin AM, Panwar V, Woldu SL, Freifeld Y, Wood CG, Karam JA, Weizer AZ, Raman JD, Remzi M, Rioux-Leclercq N, Haitel A, Roscigno M, Bolenz C, Bensalah K, Sagalowsky AI, **Shariat SF**, Lotan Y, Bagrodia A, Kapur P, Margulis V. Multi-institutional evaluation of the prognostic significance of EZH2 expression in high-grade upper tract urothelial carcinoma. *Urol Oncol*. 2018 May 7. PMID: 29748098
599. Marchioni M, Nazzani S, Preisser F, Bandini M, Tian Z, Kapoor A, Cindolo L, Primiceri G, Carmignani L, Briganti A, Montorsi F, **Shariat SF**, Schips L, Karakiewicz PI. The effect of institution teaching status on perioperative outcomes after robotic partial or radical nephrectomy. *J Endourol*. 2018 May 9. PMID: 29739253
600. D'Andrea D, Hassler MR, Abufaraj M, Soria F, Ertl IE, Ilijazi D, Mari A, Foerster B, Egger G, **Shariat SF**. Progressive tissue biomarker profiling in non-muscle-invasive bladder cancer. *Expert Rev Anticancer Ther*. 2018 May 9;1-9. PMID: 29737231
601. Palou J, Pisano F, Sylvester R, Joniau S, Serretta V, Larré S, Di Stasi S, van Rhijn B, Witjes AJ, Grotenhuis A, Colombo R, Briganti A, Babjuk M, Soukup V, Malmstrom PU, Irani J, Malats N, Baniel J, Mano R, Cai T, Cha EK, Ardelt P, Varkarakis J, Bartoletti R, Dalbagni G, **Shariat SF**, Xylinas E, Karnes RJ, Gontero P. Recurrence, progression and cancer-specific mortality according to stage at re-TUR in T1G3 bladder cancer patients treated with BCG: not as bad as previously thought. *World J Urol*. 2018 May 2. PMID: 29721611
602. Bandini M, Marchioni M, Preisser F, Zaffuto E, Tian Z, Tilki D, Montorsi F, **Shariat SF**, Saad F, Briganti A, Karakiewicz PI. Survival after radical prostatectomy or radiotherapy for locally advanced (cT3) prostate cancer. *World J Urol*. 2018 May 2. PMID: 29717358
603. Marchioni M, Harmouch SS, Nazzani S, Bandini M, Preisser F, Tian Z, Kapoor A, Cindolo L, Briganti A, **Shariat SF**, Schips L, Karakiewicz PI. Effect of African-American race on cancer specific mortality differs according to clear cell vs. non-clear cell histologic subtype in metastatic renal cell carcinoma. *Cancer Epidemiol*. 2018 Apr 28;54:112-118. PMID: 29715680
604. Vartolomei MD, Kimura S, Ferro M, Foerster B, Abufaraj M, Briganti A, Karakiewicz PI, **Shariat SF**. The impact of moderate wine consumption on the risk of developing prostate cancer. *Clin Epidemiol*. 2018 Apr 17;10:431-444. PMID: 29713200
605. Zaffuto E, Bandini M, Gazdovich S, Valiquette AS, Leyh-Bannurah SR, Tian Z, Dell'Oglio P, Graefen M, Moschini M, Necchi A, **Shariat SF**, Briganti A, Montorsi F, Karakiewicz PI. Contemporary rates of adherence to international guidelines for pelvic lymph node dissection in radical cystectomy: a population-based study. *World J Urol*. 2018 Apr 27. PMID: 29704059

606. Mari A, Kimura S, Foerster B, Abufaraj M, D'Andrea D, Gust KM, **Shariat SF**. A systematic review and meta-analysis of lymphovascular invasion in patients treated with radical cystectomy for bladder cancer. *Urol Oncol*. 2018 Apr 20. PubMed PMID: 29685374.
607. Khene ZE, Bensalah K, Largent A, **Shariat S**, Verhoest G, Peyronnet B, Acosta O, DeCrevoisier R, Mathieu R. Role of quantitative computed tomography texture analysis in the prediction of adherent perinephric fat. *World J Urol*. 2018 Apr 19. PMID: 29675631.
608. Pompe RS, Tilki D, Preisser F, Leyh-Bannurah SR, Bandini M, Marchioni M, Gild P, Tian Z, Fossati N, Cindolo L, **Shariat SF**, Huland H, Graefen M, Briganti A, Karakiewicz PI. Survival benefit of local versus no local treatment for metastatic prostate cancer-Impact of baseline PSA and metastatic substages. *Prostate*. 2018 Apr 16. PMID: 29663462.
609. Leisser A, Nejabat M, Hartenbach M, Agha Mohammadi Sareshgi R, **Shariat S**, Kramer G, Krainer M, Hacker M, Haug AR. Analysis of hematological parameters as prognostic markers for toxicity and survival of (223)Radium treatment. *Oncotarget*. 2018 Mar 5;9(22):16197-16204. PMID: 29662636;
610. Rieken M, Kluth LA, Fajkovic H, Capitanio U, Briganti A, Krabbe LM, Margulis V, Abufaraj M, Mari A, Foerster B, Raman JD, Regelman M, Brookman-May S, Sjoberg DD, Karakiewicz PI, **Shariat SF**. Predictors of Cancer-specific Survival After Disease Recurrence in Patients With Renal Cell Carcinoma: The Effect of Time to Recurrence. *Clin Genitourin Cancer*. 2018 Mar 24. PMID: 29653814.
611. Nazzani S, Bandini M, Marchioni M, Preisser F, Tian Z, Soulières D, Montanari E, Motta G, Acquati P, Briganti A, **Shariat SF**, Abdollah F, Carmignani L, Karakiewicz PI. A contemporary analysis of radiotherapy effect in surgically treated retroperitoneal sarcoma. *Radiother Oncol*. 2018 Apr 6. PMID: 29631934.
612. Szarvas T, Sevcenco S, Módos O, Keresztes D, Nyirády P, Kubik A, Romics M, Kovalszky I, Reis H, Hadaschik B, **Shariat SF**, Kramer G. Circulating syndecan-1 is associated with chemotherapy-resistance in castration-resistant prostate cancer. *Urol Oncol*. 2018 Apr 5. PMID: 29628317.
613. Resch I, **Shariat SF**, Gust KM. PD-1 and PD-L1 inhibitors after platinum-based chemotherapy or in first-line therapy in cisplatin-ineligible patients: Dramatic improvement of prognosis and overall survival after decades of hopelessness in patients with metastatic urothelial cancer. *Memo*. 2018;11(1):43-46. PMID: 29606979;
614. Bandini M, Marchioni M, Pompe RS, Tian Z, Martel T, Chun FK, Cindolo L, Kapoor A, Montorsi F, **Shariat SF**, Briganti A, Karakiewicz PI. The effect of age on cancer specific mortality in patients with small renal masses: A population-based analysis. *Can Urol Assoc J*. 2018 Mar 19. PMID: 29603918.
615. Dell'oglio P, Valiquette AS, Leyh-Bannurah SR, Tian Z, Trudeau V, Larcher A, **Shariat SF**, Capitanio U, Briganti A, Graefen M, Montorsi F, Karakiewicz PI. Treatment trends and Medicare reimbursements for localized prostate cancer in elderly patients. *Can Urol Assoc J*. 2018 Mar 19. PMID: 29603911.
616. Tilki D, Preisser F, Karakiewicz P, **Shariat SF**, Graefen M, Huland H, Chun FK, Pompe RS. The impact of time to catheter removal on short-, intermediate- and long-term urinary continence after radical prostatectomy. *World J Urol*. 2018 Mar 26. PubMed PMID: 29582100.
617. Moschini M, Arbelaez E, Cornelius J, Mattei A, **Shariat SF**, Dell'Oglio P, Zaffuto E, Salonia A, Montorsi F, Briganti A, Colombo R, Gallina A. Pattern of node metastases in patients treated with radical cystectomy and extended or superextended pelvic lymph node dissection due to bladder cancer. *Urol Oncol*. 2018 Mar 27. PubMed PMID: 29602638.

618. Soria F, Beleni AI, D'Andrea D, Resch I, Gust KM, Gontero P, **Shariat SF**. Pseudoprogression and hyperprogression during immune checkpoint inhibitor therapy for urothelial and kidney cancer. *World J Urol*. 2018 Mar 16. PMID: 29549485
619. Fossati N, Parker WP, Karnes RJ, Colicchia M, Bossi A, Seisen T, Di Muzio N, Cozzarini C, Chiorda BN, Fiorino C, Gandaglia G, Bartkowiak D, Wiegel T, **Shariat S**, Goldner G, Battaglia A, Joniau S, Haustermans K, De Meerleer G, Fonteyne V, Ost P, Van Poppel H, Montorsi F, Briganti A, Boorjian SA. More extensive lymph node dissection at radical prostatectomy is associated with improved outcomes with salvage radiotherapy for rising prostate-specific antigen after surgery: a long-term, multi-institutional Analysis. *Eur Urol*. 2018 Mar 12 PMID:29544737
620. Ilijazi D, Abufaraj M, Hassler MR, Ertl IE, D'Andrea D, **Shariat SF**. Waiting in the wings: the emerging role of molecular biomarkers in bladder cancer. *Expert Rev Mol Diagn*. 2018 Mar 15. PMID:29542328
621. Vince R, Hampton LJ, Vartolomei MD, **Shariat SF**, Porpiglia F, Autorino R. Robotic assisted simple prostatectomy: recent advances. *Curr Opin Urol*. 2018 Mar 9 PMID: 29528970
622. Cumberbatch MGK, Foerster B, Catto JWF, Kamat AM, Kassouf W, Jubber I, **Shariat SF**, Sylvester RJ, Gontero P. Repeat Transurethral Resection in Non-muscle-invasive Bladder Cancer: A Systematic Review. *Eur Urol*. 2018 Mar 6 PMID:29523366
623. D Andrea D, Abufaraj M, Susani M, Ristl R, Foerster B, Kimura S, Mari A, Soria F, Briganti A, Karakiewicz PI, Gust KM, Rouprêt M, **Shariat SF**. Accurate prediction of progression to muscle-invasive disease in patients with pT1G3 bladder cancer: A clinical decision-making tool. *Urol Oncol*. 2018 Mar 2. PMID: 29506941
624. von Landenberg N, Aziz A, von Rundstedt FC, Dobruch J, Kluth LA, Necchi A, Noon A, Rink M, Hendricksen K, Decaestecker KPJ, Seiler R, Poyet C, Fajkovic H, **Shariat SF**, Xylinas E, Roghmann F; Young Academic Urologists' Working Group on Urothelial Cancer of the European Association of Urology. Conditional analyses of recurrence and progression in patients with TaG1 non-muscle-invasive bladder cancer. *Urol Oncol*. 2018 Mar 2. PMID: 29506940
625. Pompe RS, Bandini M, Preisser F, Marchioni M, Zaffuto E, Tian Z, Salomon G, Schlomm T, Huland H, Graefen M, Tilki D, **Shariat SF**, Karakiewicz PI. Contemporary approach to predict early biochemical recurrence after radical prostatectomy: update of the Walz nomogram. *Prostate Cancer Prostatic Dis*. 2018 Feb 27. PMID: 29487397
626. Vartolomei MD, Kimura S, Ferro M, Vartolomei L, Foerster B, Abufaraj M, **Shariat SF**. Is neutrophil-to-lymphocytes ratio a clinical relevant preoperative biomarker in upper tract urothelial carcinoma? A meta-analysis of 4385 patients. *World J Urol*. 2018 Feb 21. PMID: 29468284
627. Preisser F, Bandini M, Marchioni M, Nazzani S, Tian Z, Pompe RS, Fossati N, Briganti A, Saad F, **Shariat SF**, Heinzer H, Huland H, Graefen M, Tilki D, Karakiewicz PI. Extent of lymph node dissection improves survival in prostate cancer patients treated with radical prostatectomy without lymph node invasion. *Prostate*. 2018 May;78(6):469-475. PMID: 9460290
628. Bandini M, Smith A, Marchioni M, Pompe RS, Martel TF, Cindolo L, Montorsi F, **Shariat SF**, Briganti A, Kapoor A, Capitanio U, Karakiewicz PI. Adjuvant Therapies in Nonmetastatic Renal-Cell Carcinoma: A Review of the Literature. *Clin Genitourin Cancer*. 2018 Feb 2. PMID: 29449091
629. Westhoff E, Witjes JA, Fleshner NE, Lerner SP, **Shariat SF**, Steineck G, Kampman E, Kiemeny LA, Vrieling A. Body Mass Index, Diet-Related Factors, and Bladder Cancer Prognosis: A Systematic Review and Meta-Analysis. *Bladder Cancer*. 2018 PMID:29430510

630. Marchioni M, Preisser F, Bandini M, Nazzani S, Tian Z, Kapoor A, Cindolo L, Abdollah F, Tilki D, Briganti A, Montorsi F, **Shariat SF**, Schips L, Karakiewicz PI. Comparison of Partial Versus Radical Nephrectomy Effect on Other-cause Mortality, Cancer-specific Mortality, and 30-day Mortality in Patients Older Than 75 Years. *Eur Urol Focus*. 2018 Feb PMID: 29398456
631. Territo A, Foerster B, **Shariat SF**, Rouprêt M, Gaya JM, Palou J, Breda A. Diagnosis and kidney-sparing treatments for upper tract urothelial carcinoma: state of the art. *Minerva Urol Nefrol*. 2018 Feb 1. PMID: 29392926
632. Moschini M, Mattei A, Cornelius J, **Shariat SF**, Dell'Oglio P, Zaffuto E, Salonia A, Montorsi F, Briganti A, Colombo R, Gallina A. Surgical treatment for clinical node-positive bladder cancer patients treated with radical cystectomy without neoadjuvant chemotherapy. *World J Urol*. 2018 Jan 24. PMID: 29368231
633. Bandini M, Preisser F, Nazzani S, Marchioni M, Tian Z, Fossati N, Gandaglia G, Gallina A, Abdollah F, **Shariat SF**, Montorsi F, Saad F, Tilki D, Briganti A, Karakiewicz PI. Contemporary Trends and Survival Outcomes After Aborted Radical Prostatectomy in Lymph Node Metastatic Prostate Cancer Patients. *Eur Urol Focus*. 2018 Jan 20. PMID:29366856
634. Compérat EM, Burger M, Gontero P, Mostafid AH, Palou J, Rouprêt M, van Rhijn BWG, **Shariat SF**, Sylvester RJ, Zigeuner R, Babjuk M. Grading of Urothelial Carcinoma and The New "World Health Organisation Classification of Tumours of the Urinary System and Male Genital Organs 2016, *Eur Urol Focus*. 2018 Jan 20. PMID: 29366854
635. Bandini M, Fossati N, Gandaglia G, Preisser F, Dell'Oglio P, Zaffuto E, Stabile A, Gallina A, Suardi N, **Shariat SF**, Montorsi F, Karakiewicz PI, Briganti A. Neoadjuvant and adjuvant treatment in high-risk prostate cancer. *Expert Rev Clin Pharmacol*. 2018 Apr;11(4):425-438. PMID:29355037
636. Mari A, D'Andrea D, Abufaraj M, Foerster B, Kimura S, **Shariat SF**. Genetic determinants for chemo- and radiotherapy resistance in bladder cancer. *Transl Androl Urol*. 2017 Dec;6(6):1081-1089. PMID:29354495
637. Vetterlein MW, Roschinski J, Gild P, Marks P, Soave A, Doh O, Isbarn H, Höppner W, Wagner W, **Shariat SF**, Brausi M, Büscheck F, Sauter G, Fisch M, Rink M. Impact of the Ki-67 labeling index and p53 expression status on disease-free survival in pT1 urothelial carcinoma of the bladder. *Transl Androl Urol*. 2017 Dec;6(6):1018-1026. PMID: 29354488
638. Pompe RS, Smith A, Bandini M, Marchioni M, Martel T, Preisser F, Leyh-Bannurah SR, Schiffmann J, Saad F, Huland H, Graefen M, **Shariat SF**, Tilki D, Karakiewicz PI. Tumor characteristics, treatments, and oncological outcomes of prostate cancer in men aged ≤ 50 years: a population-based study. *Prostate Cancer Prostatic Dis*. 2018 Jan 16. PMID: 29339806
639. Leisser A, Nejabat M, Hartenbach M, Duan H, **Shariat SF**, Kramer G, Krainer M, Hacker M, Haug AR. Hematopoiesis is prognostic for toxicity and survival of $^{223}\text{Radium}$ treatment in patients with metastatic castration-resistant prostate cancer. *Hell J Nucl Med*. 2017 Sep-Dec;20 Suppl:157. PMID: 29324927
640. Özsoy M, D'Andrea D, Moschini M, Foerster B, Abufaraj M, Mathieu R, Briganti A, Karakiewicz PI, Roupret M, Seitz C, Czech AK, Susani M, **Shariat SF**. Tertiary Gleason pattern in radical prostatectomy specimens is associated with worse outcomes than the next higher Gleason score group in localized prostate cancer. *Urol Oncol*. 2017 Dec 26. PMID: 29288003
641. Foerster B, Kimura S, Vartolomei MD, Abufaraj M, Gust K, Fajkovic H, **Shariat SF**, Seitz C. Robot-assisted partial nephrectomy: systematic review of functional results. *Curr Opin Urol*. 2017 Dec 22. PMID: 29278584

642. Vartolomei MD, Foerster B, Kimura S, Autorino R, **Shariat SF**, Seitz C. Oncologic outcomes after minimally invasive surgery for cT1 renal masses: a comprehensive review. *Curr Opin Urol*. 2017 Dec 22. PMID: 29278581
643. Bandini M, Marchioni M, Preisser F, Nazzani S, Tian Z, Fossati N, Gandaglia G, **Shariat SF**, Montorsi F, Saad F, Briganti A, Tilki D, Karakiewicz PI. A Head-to-head Comparison of Four Prognostic Models for Prediction of Lymph Node Invasion in African American and Caucasian Individuals. *Eur Urol Focus*. 2017 Dec 14. PMID: 29249688
644. Leyh-Bannurah SR, Budäus L, Zaffuto E, Pompe RS, Bandini M, Briganti A, Montorsi F, Schiffmann J, **Shariat SF**, Fisch M, Chun F, Huland H, Graefen M, Karakiewicz PI. Adherence to pelvic lymph node dissection recommendations according to the National Comprehensive Cancer Network pelvic lymph node dissection guideline and the D'Amico lymph node invasion risk stratification. *Urol Oncol*. 2017 Dec 13. PMID: 29248430
645. Mari A, Abufaraj M, Foerster B, Özsoy M, Briganti A, Rouprêt M, Karakiewicz PI, Mathieu R, D'Andrea D, Chade DC, **Shariat SF**. Oncologic effect of cumulative smoking exposure in patients treated with salvage radical prostatectomy for radiation-recurrent prostate cancer. *Clin Genitourin Cancer*. 2017 Nov 10. PMID: 29239845
646. Özsoy M, Moschini M, Fajkovic H, Soria F, Seitz C, Klatte T, Gust K, Briganti A, Karakiewicz PI, Roupret M, Kramer G, **Shariat SF**. Elevated preoperative neutrophil-lymphocyte ratio predicts upgrading at radical prostatectomy. *Prostate Cancer Prostatic Dis*. 2017 Dec 11. PMID: 29230007
647. Marchioni M, Bandini M, Preisser F, Tian Z, Kapoor A, Cindolo L, Primiceri G, Berardinelli F, Briganti A, **Shariat SF**, Schips L, Karakiewicz PI. Survival after cytoreductive nephrectomy in metastatic non-clear cell renal cell carcinoma patients: a population-based study. *Eur Urol Focus*. 2017 Dec 8. PMID: 29229582
648. Gandaglia G, Fossati N, Karnes RJ, Boorjian SA, Colicchia M, Bossi A, Seisen T, Cozzarini C, Di Muzio N, Noris Chiorda B, Zaffuto E, Wiegel T, **Shariat SF**, Goldner G, Joniau S, Battaglia A, Haustermans K, De Meerleer G, Fonteyne V, Ost P, Van Poppel H, Montorsi F, Briganti A. Use of concomitant androgen deprivation therapy in patients treated with early salvage radiotherapy for biochemical recurrence after radical prostatectomy: long-term results from a large, multi-institutional series. *Eur Urol*. 2017 Dec 8. PMID: 29229176
649. Xylinas E, Kent M, Dabi Y, Rieken M, Kluth LA, Al Awamlh BAH, Ouzaid I, Pycha A, Comploj E, Svatek RS, Lotan Y, Karakiewicz PI, Holmang S, **Shariat SF**. Impact of age on outcomes of patients with non-muscle-invasive bladder cancer treated with immediate postoperative instillation of mitomycin C. *Urol Oncol*. 2017 Dec 5. PMID: 29221642
650. Dominguez-Escrig JL, Peyronnet B, Seisen T, Bruins HM, Yuan CY, Babjuk M, Böhle A, Burger M, Compérat EM, Gontero P, Lam T, MacLennan S, Mostafid H, Palou J, van Rhijn BWG, Sylvester RJ, Zigeuner R, **Shariat SF**, Rouprêt M. Potential benefit of lymph node dissection during radical nephroureterectomy for upper tract urothelial carcinoma: a systematic review by the european association of urology guidelines panel on non-muscle-invasive bladder cancer. *Eur Urol Focus*. 2017 Nov 17. PMID: 29158169
651. Moschini M, **Shariat SF**, Rouprêt M, De Santis M, Bellmunt J, Sternberg CN, Tombal B, Collette L. Impact of primary tumor location on survival from EORTC advanced urothelial cancer studies. *J Urol*. 2017 Nov 17. PMID: 29158104
652. Peyronnet B, Seisen T, Dominguez-Escrig JL, Bruins HM, Yuan CY, Lam T, MacLennan S, N'dow J, Babjuk M, Comperat E, Zigeuner R, Sylvester RJ, Burger M, Mostafid H, van Rhijn BWG, Gontero P, Palou J, **Shariat SF**, Roupret M. Oncological outcomes of laparoscopic

- nephroureterectomy versus open radical nephroureterectomy for upper tract urothelial carcinoma: an european association of urology guidelines systematic review. *Eur Urol Focus*. 2017 Nov 15. PMID: 29154042
653. Mari A, Campi R, Tellini R, Gandaglia G, Albisinni S, Abufaraj M, Hatzichristodoulou G, Montorsi F, van Velthoven R, Carini M, Minervini A, **Shariat SF**. Patterns and predictors of recurrence after open radical cystectomy for bladder cancer: a comprehensive review of the literature. *World J Urol*. 2017 Nov 16. PMID: 29147759
654. Polanec SH, Lazar M, Wengert GJ, Bickel H, Spick C, Susani M, **Shariat SF**, Clauser P, Baltzer PAT. 3D T2-weighted imaging to shorten multiparametric prostate MRI protocols. *Eur Radiol*. 2017 Nov 13. PMID: 29134351
655. Tilki D, Chandrasekar T, Capitano U, Ciancio G, Daneshmand S, Gontero P, Gonzalez J, Haferkamp A, Hohenfellner M, Huang WC, Linares Espinós E, Lorentz A, Martinez-Salamanca JI, Master VA, McKiernan JM, Montorsi F, Novara G, Pahernik S, Palou J, Pruthi RS, Rodriguez-Faba O, Russo P, Scherr DS, **Shariat SF**, Spahn M, Terrone C, Vera-Donoso C, Zigeuner R, Libertino JA, Evans CP. Impact of lymph node dissection at the time of radical nephrectomy with tumor thrombectomy on oncological outcomes: Results from the International Renal Cell Carcinoma-Venous Thrombus Consortium (IRCC-VTC). *Urol Oncol*. 2017 Nov 9. PMID: 29129353
656. Abufaraj M, **Shariat SF**, Foerster B, Pozo C, Moschini M, D'Andrea D, Mathieu R, Susani M, Czech AK, Karakiewicz PI, Seebacher V. Accuracy and prognostic value of variant histology and lymphovascular invasion at transurethral resection of bladder. *World J Urol*. 2017 Nov 11. PMID: 29127452
657. Bandini M, Marchioni M, Pompe RS, Tian Z, Gandaglia G, Fossati N, Abdollah F, Graefen M, Montorsi F, Saad F, **Shariat SF**, Briganti A, Karakiewicz PI. First North American validation and head-to-head comparison of four preoperative nomograms for prediction of lymph node invasion before radical prostatectomy. *BJU Int*. 2017 Nov 10. PMID: 29124911
658. Abufaraj M, Dalbagni G, Daneshmand S, Horenblas S, Kamat AM, Kanzaki R, Zlotta AR, **Shariat SF**. The role of surgery in metastatic bladder cancer: a systematic review. *Eur Urol*. 2017 Nov 6. PMID: 29122377
659. Grubmüller B, Baltzer P, D'Andrea D, Korn S, Haug AR, Hacker M, Grubmüller KH, Goldner GM, Wadsak W, Pfaff S, Babich J, Seitz C, Fajkovic H, Susani M, Mazal P, Kramer G, **Shariat SF**, Hartenbach M. 68Ga-PSMA 11 ligand PET imaging in patients with biochemical recurrence after radical prostatectomy - diagnostic performance and impact on therapeutic decision-making. *Eur J Nucl Med Mol Imaging*. 2017 Oct 26. PMID: 29075832
660. Hendricksen K, Aziz A, Bes P, Chun FK, Dobruch J, Kluth LA, Gontero P, Necchi A, Noon AP, van Rhijn BWG, Rink M, Roghmann F, Rouprêt M, Seiler R, **Shariat SF**, Qvick B, Babjuk M, Xylinas E; Young Academic Urologists Urothelial Carcinoma Group of the European Association of Urology. Discrepancy Between European Association of Urology Guidelines and Daily Practice in the Management of Non-muscle-invasive Bladder Cancer: Results of a European Survey. *Eur Urol Focus*. 2017 Oct 23. PMID: 29074050
661. Bandini M, Pompe RS, Marchioni M, Tian Z, Gandaglia G, Fossati N, Tilki D, Graefen M, Montorsi F, **Shariat SF**, Briganti A, Saad F, Karakiewicz PI. Radical prostatectomy or radiotherapy reduce prostate cancer mortality in elderly patients: a population-based propensity score adjusted analysis. *World J Urol*. 2017 Oct 23. PMID: 29063268

662. Mari A, Abufaraj M, Gust KM, **Shariat SF**. Novel endoscopic visualization techniques for bladder cancer detection: a review of the contemporary literature. *Curr Opin Urol*. 2017 PMID: 29045251
663. Bandini M, Smith A, Zaffuto E, Pompe RS, Marchioni M, Capitanio U, Chun FK, Kapoor AB, **Shariat SF**, Montorsi F, Briganti A, Karakiewicz PI. Effect of pathological high-risk features on cancer-specific mortality in non-metastatic clear cell renal cell carcinoma: a tool for optimizing patient selection for adjuvant therapy. *World J Urol*. 2017 PMID: 29022072
664. D'Andrea D, Moschini M, Soria F, Gust KM, Briganti A, Karakiewicz PI, Rouprêt M, **Shariat SF**. ABO Blood Group and Rhesus Factor Are Not Associated with Outcomes After Radical Cystectomy for Non-metastatic Urothelial Carcinoma of the Bladder. *Anticancer Res*. 2017 Oct;37(10):5747-5753. PMID: 28982896
665. Rieken M, **Shariat SF**, Kluth L, Crivelli JJ, Abufaraj M, Foerster B, Mari A, Ilijazi D, Karakiewicz PI, Babjuk M, Gönen M, Xylinas E. Comparison of the EORTC tables and the EAU categories for risk stratification of patients with nonmuscle-invasive bladder cancer. *Urol Oncol*. 2017 PMID: 28947304
666. Marchioni M, Bandini M, Pompe RS, Martel T, Tian Z, **Shariat SF**, Kapoor A, Cindolo L, Briganti A, Schips L, Capitanio U, Karakiewicz PI. The impact of lymph node dissection and positive lymph nodes on cancer specific mortality in contemporary pT2-3 non-metastatic renal cell carcinoma treated with radical nephrectomy. *BJU Int*. 2017 PMID: 28940649
667. Necchi A, Lo Vullo S, Mariani L, Moschini M, Hendricksen K, Rink M, Sosnowski R, Dobruch J, Raman JD, Wood CG, Margulis V, Roupret M, Briganti A, Montorsi F, Xylinas E, **Shariat SF**; European Association of Urology - Young Academic Urologists (EAU-YAU) Urothelial Cancer Group the Upper Tract Urothelial Carcinoma Collaboration group. Adjuvant chemotherapy after radical nephroureterectomy does not improve survival in patients with upper tract urothelial carcinoma: a joint study of the EAU-Young Academic Urologists and the Upper Tract Urothelial Carcinoma Collaboration. *BJU Int*. 2017 PMID: 28940605
668. Marchioni M, Bandini M, Pompe RS, Tian Z, Martel T, Kapoor A, Cindolo L, Berardinelli F, Briganti A, **Shariat SF**, Schips L, Karakiewicz PI. Survival of metastatic renal cell carcinoma patients continues to improve over time, even in targeted therapy era. *Int Urol Nephrol*. 2017 PMID: 28932952
669. Malte R, Kluth LA, Kaushik D, Boorjian SA, Abufaraj M, Foerster B, Rink M, Gust K, Roghmann F, Noldus J, Vordos D, Hagiwara M, Kikuchi E, Ikeda M, Matsumoto K, Karakiewicz PI, Rouprêt M, Briganti A, Scherr DS, **Shariat SF**, Seebacher V. Frequency and prognostic significance of incidental prostate cancer at radical cystectomy: Results from an international retrospective study. *Eur J Surg Oncol*. 2017 PMID: 28928012
670. Rieken M, Kluth LA, Seitz C, Abufaraj M, Foerster B, Mathieu R, Karakiewicz PI, Bachmann A, Briganti A, Rouprêt M, Gönen M, **Shariat SF**, Seebacher V. External Validation of the Pathologic Nodal Staging Score for Prostate Cancer: A Population -based Study. *Clin Genitourin Cancer*. 2017 PMID: 28916272
671. Moschini M, D'Andrea D, Korn S, Irmak Y, Soria F, Compérat E, **Shariat SF**. Characteristics and clinical significance of histological variants of bladder cancer. *Nat Rev Urol*. 2017 PMID: 28895563
672. Rink M, Engel O, Gakis G, Fritsche HM, Vetterlein MW, Soave A, Peine S, Aziz A, Dahlem R, Stenzl A, Burger M, **Shariat SF**, Fisch M, Gild P. The effect of ABO and Rhesus blood grouping

- systems on oncological outcome in patients undergoing radical nephroureterectomy for upper tract urothelial carcinoma. *Urol Oncol*. 2017 PMID: 28889922
673. Moschini M, **Shariat SF**, Abufaraj M, Foerster B, D'Andrea D, Soria F, Dell'Oglio P, Mattei A, Montorsi F, Colombo R, Briganti A, Gallina A. Predicting local failure after radical cystectomy in patients with bladder cancer: Implications for the selection of candidates at adjuvant radiation therapy. *Urol Oncol*. 2017 PMID: 28887096
 674. Rouprêt M, Babjuk M, Compérat E, Zigeuner R, Sylvester RJ, Burger M, Cowan NC, Gontero P, Van Rhijn BWG, Mostafid AH, Palou J, **Shariat SF**. European Association of Urology Guidelines on Upper Urinary Tract Urothelial Carcinoma: 2017 Update. *Eur Urol*. 2017 PMID: 28867446
 675. Dell'Oglio P, Stabile A, Gandaglia G, Zaffuto E, Fossati N, Bandini M, Suardi N, Karakiewicz PI, **Shariat SF**, Montorsi F, Briganti A. New surgical approaches for clinically high-risk or metastatic prostate cancer. *Expert Rev Anticancer Ther*. 2017 Sep 1. PMID: 28862047
 676. Abufaraj M, Haitel A, Moschini M, Gust K, Foerster B, Özsoy M, D'Andrea D, Karakiewicz PI, Rouprêt M, Briganti A, **Shariat SF**. Prognostic Role of N-cadherin Expression in Patients With Invasive Bladder Cancer. *Clin Genitourin Cancer*. 2017 Aug 15. PMID: 28851591
 677. Marchioni M, Martel T, Bandini M, Pompe RS, Tian Z, Kapoor A, Cindolo L, Autorino R, Briganti A, **Shariat SF**, Schips L, Karakiewicz PI. Marital status and gender affect stage, tumor grade, treatment type and cancer specific mortality in T1-2 N0 M0 renal cell carcinoma. *World J Urol*. 2017 Aug 28. PMID: 28849260
 678. Borgmann H, Musquera M, Haferkamp A, Vilaseca A, Klatte T, **Shariat SF**, Scavuzzo A, Jimenez Rios MA, Wolff I, Capitanio U, Dell'Oglio P, Krabbe LM, Herrmann E, Ecke T, Verghe D, Huck N, Wagener N, Pahernik S, Zastrow S, Wirth M, Surcel C, Mirvald C, Prochazkova K, Hutterer G, Zigeuner R, Cindolo L, Hora M, Stief CG, May M, Brookman-May SD. Prognostic significance of Fuhrman grade and age for cancer-specific and overall survival in patients with papillary renal cell carcinoma: results of an international multi-institutional study on 2189 patients. *World J Urol*. 2017 Aug 23. PMID: 28836063
 679. Moschini M, Soria F, Susani M, Korn S, Briganti A, Roupret M, Seitz C, Gust K, Haitel A, Montorsi F, Wirth G, Robinson BD, Karakiewicz PI, Özsoy M, Rink M, **Shariat SF**. Impact of the Level of Urothelial Carcinoma Involvement of the Prostate on Survival after Radical Cystectomy. *Bladder Cancer*. 2017 Jul 27;3(3):161-169. PMID: 28824943
 680. Bedke J, Heide J, Ribback S, Rausch S, de Martino M, Scharpf M, Haitel A, Zimmermann U, Pechoel M, Alkhayat H, **Shariat SF**, Dombrowski F, Stenzl A, Burchardt M, Klatte T, Kroeger N. Microvascular and lymphovascular tumor invasion are associated with poor prognosis and metastatic spread in renal cell carcinoma: A validation study in clinical practice. *BJU Int*. 2017 PMID: 28803448
 681. Wolff I, Scavuzzo A, Capitanio U, Klatte T, **Shariat SF**, Wagener N, Zastrow S, Borgmann H, Krabbe LM, Hutterer G, May M, Brookman-May SD. Organ Preservation is Less Frequently Performed in Women Surgically Treated for Papillary Renal Cell Carcinoma - Results of a Comprehensive Multicenter Study. *Urology*. 2017 PMID: 28802570
 682. Fossati N, Karnes RJ, Colicchia M, Boorjian SA, Bossi A, Seisen T, Di Muzio N, Cozzarini C, Noris Chiorda B, Fiorino C, Gandaglia G, Dell'Oglio P, **Shariat SF**, Goldner G, Joniau S, Battaglia A, Haustermans K, De Meerleer G, Fonteyne V, Ost P, Van Poppel H, Wiegel T, Montorsi F, Briganti A. Impact of Early Salvage Radiation Therapy in Patients with Persistently Elevated or Rising Prostate-specific Antigen After Radical Prostatectomy. *Eur Urol*. 2017 Aug 2. PMID: 28779974

683. Zaffuto E, Pompe R, Bondarenko HD, Moschini M, Dell'Oglio P, Gandaglia G, Fossati N, **Shariat SF**, Montorsi F, Briganti A, Karakiewicz PI. Hospitalization before surgery and subsequent risk of infective complications after radical cystectomy: A population-based analysis. *Urol Oncol*. 2017 Jul 26. PMID: 28755960
684. Aumayr K, Klatte T, Neudert B, Birner P, **Shariat S**, Schmidinger M, Susani M, Haitel A. HER2 and TOP2A Gene Amplification and Protein Expression in Upper Tract Urothelial Carcinomas. *Pathol Oncol Res*. 2017 PMID: 28755093
685. D'Andrea D, Moschini M, Foerster B, Abufaraj M, Margulis V, Karam J, Lotan Y, Raman J, Mathieu R, Rouprêt M, Karakiewicz PI, Briganti A, Haitel A, **Shariat SF**. Caveolin-1 Expression in Upper Tract Urothelial Carcinoma. *Eur Urol Focus*. 2017 Jul 1. PMID: 28753840
686. Vetterlein MW, Seisen T, May M, Nuhn P, Gierth M, Mayr R, Fritsche HM, Burger M, Novotny V, Froehner M, Wirth MP, Protzel C, Hakenberg OW, Roghmann F, Palisaar RJ, Noldus J, Pycha A, Bastian PJ, Trinh QD, Xylinas E, **Shariat SF**, Rink M, Chun FK, Dahlem R, Fisch M, Aziz A; PROMETRICS 2011 Study Group. Effectiveness of Adjuvant Chemotherapy After Radical Cystectomy for Locally Advanced and/or Pelvic Lymph Node-Positive Muscle-invasive Urothelial Carcinoma of the Bladder: A Propensity Score-Weighted Competing Risks Analysis. *Eur Urol Focus*. 2016 Jul 18. PMID: 28753775
687. de Martino M, Leitner CV, Hofbauer SL, Lucca I, Haitel A, **Shariat SF**, Klatte T. Serum Adiponectin Predicts Cancer-specific Survival of Patients with Renal Cell Carcinoma. *Eur Urol Focus*. 2016 Jun;2(2):197-203. PMID: 28723535
688. Rieken M, **Shariat SF**, Karam JA, Foerster B, Khani F, Gust K, Abufaraj M, Wood CG, Weizer AZ, Raman JD, Guo CC, Rioux-Leclercq N, Haitel A, Bensalah K, Lotan Y, Bachmann A, De Marzo AM, Robinson BD, Margulis V. Frequency and prognostic value of PTEN loss in patients with upper tract urothelial carcinoma treated with radical nephroureterectomy. *J Urol*. 2017 Jul 11. PMID: 28709887
689. Foerster B, Moschini M, Abufaraj M, Soria F, Gust KM, Rouprêt M, Karakiewicz PI, Briganti A, Rink M, Kluth L, Mathieu R, Margulis V, Lotan Y, Aziz A, John H, **Shariat SF**; UTUC Collaboration. Predictive and Prognostic Value of Preoperative Thrombocytosis in Upper Tract Urothelial Carcinoma. *Clin Genitourin Cancer*. 2017 Jun 19. PMID: 28694147
690. Krabbe LM, Heitzplatz B, Preuss S, Hutchinson RC, Woldu SL, Singla N, Boegemann M, Wood CG, Karam JA, Weizer AZ, Raman JD, Remzi M, Rioux-Leclercq N, Haitel A, Rapoport LM, Glybochko PV, Roscigno M, Bolenz C, Bensalah K, Sagalowsky AI, **Shariat SF**, Lotan Y, Xylinas E, Margulis V. Prognostic Value of PD-1 and PD-L1 Expression in Patients with High-Grade Upper Tract Urothelial Carcinoma. *J Urol*. 2017 Jun 28 PMID: 28668287
691. Gschliesser T, Eredics K, Berger I, Szelinger M, Klingler HC, Colombo T, Ponholzer A, Plas E, Grubmüller K, Dunzinger M, Jeschke K, Würnschimmel E, Krause FS, **Shariat S**, Leeb K, Pelzer A, Riedl C, Rauchenwald M, Hübner W, Brössner C, Madersbacher S; Cystectomy Registry of the Austrian Society of Urology. The Impact of Gender on Tumour Stage in In-House Complications and Choice of Urinary Diversion: Results of the Austrian Cystectomy Registry. *Urol Int*. 2017 Jun 23. PMID: 28641294
692. Marchioni M, Primiceri G, Cindolo L, Hampton LJ, Grob MB, Guruli G, Schips L, **Shariat SF**, Autorino R. Impact of diagnostic ureteroscopy on intravesical recurrence in patients undergoing radical nephroureterectomy for upper tract urothelial cancer: a systematic review and meta-analysis. *BJU Int*. 2017 Jun 16. PMID: 28621055

693. Soria F, Moschini M, Wirth GJ, Gust KM, Klatte T, Briganti A, Gontero P, Abufaraj M, Özsoy M, Karakiewicz PI, **Shariat SF**. Characterization of Late Recurrence after Radical Cystectomy in a Large Multicenter Cohort of Bladder Cancer Patients. *Urology*. 2017 May 12. PMID: 28506860
694. Maj-Hes AB, Mathieu R, Özsoy M, Soria F, Moschini M, Abufaraj M, Briganti A, Roupret M, Karakiewicz PI, Klatte T, **Shariat SF**. Obesity is associated with biochemical recurrence after radical prostatectomy: A multi-institutional extended validation study. *Urol Oncol*. 2017 PMID: 28460801
695. Soukup V, Čapoun O, Cohen D, Hernández V, Babjuk M, Burger M, Compérat E, Gontero P, Lam T, MacLennan S, Mostafid AH, Palou J, van Rhijn BWG, Rouprêt M, **Shariat SF**, Sylvester R, Yuan Y, Zigeuner R. Prognostic Performance and Reproducibility of the 1973 and 2004/2016 World Health Organization Grading Classification Systems in Non-muscle-invasive Bladder Cancer: A European Association of Urology Non-muscle Invasive Bladder Cancer Guidelines Panel Systematic Review. *Eur Urol*. 2017 PMID: 28457661
696. Moschini M, **Shariat SF**, Freschi M, Soria F, D'Andrea D, Abufaraj M, Foerster B, Dell'Oglio P, Zaffuto E, Mattei A, Salonia A, Montorsi F, Briganti A, Gallina A, Colombo R. Is transurethral resection alone enough for the diagnosis of histological variants? A single-center study. *Urol Oncol*. 2017 PMID: 28433471
697. D'Andrea D, Moschini M, Gust K, Abufaraj M, Özsoy M, Mathieu R, Soria F, Briganti A, Rouprêt M, Karakiewicz PI, **Shariat SF**. Prognostic Role of Neutrophil-to-Lymphocyte Ratio in Primary Non-muscle-invasive Bladder Cancer. *Clin Genitourin Cancer*. 2017 PMID: 28420564
698. May M, Surcel C, Capitanio U, Dell'Oglio P, Klatte T, **Shariat S**, Ecke T, Wolff I, Verghe D, Wagener N, Huck N, Pahernik S, Zastrow S, Wirth M, Borgmann H, Haferkamp A, Musquera M, Krabbe LM, Herrmann E, Scavuzzo A, Mirvald C, Hutterer G, Zigeuner R, Stief CG, Waidelich R, Cindolo L, Kalusova K, Brookman-May SD Prognostic and discriminative power of the 7th TNM classification for patients with surgically treated papillary renal cell carcinoma: results of a multi-institutional validation study (CORONA subtype project). *Scand J Urol*. 2017 Apr 12:1-8. PMID: 28399699
699. Leyh-Bannurah SR, Gazdovich S, Budäus L, Zaffuto E, Briganti A, Abdollah F, Montorsi F, Schiffmann J, Menon M, **Shariat SF**, Fisch M, Chun F, Steuber T, Huland H, Graefen M, Karakiewicz PI. Local Therapy Improves Survival in Metastatic Prostate Cancer. *Eur Urol*. 2017 PMID: 28385454
700. Lotan Y, O'Sullivan P, Raman JD, **Shariat SF**, Kavalieris L, Frampton C, Guilford P, Luxmanan C, Suttie J, Crist H, Scherr D, Asroff S, Goldfischer E, Thill J, Darling D. Clinical comparison of noninvasive urine tests for ruling out recurrent urothelial carcinoma. *Urol Oncol*. 2017 Mar 30. PMID: 28366272
701. Soria F, Lucca I, Moschini M, Mathieu R, Rouprêt M, Karakiewicz PI, Briganti A, Rink M, Gust KM, Hassler MR, Foerster B, Abufaraj M, Haitel A, Klatte T, **Shariat SF**. Caveolin-1 as prognostic factor of disease recurrence and survival in patients treated with radical cystectomy for bladder cancer. *Urol Oncol*. 2017 Mar 22. PMID: 28342660
702. Dell'Oglio P, Zaffuto E, Boehm K, Trudeau V, Larcher A, Tian Z, Moschini M, **Shariat SF**, Graefen M, Saad F, Capitanio U, Briganti A, Montorsi F, Karakiewicz PI. Long-term survival of patients aged 80 years or older treated with radical prostatectomy for prostate cancer. *Eur J Surg Oncol*. 2017 Mar 10. PMID: 28330822
703. Moschini M, Foerster B, Abufaraj M, Soria F, Seisen T, Roupret M, Colin P, De la Taille A, Peyronnet B, Bensalah K, Herout R, Wirth MP, Novotny V, Chlosta P, Bandini M, Montorsi F,

- Simone G, Gallucci M, Romeo G, Matsumoto K, Karakiewicz P, Briganti A, **Shariat SF**. Trends of lymphadenectomy in upper tract urothelial carcinoma (UTUC) patients treated with radical nephroureterectomy. *World J Urol*. 2017 Feb 28. PMID: 28247066
704. Abufaraj M, **Shariat SF**, Haitel A, Moschini M, Foerster B, Chłosta P, Gust K, Babjuk M, Briganti A, Karakiewicz PI, Albrecht W. Prognostic role of N-cadherin expression in patients with non-muscle-invasive bladder cancer. *Urol Oncol*. 2017 Feb 14. PMID: 28214283
705. Moschini M, Soria F, Abufaraj M, Foerster B, D'Andrea D, Damiano R, Klatte T, Montorsi F, Briganti A, Colombo R, Gallina A, **Shariat SF**. Impact of intra- and postoperative blood transfusion on the incidence, timing, and pattern of disease recurrence after radical cystectomy. *Clin Genitourin Cancer*. 2017 Jan 11. PMID: 28162943
706. Pompe RS, Davis-Bondarenko H, Zaffuto E, Tian Z, **Shariat SF**, Leyh-Bannurah SR, Schiffmann J, Saad F, Huland H, Graefen M, Tilki D, Karakiewicz PI. Population-based validation of the 2014 ISUP Gleason grade groups in patients treated with radical prostatectomy, brachytherapy, external beam radiation or no local treatment. *Prostate*. 2017 Feb 3. PMID: 28156003
707. Moschini M, **Shariat SF**, Freschi M, Soria F, Abufaraj M, Gandaglia G, Dell'Oglio P, Mattei A, Damiano R, Salonia A, Montorsi F, Briganti A, Gallina A, Colombo R. Impact of Prostate Involvement on Outcomes in Patients Treated with Radical Cystoprostatectomy for Bladder Cancer. *Urol Int*. 2017 Feb 1. PMID: 28142141
708. Sosnowski R, Bjurlin MA, Verze P, De Nunzio C, **Shariat SF**, Brausi M, Donin NM. Role of cigarette smoking in urological malignancies and clinical interventions for smoking cessation. *Cent European J Urol*. 2016;69(4):366-369. PMID: 28127452
709. D'Andrea D, Moschini M, Gust KM, Abufaraj M, Özsoy M, Mathieu R, Soria F, Briganti A, Rouprêt M, Karakiewicz PI, **Shariat SF**. Lymphocyte-to-monocyte ratio and neutrophil-to-lymphocyte ratio as biomarkers for predicting lymph node metastasis and survival in patients treated with radical cystectomy. *J Surg Oncol*. 2017 Jan 20. PMID: 28105663
710. Leyh-Bannurah SR, Budäus L, Pompe R, Zaffuto E, Briganti A, Abdollah F, Montorsi F, Schiffmann J, Menon M, **Shariat SF**, Fisch M, Chun F, Huland H, Graefen M, Karakiewicz PI. North American population-based validation of the national comprehensive cancer network practice guideline recommendation of pelvic lymphadenectomy in contemporary prostate cancer. *Prostate*. 2017 Jan 17. PMID: 28093788
711. Soria F, de Martino M, Leitner CV, Moschini M, **Shariat SF**, Klatte T. Perioperative allogenic blood transfusion in renal cell carcinoma: risk factors and effect on long-term outcomes. *Clin Genitourin Cancer*. 2016 Dec 29. PMID: 28089722
712. Moschini M, Dell'Oglio P, Luciano' R, Gandaglia G, Soria F, Mattei A, Klatte T, Damiano R, **Shariat SF**, Salonia A, Montorsi F, Briganti A, Colombo R, Gallina A. Incidence and effect of variant histology on oncological outcomes in patients with bladder cancer treated with radical cystectomy. *Urol Oncol*. 2017 Jan 10. PMID: 28087131
713. Rink M, **Shariat SF**, Soave A. Liquid biopsies in bladder cancer-did we find the Holy Grail for biomarker analyses? *Transl Androl Urol*. 2016 Dec;5(6):980-983. PMID: 28078238
714. Aziz A, Dobruch J, Hendricksen K, Kluth LA, Necchi A, Noon A, Rink M, Roghmann F, Seiler R, Gontero P, Kassouf W, **Shariat SF**, Xylinas E; Young Academic Urologists Urothelial Carcinoma Group of the European Association of Urology. Perioperative chemotherapy in upper tract urothelial carcinoma: a comprehensive review. *World J Urol*. 2017 Jan 10. doi: 10.1007/s00345-016-1995-z. PMID: 28074261

715. Mathieu R, Moschini M, Beyer B, Gust KM, Seisen T, Briganti A, Karakiewicz P, Seitz C, Salomon L, de la Taille A, Rouprêt M, Graefen M, **Shariat SF**. Prognostic value of the new Grade Groups in Prostate Cancer: a multi-institutional European validation study. *Prostate Cancer Prostatic Dis.* 2017 Jan 10. PMID: 28071673
716. Moschini M, **Shariat SF**, Lucianò R, D'Andrea D, Foerster B, Abufaraj M, Bandini M, Dell'Oglio P, Damiano R, Salonia A, Montorsi F, Briganti A, Colombo R, Gallina A. Pure but not mixed histologic variants are associated with poor survival at radical cystectomy in bladder cancer patients. *Clin Genitourin Cancer.* 2016 Dec 14. PMID: 28040422
717. Kavalieris L, O'Sullivan P, Frampton C, Guilford P, Darling D, Jacobson E, Suttie J, Raman JD, **Shariat SF**, Lotan Y. Performance characteristics of a multigene urine biomarker test for monitoring for recurrent urothelial carcinoma in a multicenter study. *J Urol.* 2016 Dec 13. PMID: 27986532
718. Anract J, Barry Delongchamps N, Gontero P, Dobruch J, Necchi A, Seisen T, Rouprêt M, **Shariat S**, Aziz A, Rink M, Xylinas E. L'impact de l'intoxication tabagique sur l'agressivité tumorale au moment de la cystectomie totale. *Prog Urol.* 2016 Nov;26(13):764-765. PMID: 27969287
719. Aziz A, Bes P, Masson-Lecomte A, Barry-Delongchamps N, Rouprêt M, **Shariat S**, Qvick B, Xylinas E. Discordance entre les recommandations et la pratique quotidienne dans la prise en charge des tumeurs de vessie n'infiltrant pas le muscle. *Prog Urol.* 2016 Nov;26(13):704-705. PMID: 27969169
720. Duquesne I, Barry Delongchamps N, Barry Delongchamps N, Pisano F, Aziz A, Masson-Lecomte A, **Shariat S**, Gontero P, Xylinas E. Évaluation de la morbidité de la cystectomie totale après radiothérapie abdomino-pelvienne. *Prog Urol.* 2016 Nov;26(13):673-674. PMID: 27969107
721. Babjuk M, Burger M, Compérat E, Palou J, Rouprêt M, van Rhijn B, **Shariat S**, Sylvester R, Zigeuner R, Gontero P, Mostafid H. Reply to Harry Herr's Letter to the Editor re: Marko Babjuk, Andreas Böhle, Maximilian Burger, et al. EAU Guidelines on Non-muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016. *Eur Urol.* 2016 Dec 7. pii: S0302-2838(16)30881-8. PMID: 27939074
722. Moschini M, **Shariat SF**, Abufaraj M, Soria F, Klatte T, Croce G, Mattei A, Damiano R, Salonia A, Montorsi F, Briganti A, Colombo R, Gallina A. The presence of carcinoma in situ at radical cystectomy increases the risk of urothelial recurrence: Implications for follow-up schemes. *Urol Oncol.* 2016 Dec 5. PMID: 27932269
723. Soria F, Moschini M, Abufaraj M, Wirth GJ, Foerster B, Gust KM, Özsoy M, Briganti A, Gontero P, Mathieu R, Rouprêt M, Karakiewicz PI, **Shariat SF**. Preoperative anemia is associated with disease recurrence and progression in patients with non-muscle-invasive bladder cancer. *Urol Oncol.* 2016 Nov 28. PMID: 27908681
724. May M, Protzel C, Vetterlein MW, Gierth M, Noldus J, Karl A, Grimm T, Wullich B, Grimm MO, Nuhn P, Bastian PJ, Roigas J, Hadaschik B, Gilfrich C, Burger M, Fisch M, Brookman-May S, Aziz A, **Shariat S.**, Hakenberg OW; PROMETRICS 2011 Research Group.. Is there evidence for a close connection between side of intravesical tumor location and ipsilateral lymphatic spread in lymph node-positive bladder cancer patients at radical cystectomy? Results of the PROMETRICS 2011 database. *Int Urol Nephrol.* 2016 Nov 28. PMID: 27896578
725. Schiffmann J, Larcher A, Sun M, Tian Z, Berdugo J, Leva I, Widmer H, Lattouf JB, Zorn KC, **Shariat SF**, Montorsi F, Graefen M, Saad F, Karakiewicz PI. Suboptimal use of pelvic lymph node dissection: Differences in guideline adherence between robot-assisted and open radical prostatectomy. *Can Urol Assoc J.* 2016 Aug;10(7-8):269-276. PMID: 27878050

726. Zaffuto E, Gazdovich S, Leyh-Bannurah SR, Huland H, Abdollah F, **Shariat SF**, Menon M, Briganti A, Montorsi F, Karakiewicz PI. Contemporary rates of pathological features and mortality for adenocarcinoma of the urinary bladder in the USA. *Int J Urol*. 2016 Nov 22. PMID: 27875858
727. Abufaraj M, Moschini M, Soria F, Gust K, Özsoy M, Mathieu R, Rouprêt M, Margulis V, Karam JA, Wood CG, Briganti A, Bensalah K, Haitel A, **Shariat SF**. Prognostic role of expression of N-cadherin in patients with upper tract urothelial carcinoma: a multi-institutional study. *World J Urol*. 2016 Nov 9. PMID: 27830374
728. Xylinas E, Kluth L, Rieken M, Rouprêt M, Al Awamlh BA, Clozel T, Sun M, Karakiewicz PI, Gonen M, **Shariat SF**. External validation of the pathological nodal staging score in upper tract urothelial carcinoma: A population-based study. *Urol Oncol*. 2016 Nov 2. PMID: 27816402
729. Peyronnet B, Seisen T, Oger E, Vaessen C, Grassano Y, Benoit T, Carrouget J, Pradère B, Khene Z, Giwerc A, Mathieu R, Beauval JB, Nouhaud FX, Bigot P, Doumerc N, Bernhard JC, Mejean A, Patard JJ, **Shariat S**, Roupert M, Bensalah K; French Committee of Urologic Oncology (CCAFU). Comparison of 1800 Robotic and Open Partial Nephrectomies for Renal Tumors. *Ann Surg Oncol*. 2016 Dec;23(13):4277-4283. PMID: 27411552
730. Krabbe LM, Woldu SL, **Shariat SF**, Lotan Y. Improving diagnostic molecular tests to monitor urothelial carcinoma recurrence. *Expert Rev Mol Diagn*. 2016 Nov;16(11):1189-1199. PMID: 27696932
731. Mager R, Daneshmand S, Evans CP, Palou J, Martínez-Salamanca JI, Master VA, McKiernan JM, Libertino JA, Haferkamp A; International Renal Cell Carcinoma-Venous Thrombus Consortium., Haferkamp A, Capitanio U, Carballido JA, Chantada V, Chromecki T, Ciancio G, Daneshmand S, Evans CP, Gontero P, González J, Hohenfellner M, Huang WC, Koppie TM, Libertino JA, Espinós EL, Lorentz A, Martínez-Salamanca JI, Master VA, McKiernan JM, Montorsi F, Novara G, O'Malley P, Pahernik S, Palou J, Moreno JL, Pruthi RS, Faba OR, Russo P, Scherr DS, **Shariat SF**, Spahn M, Terrone C, Tilki D, Vázquez-Martul D, Donoso CV, Vergho D, Wallen EM, Zigeuner R. Renal cell carcinoma with inferior vena cava involvement: Prognostic effect of tumor thrombus consistency on cancer specific survival. *J Surg Oncol*. 2016 Nov;114(6):764-768. PMID: 27562252
732. Bianchi L, Gandaglia G, Fossati N, Suardi N, Moschini M, Cucchiara V, Bianchi M, Damiano R, Schiavina R, **Shariat SF**, Montorsi F, Briganti A. Pelvic lymph node dissection in prostate cancer: indications, extent and tailored approaches. *Urologia*. 2015 Dec 16;0. doi: 10.5301/uro.5000139. PMID: 26689534
733. Mathieu R, **Shariat SF**. Building bridges in urothelial carcinoma to face common challenges. *Transl Androl Urol*. 2016 Oct;5(5):745-748. PMID: 27785431
734. Abufaraj M, Gust K, Moschini M, Foerster B, Soria F, Mathieu R, **Shariat SF**. Management of muscle invasive, locally advanced and metastatic urothelial carcinoma of the bladder: a literature review with emphasis on the role of surgery. *Transl Androl Urol*. 2016 Oct;5(5):735-744. PMID: 27785430
735. Mbeutcha A, Mathieu R, Rouprêt M, Gust KM, Briganti A, Karakiewicz PI, **Shariat SF**. Predictive models and prognostic factors for upper tract urothelial carcinoma: a comprehensive review of the literature. *Transl Androl Urol*. 2016 Oct;5(5):720-734. PMID: 27785429
736. Khene ZE, Mathieu R, Kammerer-Jacquet SF, Seisen T, Roupert M, **Shariat SF**, Peyronnet B, Bensalah K. Risk stratification for kidney sparing procedure in upper tract urothelial carcinoma. *Transl Androl Urol*. 2016 Oct;5(5):711-719. PMID: 27785428
737. Sargos P, Baumann BC, Eapen LJ, Bahl A, Murthy V, Roubaud G, Orré M, Efstathiou JA, **Shariat S**, Larré S, Richaud P, Christodouleas JP. Adjuvant radiotherapy for pathological high-risk

- muscle invasive bladder cancer: time to reconsider? *Transl Androl Urol.* 2016 Oct;5(5):702-710. PMID: 27785427
738. Soria F, Moschini M, Korn S, **Shariat SF**. How to optimally manage elderly bladder cancer patients? *Transl Androl Urol.* 2016 Oct;5(5):683-691. PMID: 27785425
739. Marks P, Soave A, **Shariat SF**, Fajkovic H, Fisch M, Rink M. Female with bladder cancer: what and why is there a difference? *Transl Androl Urol.* 2016 Oct;5(5):668-682. PMID: 27785424
740. Colin P, Seisen T, Mathieu R, **Shariat SF**, Rouprêt M. Lynch syndrome and exposure to aristolochic acid in upper-tract urothelial carcinoma: its clinical impact? *Transl Androl Urol.* 2016 Oct;5(5):648-654. PMID: 27785421
741. **Shariat SF**, Mathieu R. Contemporary concepts and controversies in the diagnosis and management of urothelial carcinoma. *Transl Androl Urol.* 2016 Oct;5(5):633-635. PMID: 27785419
742. Moschini M, Soria F, Briganti A, **Shariat SF**. The impact of local treatment of the primary tumor site in node positive and metastatic prostate cancer patients. *Prostate Cancer Prostatic Dis.* 2016 Oct 25. PMID: 27779202
743. Módos O, Reis H, Niedworok C, Rübber H, Szendrői A, Szász MA, Tímár J, Baghy K, Kovalszky I, Golabek T, Chlosta P, Okon K, Peyronnet B, Mathieu R, **Shariat SF**, Hollósi P, Nyirády P, Szarvas T. Mutations of KRAS, NRAS, BRAF, EGFR, and PIK3CA genes in urachal carcinoma: Occurrence and prognostic significance. *Oncotarget.* 2016 Jun 28;7(26):39293-39301. PMID: 27283768
744. Munbaurhal G, Seisen T, Gomez FD, Peyronnet B, Cussenot O, **Shariat SF**, Rouprêt M. Current perspectives of sentinel lymph node dissection at the time of radical surgery for prostate cancer. *Cancer Treat Rev.* 2016 Oct 6;50:228-239. PMID: 27768918
745. Bianchi L, Gandaglia G, Fossati N, Suardi N, Moschini M, Cucchiara V, Bianchi M, Damiano R, Schiavina R, **Shariat SF**, Montorsi F, Briganti A. Pelvic lymph node dissection in prostate cancer: indications, extent and tailored approaches. *Urologia.* 2015 Dec 16:0. PMID: 26689534
746. Sevcenco S, Spick C, Helbich TH, Heinz G, **Shariat SF**, Klingler HC, Rauchenwald M, Baltzer PA. Malignancy rates and diagnostic performance of the Bosniak classification for the diagnosis of cystic renal lesions in computed tomography - a systematic review and meta-analysis. *Eur Radiol.* 2016 Oct 19.
747. Schiffmann J, Sun M, Gandaglia G, Tian Z, Popa I, Larcher A, Briganti A, McCormack M, **Shariat SF**, Montorsi F, Graefen M, Saad F, Karakiewicz PI. Use of adjuvant chemotherapy in radical cystectomy patients aged >65 years: a population-based study from the surveillance epidemiology and end results (SEER)- medicare database. *Minerva Urol Nefrol.* 2016 Oct 12. PMID: 27733752
748. Wirth GJ, Haitel A, Moschini M, Soria F, Klatte T, Hassler MR, Bensalah K, Briganti A, Karam JA, Lotan Y, Margulis V, Raman JD, Remzi M, Rioux-Leclercq N, Robinson BD, Rouprêt M, Wood CG, **Shariat SF**. Androgen receptor expression is associated with adverse pathological features in ureteral but not in pelvicalyceal urothelial carcinomas of the upper urinary tract. *World J Urol.* 2016 Oct 11. PMID: 27730305
749. Moschini M, Luzzago S, Zaffuto E, Dell'Oglio P, Gandaglia G, Mattei A, Damiano R, Soria F, Klatte T, **Shariat SF**, Salonia A, Montorsi F, Briganti A, Gallina A, Colombo R. The surgical management of patients with clinical stage T4 bladder cancer: A single institution experience. *Eur J Surg Oncol.* 2016 Sep 28. PMID: 27720312

750. Grubmüller B, Baum RP, Capasso E, Singh A, Ahmadi Y, Knoll P, Floth A, Righi S, Zandieh S, Meleddu C, **Shariat SF**, Klingler HC, Mirzaei S. 64Cu-PSMA-617 PET/CT Imaging of Prostate Adenocarcinoma: First In-Human Studies. *Cancer Biother Radiopharm*. 2016 Oct 7. PMID: 27715146
751. Krabbe LM, Woldu SL, **Shariat SF**, Lotan Y. Improving diagnostic molecular tests to monitor urothelial carcinoma recurrence. *Expert Rev Mol Diagn*. 2016 Oct 4. PMID: 27696932
752. Leyh-Bannurah SR, Gazdovich S, Budäus L, Zaffuto E, Dell'Oglio P, Briganti A, Abdollah F, Montorsi F, Schiffmann J, Menon M, **Shariat SF**, Fisch M, Chun F, Graefen M, Karakiewicz PI. Population-based external validation of the updated 2012 Partin tables in contemporary North American prostate cancer patients. *Prostate*. 2016 Sep 29. PMID: 27683103
753. Rieken M, Bachmann A, **Shariat SF**. Long-term results after prostate vaporisation: GreenLight™ laser vaporisation of the prostate and electrovaporisation. *Urologe A*. 2016 Sep 28. PMID: 27680971
754. Krabbe LM, Eminaga O, **Shariat SF**, Hutchinson RC, Lotan Y, Sagalowsky AI, Raman JD, Wood CG, Weizer AZ, Roscigno M, Montorsi F, Bolenz C, Novara G, Kikuchi E, Fajkovic H, Rapoport LM, Glybochko PV, Zigeuner R, Remzi M, Bensalah K, Kassouf W, Margulis V. Post-operative nomogram for relapse-free survival in patients with high-grade upper tract urothelial carcinoma. *J Urol*. 2016 Sep 23. PMID: 27670916
755. Zaffuto E, Gandaglia G, Fossati N, Dell'Oglio P, Moschini M, Cucchiara V, Suardi N, Mirone V, Bandini M, **Shariat SF**, Karakiewicz PI, Montorsi F, Briganti A. Early post-operative radiotherapy is associated with worse functional outcomes in prostate cancer patients. *J Urol*. 2016 Sep 23. PMID: 27670915
756. Soria F, Moschini M, Haitel A, Wirth GJ, Gust KM, Briganti A, Rouprêt M, Klatte T, Hassler MR, Karakiewicz PI, **Shariat SF**. The effect of HER2 status on oncological outcomes of patients with invasive bladder cancer. *Urol Oncol*. 2016 Sep 21. PMID: 27665356
757. Redrow GP, Guo CC, Brausi MA, Coleman JA, Fernandez MI, Kassouf W, Keeley FX Jr, Margulis V, Raman JD, Roupret M, **Shariat SF**, Spiess PE, Thalmann GN, Matin SF. Upper urinary tract carcinoma in situ: current knowledge, future direction. *J Urol*. 2016 Sep 21. PMID: 27664578
758. Mbeutcha A, **Shariat SF**, Rieken M, Rink M, Xylinas E, Seitz C, Lucca I, Mathieu R, Rouprêt M, Briganti A, Karakiewicz PI, Klatte T. Prognostic significance of markers of systemic inflammatory response in patients with non-muscle-invasive bladder cancer. *Urol Oncol*. 2016 Sep 16. PMID: 27646875
759. Schmitz-Dräger BJ, Kuckuck EC, Zuiverloon TC, Zwarthoff EC, Saltzman A, Srivastava A, Hudson MA, Seiler R, Todenhöfer T, Vlahou A, Grossman HB, Schoenberg MP, Sanchez-Carbayo M, Brünn LA, van Rhijn BW, Goebell PJ, Kamat AM, Roupret M, **Shariat SF**, Kiemeny LA. Microhematuria assessment an IBCN consensus-Based upon a critical review of current guidelines. *Urol Oncol*. 2016 Oct;34(10):437-51. PMID: 27641313
760. Witjes JA, Dalbagni G, Karnes RJ, **Shariat S**, Joniau S, Palou J, Serretta V, Larré S, di Stasi S, Colombo R, Babjuk M, Malmström PU, Malats N, Irani J, Baniel J, Cai T, Cha E, Ardelt P, Varkarakis J, Bartoletti R, Spahn M, Pisano F, Gontero P, Sylvester R. The efficacy of BCG TICE and BCG Connaught in a cohort of 2,099 patients with T1G3 non-muscle-invasive bladder cancer. *Urol Oncol*. 2016 Sep 14. PMID: 27639776
761. Passoni N, Gayed B, Kapur P, Sagalowsky AI, **Shariat SF**, Lotan Y. Cell-cycle markers do not improve discrimination of EORTC and CUETO risk models in predicting recurrence and

- p>progression of non-muscle-invasive high-grade bladder cancer.
- Urol Oncol*
- . 2016 Sep 13. PMID: 27637323
762. Soria F, **Shariat SF**, Lerner SP, Fritsche HM, Rink M, Kassouf W, Spiess PE, Lotan Y, Ye D, Fernández MI, Kikuchi E, Chade DC, Babjuk M, Grollman AP, Thalmann GN. Epidemiology, diagnosis, preoperative evaluation and prognostic assessment of upper-tract urothelial carcinoma (UTUC). *World J Urol*. 2016 Sep 7. PMID: 27604375
 763. Xylinas E, Hassler MR, Zhuang D, Krzywinski M, Erdem Z, Robinson BD, Elemento O, Clozel T, **Shariat SF**. An epigenomic approach to improving response to neoadjuvant cisplatin chemotherapy in bladder cancer. *Biomolecules*. 2016 Sep 2;6(3). PMID: 27598218
 764. Moschini M, Luzzago S, Cazzaniga W, Cucchiara V, Bandini M, Damiano R, Soria F, Klatte T, **Shariat SF**, Salonia A, Montorsi F, Briganti A, Colombo R, Gallina A. Effect of stage migration on bladder cancer: a slow but steady improvement in long-term survival rates after radical cystectomy in previous 25 years. *Clin Genitourin Cancer*. 2016 Aug 8. PMID: 27589904
 765. Heidenreich A, Moul JW, **Shariat S**, Karnes RJ. Role of salvage lymph node dissection in prostate cancer. *Curr Opin Urol*. 2016 Aug 31. PMID: 27584024
 766. Mager R, Daneshmand S, Evans CP, Palou J, Martínez-Salamanca JI, Master VA, McKiernan JM, Libertino JA, Haferkamp A; International Renal Cell Carcinoma-Venous Thrombus Consortium, Haferkamp A, Capitanio U, Carballido JA, Chantada V, Chromecki T, Ciano G, Daneshmand S, Evans CP, Gontero P, González J, Hohenfellner M, Huang WC, Koppie TM, Libertino JA, Espinós EL, Lorentz A, Martínez-Salamanca JI, Master VA, McKiernan JM, Montorsi F, Novara G, O'Malley P, Pahernik S, Palou J, Moreno JL, Pruthi RS, Faba OR, Russo P, Scherr DS, **Shariat SF**, Spahn M, Terrone C, Tilki D, Vázquez-Martul D, Donoso CV, Verghe D, Wallen EM, Zigeuner R. Renal cell carcinoma with inferior vena cava involvement: Prognostic effect of tumor thrombus consistency on cancer specific survival. *J Surg Oncol*. 2016 Aug 26. PMID: 27562252
 767. Moschini M, Soria F, Klatte T, Wirth GJ, Özsoy M, Gust K, Briganti A, Roupret M, Susani M, Haitel A, **Shariat SF**. Validation of preoperative risk grouping of the selection of patients most likely to benefit from neoadjuvant chemotherapy before radical cystectomy. *Clin Genitourin Cancer*. 2016 Jul 22. PMID: 27530435
 768. Mathieu R, Korn SM, Bensalah K, Kramer G, **Shariat SF**. Cytoreductive radical prostatectomy in metastatic prostate cancer: Does it really make sense? *World J Urol*. 2016 Aug 8. PMID: 27502935
 769. Fiorino C, Broggi S, Fossati N, Cozzarini C, Goldner G, Wiegel T, Hinkelbein W, Karnes RJ, Boorjian SA, Hausermans K, Joniau S, Palorini F, **Shariat S**, Montorsi F, Van Poppel H, Di Muzio N, Calandrino R, Briganti A. Predicting the 5-Year risk of biochemical relapse after postprostatectomy radiation therapy in $\geq$ pT2, pN0 patients with a comprehensive tumor control probability Model. *Int J Radiat Oncol Biol Phys*. 2016 Jun 18. PMID: 27497691
 770. Schiffmann J, Larcher A, Sun M, Tian Z, Berdugo J, Leva I, Widmer H, Lattouf JB, Zorn K, Haese A, **Shariat SF**, Saad F, Montorsi F, Graefen M, Karakiewicz PI. Differences in patient characteristics among men choosing open or robot-assisted radical prostatectomy in contemporary practice - analysis of Surveillance, Epidemiology, and End Results database. *Urol Int*. 2016 Aug 4. PMID: 27486887
 771. Fossati N, Karnes RJ, Boorjian SA, Moschini M, Morlacco A, Bossi A, Seisen T, Cozzarini C, Fiorino C, Chiorda BN, Gandaglia G, Dell'Oglio P, Joniau S, Tosco L, **Shariat S**, Goldner G, Hinkelbein W, Bartkowiak D, Hausermans K, Tombal B, Montorsi F, Van Poppel H, Wiegel T, Briganti A. Long-term impact of adjuvant versus early salvage radiation therapy in pT3N0 prostate

- cancer patients treated with radical prostatectomy: results from a multi-institutional series. *Eur Urol*. 2016 Jul 30. PMID: 27484843
772. Dell'Oglio P, Boehm K, Trudeau V, Tian Z, Larcher A, Leyh-Bannurah SR, Moschini M, Capitanio U, **Shariat SF**, Briganti A, Montorsi F, Saad F, Karakiewicz PI. Survival after conservative management versus external beam radiation therapy in elderly patients with localized prostate cancer. *Int J Radiat Oncol Biol Phys*. 2016 May 10. PMID: 27478167
773. Seisen T, Peyronnet B, Dominguez-Escrig JL, Bruins HM, Yuan CY, Babjuk M, Böhle A, Burger M, Compérat EM, Cowan NC, Kaasinen E, Palou J, van Rhijn BW, Sylvester RJ, Zigeuner R, **Shariat SF**, Roupřet M. Oncologic outcomes of kidney-sparing surgery versus radical nephroureterectomy for upper tract urothelial carcinoma: a systematic review by the eau non-muscle invasive bladder cancer guidelines panel. *Eur Urol*. 2016 Jul 28. PMID: 27477528
774. Moschini M, Gandaglia G, Fossati N, Dell'Oglio P, Cucchiara V, Luzzago S, Zaffuto E, Suardi N, Damiano R, **Shariat SF**, Montorsi F, Briganti A. Incidence and predictors of 30-day readmission after robot-assisted radical prostatectomy. *Clin Genitourin Cancer*. 2016 Jun 29. PMID: 27452733
775. Mathieu R, Lucca I, Roupřet M, Briganti A, **Shariat SF**. The prognostic role of lymphovascular invasion in urothelial carcinoma of the bladder. *Nat Rev Urol*. 2016 Jul 19. PMID: 27431340
776. Peyronnet B, Seisen T, Oger E, Vaessen C, Grassano Y, Benoit T, Carrouget J, Pradère B, Khene Z, Giwerc A, Mathieu R, Beauval JB, Nouhaud FX, Bigot P, Doumerc N, Bernhard JC, Mejean A, Patard JJ, **Shariat SF**, Roupřet M, Bensalah K; French Committee of Urologic Oncology (CCAFU). Comparison of 1800 robotic and open partial nephrectomies for renal tumors. *Ann Surg Oncol*. 2016 Jul 13. PMID: 27411552
777. Passoni NM, **Shariat SF**, Bagrodia A, Francis F, Rachakonda V, Xylinas E, Kapur P, Sagalowsky AI, Lotan Y. Concordance in biomarker status between bladder tumors at time of transurethral resection and subsequent radical cystectomy: results of a 5-year prospective study. *BJ Cancer*. 2016 Jan 7;2(1):91-99. PMID: 27376130
778. Schiffmann J, Sun M, Gandaglia G, Tian Z, Popa I, Larcher A, Meskawi M, Briganti A, McCormack M, **Shariat SF**, Montorsi F, Graefen M, Saad F, Karakiewicz PI. Suboptimal use of neoadjuvant chemotherapy in radical cystectomy patients: a population-based study. *Can Urol Assoc J*. 2016 Mar-Apr;10(3-4):E82-6. PMID: 27330584
779. Seisen T, Roupřet M, Gomez F, Malouf GG, **Shariat SF**, Peyronnet B, Spano JP, Cancel-Tassin G, Cussenot O. A comprehensive review of genomic landscape, biomarkers and treatment sequencing in castration-resistant prostate cancer. *Cancer Treat Rev*. 2016 Jun 15;48:25-33. PMID: 27327958
780. Babjuk M, Böhle A, Burger M, Capoun O, Cohen D, Compérat EM, Hernández V, Kaasinen E, Palou J, Roupřet M, van Rhijn BW, **Shariat SF**, Soukup V, Sylvester RJ, Zigeuner R. eau guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2016. *Eur Urol*. 2016 Jun 17. PMID: 27324428
781. Raman JD, Lin YK, **Shariat SF**, Krabbe LM, Margulis V, Arnouk A, Lallas CD, Trabulsi EJ, Drouin SJ, Roupřet M, Bozzini G, Colin P, Peyronnet B, Bensalah K, Bailey K, Canes D, Klatte T. Preoperative nomogram to predict likelihood of complications following radical nephroureterectomy. *BJU Int*. 2016 Jun 20. PMID: 27322735
782. Lucca I, Hofbauer SL, Leitner CV, de Martino M, Özsoy M, Susani M, **Shariat SF**, Klatte T. Development of a preoperative nomogram incorporating biomarkers of systemic inflammatory response to predict non-organ-confined urothelial carcinoma of the bladder at radical cystectomy. *Urology*. 2016 Jun 14. PMID: 27316373

783. May M, Fritsche HM, Vetterlein MW, Bastian PJ, Gierth M, Nuhn P, Aziz A, Fisch M, Stief CG, Hohenfellner M, Wirth MP, Novotny V, Hakenberg OW, Noldus J, Gilfrich C, Bolenz C, Burger M, Brookman-May SD; **Shariat SF**; PROMETRICS 2011 Research Group. Impact of photodynamic diagnosis-assisted transurethral resection of bladder tumors on the prognostic outcome after radical cystectomy: results from PROMETRICS 2011. *World J Urol.* 2016 Jun 14. PMID: 27300339
784. Leyh-Bannurah SR, Dell'Oglio P, Tian Z, Schiffmann J, **Shariat SF**, Suardi N, Francesco M, Alberto B, Heinzer H, Huland H, Graefen M, Budäus L, Karakiewicz PI. A proposal of a new nomogram for predicting upstaging in contemporary D'Amico low-risk prostate cancer patients. *World J Urol.* 2016 Jun 11. PMID: 27289238
785. Módos O, Reis H, Niedworok C, Rübber H, Szendrői A, Szász MA, Tímár J, Baghy K, Kovalszky I, Golabek T, Chlosta P, Okon K, Peyronnet B, Mathieu R, **Shariat SF**, Hollósi P, Nyirády P, Szarvas T. Mutations of KRAS, NRAS, BRAF, EGFR, and PIK3CA genes in urachal carcinoma - occurrence and prognostic significance. *Oncotarget.* 2016 Jun 5. PMID: 27283768
786. Soria F, Moschini M, Haitel A, Wirth GJ, Karam JA, Wood CG, Rouprêt M, Margulis V, Karakiewicz PI, Briganti A, Raman JD, Kammerer-Jacquet SF, Mathieu R, Bensalah K, Lotan Y, Özsoy M, Remzi M, Gust KM, **Shariat SF**. HER2 overexpression is associated with worse outcomes in patients with upper tract urothelial carcinoma (UTUC). *World J Urol.* 2016 Jun 7. PMID: 27272502
787. Trudeau V, Karakiewicz PI, Boehm K, Dell'Oglio P, Tian Z, Briganti A, **Shariat SF**, Valiquette L, Bhojani N. The effect of obesity on perioperative outcomes following percutaneous nephrolithotomy. *J Endourol.* 2016 Jun 2. PMID: 27257037
788. Raman JD, Warrick JI, Caruso C, Yang Z, Shuman L, Bruggeman RD, **Shariat S**, Karam JA, Wood C, Weizer AZ, Remzi M, Haitel A, Bensalah K, Rioux-Leclercq N, Bolenz C, Roscigno M, Krabbe LM, Kapur P, Lotan Y, Margulis V, DeGraff DJ. Altered expression of the transcription factor forkhead box a1 (foxa1) is associated with poor prognosis in urothelial carcinoma of the upper urinary tract. *Urology.* 2016 May 20. PMID: 27215483
789. D'Andrea D, **Shariat SF**, Klatte T. Update on ablative therapies of renal tumors. *Curr Opin Urol.* 2016 May 20. PMID: 27214581
790. Vartolomei MD, Mathieu R, Margulis V, Karam JA, Rouprêt M, Lucca I, Mbeutcha A, Seitz C, Karakiewicz PI, Fajkovic H, Wood CG, Weizer AZ, Raman JD, Rioux-Leclercq N, Haitel A, Bensalah K, Rink M, Briganti A, Xylinas E, **Shariat SF**. Promising role of preoperative neutrophil-to-lymphocyte ratio in patients treated with radical nephroureterectomy. *World J Urol.* 2016 May 21. PMID: 27209168
791. Polanec S, Helbich TH, Bickel H, Pinker-Domenig K, Georg D, **Shariat SF**, Aulitzky W, Susani M, Baltzer PA. Head-to-head comparison of PI-RADS v2 and PI-RADS v1. *Eur J Radiol.* 2016 Jun;85(6):1125-31. PMID: 27161062
792. Favaretto RL, Bahadori A, Mathieu R, Haitel A, Grubmüller B, Margulis V, Karam JA, Rouprêt M, Seitz C, Karakiewicz PI, Cunha IW, Zequi SC, Wood CG, Weizer AZ, Raman JD, Remzi M, Rioux-Leclercq N, Jacquet-Kammerer S, Bensalah K, Lotan Y, Bachmann A, Rink M, Briganti A, **Shariat SF**. Prognostic role of decreased E-cadherin expression in patients with upper tract urothelial carcinoma: a multi-institutional study. *World J Urol.* 2016 Apr 29. PMID: 27129576
793. Mathieu R, Vartolomei MD, Mbeutcha A, Karakiewicz PI, Briganti A, Rouprêt M, **Shariat SF**. Urothelial cancer of the upper urinary tract: emerging biomarkers and integrative models for risk stratification. *Minerva Urol Nefrol.* 2016 Apr 28. PMID: 27124417

794. Mbeutcha A, Rouprêt M, Kamat AM, Karakiewicz PI, Lawrentschuk N, Novara G, Raman JD, Seitz C, Xylinas E, **Shariat SF**. Prognostic factors and predictive tools for upper tract urothelial carcinoma: a systematic review. *World J Urol*. 2016 Apr 21. PMID: 27101100
795. Pouessel D, Neuzillet Y, Mertens LS, van der Heijden MS, de Jong J, Sanders J, Peters D, Leroy K, Manceau A, Maille P, Soyeux P, Moktefi A, Semprez F, Vordos D, de la Taille A, Hurst CD, Tomlinson DC, Harnden P, Bostrom PJ, Mirtti T, Horenblas S, Lorient Y, Houédé N, Chevreau C, Beuzeboc P, **Shariat SF**, Sagalowsky AI, Ashfaq R, Burger M, Jewett MA, Zlotta AR, Broeks A, Bapat B, Knowles MA, Lotan Y, van der Kwast TH, Culine S, Allory Y, van Rhijn BW. Tumor Heterogeneity of Fibroblast Growth Factor Receptor 3 (FGFR3) Mutations in Invasive Bladder Cancer: Implications for Peri-Operative anti-FGFR3 Treatment. *Ann Oncol*. 2016 Apr 18. PMID: 27091807
796. Gakis G, Schubert T, Alemozaffar M, Bellmunt J, Bochner BH, Boorjian SA, Daneshmand S, Huang WC, Kondo T, Konety BR, Laguna MP, Martin SF, Siefker-Radtke AO, **Shariat SF**, Stenzl A. Update of the ICUD-SIU consultation on upper tract urothelial carcinoma 2016: treatment of localized high-risk disease. *World J Urol*. 2016 Apr 4. PMID: 27043218
797. Bishr M, Boehm K, Trudeau V, Tian Z, Dell'Oglio P, Schiffmann J, Jeldres C, Sun M, **Shariat SF**, **Graefen** M, Saad F, Karakiewicz PI. Medical management of benign prostatic hyperplasia: Results from a population-based study. *Can Urol Assoc J*. 2016 Jan-Feb;10(1-2):55-9. PMID: 26977208
798. Fajkovic H, Mathieu R, Lucca I, Hiess M, Hübner N, Al Awamlh BA, Lee R, Briganti A, Karakiewicz P, Lotan Y, Roupret M, Rink M, Kluth L, Loidl W, Seitz C, Klatte T, Kramer G, Susani M, **Shariat SF**. Validation of lymphovascular invasion is an independent prognostic factor for biochemical recurrence after radical prostatectomy. *Urol Oncol*. 2016 Mar 10. PMID: 26973136
799. Dell'Oglio P, Abou-Haidar H, Leyh-Bannurah SR, Tian Z, Larcher A, Gandaglia G, Fossati N, **Shariat SF**, Capitanio U, Briganti A, Montorsi F, Graefen M, Saad F, Karakiewicz PI. Assessment of the rate of adherence to international guidelines for androgen deprivation therapy with external-beam radiation therapy: a population-based study. *Eur Urol*. 2016 Mar 4. PMID: 26951945
800. Mathieu R, Lucca I, Vartolomei MD, MBeutcha A, Klatte T, Seitz C, Karakiewicz PI, Fajkovic H, Sun M, Lotan Y, Montorsi F, Briganti A, Rouprêt M, Margulis V, Rink M, Rieken M, Kenner L, Susani M, Wolfgang L, **Shariat SF**. Role of Survivin expression in predicting biochemical recurrence after radical prostatectomy: a multi-institutional study. *BJU Int*. 2016 Mar 4. PMID: 26940243
801. Moschini M, Karnes RJ, Sharma V, Gandaglia G, Fossati N, Dell'Oglio P, Cucchiara V, Capogrosso P, **Shariat SF**, Damiano R, Salonia A, Montorsi F, Briganti A, Gallina A, Colombo R. Patterns and prognostic significance of clinical recurrences after radical cystectomy for bladder cancer: A 20-year single center experience. *Eur J Surg Oncol*. 2016 Feb 18. PMID: 26927300
802. Trudeau V, Larcher A, Sun M, Boehm K, Dell'Oglio P, Sosa J, Tian Z, Fossati N, Briganti A, **Shariat SF**, Karakiewicz PI. Comparison of oncologic outcomes between sarcomatoid and clear cell renal cell carcinoma. *World J Urol*. 2016 Feb 22. PubMed PMID: 26902877.
803. Wolff I, May M, Hoschke B, Zigeuner R, Cindolo L, Hutterer G, Schips L, De Cobelli O, Rocco B, De Nunzio C, Tubaro A, Coman I, Feciche B, Truss M, Dalpiaz O, Figenschau RS, Madison K, Sánchez-Chapado M, Santiago Martin MD, Salzano L, Lotrecchiano G, **Shariat SF**, Hohenfellner M, Waidelich R, Stief C, Miller K, Pahernik S, Brookman-May S; Members of the CORONA Project and the European Association of Urology (EAU) Young Academic Urologists (YAU) Renal Cancer Group. Do we need new high-risk criteria for surgically treated renal cancer patients to improve the outcome of future clinical trials in the adjuvant setting? Results of a comprehensive

- analysis based on the multicenter CORONA database. *Eur J Surg Oncol*. 2016 Jan 22. PubMed PMID: 26899942.
804. Fajkovic H, **Shariat SF**, Klatte T, Vartolomei MD, Lucca I, Mbeutcha A, Rouprêt M, Briganti A, Karakiewicz PI, Margulis V, Rink M, Remzi M, Seitz C, Bensalah K, Mathieu R. Impact of smoking status on survival after cytoreductive nephrectomy for metastatic renal cell carcinoma. *World J Urol*. 2016 Feb 15. PubMed PMID: 26879416.
805. Gandaglia G, Lista G, Fossati N, Suardi N, Gallina A, Moschini M, Bianchi L, Rossi MS, Schiavina R, **Shariat SF**, Salonia A, Montorsi F, Briganti A. Non-surgically related causes of erectile dysfunction after bilateral nerve-sparing radical prostatectomy. *Prostate Cancer Prostatic Dis*. 2016 Feb 9. PubMed PMID: 26857023.
806. Moschini M, Bianchi M, Rossi MS, Dell'Oglio P, Gandaglia G, Fossati N, Mattei A, Damiano R, **Shariat SF**, Salonia A, Montorsi F, Briganti A, Colombo R, Gallina A. Timing of blood transfusion and not ABO blood type is associated with survival in patients treated with radical cystectomy for nonmetastatic bladder cancer: Results from a single high-volume institution. *Urol Oncol*. 2016 Feb 2. PubMed PMID: 26850780.
807. Leitner CV, Ederer IA, de Martino M, Hofbauer SL, Lucca I, Mbeutcha A, Mathieu R, Haitel A, Susani M, **Shariat SF**, Klatte T. Dynamic prognostication using conditional recurrence and progression estimates for patients with non-muscle invasive bladder cancer. *J Urol*. 2016 Jan 30. PubMed PMID: 26835832.
808. Mathieu R, Bensalah K, Lucca I, Mbeutcha A, Rouprêt M, **Shariat SF**. Upper urinary tract disease: what we know today and unmet needs. *Transl Androl Urol*. 2015 Jun;4(3):261-72. PubMed Central PMCID: PMC4708228.
809. Gandaglia G, Suardi N, Cucchiara V, Bianchi M, **Shariat SF**, Roupret M, Salonia A, Montorsi F, Briganti A. Penile rehabilitation after radical prostatectomy: does it work? *Transl Androl Urol*. 2015 Apr;4(2):110-23. PubMed PMID: 26816818; PubMed Central PMCID: PMC4708129.
810. Sevcenco S, Mathieu R, Baltzer P, Klatte T, Fajkovic H, Seitz C, Karakiewicz PI, Rouprêt M, Rink M, Kluth L, Trinh QD, Loidl W, Briganti A, Scherr DS, **Shariat SF**. The prognostic role of preoperative serum C-reactive protein in predicting the biochemical recurrence in patients treated with radical prostatectomy. *Prostate Cancer Prostatic Dis*. 2016 Jan 26. PubMed PMID: 26810014.
811. Seisen T, **Shariat SF**, Cussenot O, Peyronnet B, Renard-Penna R, Colin P, Rouprêt M. Contemporary role of lymph node dissection at the time of radical nephroureterectomy for upper tract urothelial carcinoma. *World J Urol*. 2016 Jan 25. PubMed PMID: 26809456.
812. Moschini M, Gandaglia G, Dell'Oglio P, Fossati N, Cucchiara V, Burgio G, Mattei A, Damiano R, **Shariat SF**, Salonia A, Montorsi F, Briganti A, Colombo R, Gallina A. Incidence and Predictors of 30-Day Readmission in Patients Treated With Radical Cystectomy: A Single Center European Experience. *Clin Genitourin Cancer*. 2015 Dec 23. PubMed PMID: 26797584.
813. Grubmueller B, Seitz C, **Shariat SF**. The treatment of muscle-invasive bladder cancer in geriatric patients. *Curr Opin Urol*. 2016 Mar;26(2):160-4. PubMed PMID: 26765044.
814. Bianchi L, Gandaglia G, Fossati N, Suardi N, Moschini M, Cucchiara V, Bianchi M, Damiano R, Schiavina R, **Shariat SF**, Montorsi F, Briganti A. Pelvic lymph node dissection in prostate cancer: indications, extent and tailored approaches. *Urologia*. 2015 Dec 16:0. PubMed PMID: 26689534.
815. Moschini M, Karnes RJ, Gandaglia G, Luzzago S, Dell'Oglio P, Rossi MS, di Trapani E, La Croce G, Damiano R, Salonia A, **Shariat SF**, Montorsi F, Briganti A, Gallina A, Colombo R. Preoperative Favorable Characteristics in Bladder Cancer Patients Cannot Substitute the Necessity

- of Extended Lymphadenectomy During Radical Cystectomy: A Sensitivity Curve Analysis. *Urology*. 2015 Dec 9. PubMed PMID: 26683751.
816. Seisen T, Nison L, Remzi M, Klatte T, Mathieu R, Lucca I, Bozzini G, Capitanio U, Novara G, Cussenot O, Comp  rat E, Renard-Penna R, Peyronnet B, Merseburger AS, Fritsche HM, Hora M, **Shariat SF**, Colin P, Roupr  t M. Oncologic Outcomes of Kidney Sparing Surgery versus Radical Nephroureterectomy for the Elective Treatment of Clinically Organ Confined Upper Tract Urothelial Carcinoma of the Distal Ureter. *J Urol*. 2015 Nov 21. PubMed PMID: 26612196.
817. Mbeutcha A, Lucca I, Mathieu R, Lotan Y, **Shariat SF**. Current Status of Urinary Biomarkers for Detection and Surveillance of Bladder Cancer. *Urol Clin North Am*. 2016 Feb;43(1):47-62. PubMed PMID: 26614028.
818. Mbeutcha A, Lucca I, Margulis V, Karam JA, Wood CG, de Martino M, Mathieu R, Haitel A, Xylinas E, Kluth L, Roupr  t M, Karakiewicz PI, Briganti A, Rink M, Rieken M, Weizer AZ, Raman JD, Rioux-Leclecq N, Bolenz C, Bensalah K, Lotan Y, Seitz C, Remzi M, **Shariat SF**, Klatte T. Prognostic role of ERCC1 protein expression in upper tract urothelial carcinoma following radical nephroureterectomy with curative intent. *World J Urol*. 2015 Dec 11. PubMed PMID: 26658888.
819. Lotan Y, Karam JA, **Shariat SF**, Gupta A, Roupret M, Bensalah K, Margulis V. Renal-cell carcinoma risk estimates based on participants in the prostate, lung, colorectal, and ovarian cancer screening trial and national lung screening trial. *Urol Oncol*. 2015 Nov 18. PubMed PMID: 26602092.
820. Hofbauer SL, **Shariat SF**, Chade DC, Sarkis AS, Ribeiro-Filho LA, Nahas WC, Klatte T. The Moreau Strain of Bacillus Calmette-Guerin (BCG) for High-Risk Non-Muscle Invasive Bladder Cancer: An Alternative during Worldwide BCG Shortage? *Urol Int*. 2015 Nov 11. PMID: 265557
821. Rieken M, Bachmann A, **Shariat SF**. Long-term follow-up data more than 5 years after surgical management of benign prostate obstruction: who stands the test of time? *Curr Opin Urol*. 2015 Nov 9. PMID: 2655569
822. Moschini M, Fossati N, Abdollah F, Gandaglia G, Cucchiar   V, Dell'Oglio P, Luzzago S, **Shariat SF**, Deh   F, Salonia A, Montorsi F, Briganti A. Determinants of long-term survival of patients with locally advanced prostate cancer: the role of extensive pelvic lymph node dissection. *Prostate Cancer Prostatic Dis*. 2015 Nov 10. PMID: 26553644
823. Nison L, Colin P, Remzi M, **Shariat S**, Klatte T, Yakoubi R, Bozzini G, Capitanio U, Babjuk M, Merseburger A, Cha E, Fritsche H, Novara G, Montorsi F, Hora M, Roupret M. R  sultats oncologiques du traitement des TVES  pT2 de l'uret  re pelvien par n  phro-ur  t  rectomie, r  section segmentaire et chirurgie endoscopique : r  sultats d'une   tude multicentrique europ  enne. *Prog Urol*. 2015 Nov;25(13):807. PMID: 26544377
824. Seisen T, Granger B, Colin P, L  on P, Utard G, Renard Penna R, Comp  rat E, Mozer P, Cussenot O, **Shariat S**, Roupr  t M. Revue syst  matique de la litt  rature et m  ta-analyse des facteurs de risque de r  cidive v  sicale apr  s n  phro-ur  t  rectomie totale pour le traitement d'une tumeur de la voie excr  trice urinaire sup  rieure. *Prog Urol*. 2015 Nov;25(13):805. PMID: 26544373
825. Riccio R, Aziz A, Rink M, Peyromaure M, **Shariat S**, May M, Xylinas E. Optimisation de la transcription des r  sultats de la cystectomie totale : vers la d  finition d'un Trifecta et d'un Pentafecta. *Prog Urol*. 2015 Nov;25(13):770. PMID: 26544307
826. Xylinas E, Huillard O, Peyromaure M, Black P, **Shariat SF**. L'intervalle entre le diagnostic et la cystectomie totale n'a pas d'impact sur le devenir oncologique des patients trait  s par chimioth  rapie n  oadjuvante. *Prog Urol*. 2015 Nov;25(13):767. PMID: 26544301

827. Mbeutcha A, Lucca I, De Martino M, Mathieu R, Rieken M, Xylinas E, Kluth L, Crivelli J, Lotan Y, **Shariat S**, Klatte T, Karakiewicz P. Le rapport neutrophiles/lymphocytes est un facteur prédictif indépendant de récurrence et de progression dans les tumeurs de vessie non infiltrantes. *Prog Urol*. 2015 Nov;25(13):759-60. PMID: 26544285
828. Mathieu R, Lucca I, Mbeutcha A, Seitz C, Karakiewicz P, Sun M, Montorsi F, Briganti A, Rouprêt M, Robinson B, Xylinas E, **Shariat S**. Valeur pronostique de Caveolin-1 dans le cancer de prostate : une étude multicentrique internationale. *Prog Urol*. 2015 Nov;25(13):741-2. PMID: 26544248
829. Mathieu R, Mbeutcha A, Lucca I, Briganti A, Karakiewicz P, Rouprêt M, Seitz C, Klatte T, **Shariat SF**. L'obésité est associée à la récurrence biologique après prostatectomie radicale : une étude multicentrique internationale. *Prog Urol*. 2015 Nov;25(13):740. PMID: 26544245
830. Trudeau V, Larcher A, Boehm K, Dell'Oglio P, Sun M, Tian Z, Briganti A, **Shariat SF**, Jeldres C, Karakiewicz PI. Comparison of Postoperative Complications and Mortality Between Laparoscopic and Percutaneous Local Tumor Ablation for T1a Renal Cell Carcinoma: a Population-Based Study. *Urology*. 2015 Oct 26. PMID: 26514977
831. Rink M, Soave A, Dahlem R, Aziz A, Al-Sayed F, Peine S, Engel O, Kluth LA, Stenzl A, Burger M, **Shariat SF**, Fisch M, Fritsche HM, Gakis G. Impact of Perioperative Allogenic Blood Transfusion on Survival After Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma. *Clin Genitourin Cancer*. 2015 Oct 20. PMID: 26506908
832. Fossati N, Karnes RJ, Cozzarini C, Fiorino C, Gandaglia G, Joniau S, Boorjian SA, Goldner G, Hinkelbein W, Haustermans K, Tombal B, **Shariat SF**, Karakiewicz PI, Montorsi F, Van Poppel H, Wiegel T, Briganti A. Assessing the Optimal Timing for Early Salvage Radiation Therapy in Patients with Prostate-specific Antigen Rise After Radical Prostatectomy. *Eur Urol*. 2015 Oct 20. PMID: 26497924
833. Lucca I, Klatte T, Fajkovic H, de Martino M, **Shariat SF**. Gender differences in incidence and outcomes of urothelial and kidney cancer. *Nat Rev Urol*. 2015 Oct 20. PMID: 2648157
834. Gontero P, Sylvester R, Pisano F, Joniau S, Oderda M, Serretta V, Larre S, Stasi SD, Van Rhijn B, Witjes AJ, Grotenhuis AJ, Colombo R, Briganti A, Babjuk M, Soukup V, Malmstrom PU, Irani J, Malats N, Baniel J, Mano R, Cai T, Cha EK, Ardelt P, Vakarakis J, Bartoletti R, Dalbagni G, **Shariat SF**, Xylinas E, Karnes RJ, Palou J. The impact of re-TUR on clinical outcomes in a large multi-centre cohort of T1-HG/G3 patients treated with BCG. *BJU Int*. 2015 Oct 15. PMID: 26469362
835. Xylinas E, Rieken M, **Shariat S**. Comparaison des tables de l'EORTC et de la nouvelle classification simplifiée EAU pour la prédiction de la récurrence tumorale et de la progression des TVNIM. *Prog Urol*. 2014 Nov;24(13):846-7. PMID: 26461666
836. Seisen T, Colin P, Hupertan V, Léon P, Bozzini G, Nison L, Phé V, Rozet F, **Shariat S**, Cussenot O, Rouprêt M. Validation externe du nomogramme prédictif de la récurrence vésicale après néphro-urétérectomie totale pour le traitement des tumeurs de la voie excrétrice urinaire supérieure. *Prog Urol*. 2014 Nov;24(13):845-6. PMID: 26461665
837. Xylinas E, Rink M, Rouprêt M, **Shariat SF**. Impact de la consommation tabagique sur la récurrence vésicale après néphro-urétérectomie totale pour tumeur de la voie excrétrice supérieure. *Prog Urol*. 2014 Nov;24(13):845. PMID: 26461663
838. Neuzillet Y, Mertens L, **Shariat S**, Bostrom P, Mirtti T, Sagalowsky A, Ashfaq R, Broeks A, Van der Heijden M, Peters D, Curial C, De Jong J, Horenblas S, Hurst C, Tomlinson D, Knowles M, Bapat B, Jewett M, Zlotta A, Sanders J, Lotan Y, Van der Kwast T, Van Rhijn B. Le Fibroblast Growth Factor Receptor 3 (FGFR3), cible thérapeutique pour le traitement personnalisé du cancer

- de la vessie : validation anatomo-pathologique du concept. *Prog Urol.* 2014 Nov;24(13):806-7. PMID: 26461579
839. Vom Dorp F, Tschirdewahn S, Niedworok C, Reis H, Krause H, Kempkensteffen C, Busch J, Kramer G, **Shariat SF**, Nyirady P, Rübber H, Szarvas T. Circulating and tissue expression levels of YKL-40 in renal cell cancer. *J Urol.* 2015 Oct 7. PMID: 26454102
840. Lucca I, Klatte T, Fajkovic H, de Martino M, **Shariat SF**. Gender differences in incidence and outcomes of urothelial and kidney cancer. *Nat Rev Urol.* 2015 Oct 5;12(10):585-92. PMID: 26436686
841. Suardi N, Dell'Oglio P, Gallina A, Gandaglia G, Buffi N, Moschini M, Fossati N, Lughezzani G, Karakiewicz PI, Freschi M, Lucianò R, **Shariat SF**, Guazzoni G, Gaboardi F, Montorsi F, Briganti A. Evaluation of positive surgical margins in patients undergoing robot-assisted and open radical prostatectomy according to preoperative risk groups. *Urol Oncol.* 2015 Sep 28. PMID: 26427694
842. Polanec SH, Pinker-Domenig K, Brader P, Georg D, **Shariat SF**, Spick C, Susani M, Helbich TH, Baltzer PA. Multiparametric MRI of the prostate at 3 T: limited value of 3D 1H-MR spectroscopy as a fourth parameter. *World J Urol.* 2015 Sep 25. PMID: 26407583
843. Larcher A, Trudeau V, Sun M, Boehm K, Meskawi M, Tian Z, Fossati N, Dell'Oglio P, Capitanio U, Briganti A, **Shariat SF**, Montorsi F, Karakiewicz PI. Population-based assessment of cancer specific mortality after local tumour ablation or observation for kidney cancer: a competing risks analysis. *BJU Int.* 2015 Sep 19. PMID: 26384713
844. Castells X, Karanović S, Ardin M, Tomić K, Xylinas E, Durand G, Villar S, Forey N, Le Calvez-Kelm F, Voegelé C, Karlović K, Mišić M, Dittrich D, Dolgalev I, McKay JD, **Shariat SF**, Sidorenko VS, Fernandes A, Heguy A, Dickman KG, Olivier M, Grollman AP, Jelaković B, Zavadil J. Low-coverage exome sequencing screen in formalin-fixed paraffin-embedded tumors reveals evidence of exposure to carcinogenic aristolochic acid. *Cancer Epidemiol Biomarkers Prev.* 2015 Sep 17. PMID: 26383547
845. Grubmueller B, Rouprêt M, Briganti A, **Shariat SF**. The use of biomarkers for bladder cancer diagnosis and surveillance. *Mini Rev Med Chem.* 2015 Sep 9. PMID: 26349498
846. Dobruch J, Daneshmand S, Fisch M, Lotan Y, Noon AP, Resnick MJ, **Shariat SF**, Zlotta AR, Boorjian SA. Gender and Bladder Cancer: A Collaborative Review of Etiology, Biology, and Outcomes. *Eur Urol.* 2015 Sep 4. PMID: 26346676
847. Brooks M, Godoy G, Sun M, **Shariat SF**, Amiel GE, Lerner SP. External Validation of Bladder Cancer Predictive Nomograms for Recurrence, Cancer-Free Survival, and Overall Survival Following Radical Cystectomy. *J Urol.* 2015 Sep 4. PMID: 26343350
848. de Martino M, Taus C, Lucca I, Hofbauer SL, Haitel A, **Shariat SF**, Klatte T. Association of human telomerase reverse transcriptase gene polymorphisms, serum levels, and telomere length with renal cell carcinoma risk and pathology. *Mol Carcinog.* 2015 Aug 21. PMID: 26294352
849. Leisser A, Pruscha K, Ubl P, Wadsak W, Mayerhöfer M, Mitterhauser M, Hacker M, Kramer G, **Shariat S**, Karanikas G, Hartenbach M, Haug AR. Evaluation of fatty acid synthase in prostate cancer recurrence: SUV of [11 C] acetate PET as a prognostic marker. *Prostate.* 2015 Aug 18. PMID: 26282590
850. Veneziano D, Minervini A, Beatty J, Fornara P, Gozen A, Greco F, Langenhuijsen JF, Lunelli L, Overgaauw D, Rassweiler J, Rocco B, Salas RS, **Shariat S**, Sweet RM, Simone G, Springer C, Tuccio A, Van Cleynebreugel B, Weibl P, Cozzupoli P. Construct, content and face validity of the

- camera handling trainer (CHT): a new E-BLUS training task for 30° laparoscope navigation skills. *World J Urol.* 2015 Aug 6. PMID: 26245746
851. Mathieu R, Klatte T, Margulis V, Karam JA, Rouprêt M, Seitz C, Karakiewicz PI, Fajkovic H, Wood CG, Weizer AZ, Raman JD, Remzi M, Rioux-Leclercq N, Haitel A, Bensalah K, Lotan Y, Rink M, Kluth LA, Scherr DS, Robinson BD, **Shariat SF**. Survivin is not an independent prognostic factor for patients with upper tract urothelial carcinoma: A multi-institutional study. *Urol Oncol.* 2015 Jul 27. PMID: 26228160
852. Mathieu R, Klatte T, Lucca I, Beutcha AM, Seitz C, Karakiewicz PI, Fajkovic H, Sun M, Lotan Y, Scherr DS, Montorsi F, Briganti A, Rouprêt M, Margulis V, Rink M, Kluth LA, Rieken M, Kenner L, Susani M, Robinson BD, Xylinas E, Loidl W, **Shariat SF**. Prognostic value of Caveolin-1 in patients treated with radical prostatectomy: a multicentric validation study. *BJU Int.* 2015 Jul 18. PMID: 26189876
853. Rouprêt M, Babjuk M, Compérat E, Zigeuner R, Sylvester RJ, Burger M, Cowan NC, Böhle A, Van Rhijn BW, Kaasinen E, Palou J, **Shariat SF**. European Association of Urology Guidelines on Upper Urinary Tract Urothelial Cell Carcinoma: 2015 Update. *Eur Urol.* 2015 Jul 15. PMID: 26188393
854. Klatte T, Seitz C, Rink M, Rouprêt M, Xylinas E, Karakiewicz P, Susani M, **Shariat SF**. ERCC1 as a prognostic and predictive biomarker for urothelial carcinoma of the bladder following radical cystectomy. *J Urol.* 2015 Jul 7. PMID: 26162296
855. de Martino M, Lucca I, Mbeutcha A, Wiener HG, Haitel A, Susani M, **Shariat SF**, Klatte T. Carbonic anhydrase IX as a diagnostic urinary marker for urothelial bladder cancer. *Eur Urol.* 2015 Oct;68(4):552-4. PMID: 26138037
856. Mathieu R, Lucca I, Klatte T, Babjuk M, **Shariat SF**. Trimodal therapy for invasive bladder cancer: is it really equal to radical cystectomy? *Curr Opin Urol.* 2015 Jun 29. PMID: 26125510
857. Rieken M, **Shariat SF**, Kluth LA, Fajkovic H, Rink M, Karakiewicz PI, Seitz C, Briganti A, Rouprêt M, Loidl W, Trinh QD, Bachmann A, Pourmand G. Association of cigarette smoking and smoking cessation with biochemical recurrence of prostate cancer in patients treated with radical prostatectomy. *Eur Urol.* 2015 Jun 3. PMID: 26050111
858. Krabbe LM, Bagrodia A, Westerman ME, Gayed BA, Haddad AQ, Sagalowsky AI, **Shariat SF**, Kapur P, Lotan Y, Margulis V. Molecular profile of urothelial carcinoma of the upper urinary tract: are pelvicalyceal and ureteral tumors different? *World J Urol.* 2015 May 20. PMID: 25991599
859. Ghoneim TP, Sjoberg DD, Lowrance W, **Shariat SF**, Savage C, Bernstein M, Russo P. Partial nephrectomy for renal tumors in solitary kidneys: postoperative renal function dynamics. *World J Urol.* 2015 May 13. PMID: 25966661
860. Youssef RF, Krabbe LM, **Shariat SF**, Lotan Y, Sagalowsky AI, Raman J, Wood CG, Weizer A, Roscigno M, Montorsi F, Bolenz C, Remzi M, Bensalah K, Kassouf W, Margulis V.: TALL score for prediction of oncological outcomes after radical nephroureterectomy for high-grade upper tract urothelial carcinoma. *World J Urol.* 2015 May 10. PMID: 25957592
861. Aziz A, Gierth M, Rink M, Schmid M, Chun FK, Dahlem R, Roghmann F, Palisaar RJ, Noldus J, Ellinger J, Müller SC, Pycha A, Martini T, Bolenz C, Moritz R, Herrmann E, Keck B, Wullich B, Mayr R, Fritsche HM, Burger M, Bastian PJ, Seitz C, Brookman-May S, Xylinas E, **Shariat SF**, Fisch M, May M; PROMETRICS 2011 Research Group. Optimizing outcome reporting after radical cystectomy for organ-confined urothelial carcinoma of the bladder using oncological trifecta and pentapecta. *World J Urol.* 2015 May 7. PMID: 25947885

862. Weibl P, **Shariat SF**, Klatte T. Partial nephrectomy driven by cavitron ultrasonic surgical aspirator under zero ischemia: a pilot study. *World J Urol.* 2015 May 3. PMID: 25935329
863. Lucca I, de Martino M, Hofbauer SL, Zamani N, **Shariat SF**, Klatte T. Comparison of the prognostic value of pretreatment measurements of systemic inflammatory response in patients undergoing curative resection of clear cell renal cell carcinoma. *World J Urol.* 2015 Apr 17. PMID: 25894368
864. Lucca I, de Martino M, Klatte T, **Shariat SF**. Novel biomarkers to predict response and prognosis in localized bladder cancer. *Urol Clin North Am.* 2015 May;42(2):225-233. PMID: 25882564
865. Ederer IA, Lucca I, Hofbauer SL, Haidinger M, Haitel A, Susani M, **Shariat SF**, Klatte T. Histopathology and prognosis of de novo bladder tumors following solid organ transplantation. *World J Urol.* 2015 Apr 10. PMID: 25860378
866. Lucca I, Leow JJ, **Shariat SF**, Chang SL. Diagnosis and Management of Upper Tract Urothelial Carcinoma. *Hematol Oncol Clin North Am.* 2015 Apr;29(2):271-288. PMID: 25836934
867. Nguyen HG, Tilki D, Dall'Era MA, Durbin-Johnson B, Carballido JA, Chandrasekar T, Chromecki T, Ciano G, Daneshmand S, Gontero P, Gonzalez J, Haferkamp A, Hohenfellner M, Huang WC, Linares Espinós E, Mandel P, Martinez-Salamanca JI, Master VA, McKiernan JM, Montorsi F, Novara G, Pahernik S, Palou J, Pruthi RS, Rodriguez-Faba O, Russo P, Scherr DS, **Shariat SF**, Spahn M, Terrone C, Vergho D, Wallen EM, Xylinas E, Zigeuner R, Libertino JA, Evans CP. Cardiopulmonary bypass (CPB) has no significant impact on survival in patients undergoing nephrectomy and level III-IV inferior vena cava thrombectomy; a multi-institutional analysis. *J Urol.* 2015 Mar 19. PMID: 25797392
868. Moschini M, Gandaglia G, Suardi N, Fossati N, Cucchiara V, Damiano R, Cantiello F, **Shariat SF**, Montorsi F, Briganti A. Importance of prostate volume in the stratification of patients with intermediate-risk prostate cancer. *Int J Urol.* 2015 Mar 17. PMID: 25783998
869. Engel O, Soave A, Peine S, Kluth LA, Schmid M, **Shariat SF**, Dahlem R, Fisch M, Rink M. The impact of the AB0 and the Rhesus blood group system on outcomes in bladder cancer patients treated with radical cystectomy. *World J Urol.* 2015 Mar 18. PMID: 25782867
870. Mork M, Hubosky SG, Roupret M, Margulis V, Raman J, Lotan Y, O'Brien T, You N, **Shariat SF**, Matin SF. Lynch Syndrome: A Primer for Urologists and Panel Recommendations. *J Urol.* 2015 Feb 21. PMID: 25711197
871. Kluth LA, Black PC, Bochner BH, Catto J, Lerner SP, Stenzl A, Sylvester R, Vickers AJ, Xylinas E, **Shariat SF**. Prognostic and Prediction Tools in Bladder Cancer: A Comprehensive Review of the Literature. *Eur Urol.* 2015 Feb 20. PMID: 25709027
872. Brookman-May SD, May M, Wolff I, Zigeuner R, Hutterer GC, Cindolo L, Schips L, De Cobelli O, Rocco B, De Nunzio C, Tubaro A, Coman I, Truss M, Dalpiaz O, Feciche B, Figenschau RS, Madison K, Sánchez-Chapado M, Del Carmen Santiago Martin M, Salzano L, Lotrecchiano G, Zastrow S, Wirth M, Sountoulides P, **Shariat S**, Waidelich R, Stief C, Gunia S; members of the CORONA Project and the European Association of Urology (EAU) Young Academic Urologists (YAU) Renal Cancer Group. Evaluation of the Prognostic Significance of Perirenal Fat Invasion and Tumor Size in Patients with pT1-pT3a Localized Renal Cell Carcinoma in a Comprehensive Multicenter Study of the CORONA project. Can We Improve Prognostic Discrimination for Patients with Stage pT3a tumors? *Eur Urol.* 2015 Feb 12. PMID: 25684695
873. Hwang IC, Park SM, Shin D, Ahn HY, Rieken M, **Shariat SF**. Metformin Association with Lower Prostate Cancer Recurrence in Type 2 Diabetes: a Systematic Review and Meta-analysis. *Asian Pac J Cancer Prev.* 2015;16(2):595-600. PMID: 25684493

874. Al Hussein Al Awamlh B, Lee DJ, Nguyen DP, Green DA, **Shariat SF**, Scherr DS. Assessment of the Quality-of-life and Functional Outcomes in Patients Undergoing Cystectomy and Urinary Diversion for the Management of Radiation-induced Refractory Benign Disease. *Urology*. 2015 Feb;85(2):394-401. PMID: 25623700
875. Soave A, Engel O, von Amsberg G, Becker A, Dahlem R, **Shariat SF**, Fisch M, Rink M. The management of advanced bladder cancer in the era of targeted therapies. *Minerva Urol Nefrol*. 2015 Jan 21. PMID: 25604695
876. Lucca I, Klatte T, Rouprêt M, **Shariat SF**. Kidney-sparing surgery for upper tract urothelial cancer. *Curr Opin Urol*. 2015 Mar;25(2):100-4. PMID: 25581542
877. Otto BJ, Osterberg EC, Salgado S, Scherr DS, **Shariat SF**. Prostate Cancer Risk Estimation Tool Usage Among Members of the American Urological Association (AUA): A Survey-Based Study. *J Urol*. 2015 Jan 3. PMID: 25562444
878. Gandaglia G, Sun M, Popa I, Schiffmann J, Trudeau V, **Shariat SF**, Trinh QD, Graefen M, Widmer H, Saad F, Briganti A, Montorsi F, Karakiewicz PI. Cardiovascular Mortality in Patients With Metastatic Prostate Cancer Exposed to Androgen Deprivation Therapy: A Population-Based Study. *Clin Genitourin Cancer*. 2014 Dec 9. PMID: 25547676
879. Seisen T, Granger B, Colin P, Léon P, Utard G, Renard-Penna R, Compérat E, Mozer P, Cussenot O, **Shariat SF**, Rouprêt M. A Systematic Review and Meta-analysis of Clinicopathologic Factors Linked to Intravesical Recurrence After Radical Nephroureterectomy to Treat Upper Tract Urothelial Carcinoma. *Eur Urol*. 2014 Dec 5. PMID: 2548868
880. Schmitz-Dräger BJ, Droller M, Lokeshwar VB, Lotan Y, Hudson MA, van Rhijn BW, Marberger MJ, Fradet Y, Hemstreet GP, Malmstrom PU, Ogawa O, Karakiewicz PI, **Shariat SF**. Molecular Markers for Bladder Cancer Screening, Early Diagnosis, and Surveillance: The WHO/ICUD Consensus. *Urol Int*. 2014 Dec 10. PMID: 25501325
881. Larcher A, Sun M, Schiffmann J, Tian Z, **Shariat SF**, McCormack M, Saad F, Fossati N, Abdollah F, Briganti A, Buffi N, Graefen M, Guazzoni G, Montorsi F, Karakiewicz PI. Differential effect on survival of pelvic lymph node dissection at radical cystectomy for muscle invasive bladder cancer. *Eur J Surg Oncol*. 2014 Nov 21. PMID: 25477269
882. Casey RG, Catto JW, Cheng L, Cookson MS, Herr H, **Shariat S**, Witjes JA, Black PC. Diagnosis and Management of Urothelial Carcinoma In Situ of the Lower Urinary Tract: A Systematic Review. *Eur Urol*. 2014 Nov 14. PMID: 25466937
883. Soave A, Schmidt S, Dahlem R, Minner S, Engel O, Kluth LA, John LM, Hansen J, Schmid M, Sauter G, **Shariat SF**, Fisch M, Rink M. Does the extent of variant histology affect oncological outcomes in patients with urothelial carcinoma of the bladder treated with radical cystectomy? *Urol Oncol*. 2014 Nov 24. PMID: 25465301
884. Schiffmann J, Gandaglia G, Larcher A, Sun M, Tian Z, **Shariat SF**, McCormack M, Valiquette L, Montorsi F, Graefen M, Saad F, Karakiewicz PI. Contemporary 90-day mortality rates after radical cystectomy in the elderly. *Eur J Surg Oncol*. 2014 Oct 15. PMID: 25454826
885. Krabbe LM, Bagrodia A, Haddad AQ, Kapur P, Khalil D, Hynan LS, Wood CG, Karam JA, Weizer AZ, Raman JD, Remzi M, Rioux-Leclercq N, Haitel A, Roscigno M, Bolenz C, Bensalah K, Sagalowsky AI, **Shariat SF**, Lotan Y, Margulis V. Multi-Institutional Validation of the Predictive Value of KI-67 in Patients with High-Grade Urothelial Carcinoma of the Upper Urinary Tract. *J Urol*. 2014 Nov 11. PMID 25451830

886. Weibl P, Klatte T, Laurinc P, Tomaškin R, **Shariat SF**, Helbich M, Fackovcova D, Bujdák P. Patient's behavior and attitudes toward the management of benign prostatic hyperplasia among patients with the risk of disease progression: prospective study by "Prostate and Expectations of Treatment Epidemiology Research (PETER) study group". *Wien Klin Wochenschr.* 2014 Dec 2. PMID: 25447967
887. Bagrodia A, Krabbe LM, Gayed BA, Kapur P, Bernstein I, Xie XJ, Wood CG, Karam JA, Weizer AZ, Raman JD, Remzi M, Rioux-Leclercq N, Haitel A, Roscigno M, Bolenz C, Bensalah K, Sagalowsky AI, **Shariat SF**, Lotan Y, Margulis V. Evaluation of the prognostic significance of altered Mammalian target of rapamycin pathway biomarkers in upper tract urothelial carcinoma. *Urology.* 2014 Nov;84(5):1134-40. PMID: 25443916
888. Lucca I, **Shariat SF**, Briganti A, Lotan Y, Roehrborn CG, Montorsi F, Remzi M, Seitz C, Fajkovic H, Klingler C, Karakiewicz PI, Sun M, Rouprêt M, Loidl W, Pummer K, Klatte T. Validation of tertiary Gleason pattern 5 in Gleason score 7 prostate cancer as an independent predictor of biochemical recurrence and development of a prognostic model. *Urol Oncol.* 2014 Oct 23. PMID: 25443275
889. de Martino M, Taus C, Wessely IS, Lucca I, Hofbauer SL, Haitel A, **Shariat SF**, Klatte T. The T309G Murine Double Minute 2 Gene Polymorphism Is an Independent Prognostic Factor for Patients with Renal Cell Carcinoma. *DNA Cell Biol.* 2014 Nov 21. PMID: 25415135
890. Trudeau V, Gandaglia G, Shiffmann J, Popa I, **Shariat SF**, Montorsi F, Perrotte P, Trinh QD, Karakiewicz PI, Sun M Robot-assisted versus laparoscopic nephroureterectomy for upper-tract urothelial cancer: A population-based assessment of costs and perioperative outcomes. *Can Urol Assoc J.* 2014 Sep;8(9-10):E695-E701. PMID: 25408809
891. Aziz A, **Shariat SF**, Roghmann F, Brookman-May S, Stief CG, Rink M, Chun FK, Fisch M, Novotny V, Froehner M, Wirth MP, Schnabel MJ, Fritsche HM, Burger M, Pycha A, Brisuda A, Babjuk M, Vallo S, Haferkamp A, Roigas J, Noldus J, Stredele R, Volkmer B, Bastian PJ, Xylinas E, May M. Prediction of cancer-specific survival after radical cystectomy in pT4a urothelial carcinoma of the bladder - development of a tool for clinical decision-making. *BJU Int.* 2014 Nov 10. PMID: 25381844
892. Mathieu R, **Shariat SF**, Seitz C, Karakiewicz PI, Fajkovic H, Sun M, Lotan Y, Scherr DS, Tewari A, Montorsi F, Briganti A, Rouprêt M, Lucca I, Margulis V, Rink M, Kluth LA, Rieken M, Bachman A, Xylinas E, Robinson BD, Bensalah K, Margreiter M. Multi-institutional validation of the prognostic value of Ki-67 labeling index in patients treated with radical prostatectomy. *World J Urol.* 2014 Oct 26. PMID: 25344896
893. Colin P, Irani J, Drouin SJ, **Shariat SF**, Rouprêt M. Prognostic factors of upper tract urothelial carcinomas and impact on survival: A systematic review for the yearly scientific report of the French National Association of Urology. *J Prog Urol.* 2014 PMID: 25199726
894. Haddad AQ, Kapur P, Singla N, Raman JD, Then MT, Nuhn P, Buchner A, Bastian P, Seitz C, **Shariat SF**, Bensalah K, Rioux-Leclercq N, Sagalowsky A, Lotan Y, Margulis V. Validation of mammalian target of rapamycin biomarker panel in patients with clear cell renal cell carcinoma. *Cancer.* 2014 Sep 3. PMID: 25186283
895. Zargar H, Espiritu PN, Fairey AS, Mertens LS, Dinney CP, Mir MC, Krabbe LM, Cookson MS, Jacobsen NE, Gandhi NM, Griffin J, Montgomery JS, Vasdev N, Yu EY, Youssef D, Xylinas E, Campain NJ, Kassouf W, Dall'Era MA, Seah JA, Ercole CE, Horenblas S, Sridhar SS, McGrath JS, Aning J, **Shariat SF**, Wright JL, Thorpe AC, Morgan TM, Holzbeierlein JM, Bivalacqua TJ, North S, Barocas DA, Lotan Y, Garcia JA, Stephenson AJ, Shah JB, van Rhijn BW, Daneshmand S,

- Spiess PE, Black PC. Multicenter Assessment of Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer. *Eur Urol.* 2014 Sep 22. PMID: 25257030
896. Hofbauer SL, Pantuck AJ, de Martino M, Lucca I, Haitel A, **Shariat SF**, Belldegrün AS, Klatte T. The preoperative prognostic nutritional index is an independent predictor of survival in patients with renal cell carcinoma. *Urol Oncol.* 2014 Sep 15. PMID: 25240758
897. van Rhijn BW, Catto JW, Goebell PJ, Knüchel R, **Shariat SF**, van der Poel HG, Sanchez-Carbayo M, Thalmann GN, Schmitz-Dräger BJ, Kiemeny LA. Molecular markers for urothelial bladder cancer prognosis: Toward implementation in clinical practice. *Urol Oncol.* 2014 Sep 9. PMID: 25217465
898. Sevcenco S, Haitel A, Ponhold L, Susani M, Fajkovic H, **Shariat SF**, Hiess M, Spick C, Szarvas T, Baltzer PA. Quantitative apparent diffusion coefficient measurements obtained by 3-tesla MRI are correlated with biomarkers of bladder cancer proliferative activity. *PLoS One.* 2014 Sep 9;9(9):e106866. PMID: 25202965
899. Colin P, Irani J, Drouin SJ, **Shariat SF**, Rouprêt M. Prognostic factors of upper tract urothelial carcinomas and impact on survival: A systematic review for the yearly scientific report of the French National Association of Urology. *Prog Urol.* 2014 Sep 5. pii: S1166-7087(14)00204-8. PMID: 25199726
900. Haddad AQ, Kapur P, Singla N, Raman JD, Then MT, Nuhn P, Buchner A, Bastian P, Seitz C, **Shariat SF**, Bensalah K, Rioux-Leclercq N, Sagalowsky A, Lotan Y, Margulis V. Validation of mammalian target of rapamycin biomarker panel in patients with clear cell renal cell carcinoma. *Cancer.* 2014 Sep 3. PMID: 25186283
901. Gupta A, Atoria CL, Ehdaie B, **Shariat SF**, Rabbani F, Herr HW, Bochner BH, Elkin EB. Risk of Fracture After Radical Cystectomy and Urinary Diversion for Bladder Cancer. *J Clin Oncol.* 2014 Sep 2. PMID: 25185104
902. Al Hussein Al Awamlh B, Wang LC, Nguyen DP, Rieken M, Lee RK, Lee DJ, Flynn T, Chrystal J, **Shariat SF**, Scherr DS. Is continent cutaneous urinary diversion a suitable alternative to orthotopic bladder substitute and ileal conduit after cystectomy? *BJU Int.* 2014 Aug 28. PMID: 25168771
903. Tilki D, Hu B, Nguyen HG, Dall'Era MA, Bertini R, Carballido JA, Chandrasekar T, Chromecki T, Ciano G, Daneshmand S, Gontero P, Gonzalez J, Haferkamp A, Hohenfellner M, Huang WC, Koppie TM, Linares E, Lorentz CA, Mandel P, Martinez-Salamanca JI, Master VA, Matloob R, McKiernan JM, Mlynarczyk CM, Montorsi F, Novara G, Pahernik S, Palou J, Pruthi RS, Ramaswamy K, Faba OR, Russo P, **Shariat SF**, Spahn M, Terrone C, Thieu W, Vergho D, Wallen EM, Xylinas E, Zigeuner R, Libertino JA, Evans CP. Impact of synchronous metastasis distribution on cancer-specific survival in renal cell carcinoma after radical nephrectomy with tumor thrombectomy. *J Urol.* 2014 Jul 22. PMID: 25063493
904. Neuzillet Y, Colin P, Phé V, **Shariat SF**, Rouprêt M. Surgical treatment of upper tract urothelial carcinomas by nephroureterectomy: State of the art for the yearly scientific report of the French National Association of Urology. *Prog Urol.* 2014 Aug 26. PMID: 25158323
905. Ploussard G, Xylinas E, Lotan Y, Novara G, Margulis V, Rouprêt M, Matsumoto K, Karakiewicz PI, Montorsi F, Remzi M, Seitz C, Scherr DS, Kapoor A, Fairey AS, Rendon R, Izawa J, Black PC, Lacombe L, **Shariat SF**, Kassouf W. Conditional Survival After Radical Nephroureterectomy for Upper Tract Carcinoma. *Eur Urol.* 2014 Aug 18. PMID: 25145551
906. Hofbauer SL, de Martino M, Seemann C, Zamani N, Lucca I, Haitel A, **Shariat SF**, Klatte T. Associations between presenting symptoms, clinicopathological parameters, and prognosis in a

- contemporary series of patients with renal cell carcinoma. *Korean J Urol*. 2014 Aug;55(8):505-10. Epub 2014 Aug 8. PMID:25132943
907. Hofbauer SL, Stangl KI, de Martino M, Lucca I, Haitel A, **Shariat SF**, Klatte T. Pretherapeutic gamma-glutamyltransferase is an independent prognostic factor for patients with renal cell carcinoma. *Br J Cancer*. 2014 Aug 12. PMID: 25117808
908. Yakoubi R, Colin P, Seisen T, Léon P, Nison L, Bozzini G, **Shariat SF**, Rouprêt M. Radical nephroureterectomy versus endoscopic procedures for the treatment of localised upper tract urothelial carcinoma: A meta-analysis and a systematic review of current evidence from comparative studies. *Eur J Surg Oncol*. 2014 Jul 25. Review. PMID: 25108813
909. Nuhn P, Novara G, Seitz C, Gupta A, Matsumoto K, Kassouf W, Walton TJ, Fritsche HM, Tritschler S, Martínez-Salamanca JI, Ficarra V, Karakiewicz PI, Mazzoleni G, **Shariat SF**, Bastian PJ. Prognostic value of prior history of urothelial carcinoma of the bladder in patients with upper urinary tract urothelial carcinoma: results from a retrospective multicenter study. *World J Urol*. 2014 Jul 22. PMID: 25048439
910. Krabbe LM, Svatek RS, **Shariat SF**, Messing E, Lotan Y. Bladder cancer risk: Use of the PLCO and NLST to identify a suitable screening cohort. *Urol Oncol*. 2014 Jul 16. PMID: 25044253
911. Gontero P, Sylvester R, Pisano F, Joniau S, Vander Eeckt K, Serretta V, Larré S, Di Stasi S, Van Rhijn B, Witjes AJ, Grotenhuis AJ, Kiemeny LA, Colombo R, Briganti A, Babjuk M, Malmström PU, Oderda M, Irani J, Malats N, Baniel J, Mano R, Cai T, Cha EK, Ardelt P, Varkarakis J, Bartoletti R, Spahn M, Johansson R, Freja B, Soukup V, Xylinas E, Dalbagni G, Karnes RJ, **Shariat SF**, Palou J. Prognostic Factors and Risk Groups in T1G3 Non-Muscle-invasive Bladder Cancer Patients Initially Treated with Bacillus Calmette-Guérin: Results of a Retrospective Multicenter Study of 2451 Patients. *Eur Urol*. 2014 Jul 16. PMID: 25043942
912. Kluth LA, Abdollah F, Xylinas E, Rieken M, Fajkovic H, Seitz C, Sun M, Karakiewicz PI, Schramek P, Herman MP, Becker A, Hansen J, Ehdaie B, Loidl W, Pummer K, Lee RK, Lotan Y, Scherr DS, Seiler D, Ahyai SA, Chun FK, Graefen M, Tewari A, Nonis A, Bachmann A, Montorsi F, Gönen M, Briganti A, **Shariat SF**. Clinical nodal staging scores for prostate cancer: a proposal for preoperative risk assessment. *Br J Cancer*. 2014 Jul 15;111(2):213-9. PMID: 25003663
913. de Martino M, Zhuang D, Klatte T, Rieken M, Rouprêt M, Xylinas E, Clozel T, Krzywinski M, Elemento O, **Shariat SF**. Impact of ERBB2 mutations on in vitro sensitivity of bladder cancer to lapatinib. *Cancer Biol Ther*. 2014 Jun 27;15(9). PMID: 24971884
914. Comploj E, West J, Mian M, Kluth LA, Karl A, Dechet C, **Shariat SF**, Stief CG, Trenti E, Palermo S, Lodde M, Horninger W, Madersbacher S, Pycha A. Comparison of Complications from Radical Cystectomy between Old-Old versus Oldest-Old Patients. *Urol Int*. 2014 Jun 24. PMID: 24969739
915. Sevcenco S, Ponhold L, Heinz-Peer G, Fajkovic H, Haitel A, Susani M, **Shariat SF**, Szarvas T, Baltzer PA. Prospective evaluation of diffusion-weighted MRI of the bladder as a biomarker for prediction of bladder cancer aggressiveness. *Urol Oncol*. 2014 Jun 21. PMID: 24962659
916. Becker A, Ravi P, Roghmann F, Trinh QD, Tian Z, Larouche A, Kim S, **Shariat SF**, Kluth L, Dahlem R, Fisch M, Graefen M, Eichelberg C, Karakiewicz PI, Sun M. Laparoscopic radical nephrectomy vs laparoscopic or open partial nephrectomy for T1 renal cell carcinoma: comparison of complication rates in elderly patients during the initial phase of adoption. *Urology*. 2014 Jun;83(6):1285-93. PubMed PMID: 24862392.
917. Abdollah F, Gandaglia G, Suardi N, Capitanio U, Salonia A, Nini A, Moschini M, Sun M, Karakiewicz PI, **Shariat SF**, Montorsi F, Briganti A. More Extensive Pelvic Lymph Node

- Dissection Improves Survival in Patients with Node-positive Prostate Cancer. *Eur Urol.* 2014 May 29. PMID: 24882672.
918. Lucca I, **Shariat SF**, Hofbauer SL, Klatte T. Outcomes of minimally invasive simple prostatectomy for benign prostatic hyperplasia: a systematic review and meta-analysis. *World J Urol.* 2014 May 31. PubMed PMID: 24879405.
919. Rieken M, Djajadiningrat RS, Kluth LA, Favaretto RL, Xylinas E, Guimaraes GC, Soares FA, Kent M, Sjoberg DD, Horenblas S, **Shariat SF**. Predictors of Cancer-specific Mortality After Disease Recurrence in Patients with Squamous Cell Carcinoma of the Penis. *Eur Urol.* 2014 Jun 9. PMID: 24924553.
920. Lucca I, Rouprêt M, Kluth L, Rink M, Tilki D, Fajkovic H, Kassouf W, Hofbauer SL, de Martino M, Karakiewicz PI, Briganti A, Trinh QD, Seitz C, Fritsche HM, Burger M, Lotan Y, Kramer G, **Shariat SF**, Klatte T. Adjuvant cisplatin-based combination chemotherapy for lymph node-positive urothelial carcinoma of the bladder following radical cystectomy: a retrospective international study of more than 1500 patients. *BJU Int.* 2014 Jun 6. PubMed PMID: 24905084.
921. Simonis K, **Shariat SF**, Rink M. Smoking and smoking cessation effects on oncological outcomes in nonmuscle invasive bladder cancer. *Curr Opin Urol.* 2014 May 30. PubMed PMID: 24887046.
922. Lotan Y, Svatek RS, Krabbe LM, Xylinas E, Klatte T, **Shariat SF**. Prospective External Validation of Model for Bladder Cancer Detection. *J Urol.* 2014 May 21. PubMed PMID: 24859442.
923. Aziz A, Fritsche HM, Gakis G, Kluth LA, Al-Sayed Hassan F, Engel O, Dahlem R, Otto W, Gierth M, Denzinger S, Schwentner C, Stenzl A, **Shariat SF**, Fisch M, Burger M, Rink M. Comparative analysis of comorbidity and performance indices for prediction of oncological outcomes in patients with upper tract urothelial carcinoma who were treated with radical nephroureterectomy. *Urol Oncol.* 2014 May 22. PubMed PMID: 24856977.
924. Lucca I, Kassouf W, Kapoor A, Fairey A, Rendon RA, Izawa JI, Black PC, Fajkovic H, Seitz C, Remzi M, Nyirády P, Rouprêt M, Margulis V, Lotan Y, de Martino M, Hofbauer SL, Karakiewicz PI, Briganti A, Novara G, **Shariat SF**, Klatte T. The role of adjuvant chemotherapy for lymph node-positive upper tract urothelial carcinoma following radical nephroureterectomy: a retrospective study. *BJU Int.* 2014 May 13. PubMed PMID: 24825476.
925. Tschirdewahn S, Reis H, Niedworok C, Nyirady P, Szendrői A, Schmid KW, **Shariat SF**, Kramer G, Vom Dorp F, Rübber H, Szarvas T. Prognostic effect of serum and tissue YKL-40 levels in bladder cancer. *Urol Oncol.* 2014 May 7. PubMed PMID: 24814404.
926. Ehdaie B, **Shariat SF**, Savage C, Coleman J, Dalbagni G. Postoperative nomogram for disease recurrence and cancer-specific death for upper tract urothelial carcinoma: comparison to american joint committee on cancer staging classification. *Urol J.* 2014 May 6;11(2):1435-41. PubMed PMID: 24807756.
927. Margreiter M, Heinisch BB, Schwarzer R, Klatte T, **Shariat SF**, Ferlitsch A. Lower urinary tract symptoms in patients with liver cirrhosis. *World J Urol.* 2014 May 6. PubMed PMID: 24798455.
928. Rieken M, Schubert T, Xylinas E, Kluth L, Rouprêt M, Trinh QD, Lee RK, Al Hussein Al Awamlh B, Fajkovic H, Novara G, Margulis V, Lotan Y, Martinez-Salamanca JI, Matsumoto K, Seitz C, Remzi M, Karakiewicz PI, Scherr DS, Briganti A, Bachmann A, **Shariat SF**; for the UTUC Collaboration. Association of perioperative blood transfusion with oncologic outcomes after radical nephroureterectomy for upper tract urothelial carcinoma. *Eur J Surg Oncol.* 2014 Apr 13. pii: S0748-7983(14)00380-1. PubMed PMID: 24780094.

929. Schmid M, **Shariat SF**, Soave A, Engel O, Fisch M, Rink M. Contemporary gender-specific outcomes in Germany after radical cystectomy for bladder cancer. *Curr Urol Rep*. 2014 Jun;15(6):409. PubMed PMID: 24756451.
930. Weibl P, Hora M, Kollarik B, **Shariat SF**, Klatte T. Management, pathology and outcomes of Bosniak category IIF and III cystic renal lesions. *World J Urol*. 2014 Apr 18. PubMed PMID: 24744224.
931. Sevcenco S, Heinz-Peer G, Ponhold L, Javor D, Kuehhas FE, Klingler HC, Remzi M, Weibl P, **Shariat SF**, Baltzer PA. Utility and limitations of 3-Tesla diffusion-weighted magnetic resonance imaging for differentiation of renal tumors. *Eur J Radiol*. 2014 Jun;83(6):909-13. doi: 10.1016/j.ejrad.2014.02.026. Epub 2014 Mar 24. PubMed PMID: 24709332.
932. Gacci M, Ficarra V, Sebastianelli A, Corona G, Serni S, **Shariat SF**, Maggi M, Zattoni F, Carini M, Novara G. Impact of Medical Treatments for Male Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia on Ejaculatory Function: A Systematic Review and Meta-Analysis. *J Sex Med*. 2014 Apr 7. PubMed PMID: 24708055.
933. de Martino M, Leitner CV, Seemann C, Hofbauer SL, Lucca I, Haitel A, **Shariat SF**, Klatte T. Preoperative serum cholesterol is an independent prognostic factor for patients with renal cell carcinoma. *BJU Int*. 2014 Apr 4. PubMed PMID: 24698164.
934. Martínez-Salamanca JI, Linares E, González J, Bertini R, Carballido JA, Chromecki T, Ciancio G, Daneshmand S, Evans CP, Gontero P, Haferkamp A, Hohenfellner M, Huang WC, Koppie TM, Master VA, Matloob R, McKiernan JM, Mlynarczyk CM, Montorsi F, Nguyen HG, Novara G, Pahernik S, Palou J, Pruthi RS, Ramaswamy K, Faba OR, Russo P, **Shariat SF**, Spahn M, Terrone C, Tilki D, Vergho D, Wallen EM, Xylinas E, Zigeuner R, Libertino JA. Lessons learned from the International Renal Cell Carcinoma-Venous Thrombus Consortium (IRCC-VTC). *Curr Urol Rep*. 2014 May;15(5):404. PubMed PMID: 24682884.
935. **Shariat SF**. Incorporating biomarker research in a real-world setting: challenges of a prophecy. *Urol Oncol*. 2014 Apr;32(3):219-21. PubMed PMID: 24679461.
936. Soave A, Dahlem R, Hansen J, Weisbach L, Minner S, Engel O, Kluth LA, Chun FK, **Shariat SF**, Fisch M, Rink M. Gender-specific outcomes of bladder cancer patients: A stage-specific analysis in a contemporary, homogenous radical cystectomy cohort. *Eur J Surg Oncol*. 2014 Mar 13. pii: S0748-7983(14)00348-5. PubMed PMID: 24674298.
937. Ravi P, Trinh VQ, Sun M, Sammon J, Sukumar S, Gervais MK, **Shariat SF**, Kim SP, Kowalczyk KJ, Hu JC, Menon M, Karakiewicz PI, Trinh QD. Is there any evidence of a "July effect" in patients undergoing major cancer surgery? *Can J Surg*. 2014 Apr;57(2):82-8. PubMed PMID: 24666444; PubMed Central PMCID: PMC3968195.
938. Gandaglia G, Suardi N, Gallina A, Zaffuto E, Cucchiaro V, Vizziello D, **Shariat S**, Cantiello F, Damiano R, Guazzoni G, Montorsi F, Briganti A. How to Optimize Patient Selection for Robot-Assisted Radical Prostatectomy: Functional Outcome Analyses from a Tertiary Referral Center. *J Endourol*. 2014 Mar 24. PubMed PMID: 24660774.
939. Szarvas T, Reis H, Kramer G, **Shariat SF**, Vom Dorp F, Tschirdewahn S, Schmid KW, Kovalszky I, Rübber H. Enhanced stromal syndecan-1 expression is an independent risk factor for poor survival in bladder cancer. *Hum Pathol*. 2014 Apr;45(4):674-82. PubMed PMID: 24656090.
940. **Shariat SF**, Klatte T. Optimal results come from optimal surgery and optimal (neoadjuvant) systemic therapy. *BJU Int*. 2014 Apr;113(4):516-7. PubMed PMID: 24629083.

941. Szarvas T, Tschirdewahn S, Niedworok C, Kramer G, Sevcenco S, Reis H, **Shariat SF**, Rübben H, Dorp FV. Prognostic value of tissue and circulating levels of IMP3 in prostate cancer. *Int J Cancer*. 2014 Feb 24. doi: 10.1002/ijc.28808. PubMed PMID: 24615121.
942. Ploussard G, Daneshmand S, Efstathiou JA, Herr HW, James ND, Rödel CM, **Shariat SF**, Shipley WU, Sternberg CN, Thalmann GN, Kassouf W. Critical analysis of bladder sparing with trimodal therapy in muscle-invasive bladder cancer: a systematic review. *Eur Urol*. 2014 Feb 26. pii: S0302-2838(14)00167-5. PubMed PMID: 24613684.
943. Sevcenco S, Krssak M, Javor D, Ponhold L, Kuehhas FE, Fajkovic H, Haitel A, **Shariat SF**, Baltzer PA. Diagnosis of renal tumors by in vivo proton magnetic resonance spectroscopy. *World J Urol*. 2014 Mar 9. PubMed PMID: 24609220.
944. de Martino M, **Shariat SF**, Hofbauer SL, Lucca I, Taus C, Wiener HG, Haitel A, Susani M, Klatte T. Aurora A Kinase as a diagnostic urinary marker for urothelial bladder cancer. *World J Urol*. 2014 Feb 23. PubMed PMID: 24562316.
945. Schoenthaler M, Avcil T, Sevcenco S, Nagele U, Hermann TE, Kuehhas FE, **Shariat SF**, Frankenschmidt A, Wetterauer U, Miernik A. Single-Incision Transumbilical Surgery (SITUS) versus Single-Port Laparoscopic Surgery and conventional laparoscopic surgery: a prospective randomized comparative study of performance with novices in a dry laboratory. *World J Urol*. 2014 Feb 23. [Epubahead of print] PubMed PMID: 24562315.
946. Hansen J, Gandaglia G, Bianchi M, Sun M, Rink M, Tian Z, Meskawi M, Trinh QD, **Shariat SF**, Perrotte P, Chun FK, Graefen M, Karakiewicz PI. Re-assessment of 30-, 60- and 90-day mortality rates in non-metastatic prostate cancer patients treated either with radical prostatectomy or radiation therapy. *Can Urol Assoc J*. 2014 Jan-Feb;8(1-2):E75-80. doi: 10.5489/cuaj.749. PubMed PMID: 24554978; PubMed Central PMCID: PMC3926930.
947. Becker A, Bianchi M, Hansen J, Tian Z, **Shariat SF**, Popa I, Perrotte P, Trinh QD, Karakiewicz PI, Sun M. Benefit in regionalization of care for patients treated with nephrectomy: a Nationwide Inpatient Sample. *World J Urol*. 2014 Feb 11. PubMed PMID: 24515596.
948. Gandaglia G, Sun M, Hu JC, Novara G, Choueiri TK, Nguyen PL, Schiffmann J, Graefen M, **Shariat SF**, Abdollah F, Briganti A, Montorsi F, Trinh QD, Karakiewicz PI. Gonadotropin-releasing Hormone Agonists and Acute Kidney Injury in Patients with Prostate Cancer. *Eur Urol*. 2014 Jan 28. pii: S0302-2838(14)00095-5. doi: 10.1016/j.eururo.2014.01.026. PubMed PMID: 24495466.
949. Klatte T, Xylinas E, Rieken M, Rouprêt M, Fajkovic H, Seitz C, Karakiewicz PI, Lotan Y, Babjuk M, de Martino M, **Shariat SF**. Effect of ABO blood type on mortality in patients with urothelial carcinoma of the bladder treated with radical cystectomy. *Urol Oncol*. 2014 Feb 1. PubMed PMID: 24495451.
950. Gandaglia G, Popa I, Abdollah F, Schiffmann J, **Shariat SF**, Briganti A, Montorsi F, Trinh QD, Karakiewicz PI, Sun M. The Effect of Neoadjuvant Chemotherapy on Perioperative Outcomes in Patients Who Have Bladder Cancer Treated with Radical Cystectomy: A Population-based Study. *Eur Urol*. 2014 Jan 24. PubMed PMID: 24486024.
951. Messer JC, **Shariat SF**, Dinney CP, Novara G, Fradet Y, Kassouf W, Karakiewicz PI, Fritsche HM, Izawa JJ, Lotan Y, Skinner EC, Tilki D, Ficarra V, Volkmer BG, Isbarn H, Wei C, Lerner SP, Curiel TJ, Kamat AM, Svatek RS. Female gender is associated with a worse survival after radical cystectomy for urothelial carcinoma of the bladder: a competing risk analysis. *Urology*. 2014 Apr;83(4):863-7. PubMed PMID: 24485993.

952. Seisen T, Colin P, Hupertan V, Yates DR, Xylinas E, Nison L, Cussenot O, Neuzillet Y, Bensalah K, Novara G, Montorsi F, Zigeuner R, Remzi M, **Shariat SF**, Roupriet M. Post-operative nomogram to predict cancer-specific survival after radical nephroureterectomy in patients with localized and/or locally advanced upper tract urothelial carcinoma without metastasis. *BJU Int*. 2014 Jan 21. PubMed PMID: 24447471.
953. Wang LC, Xylinas E, Kent MT, Kluth LA, Rink M, Jamzadeh A, Rieken M, Al Awamlh BA, Trinh QD, Sun M, Karakiewicz PI, Novara G, Chrystal J, Zerbib M, Scherr DS, Lotan Y, Vickers A, **Shariat SF**. Combining smoking information and molecular markers improves prognostication in patients with urothelial carcinoma of the bladder. *Urol Oncol*. 2014 May;32(4):433-40. PubMed PMID: 24433754.
954. Lee DJ, Xylinas E, Rieken M, Khani F, Klatte T, Wood CG, Karam JA, Weizer AZ, Raman JD, Remzi M, Guo CC, Rioux-Leclercq N, Haitel A, Bolenz C, Bensalah K, Sagalowsky AI, Montorsi F, Lotan Y, **Shariat SF**, Robinson BD, Margulis V. Insulin-like Growth Factor Messenger RNA-binding Protein 3 Expression Helps Prognostication in Patients with Upper Tract Urothelial Carcinoma. *Eur Urol*. 2013 Dec 25. PMID: 24388440.
955. Aziz A, May M, Burger M, Palisaar RJ, Trinh QD, Fritsche HM, Rink M, Chun F, Martini T, Bolenz C, Mayr R, Pycha A, Nuhn P, Stief C, Novotny V, Wirth M, Seitz C, Noldus J, Gilfrich C, **Shariat SF**, Brookman-May S, Bastian PJ, Denzinger S, Gierth M, Roghmann F; PROMETRICS 2011 research group. Prediction of 90-day Mortality After Radical Cystectomy for Bladder Cancer in a Prospective European Multicenter Cohort. *Eur Urol*. 2013 Dec 27. PubMed PMID: 24388438.
956. Rink M, Sharifi N, Fritsche HM, Aziz A, Miller F, Kluth LA, Ngamsri T, Dahlem R, Chun FK, **Shariat SF**, Stenzl A, Fisch M, Gakis G. Impact of preoperative anemia on oncologic outcomes of upper tract urothelial carcinoma treated with radical nephroureterectomy. *J Urol*. 2014 Feb;191(2):316-22. vPMID:24036235
957. Sevcenco S, Heinz-Peer G, Ponhold L, Javor D, Kuehhas FE, Klingler HC, Remzi M, Weibl P, **Shariat SF**, Baltzer PA. Utility and limitations of 3-Tesla diffusion-weighted magnetic resonance imaging for differentiation of renal tumors. *Eur J Radiol*. 2014 Mar 24. PMID: 24709332
958. Gacci M, Ficarra V, Sebastianelli A, Corona G, Serni S, **Shariat SF**, Maggi M, Zattoni F, Carini M, Novara G. Impact of Medical Treatments for Male Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia on Ejaculatory Function: A Systematic Review and Meta-Analysis. *J Sex Med*. 2014 Apr 7. PMID: 24708055
959. de Martino M, Leitner CV, Seemann C, Hofbauer SL, Lucca I, Haitel A, **Shariat SF**, Klatte T. Preoperative serum cholesterol is an independent prognostic factor for patients with renal cell carcinoma. *BJU Int*. 2014 Apr 4. PMID:24698164
960. Martínez-Salamanca JI, Linares E, González J, Bertini R, Carballido JA, Chromecki T, Ciancio G, Daneshmand S, Evans CP, Gontero P, Haferkamp A, Hohenfellner M, Huang WC, Koppie TM, Master VA, Matloob R, McKiernan JM, Mlynarczyk CM, Montorsi F, Nguyen HG, Novara G, Pahernik S, Palou J, Pruthi RS, Ramaswamy K, Faba OR, Russo P, **Shariat SF**, Spahn M, Terrone C, Tilki D, Vergho D, Wallen EM, Xylinas E, Zigeuner R, Libertino JA. Lessons learned from the International Renal Cell Carcinoma-Venous Thrombus Consortium (IRCC-VTC). *Curr Urol Rep*. 2014 May;15(5):404. PMID: 24682884
961. Soave A, Dahlem R, Hansen J, Weisbach L, Minner S, Engel O, Kluth LA, Chun FK, **Shariat SF**, Fisch M, Rink M. Gender-specific outcomes of bladder cancer patients: A stage-specific analysis in a contemporary, homogenous radical cystectomy cohort. *Eur J Surg Oncol*. 2014 Mar 13. PMID:24674298

962. Ravi P, Trinh VQ, Sun M, Sammon J, Sukumar S, Gervais MK, **Shariat SF**, Kim SP, Kowalczyk KJ, Hu JC, Menon M, Karakiewicz PI, Trinh QD. Is there any evidence of a "July effect" in patients undergoing major cancer surgery? *Can J Surg.* 2014 Apr;57(2):82-8. PMID: 24666444
963. Gandaglia G, Suardi N, Gallina A, Zaffuto E, Cucchiara V, Vizziello D, **Shariat S**, Cantiello F, Damiano R, Guazzoni G, Montorsi F, Briganti A. How to Optimize Patient Selection for Robot-Assisted Radical Prostatectomy: Functional Outcome Analyses from a Tertiary Referral Center. *J Endourol.* 2014 Mar 24. PMID :24660774
964. **Shariat SF**. Incorporating biomarker research in a real-world setting: Challenges of a prophecy. *Urol Oncol.* 2014 Apr;32(3):219-221. doi: 10.1016/j.urolonc.2014.01.006. Review. PMID: 24679461
965. Szarvas T, Reis H, Kramer G, **Shariat SF**, Vom Dorp F, Tschirdewahn S, Schmid KW, Kovalszky I, Rübben H. Enhanced stromal syndecan-1 expression is an independent risk factor for poor survival in bladder cancer. *Hum Pathol.* 2014 Apr;45(4):674-82. PMID: 24656090
966. Szarvas T, Tschirdewahn S, Niedworok C, Kramer G, Sevcenco S, Reis H, **Shariat SF**, Rübben H, Dorp FV. Prognostic value of tissue and circulating levels of IMP3 in prostate cancer. *Int J Cancer.* 2014 Feb 24. PMID: 24615121
967. Ploussard G, Daneshmand S, Efsthathiou JA, Herr HW, James ND, Rödel CM, **Shariat SF**, Shipley WU, Sternberg CN, Thalmann GN, Kassouf W. Critical analysis of bladder sparing with trimodal therapy in muscle-invasive bladder cancer: a systematic review. *Eur Urol.* 2014 Feb 26. pii: S0302-2838(14)00167-5. PMID: 24613684
968. Sevcenco S, Krssak M, Javor D, Ponhold L, Kuehhas FE, Fajkovic H, Haitel A, **Shariat SF**, Baltzer PA. Diagnosis of renal tumors by in vivo proton magnetic resonance spectroscopy. *World J Urol.* 2014 Mar 9. PMID: 24609220
969. Xylinas E, Green DA, Otto B, Jamzadeh A, Kluth L, Lee RK, Robinson BD, **Shariat SF**, Scherr DS. Robotic-assisted radical cystectomy with extracorporeal urinary diversion for urothelial carcinoma of the bladder: analysis of complications and oncologic outcomes in 175 patients with a median follow-up of 3 years. *Urology.* 2013 Dec;82(6):1323-9. PMID: 24295248
970. Gandaglia G, Sun M, Hu JC, Novara G, Choueiri TK, Nguyen PL, Schiffmann J, Graefen M, **Shariat SF**, Abdollah F, Briganti A, Montorsi F, Trinh QD, Karakiewicz PI. Gonadotropin-releasing Hormone Agonists and Acute Kidney Injury in Patients with Prostate Cancer. *Eur Urol.* 2014 Jan 28. PMID: 24495466
971. Becker A, Bianchi M, Hansen J, Tian Z, **Shariat SF**, Popa I, Perrotte P, Trinh QD, Karakiewicz PI, Sun M. Benefit in regionalization of care for patients treated with nephrectomy: a Nationwide Inpatient Sample. *World J Urol.* 2014 Feb 11. PMID: 24515596
972. Klatte T, Xylinas E, Rieken M, Rouprêt M, Fajkovic H, Seitz C, Karakiewicz PI, Lotan Y, Babjuk M, de Martino M, **Shariat SF**. Effect of ABO blood type on mortality in patients with urothelial carcinoma of the bladder treated with radical cystectomy. *Urol Oncol.* 2014 Feb 1. PMID: 24495451
973. Gandaglia G, Popa I, Abdollah F, Schiffmann J, **Shariat SF**, Briganti A, Montorsi F, Trinh QD, Karakiewicz PI, Sun M. The Effect of Neoadjuvant Chemotherapy on Perioperative Outcomes in Patients Who Have Bladder Cancer Treated with Radical Cystectomy: A Population-based Study. *Eur Urol.* 2014 Jan 24. PMID: 24486024
974. Messer JC, **Shariat SF**, Dinney CP, Novara G, Fradet Y, Kassouf W, Karakiewicz PI, Fritsche HM, Izawa JI, Lotan Y, Skinner EC, Tilki D, Ficarra V, Volkmer BG, Isbarn H, Wei C, Lerner SP,

- Curiel TJ, Kamat AM, Svatek RS. Female Gender Is Associated With a Worse Survival After Radical Cystectomy for Urothelial Carcinoma of the Bladder: A Competing Risk Analysis. *Urology*. 2014 Jan 30. PMID: 24485993
975. Seisen T, Colin P, Hupertan V, Yates DR, Xylinas E, Nison L, Cussenot O, Neuzillet Y, Bensalah K, Novara G, Montorsi F, Zigeuner R, Remzi M, **Shariat SF**, Rouprêt M. Post-operative nomogram to predict cancer-specific survival after radical nephroureterectomy in patients with localized and/or locally advanced upper tract urothelial carcinoma without metastasis. *BJU Int*. 2014 Jan 21. PMID: 24447471
976. Wang LC, Xylinas E, Kent MT, Kluth LA, Rink M, Jamzadeh A, Rieken M, Al Awamlh BA, Trinh QD, Sun M, Karakiewicz PI, Novara G, Chrystal J, Zerbib M, Scherr DS, Lotan Y, Vickers A, **Shariat SF**. Combining smoking information and molecular markers improves prognostication in patients with urothelial carcinoma of the bladder. *Urol Oncol*. 2014 Jan 13. PMID: 24433754
977. Matin SF, **Shariat SF**, Milowsky MI, Hansel DE, Kassouf W, Koppie T, Bajorin D, Grollman AP. Highlights from the first symposium on upper tract urothelial carcinoma. *Urol Oncol*. 2014 Jan 4. pii: S1078-1439(13)00340-2. PMID: 24397995
978. Lee DJ, Xylinas E, Rieken M, Khani F, Klatte T, Wood CG, Karam JA, Weizer AZ, Raman JD, Remzi M, Guo CC, Rioux-Leclercq N, Haitel A, Bolenz C, Bensalah K, Sagalowsky AI, Montorsi F, Lotan Y, **Shariat SF**, Robinson BD, Margulis V. Insulin-like growth factor messenger rna-binding protein 3 expression helps prognostication in patients with upper tract urothelial carcinoma. *Eur Urol*. 2013 Dec 25. PMID: 2438844
979. Aziz A, May M, Burger M, Palisaar RJ, Trinh QD, Fritsche HM, Rink M, Chun F, Martini T, Bolenz C, Mayr R, Pycha A, Nuhn P, Stief C, Novotny V, Wirth M, Seitz C, Noldus J, Gilfrich C, **Shariat SF**, Brookman-May S, Bastian PJ, Denzinger S, Gierth M, Roghmann F; PROMETRICS 2011 research group. Prediction of 90-day mortality after radical cystectomy for bladder cancer in a prospective European multicenter cohort. *Eur Urol*. 2013 Dec 27. PMID: 24388438
980. Xylinas E, **Shariat SF**. BCG maintenance treatment: an optimal scheme? *Prog Urol*. 2014 Jan;24(1):1-2. doi: 10.1016/j.purol.2013.08.319. Epub 2013 Sep 21. PubMed PMID: 24365621.
981. Krabbe LM, Westerman ME, Bagrodia A, Gayed BA, Khalil D, Kapur P, **Shariat SF**, Raj GV, Sagalowsky AI, Cadeddu JA, Lotan Y, Margulis V. Surgical management of the distal ureter during radical nephroureterectomy is an independent predictor of oncological outcomes: Results of a current series and a review of the literature. *Urol Oncol*. 2014 Jan;32(1):54.e19-26. PubMed PMID: 24360665.
982. Trudeau V, Becker A, Roghmann F, **Shariat SF**, Kluth LA, Hanna N, Abdo A, Gandaglia G, Tian Z, Perrotte P, Trinh QD, Karakiewicz PI, Sun M. Local tumor destruction in renal cell carcinoma- An inpatient population-based study. *Urol Oncol*. 2014 Jan;32(1):54.e1-7. PMID:24360664.
983. Briganti A, Joniau S, Gandaglia G, Cozzarini C, Sun M, Tombal B, Haustermans K, Hinkelbein W, **Shariat SF**, Karakiewicz PI, Montorsi F, Van Poppel H, Wiegel T. Patterns and Predictors of Early Biochemical Recurrence After Radical Prostatectomy and Adjuvant Radiation Therapy in Men With pT3N0 Prostate Cancer: Implications for Multimodal Therapies. *Int J Radiat Oncol Biol Phys*. 2013 Dec 1;87(5):960-7. Epub 2013 Oct 23. PMID: 24351411
984. Briganti A, Karnes RJ, Joniau S, Boorjian SA, Cozzarini C, Gandaglia G, Hinkelbein W, Haustermans K, Tombal B, **Shariat S**, Sun M, Karakiewicz PI, Montorsi F, Van Poppel H, Wiegel T. Prediction of Outcome Following Early Salvage Radiotherapy Among Patients with Biochemical Recurrence After Radical Prostatectomy. *Eur Urol*. 2013 Dec 12. PMID: 24345725

985. Klatte T, Xylinas E, Rieken M, Kluth LA, Rouprêt M, Pycha A, Fajkovic H, Seitz C, Karakiewicz PI, Lotan Y, Babjuk M, de Martino M, Scherr DS, **Shariat SF**. Impact of ABO blood type on outcomes of patients with primary non-muscle-invasive bladder cancer. *J Urol*. 2013 Dec 10; PMID: 24333243
986. Xylinas E, Kluth LA, Lotan Y, Daneshmand S, Rieken M, Karakiewicz PI, **Shariat SF**. Blood- and tissue-based biomarkers for prediction of outcomes in urothelial carcinoma of the bladder. *Urol Oncol*. 2013 Dec 11. PMID: 24332648
987. Kluth LA, Rieken M, Xylinas E, Kent M, Rink M, Rouprêt M, Sharifi N, Jamzadeh A, Kassouf W, Kaushik D, Boorjian SA, Roghmann F, Noldus J, Masson-Lecomte A, Vordos D, Ikeda M, Matsumoto K, Hagiwara M, Kikuchi E, Fradet Y, Izawa J, Rendon R, Fairey A, Lotan Y, Bachmann A, Zerbib M, Fisch M, Scherr DS, Vickers A, **Shariat SF**. Gender-specific Differences in Clinicopathologic Outcomes Following Radical Cystectomy: An International Multi-institutional Study of More Than 8000 Patients. *Eur Urol*. 2013 Dec 5. PMID: 24331151
988. Lee RK, Abol-Enein H, Artibani W, Bochner B, Dalbagni G, Daneshmand S, Fradet Y, Hautmann RE, Lee CT, Lerner SP, Pycha A, Sievert KD, Stenzl A, Thalmann G, **Shariat SF**. Urinary diversion after radical cystectomy for bladder cancer: options, patient selection, and outcomes. *BJU Int*. 2014 Jan;113(1):11-23. PMID: 24330062
989. Kaag M, Trost L, Thompson RH, Favaretto R, Elliott V, **Shariat SF**, Maschino A, Vertosick E, Raman JD, Dalbagni G. Pre-operative predictors of renal function decline following radical nephroureterectomy for upper tract urothelial carcinoma. *BJU Int*. 2013 Dec 9. PMID: 24314050
990. Xylinas E, Green DA, Otto B, Jamzadeh A, Kluth L, Lee RK, Robinson BD, **Shariat SF**, Scherr DS. Robotic-assisted Radical cystectomy with extracorporeal urinary diversion for urothelial carcinoma of the bladder: analysis of complications and oncologic outcomes in 175 patients with a median follow-up of 3 years. *Urology*. 2013 Dec;82(6):1323-9. PMID: 24295248
991. Sooriakumaran P, Srivastava A, **Shariat SF**, Stricker PD, Ahlering T, Eden CG, Wiklund PN, Sanchez-Salas R, Mottrie A, Lee D, Neal DE, Ghavamian R, Nyirady P, Nilsson A, Carlsson S, Xylinas E, Loidl W, Seitz C, Schramek P, Roehrborn C, Cathelineau X, Skarecky D, Shaw G, Warren A, Delprado WJ, Haynes AM, Steyerberg E, Roobol MJ, Tewari AKA Multinational, Multi-institutional Study Comparing Positive Surgical Margin Rates Among 22393 Open, Laparoscopic, and Robot-assisted Radical Prostatectomy Patients. *Eur Urol*. 2013 Nov 24. PMID: 24290695
992. Youssef RF, Lotan Y, Sagalowsky AI, **Shariat SF**, Wood CG, Raman JD, Langner C, Zigeuner R, Roscigno M, Montorsi F, Bolenz C, Kassouf W, Margulis V. Radical nephroureterectomy for pathologic T4 upper tract urothelial cancer: can oncologic outcomes be improved with multimodality therapy? *Int Braz J Urol*. 2013 Sep-Oct;39(5):614-21. doi: 10.1590/S1677-5538.IBJU.2013.05.02. PMID: 24267122
993. Klatte T, **Shariat SF**, Remzi M. Systematic review and meta-analysis of perioperative and oncological outcomes of laparoscopic cryoablation versus laparoscopic partial nephrectomy for the treatment of small renal tumors. *J Urol*. 2013 Nov 11. PMID: 24231845
994. Xylinas E, Rouprêt M, **Shariat SF**. Segmental ureterectomy for upper tract urothelial carcinoma: Two procedures with different indications. *Urol Oncol*. 2013 Nov;31(8):1841-3. PMID: 24210083
995. Trinh VQ, Karakiewicz PI, Sammon J, Sun M, Sukumar S, Gervais MK, **Shariat SF**, Tian Z, Kim SP, Kowalczyk KJ, Hu JC, Menon M, Trinh QD. Venous Thromboembolism After Major Cancer Surgery: Temporal Trends and Patterns of Care. *JAMA Surg*. 2013 Nov 6. PMID: 24197279

996. Dell'oglio P, Abdollah F, Suardi N, Gallina A, Cucchiara V, Vizziello D, Zaffuto E, Cantiello F, Damiano R, **Shariat SF**, Montorsi F, Briganti A. External validation of the european association of urology recommendations for pelvic lymph node dissection in patients treated with robotic-assisted radical prostatectomy. *J Endourol*. 2013 Nov 4. PMID: 24188052
997. Raman JD, Lin YK, Kaag M, Atkinson T, Crispen P, Wille M, Smith N, Hockenberry M, Guzzo T, Peyronnet B, Bensalah K, Simhan J, Kutikov A, Cha E, Herman M, Scherr D, **Shariat SF**, Boorjian SA. High rates of advanced disease, complications, and decline of renal function after radical nephroureterectomy. *Urol Oncol*. 2013 Oct 17. PMID: 24140248
998. Rieken M, Xylinas E, Kluth L, Crivelli JJ, Chrystal J, Faison T, Lotan Y, Karakiewicz PI, Sun M, Fajkovic H, Babjuk M, Bachmann A, Scherr DS, **Shariat SF**. Effect of diabetes mellitus and metformin use on oncologic outcomes of patients treated with radical cystectomy for urothelial carcinoma. *Urol Oncol*. 2013 Oct 17. PMID: 24140245
999. Xylinas E, Robinson BD, Kluth LA, Volkmer BG, Hautmann R, Küfer R, Zerbib M, Kwon E, Thompson RH, Boorjian SA, **Shariat SF**. Association of T-cell co-regulatory protein expression with clinical outcomes following radical cystectomy for urothelial carcinoma of the bladder. *Eur J Surg Oncol*. 2013 Sep 18. PMID:24140000
1000. Ploussard G, **Shariat SF**, Dragomir A, Kluth LA, Xylinas E, Masson-Lecomte A, Rieken M, Rink M, Matsumoto K, Kikuchi E, Klatte T, Boorjian SA, Lotan Y, Roghmann F, Fairey AS, Fradet Y, Black PC, Rendon R, Izawa J, Kassouf W. Conditional Survival After Radical Cystectomy for Bladder Cancer: Evidence for a Patient Changing Risk Profile over Time. *Eur Urol*. 2013 Oct 9. PMID:24139235
1001. Gandaglia G, Abdollah F, Schiffmann J, Trudeau V, **Shariat SF**, Kim SP, Perrotte P, Montorsi F, Briganti A, Trinh QD, Karakiewicz PI, Sun M. Distribution of metastatic sites in patients with prostate cancer: A population-based analysis.*Prostate*. 2013 Oct 16. PMID: 24132735
1002. Solomon DA, Kim JS, Bondaruk J, **Shariat SF**, Wang ZF, Elkahoul AG, Ozawa T, Gerard J, Zhuang D, Zhang S, Navai N, Siefker-Radtke A, Phillips JJ, Robinson BD, Rubin MA, Volkmer B, Hautmann R, Küfer R, Hogendoorn PC, Netto G, Theodorescu D, James CD, Czerniak B, Miettinen M, Waldman T. Frequent truncating mutations of STAG2 in bladder cancer.*Nat Genet*. 2013 Dec;45(12):1428-30. PMID:24121789
1003. Rieken M, Xylinas E, Kluth L, Trinh QD, Lee RK, Fajkovic H, Novara G, Margulis V, Lotan Y, Martinez-Salamanca JI, Matsumoto K, Seitz C, Remzi M, Karakiewicz PI, Scherr DS, Briganti A, Kautzky-Willer A, Bachmann A, **Shariat SF**. Diabetes mellitus without metformin intake is associated with worse oncologic outcomes after radical nephroureterectomy for upper tract urothelial carcinoma. *Eur J Surg Oncol*. 2013 Sep 20. PMID:24113620
1004. Babjuk M., Burger M., Zigeuner R., **Shariat S.**, VanRhijn B., Comperat E., Sylvester R., Kaasinen E., Boeche A., Palou J., Roupert M.: Recommendations on the treatment of non-muscle invasive bladder cancer. *Egyptian Journal of Urology* 19 (2): 58-62, 2013
1005. Pummer K, Rieken M, Augustin H, Gutsch T, **Shariat SF**. Innovations in diagnostic imaging of localized prostate cancer. *World J Urol*. 2013 Sep 28. PMID: 24078105
1006. Kapur P, Christie A, Raman JD, Then MT, Nuhn P, Buchner A, Bastian P, Seitz C, **Shariat SF**, Bensalah K, Rioux-Leclercq N, Xie XJ, Lotan Y, Margulis V, Brugarolas J. BAP1 immunohistochemistry in a multi-institutional cohort predicts outcomes in patients with clear cell renal cell carcinoma. *J Urol*. 2013 Sep 24. PMID: 24076305
1007. Misraï V, Faron M, Guillotreau J, Bruguère E, Bordier B, **Shariat SF**, Rouprêt M. Assessment of the learning curves for photoselective vaporization of the prostate using GreenLight™ 180-Watt-

- XPS laser therapy: defining the intra-operative parameters within a prospective cohort. *World J Urol.* 2013 Sep 26. PMID: 24072009
1008. Xylinas E, Kluth L, Passonni N, Trinh QD, Rieken M, Lee RK, Fajkovic H, Novara G, Margulis V, Raman JD, Lotan Y, Rouprêt M, Aziz A, Fritsche HM, Weizer A, Martinez-Salamanca JI, Matsumoto K, Seitz C, Remzi M, Walton T, Karakiewicz PI, Montorsi F, Zerbib M, Scherr DS, **Shariat SF**. Prediction of Intravesical Recurrence After Radical Nephroureterectomy: Development of a Clinical Decision-making Tool. *Eur Urol.* 2013 Sep 19. PMID: 24070577
1009. Roghmann F, Becker A, Trinh QD, Djahagirian O, Tian Z, Meskawi M, **Shariat SF**, Graefen M, Karakiewicz P, Noldus J, Sun M. Updated assessment of neobladder utilization and morbidity according to urinary diversion after radical cystectomy: A contemporary US-population-based cohort. *Can Urol Assoc J.* 2013 Sep;7(9-10):E552-60. PMID:24069095
1010. Rieken M, Kluth LA, Xylinas E, Fajkovic H, Becker A, Karakiewicz PI, Herman M, Lotan Y, Seitz C, Schramek P, Remzi M, Loidl W, Pummer K, Lee RK, Faison T, Scherr DS, Kautzky-Willer A, Bachmann A, Tewari A, **Shariat SF**. Association of diabetes mellitus and metformin use with biochemical recurrence in patients treated with radical prostatectomy for prostate cancer. *World J Urol.* 2013 Sep 24. PMID:24062093
1011. Krabbe LM, Lotan Y, Bagrodia A, Gayed BA, Darwish OM, Youssef RF, Bolenz C, Sagalowsky AI, Raj GV, **Shariat SF**, Kapur P, Margulis V. Prospective comparison of molecular signatures in urothelial cancer of the bladder and the upper urinary tract: is there evidence for discordant biology? *J Urol.* 2013 Sep 20. PMID: 24060642
1012. Kluth LA, Xylinas E, Rieken M, Chun FK, Fajkovic H, Becker A, Karakiewicz PI, Passoni N, Herman M, Lotan Y, Seitz C, Schramek P, Remzi M, Loidl W, Guillonneau B, Rouprêt M, Briganti A, Scherr DS, Graefen M, Tewari AK, **Shariat SF**. Does increasing the nodal yield improve outcomes in contemporary patients without nodal metastasis undergoing radical prostatectomy? *Urol Oncol.* 2013 Sep 18. PMID: 24055425
1013. Xylinas E, Kluth LA, Rieken M, Karakiewicz PI, Lotan Y, **Shariat SF**. Urine markers for detection and surveillance of bladder cancer. *Urol Oncol.* 2013 Sep 17 PMID: 24054865
1014. Rieken M, Xylinas E, Kluth L, Crivelli JJ, Chrystal J, Faison T, Lotan Y, Karakiewicz PI, Fajkovic H, Babjuk M, Kautzky-Willer A, Bachmann A, Scherr DS, **Shariat SF**. Association of Diabetes Mellitus and Metformin Use with Oncological Outcomes of Patients with non-muscle invasive Bladder Cancer. *BJU Int.* 2013 Sep 5. PMID: 24053906
1015. Kluth LA, Xylinas E, Kent M, Hagiwara M, Kikuchi E, Matsumoto K, Ikeda M, Dalpiaz O, Zigeuner R, Aziz A, Fritsche HM, Deliere A, Raman JD, Bensalah K, Al-Matar B, Gakis G, Novara G, Klatte T, Remzi M, Comploj E, Pycha A, Rouprêt M, Tagawa ST, Chun FK, Scherr DS, Vickers A, **Shariat SF**. Predictors of survival in patients with disease recurrence following radical nephroureterectomy. *BJU Int.* 2013 Jul 19. PMID: 24053651
1016. Kluth LA, Xylinas E, Rieken M, Ghouayel ME, Sun M, Karakiewicz PI, Lotan Y, Chun FK, Boorjian SA, Lee RK, Briganti A, Rouprêt M, Fisch M, Scherr DS, **Shariat SF**. Impact of perioperative blood transfusion on the outcome of patients undergoing radical cystectomy for urothelial carcinoma of the bladder. *BJU Int.* 2013 Sep 5. PMID: 24053618
1017. Rom M, Waldert M, Schatzl G, Swietek N, **Shariat SF**, Klatte T. Bladder outlet obstruction in men with castration-resistant prostate cancer. *BJU Int.* 2013 PMID: 24053594
1018. **Shariat SF**, Passoni N, Bagrodia A, Rachakonda V, Xylinas E, Robinson B, Kapur P, Sagalowsky AI, Lotan Y. Prospective evaluation of a preoperative biomarker panel for prediction of upstaging at radical cystectomy. *BJU Int.* 2013 Jul 2. PMID: 24053584

1019. Passoni NM, Fajkovic H, Xylinas E, Kluth L, Seitz C, Robinson BD, Rouprêt M, Chun FK, Lotan Y, Roehrborn CG, Crivelli JJ, Karakiewicz PI, Scherr DS, Rink M, Graefen M, Schramek P, Briganti A, Montorsi F, Tewari A, **Shariat SF**. Prognosis of patients with pelvic lymph node metastasis following radical prostatectomy: value of extranodal extension and size of the largest lymph node metastasis. *BJU Int*. 2013 Jul 2. PMID: 24053552
1020. de Martino M, Waldert M, Haitel A, Schatzl G, **Shariat SF**, Klatte T. Evaluation of ABO blood group as a prognostic marker in renal cell carcinoma. *BJU Int*. 2013 Sep 5. PMID: 24053513
1021. Xylinas E, Kluth LA, Rieken M, Lee RK, Elghouayel M, Ficarra V, Margulis V, Lotan Y, Rouprêt M, Martinez-Salamanca JJ, Matsumoto K, Seitz C, Karakiewicz PI, Zerbib M, Scherr DS, **Shariat SF**. Impact of smoking status and cumulative exposure on intravesical recurrence of upper tract urothelial carcinoma after radical nephroureterectomy. *BJU Int*. 2013 Aug 12. PMID: 24053463
1022. Hansen J, Bianchi M, Sun M, Rink M, Castiglione F, Abdollah F, Steuber T, Ahyai SA, Steurer S, Göbel C, Freschi M, Montorsi F, **Shariat SF**, Fisch M, Graefen M, Karakiewicz PI, Briganti A, Chun FK. Percentage of High-Grade Tumor Volume does not Meaningfully Improve Prediction of Early Biochemical Recurrence after Radical Prostatectomy Compared to Gleason Score. *BJU Int*. 2013 Aug 23. PMID: 24053339
1023. Rink M, Sharifi N, Fritsche HM, Aziz A, Miller F, Kluth LA, Ngamsri T, Dahlem R, Chun FK, **Shariat SF**, Stenzl A, Fisch M, Gakis G. Impact of Preoperative Anemia on Oncological Outcomes of Upper Tract Urothelial Carcinoma Treated with Radical Nephroureterectomy. *J Urol*. 2013 Sep 11. PMID:24036235
1024. Gandaglia G, Bianchi M, Trinh QD, Becker A, Larouche A, Abdollah F, Roghmann F, Tian Z, **Shariat SF**, Briganti A, Montorsi F, Karakiewicz PI, Sun M. Survival after nephroureterectomy for upper tract urothelial carcinoma: A population-based competing-risks analysis. *Int J Urol*. 2013 Aug 29. PMID: 24033809
1025. Ravi P, Bianchi M, Hansen J, Trinh QD, Tian Z, Meskawi M, Abdollah F, Briganti A, **Shariat SF**, Perrotte P, Montorsi F, Karakiewicz PI, Sun M. Benefit in regionalisation of care for patients treated with radical cystectomy: a nationwide inpatient sample analysis. *BJU Int*. 2013 Jun 13. PMID: 24007240
1026. Kluth LA, **Shariat SF**, Kratzik C, Tagawa S, Sonpavde G, Rieken M, Scherr DS, Pummer K. The hypothalamic-pituitary-gonadal axis and prostate cancer: implications for androgen deprivation therapy. *World J Urol*. 2013 Sep 3. PMID: 23999854
1027. Rieken M, Kluth LA, Xylinas E, Seitz C, Fajkovic H, Karakiewicz PI, Lotan Y, Briganti A, Loidl W, Faison T, Crivelli JJ, Scherr DS, Bachmann A, Tewari AK, Kautzky-Willer A, Pummer K, **Shariat SF**. Impact of statin use on biochemical recurrence in patients treated with radical prostatectomy. *Prostate Cancer Prostatic Dis*. 2013 PMID: 23999669
1028. Rieken M, Xylinas E, Kluth L, Crivelli JJ, Chrystal J, Faison T, Lotan Y, Karakiewicz PI, Holmäng S, Babjuk M, Fajkovic H, Seitz C, Klatte T, Pycha A, Bachmann A, Scherr DS, **Shariat SF**. Long-term Cancer-specific Outcomes of TaG1 Urothelial Carcinoma of the Bladder. *Eur Urol*. 2013 Aug 27. PMID: 23998688
1029. Xylinas E, Cha EK, Khani F, Kluth LA, Rieken M, Volkmer BG, Hautmann R, Küfer R, Chen YT, Zerbib M, Rubin MA, Scherr DS, **Shariat SF**, Robinson BD. Association of oncofetal protein expression with clinical outcomes in patients with urothelial carcinoma of the bladder. *J Urol*. 2013 Aug 28. PMID: 23994370
1030. Xylinas E, Kent M, Kluth L, Pycha A, Comploj E, Svatek RS, Lotan Y, Trinh QD, Karakiewicz PI, Holmang S, Scherr DS, Zerbib M, Vickers AJ, **Shariat SF**. Accuracy of the EORTC risk tables

- and of the CUETO scoring model to predict outcomes in non-muscle-invasive urothelial carcinoma of the bladder. *Br J Cancer*. 2013 Sep 17;109(6):1460-6. PMID:23982601
1031. Rink M, Babjuk M, Catto JW, Jichlinski P, **Shariat SF**, Stenzl A, Stepp H, Zaak D, Witjes JA. Hexyl Aminolevulinic-Guided Fluorescence Cystoscopy in the Diagnosis and Follow-up of Patients with Non-Muscle-invasive Bladder Cancer: A Critical Review of the Current Literature. *Eur Urol*. 2013 Jul 19. PMID: 23906669
1032. Brookman-May SD, May M, **Shariat SF**, Novara G, Zigeuner R, Cindolo L, De Cobelli O, De Nunzio C, Pahernik S, Wirth MP, Longo N, Simonato A, Serni S, Siracusano S, Volpe A, Morgia G, Bertini R, Dalpiaz O, Stief C, Ficarra V; Members of the CORONA-Project, the SATURN-Project, and the Young Academic Urologists Renal Cancer Group. Time to recurrence is a significant predictor of cancer-specific survival after recurrence in patients with recurrent renal cell carcinoma - results from a comprehensive multi-centre database (CORONA/SATURN-Project). *BJU Int*. 2013 May 23. PMID: 23890378
1033. Weisbach L, Dahlem R, Simone G, Hansen J, Soave A, Engel O, Chun FK, **Shariat SF**, Fisch M, Rink M. Lymph node dissection during radical cystectomy for bladder cancer treatment: considerations on relevance and extent. *Int Urol Nephrol*. 2013 Jul 25. PMID: 23884728
1034. Audenet F, Audouin M, Drouin SJ, Comperat E, Mozer P, Chartier-Kastler E, Méjean A, Cussenot O, **Shariat SF**, Rouprêt M. Charlson score as a single pertinent criterion to select candidates for active surveillance among patients with small renal masses. *World J Urol*. 2013 Jul 20. PMID: 23873357
1035. Krabbe LM, Bagrodia A, Lotan Y, Gayed BA, Darwish OM, Youssef RF, John G, Harrow B, Jacobs C, Gaitonde M, Sagalowsky AI, **Shariat SF**, Kapur P, Margulis V. Ki-67 is an independent predictor of oncological outcomes in patients with high-grade upper tract urothelial carcinoma: results of a prospective analysis and a review of the literature. *J Urol*. 2013 Jul 16. PMID: 23871758
1036. Tilki D, Nguyen HG, Dall'era MA, Bertini R, Carballido JA, Chromecki T, Ciancio G, Daneshmand S, Gontero P, Gonzalez J, Haferkamp A, Hohenfellner M, Huang WC, Koppie TM, Lorentz CA, Mandel P, Martinez-Salamanca JI, Master VA, Matloob R, McKiernan JM, Mlynarczyk CM, Montorsi F, Novara G, Pahernik S, Palou J, Pruthi RS, Ramaswamy K, Rodriguez Faba O, Russo P, **Shariat SF**, Spahn M, Terrone C, Vergho D, Wallen EM, Xylinas E, Zigeuner R, Libertino JA, Evans CP. Impact of Histologic Subtype on Cancer-specific Survival in Patients with Renal Cell Carcinoma and Tumor Thrombus. *Eur Urol*. 2013 Jul 10. PMID: 23871402
1037. Kluth LA, Abdollah F, Xylinas E, Rieken M, Fajkovic H, Sun M, Karakiewicz PI, Seitz C, Schramek P, Herman MP, Becker A, Loidl W, Pummer K, Nonis A, Lee RK, Lotan Y, Scherr DS, Seiler D, Chun FK, Graefen M, Tewari A, Gönen M, Montorsi F, **Shariat SF**, Briganti A. Pathologic Nodal Staging Scores in Patients Treated with Radical Prostatectomy: A Postoperative Decision Tool. *Eur Urol*. 2013 Jul 2. PMID: 23850255
1038. Sammon JD, Karakiewicz PI, Sun M, Ravi P, Ghani KR, Jeong W, Bianchi M, Hansen J, Perrotte P, Peabody JO, Rogers CG, **Shariat SF**, Menon M, Trinh QD. Robot-assisted vs. Laparoscopic Partial Nephrectomy: utilization rates and perioperative outcomes. *Int Braz J Urol*. 2013 May-Jun;39(3):377-86. PMID: 23849569
1039. de Martino M, Pantuck AJ, Hofbauer S, Waldert M, **Shariat SF**, Belldegrun AS, Klatte T. Prognostic impact of preoperative neutrophil-to-lymphocyte ratio in localized non-clear cell renal cell carcinoma. *J Urol*. 2013 Jul 2. PMID: 23831313

1040. Babjuk M, Burger M, Zigeuner R, **Shariat SF**, van Rhijn BW, Comp  rat E, Sylvester RJ, Kaasinen E, B  hle A, Palou Redorta J, Roupr  t M. EAU Guidelines on Non-Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2013. *Eur Urol*. 2013 Jun 12. PMID: 23827737
1041. Brookman-May S, May M, **Shariat SF**, Zigeuner R, Chromecki T, Cindolo L, Schips L, De Cobelli O, Rocco B, De Nunzio C, Tubaro A, Feciche B, Coman I, Truss M, Pahernik S, Wirth MP, Zastrow S, Dalpiaz O, Fenske F, Waidelich R, Stief C, Gunia S; Members of the CORONA Project. Prognostic Effect of Sarcomatoid Dedifferentiation in Patients With Surgically Treated Renal Cell Carcinoma: A Matched-Pair Analysis. *Clin Genitourin Cancer*. 2013 Jun 29. doi:pii: S1558-7673(13)00087-6. 10.1016/j.clgc.2013.04.026. PMID: 23820063
1042. Crivelli JJ, Xylinas E, Kluth LA, Rieken M, Rink M, **Shariat SF**. Effect of Smoking on Outcomes of Urothelial Carcinoma: A Systematic Review of the Literature. *Eur Urol*. 2013 Jun 19. doi:pii: S0302-2838(13)00608-8. 10.1016/j.eururo.2013.06.010. PMID: 23810104
1043. Crivelli JJ, Xylinas E, Kluth LA, da Silva RD, Chrystal J, Novara G, Karakiewicz PI, David SG, Scherr DS, Lotan Y, **Shariat SF**. Effect of statin use on outcomes of non-muscle-invasive bladder cancer. *BJU Int*. 2013 Jul;112(2):E4-E12. doi: 10.1111/bju.12150. PMID: 23795797
1044. Trinh VQ, Trinh QD, Tian Z, Hu JC, **Shariat SF**, Perrotte P, Karakiewicz PI, Sun M. In-hospital mortality and failure-to-rescue rates after radical cystectomy. *BJU Int*. 2013 Jul;112(2):E20-7. doi: 10.1111/bju.12214. PMID: 23795794
1045. Merseburger AS, Herrmann TR, **Shariat SF**, Kyriazis I, Nagele U, Traxer O, Liatsikos EN. EAU Guidelines on Robotic and Single-site Surgery in Urology. *Eur Urol*. 2013 Aug;64(2):277-91. doi: 10.1016/j.eururo.2013.05.034. Epub 2013 May 25. PMID: 23764016
1046. Gakis G, Boorjian SA, Briganti A, Joniau S, Karazanashvili G, Karnes RJ, Mattei A, **Shariat SF**, Stenzl A, Wirth M, Stief CG. The Role of Radical Prostatectomy and Lymph Node Dissection in Lymph Node-Positive Prostate Cancer: A Systematic Review of the Literature. *Eur Urol*. 2013 May 22. doi:pii: S0302-2838(13)00500-9. 10.1016/j.eururo.2013.05.033. PMID: 23735200
1047. Drouin SJ, Comperat E, Varinot J, Vaessen C, Bitker MO, Chartier-Kastler E, Mozer P, **Shariat SF**, Cussenot O, Roupr  t M. The surgical approach can be determined from the pathological specimen obtained after open or robot-assisted laparoscopic radical prostatectomy. *World J Urol*. 2013 May 31. PMID: 23723015
1048. Bianchi M, Becker A, Hansen J, Trinh QD, Tian Z, Abdollah F, Briganti A, **Shariat SF**, Perrotte P, Montorsi F, Karakiewicz PI, Sun M. Conditional survival after nephrectomy for renal cell carcinoma (RCC): changes in future survival probability over time. *BJU Int*. 2013 Jun;111(8):E283-9. PMID: 23714646
1049. Becker A, Roghmann F, Trinh QD, Hansen J, Tian Z, **Shariat SF**, Noldus J, Perrotte P, Graefen M, Karakiewicz PI, Sun M. Sociodemographic disparities in the treatment of small renal masses. *BJU Int*. 2013 Jun;111(8):E274-82. doi: 10.1111/bju.12111. PMID: 23714645
1050. Kluth LA, Rink M, Ahyai SA, Fisch M, **Shariat SF**, Dahm P. [Randomized controlled trials terminated prematurely : Beneficial therapy effects.] *Urologe A*. 2013 May 29. German. PMID: 23712423
1051. Kluth LA, Rink M, Chun FK, Fisch M, **Shariat SF**, Dahm P. [The likelihood ratio : Estimation of the impact of a diagnostic test on treatment decision]. *Urologe A*. 2013 Jul;52(7):982-5. doi: 10.1007/s00120-013-3145-1. German. PMID: 23708004

1052. Rink M, Kluth LA, **Shariat SF**, Fisch M, Dahlem R, Dahm P. [Kaplan-Meier analysis in urological practice]. *Urologe A*. 2013 Jun;52(6):838-41. doi: 10.1007/s00120-013-3150-4. German. PMID: 23703691
1053. Trinh QD, Bjartell A, Freedland SJ, Hollenbeck BK, Hu JC, **Shariat SF**, Sun M, Vickers AJ. A Systematic Review of the Volume-Outcome Relationship for Radical Prostatectomy. *Eur Urol*. 2013 Apr 19. doi:pii: S0302-2838(13)00375-8. 10.1016/j.eururo.2013.04.012. PMID 23664423
1054. Bianchi M, Becker A, Trinh QD, Abdollah F, Tian Z, **Shariat SF**, Montorsi F, Perrotte P, Graefen M, Karakiewicz PI, Sun M. An analysis of patients with T2 renal cell carcinoma (RCC) according to tumour size: a population-based analysis. *BJU Int*. 2013 Apr 12. PMID: 23651446
1055. Tilki D, Brausi M, Colombo R, Evans CP, Fradet Y, Fritsche HM, Lerner SP, Sagalowsky A, **Shariat SF**, Bochner BH. lymphadenectomy for bladder cancer at the time of radical cystectomy. *Eur Urol*. 2013 Apr 29. PMID: 23648149
1056. Lotan Y, Bagrodia A, Passoni N, Rachakonda V, Kapur P, Arriaga Y, Bolenz C, Margulis V, Raj GV, Sagalowsky AI, **Shariat SF**. Prospective evaluation of a molecular marker panel for prediction of recurrence and cancer-specific survival after radical cystectomy. *Eur Urol*. 2013 Apr 3. PMID: 23571005
1057. Sun M, **Shariat SF**, Trinh QD, Meskawi M, Bianchi M, Hansen J, Abdollah F, Perrotte P, Karakiewicz PI. An evidence-based guide to the selection of sequential therapies in metastatic renal cell carcinoma. *Ther Adv Urol*. 2013 Apr;5(2):121-8. PMID: 23554847
1058. Gontero P, Oderda M, Mehnert A, Gurioli A, Marson F, Lucca I, Rink M, Schmid M, Kluth LA, Pappagallo G, Sogni F, Sanguedolce F, Schiavina R, Martorana G, **Shariat SF**, Chun F. The impact of intravesical Gemcitabine and 1/3 dose Bacillus Calmette Guérin instillation therapy on the quality of life in non-muscle-invasive bladder cancer patients: results of a prospective, randomised phase II trial. *J Urol*. 2013 Mar 29. PMID: 23545101
1059. Xylinas E, Kluth LA, Crivelli JJ, Rieken M, Margulis V, Seitz C, **Shariat SF**. Impact of statin use on oncologic outcomes of patients with upper tract urothelial carcinoma treated with radical nephroureterectomy. *Eur Urol*. 2013 Jun;63(6):1134-5. PMID: 23540954
1060. Rouprêt M, Babjuk M, Compérat E, Zigeuner R, Sylvester R, Burger M, Cowan N, Böhle A, Van Rhijn BW, Kaasinen E, Palou J, **Shariat SF**. European guidelines on upper tract urothelial carcinomas: 2013 update. *Eur Urol*. 2013 Jun;63(6):1059-71. PMID: 23540953
1061. Kluth LA, Rink M, **Shariat SF**, Chun FK, Fisch M, Dahm P. Use and interpretation of the number needed to treat in urological practice. *Urologe A*. 2013 May;52(5):682-5. PMID: 23532201
1062. Bagrodia A, Kuehhas FE, Gayed BA, Wood CG, Raman JD, Kapur P, Derweesh IH, Bensalah K, Sagalowsky AI, **Shariat SF**, Lotan Y, Margulis V. Comparative analysis of oncologic outcomes of partial ureterectomy vs radical nephroureterectomy in upper tract urothelial carcinoma. *Urology*. 2013 May;81(5):972-8. PMID: 23523292
1063. Sammon J, Trinh VQ, Ravi P, Sukumar S, Gervais MK, **Shariat SF**, Larouche A, Tian Z, Kim SP, Kowalczyk KJ, Hu JC, Menon M, Karakiewicz PI, Trinh QD, Sun M. Health care-associated infections after major cancer surgery: Temporal trends, patterns of care, and effect on mortality. *Cancer*. 2013 Mar 19. PMID: 23512473
1064. Dariane C, Le Cossec C, Drouin SJ, Wolff B, Granger B, Mozer P, Bitker MO, **Shariat SF**, Cussenot O, Rouprêt M. Comparison of oncologic outcomes after radical prostatectomy in men diagnosed with prostate cancer with PSA levels below and above 4 ng/mL. *World J Urol*. 2013 Apr 26. PMID: 23619479

1065. Rink M, Kluth LA, **Shariat SF**, Dahlem R, Fisch M, Dahm P. [Confidence intervals and p-values in urology: Interpretation and misinterpretation.] *Urologe A*. 2013 Mar 21. German. PMID: 2351185
1066. Rink M, Kluth LA, **Shariat SF**, Chun FK, Fisch M, Dahm P. [Use of PubMed to improve evidence-based medicine in routine urological practice]. *Urologe A*. 2013 Mar;52(3):367-72. German. PMID: 23503794
1067. Sun M, Trinh QD, Bianchi M, Hansen J, Abdollah F, Tian Z, **Shariat SF**, Montorsi F, Perrotte P, Karakiewicz PI. Extent of lymphadenectomy does not improve the survival of patients with renal cell carcinoma and nodal metastases: biases associated with the handling of missing data. *BJU Int*. 2013 Mar 12. PMID: 23490031
1068. Abdollah F, Gandaglia G, Thuret R, Schmitges J, Tian Z, Jeldres C, Passoni NM, Briganti A, **Shariat SF**, Perrotte P, Montorsi F, Karakiewicz PI, Sun M. Incidence, survival and mortality rates of stage-specific bladder cancer in United States: A trend analysis. *Cancer Epidemiol*. 2013 Feb 25. PMID: 2348548
1069. Cindolo L, Chiodini P, Brookman-May S, De Cobelli O, May M, Squillacioti S, De Nunzio C, Tubaro A, Coman I, Feciche B, Truss M, Wirth MP, Dalpiaz O, Chromecki TF, **Shariat SF**, Sanchez-Chapado M, Del Carmen Santiago Martin M, Rocco B, Salzano L, Lotrecchiano G, Berardinelli F, Schips L. Assessing the accuracy and generalizability of the preoperative and postoperative Karakiewicz nomograms for renal cell carcinoma: results from a multicentre European and US study. *BJU Int*. 2013 Mar 7 PMID: 23470199
1070. Xylinas E, Rink M, Robinson BD, Lotan Y, Babjuk M, Brisuda A, Green DA, Kluth LA, Pycha A, Fradet Y, Faison T, Lee RK, Karakiewicz PI, Zerbib M, Scherr DS, **Shariat SF**. Impact of histological variants on oncological outcomes of patients with urothelial carcinoma of the bladder treated with radical cystectomy. *Eur J Cancer*. 2013 Mar 2. PMID: 23466126
1071. Rink M, Xylinas E, Trinh QD, Lotan Y, Margulis V, Raman JD, Fisch M, Lee RK, Chun FK, Abdennabi J, Seitz C, Pycha A, Zlotta AR, Karakiewicz PI, Babjuk M, Scherr DS, **Shariat SF**: Gender-specific effect of smoking on upper tract urothelial carcinoma outcomes. *BJU Int*. 2013 Mar 6. PMID: 23465088
1072. Xylinas E, Rink M, Margulis V, Clozel T, Lee RK, Comploj E, Novara G, Raman JD, Lotan Y, Weizer A, Roupert M, Pycha A, Scherr DS, Seitz C, Ficarra V, Trinh QD, Karakiewicz PI, Montorsi F, Zerbib M, **Shariat SF**: Impact of renal function on eligibility for chemotherapy and survival in patients who have undergone radical nephro-ureterectomy. *BJU Int*. 2013 Mar 6. PMID: 23464979
1073. Trinh QD, Sun M, Kim SP, Sammon J, Kowalczyk KJ, Friedman AA, Sukumar S, Ravi P, Muhletaler F, Agarwal PK, **Shariat SF**, Hu JC, Menon M, Karakiewicz PI. The impact of hospital volume, residency, and fellowship training on perioperative outcomes after radical prostatectomy. *Urol Oncol*. 2013 Feb 28. PMID: 23453659
1074. May M, Ficarra V, **Shariat SF**, Zigeuner R, Chromecki T, Cindolo L, Burger M, Gunia S, Feciche B, Wenzl V, Aziz A, Chun F, Becker A, Pahernik S, Simeone C, Longo N, Zucchi A, Antonelli A, Mirone V, Stief C, Novara G, Brookman-May S; Members of the CORONA- and the SATURN projects, and the Young Academic Urologists Renal Cancer Group. Impact of clinical and histopathological parameters on disease-specific survival in patients with collecting duct renal cell carcinoma - Development of a disease-specific risk-model. *J Urol*. 2013 Feb 19. PMID: 23434943
1075. Bianchi M, Becker A, Abdollah F, Trinh QD, Hansen J, Tian Z, **Shariat SF**, Perrotte P, Karakiewicz PI, Sun M. Rates of open versus laparoscopic and partial versus radical nephrectomy

- for T1a renal cell carcinoma: A population-based evaluation. *Int J Urol*. 2013 Feb 19. PMID: 23418921
1076. Sun M, Ravi P, Karakiewicz PI, Sukumar S, Sammon J, Bianchi M, **Shariat SF**, Jeong W, Ghani KR, Hansen J, Friedman A, Perrotte P, Peabody JO, Menon M, Trinh QD. Is there a relationship between leapfrog volume thresholds and perioperative outcomes after radical cystectomy? *Urol Oncol*. 2013 Feb 9. PMID: 23403162
1077. da Silva RD, Xylinas E, Kluth L, Crivelli JJ, Chrystal J, Chade D, Guglielmetti GB, Pycha A, Lotan Y, Karakiewicz PI, Sun M, Fajkovic H, Zerbib M, Scherr DS, **Shariat SF**: Impact of Statin Use on Oncological Outcomes of Patients with Urothelial Carcinoma of the Bladder Treated With Radical Cystectomy. *J Urol*. 2013 Feb 7. PMID: 23395802
1078. Kluth LA, Xylinas E, Crivelli JJ, Passoni N, Comploj E, Pycha A, Chrystal J, Sun M, Karakiewicz PI, Gontero P, Lotan Y, Chun FK, Fisch M, Scherr DS, **Shariat SF**. Obesity is associated with worse outcomes in patients with T1 high grade urothelial carcinoma of the bladder. *J Urol*. 2013 Jan 31. PMID: 23376707
1079. Larré S, Catto JW, Cookson MS, Messing EM, **Shariat SF**, Soloway MS, Svatek RS, Lotan Y, Zlotta AR, Grossman HB. Screening for bladder cancer: rationale, limitations, whom to target, and perspectives. *Eur Urol*. 2013 PMID: 23313034
1080. Hansen J, Rink M, Graefen M, **Shariat S**, Chun FK: Assays for Prostate Cancer: Changing the Screening Paradigm? *Mol Diagn Ther*. 2013 Jan 25. PMID:23355098
1081. Margulis V, **Shariat SF**, Rapoport Y, Rink M, Sjöberg DD, Tannir NM, Abel EJ, Culp SH, Tamboli P, Wood CG. Development of accurate models for individualized prediction of survival after cytoreductive nephrectomy for metastatic renal cell carcinoma. *Eur Urol*. 2012 PMID: 23273681
1082. Xylinas E, Rink M, Margulis V, Faison T, Comploj E, Novara G, Raman JD, Lotan Y, Guillonneau B, Weizer A, Pycha A, Scherr DS, Seitz C, Sun M, Trinh QD, Karakiewicz PI, Montorsi F, Zerbib M, Gönen M, **Shariat SF**. Prediction of true nodal status in patients with pathological lymph node negative upper tract urothelial carcinoma at radical nephroureterectomy. *J Urol*. 2012 Dec 14. PMID: 23253960
1083. Trinh QD, Sukumar S, Schmitges J, Bianchi M, Sun M, **Shariat SF**, Sammon JD, Jeldres C, Zorn KC, Perrotte P, Graefen M, Rogers CG, Peabody JO, Menon M, Karakiewicz PI: Effect of nodal metastases on cancer-specific mortality after cytoreductive nephrectomy. *Ann Surg Oncol*. 2012 Dec 23. PMID: 23263779
1084. Rink M, Zabor EC, Furberg H, Xylinas E, Ehdaie B, Novara G, Babjuk M, Pycha A, Lotan Y, Trinh QD, Chun FK, Lee RK, Karakiewicz PI, Fisch M, Robinson BD, Scherr DS, **Shariat SF**. Impact of smoking and smoking cessation on outcomes in bladder cancer patients treated with radical cystectomy. *Eur Urol*. 2012 Nov 27 PMID: 23206854 the
1085. Najari BB, Rink M, Li PS, Karakiewicz PI, Scherr DS, Shabsigh R, Meryn S, Schlegel PN, **Shariat SF**. Sex disparities in cancer mortality: risks of being a man in the U.S. *J Urol*. 2012 Nov 30. PMID: 23206422
1086. Kluth LA, Fajkovic H, Xylinas E, Crivelli JJ, Passoni N, Rouprêt M, Becker A, Comploj E, Pycha A, Holmang S, Gupta A, Lotan Y, Karakiewicz PI, Gontero P, Chun FK, Fisch M, Scherr DS, **Shariat SF**. Female gender is associated with higher risk of disease recurrence in patients with primary T1 high-grade urothelial carcinoma of the bladder. *World J Urol*. 2012 Nov 30. PMID: 23196773

1087. Tilki D, **Shariat SF**, Lotan Y, Rink M, Karakiewicz PI, Schoenberg MP, Lerner SP, Sonpavde G, Sagalowsky AI, Gupta A. Lymphovascular invasion is independently associated with bladder cancer recurrence and survival in patients with final stage T1 disease and negative lymph nodes after radical cystectomy. *BJU Int*. 2012 Nov 26. PMID: 23181623
1088. Xylinas E, Cha EK, Sun M, Rink M, Trinh QD, Novara G, Green DA, Pycha A, Fradet Y, Daneshmand S, Svatek RS, Fritsche HM, Kassouf W, Scherr DS, Faison T, Crivelli JJ, Tagawa ST, Zerbib M, Karakiewicz PI, **Shariat SF**. Risk stratification of pT1-3N0 patients after radical cystectomy for adjuvant chemotherapy counselling. *Br J Cancer*. 2012 Nov 20;107(11):1826-32. PMID: 23169335
1089. Green DA, Osterberg EC, Xylinas E, Rink M, Karakiewicz PI, Scherr DS, **Shariat SF**. Predictive tools for prostate cancer staging, treatment response and outcomes. *Arch Esp Urol*. 2012 Nov;65(9):787-807. English, Spanish. PMID:23154603
1090. Cha EK, Tirsar LA, Schwentner C, Hennenlotter J, Christos PJ, Stenzl A, Mian C, Martini T, Pycha A, Schmitz-Dräger BJ **Shariat SF**. Accurate risk assessment of patients with asymptomatic hematuria for the presence of bladder cancer. *World J Urol*. 2012 Nov 5. PMID: 23124847
1091. Thuret R, Sun M, Budaus L, Abdollah F, Liberman D, **Shariat SF**, Iborra F, Guiter J, Patard JJ, Perrotte P, Karakiewicz PI. A population-based analysis of the effect of marital status on overall and cancer-specific mortality in patients with squamous cell carcinoma of the penis. *Cancer Causes Control*. 2012 Oct 30. PMID: 23109172
1092. Rouprêt M, Hupertan V, Seisen T, Colin P, Xylinas E, Yates DR, Fajkovic H, Lotan Y, Raman JD, Zigeuner R, Remzi M, Bolenz C, Novara G, Kassouf W, Ouzzane A, Rozet F, Cussenot O, Martinez-Salamanca JI, Fritsche HM, Walton TJ, Wood CG, Bensalah K, Karakiewicz PI, Montorsi F, Margulis V, **Shariat SF**. Prediction of cancer-specific survival after radical nephroureterectomy for upper tract urothelial carcinoma: development of an optimized post-operative nomogram using decision curve analysis. *J Urol*. 2012 Oct 23. PMID: 23103802
1093. Xylinas E, Rink M, Novara G, Green DA, Clozel T, Fritsche HM, Guillonneau B, Lotan Y, Kassouf W, Tilki D, Babjuk M, Karakiewicz PI, Montorsi F, Abdennabi J, Trinh QD, Svatek RS, Scherr DS, Zerbib M, **Shariat SF**. Predictors of Survival in Patients With Soft Tissue Surgical Margin Involvement at Radical Cystectomy. *Ann Surg Oncol*. 2012 Oct 26. PMID: 23099729
1094. Bianchi M, Trinh QD, Sun M, Meskawi M, Schmitges J, **Shariat SF**, Briganti A, Tian Z, Jeldres C, Sukumar S, Peabody JO, Graefen M, Perrotte P, Menon M, Montorsi F, Karakiewicz PI. Impact of academic affiliation on radical cystectomy outcomes in North America: A population-based study. *Can Urol Assoc J*. 2012 Aug;6(4):245-50. PMID: 23093532
1095. Carlsson SV, Tafe LJ, Chade DC, Sjoberg DD, Passoni N, **Shariat SF**, Eastham J, Scardino PT, Fine SW, Touijer KA. Pathological features of lymph node metastases in predicting biochemical recurrence after radical prostatectomy for prostate cancer. *J Urol*. 2012 Oct 18. PMID: 23085057
1096. Sammon JD, Karakiewicz PI, Sun M, Sukumar S, Ravi P, Ghani KR, Bianchi M, Peabody JO, **Shariat SF**, Perrotte P, Hu JC, Menon M, Trinh QD. Robot-assisted vs. Open radical prostatectomy: The differential effect of regionalization, procedure volume and operative approach. *J Urol*. 2012 Oct 18. PMID: 23085052
1097. Kamat AM, Hegarty PK, Gee JR, Clark PE, Svatek RS, Hegarty N, **Shariat SF**, Xylinas E, Schmitz-Dräger BJ, Lotan Y, Jenkins LC, Droller M, van Rhijn BW, Karakiewicz PI. ICUD-EAU International Consultation on Bladder Cancer 2012: Screening, Diagnosis, and Molecular Markers. *Eur Urol*. 2012 Oct 4. PMID: 23083902

1098. Rink M, Xylinas E, Babjuk M, Hansen J, Pycha A, Comploj E, Lotan Y, Sun M, Karakiewicz PI, Abdennabi J, Fajkovic H, Loidl W, Chun FK, Fisch M, Scherr DS, **Shariat SF**. Impact of Smoking on Outcomes of Patients with a History of Recurrent Nonmuscle Invasive Bladder Cancer. *J Urol*. 2012 Oct 17. PMID: 23083868
1099. Thuret R, Sun M, Abdollah F, Budaus L, **Shariat SF**, Iborra F, Guiter J, Patard JJ, Karakiewicz PI. Competing-risks analysis in patients with T1 squamous cell carcinoma of the penis. *BJU Int*. 2012 Oct 12. PMID: 23057865
1100. Rouprêt M, Xylinas E, Colin P, Kluth L, Karakiewicz P, **Shariat SF**. Oncologic Outcomes and Survival in pT0 Tumors After Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma: Results from of a Large Multicenter International Collaborative Study. *Eur Urol*. 2012 Sep 23. PMID: 23040206
1101. Abdollah F, Abdo A, Sun M, Schmitges J, Tian Z, Briganti A, **Shariat SF**, Perrotte P, Montorsi F, Karakiewicz PI. Pelvic lymph node dissection for prostate cancer: Adherence and accuracy of the recent guidelines. *Int J Urol*. 2012 Oct 8. PMID: 23039245
1102. Sun M, Bianchi M, Hansen J, Abdollah F, Trinh QD, Lughezzani G, **Shariat SF**, Montorsi F, Perrotte P, Karakiewicz PI. Nodal involvement at nephrectomy is associated with worse survival: A stage-for-stage and grade-for-grade analysis. *Int J Urol*. 2012 Oct 8. PMID: 23039208
1103. Catto JW, **Shariat SF**. The Changing Face of Renal Cell Carcinoma: The Impact of Systematic Genetic Sequencing on Our Understanding of This Tumor's Biology. *Eur Urol*. 2012 Sep 26. PMID: 23026395
1104. Green DA, Rink M, Xylinas E, Matin SF, Stenzl A, Roupret M, Karakiewicz PI, Scherr DS, **Shariat SF**. Urothelial Carcinoma of the Bladder and the Upper Tract: Disparate Twins. *J Urol*. 2012 Sep 27. PMID: 23023150
1105. Fajkovic H, Cha EK, Xylinas E, Rink M, Pycha A, Seitz C, Bolenz C, Dunning A, Novara G, Trinh QD, Karakiewicz PI, Margulis V, Raman JD, Walton TJ, Baba S, Carballido J, Otto W, Montorsi F, Lotan Y, Kassouf W, Fritsche HM, Bensalah K, Zigeuner R, Scherr DS, Sonpavde G, Roupret M, **Shariat SF**. Disease-free survival as a surrogate for overall survival in upper tract urothelial carcinoma. *World J Urol*. 2012 Sep 26. PMID: 23011256
1106. Xylinas E, Kluth L, Mangal S, Roupret M, Karakiewicz PI, **Shariat SF**. Predictive tools for clinical decision-making and counseling of patients with upper tract urothelial carcinoma. *World J Urol*. 2012 Sep 18. PMID: 22986907
1107. Trinh QD, Bianchi M, Hansen J, Tian Z, Abdollah F, **Shariat SF**, Montorsi F, Perrotte P, Karakiewicz PI, Sun M. In-hospital Mortality and Failure to Rescue After Cytoreductive Nephrectomy. *Eur Urol*. 2012 Sep 7. pii: S0302-2838(12)01022-6. PMID: 22981674
1108. Rink M, Xylinas E, Babjuk M, Pycha A, Karakiewicz PI, Novara G, Dahlem R, **Shariat SF**. Smoking Reduces the Efficacy of Intravesical Bacillus Calmette-Guérin Immunotherapy in Non-muscle-invasive Bladder Cancer. *Eur Urol*. 2012 Sep 5. . PMID: 22980442
1109. Yates DR, Brausi MA, Catto JW, Dalbagni G, Rouprêt M, **Shariat SF**, Sylvester RJ, Witjes JA, Zlotta AR, Palou-Redorta J. Treatment Options Available for Bacillus Calmette-Guérin Failure in Non-muscle-invasive Bladder Cancer. *Eur Urol*. 2012 Sep 3. PMID: 22959049
1110. Green DA, Rink M, Cha EK, Xylinas E, Chughtai B, Scherr DS, **Shariat SF**, Lee RK. Cost-effective treatment of low-risk carcinoma not invading bladder muscle. *BJU Int*. 2012 Sep 7. PMID: 22958598

1111. Rink M, Park K, Volkmer BG, Xylinas E, Hansen J, Cha EK, Robinson BD, Hautmann R, Küfer R, Engel O, Chun FK, Dahlem R, Rubin MA, **Shariat SF**, Mosquera JM. Loss of SPINK1 expression is associated with unfavorable outcomes in urothelial carcinoma of the bladder after radical cystectomy. *Urol Oncol*. 2012 Sep 1. pii: S1078-1439(12)00237-2. PMID: 22944196
1112. Rink M, Lee DJ, Kent M, Xylinas E, Fritsche HM, Babjuk M, Brisuda A, Hansen J, Green DA, Aziz A, Cha EK, Novara G, Chun FK, Lotan Y, Bastian PJ, Tilki D, Gontero P, Pycha A, Baniel J, Mano R, Ficarra V, Trinh QD, Tagawa ST, Karakiewicz PI, Scherr DS, Sjoberg DD, **Shariat SF**; for the Bladder Cancer Research Consortium. Predictors of cancer-specific mortality after disease recurrence following radical cystectomy. *BJU Int*. 2012 Sep 3. PMID: 22938654
1113. Bachir BG, **Shariat SF**, Zlotta A, Svatek R, Black PC, Shah JB, Kassouf W; on behalf of the Bladder Cancer Think Tank (Bladder Cancer Advocacy Network) and Canadian Bladder Cancer Network (Bladder Cancer Canada). Demographic analysis of randomized controlled trials in bladder cancer. *BJU Int*. 2012 Aug 29. doi: 10.1111/j.1464-410X.2012.11401.x. PMID: 22928764
1114. Rink M, Furberg H, Zabor EC, Xylinas E, Babjuk M, Pycha A, Lotan Y, Karakiewicz PI, Novara G, Robinson BD, Montorsi F, Chun FK, Scherr DS, **Shariat SF**. Impact of Smoking and Smoking Cessation on Oncologic Outcomes in Primary Non-muscle-invasive Bladder Cancer. *Eur Urol*. 2012 Aug 21. PMID: 22925575
1115. Xylinas E, Rouprêt M, Kluth L, Scherr DS, **Shariat SF**; for the Upper Tract Urothelial Carcinoma Collaboration (UTUCC). Collaborative Research Networks as a Platform for Virtual Multidisciplinary, International Approach to Managing Difficult Clinical Cases: An Example from the Upper Tract Urothelial Carcinoma Collaboration. *Eur Urol*. 2012 Aug 20. PMID: 22921717
1116. Reifsnnyder JE, Ramasamy R, Ng CK, Dipietro J, Shin B, **Shariat SF**, Del Pizzo JJ, Scherr DS. Laparoscopic and open partial nephrectomy: complication comparison using the Clavien system. *JSLs*. 2012 Jan-Mar;16(1):38-44. PMID: 22906328
1117. Sammon J, Trinh QD, Sun M, Bianchi M, Schmitges J, **Shariat SF**, Ghani KR, Sukumar S, Jeldres C, Briganti A, Perrotte P, Rogers CG, Peabody JO, Montorsi F, Menon M, Karakiewicz PI. The effect of gender on nephrectomy perioperative outcomes: a national survey. *Can J Urol*. 2012 Aug;19(4):6337-44. PMID: 22892256
1118. Skeldon SC, Semotiuk K, Aronson M, Holter S, Gallinger S, Pollett A, Kuk C, van Rhijn B, Bostrom P, Cohen Z, Fleshner NE, Jewett MA, Hanna S, **Shariat SF**, Van Der Kwast TH, Evans A, Catto J, Bapat B, Zlotta AR. Patients with Lynch Syndrome Mismatch Repair Gene Mutations Are at Higher Risk for Not Only Upper Tract Urothelial Cancer but Also Bladder Cancer. *Eur Urol*. 2012 Aug 2. PMID: 22883484
1119. Adibi M, Youssef R, **Shariat SF**, Lotan Y, Wood CG, Sagalowsky AI, Zigeuner R, Montorsi F, Bolenz C, Margulis V. Oncological outcomes after radical nephroureterectomy for upper tract urothelial carcinoma: Comparison over the three decades. *Int J Urol*. 2012 Aug 12. PMID: 22882743
1120. Fajkovic H, Cha EK, Jeldres C, Robinson BD, Rink M, Xylinas E, Chromecki TF, Breinl E, Svatek RS, Donner G, Tagawa ST, Tilki D, Bastian PJ, Karakiewicz PI, Volkmer BG, Novara G, Joual A, Faison T, Sonpavde G, Daneshmand S, Lotan Y, Scherr DS, **Shariat SF**. Extranodal Extension Is a Powerful Prognostic Factor in Bladder Cancer Patients with Lymph Node Metastasis. *Eur Urol*. 2012 Jul 20. PMID: 22877503
1121. Burger M, Catto JW, Dalbagni G, Grossman HB, Herr H, Karakiewicz P, Kassouf W, Kiemeny LA, La Vecchia C, **Shariat SF**, Lotan Y. Epidemiology and Risk Factors of Urothelial Bladder Cancer. *Eur Urol*. 2012 Jul 25. PMID: 22877502

1122. Hansen J, Auprich M, Ahyai SA, de la Taille A, van Poppel H, Marberger M, Stenzl A, Mulders PF, Huland H, Fisch M, Abbou CC, Schalken JA, Fradet Y, Marks LS, Ellis W, Partin AW, Pummer K, Graefen M, Haese A, Walz J, Briganti A, **Shariat SF**, Chun FK. Initial Prostate Biopsy: Development and Internal Validation of a Biopsy-specific Nomogram Based on the Prostate Cancer Antigen 3 Assay. *Eur Urol*. 2012 Jul 20. PMID: 22854248
1123. Xylinas E, **Shariat SF**, Zerbib M. Uptake of Laparoscopic Radical Nephroureterectomy in France: A 2003-2011 National Practice Report. *Eur Urol*. 2012 Jul 21. PMID: 22840352
1124. Rink M, **Shariat SF**, Xylinas E, Fitzgerald JP, Hansen J, Green DA, Kamat AM, Novara G, Daneshmand S, Fradet Y, Tagawa ST, Bastian PJ, Kassouf W, Trinh QD, Karakiewicz PI, Fritsche HM, Tilki D, Chun FK, Volkmer BG, Babjuk M, Merseburger AS, Scherr DS, Lotan Y, Svatek RS. Does increasing the nodal yield improve outcomes in patients without nodal metastasis at radical cystectomy? *World J Urol*. 2012 Jul 26. PMID: 22832587
1125. Hansen J, Rink M, Bianchi M, Kluth LA, Tian Z, Ahyai SA, **Shariat SF**, Briganti A, Steuber T, Fisch M, Graefen M, Karakiewicz PI, Chun FK. External validation of the updated briganti nomogram to predict lymph node invasion in prostate cancer patients undergoing extended lymph node dissection. *Prostate*. 2012 Jul 20. doi: 10.1002/pros.22559. PMID: 22821742
1126. Sukumar S, Sun M, Karakiewicz PI, Friedman AA, Chun FK, Sammon J, Ghani KR, Ravi P, Bianchi M, Jeong W, **Shariat SF**, Hansen J, Peabody JO, Elder JS, Menon M, Trinh QD. National trends and disparities in the use of minimally invasive adult pyeloplasty. *J Urol*. 2012 Sep;188(3):913-8. Epub 2012 Jul 20. PMID: 22819404
1127. Rink M, Hansen J, Cha EK, Green DA, Babjuk M, Svatek RS, Xylinas E, Tagawa ST, Faison T, Novara G, Karakiewicz PI, Daneshmand S, Lotan Y, Kassouf W, Fritsche HM, Pycha A, Comploj E, Tilki D, Bastian PJ, Chun FK, Dahlem R, Scherr DS, **Shariat SF**: Outcomes and prognostic factors in patients with a single lymph node metastasis at time of radical cystectomy. *BJU Int*. 2012 Jul 19. PMID: 22809039
1128. Rink M, Sjoberg D, Comploj E, Margulis V, Xylinas E, Lee RK, Hansen J, Cha EK, Raman JD, Remzi M, Bensalah K, Novara G, Matin SF, Chun FK, Kikuchi E, Kassouf W, Martinez-Salamanca JJ, Lotan Y, Seitz C, Pycha A, Zigeuner R, Karakiewicz PI, Scherr DS, Vickers AJ, **Shariat SF**. Risk of Cancer-specific Mortality following Recurrence After Radical Nephroureterectomy. *Ann Surg Oncol*. 2012 Jul 18. PMID: 22805867
1129. Green DA, Rink M, Hansen J, Cha EK, Robinson B, Tian Z, Chun FK, Tagawa S, Karakiewicz PI, Fisch M, Scherr DS, **Shariat SF**: Accurate preoperative prediction of non-organ-confined bladder urothelial carcinoma at cystectomy. *BJU Int*. 2012 Jul 13. PMID: 22805163
1130. Novara G, Ficarra V, Rosen RC, Artibani W, Costello A, Eastham JA, Graefen M, Guazzoni G, **Shariat SF**, Stolzenburg JU, Van Poppel H, Zattoni F, Montorsi F, Motttrie A, Wilson TG. Systematic Review and Meta-analysis of Perioperative Outcomes and Complications After Robot-assisted Radical Prostatectomy. *Eur Urol*. 2012 Jun 2. PMID: 22749853
1131. Novara G, Ficarra V, Mocellin S, Ahlering TE, Carroll PR, Graefen M, Guazzoni G, Menon M, Patel VR, **Shariat SF**, Tewari AK, Van Poppel H, Zattoni F, Montorsi F, Motttrie A, Rosen RC, Wilson TG. Systematic Review and Meta-analysis of Studies Reporting Oncologic Outcome After Robot-assisted Radical Prostatectomy. *Eur Urol*. 2012 Jun 2. PMID: 22749851
1132. Brookman-May S, May M, **Shariat SF**, Xylinas E, Stief C, Zigeuner R, Chromecki T, Burger M, Wieland WF, Cindolo L, Schips L, De Cobelli O, Rocco B, De Nunzio C, Feciche B, Truss M, Gilfrich C, Pahernik S, Hohenfellner M, Zastrow S, Wirth MP, Novara G, Carini M, Minervini A, Simeone C, Antonelli A, Mirone V, Longo N, Simonato A, Carmignani G, Ficarra V; members of

- the CORONA project and the SATURN project. Features Associated with Recurrence beyond 5 Years after Nephrectomy and Nephron-Sparing Surgery for Renal Cell Carcinoma: Development and Internal Validation of a Risk Model (PRELANE score) to Predict Late Recurrence Based on a Large Multicenter Database (CORONA/SATURN Project). *Eur Urol.* 2012 Jun 22. PMID: 22748912
1133. Rink M, Xylinas E, Margulis V, Cha EK, Ehdaie B, Raman JD, Chun FK, Matsumoto K, Lotan Y, Furberg H, Babjuk M, Pycha A, Wood CG, Karakiewicz PI, Fisch M, Scherr DS, **Shariat SF**; for the Upper Tract Urothelial Carcinoma Collaboration. Impact of Smoking on Oncologic Outcomes of Upper Tract Urothelial Carcinoma After Radical Nephroureterectomy. *Eur Urol.* 2012 Jun 22. PMID: 22743166
 1134. Chromecki TF, Cha EK, Fajkovic H, Rink M, Ehdaie B, Svatek RS, Karakiewicz PI, Lotan Y, Tilki D, Bastian PJ, Daneshmand S, Kassouf W, Durand M, Novara G, Fritsche HM, Burger M, Izawa JI, Brisuda A, Babjuk M, Pummer K, **Shariat SF**: Obesity is associated with worse oncological outcomes in patients treated with radical cystectomy. *BJU Int.* 2012 Jun 21. PMID: 22727036
 1135. **Shariat SF**, Rink M, Ehdaie B, Xylinas E, Babjuk M, Merseburger AS, Svatek RS, Cha EK, Tagawa ST, Fajkovic H, Novara G, Karakiewicz PI, Trinh QD, Daneshmand S, Lotan Y, Kassouf W, Fritsche HM, Chun FK, Sonpavde G, Joulal A, Scherr DS, Gonen M. Pathologic nodal staging score for bladder cancer: a decision tool for adjuvant therapy after radical cystectomy. *Eur Urol.* 2012 Jun 16. PMID: 22727174
 1136. Rink M, Adam M, Hansen J, Chun FK, Ahyai SA, Remzi M, Schlomm T, Engel O, Heuer R, Eichelberg C, Fisch M, Dahlem R, **Shariat SF**: Upper tract urothelial carcinoma : An update on clinical and pathological prognostic factors. *Urologe A.* 2012 Jun 16. PMID: 22699513
 1137. Rink M, Robinson BD, Green DA, Cha EK, Hansen J, Comploj E, Margulis V, Raman JD, Ng CK, Remzi M, Bensalah K, Kabbani W, Haitel A, Rioux-Leclercq N, Guo CC, Chun FK, Kikuchi E, Kassouf W, Sircar K, Sun M, Sonpavde G, Lotan Y, Pycha A, Karakiewicz PI, Scherr DS, **Shariat SF**. Impact of histological variants on clinical outcomes of patients with upper urinary tract urothelial carcinoma. *J Urol.* 2012 Jun 12. PMID: 22698626
 1138. Hansen J, Sun M, Bianchi M, Rink M, Tian Z, Hanna N, Meskawi M, Schmitges J, **Shariat SF**, Chun FK, Perrotte P, Graefen M, Karakiewicz PI. Assessment of cancer control outcomes in patients with high-risk renal cell carcinoma treated with partial nephrectomy. *Urology.* 2012 Jun 12. PMID: 22698478
 1139. Sun M, Abdollah F, Hansen J, Trinh QD, Bianchi M, Tian Z, Briganti A, **Shariat SF**, Montorsi F, Perrotte P, Karakiewicz PI. Is a treatment delay in radical prostatectomy safe in individuals with low-risk prostate cancer? *J Sex Med.* 2012 Jun 6. PMID: 22672479
 1140. Ehdaie B, Furberg H, Zabor EC, Ostroff JS, **Shariat SF**, Bochner BH, Coleman JA, Dalbagni G. Impact of smoking status at diagnosis on disease recurrence and death in upper tract urothelial carcinoma. *BJU Int.* 2012 May 29. PMID: 22642265
 1141. Sun M, Bianchi M, Trinh QD, Hansen J, Abdollah F, Hanna N, Tian Z, **Shariat SF**, Montorsi F, Perrotte P, Karakiewicz PI. Comparison of partial vs radical nephrectomy with regard to other-cause mortality in T1 renal cell carcinoma among patients aged ≥ 75 years with multiple comorbidities. *BJU Int.* 2012 May 22. PMID: 22612472
 1142. Degraff DJ, Clark PE, Cates JM, Yamashita H, Robinson VL, Yu X, Smolkin ME, Chang SS, Cookson MS, Herrick MK, **Shariat SF**, Steinberg GD, Frierson HF, Wu XR, Theodorescu D, Matusik RJ. Loss of the urothelial differentiation marker FOXA1 is associated with high grade, late

- stage bladder cancer and increased tumor proliferation. PLoS One. 2012;7(5):e36669. Epub 2012 May 10. PMID: 22590586
1143. Xylinas E, Rink M, Cha EK, Clozel T, Lee RK, Fajkovic H, Comploj E, Novara G, Margulis V, Raman JD, Lotan Y, Kassouf W, Fritsche HM, Weizer A, Martinez-Salamanca JI, Matsumoto K, Zigeuner R, Pycha A, Scherr DS, Seitz C, Walton T, Trinh QD, Karakiewicz PI, Matin S, Montorsi F, Zerbib M, **Shariat SF**. Impact of distal ureter management on oncologic outcomes following radical nephroureterectomy for upper tract urothelial carcinoma. Eur Urol. 2012 May 4. PMID: 22579047
1144. Abdollah F, Sun M, Schmitges J, Thuret R, Bianchi M, **Shariat SF**, Briganti A, Jeldres C, Perrotte P, Montorsi F, Karakiewicz PI. Survival benefit of radical prostatectomy in patients with localized prostate cancer: estimations of the number needed to treat according to tumor and patient characteristics. J Urol. 2012 May 12. PMID: 22578732
1145. Meskawi M, Sun M, Trinh QD, Bianchi M, Hansen J, Tian Z, Rink M, Ismail S, **Shariat SF**, Montorsi F, Perrotte P, Karakiewicz PI. A Review of Integrated Staging Systems for Renal Cell Carcinoma. Eur Urol. 2012 May 3. PMID: 22575911
1146. Abdollah F, Schmitges J, Sun M, Jeldres C, Tian Z, Briganti A, **Shariat SF**, Perrotte P, Montorsi F, Karakiewicz PI. Comparison of mortality outcomes after radical prostatectomy versus radiotherapy in patients with localized prostate cancer: A population-based analysis. Int J Urol. 2012 May 10. PMID: 22574746
1147. Bagrodia A, Youssef RF, Kapur P, Darwish OM, Cannon C, Belsante MJ, Gerecci D, Sagalowsky AI, **Shariat SF**, Lotan Y, Margulis V. Prospective Evaluation of Molecular Markers for the Staging and Prognosis of Upper Tract Urothelial Carcinoma. Eur Urol. 2012 Apr 17. PMID: 22552216
1148. Xylinas E, Rink M, Margulis V, Karakiewicz PI, Bensalah K, **Shariat SF**. Histologic Variants of Upper Tract Urothelial Carcinoma Do Not Affect Response to Adjuvant Chemotherapy After Radical Nephroureterectomy. Eur Urol. 2012 Apr 17. No abstract available. PMID: 22537797
1149. Green DA, Durand M, Gumpeni N, Rink M, Cha EK, Karakiewicz PI, Scherr DS, **Shariat SF**. Role of magnetic resonance imaging in bladder cancer: current status and emerging techniques. BJU Int. 2012 PMID: 22500557
1150. Abdollah F, Sun M, Thuret R, Jeldres C, Tian Z, Briganti A, **Shariat SF**, Perrotte P, Montorsi F, Karakiewicz PI. Lymph node count threshold for optimal pelvic lymph node staging in prostate cancer. Int J Urol. 2012 Mar 14. PubMed PMID: 22416788.
1151. Sammon JD, Morgan M, Djahangirian O, Trinh QD, Sun M, Ghani KR, Jeong W, Jhaveri J, Ehlert M, Schmitges J, Bianchi M, **Shariat SF**, Perrotte P, Rogers CG, Peabody JO, Menon M, Karakiewicz PI. Marital status: a gender-independent risk factor for poorer survival after radical cystectomy. BJU Int. 2012 Mar 27. PubMed PMID: 22449122.
1152. Schmitges J, Trinh QD, Sun M, Abdollah F, Bianchi M, Budäus L, Hansen J, Eichelberg C, Perrotte P, **Shariat SF**, Menon M, Montorsi F, Graefen M, Karakiewicz PI. Annual prostatectomy volume is related to rectal laceration rate after radical prostatectomy. Urology. 2012 Apr;79(4):796-803. PubMed PMID: 22469573.
1153. Sun M, Bianchi M, Hansen J, Trinh QD, Abdollah F, Tian Z, Sammon J, **Shariat SF**, Graefen M, Montorsi F, Perrotte P, Karakiewicz PI. Chronic kidney disease after nephrectomy in patients with small renal masses: a retrospective observational analysis. Eur Urol. 2012 Mar 31. PubMed PMID: 22483407.

1154. Lotan Y, Goodman PJ, Youssef RF, Svatek RS, **Shariat SF**, Tangen CM, Thompson IM Jr, Klein EA. Evaluation of vitamin E and Selenium supplementation for the prevention of bladder cancer in SWOG coordinated SELECT. *J Urol*. 2012 Apr 11. PubMed PMID: 22498220.
1155. Green DA, Durand M, Gumpeni N, Rink M, Cha EK, Karakiewicz PI, Scherr DS, **Shariat SF**. Role of magnetic resonance imaging in bladder cancer: current status and emerging techniques. *BJU Int*. 2012 Apr 13. PubMed PMID: 22500557.
1156. Xylinas E, Rink M, Margulis V, Karakiewicz PI, Bensalah K, **Shariat SF**. Histologic variants of upper tract urothelial carcinoma do not affect response to adjuvant chemotherapy after radical nephroureterectomy. *Eur Urol*. 2012 Apr 17. PubMed PMID: 22537797.
1157. Bagrodia A, Youssef RF, Kapur P, Darwish OM, Cannon C, Belsante MJ, Gerecci D, Sagalowsky AI, **Shariat SF**, Lotan Y, Margulis V. Prospective evaluation of molecular markers for the staging and prognosis of upper tract urothelial carcinoma. *Eur Urol*. 2012 Apr 17. PubMed PMID: 22552216.
1158. Xylinas E, Rink M, Margulis V, Karakiewicz P, Novara G, **Shariat SF**: Multifocal carcinoma in situ of the upper tract is associated with high risk of bladder cancer recurrence. *Eur Urol*. 2012 Feb 25. PMID: 22402109
1159. Trinh QD, Sun M, Sammon J, Tian Z, Bianchi M, **Shariat SF**, Jeong W, Ghani KR, Jeldres C, Perrotte P, Agarwal PK, Rogers CG, Peabody JO, Menon M, Karakiewicz PI: Leapfrog volume thresholds and perioperative complications after radical prostatectomy. *Cancer*. 2012 Mar 5. doi: 10.1002/cncr.27486. PMID: 22392599
1160. Lughezzani G, Burger M, Margulis V, Matin SF, Novara G, Roupret M, **Shariat SF**, Wood CG, Zigeuner R. Prognostic factors in upper urinary tract urothelial carcinomas: a comprehensive review of the current literature. *Eur Urol*. 2012 Feb 23. PMID 22381168
1161. Youssef R, Kapur P, **Shariat SF**, Arendt T, Kabbani W, Mosbah A, Abol-Enein H, Ghoneim M, Lotan Y. Prognostic value of apoptotic markers in squamous cell carcinoma of the urinary bladder. *BJU Int*. 2012 Feb 28. PMID: 22372762
1162. Marberger M, Barentsz J, Emberton M, Hugosson J, Loeb S, Klotz L, Koch M, **Shariat SF**, Vickers A. Novel approaches to improve prostate cancer diagnosis and management in early-stage disease. *BJU Int*. 2012 Mar;109 Suppl 2:1-7. PMID: 22257098
1163. Rink M, Cha EK, Green D, Hansen J, Robinson BD, Lotan Y, Sagalowsky AI, Chun FK, Karakiewicz PI, Fisch M, Scherr DS, **Shariat SF**. Biomolecular predictors of urothelial cancer behavior and treatment outcomes. *Curr Urol Rep*. 2012 Feb 23. PMID: 22354565
1164. Bianchi M, Trinh QD, Sun M, Sammon J, Schmitges J, **Shariat SF**, Sukumar S, Ghani KR, Jeldres C, Perrotte P, Rogers CG, Briganti A, Peabody JO, Montorsi F, Menon M, Karakiewicz PI: Discharge patterns after radical cystectomy: contemporary trends in the United States. *J Urol*. 2012 Feb 13. PMID: 22335867
1165. Rink M, Ehdaie B, Cha EK, Green DA, Karakiewicz PI, Babjuk M, Margulis V, Raman JD, Svatek RS, Fajkovic H, Lee RK, Novara G, Hansen J, Daneshmand S, Lotan Y, Kassouf W, Fritsche HM, Pycha A, Fisch M, Scherr DS, **Shariat SF**: Stage-specific impact of tumor location on oncologic outcomes in patients with upper and lower tract urothelial carcinoma following radical surgery. *Eur Urol*. 2012 Feb 15. PMID: 22349570
1166. Roscigno M, Cha EK, Rink M, Seitz C, Novara G, Chromecki TF, Fritsche HM, Matsumoto K, Walton TJ, Carballido J, Filippo Da Pozzo L, Bertini R, Ficarra V, Otto W, Karakiewicz PI, Pycha A, Fajkovic H, Naspro R, Scherr DS, Montorsi F, **Shariat SF**. International validation of the

- prognostic value of subclassification for AJCC stage pT3 upper tract urothelial carcinoma of the renal pelvis. *BJU Int.* 2012 Feb 20. PMID: 22348322
1167. Abdollah F, Sun M, Schmitges J, Thuret R, Tian Z, **Shariat SF**, Briganti A, Jeldres C, Perrotte P, Montorsi F, Karakiewicz PI: Competing-risks Mortality After Radiotherapy vs. Observation for Localized Prostate Cancer: A Population-based Study. *Int J Radiat Oncol Biol Phys.* 2012 Feb 11. PMID: 22330991
 1168. Sun M, Abdollah F, Bianchi M, Trinh QD, Jeldres C, Thuret R, Tian Z, **Shariat SF**, Montorsi F, Perrotte P, Karakiewicz PI. Treatment Management of Small Renal Masses in the 21st Century: A Paradigm Shift. *Ann Surg Oncol.* 2012 Feb 10. PMID: 2232295
 1169. Schmitges J, Trinh QD, Sun M, Hansen J, Bianchi M, Jeldres C, Perrotte P, Dahlem R, **Shariat SF**, Chun FK, Montorsi F, Menon M, Fisch M, Graefen M, Karakiewicz PI. Higher perioperative morbidity and in-hospital mortality in patients with end-stage renal disease undergoing nephrectomy for non-metastatic kidney cancer: a population-based analysis. *BJU Int.* 2012 Feb 9. PMID: 22321256
 1170. Schmitges J, Trinh QD, Sun M, Abdollah F, Bianchi M, Budäus L, Salomon G, Schlomm T, Perrotte P, **Shariat SF**, Montorsi F, Menon M, Graefen M, Karakiewicz PI. Venous thromboembolism after radical prostatectomy: the effect of surgical caseload. *BJU Int.* 2012 Feb 7. PMID: 22313499
 1171. Trinh QD, Sun M, Sammon J, Bianchi M, Sukumar S, Ghani KR, Jeong W, Dabaja A, **Shariat SF**, Perrotte P, Agarwal PK, Rogers CG, Peabody JO, Menon M, Karakiewicz PI. Disparities in access to care at high-volume institutions for uro-oncologic procedures. *Cancer.* 2012 Feb 1. PMID: 22298310
 1172. Rink M, Chun FK, Chromecki TF, Fajkovic H, Dahlem R, Fisch M, **Shariat SF**. [Advanced bladder cancer in elderly patients : Prognostic outcomes and therapeutic strategies.] *Urologe A.* 2012 Jan 28. German. PMID: 22282102
 1173. Cha EK, **Shariat SF**, Kormaksson M, Novara G, Chromecki TF, Scherr DS, Lotan Y, Raman JD, Kassouf W, Zigeuner R, Remzi M, Bensalah K, Weizer A, Kikuchi E, Bolenz C, Roscigno M, Koppie TM, Ng CK, Fritsche HM, Matsumoto K, Walton TJ, Ehdaie B, Tritschler S, Fajkovic H, Martínez-Salamanca JJ, Pycha A, Langner C, Ficarra V, Patard JJ, Montorsi F, Wood CG, Karakiewicz PI, Margulis V. Predicting clinical outcomes after radical nephroureterectomy for upper tract urothelial carcinoma. *Eur Urol.* 2012 Jan 23. PMID: 22284969
 1174. **Shariat SF**, Zigeuner R, Rink M, Margulis V, Hansen J, Kikuchi E, Kassouf W, Raman JD, Remzi M, Koppie TM, Bensalah K, Guo CC, Mikami S, Sircar K, Ng CK, Haitel A, Kabbani W, Chun FK, Wood CG, Scherr DS, Karakiewicz PI, Langner C. Subclassification of pT3 urothelial carcinoma of the renal pelvicalyceal system is associated with recurrence-free and cancer-specific survival: proposal for a revision of the current tnm classification. *Eur Urol.* 2012 Jan 24. PMID: 22285763
 1175. Chade DC, Eastham J, Graefen M, Hu JC, Karnes RJ, Klotz L, Montorsi F, van Poppel H, Scardino PT, **Shariat SF**. Cancer control and functional outcomes of salvage radical prostatectomy for radiation-recurrent prostate cancer: a systematic review of the literature. *Eur Urol.* 2012 Jan 23. PMID: 22280856
 1176. Rink M, Chun FK, Dahlem R, Soave A, Minner S, Hansen J, Stoupiec M, Coith C, Kluth LA, Ahyai SA, Friedrich MG, **Shariat SF**, Fisch M, Pantel K, Riethdorf S. Prognostic Role and HER2 Expression of circulating tumor cells in peripheral blood of patients prior to radical cystectomy: a prospective study. *Eur Urol.* 2012 Jan 20. PMID: 22277196

1177. Fajkovic H, Cha EK, Jeldres C, Donner G, Chromecki TF, Margulis V, Novara G, Lotan Y, Raman JD, Kassouf W, Seitz C, Bensalah K, Weizer A, Kikuchi E, Roscigno M, Remzi M, Matsumoto K, Breinl E, Pycha A, Ficarra V, Montorsi F, Karakiewicz PI, Scherr DS, **Shariat SF**. Prognostic value of extranodal extension and other lymph node parameters in patients with upper tract urothelial carcinoma. *J Urol*. 2012 Jan 14. PMID:22248522
1178. Rink M, Fajkovic H, Cha EK, Gupta A, Karakiewicz PI, Chun FK, Lotan Y, **Shariat SF**: Death certificates are valid for the determination of cause of death in patients with upper and lower tract urothelial carcinoma. *Eur Urol*. 2012 Jan 5. PMID: 22226583
1179. Hanna N, Sun M, Trinh QD, Hansen J, Bianchi M, Montorsi F, **Shariat SF**, Graefen M, Perrotte P, Karakiewicz PI. Propensity-Score-Matched Comparison of Perioperative Outcomes Between Open and Laparoscopic Nephroureterectomy: A National Series. *Eur Urol*. 2011 Dec 22. PMID: 22209172
1180. Trinh QD, Sammon J, Sun M, Ravi P, Ghani KR, Bianchi M, Jeong W, **Shariat SF**, Hansen J, Schmitges J, Jeldres C, Rogers CG, Peabody JO, Montorsi F, Menon M, Karakiewicz PI. Perioperative Outcomes of Robot-Assisted Radical Prostatectomy Compared With Open Radical Prostatectomy: Results From the Nationwide Inpatient Sample. *Eur Urol*. 2011 Dec 22. PMID: 22206800
1181. Sun M, Abdollah F, Bianchi M, Trinh QD, **Shariat SF**, Jeldres C, Tian Z, Hansen J, Briganti A, Graefen M, Montorsi F, Perrotte P, Karakiewicz PI. Conditional survival of patients with urothelial carcinoma of the urinary bladder treated with radical cystectomy. *Eur J Cancer*. 2011 Dec 21. PMID: 22196034
1182. Clements T, Messer JC, Terrell JD, Herman MP, Ng C, Scherr D, Scoll B, Boorjian SA, Uzzo RG, Wille M, Eggener SE, Lucas SM, Lotan Y, **Shariat SF**, Raman JD: High grade ureteroscopic biopsy is associated with advanced pathology of upper tract urothelial carcinoma tumors at definitive surgical resection. *J Endourol*. 2011 Dec 22. PMID: 22192113
1183. Yafi FA, Novara G, **Shariat SF**, Gupta A, Matsumoto K, Walton TJ, Fritsche HM, El-Hakim A, Trischler S, Martínez-Salamanca JJ, Seitz C, Ficarra V, Zattoni F, Karakiewicz PI, Kassouf W. Impact of tumour location versus multifocality in patients with upper tract urothelial carcinoma treated with nephroureterectomy and bladder cuff excision: a homogeneous series without perioperative chemotherapy. *BJU Int*. 2011 Dec 16. PMID: 22177329
1184. Kroeger N, Rampersaud EN, Patard JJ, Klatte T, Birkhäuser FD, **Shariat SF**, Lang H, Rioux-Leclercq N, Remzi M, Zomorodian N, Kabbinavar FF, Belldegrun AS, Pantuck AJ Prognostic value of microvascular invasion in predicting the cancer specific survival and risk of metastatic disease in renal cell carcinoma: a multicenter investigation. *J Urol*. 2012 Feb;187(2):418-23. Epub 2011 Dec 15. PMID: 22177164
1185. Schmitges J, Trinh QD, Bianchi M, Sun M, Abdollah F, Ahyai SA, Jeldres C, Steuber T, Perrotte P, **Shariat SF**, Menon M, Montorsi F, Graefen M, Karakiewicz PI: The effect of annual surgical caseload on the rates of in-hospital pneumonia and other in-hospital outcomes after radical prostatectomy. *Int Urol Nephrol*. 2011 Dec 13. PMID: 22160759
1186. Sun M, Trinh QD, Bianchi M, Hansen J, Hanna N, Abdollah F, **Shariat SF**, Briganti A, Montorsi F, Perrotte P, Karakiewicz PI. A Non-Cancer-Related Survival Benefit Is Associated With Partial Nephrectomy. *Eur Urol*. 2011 Dec 3. PMID: 22172373
1187. **Shariat SF**, Chromecki TF, Cha EK, Karakiewicz PI, Sun M, Fradet Y, Isbarn H, Scherr DS, Bastian PJ, Pummer K, Fajkovic H, Sagalowsky AI, Ashfaq R, Doblinger M, Cote RJ, Lotan Y. Risk Stratification of Organ Confined Bladder Cancer After Radical Cystectomy Using Cell Cycle

- Related Biomarkers. J Urol. 2011 Dec 14. PMID: 22177145
1188. Sun M, Bianchi M, Trinh QD, Abdollah F, Schmitges J, Jeldres C, **Shariat SF**, Graefen M, Montorsi F, Perrotte P, Karakiewicz PI. Hospital Volume is a Determinant of Postoperative Complications, Blood Transfusion and Length of Stay After Radical or Partial Nephrectomy. J Urol. 2011 Dec 14. PMID: 22177151
 1189. Abdollah F, Schmitges J, Sun M, Thuret R, Djahangirian O, Tian Z, **Shariat SF**, Briganti A, Perrotte P, Montorsi F, Karakiewicz PI. Head-to-head comparison of three commonly used preoperative tools for prediction of lymph node invasion at radical prostatectomy. Urology. 2011 Dec;78(6):1363-7. PMID:22137704
 1190. Trinh QD, Bianchi M, Sun M, Sammon J, Schmitges J, **Shariat SF**, Sukumar S, Jeldres C, Zorn K, Perrotte P, Rogers CG, Peabody JO, Montorsi F, Menon M, Karakiewicz PI. Discharge patterns after radical prostatectomy in the United States of America. Urol Oncol. 2011 Nov 17. PMID: 22100070
 1191. Ehdaie B, Maschino A, **Shariat SF**, Rioja J, Hamilton RJ, Lowrance WT, Poon SA, Al-Ahmadie HA, Herr HW. Comparative Outcomes of Pure Squamous Cell Carcinoma and Urothelial Carcinoma With Squamous Differentiation in Patients Treated With Radical Cystectomy. J Urol. 2011 Nov 14. PMID: 22088332
 1192. Chromecki TF, Cha EK, Pummer K, Scherr DS, Tewari AK, Sun M, Fajkovic H, Roehrborn CG, Ashfaq R, Karakiewicz PI, **Shariat SF**. Prognostic value of insulin-like growth factor II mRNA binding protein 3 in patients treated with radical prostatectomy. BJU Int. 2011 Nov 11. PMID: 22077633
 1193. Lotan Y, Amiel G, Boorjian SA, Clark PE, Droller M, Gingrich JR, Guzzo TJ, Inman BA, Kamat AM, Karsh L, Nielsen ME, Smith ND, **Shariat SF**, Svatek RS, Taylor JM; on Behalf of the Bladder Cancer Think Tank, and Bladder Cancer Advocacy Network: Comprehensive handbook for developing a bladder cancer cystectomy database. Urol Oncol. 2011 Nov 4. PMID: 22056403
 1194. Trinh QD, Schmitges J, Bianchi M, Sun M, **Shariat SF**, Sammon J, Jeldres C, Zorn K, Sukumar S, Perrotte P, Graefen M, Rogers CG, Peabody JO, Menon M, Karakiewicz PI. Node-positive renal cell carcinoma in the absence of distant metastases: predictors of cancer-specific mortality in a population-based cohort. BJU Int. 2011 Nov 1. PMID: 22044638
 1195. Lee DJ, Cha EK, Dubin JM, Beltran H, Chromecki TF, Fajkovic H, Scherr DS, Tagawa ST, **Shariat SF**. Novel therapeutics for the management of castration-resistant prostate cancer (CRPC). BJU Int. 2011 Oct 28. PMID: 22035221
 1196. **Shariat SF**, Ehdaie B, Rink M, Cha EK, Svatek RS, Chromecki TF, Fajkovic H, Novara G, David SG, Daneshmand S, Fradet Y, Lotan Y, Sagalowsky AI, Clozel T, Bastian PJ, Kassouf W, Fritsche HM, Burger M, Izawa JJ, Tilki D, Abdollah F, Chun FK, Sonpavde G, Karakiewicz PI, Scherr DS, Gonen M. Clinical Nodal Staging Scores for Bladder Cancer: A Proposal for Preoperative Risk Assessment. Eur Urol. 2011 Oct 21. PMID: 22033174
 1197. Najari BB, Rink M, Graefen M, **Shariat SF**, Chun FK. Does low-risk prostate cancer detection change with repeat biopsies? Eur Urol. 2012 Jan;61(1):230-1. Epub 2011 Oct 18. PMID: 22024602
 1198. Brookman-May S, May M, Zigeuner R, **Shariat SF**, Scherr DS, Chromecki T, Moch H, Wild PJ, Mohamad-Al-Ali B, Cindolo L, Wieland WF, Schips L, De Cobelli O, Rocco B, Santoro L, De Nunzio C, Tubaro A, Coman I, Feciche B, Truss M, Dalpiaz O, Hohenfellner M, Gilfrich C, Wirth MP, Burger M, Pahernik S; Members of the CORONA Project (Collaborative Research on Renal Neoplasms Association). Collecting System Invasion and Fuhrman Grade But Not Tumor Size Facilitate Prognostic Stratification of Patients With pT2 Renal Cell Carcinoma. J Urol. 2011

- Dec;186(6):2175-81. Epub 2011 Oct 19. PMID: 22014800
1199. **Shariat S.**, Scherr D., Gupta A. , Bianco F., Karakiewicz P., Zeltser I., Samadi D., Akhavan A.: Emerging biomarkers for prostate cancer diagnosis, staging, and prognosis. Arch. Esp. Urol. 2011; 64 (8): 681-694. way. PMID:22052751
 1200. Trinh QD, Schmitges J, Sun M, Sammon J, **Shariat SF**, Zorn K, Sukumar S, Bianchi M, Perrotte P, Graefen M, Rogers CG, Peabody JO, Menon M, Karakiewicz PI: Morbidity and mortality of radical prostatectomy differs by insurance status.Cancer. 2011 Aug 25. PMID: 22009603
 1201. Chromecki TF, Mauermann J, Cha EK, Svatek RS, Fajkovic H, Karakiewicz PI, Lotan Y, Tilki D, Bastian PJ, Volkmer BG, Montorsi F, Kassouf W, Novara G, Fritsche HM, Ficarra V, Stief CG, Dinney CP, Skinner E, Pummer K, Fradet Y, **Shariat SF**: Multicenter validation of the prognostic value of patient age in patients treated with radical cystectomy. World J Urol. 2011 Oct 19. PMID: 22009117
 1202. Rink M, Chun FK, Robinson B, Sun M, Karakiewicz PI, Bensalah K, Fisch M, Scherr DS, Lee RK, Margulis V, **Shariat SF**: Tissue-based molecular markers for renal cell carcinoma. Minerva Urol Nefrol. 2011 Dec;63(4):293-308. PMID: 21996985
 1203. Sun M, Abdollah F, **Shariat SF**, Schmitges J, Trinh QD, Tian Z, Jeldres C, Abdo A, Bianchi M, Briganti A, Montorsi F, Perrotte P, Karakiewicz PI : Propensity-score matched comparison of complications, blood transfusions, length of stay, and in-hospital mortality between open and laparoscopic partial nephrectomy: A national series. Eur J Surg Oncol. 2011 Oct 11. PMID: 21996370
 1204. Putluri N, Shojai A, Vasu VT, Vareed SK, Nalluri S, Putluri V, Thangjam GS, Panzitt K, Tallman CT, Butler C, Sana TR, Fischer SM, Sica G, Brat DJ, Shi H, Palapattu GS, Lotan Y, Weizer AZ, Terris MK, **Shariat SF**, Michailidis G, Sreekumar A: Metabolomic Profiling Reveals Potential Markers and Bioprocesses Altered in Bladder Cancer Progression. Cancer Res. 2011 Oct 11. PMID: 21990318
 1205. Alkhateeb SS, Neill M, Bar-Moshe S, Rhijn BV, Kakiashvili DM, Fleshner N, Jewett M, Petein M, Schulman C, Hanna S, Bostrom PJ, Roumeguere T, **Shariat SF**, Rorive S, Zlotta AR: Long-term prognostic value of the combination of EORTC risk group calculator and molecular markers in non-muscle-invasive bladder cancer patients treated with intravesical Bacille Calmette-Guérin. Urol Ann. 2011 Sep;3(3):119-26. PMID:21976923
 1206. Chromecki TF, Cha EK, Fajkovic H, Margulis V, Novara G, Scherr DS, Lotan Y, Raman JD, Kassouf W, Bensalah K, Weizer A, Kikuchi E, Roscigno M, Remzi M, Matsumoto K, Walton TJ, Pycha A, Ficarra V, Karakiewicz PI, Zigeuner R, Pummer K, **Shariat SF**: The impact of tumor multifocality on outcomes in patients treated with radical nephroureterectomy. Eur Urol. 2011 Sep 28. PMID: 21975249
 1207. Abdollah F, Sun M, Schmitges J, Tian Z, Jeldres C, Briganti A, **Shariat SF**, Perrotte P, Montorsi F, Karakiewicz PI: Cancer-specific and other-cause mortality after radical prostatectomy versus observation in patients with prostate cancer: competing-risks analysis of a large north american population-based cohort. Eur Urol. 2011 Nov;60(5):920-30. Epub 2011 Jun 29. PMID: 21741762
 1208. Youssef RF, **Shariat SF**, Lotan Y, Wood CG, Sagalowsky AI, Zigeuner R, Kikuchi E, Weizer A, Raman JD, Remzi M, Kabbani W, Langner C, Guo CC, Roscigno M, Montorsi F, Bolenz C, Kassouf W, Margulis V. Upper urinary tract urothelial carcinoma with loco-regional nodal metastases: insights from the Upper Tract Urothelial Carcinoma Collaboration. BJU Int. 2011 Oct;108(8):1286-1291. Epub 2011 Feb 18. PMID: 21332905
 1209. Sun M, Abdollah F, Schmitges J, Bianchi M, Tian Z, **Shariat SF**, Zorn K, Pharand D, Widmer H,

- Graefen M, Montorsi F, Perrotte P, Karakiewicz PI: Cytoreductive nephrectomy in the elderly: a population-based cohort from the USA. *BJU Int.* 2011 Sep 27. PMID: 21951647
1210. **Shariat SF**, Chromecki TF, Hoefer J, Barbieri CE, Scherr DS, Karakiewicz PI, Roehrborn CG, Montorsi F, Culig Z, Cavarretta IT: Soluble gp130 regulates prostate cancer invasion and progression in an interleukin-6 dependent and independent manner. *J Urol.* 2011 Sep 22. PMID: 21944124
1211. Trinh QD, Schmitges J, Sun M, **Shariat SF**, Sukumar S, Bianchi M, Tian Z, Jeldres C, Sammon J, Perrotte P, Graefen M, Peabody JO, Menon M, Karakiewicz PI: Radical prostatectomy at academic versus nonacademic institutions: a population based analysis. *J Urol.* 2011 Sep 22. PMID: 21944081
1212. Auprich M, Augustin H, Budäus L, Kluth L, Mannweiler S, **Shariat SF**, Fisch M, Graefen M, Pummer K, Chun FK: A comparative performance analysis of total prostate-specific antigen, percentage free prostate-specific antigen, prostate-specific antigen velocity and urinary prostate cancer gene 3 in the first, second and third repeat prostate biopsy. *BJU Int.* 2011 Sep 21. PMID: 21939492
1213. Cha EK, Tirsar LA, Schwentner C, Christos PJ, Mian C, Hennenlotter J, Martini T, Stenzl A, Pycha A, **Shariat SF**, Schmitz-Dräger BJ: Immunocytology is a strong predictor of bladder cancer presence in patients with painless hematuria: a multicentre study. *Eur Urol.* 2011 Sep 9. PMID: 21924544
1214. Lee R, Chughtai B, Herman M, **Shariat SF**, Scherr DS: Cost-analysis comparison of robot-assisted laparoscopic radical cystectomy (RC) vs open RC. *BJU Int.* 2011 Sep;108(6):976-83. PMID: 21917100
1215. Messer JC, Terrell JD, Herman MP, Ng CK, Scherr DS, Scoll B, Boorjian SA, Uzzo RG, Wille M, Eggener SE, Lucas SM, Lotan Y, **Shariat SF**, Raman JD: Multi-institutional validation of the ability of preoperative hydronephrosis to predict advanced pathologic tumor stage in upper-tract urothelial carcinoma. *Urol Oncol.* 2011 Sep 7. PMID: 21906967
1216. Trinh QD, Schmitges J, Sun M, Sammon J, **Shariat SF**, Sukumar S, Zorn K, Bianchi M, Jeldres C, Perrotte P, Graefen M, Rogers CG, Peabody JO, Menon M, Karakiewicz PI: Does partial nephrectomy at an academic institution result in better outcomes? *World J Urol.* 2011 Sep 9. PMID: 21904920
1217. Trinh QD, Schmitges J, Sun M, Sukumar S, Sammon J, **Shariat SF**, Jeldres C, Bianchi M, Tian Z, Perrotte P, Rogers CG, Graefen M, Peabody JO, Menon M, Karakiewicz PI: Improvement of racial disparities with respect to the utilization of minimally invasive radical prostatectomy in the United States. *Cancer.* 2011 Sep 6. doi: 10.1002/cncr.26527. PMID: 21898379
1218. Trinh QD, Schmitges J, Sun M, **Shariat SF**, Sukumar S, Tian Z, Bianchi M, Sammon J, Perrotte P, Rogers CG, Graefen M, Peabody JO, Menon M, Karakiewicz PI: Open radical prostatectomy in the elderly: a case for concern? *BJU Int.* 2011 Sep 6. PMID:21895940
1219. Abdo A, Trinh QD, Sun M, Schmitges J, Bianchi M, Sammon J, **Shariat SF**, Sukumar S, Zorn K, Jeldres C, Perrotte P, Rogers CG, Peabody JO, Menon M, Karakiewicz PI: The effect of insurance status on outcomes after partial nephrectomy. *Int Urol Nephrol.* 2011 Sep 6. PMID: 21894468
1220. Bianchi M, Sun M, Jeldres C, **Shariat SF**, Trinh QD, Briganti A, Tian Z, Schmitges J, Graefen M, Perrotte P, Menon M, Montorsi F, Karakiewicz PI: Distribution of metastatic sites in renal cell carcinoma: a population-based analysis. *Ann Oncol.* 2011 Sep 2. PMID: 21890909
1221. Martinez-Salamanca JI, **Shariat SF**, Rodriguez JC, Chromecki TF, Ficarra V, Fritsche HM,

- Kassouf W, Matsumoto K, Cabello LO, Seitz C, Tritschler S, Walton TJ, Zattoni F, Novara G: Prognostic role of ECOG performance status in patients with urothelial carcinoma of the upper urinary tract: an international study. *BJU Int.* 2011 Aug 24. PMID: 21883847
1222. Abdollah F, Schmitges J, Sun M, **Shariat SF**, Briganti A, Abdo A, Tian Z, Perrotte P, Montorsi F, Karakiewicz PI: A population-based assessment of the National Comprehensive Cancer Network practice guideline indications for pelvic lymph node dissection at radical prostatectomy. *BJU Int.* 2011 Aug 22. PMID: 21880105
1223. Sun M, Abdollah F, Schmitges J, Jeldres C, **Shariat SF**, Perrotte P, Karakiewicz PI: Clinical experience and critical evaluation of the role of everolimus in advanced renal cell carcinoma. *Open Access Journal of Urology* April 2011 Volume 2011:3 Pages 43 - 48
1224. Sun M, Abdollah F, Bianchi M, Trinh QD, Jeldres C, Tian Z, **Shariat SF**, Widmer H, Zorn K, Menon M, Montorsi F, Perrotte P, Karakiewicz PI: A stage-for-stage and grade-for-grade analysis of cancer-specific mortality rates in renal cell carcinoma according to age: a competing-risks regression analysis. *Eur Urol.* 2011 Aug 5. PMID: 21868147
1225. Barbieri CE, Cha EK, Chromecki TF, Dunning A, Lotan Y, Svatek RS, Scherr DS, Karakiewicz PI, Sun M, Mazumdar M, **Shariat SF**: Decision curve analysis assessing the clinical benefit of NMP22 in the detection of bladder cancer: secondary analysis of a prospective trial. *BJU Int.* 2011. PMID: 21851550
1226. Abdollah F, Sun M, Schmitges J, Djahangirian O, Tian Z, Jeldres C, Perrotte P, **Shariat SF**, Montorsi F, Karakiewicz PI: Stage-specific impact of pelvic lymph node dissection on survival in patients with non-metastatic bladder cancer treated with radical cystectomy. *BJU Int.* 2011 Aug 24. PMID: 21883849
1227. Remzi M, **Shariat S**, Huebner W, Fajkovic H, Seitz C.: Upper urinary tract urothelial carcinoma: what have we learned in the last 4 years? *Ther Adv Urol.* 2011 Apr;3(2):69-80. PMID: 21869907
1228. Abdollah F, Sun M, Jeldres C, Schmitges J, Thuret R, Djahangirian O, Tian Z, **Shariat SF**, Perrotte P, Montorsi F, Karakiewicz PI: Survival after radical cystectomy of non-bilharzial squamous cell carcinoma vs urothelial carcinoma: a competing-risks analysis. *BJU Int.* 2011 Aug 2. PMID: 21810161
1229. Roscigno M, Brausi M, Heidenreich A, Lotan Y, Margulis V, **Shariat SF**, Van Poppel H, Zigeuner R: Lymphadenectomy at the time of nephroureterectomy for upper tract urothelial cancer. *Eur Urol.* 2011 Jul 14. PMID: 21798659
1230. Abdollah F, Schmitges J, Sun M, Thuret R, Djahangirian O, Jeldres C, **Shariat SF**, Graefen M, Perrotte P, Montorsi F, Karakiewicz PI: Hospital and surgical caseload are predictors of comprehensive surgical treatment for bladder cancer: a population based study. *J Urol.* 2011 Jul 23. PMID:21788051
1231. Matsushita K, Cha EK, Matsumoto K, Baba S, Chromecki TF, Fajkovic H, Sun M, Karakiewicz PI, Scherr DS, **Shariat SF**: Immunohistochemical biomarkers for bladder cancer prognosis. *Int J Urol.* 2011 Jul 20. PMID: 21771101
1232. Sun M, **Shariat SF**, Cheng C, Ficarra V, Murai M, Oudard S, Pantuck AJ, Zigeuner R, Karakiewicz PI: Prognostic factors and predictive models in renal cell carcinoma: a contemporary review. *Eur Urol.* 2011 Jun 30. PMID: 21741163
1233. **Shariat SF**, Patschan O, Chade DC, Karakiewicz PI, Ashfaq R, Lotan Y, Hotakainen K, Stenman UH, Bjartell A.: Association of tumor-associated trypsin inhibitor (TATI) expression with molecular markers, pathologic features and clinical outcomes of urothelial carcinoma of the urinary

- bladder. *World J Urol.* 2011 Jul 8. PMID: 21739120
1234. Chromecki TF, Bensalah K, Remzi M, Verhoest G, Cha EK, Scherr DS, Novara G, Karakiewicz PI, **Shariat SF**: Prognostic factors for upper urinary tract urothelial carcinoma. *Nat Rev Urol.* 2011 PMID: 21727942
1235. Jerónimo C, Bastian PJ, Bjartell A, Carbone GM, Catto JW, Clark SJ, Henrique R, Nelson WG, **Shariat SF**: Epigenetics in prostate cancer: biologic and clinical relevance. *Eur Urol.* 2011 Jun 22. PMID: 21719191
1236. Youssef RF, **Shariat SF**, Lotan Y, Cost N, Wood CG, Sagalowsky AI, Zigeuner R, Langner C, Chromecki TF, Montorsi F, Bolenz C, Margulis V: Urothelial carcinoma at the uretero-enteric junction: Multi-center evaluation of oncologic outcomes after radical nephroureterectomy. *Urol Oncol.* 2011 Jun 23. PMID: 21704538
1237. Abdollah F, Sun M, Schmitges J, Thuret R, Djahangirian O, Jeldres C, Tian Z, **Shariat SF**, Perrotte P, Montorsi F, Karakiewicz PI: Development and validation of a reference table for prediction of postoperative mortality rate in patients treated with radical cystectomy: a population-based study. *Ann Surg Oncol.* 2011 Jun 24. PMID: 21701925
1238. **Shariat SF**, Savage C, Chromecki TF, Sun M, Scherr DS, Lee RK, Lughezzani G, Remzi M, Marberger MJ, Karakiewicz PI, Vickers AJ: Assessing the clinical benefit of nuclear matrix protein 22 in the surveillance of patients with non muscle-invasive bladder cancer and negative cytology: A decision-curve analysis. *Cancer.* 2011 Jul 1;117(13):2892-7. PMID: 21692050
1239. Tilki D, Burger M, Dalbagni G, Grossman HB, Hakenberg OW, Palou J, Reich O, Rouprêt M, **Shariat SF**, Zlotta AR: Urine markers for detection and surveillance of non-muscle-invasive bladder cancer. *Eur Urol.* 2011 Jun 12. PMID: 21684071
1240. Verhoest G, **Shariat SF**, Chromecki TF, Raman JD, Margulis V, Novara G, Seitz C, Remzi M, Rouprêt M, Scherr DS, Bensalah K: Predictive factors of recurrence and survival of upper tract urothelial carcinomas. *World J Urol.* 2011 Jun 17. PMID: 21681525
1241. Chromecki TF, Cha EK, **Shariat SF**: Stage pT0 after radical cystectomy: are all patients equal? *Eur Urol.* 2011 Jun 7. PMID: 21665358
1242. Nuhn P, Bastian PJ, Novara G, Svatek RS, Karakiewicz PI, Skinner E, Fradet Y, Izawa JJ, Kassouf W, Montorsi F, Müller SC, Fritsche HM, Sonpavde G, Tilki D, Isbarn H, Ficarra V, Dinney CP, **Shariat SF**: Concomitant carcinoma in situ in cystectomy specimens is not associated with clinical outcomes after surgery. *Urol Int.* 2011 Jun 9. PMID: 21659717
1243. Fajkovic H, Halpern JA, Cha EK, Bahadori A, Chromecki TF, Karakiewicz PI, Breinl E, Merseburger AS, **Shariat SF**: Impact of gender on bladder cancer incidence, staging, and prognosis. *World J Urol.* 2011 Jun 9. PMID: 21656173
1244. Abdollah F, Sun M, Thuret R, Abdo A, Morgan M, Jeldres C, **Shariat SF**, Perrotte P, Montorsi F, Karakiewicz PI.: The effect of marital status on stage and survival of prostate cancer patients treated with radical prostatectomy: a population-based study. *Cancer Causes Control.* 2011 Jun 5. PMID: 21643929
1245. Cha EK, Ng CK, Jeun B, Dunning A, Reifsnnyder JE, Dipietro JR, Mazumdar M, Shih G, Auh YH, Del Pizzo JJ, **Shariat SF**, Scherr DS.: Preoperative radiographic parameters predict long-term renal impairment following partial nephrectomy. *World J Urol.* 2011 May 21. PMID: 21604019
1246. Favaretto RL, **Shariat SF**, Savage C, Godoy G, Chade DC, Kaag M, Bochner BH, Coleman J, Dalbagni G.: Combining imaging and ureteroscopy variables in a preoperative multivariable model for prediction of muscle-invasive and non-organ confined disease in patients with upper tract

- urothelial carcinoma. *BJU Int.* 2011 Jun 1. PMID:21631698
1247. **Shariat SF**, Semjonow A, Lilja H, Savage C, Vickers AJ, Bjartell A.: Tumor markers in prostate cancer I: blood-based markers. *Acta Oncol.* 2011 Jun;50 Suppl 1:61-75. PMID: 21604943
1248. Burger M, **Shariat SF**, Fritsche HM, Martinez-Salamanca JI, Matsumoto K, Chromecki TF, Ficarra V, Kassouf W, Seitz C, Pycha A, Tritschler S, Walton TJ, Novara G: No overt influence of lymphadenectomy on cancer-specific survival in organ-confined versus locally advanced upper urinary tract urothelial carcinoma undergoing radical nephroureterectomy: a retrospective international, multi-institutional study. *World J Urol.* 2011 Jun 1. PMID: 21630120
1249. Ehdaie B, Chromecki TF, Lee RK, Lotan Y, Margulis V, Karakiewicz PI, Novara G, Raman JD, Ng C, Lowrance WT, Scherr DS, **Shariat SF**: Obesity adversely impacts disease specific outcomes in patients with upper tract urothelial carcinoma. *J Urol.* 2011 May 13. PMID: 21571333
1250. Sun M, Abdollah F, Budaüs L, Liberman D, Tian Z, Morgan M, Johal R, Schmitges J, **Shariat SF**, Montorsi F, Greafer M, Perrotte P, Karakiewicz PI: Trends of retroperitoneal lymphadenectomy use in patients with nonseminomatous germ cell tumor of the testis: a population-based study. *Ann Surg Oncol.* 2011 Apr 21. PMID: 21509630
1251. Lee R, Ng CK, **Shariat SF**, Borkina A, Guimento R, Brumit KF, Scherr DS.: The economics of robotic cystectomy: cost comparison of open versus robotic cystectomy. *BJU Int.* 2011 Apr 18. PMID: 21501370
1252. Matsumoto K, Novara G, Gupta A, Margulis V, Walton TJ, Roscigno M, Ng C, Kikuchi E, Zigeuner R, Kassouf W, Fritsche HM, Ficarra V, Martignoni G, Tritschler S, Rodriguez JC, Seitz C, Weizer A, Remzi M, Raman JD, Bolenz C, Bensalah K, Koppie TM, Karakiewicz PI, Wood CG, Montorsi F, Iwamura M, **Shariat SF**: Racial differences in the outcome of patients with urothelial carcinoma of the upper urinary tract: an international study. *BJU Int.* 2011 Apr 20. PMID: 21507184
1253. Abdollah F, Sun M, Briganti A, Thuret R, Schmitges J, Gallina A, Suardi N, Capitanio U, Salonia A, **Shariat SF**, Perrotte P, Rigatti P, Montorsi F, Karakiewicz PI.: Critical assessment of the European Association of Urology guideline indications for pelvic lymph node dissection at radical prostatectomy. *BJU Int.* 2011 Apr 20. PMID:21507189
1254. Chromecki TF, Ehdaie B, Novara G, Pummer K, Zigeuner R, Seitz C, Pycha A, Lee RK, Cha EK, Karakiewicz PI, Ng C, Raman JD, Chun FK, Fritsche HM, Matsumoto K, Kassouf W, Walton TJ, Bastian PJ, Martínez-Salamanca JI, Scherr DS, **Shariat SF**: Chronological age is not an independent predictor of clinical outcomes after radical nephroureterectomy. *World J Urol.* 2011 Apr 17.
1255. Abdollah F, Sun M, Thuret R, Schmitges J, **Shariat SF**, Perrotte P, Montorsi F, Karakiewicz PI: Mortality and morbidity after cytoreductive nephrectomy for metastatic renal cell carcinoma: a population-based study. *Ann Surg Oncol.* 2011 Apr 16.
1256. Abdollah F, Sun M, **Shariat SF**, Schmitges J, Djahangirian O, Tian Z, Jeldres C, Perrotte P, Montorsi F, Karakiewicz PI: The importance of pelvic lymph node dissection in the elderly population: implications for interpreting the 2010 National Comprehensive Cancer Network practice guidelines for bladder cancer treatment. *J Urol.* 2011 Apr 13.
1257. Abdollah F, Schmitges J, Sun M, Tian Z, Briganti A, **Shariat SF**, Perrotte P, Montorsi F, Karakiewicz PI: A critical assessment of the value of lymph node dissection at radical prostatectomy: A population-based study. *Prostate.* 2011 Apr 7. doi: 10.1002/pros.21376.
1258. Kassouf W, Svatek RS, **Shariat SF**, Novara G, Lerner SP, Fradet Y, Bastian PJ, Aprikian A,

- Karakiewicz PI, Fritsche HM, Dinney CP, Tilki D, Kamat AM, Izawa JI, Ficarra V, Lotan Y, Sagalowsky AI, Schoenberg MP, Skinner EC. Critical analysis and validation of lymph node density as prognostic variable in urothelial carcinoma of bladder. *Urol Oncol*. 2011 Apr 7. [Epub ahead of print]
1259. Zlotta AR, Roumeguere T, Kuk C, Alkhateeb S, Rorive S, Lemy A, van der Kwast TH, Fleshner NE, Jewett MA, Finelli A, Schulman C, Lotan Y, **Shariat SF**, Nortier J: Select screening in a specific high-risk population of patients suggests a stage migration toward detection of non-muscle-invasive bladder cancer. *Eur Urol*. 2011 Mar 30. PMID: 21458152
1260. Chade DC, **Shariat SF**, Cronin AM, Savage CJ, Karnes RJ, Blute ML, Briganti A, Montorsi F, van der Poel HG, Van Poppel H, Joniau S, Godoy G, Hurtado-Coll A, Gleave ME, Dall'oglio M, Srougi M, Scardino PT, Eastham JA.: Salvage radical prostatectomy for radiation-recurrent prostate cancer: a multi-institutional collaboration. *Eur Urol*. 2011 Mar 17. PMID: 21420229
1261. Gurbuz C, Youssef RF, **Shariat SF**, Lotan Y, Wood CG, Sagalowsky AI, Zigeuner R, Kikuchi E, Weizer A, Raman JD, Remzi M, Roscigno M, Montorsi F, Bolenz C, Kassouf W, Margulis V.: The impact of previous ureteroscopic tumor ablation on oncologic outcomes after radical nephroureterectomy for upper urinary tract urothelial carcinoma. *J Endourol*. 2011 Mar 9. PMID: 21388245
1262. Sun M, Abdollah F, Liberman D, Abdo A, Thuret R, Tian Z, **Shariat SF**, Montorsi F, Perrotte P, Karakiewicz PI.: Racial disparities and socioeconomic status in men diagnosed with testicular germ cell tumors: A survival analysis. *Cancer*. 2011 Mar 8. doi: 10.1002/cncr.25969. PMID: 21387261
1263. Thuret R, Sun M, Abdollah F, Schmitges J, **Shariat SF**, Iborra F, Guiter J, Patard JJ, Perrotte P, Karakiewicz PI.: Conditional survival predictions after surgery for patients with penile carcinoma. *Cancer*. 2011 Feb 24. PMID: 21360525
1264. Abdollah F, Sun M, Schmitges J, Thuret R, Djahangirian O, Jeldres C, Tian Z, **Shariat SF**, Perrotte P, Montorsi F, Karakiewicz PI. Surgical caseload is an important determinant of continent urinary diversion rate at radical cystectomy: a population-based study. *Ann Surg Oncol*. 2011 Feb 23. PMID: 21347778
1265. Sonpavde G, Khan MM, Svatek RS, Lee R, Novara G, Tilki D, Lerner SP, Amiel GE, Skinner E, Karakiewicz PI, Bastian PJ, Kassouf W, Fritsche HM, Izawa JI, Scherr DS, Ficarra V, Dinney CP, Lotan Y, Fradet Y, **Shariat SF**: Prognostic risk stratification of pathological stage T3N0 bladder cancer after radical cystectomy. *J Urol*. 2011 Apr;185(4):1216-21. Epub 2011 Feb 22. PMID: 21334687
1266. Messer J, **Shariat SF**, Brien JC, Herman MP, Ng CK, Scherr DS, Scoll B, Uzzo RG, Wille M, Eggener SE, Steinberg G, Terrell JD, Lucas SM, Lotan Y, Boorjian SA, Raman JD. Urinary cytology has a poor performance for predicting invasive or high-grade upper-tract urothelial carcinoma. *BJU Int*. 2011 Feb 14. PMID: 21320275.
1267. Youssef R, **Shariat S**, Kapur P, Kabbani W, Mosbah A, Abol-Enein H, Ghoniem M, Lotan Y: Prognostic value of cyclooxygenase-2 expression in squamous cell carcinoma of the bladder. *J Urol*. 2011 Jan 20. PMID: 21255800.
1268. Liberman D, Lughezzani G, Sun M, Alasker A, Thuret R, Abdollah F, Budaus L, Widmer H, Graefen M, Montorsi F, **Shariat SF**, Perrotte P, Karakiewicz PI: Perioperative mortality is significantly greater in septuagenarian and octogenarian patients treated with radical cystectomy for urothelial carcinoma of the bladder. *Urology*. 2011 Jan 20. PMID: 21256568.
1269. Otto W, **Shariat SF**, Fritsche HM, Gupta A, Matsumoto K, Kassouf W, Martignoni G, Walton TJ, Tritschler S, Baba S, Bastian PJ, Martínez-Salamanca JI, Seitz C, Pycha A, Burger M, Karakiewicz

- PI, Ficarra V, Novara G: Concomitant carcinoma in situ as an independent prognostic parameter for recurrence and survival in upper tract urothelial carcinoma: a multicenter analysis of 772 patients. *World J Urol.* 2011 Jan 20. PMID: 21249372.
1270. Svatek RS, **Shariat SF**, Novara G, Skinner EC, Fradet Y, Bastian PJ, Kamat AM, Kassouf W, Karakiewicz PI, Fritsche HM, Izawa JI, Tilki D, Ficarra V, Volkmer BG, Isbarn H, Dinney CP: Discrepancy between clinical and pathological stage: external validation of the impact on prognosis in an international radical cystectomy cohort. *BJU Int.* 2011 Jan 18. PMID: 21244604.
1271. Mazzola CR, Ghoneim T, **Shariat SF**: [Emerging biomarkers for the diagnosis, staging and prognosis of prostate cancer]. *Prog Urol.* 2011 Jan;21(1):1-10. Epub 2010 Aug 14. French. PMID: 21193139
1272. Youssef RF, **Shariat SF**, Lotan Y, Wood CG, Sagalowsky AI, Zigeuner R, Langner C, Montorsi F, Bolenz C, Margulis V.: Prognostic Effect of Urinary Bladder Carcinoma In Situ on Clinical Outcome of Subsequent Upper Tract Urothelial Carcinoma. *Urology.* 2010 Dec 15. PMID: 21167566
1273. Sonpavde G, Khan MM, Lerner SP, Svatek RS, Novara G, Karakiewicz PI, Skinner E, Tilki D, Kassouf W, Fradet Y, Dinney CP, Fritsche HM, Izawa JI, Bastian PJ, Ficarra V, Schoenberg M, Sagalowsky AI, Lotan Y, **Shariat SF**.: Disease-free survival at 2 or 3 years correlates with 5-year overall survival of patients undergoing radical cystectomy for muscle invasive bladder cancer. *J Urol.* 2010 Dec 16. PMID: 21167527
1274. Thuret R, Sun M, Abdollah F, Budaus L, Lughezzani G, Liberman D, Morgan M, Johal R, Jeldres C, Latour M, **Shariat SF**, Iborra F, Guiter J, Patard JJ, Perrotte P, Karakiewicz PI.: Tumor grade improves the prognostic ability of American Joint Committee on cancer stage in patients with penile carcinoma. *J Urol.* 2010 Dec 16. PMID: 21167526
1275. Ahallal Y, **Shariat SF**, Chade DC, Mazzola C, Reuter VE, Sandhu JS, Laudone VP, Touijer KA, Guillonneau BD.: Pilot study of salvage laparoscopic prostatectomy for the treatment of recurrent prostate cancer. *BJU Int.* 2010 Dec 16. PMID: 21166755
1276. Budäus L, Abdollah F, Sun M, Johal R, Morgan M, Thuret R, Zorn KC, Lughezzani G, Isbarn H, Haese A, **Shariat SF**, Montorsi F, Perrotte P, Graefen M, Karakiewicz PI.: The impact of surgical experience on total hospital charges for minimally invasive prostatectomy: a population-based study. *BJU Int.* 2010 Dec 13. PMID: 21156018
1277. Sfakianos J, **Shariat SF**, Favaretto RL, Rioja J, Herr HW: Impact of smoking on outcomes after intravesical Bacillus Calmette-Guérin therapy for urothelial carcinoma not invading muscle of the bladder. *BJU Int.* 2010 Nov 29. PMID: 2111461
1278. Youssef RF, **Shariat SF**, Kapur P, Kabbani W, Ghoneim T, King E, Cockburn A, Mosbah A, Abol-Enein H, Ghoneim M, Lotan Y. Expression of cell cycle-related molecular markers in patients treated with radical cystectomy for squamous cell carcinoma of the bladder. *Hum Pathol.* 2010 Nov 25. PMID: 2111452.
1279. Sun M, Abdo A, Abdollah F, Schmitges J, Thuret R, Jeldres C, **Shariat SF**, Perrotte P, Karakiewicz PI. Management of upper urinary tract urothelial carcinoma. *Expert Rev Anticancer Ther.* 2010 Dec; PMID: 21110761.
1280. Youssef R, Kapur P, Kabbani W, **Shariat SF**, Mosbah A, Abol-Enein H, Ghoniem M, Lotan Y. Bilharzial vs non-bilharzial related bladder cancer: pathological characteristics and value of cyclooxygenase-2 expression. *BJU Int.* 2010 Nov 24. PMID: 21105986.

1281. Lowrance WT, Tarin TV, **Shariat SF**. Evidence-based comparison of robotic and open radical prostatectomy. *Scientific World Journal*. 2010 Nov 16; PMID: 21103791.
1282. Sonpavde G, Khan MM, Svatek RS, Lee R, Novara G, Tilki D, Lerner SP, Amiel GE, Skinner E, Karakiewicz PI, Bastian PJ, Kassouf W, Fritzsche HM, Izawa JI, Ficarra V, Dinney CP, Lotan Y, Fradet Y, **Shariat SF**. Prognostic risk stratification of pathological stage T2N0 bladder cancer after radical cystectomy. *BJU Int*. 2010 Nov 19. PMID: 21087453.
1283. Walton TJ, Novara G, Matsumoto K, Kassouf W, Fritzsche HM, Artibani W, Bastian PJ, Martínez-Salamanca JI, Seitz C, Thomas SA, Ficarra V, Burger M, Tritschler S, Karakiewicz PI, **Shariat SF**. Oncological outcomes after laparoscopic and open radical nephroureterectomy: results from an international cohort. *BJU Int*. 2010 Nov 15. PMID: 21078048.
1284. Mir C, **Shariat SF**, Van Der Kwast TH, Ashfaq R, Lotan Y, Evans A, Skeldon S, Hanna S, Vajpeyi R, Kuk C, Alkhateeb S, Morote J, Van Rhijn BW, Bostrom P, Yao J, Miyamoto H, Jewett M, Fleshner N, Messing E, Zlotta AR. Loss of androgen receptor expression is not associated with pathological stage, grade, gender or outcome in bladder cancer: a large multi-institutional study. *BJU Int*. 2010 Nov 10. PMID: 21070579.
1285. Yee DS, **Shariat SF**, Lowrance WT, Maschino AC, Savage CJ, Cronin AM, Scardino PT, Eastham JA. Prognostic significance of lymphovascular invasion in radical prostatectomy specimens. *BJU Int*. 2010 Nov 2. PMID: 21050364.
1286. Sun M, Thuret R, Abdollah F, Lughezzani G, Schmitges J, Tian Z, **Shariat SF**, Montorsi F, Pataard JJ, Perrotte P, Karakiewicz PI. Age-Adjusted Incidence, Mortality, and Survival Rates of Stage-Specific Renal Cell Carcinoma in North America: A Trend Analysis. *Eur Urol*. 2010 Oct 27. PMID: 21035250.
1287. Abdollah F, Sun M, Thuret R, Jeldres C, Tian Z, Briganti A, **Shariat SF**, Perrotte P, Rigatti P, Montorsi F, Karakiewicz PI. A Competing-Risks Analysis of Survival After Alternative Treatment Modalities for Prostate Cancer Patients: 1988-2006. *Eur Urol*. 2010 Oct 14. PMID: 20965646.
1288. Budäus L, Sun M, Abdollah F, Zorn KC, Morgan M, Johal R, Liberman D, Thuret R, Isbarn H, Salomon G, Haese A, Montorsi F, **Shariat SF**, Perrotte P, Graefen M, Karakiewicz PI. Impact of Surgical Experience on In-Hospital Complication Rates in Patients Undergoing Minimally Invasive Prostatectomy: A Population-Based Study. *Ann Surg Oncol*. 2010 Oct 16. PMID: 20953720.
1289. Budäus L, Abdollah F, Sun M, Morgan M, Johal R, Thuret R, Zorn KC, Isbarn H, **Shariat SF**, Montorsi F, Perrotte P, Graefen M, Karakiewicz PI. Annual surgical caseload and open radical prostatectomy outcomes: improving temporal trends. *J Urol*. 2010 Dec; Epub 2010 Oct 16. PMID: 20952010.
1290. Barbieri CE, Lotan Y, Lee RK, Sonpavde G, Karakiewicz PI, Robinson B, Scherr DS, **Shariat SF**. Tissue-based molecular markers for bladder cancer. *Minerva Urol Nefrol*. 2010 Sep; PMID: 20940694.
1291. Fritzsche HM, Novara G, Burger M, Gupta A, Matsumoto K, Kassouf W, Sircar K, Zattoni F, Walton T, Tritschler S, Baba S, Bastian PJ, Martínez-Salamanca JI, Seitz C, Otto W, Wieland WF, Karakiewicz PI, Ficarra V, Hartmann A, **Shariat SF**. Macroscopic sessile tumor architecture is a pathologic feature of biologically aggressive upper tract urothelial carcinoma. *Urol Oncol*. 2010 Oct 6. PMID: 20933445.
1292. Crépel M, Jeldres C, Sun M, Lughezzani G, Isbarn H, Alasker A, Capitanio U, **Shariat SF**, Arjane P, Widmer H, Graefen M, Montorsi F, Perrotte P, Karakiewicz PI. A population-based comparison of cancer-control rates between radical and partial nephrectomy for T1A renal cell carcinoma. *Urology*. 2010 Oct; PMID: 20932408.

1293. **Shariat SF**, Favaretto RL, Gupta A, Fritsche HM, Matsumoto K, Kassouf W, Walton TJ, Tritschler S, Baba S, Matsushita K, Bastian PJ, Martínez-Salamanca JI, Seitz C, Pycha A, Otto W, Karakiewicz PI, Ficarra V, Novara G. Gender differences in radical nephroureterectomy for upper tract urothelial carcinoma. *World J Urol.* 2010 Oct 1. PMID: 20886219.
1294. Chun FK, Epstein JI, Ficarra V, Freedland SJ, Montironi R, Montorsi F, **Shariat SF**, Schröder FH, Scattoni V. Optimizing Performance and Interpretation of Prostate Biopsy: A Critical Analysis of the Literature. *Eur Urol.* 2010 Sep 4. PMID: 20884114.
1295. Liberman D, Alasker A, Sun M, Ismail S, Lughezzani G, Jeldres C, Budaus L, Thuret R, **Shariat SF**, Widmer H, Perrotte P, Graefen M, Montorsi F, Karakiewicz PI. Radical cystectomy for patients with pT4 urothelial carcinoma in a large population-based study. *BJU Int.* 2010 Sep 22. PMID: 20860649.
1296. Seitz C, Gupta A, **Shariat SF**, Matsumoto K, Kassouf W, Walton TJ, Fritsche HM, Otto W, Tritschler S, Bastian PJ, Carballido J, Ficarra V, Karakiewicz PI, Artibani W, Mazzoleni G, Novara G. Association of tumor necrosis with pathological features and clinical outcome in 754 patients undergoing radical nephroureterectomy for upper tract urothelial carcinoma: an international validation study. *J Urol.* 2010 Nov; Epub 2010 Sep 17. PMID: 20846680.
1297. Thuret R, Sun M, Lughezzani G, Budaus L, Liberman D, Abdollah F, Morgan M, Johal R, Jeldres C, Latour M, **Shariat SF**, Iborra F, Guiter J, Patard JJ, Perrotte P, Karakiewicz PI. A Contemporary Population-Based Assessment of the Rate of Lymph Node Dissection for Penile Carcinoma. *Ann Surg Oncol.* 2010 Sep 14. PMID: 20839061.
1298. Lughezzani G, Sun M, **Shariat SF**, Budäus L, Thuret R, Jeldres C, Liberman D, Montorsi F, Perrotte P, Karakiewicz PI. A population-based competing-risks analysis of the survival of patients treated with radical cystectomy for bladder cancer. *Cancer.* 2010 Aug 27. PMID: 20803606.
1299. Lughezzani G, Briganti A, Karakiewicz PI, Kattan MW, Montorsi F, **Shariat SF**, Vickers AJ. Predictive and Prognostic Models in Radical Prostatectomy Candidates: A Critical Analysis of the Literature. *Eur Urol.* 2010 Aug 6. PMID: 20727668.
1300. Favaretto RL, **Shariat SF**, Chade DC, Godoy G, Kaag M, Cronin AM, Bochner BH, Coleman J, Dalbagni G. Comparison between laparoscopic and open radical nephroureterectomy in a contemporary group of patients: are recurrence and disease-specific survival associated with surgical technique? *Eur Urol.* 2010 Aug 11. PMID: 20724065.
1301. Svatek RS, **Shariat SF**, Lasky RE, Skinner EC, Novara G, Lerner SP, Fradet Y, Bastian PJ, Kassouf W, Karakiewicz PI, Fritsche HM, Müller SC, Izawa JI, Ficarra V, Sagalowsky AI, Schoenberg MP, Siefker-Radtke AO, Millikan RE, Dinney CP. The effectiveness of off-protocol adjuvant chemotherapy for patients with urothelial carcinoma of the urinary bladder. *Clin Cancer Res.* 2010 Sep 1;16(17):4461-7. Epub 2010 Jul 22. PMID: 20651056.
1302. Tilki D, Svatek RS, Novara G, Seitz M, Godoy G, Karakiewicz PI, Kassouf W, Fradet Y, Fritsche HM, Sonpavde G, Izawa JI, Ficarra V, Lerner SP, Schoenberg M, Stief CG, Dinney CP, Skinner E, Lotan Y, Sagalowsky AI, Reich O, **Shariat SF**. Stage pT0 at radical cystectomy confers improved survival: an international study of 4,430 patients. *J Urol.* 2010 Sep; Erratum in: *J Urol.* 2010 Nov; PMID: 20643448.
1303. Favaretto RL, **Shariat SF**, Chade DC, Godoy G, Adamy A, Kaag M, Bochner BH, Coleman J, Dalbagni G. The effect of tumor location on prognosis in patients treated with radical nephroureterectomy at Memorial Sloan-Kettering Cancer Center. *Eur Urol.* 2010 Oct; Epub 2010 Jul 9. PMID: 20637540.

1304. **Shariat SF**, Chade DC, Karakiewicz PI, Scherr DS, Dalbagni G. Update on intravesical agents for non-muscle-invasive bladder cancer. Immunotherapy. 2010 May; Review. PMID: 20635902.
1305. Tilki D, Svatek RS, Karakiewicz PI, Novara G, Seitz M, Sonpavde G, Gupta A, Kassouf W, Fradet Y, Ficarra V, Skinner E, Lotan Y, Sagalowsky AI, Stief CG, Reich O, **Shariat SF**. pT3 Substaging is a prognostic indicator for lymph node negative urothelial carcinoma of the bladder. J Urol. 2010 Aug; Epub 2010 Jun 17. PMID: 20620401.
1306. Chade DC, **Shariat SF**, Adamy A, Bochner BH, Donat SM, Herr HW, Dalbagni G. Clinical outcome of primary versus secondary bladder carcinoma in situ. J Urol. 2010 Aug; Epub 2010 Jun 17. PMID: 20620399.
1307. Margulis V, Youssef RF, Karakiewicz PI, Lotan Y, Wood CG, Zigeuner R, Kikuchi E, Weizer A, Raman JD, Remzi M, Roscigno M, Montorsi F, Bolenz C, Kassouf W, **Shariat SF**; Upper Tract Urothelial Carcinoma Collaborative Group. Preoperative multivariable prognostic model for prediction of nonorgan confined urothelial carcinoma of the upper urinary tract. J Urol. 2010 Aug; Epub 2010 Jun 17. PMID: 20620397.
1308. Lotan Y, **Shariat SF**, Schmitz-Dräger BJ, Sanchez-Carbayo M, Jankevicius F, Racioppi M, Minner SJ, Stöhr B, Bassi PF, Grossman HB. Considerations on implementing diagnostic markers into clinical decision making in bladder cancer. Urol Oncol. 2010 Jul-Aug; PMID: 20610281.
1309. **Shariat SF**, Lotan Y, Vickers A, Karakiewicz PI, Schmitz-Dräger BJ, Goebell PJ, Malats N. Statistical consideration for clinical biomarker research in bladder cancer. Urol Oncol. 2010 Jul-Aug; Review. PMID: 20610277.
1310. Sun M, **Shariat SF**, Karakiewicz PI. Factors affecting outcome in renal cell carcinoma. Curr Opin Urol. 2010 Sep; Review. PMID: 20592610.
1311. Jeldres C, Sun M, Lughezzani G, Isbarn H, **Shariat SF**, Widmer H, Graefen M, Montorsi F, Perrotte P, Karakiewicz PI. Highly predictive survival nomogram after upper urinary tract urothelial carcinoma. Cancer. 2010 Aug 5; PMID: 20564085.
1312. Chade DC, **Shariat SF**, Godoy G, Savage CJ, Cronin AM, Bochner BH, Donat SM, Herr HW, Dalbagni G. Clinical outcomes of primary bladder carcinoma in situ in a contemporary series. J Urol. 2010 Jul; PMID: 20546806.
1313. Brien JC, **Shariat SF**, Herman MP, Ng CK, Scherr DS, Scoll B, Uzzo RG, Wille M, Eggener SE, Terrell JD, Lucas SM, Lotan Y, Boorjian SA, Raman JD. Preoperative hydronephrosis, ureteroscopic biopsy grade and urinary cytology can improve prediction of advanced upper tract urothelial carcinoma. J Urol. 2010 Jul; Epub 2010 May 15. PMID: 20478585.
1314. Bigot P, Bernhard JC, Crepel M, Bensalah K, Azzouzi AR, de la Taille A, Salomon L, Tostain J, Ficarra V, Pantuck AJ, Belldegrun AS, Méjean A, Ferrière JM, Pfister C, Albouy B, Colombel M, Zini L, Villers A, Montorsi F, **Shariat S**, Rioux-Leclercq N, Patard JJ. [How radical nephrectomy compares to partial nephrectomy for the treatment of pT1a papillary renal cell carcinomas?]. Prog Urol. 2010 May; Epub 2010 Mar 29. French. PMID: 20471579.
1315. Wheat JC, Weizer AZ, Wolf JS Jr, Lotan Y, Remzi M, Margulis V, Wood CG, Montorsi F, Roscigno M, Kikuchi E, Zigeuner R, Langner C, Bolenz C, Koppie TM, Raman JD, Fernández M, Karakiewicz P, Capitanio U, Bensalah K, Patard JJ, **Shariat SF**. Concomitant carcinoma in situ is a feature of aggressive disease in patients with organ confined urothelial carcinoma following radical nephroureterectomy. Urol Oncol. 2010 May 5. PMID: 20451416.
1316. Novara G, Svatek RS, Karakiewicz PI, Skinner E, Ficarra V, Fradet Y, Lotan Y, Isbarn H, Capitanio U, Bastian PJ, Kassouf W, Fritsche HM, Izawa JJ, Tilki D, Dinney CP, Lerner SP,

- Schoenberg M, Volkmer BG, Sagalowsky AI, **Shariat SF**. Soft tissue surgical margin status is a powerful predictor of outcomes after radical cystectomy: a multicenter study of more than 4,400 patients. *J Urol*. 2010 Jun; PMID: 20399473.
1317. **Shariat SF**, Tilki D. Bladder cancer: Nomogram aids clinical decision making after radical cystectomy. *Nat Rev Urol*. 2010 Apr; PMID: 20383183.
1318. Tilki D, Reich O, Svatek RS, Karakiewicz PI, Kassouf W, Novara G, Ficarra V, Chade DC, Fritsche HM, Gerwens N, Izawa JI, Lerner SP, Schoenberg M, Stief CG, Skinner E, Lotan Y, Sagalowsky AI, **Shariat SF**. Characteristics and outcomes of patients with clinical carcinoma in situ only treated with radical cystectomy: an international study of 243 patients. *J Urol*. 2010 May; Epub 2010 Mar 17. PMID: 20299059.
1319. **Shariat SF**, Youssef RF, Gupta A, Chade DC, Karakiewicz PI, Isbarn H, Jeldres C, Sagalowsky AI, Ashfaq R, Lotan Y. Association of angiogenesis related markers with bladder cancer outcomes and other molecular markers. *J Urol*. 2010 May; Epub 2010 Mar 17. PMID: 20299037.
1320. Yee DS, **Shariat SF**, Lowrance WT, Sterbis JR, Vora KC, Bochner BH, Donat SM, Herr HW, Dalbagni G, Sandhu JS. Impact of previous radiotherapy for prostate cancer on clinical outcomes of patients with bladder cancer. *J Urol*. 2010 May; Epub 2010 Mar 17. PMID: 20299035.
1321. Lughezzani G, Sun M, Budäus L, Thuret R, **Shariat SF**, Perrotte P, Karakiewicz PI. Effect of the number of biopsy cores on prostate cancer detection and staging. *Future Oncol*. 2010 Mar; Review. PMID: 20222795.
1322. Jeldres C, Lughezzani G, Sun M, Isbarn H, **Shariat SF**, Budaus L, Lattouf JB, Widmer H, Graefen M, Montorsi F, Perrotte P, Karakiewicz PI. Segmental ureterectomy can safely be performed in patients with transitional cell carcinoma of the ureter. *J Urol*. 2010 Apr; Epub 2010 Feb 19. PMID: 20171666.
1323. **Shariat SF**, Svatek RS, Tilki D, Skinner E, Karakiewicz PI, Capitanio U, Bastian PJ, Volkmer BG, Kassouf W, Novara G, Fritsche HM, Izawa JI, Ficarra V, Lerner SP, Sagalowsky AI, Schoenberg MP, Kamat AM, Dinney CP, Lotan Y, Marberger MJ, Fradet Y. International validation of the prognostic value of lymphovascular invasion in patients treated with radical cystectomy. *BJU Int*. 2010 May; Epub 2010 Feb 2. PMID: 20132195.
1324. Bhojani N, Capitanio U, Suardi N, Jeldres C, Isbarn H, **Shariat SF**, Graefen M, Arjane P, Duclos A, Lattouf JB, Saad F, Valiquette L, Montorsi F, Perrotte P, Karakiewicz PI. The rate of secondary malignancies after radical prostatectomy versus external beam radiation therapy for localized prostate cancer: a population-based study on 17,845 patients. *Int J Radiat Oncol Biol Phys*. 2010 Feb 1; PMID: 20117287.
1325. Tilki D, Reich O, Karakiewicz PI, Novara G, Kassouf W, Ergün S, Fradet Y, Ficarra V, Sonpavde G, Stief CG, Skinner E, Svatek RS, Lotan Y, Sagalowsky AI, **Shariat SF**. Validation of the AJCC TNM substaging of pT2 bladder cancer: deep muscle invasion is associated with significantly worse outcome. *Eur Urol*. 2010 Jul; Epub 2010 Jan 20. PMID: 20097469.
1326. Bolenz C, **Shariat SF**, Karakiewicz PI, Ashfaq R, Ho R, Sagalowsky AI, Lotan Y. Human epidermal growth factor receptor 2 expression status provides independent prognostic information in patients with urothelial carcinoma of the urinary bladder. *BJU Int*. 2010 Jan 19. PMID: 20089105.
1327. Baillargeon-Gagné S, Jeldres C, Lughezzani G, Sun M, Isbarn H, Capitanio U, **Shariat SF**, Crépel M, Alasker A, Widmer H, Arjane P, Patard JJ, Perrotte P, Montorsi F, Graefen M, Karakiewicz PI. A comparative population-based analysis of the rate of partial vs radical nephrectomy for clinically localized renal cell carcinoma. *BJU Int*. 2010 Feb; PMID: 20089096.

1328. Sun M, Lughezzani G, Alasker A, Isbarn H, Jeldres C, **Shariat SF**, Budäus L, Lattouf JB, Valiquette L, Graefen M, Montorsi F, Perrotte P, Karakiewicz PI. Comparative study of inguinal hernia repair after radical prostatectomy, prostate biopsy, transurethral resection of the prostate or pelvic lymph node dissection. *J Urol*. 2010 Mar; Epub 2010 Jan 18. PMID: 20083257.
1329. Novara G, Matsumoto K, Kassouf W, Walton TJ, Fritsche HM, Bastian PJ, Martínez-Salamanca JJ, Seitz C, Lemberger RJ, Burger M, El-Hakim A, Baba S, Martignoni G, Gupta A, Karakiewicz PI, Ficarra V, **Shariat SF**. Prognostic role of lymphovascular invasion in patients with urothelial carcinoma of the upper urinary tract: an international validation study. *Eur Urol*. 2010 Jun; Epub 2010 Jan 6. PMID: 20071073.
1330. Raman JD, **Shariat SF**, Karakiewicz PI, Lotan Y, Sagalowsky AI, Roscigno M, Montorsi F, Bolenz C, Weizer AZ, Wheat JC, Ng CK, Scherr DS, Remzi M, Waldert M, Wood CG, Margulis V; for the Upper-Tract Urothelial Carcinoma Collaborative Group. Does preoperative symptom classification impact prognosis in patients with clinically localized upper-tract urothelial carcinoma managed by radical nephroureterectomy? *Urol Oncol*. 2010 Jan 5. PMID: 20056458.
1331. Lughezzani G, Sun M, Perrotte P, Jeldres C, Alasker A, Isbarn H, Budäus L, **Shariat SF**, Guazzoni G, Montorsi F, Karakiewicz PI. The European Network for the Study of Adrenal Tumors staging system is prognostically superior to the international union against cancer-staging system: a North American validation. *Eur J Cancer*. 2010 Mar; Epub 2010 Jan 13. PMID: 20044246.
1332. Chade DC, **Shariat SF**, Dalbagni G. Intravesical therapy for urothelial carcinoma of the urinary bladder: a critical review. *Int Braz J Urol*. 2009 Nov-Dec; discussion 651. PMID: 20028569.
1333. Lughezzani G, Sun M, Jeldres C, Alasker A, Budäus L, **Shariat SF**, Latour M, Widmer H, Duclos A, Jolivet-Tremblay M, Montorsi F, Perrotte P, Karakiewicz PI. Adenocarcinoma versus urothelial carcinoma of the urinary bladder: comparison between pathologic stage at radical cystectomy and cancer-specific mortality. *Urology*. 2010 Feb; PMID: 20022091.
1334. Lughezzani G, Sun M, Perrotte P, **Shariat SF**, Jeldres C, Budaus L, Alasker A, Duclos A, Widmer H, Latour M, Guazzoni G, Montorsi F, Karakiewicz PI. Should bladder cuff excision remain the standard of care at nephroureterectomy in patients with urothelial carcinoma of the renal pelvis? A population-based study. *Eur Urol*. 2010 Jun; Epub 2009 Dec 10. PMID: 20018438.
1335. Zaak D, Burger M, Otto W, Bastian PJ, Denzinger S, Stief CG, Buchner H, Hartmann A, Wieland WF, **Shariat SF**, Fritsche HM. Predicting individual outcomes after radical cystectomy: an external validation of current nomograms. *BJU Int*. 2010 Aug; Epub 2009 Dec 11. PMID: 20002664.
1336. **Shariat SF**, Kattan MW, Vickers AJ, Karakiewicz PI, Scardino PT. Critical review of prostate cancer predictive tools. *Future Oncol*. 2009 Dec; Review. PMID: 20001796.
1337. Jeldres C, Sun M, Isbarn H, Lughezzani G, Budäus L, Alasker A, **Shariat SF**, Lattouf JB, Widmer H, Pharand D, Arjane P, Graefen M, Montorsi F, Perrotte P, Karakiewicz PI. A population-based assessment of perioperative mortality after nephroureterectomy for upper-tract urothelial carcinoma. *Urology*. 2010 Feb; Epub 2009 Dec 6. PMID: 19963237.
1338. Crépel M, Jeldres C, Perrotte P, Capitanio U, Isbarn H, **Shariat SF**, Liberman D, Sun M, Lughezzani G, Arjane P, Widmer H, Graefen M, Montorsi F, Patard JJ, Karakiewicz PI. Nephron-sparing surgery is equally effective to radical nephrectomy for T1bN0M0 renal cell carcinoma: a population-based assessment. *Urology*. 2010 Feb; Epub 2009 Dec 4. PMID: 19962740.
1339. Lughezzani G, Sun M, Perrotte P, **Shariat SF**, Jeldres C, Budäus L, Latour M, Widmer H, Duclos A, Bénard F, McCormack M, Montorsi F, Karakiewicz PI. Gender-related differences in patients with stage I to III upper tract urothelial carcinoma: results from the Surveillance, Epidemiology, and End Results database. *Urology*. 2010 Feb; Epub 2009 Dec 4. PMID: 19962727.

1340. Zigeuner R, **Shariat SF**, Margulis V, Karakiewicz PI, Roscigno M, Weizer A, Kikuchi E, Remzi M, Raman JD, Bolenz C, Bensalah K, Capitanio U, Koppie TM, Kassouf W, Sircar K, Patard JJ, Fernández MI, Wood CG, Montorsi F, Ströbel P, Wheat JC, Haitel A, Oya M, Guo CC, Ng C, Chade DC, Sagalowsky A, Langner C. Tumour necrosis is an indicator of aggressive biology in patients with urothelial carcinoma of the upper urinary tract. *Eur Urol.* 2010 Apr; Epub 2009 Nov 25. PMID: 19959276.
1341. Tilki D, Svatek RS, Karakiewicz PI, Isbarn H, Reich O, Kassouf W, Fradet Y, Novara G, Fritsche HM, Bastian PJ, Izawa JI, Stief CG, Ficarra V, Lerner SP, Schoenberg M, Dinney CP, Skinner E, Lotan Y, Sagalowsky AI, **Shariat SF**. Characteristics and outcomes of patients with pT4 urothelial carcinoma at radical cystectomy: a retrospective international study of 583 patients. *J Urol.* 2010 Jan; Epub PubMed PMID: 19942232.
1342. **Shariat SF**, Chade DC, Karakiewicz PI, Ashfaq R, Isbarn H, Fradet Y, Bastian PJ, Nielsen ME, Capitanio U, Jeldres C, Montorsi F, Lerner SP, Sagalowsky AI, Cote RJ, Lotan Y. Combination of multiple molecular markers can improve prognostication in patients with locally advanced and lymph node positive bladder cancer. *J Urol.* 2010 Jan; Epub. PMID: 19913255.
1343. **Shariat SF**, Godoy G, Lotan Y, Droller M, Karakiewicz PI, Raman JD, Isbarn H, Weizer A, Remzi M, Roscigno M, Kikuchi E, Bolenz C, Bensalah K, Koppie TM, Kassouf W, Wheat JC, Zigeuner R, Langner C, Wood CG, Margulis V. Advanced patient age is associated with inferior cancer-specific survival after radical nephroureterectomy. *BJU Int.* 2010 Jun; Epub 2009 Nov 13. PMID: 19912201.
1344. **Shariat SF**, Sfakianos JP, Droller MJ, Karakiewicz PI, Meryn S, Bochner BH. The effect of age and gender on bladder cancer: a critical review of the literature. *BJU Int.* 2010 Feb;105(3):300-8. Epub 2009 Nov 13. Review. PMID: 19912200.
1345. **Shariat SF**, Karakiewicz PI, Godoy G, Karam JA, Ashfaq R, Fradet Y, Isbarn H, Montorsi F, Jeldres C, Bastian PJ, Nielsen ME, Müller SC, Sagalowsky AI, Lotan Y. Survivin as a prognostic marker for urothelial carcinoma of the bladder: a multicenter external validation study. *Clin Cancer Res.* 2009 Nov 15; Epub 2009 Nov 10. PMID: 19903782.
1346. Roscigno M, **Shariat SF**, Freschi M, Margulis V, Karakiewicz P, Suardi N, Remzi M, Zigeuner R, Bolenz C, Kikuchi E, Weizer A, Bensalah K, Sagalowsky A, Koppie TM, Raman J, Fernández M, Ströbel P, Kabbani W, Langner C, Wheat J, Guo CC, Kassouf W, Haitel A, Wood CG, Montorsi F. Assessment of the minimum number of lymph nodes needed to detect lymph node invasion at radical nephroureterectomy in patients with upper tract urothelial cancer. *Urology.* 2009 Nov; PMID: 19883824.
1347. **Shariat SF**, Milowsky M, Droller MJ. Bladder cancer in the elderly. *Urol Oncol.* 2009 Nov-Dec; Review. PMID: 19879476.
1348. Lughezzani G, Jeldres C, Isbarn H, **Shariat SF**, Sun M, Pharand D, Widmer H, Arjane P, Graefen M, Montorsi F, Perrotte P, Karakiewicz PI. A critical appraisal of the value of lymph node dissection at nephroureterectomy for upper tract urothelial carcinoma. *Urology.* 2010 Jan; Epub 2009 Oct 28. PMID: 19864000.
1349. Karakiewicz PI, Suardi N, Capitanio U, Isbarn H, Jeldres C, Perrotte P, Sun M, Ficarra V, Zigeuner R, Tostain J, Mejean A, Cindolo L, Pantuck AJ, Belldegrun AS, Zini L, de la Taille A, Chautard D, Descotes JL, **Shariat SF**, Valeri A, Mulders PF, Lang H, Lechevallier E, Patard JJ. Conditional survival predictions after nephrectomy for renal cell carcinoma. *J Urol.* 2009 Dec; Epub 2009 Oct 17. PMID: 19836798.

1350. Jeldres C, Cardinal H, Duclos A, **Shariat SF**, Suardi N, Capitanio U, Hébert MJ, Karakiewicz PI. Prediction of delayed graft function after renal transplantation. *Can Urol Assoc J*. 2009 Oct; PMID: 19829730.
1351. Lughezzani G, Capitanio U, Jeldres C, Isbarn H, **Shariat SF**, Arjane P, Widmer H, Perrotte P, Montorsi F, Karakiewicz PI. Prognostic significance of lymph node invasion in patients with metastatic renal cell carcinoma: a population-based perspective. *Cancer*. 2009 Dec 15; PMID: 19824083.
1352. Isbarn H, Patard JJ, Lughezzani G, Rioux-Leclercq N, Crépel M, Cindolo L, de la Taille A, Zini L, Villers A, **Shariat SF**, Bertini R, Karakiewicz PI. Limited prognostic value of tumor necrosis in patients with renal cell carcinoma. *Urology*. 2010 Jun; Epub 2009 Sep 25. PMID: 19781745.
1353. Fritsche HM, Burger M, Svatek RS, Jeldres C, Karakiewicz PI, Novara G, Skinner E, Denzinger S, Fradet Y, Isbarn H, Bastian PJ, Volkmer BG, Montorsi F, Kassouf W, Tilki D, Otto W, Capitanio U, Izawa JJ, Ficarra V, Lerner S, Sagalowsky AI, Schoenberg M, Kamat A, Dinney CP, Lotan Y, **Shariat SF**. Characteristics and outcomes of patients with clinical T1 grade 3 urothelial carcinoma treated with radical cystectomy: results from an international cohort. *Eur Urol*. 2010 Feb; Epub 2009 Sep 12. PMID: 19766384.
1354. Isbarn H, Jeldres C, **Shariat SF**, Liberman D, Sun M, Lughezzani G, Widmer H, Arjane P, Pharand D, Fisch M, Graefen M, Montorsi F, Perrotte P, Karakiewicz PI. Location of the primary tumor is not an independent predictor of cancer specific mortality in patients with upper urinary tract urothelial carcinoma. *J Urol*. 2009 Nov; Epub 2009 Sep 16. PMID: 19758662.
1355. **Shariat SF**, Zimmern PE, Hilton K, Gruchalla RS. Prospective questionnaire-based evaluation of the prevalence of urinary incontinence in women with chronic cough. *Urol Int*. 2009; Epub 2009 Sep 10. PMID: 19752614.
1356. Nuss GR, Morey AF, Jenkins AC, Pruitt JH, Dugi DD 3rd, Morse B, **Shariat SF**. Radiographic predictors of need for angiographic embolization after traumatic renal injury. *J Trauma*. 2009 Sep; discussion 582. PMID: 19741403.
1357. Waldert M, Karakiewicz PI, Raman JD, Remzi M, Isbarn H, Lotan Y, Capitanio U, Bensalah K, Marberger MJ, **Shariat SF**. A delay in radical nephroureterectomy can lead to upstaging. *BJU Int*. 2010 Mar; Epub 2009 Sep 3. PMID: 19732052.
1358. Lughezzani G, Jeldres C, Isbarn H, Sun M, **Shariat SF**, Widmer H, Arjane P, Graefen M, Perrotte P, Montorsi F, Karakiewicz PI. Temporal stage and grade migration in surgically treated patients with upper tract urothelial carcinoma. *BJU Int*. 2010 Mar; Epub 2009 Sep 2. PMID: 19725824.
1359. Lughezzani G, Jeldres C, Isbarn H, Perrotte P, **Shariat SF**, Sun M, Widmer H, Arjane P, Peloquin F, Pharand D, Patard JJ, Graefen M, Montorsi F, Karakiewicz PI. Tumor size is a determinant of the rate of stage T1 renal cell cancer synchronous metastasis. *J Urol*. 2009 Oct; Epub 2009 Aug 14. PMID: 19683281.
1360. **Shariat SF**, Bolenz C, Karakiewicz PI, Fradet Y, Ashfaq R, Bastian PJ, Nielsen ME, Capitanio U, Jeldres C, Rigaud J, Müller SC, Lerner SP, Montorsi F, Sagalowsky AI, Cote RJ, Lotan Y. p53 expression in patients with advanced urothelial cancer of the urinary bladder. *BJU Int*. 2010 Feb; Epub 2009 Jul 31. PMID: 19659466.
1361. Crépel M, Isbarn H, Capitanio U, Liberman D, Jeldres C, Sun M, **Shariat SF**, Widmer H, Arjane P, Graefen M, Montorsi F, Patard JJ, Perrotte P, Karakiewicz PI. Does histologic subtype affect oncologic outcomes after nephron-sparing surgery? *Urology*. 2009 Oct; Epub 2009 Jul 22. PMID: 19628262.

1362. Capitanio U, Isbarn H, **Shariat SF**, Jeldres C, Zini L, Saad F, Graefen M, Montorsi F, Perrotte P, Karakiewicz PI. Partial cystectomy does not undermine cancer control in appropriately selected patients with urothelial carcinoma of the bladder: a population-based matched analysis. *Urology*. 2009 Oct; Epub 2009 Jul 22. PMID: 19628260.
1363. Raman JD, Ng CK, Scherr DS, Margulis V, Lotan Y, Bensalah K, Patard JJ, Kikuchi E, Montorsi F, Zigeuner R, Weizer A, Bolenz C, Koppie TM, Isbarn H, Jeldres C, Kabbani W, Remzi M, Waldert M, Wood CG, Roscigno M, Oya M, Langner C, Wolf JS, Ströbel P, Fernández M, Karakiewicz P, **Shariat SF**. Impact of tumor location on prognosis for patients with upper tract urothelial carcinoma managed by radical nephroureterectomy. *Eur Urol*. 2010 Jun; Epub 2009 Jul 15. PMID: 19619934.
1364. Jeldres C, Baillargeon-Gagne S, Liberman D, Isbarn H, Capitanio U, **Shariat SF**, Sun M, Lughezzani G, Perrotte P, Montorsi F, Graefen M, Karakiewicz PI. A population-based analysis of the rate of cytoreductive nephrectomy for metastatic renal cell carcinoma in the United States. *Urology*. 2009 Oct; Epub 2009 Jul 18. PMID: 19616828.
1365. **Shariat SF**, Lotan Y, Karakiewicz PI, Ashfaq R, Isbarn H, Fradet Y, Bastian PJ, Nielsen ME, Capitanio U, Jeldres C, Montorsi F, Müller SC, Karam JA, Heukamp LC, Netto G, Lerner SP, Sagalowsky AI, Cote RJ. p53 predictive value for pT1-2 N0 disease at radical cystectomy. *J Urol*. 2009 Sep; Epub 2009 Jul 17. PMID: 19616250.
1366. Hellenthal NJ, **Shariat SF**, Margulis V, Karakiewicz PI, Roscigno M, Bolenz C, Remzi M, Weizer A, Zigeuner R, Bensalah K, Ng CK, Raman JD, Kikuchi E, Montorsi F, Oya M, Wood CG, Fernandez M, Evans CP, Koppie TM. Adjuvant chemotherapy for high risk upper tract urothelial carcinoma: results from the Upper Tract Urothelial Carcinoma Collaboration. *J Urol*. 2009 Sep; Epub 2009 Jul 17. PMID: 19616245.
1367. Lughezzani G, Jeldres C, Isbarn H, Sun M, **Shariat SF**, Alasker A, Pharand D, Widmer H, Arjane P, Graefen M, Montorsi F, Perrotte P, Karakiewicz PI. Nephroureterectomy and segmental ureterectomy in the treatment of invasive upper tract urothelial carcinoma: a population-based study of 2299 patients. *Eur J Cancer*. 2009 Dec; Epub 2009 Jul 15. PMID: 19615885.
1368. Bolenz C, Lotan Y, Ashfaq R, **Shariat SF**. Estrogen and progesterone hormonal receptor expression in urothelial carcinoma of the bladder. *Eur Urol*. 2009 Dec; Epub 2009 Jul 7. PMID: 19596509.
1369. Isbarn H, Jeldres C, Capitanio U, Zini L, **Shariat SF**, Lughezzani G, Sun M, Ahyai SA, Duclos A, Jolivet-Tremblay M, Lattouf JB, Valiquette L, Perrotte P, Montorsi F, Graefen M, Karakiewicz PI. Thirty-day mortality after transurethral resection of the prostate in patients treated with androgen deprivation therapy. *J Endourol*. 2009 Aug; PMID: 19591615.
1370. Sun M, Lughezzani G, Jeldres C, Isbarn H, **Shariat SF**, Arjane P, Widmer H, Pharand D, Latour M, Perrotte P, Patard JJ, Karakiewicz PI. A proposal for reclassification of the Fuhrman grading system in patients with clear cell renal cell carcinoma. *Eur Urol*. 2009 Nov; Epub 2009 Jun 21. PMID: 19573980.
1371. Roscigno M, **Shariat SF**, Margulis V, Karakiewicz P, Remzi M, Kikuchi E, Zigeuner R, Weizer A, Sagalowsky A, Bensalah K, Raman JD, Bolenz C, Kassou W, Koppie TM, Wood CG, Wheat J, Langner C, Ng CK, Capitanio U, Bertini R, Fernández MI, Mikami S, Isida M, Ströbel P, Montorsi F. The extent of lymphadenectomy seems to be associated with better survival in patients with nonmetastatic upper-tract urothelial carcinoma: how many lymph nodes should be removed? *Eur Urol*. 2009 Sep; Epub 2009 Jun 18. PMID: 19559518.

1372. Jeldres C, Isbarn H, Capitanio U, Zini L, Bhojani N, **Shariat SF**, Cloutier V, Lattouf JB, Duclos A, Jolivet-Tremblay M, Valiquette L, Saad F, Graefen M, Montorsi F, Perrotte P, Karakiewicz PI. Development and external validation of a highly accurate nomogram for the prediction of perioperative mortality after transurethral resection of the prostate for benign prostatic hyperplasia. *J Urol*. 2009 Aug; Epub 2009 Jun 17. PMID: 19535100.
1373. Isbarn H, Karakiewicz PI, **Shariat SF**, Capitanio U, Palapattu GS, Sagalowsky AI, Lotan Y, Schoenberg MP, Amiel GE, Lerner SP, Sonpavde G. Residual pathological stage at radical cystectomy significantly impacts outcomes for initial T2N0 bladder cancer. *J Urol*. 2009 Aug; discussion 465. Epub 2009 Jun 13. PMID: 19524971.
1374. Capitanio U, Jeldres C, Perrotte P, Isbarn H, Crépel M, Cloutier V, Baillargeon-Gagne S, **Shariat SF**, Duclos A, Arjane P, Widmer H, Saad F, Montorsi F, Karakiewicz PI. Population-based study of perioperative mortality after retroperitoneal lymphadenectomy for nonseminomatous testicular germ cell tumors. *Urology*. 2009 Aug; Epub 2009 Jun 7. PMID: 19501893.
1375. Zini L, Capitanio U, Jeldres C, Lughezzani G, Sun M, **Shariat SF**, Isbarn H, Arjane P, Widmer H, Perrotte P, Graefen M, Montorsi F, Karakiewicz PI. External validation of a nomogram predicting mortality in patients with adrenocortical carcinoma. *BJU Int*. 2009 Dec; Epub 2009 Jun 2. PMID: 19493261.
1376. Tilki D, Singer BB, **Shariat SF**, Behrend A, Fernando M, Irmak S, Buchner A, Hooper AT, Stief CG, Reich O, Ergün S. CEACAM1: a novel urinary marker for bladder cancer detection. *Eur Urol*. 2010 Apr; Epub 2009 May 28. PMID: 19487071.
1377. Isbarn H, Jeldres C, Zini L, Perrotte P, Baillargeon-Gagne S, Capitanio U, **Shariat SF**, Arjane P, Saad F, McCormack M, Valiquette L, Peloquin F, Duclos A, Montorsi F, Graefen M, Karakiewicz PI. A population based assessment of perioperative mortality after cystectomy for bladder cancer. *J Urol*. 2009 Jul; Epub 2009 May 17. PMID: 19447427.
1378. **Shariat SF**, Bolenz C, Godoy G, Fradet Y, Ashfaq R, Karakiewicz PI, Isbarn H, Jeldres C, Rigaud J, Sagalowsky AI, Lotan Y. Predictive value of combined immunohistochemical markers in patients with pT1 urothelial carcinoma at radical cystectomy. *J Urol*. 2009 Jul; discussion 84. Epub 2009 May 17. PMID: 19447418.
1379. Capitanio U, Perrotte P, Zini L, Jeldres C, **Shariat SF**, Isbarn H, Arjane P, Peloquin F, Pharand D, Montorsi F, Karakiewicz PI. Nephrectomy improves survival in patients with invasion of adjacent viscera and absence of nodal metastases (stage T4N0 renal cell carcinoma). *BJU Int*. 2009 Sep; Epub 2009 Apr 15. PMID: 19389018.
1380. Capitanio U, Perrotte P, Zini L, Suardi N, Antebi E, Cloutier V, Jeldres C, **Shariat SF**, Duclos A, Arjane P, Saad F, Montorsi F, Karakiewicz PI. Population-based analysis of normal total PSA and percentage of free/total PSA values: results from screening cohort. *Urology*. 2009 Jun; Epub 2009 Apr 18. PMID: 19376563.
1381. Roscigno M, **Shariat SF**, Margulis V, Karakiewicz P, Remzi M, Kikuchi E, Langner C, Lotan Y, Weizer A, Bensalah K, Raman JD, Bolenz C, Guo CC, Wood CG, Zigeuner R, Wheat J, Kabbani W, Koppie TM, Ng CK, Suardi N, Bertini R, Fernández MI, Mikami S, Isida M, Michel MS, Montorsi F. Impact of lymph node dissection on cancer specific survival in patients with upper tract urothelial carcinoma treated with radical nephroureterectomy. *J Urol*. 2009 Jun; Epub 2009 Apr 16. PMID: 19371878.
1382. Capitanio U, **Shariat SF**, Isbarn H, Weizer A, Remzi M, Roscigno M, Kikuchi E, Raman JD, Bolenz C, Bensalah K, Koppie TM, Kassouf W, Fernández MI, Ströbel P, Wheat J, Zigeuner R, Langner C, Waldert M, Oya M, Guo CC, Ng C, Montorsi F, Wood CG, Margulis V, Karakiewicz

- PI. Comparison of oncologic outcomes for open and laparoscopic nephroureterectomy: a multi-institutional analysis of 1249 cases. *Eur Urol.* 2009 Jul; Epub 2009 Apr 3. PMID: 19361911.
1383. Lotan Y, Capitanio U, **Shariat SF**, Hutterer GC, Karakiewicz PI. Impact of clinical factors, including a point-of-care nuclear matrix protein-22 assay and cytology, on bladder cancer detection. *BJU Int.* 2009 May; Epub 2009 Mar 11. Erratum in: *BJU Int.* 2010 Apr; PMID: 19338566.
1384. Svatek RS, Jeldres C, Karakiewicz PI, Suardi N, Walz J, Roehrborn CG, Montorsi F, Slawin KM, **Shariat SF**. Pre-treatment biomarker levels improve the accuracy of post-prostatectomy nomogram for prediction of biochemical recurrence. *Prostate.* 2009 Jun 1; PMID: 19229851.
1385. Zini L, Perrotte P, Capitanio U, Jeldres C, **Shariat SF**, Antebi E, Saad F, Patard JJ, Montorsi F, Karakiewicz PI. Radical versus partial nephrectomy: effect on overall and noncancer mortality. *Cancer.* 2009 Apr 1; PMID: 19195042.
1386. Zini L, Cloutier V, Isbarn H, Perrotte P, Capitanio U, Jeldres C, **Shariat SF**, Saad F, Arjane P, Duclos A, Lattouf JB, Montorsi F, Karakiewicz PI. A simple and accurate model for prediction of cancer-specific mortality in patients treated with surgery for primary penile squamous cell carcinoma. *Clin Cancer Res.* 2009 Feb 1; PMID: 19188173.
1387. Margulis V, **Shariat SF**, Matin SF, Kamat AM, Zigeuner R, Kikuchi E, Lotan Y, Weizer A, Raman JD, Wood CG; Upper Tract Urothelial Carcinoma Collaboration The Upper Tract Urothelial Carcinoma Collaboration. Outcomes of radical nephroureterectomy: a series from the Upper Tract Urothelial Carcinoma Collaboration. *Cancer.* 2009 Mar 15; PMID: 19156917.
1388. **Shariat SF**, Roehrborn CG. Using biopsy to detect prostate cancer. *Rev Urol.* 2008 Fall; PMID: 19145270.
1389. Margulis V, Lotan Y, Karakiewicz PI, Fradet Y, Ashfaq R, Capitanio U, Montorsi F, Bastian PJ, Nielsen ME, Müller SC, Rigaud J, Heukamp LC, Netto G, Lerner SP, Sagalowsky AI, **Shariat SF**. Multi-institutional validation of the predictive value of Ki-67 labeling index in patients with urinary bladder cancer. *J Natl Cancer Inst.* 2009 Jan 21; Epub 2009 Jan 13. PMID: 19141773.
1390. Ng CK, **Shariat SF**, Lucas SM, Bagrodia A, Lotan Y, Scherr DS, Raman JD. Does the presence of hydronephrosis on preoperative axial CT imaging predict worse outcomes for patients undergoing nephroureterectomy for upper-tract urothelial carcinoma? *Urol Oncol.* 2008 Dec 29. PMID: 19117771.
1391. Capitanio U, Cloutier V, Zini L, Isbarn H, Jeldres C, **Shariat SF**, Perrotte P, Antebi E, Patard JJ, Montorsi F, Karakiewicz PI. A critical assessment of the prognostic value of clear cell, papillary and chromophobe histological subtypes in renal cell carcinoma: a population-based study. *BJU Int.* 2009 Jun; Epub 2008 Dec 8. PMID: 19076149.
1392. Capitanio U, Suardi N, **Shariat SF**, Lotan Y, Palapattu GS, Bastian PJ, Gupta A, Vazina A, Schoenberg M, Lerner SP, Sagalowsky AI, Karakiewicz PI. Assessing the minimum number of lymph nodes needed at radical cystectomy in patients with bladder cancer. *BJU Int.* 2009 May; Epub 2008 Dec 8. PMID: 19076140.
1393. Kikuchi E, Margulis V, Karakiewicz PI, Roscigno M, Mikami S, Lotan Y, Remzi M, Bolenz C, Langner C, Weizer A, Montorsi F, Bensalah K, Koppie TM, Fernández MI, Raman JD, Kassouf W, Wood CG, Suardi N, Oya M, **Shariat SF**. Lymphovascular invasion predicts clinical outcomes in patients with node-negative upper tract urothelial carcinoma. *J Clin Oncol.* 2009 Feb 1; Epub 2008 Dec 15. PMID: 19075275.

1394. Cloutier V, Capitanio U, Zini L, Perrotte P, Jeldres C, **Shariat SF**, Arjane P, Patard JJ, Montorsi F, Karakiewicz PI. Thirty-day mortality after nephrectomy: clinical implications for informed consent. *Eur Urol.* 2009 Dec; Epub 2008 Nov 25. PMID: 19054604.
1395. Capitanio U, Perrotte P, Hutterer GC, Suardi N, Jeldres C, **Shariat SF**, Duclos A, Arjane P, Montorsi F, Karakiewicz PI. Effect of body mass index on prostate-specific antigen and percentage free prostate-specific antigen: results from a prostate cancer screening cohort of 1490 men. *Int J Urol.* 2009 Jan; Epub 2008 Nov 27. PMID: 19054167.
1396. **Shariat SF**, Scardino PT, Lilja H. Screening for prostate cancer: an update. *Can J Urol.* 2008 Dec; Review. PMID: 19046489.
1397. Zini L, Capitanio U, Perrotte P, Jeldres C, **Shariat SF**, Arjane P, Widmer H, Montorsi F, Patard JJ, Karakiewicz PI. Population-based assessment of survival after cytoreductive nephrectomy versus no surgery in patients with metastatic renal cell carcinoma. *Urology.* 2009 Feb; Epub 2008 Nov 28. PMID: 19041122.
1398. Salonia A, Briganti A, Gallina A, Karakiewicz P, **Shariat S**, Freschi M, Zanni G, Capitanio U, Bosi E, Rigatti P, Montorsi F. Sex hormone-binding globulin: a novel marker for nodal metastases prediction in prostate cancer patients undergoing extended pelvic lymph node dissection. *Urology.* 2009 Apr; Epub 2008 Nov 26. PMID: 19038425.
1399. Karam JA, **Shariat SF**, Hsieh JT, Knowles MA. Genomics: a preview of genomic medicine. *BJU Int.* 2008 Nov;102(9 Pt B):1221-7. PMID: 19035885.
1400. Gupta A, Karakiewicz PI, Roehrborn CG, Lotan Y, Zlotta AR, **Shariat SF**. Predictive value of plasma hepatocyte growth factor/scatter factor levels in patients with clinically localized prostate cancer. *Clin Cancer Res.* 2008 Nov 15; PMID: 19010854.
1401. Bhojani N, Salomon L, Capitanio U, Suardi N, **Shariat SF**, Jeldres C, Zini L, Pharand D, Pélouquin F, Arjane P, Abbou CC, De La Taille A, Montorsi F, Karakiewicz PI. External validation of the updated partin tables in a cohort of French and Italian men. *Int J Radiat Oncol Biol Phys.* 2009 Feb 1; Epub 2008 Nov 10. PMID: 19004573.
1402. Bolenz C, **Shariat SF**, Fernández MI, Margulis V, Lotan Y, Karakiewicz P, Remzi M, Kikuchi E, Zigeuner R, Weizer A, Montorsi F, Bensalah K, Wood CG, Roscigno M, Langner C, Koppie TM, Raman JD, Mikami S, Michel MS, Ströbel P. Risk stratification of patients with nodal involvement in upper tract urothelial carcinoma: value of lymph-node density. *BJU Int.* 2009 Feb; Epub 2008 Oct 16. PMID: 18990164.
1403. Remzi M, Haitel A, Margulis V, Karakiewicz P, Montorsi F, Kikuchi E, Zigeuner R, Weizer A, Bolenz C, Bensalah K, Suardi N, Raman JD, Lotan Y, Waldert M, Ng CK, Fernández M, Koppie TM, Ströbel P, Kabbani W, Murai M, Langner C, Roscigno M, Wheat J, Guo CC, Wood CG, **Shariat SF**. Tumour architecture is an independent predictor of outcomes after nephroureterectomy: a multi-institutional analysis of 1363 patients. *BJU Int.* 2009 Feb; Epub 2008 Oct 16. Erratum in: *BJU Int.* 2009 Aug; Karakiewicz, Pierre [corrected to Karakiewicz, Pierre]. PMID: 18990163.
1404. **Shariat SF**, Capitanio U, Jeldres C, Karakiewicz PI. Can nomograms be superior to other prediction tools? *BJU Int.* 2009 Feb; Epub 2008 Sep 18. PMID: 18990135.
1405. Zorn KC, Capitanio U, Jeldres C, Arjane P, Perrotte P, **Shariat SF**, Lee DI, Shalhav AL, Zagaja GP, Shikanov SA, Gofrit ON, Thong AE, Albala DM, Sun L, Karakiewicz PI. Multi-institutional external validation of seminal vesicle invasion nomograms: head-to-head comparison of Gallina nomogram versus 2007 Partin tables. *Int J Radiat Oncol Biol Phys.* 2009 Apr 1; Epub 2008 Oct 19. PMID: 18938046.

1406. Svatek RS, Lotan Y, Karakiewicz PI, **Shariat SF**. Screening for bladder cancer using urine-based tumor markers. *Minerva Urol Nefrol*. 2008 Dec; Review. PMID: 18923361.
1407. Herman MP, Svatek RS, Lotan Y, Karakiewicz PI, **Shariat SF**. Urine-based biomarkers for the early detection and surveillance of non-muscle invasive bladder cancer. *Minerva Urol Nefrol*. 2008 Dec; Review. PMID: 18923359.
1408. Fernández MI, **Shariat SF**, Margulis V, Bolenz C, Montorsi F, Suardi N, Remzi M, Wood CG, Roscigno M, Kikuchi E, Oya M, Zigeuner R, Langner C, Weizer A, Lotan Y, Koppie TM, Raman JD, Karakiewicz P, Bensalah K, Schultz M, Bernier P. Evidence-based sex-related outcomes after radical nephroureterectomy for upper tract urothelial carcinoma: results of large multicenter study. *Urology*. 2009 Jan; Epub 2008 Oct 8. Erratum in: *Urology*. 2010 May; Karakiewicz, Pierre [corrected to Karakiewicz, Pierre]. PMID: 18845322.
1409. **Shariat SF**, Karakiewicz PI, Roehrborn CG, Kattan MW. An updated catalog of prostate cancer predictive tools. *Cancer*. 2008 Dec 1; Review. PMID: 18823041.
1410. Capitanio U, Zini L, Perrotte P, **Shariat SF**, Jeldres C, Arjane P, Pharand D, Widmer H, Péroquin F, Montorsi F, Patard JJ, Karakiewicz PI. Cytoreductive partial nephrectomy does not undermine cancer control in metastatic renal cell carcinoma: a population-based study. *Urology*. 2008 Nov; Epub 2008 Sep 16. PMID: 18799207.
1411. Bhojani N, Ahyai S, Graefen M, Capitanio U, Suardi N, **Shariat SF**, Jeldres C, Erbersdobler A, Schlomm T, Haese A, Steuber T, Heinzer H, Montorsi F, Huland H, Karakiewicz PI. Partin Tables cannot accurately predict the pathological stage at radical prostatectomy. *Eur J Surg Oncol*. 2009 Feb; Epub 2008 Sep 10. PMID: 18786800.
1412. Raman JD, Ng CK, **Shariat SF**, Margulis V, Montorsi F, Karakiewicz P; Upper-Tract Urothelial Carcinoma Collaboration. Outcomes for patients with pT0 disease after radical nephroureterectomy for upper-tract urothelial carcinoma. *BJU Int*. 2009 Jan; Epub 2008 Aug 18. PMID: 18717670.
1413. Capitanio U, Briganti A, **Shariat SF**, Karakiewicz PI. The importance of the quantification of the extent of cancer in prostatic biopsies in prediction of biochemical recurrence: a global perspective. *Eur Urol*. 2008 Oct; Epub 2008 Jul 21. PMID: 18703272.
1414. Capitanio U, Ahyai S, Graefen M, Jeldres C, **Shariat SF**, Erbersdobler A, Schlomm T, Haese A, Steuber T, Heinzer H, Perrotte P, Péroquin F, Pharand D, Arjane P, Huland H, Karakiewicz PI. Assessment of biochemical recurrence rate in patients with pathologically confirmed insignificant prostate cancer. *Urology*. 2008 Dec; Epub 2008 Aug 9. PMID: 18692880.
1415. **Shariat SF**, Karam JA, Lotan Y, Karakiewicz PI. Critical evaluation of urinary markers for bladder cancer detection and monitoring. *Rev Urol*. 2008 Spring; PMID: 18660854.
1416. Karakiewicz PI, Bhojani N, Capitanio U, Reuther AM, Suardi N, Jeldres C, Pharand D, Péroquin F, Perrotte P, **Shariat SF**, Klein EA. External validation of the updated Partin tables in a cohort of North American men. *J Urol*. 2008 Sep; Epub 2008 Jul 17. PMID: 18635222.
1417. **Shariat SF**, Karakiewicz PI, Suardi N, Kattan MW. Comparison of nomograms with other methods for predicting outcomes in prostate cancer: a critical analysis of the literature. *Clin Cancer Res*. 2008 Jul 15; Review. PMID: 18628454.
1418. Gupta A, Lotan Y, Ashfaq R, Roehrborn CG, Raj GV, Aragaki CC, Montorsi F, **Shariat SF**. Predictive value of the differential expression of the urokinase plasminogen activation axis in radical prostatectomy patients. *Eur Urol*. 2009 May; Epub 2008 Jun 23. PMID: 18585843.

1419. **Shariat SF**, Karam JA, Walz J, Roehrborn CG, Montorsi F, Margulis V, Saad F, Slawin KM, Karakiewicz PI. Improved prediction of disease relapse after radical prostatectomy through a panel of preoperative blood-based biomarkers. *Clin Cancer Res*. 2008 Jun 15; PMID: 18559597.
1420. **Shariat SF**, Trinh QD, Morey AF, Stage KH, Roehrborn CG, Valiquette L, Karakiewicz PI. Development of a highly accurate nomogram for prediction of the need for exploration in patients with renal trauma. *J Trauma*. 2008 Jun; PMID: 18545108.
1421. Svatek RS, Karam JA, Roehrborn CG, Karakiewicz PI, Slawin KM, **Shariat SF**. Preoperative plasma endoglin levels predict biochemical progression after radical prostatectomy. *Clin Cancer Res*. 2008 Jun 1. PMID: 18519764.
1422. Capitanio U, Jeldres C, **Shariat SF**, Karakiewicz P. Clinicians are most familiar with nomograms and rate their clinical usefulness highest, look-up tables are second best. *Eur Urol*. 2008 Oct; Epub 2008 May 8. PMID: 18485579.
1423. Karam JA, Margulis V, Montorsi F, Karakiewicz PI, Lotan Y, Kikuchi E, Weizer A, Zigeuner R, Bolenz C, **Shariat SF**. Carcinoma in situ of the upper urinary tract treated with radical nephroureterectomy-results from a multicenter study. *Eur Urol*. 2008 Oct; Epub 2008 May 8. PMID: 18485573.
1424. Jeldres C, Suardi N, Capitanio U, Montorsi F, **Shariat SF**, Perrotte P, Peloquin F, Pharand D, Graefen M, Karakiewicz PI. High surgical volume is associated with a lower rate of secondary therapy after radical prostatectomy for localized prostate cancer. *BJU Int*. 2008 Aug; Epub 2008 May 12. PMID: 18476966.
1425. Gallina A, Suardi N, Montorsi F, Capitanio U, Jeldres C, Saad F, Graefen M, **Shariat SF**, Widmer H, Arjane P, Pélouquin F, Perrotte P, Karakiewicz PI. Mortality at 120 days after prostatic biopsy: a population-based study of 22,175 men. *Int J Cancer*. 2008 Aug 1. PMID: 18470914.
1426. Walz J, **Shariat SF**, Suardi N, Perrotte P, Lotan Y, Palapattu GS, Gupta A, Bastian PJ, Rogers CG, Vazina A, Amiel GE, Sagalowsky AI, Schoenberg M, Lerner SP, Karakiewicz PI. Adjuvant chemotherapy for bladder cancer does not alter cancer-specific survival after cystectomy in a matched case-control study. *BJU Int*. 2008 Jun; PMID: 18454792.
1427. **Shariat SF**, Jenkins A, Roehrborn CG, Karam JA, Stage KH, Karakiewicz PI. Features and outcomes of patients with grade IV renal injury. *BJU Int*. 2008 Sep; Epub 2008 Apr 24. PMID: 18435808.
1428. Lotan Y, Bensalah K, Ruddell T, **Shariat SF**, Sagalowsky AI, Ashfaq R. Prospective evaluation of the clinical usefulness of reflex fluorescence in situ hybridization assay in patients with atypical cytology for the detection of urothelial carcinoma of the bladder. *J Urol*. 2008 Jun; Epub 2008 Apr 18. PMID: 18423745.
1429. Gallina A, Chun FK, Suardi N, Eastham JA, Perrotte P, Graefen M, Hutterer G, Huland H, Klein EA, Reuther A, Montorsi F, Briganti A, **Shariat SF**, Roehrborn CG, de la Taille A, Salomon L, Karakiewicz PI. Comparison of stage migration patterns between Europe and the USA: an analysis of 11 350 men treated with radical prostatectomy for prostate cancer. *BJU Int*. 2008 Jun; Epub 2008 Apr 16. PMID: 18422773.
1430. Walz J, Suardi N, **Shariat SF**, Jeldres C, Perrotte P, Graefen M, Widmer H, Arjane P, Valiquette L, Hutterer G, Saad F, Karakiewicz PI. Accuracy of life tables in predicting overall survival in patients after radical prostatectomy. *BJU Int*. 2008 Jul; Epub 2008 Apr 2. PMID: 18384631.
1431. **Shariat SF**, Karakiewicz PI, Margulis V, Kattan MW. Inventory of prostate cancer predictive tools. *Curr Opin Urol*. 2008 May; Review. PMID: 18382238.

1432. **Shariat SF**, Karam JA, Raman JD. Urine cytology and urine-based markers for bladder urothelial carcinoma detection and monitoring: developments and future prospects. *Biomark Med.* 2008 Apr; PMID: 20477438.
1433. Karakiewicz PI, Bhojani N, Neugut A, **Shariat SF**, Jeldres C, Graefen M, Perrotte P, Peloquin F, Kattan MW. The effect of comorbidity and socioeconomic status on sexual and urinary function and on general health-related quality of life in men treated with radical prostatectomy for localized prostate cancer. *J Sex Med.* 2008 Apr; PMID: 18371045.
1434. Bhojani N, Perrotte P, Hutterer G, Suardi N, Jeldres C, **Shariat SF**, Capitanio U, Arjane P, Widmer H, Benard F, Peloquin F, Montorsi F, Karakiewicz P. Body mass index and its association with genitourinary disorders in men undergoing prostate cancer screening. *J Sex Med.* 2008 Sep; Epub 2008 Mar 19. PMID: 18355173.
1435. **Shariat SF**, Walz J, Roehrborn CG, Zlotta AR, Perrotte P, Suardi N, Saad F, Karakiewicz PI. External validation of a biomarker-based preoperative nomogram predicts biochemical recurrence after radical prostatectomy. *J Clin Oncol.* 2008 Mar 20; PMID: 18349404.
1436. **Shariat SF**, Margulis V, Karakiewicz PI. Rebuttal from authors re: James W.F. Catto. More nomograms or better evidence of efficacy: what do we need in urologic oncology? *Eur Urol.* 2008 Jul; Epub 2008 Mar 4. PMID: 18329787.
1437. Margulis V, Lotan Y, Montorsi F, **Shariat SF**. Predicting survival after radical cystectomy for bladder cancer. *BJU Int.* 2008 Jul; Epub 2008 Mar 5. Review. PMID: 18325050.
1438. Walz J, Montorsi F, Jeldres C, Suardi N, **Shariat SF**, Perrotte P, Arjane P, Graefen M, Pharand D, Karakiewicz PI. The effect of surgical volume, age and comorbidities on 30-day mortality after radical prostatectomy: a population-based analysis of 9208 consecutive cases. *BJU Int.* 2008 Apr. PMID: 18321316.
1439. Karam JA, Svatek RS, Karakiewicz PI, Gallina A, Roehrborn CG, Slawin KM, **Shariat SF**. Use of preoperative plasma endoglin for prediction of lymph node metastasis in patients with clinically localized prostate cancer. *Clin Cancer Res.* 2008 Mar 1; PMID: 18316564.
1440. Gupta A, Lotan Y, Bastian PJ, Palapattu GS, Karakiewicz PI, Raj GV, Schoenberg MP, Lerner SP, Sagalowsky AI, **Shariat SF**; Bladder Cancer Research Consortium. Outcomes of patients with clinical T1 grade 3 urothelial cell bladder carcinoma treated with radical cystectomy. *Urology.* 2008 Feb; PMID: 18308108.
1441. **Shariat SF**, Walz J, Roehrborn CG, Montorsi F, Jeldres C, Saad F, Karakiewicz PI. Early postoperative plasma transforming growth factor-beta1 is a strong predictor of biochemical progression after radical prostatectomy. *J Urol.* 2008 Apr; Epub 2008 Mar 4. PMID: 18295256.
1442. Lotan Y, **Shariat SF**; NMP22 Study Group. Impact of risk factors on the performance of the nuclear matrix protein 22 point-of-care test for bladder cancer detection. *BJU Int.* 2008 Jun; Epub 2008 Feb 18. PMID: 18284410.
1443. Karakiewicz PI, Capitanio U, **Shariat S**. Prostate growth and prevalence of prostate diseases in early onset spinal cord injuries. *Eur Urol.* 2009 Jul; Epub 2008 Feb 8. PMID: 18280634.
1444. Bensalah K, Traxer O, **Shariat SF**, Zimmern P. [What are the differences between American and French urologists?]. *Prog Urol.* 2007 Nov; French. PMID: 18271424.
1445. **Shariat SF**, Karakiewicz PI. Perspectives on prostate cancer biomarkers. *Eur Urol.* 2008 Jul; Epub 2008 Feb 4. PMID: 18262336.

1446. Hutterer GC, Karakiewicz PI, Zippe C, Lüdecke G, Boman H, Sanchez-Carbayo M, Casella R, Mian C, Friedrich MG, Eissa S, Akaza H, Serretta V, Hedelin H, Rupesh R, Miyanaga N, Sagalowsky AI, Perrotte P, Lotan Y, Marberger MJ, **Shariat SF**. Urinary cytology and nuclear matrix protein 22 in the detection of bladder cancer recurrence other than transitional cell carcinoma. *BJU Int*. 2008 Mar. PMID: 18257856.
1447. **Shariat SF**. Selecting patients for immediate cystectomy. *Rev Urol*. 2007 Fall. PMID: 18231621.
1448. **Shariat SF**, Lamb DJ, Iyengar RG, Roehrborn CG, Slawin KM. Herbal/hormonal dietary supplement possibly associated with prostate cancer progression. *Clin Cancer Res*. 2008 Jan 15. PMID: 18223237.
1449. Bhojani N, Perrotte P, Jeldres C, Suardi N, Hutterer G, **Shariat SF**, Karakiewicz PI. The effect of comorbidities and socioeconomic status on sexual and urinary function in men undergoing prostate cancer screening. *J Sex Med*. 2008 Mar; Epub 2008 Jan 21. PMID: 18221289.
1450. **Shariat SF**, Margulis V, Lotan Y, Montorsi F, Karakiewicz PI. Nomograms for bladder cancer. *Eur Urol*. 2008 Jul; Epub 2008 Jan 15. Review. PMID: 18207314.
1451. **Shariat SF**, Karam JA, Lerner SP. Molecular markers in bladder cancer. *Curr Opin Urol*. 2008 Jan; Review. PMID: 18090481.
1452. **Shariat SF**, Karakiewicz PI. Screening for prostate cancer in 2007: the PSA era and its challenges are not over. *Eur Urol*. 2008 Mar; Epub 2007 Dec 7. PMID: 18079050.
1453. Svatek RS, Karam J, Karakiewicz PI, Gallina A, Casella R, Roehrborn CG, **Shariat SF**. Role of urinary cathepsin B and L in the detection of bladder urothelial cell carcinoma. *J Urol*. 2008 Feb; PMID: 18076936.
1454. **Shariat SF**, Ashfaq R, Sagalowsky AI, Lotan Y. Association of cyclin D1 and E1 expression with disease progression and biomarkers in patients with nonmuscle-invasive urothelial cell carcinoma of the bladder. *Urol Oncol*. 2007 Nov-Dec; PMID: 18047954.
1455. **Shariat SF**, Karakiewicz PI, Ashfaq R, Lerner SP, Palapattu GS, Cote RJ, Sagalowsky AI, Lotan Y. Multiple biomarkers improve prediction of bladder cancer recurrence and mortality in patients undergoing cystectomy. *Cancer*. 2008 Jan 15; PMID: 18008359.
1456. Bensalah K, Lotan Y, Karam JA, **Shariat SF**. New circulating biomarkers for prostate cancer. *Prostate Cancer Prostatic Dis*. 2008; Epub 2007 Nov 13. Review. PMID: 17998918.
1457. Jeldres C, Suardi N, Saad F, Montorsi F, **Shariat SF**, Perrotte P, Bhojani N, Walz J, Hutterer GC, Graefen M, Valiquette L, Karakiewicz PI. High provider volume is associated with lower rate of secondary therapies after definitive radiotherapy for localized prostate cancer. *Eur Urol*. 2008 Jul; Epub 2007 Nov 6. PMID: 17997022.
1458. Briganti A, Chun FK, Suardi N, Gallina A, Walz J, Graefen M, **Shariat S**, Ebersdobler A, Rigatti P, Perrotte P, Saad F, Montorsi F, Huland H, Karakiewicz PI. Prostate volume and adverse prostate cancer features: fact not artifact. *Eur J Cancer*. 2007 Dec; Epub 2007 Nov 8. PMID: 17996442.
1459. Jeldres C, Suardi N, Walz J, Saad F, Hutterer GC, Bhojani N, **Shariat SF**, Perrotte P, Graefen M, Montorsi F, Karakiewicz PI. Poor overall survival in septa- and octogenarian patients after radical prostatectomy and radiotherapy for prostate cancer: a population-based study of 6183 men. *Eur Urol*. 2008 Jul; Epub 2007 Oct 30. PMID: 17996358.
1460. Walz J, Gallina A, Perrotte P, Jeldres C, Trinh QD, Hutterer GC, Traumann M, Ramirez A, **Shariat SF**, McCormack M, Perreault JP, Bénard F, Valiquette L, Saad F, Karakiewicz PI.

- Clinicians are poor raters of life-expectancy before radical prostatectomy or definitive radiotherapy for localized prostate cancer. *BJU Int.* 2007 Dec; PMID: 17979925.
1461. Margulis V, Lotan Y, **Shariat SF**. Survivin: a promising biomarker for detection and prognosis of bladder cancer. *World J Urol.* 2008 Feb; Epub 2007 Oct 26. Review. PMID: 17962949.
 1462. **Shariat SF**, Karam JA, Margulis V, Karakiewicz PI. New blood-based biomarkers for the diagnosis, staging and prognosis of prostate cancer. *BJU Int.* 2008 Mar; Epub 2007 Oct 17. Review. PMID: 17941930.
 1463. Bensalah K, Montorsi F, **Shariat SF**. Challenges of cancer biomarker profiling. *Eur Urol.* 2007 Dec; 2007 Oct 1. Review. PMID: 17919807.
 1464. Karam JA, Lotan Y, Ashfaq R, Sagalowsky AI, **Shariat SF**. Survivin expression in patients with non-muscle-invasive urothelial cell carcinoma of the bladder. *Urology.* 2007 Sep; PMID: 17905101.
 1465. **Shariat SF**, Bensalah K, Karam JA, Roehrborn CG, Gallina A, Lotan Y, Slawin KM, Karakiewicz PI. Preoperative plasma HER2 and epidermal growth factor receptor for staging and prognostication in patients with clinically localized prostate cancer. *Clin Cancer Res.* 2007 Sep 15; PMID: 17875766.
 1466. **Shariat SF**, Svatek RS, Kabbani W, Walz J, Lotan Y, Karakiewicz PI, Roehrborn CG. Prognostic value of syndecan-1 expression in patients treated with radical prostatectomy. *BJU Int.* 2008 Jan; Epub 2007 Sep 13. PMID: 17868422.
 1467. Bastian PJ, Hutterer GC, **Shariat SF**, Rogers CG, Palapattu GS, Lotan Y, Vazina A, Amiel GE, Gupta A, Sagalowsky AI, Lerner SP, Schoenberg MP, Karakiewicz PI; Bladder Cancer Research Consortium. Macroscopic, but not microscopic, perivesical fat invasion at radical cystectomy is an adverse predictor of recurrence and survival. *BJU Int.* 2008 Feb; Epub 2007 Sep 10. PMID: 17850359.
 1468. Nielsen ME, Palapattu GS, Karakiewicz PI, Lotan Y, Bastian PJ, Lerner SP, Sagalowsky AI, Schoenberg MP, **Shariat SF**. A delay in radical cystectomy of >3 months is not associated with a worse clinical outcome. *BJU Int.* 2007 Nov; Epub 2007 Sep 3. PMID: 17784888.
 1469. Huang HY, **Shariat SF**, Sun TT, Lepor H, Shapiro E, Hsieh JT, Ashfaq R, Lotan Y, Wu XR. Persistent uroplakin expression in advanced urothelial carcinomas: implications in urothelial tumor progression and clinical outcome. *Hum Pathol.* 2007 Nov; Epub 2007 Aug 17. PMID: 17707461.
 1470. Walz J, Gallina A, Saad F, Montorsi F, Perrotte P, **Shariat SF**, Jeldres C, Graefen M, Bénard F, McCormack M, Valiquette L, Karakiewicz PI. A nomogram predicting 10-year life expectancy in candidates for radical prostatectomy or radiotherapy for prostate cancer. *J Clin Oncol.* 2007 Aug 20. PMID: 17704404.
 1471. **Shariat SF**, Park S, Trinh QD, Roehrborn CG, Slawin KM, Karakiewicz PI. Plasminogen activation inhibitor-1 improves the predictive accuracy of prostate cancer nomograms. *J Urol.* 2007 Oct; Epub 2007 Aug 14. PMID: 17698116.
 1472. Karam JA, **Shariat SF**, Huang HY, Pong RC, Ashfaq R, Shapiro E, Lotan Y, Sagalowsky AI, Wu XR, Hsieh JT. Decreased DOC-2/DAB2 expression in urothelial carcinoma of the bladder. *Clin Cancer Res.* 2007 Aug 1. PMID: 17671122.
 1473. **Shariat SF**, Karam JA, Roehrborn CG. Blood biomarkers for prostate cancer detection and prognosis. *Future Oncol.* 2007 Aug. PMID: 17661720.

1474. Malaeb BS, Rashid HH, Lotan Y, Khoddami SM, **Shariat SF**, Sagalowsky AI, McConnell JD, Roehrborn CG, Koeneman KS. Prostate cancer disease-free survival after radical retropubic prostatectomy in patients older than 70 years compared to younger cohorts. *Urol Oncol*. 2007 Jul-Aug. PMID: 17628294.
1475. Briganti A, **Shariat SF**, Chun FK, Hutterer GC, Roehrborn CG, Gallina A, Rigatti P, Valiquette L, Montorsi F, Karakiewicz PI. Differences in the rate of lymph node invasion in men with clinically localized prostate cancer might be related to the continent of origin. *BJU Int*. 2007 Sep; Epub 2007 Jun 15. PMID: 17573893.
1476. Gallina A, Karakiewicz PI, Hutterer GC, Chun FK, Briganti A, Walz J, Antebi E, **Shariat SF**, Suardi N, Graefen M, Erbersdobler A, Salonia A, Rigatti P, Huland H, Montorsi F. Obesity does not predispose to more aggressive prostate cancer either at biopsy or radical prostatectomy in European men. *Int J Cancer*. 2007 Aug 15; PMID: 17455251.
1477. Walz J, Gallina A, Hutterer G, Perrotte P, **Shariat SF**, Graefen M, McCormack M, Bénard F, Valiquette L, Saad F, Karakiewicz PI. Accuracy of life tables in predicting overall survival in candidates for radiotherapy for prostate cancer. *Int J Radiat Oncol Biol Phys*. 2007 Sep 1; Epub 2007 Apr 18. PMID: 17446004.
1478. **Shariat SF**, Roehrborn CG, Karakiewicz PI, Dhami G, Stage KH. Evidence-based validation of the predictive value of the American Association for the Surgery of Trauma kidney injury scale. *J Trauma*. 2007 Apr; PMID: 17426551.
1479. **Shariat SF**, Zlotta AR, Ashfaq R, Sagalowsky AI, Lotan Y. Cooperative effect of cell-cycle regulators expression on bladder cancer development and biologic aggressiveness. *Mod Pathol*. 2007 Apr; Epub 2007 Mar 2. PMID: 17384651.
1480. Chun FK, Briganti A, Gallina A, Hutterer GC, **Shariat SF**, Antebi E, Walz J, Roehrborn CG, Salonia A, Rigatti P, Saad F, Huland H, Montorsi F, Graefen M, Karakiewicz PI. Prostate-specific antigen improves the ability of clinical stage and biopsy Gleason sum to predict the pathologic stage at radical prostatectomy in the new millennium. *Eur Urol*. 2007 Oct; Epub 2007 Mar 20. PMID: 17383807.
1481. Briganti A, Chun FK, Hutterer GC, Gallina A, **Shariat SF**, Salonia A, Scattoni V, Valiquette L, Montorsi F, Rigatti P, Graefen M, Huland H, Karakiewicz PI. Systematic assessment of the ability of the number and percentage of positive biopsy cores to predict pathologic stage and biochemical recurrence after radical prostatectomy. *Eur Urol*. 2007 Sep; Epub 2007 Mar 6. PMID: 17350750.
1482. **Shariat SF**, Ashfaq R, Karakiewicz PI, Saeedi O, Sagalowsky AI, Lotan Y. Survivin expression is associated with bladder cancer presence, stage, progression, and mortality. *Cancer*. 2007 Mar 15; PMID: 17311310.
1483. Karam JA, Lotan Y, Roehrborn CG, Ashfaq R, Karakiewicz PI, **Shariat SF**. Caveolin-1 overexpression is associated with aggressive prostate cancer recurrence. *Prostate*. 2007 May 1. PMID: 17299799.
1484. Margulis V, **Shariat SF**, Ashfaq R, Thompson M, Sagalowsky AI, Hsieh JT, Lotan Y. Expression of cyclooxygenase-2 in normal urothelium, and superficial and advanced transitional cell carcinoma of bladder. *J Urol*. 2007 Mar. PMID: 17296438.
1485. Karam JA, Lotan Y, Karakiewicz PI, Ashfaq R, Sagalowsky AI, Roehrborn CG, **Shariat SF**. Use of combined apoptosis biomarkers for prediction of bladder cancer recurrence and mortality after radical cystectomy. *Lancet Oncol*. 2007 Feb. PMID: 17267327.

1486. Gallina A, Chun FK, Briganti A, **Shariat SF**, Montorsi F, Salonia A, Erbersdobler A, Rigatti P, Valiquette L, Huland H, Graefen M, Karakiewicz PI. Development and split-sample validation of a nomogram predicting the probability of seminal vesicle invasion at radical prostatectomy. *Eur Urol*. 2007 Jul; Epub 2007 Jan 22. PMID: 17267098.
1487. **Shariat SF**, Roehrborn CG, McConnell JD, Park S, Alam N, Wheeler TM, Slawin KM. Association of the circulating levels of the urokinase system of plasminogen activation with the presence of prostate cancer and invasion, progression, and metastasis. *J Clin Oncol*. 2007 Feb 1. PMID: 17264329.
1488. **Shariat SF**, Ashfaq R, Sagalowsky AI, Lotan Y. Predictive value of cell cycle biomarkers in nonmuscle invasive bladder transitional cell carcinoma. *J Urol*. 2007 Feb. PMID: 17222615.
1489. Margulis V, **Shariat SF**, Ashfaq R, Sagalowsky AI, Lotan Y. Ki-67 is an independent predictor of bladder cancer outcome in patients treated with radical cystectomy for organ-confined disease. *Clin Cancer Res*. 2006 Dec 15. PMID: 17189409.
1490. Gallina A, Jeldres C, Chun FK, **Shariat SF**, Briganti A, Walz J, Roehrborn CG, Saad F, Huland H, Graefen M, Montorsi F, Karakiewicz PI. Prediction of pathological stage is inaccurate in men with PSA values above 20 ng/mL. *Eur Urol*. 2007 Nov; Epub 2006 Dec 11. PMID: 17174466.
1491. **Shariat SF**, Karakiewicz PI, Palapattu GS, Amiel GE, Lotan Y, Rogers CG, Vazina A, Bastian PJ, Gupta A, Sagalowsky AI, Schoenberg M, Lerner SP. Nomograms provide improved accuracy for predicting survival after radical cystectomy. *Clin Cancer Res*. 2006 Nov 15. PMID: 17121885.
1492. Nielsen ME, **Shariat SF**, Karakiewicz PI, Lotan Y, Rogers CG, Amiel GE, Bastian PJ, Vazina A, Gupta A, Lerner SP, Sagalowsky AI, Schoenberg MP, Palapattu GS; Bladder Cancer Research Consortium (BCRC). Advanced age is associated with poorer bladder cancer-specific survival in patients treated with radical cystectomy. *Eur Urol*. 2007 Mar; Epub 2006 Nov 13. PMID: 17113703.
1493. **Shariat SF**, Karakiewicz PI, Palapattu GS, Lotan Y, Rogers CG, Amiel GE, Vazina A, Gupta A, Bastian PJ, Sagalowsky AI, Schoenberg MP, Lerner SP. Outcomes of radical cystectomy for transitional cell carcinoma of the bladder: a contemporary series from the Bladder Cancer Research Consortium. *J Urol*. 2006 Dec. PMID: 17085118.
1494. **Shariat SF**, Palapattu GS, Karakiewicz PI, Rogers CG, Vazina A, Bastian PJ, Schoenberg MP, Lerner SP, Sagalowsky AI, Lotan Y. Concomitant carcinoma in situ is a feature of aggressive disease in patients with organ-confined TCC at radical cystectomy. *Eur Urol*. 2007 Jan; Epub 2006 Sep 11. PMID: 17011114.
1495. Slawin KM, **Shariat S**, Canto E. BPSA: A Novel Serum Marker for Benign Prostatic Hyperplasia. *Rev Urol*. 2005. PMID: 16985891.
1496. **Shariat SF**, Naderi AS, Miles B, Slawin KM. Anomalies of the wolffian duct derivatives encountered at radical prostatectomy. *Rev Urol*. 2005 Spring. PMID: 16985813.
1497. **Shariat SF**, Sadeghi F, Slawin KM. Vaccine-based immunotherapy for prostate cancer. *Rev Urol*. 2000 Fall. PMID: 16985756.
1498. **Shariat SF**, Slawin KM. Gene therapy for prostate cancer. *Rev Urol*. 2000 Spring. PMID: 16985740.
1499. **Shariat SF**, Haddad JL, Escudier S, Lerner SP. Metastatic transitional cell carcinoma of the urinary bladder to the shoulder girdle. *Rev Urol*. 2002 Spring. PMID: 16985663.

1500. Slawin KM, Canto EI, **Shariat SF**, Gore JL, Kim E, Kattan MW, Wheeler TM, Nath RK. Sural Nerve Interposition Grafting during Radical Prostatectomy. *Rev Urol.* 2002 Winter. PMID: 16985648.
1501. **Shariat SF**, Slawin KM. Peripheral blood rt-PCR assays for detection and prognosis of prostate cancer. *Rev Urol.* 2003 Winter. PMID: 16985619.
1502. **Shariat SF**, Canto EI, Kattan MW, Slawin KM. Beyond prostate-specific antigen: new serologic biomarkers for improved diagnosis and management of prostate cancer. *Rev Urol.* 2004 Spring. PMID: 16985579.
1503. **Shariat SF**, Palapattu GS, Amiel GE, Karakiewicz PI, Rogers CG, Vazina A, Schoenberg MP, Lerner SP, Sagalowsky AI, Lotan Y. Characteristics and outcomes of patients with carcinoma in situ only at radical cystectomy. *Urology.* 2006 Sep; Epub 2006 Sep 18. PMID: 16979748.
1504. Karakiewicz PI, **Shariat SF**, Palapattu GS, Gilad AE, Lotan Y, Rogers CG, Vazina A, Gupta A, Bastian PJ, Perrotte P, Sagalowsky AI, Schoenberg M, Lerner SP. Nomogram for predicting disease recurrence after radical cystectomy for transitional cell carcinoma of the bladder. *J Urol.* 2006 Oct. PMID: 16952631.
1505. **Shariat SF**, Ashfaq R, Sagalowsky AI, Lotan Y. Correlation of cyclin D1 and E1 expression with bladder cancer presence, invasion, progression, and metastasis. *Hum Pathol.* 2006 Dec; Epub 2006 Aug 10. PMID: 16949911.
1506. **Shariat SF**, Marberger MJ, Lotan Y, Sanchez-Carbayo M, Zippe C, Lüdecke G, Boman H, Sawczuk I, Friedrich MG, Casella R, Mian C, Eissa S, Akaza H, Serretta V, Huland H, Hedelin H, Raina R, Miyanaga N, Sagalowsky AI, Roehrborn CG, Karakiewicz PI. Variability in the performance of nuclear matrix protein 22 for the detection of bladder cancer. *J Urol.* 2006 Sep. PMID: 16890655.
1507. Chun FK, Briganti A, **Shariat SF**, Graefen M, Montorsi F, Erbersdobler A, Steuber T, Salonia A, Currilin E, Scattoni V, Friedrich MG, Schlomm T, Haese A, Michl U, Colombo R, Heinzer H, Valiquette L, Rigatti P, Roehrborn CG, Huland H, Karakiewicz PI. Significant upgrading affects a third of men diagnosed with prostate cancer: predictive nomogram and internal validation. *BJU Int.* 2006 Aug. PMID: 16879673.
1508. Karakiewicz PI, **Shariat SF**, Palapattu GS, Perrotte P, Lotan Y, Rogers CG, Amiel GE, Vazina A, Gupta A, Bastian PJ, Sagalowsky AI, Schoenberg M, Lerner SP. Precystectomy nomogram for prediction of advanced bladder cancer stage. *Eur Urol.* 2006 Dec; Epub 2006 Jun 23. PMID: 16831511.
1509. Walsh LP, Zimmern PE, Pope N, **Shariat SF**; Urinary Incontinence Treatment Network. Comparison of the Q-tip test and voiding cystourethrogram to assess urethral hypermobility among women enrolled in a randomized clinical trial of surgery for stress urinary incontinence. *J Urol.* 2006 Aug. PMID: 16813912.
1510. **Shariat SF**, Palapattu GS, Karakiewicz PI, Rogers CG, Vazina A, Bastian PJ, Schoenberg MP, Lerner SP, Sagalowsky AI, Lotan Y. Discrepancy between clinical and pathologic stage: impact on prognosis after radical cystectomy. *Eur Urol.* 2007 Jan; Epub 2006 Jun 8. PMID: 16793197.
1511. Rogers CG, Palapattu GS, **Shariat SF**, Karakiewicz PI, Bastian PJ, Lotan Y, Gupta A, Vazina A, Gilad A, Sagalowsky AI, Lerner SP, Schoenberg MP. Clinical outcomes following radical cystectomy for primary nontransitional cell carcinoma of the bladder compared to transitional cell carcinoma of the bladder. *J Urol.* 2006 Jun. PMID: 16697800.

1512. Palapattu GS, **Shariat SF**, Karakiewicz PI, Bastian PJ, Rogers CG, Amiel G, Lotan Y, Vazina A, Gupta A, Sagalowsky AI, Lerner SP, Schoenberg MP; Bladder Cancer Research Consortium. Cancer specific outcomes in patients with pT0 disease following radical cystectomy. *J Urol*. 2006 May. PMID: 16600721.
1513. Karakiewicz PI, Benayoun S, Zippe C, Lüdecke G, Boman H, Sanchez-Carbayo M, Casella R, Mian C, Friedrich MG, Eissa S, Akaza H, Huland H, Hedelin H, Rupesh R, Miyanaga N, Sagalowsky AI, Marberger MJ, **Shariat SF**. Institutional variability in the accuracy of urinary cytology for predicting recurrence of transitional cell carcinoma of the bladder. *BJU Int*. 2006 May; Epub 2006 Mar 17. PMID: 16542342.
1514. Svatek RS, Herman MP, Lotan Y, Casella R, Hsieh JT, Sagalowsky AI, **Shariat SF**. Soluble Fas-- a promising novel urinary marker for the detection of recurrent superficial bladder cancer. *Cancer*. 2006 Apr 15. PMID: 16541433.
1515. **Shariat SF**, Abdel-Aziz KF, Roehrborn CG, Lotan Y. Pre-operative percent free PSA predicts clinical outcomes in patients treated with radical prostatectomy with total PSA levels below 10 ng/ml. *Eur Urol*. 2006 Feb; Epub 2005 Dec 20. PMID: 16387412.
1516. **Shariat SF**, Duchene D, Kabbani W, Mucher Z, Lotan Y. Gastrointestinal hemorrhage as first manifestation of metastatic testicular tumor. *Urology*. 2005 Dec. PMID: 16360470.
1517. **Shariat SF**, Ashfaq R, Roehrborn CG, Slawin KM, Lotan Y. Expression of survivin and apoptotic biomarkers in benign prostatic hyperplasia. *J Urol*. 2005 Nov. PMID: 16217391.
1518. Lotan Y, Gupta A, **Shariat SF**, Palapattu GS, Vazina A, Karakiewicz PI, Bastian PJ, Rogers CG, Amiel G, Perotte P, Schoenberg MP, Lerner SP, Sagalowsky AI. Lymphovascular invasion is independently associated with overall survival, cause-specific survival, and local and distant recurrence in patients with negative lymph nodes at radical cystectomy. *J Clin Oncol*. 2005 Sep 20; Epub 2005 Aug 22. PMID: 16116151.
1519. Matsumoto K, **Shariat SF**, Ayala GE, Rauen KA, Lerner SP. Loss of coxsackie and adenovirus receptor expression is associated with features of aggressive bladder cancer. *Urology*. 2005 Aug. PMID: 16040097.
1520. **Shariat SF**, Raptidis G, Masatoschi M, Bergamaschi F, Slawin KM. Pilot study of radiofrequency interstitial tumor ablation (RITA) for the treatment of radio-recurrent prostate cancer. *Prostate*. 2005 Nov 1. PMID: 16015591.
1521. **Shariat SF**, Matsumoto K, Casella R, Jian W, Lerner SP. Urinary levels of soluble e-cadherin in the detection of transitional cell carcinoma of the urinary bladder. *Eur Urol*. 2005 Jul; Epub 2005 Mar 8. PMID: 15967254.
1522. **Shariat SF**, Herman MP, Casella R, Lotan Y, Karam JA, Stenman UH. Urinary levels of tumor-associated trypsin inhibitor (TATI) in the detection of transitional cell carcinoma of the urinary bladder. *Eur Urol*. 2005 Sep. PMID: 15963628.
1523. **Shariat SF**, Zippe C, Lüdecke G, Boman H, Sanchez-Carbayo M, Casella R, Mian C, Friedrich MG, Eissa S, Akaza H, Sawczuk I, Serretta V, Huland H, Hedelin H, Rupesh R, Miyanaga N, Sagalowsky AI, Wians F Jr, Roehrborn CG, Lotan Y, Perrotte P, Benayoun S, Marberger MJ, Karakiewicz PI. Nomograms including nuclear matrix protein 22 for prediction of disease recurrence and progression in patients with Ta, T1 or CIS transitional cell carcinoma of the bladder. *J Urol*. 2005 May. PMID: 15821471.

1524. Ramirez A, Perrotte P, Valiquette L, Benard F, McCormack M, Saad F, Fournier C, **Shariat S**, Karakiewicz PI. Exploration of health-related quality of life areas that may distinguish between continent diversion and ileal conduit patients. *Can J Urol*. 2005 Feb. PMID: 15777491.
1525. Karakiewicz P, **Shariat SF**, Naderi A, Kadmon D, Slawin KM. Reliability of remembered International Index of Erectile Function domain scores in men with localized prostate cancer. *Urology*. 2005 Jan. PMID: 15667878.
1526. Defreitas GA, Zimmern PE, Lemack GE, **Shariat SF**. Refining diagnosis of anatomic female bladder outlet obstruction: comparison of pressure-flow study parameters in clinically obstructed women with those of normal controls. *Urology*. 2004 Oct. PMID: 15491697.
1527. Canto EI, Singh H, **Shariat SF**, Kadmon D, Miles BJ, Wheeler TM, Slawin KM. Effects of systematic 12-core biopsy on the performance of percent free prostate specific antigen for prostate cancer detection. *J Urol*. 2004 Sep. PMID: 15310993.
1528. Khoddami SM, **Shariat SF**, Lotan Y, Saboorian H, McConnell JD, Sagalowsky AI, Roehrborn CG, Koeneman KS. Predictive value of primary Gleason pattern 4 in patients with Gleason score 7 tumours treated with radical prostatectomy. *BJU Int*. 2004 Jul. PMID: 15217428.
1529. **Shariat SF**, Menesses-Diaz A, Kim IY, Muramoto M, Wheeler TM, Slawin KM. Tissue expression of transforming growth factor-beta1 and its receptors: correlation with pathologic features and biochemical progression in patients undergoing radical prostatectomy. *Urology*. 2004 Jun. PMID: 15183988.
1530. Singh H, Karakiewicz P, **Shariat SF**, Canto EI, Nath RK, Kattan MW, Slawin KM. Impact of unilateral interposition sural nerve grafting on recovery of urinary function after radical prostatectomy. *Urology*. 2004 Jun. PMID: 15183964.
1531. Canto EI, **Shariat SF**, Slawin KM. Molecular diagnosis of prostate cancer. *Curr Urol Rep*. 2004 Jun; Review. PMID: 15161569.
1532. Canto EI, Singh H, **Shariat SF**, Lamb DJ, Mikolajczyk SD, Linton HJ, Rittenhouse HG, Kadmon D, Miles BJ, Slawin KM. Serum BPSA outperforms both total PSA and free PSA as a predictor of prostatic enlargement in men without prostate cancer. *Urology*. 2004 May. PMID: 15134977.
1533. Link RE, **Shariat SF**, Nguyen CV, Farr A, Weinberg AD, Morton RA, Richardson B, Bernard D, Slawin KM. Variation in prostate specific antigen results from 2 different assay platforms: clinical impact on 2304 patients undergoing prostate cancer screening. *J Urol*. 2004 Jun. PMID: 15126793.
1534. Lotan Y, **Shariat SF**, Khoddami SM, Saboorian H, Koeneman KS, Cadeddu JA, Sagalowsky AI, McConnell JD, Roehrborn CG. The percent of biopsy cores positive for cancer is a predictor of advanced pathological stage and poor clinical outcomes in patients treated with radical prostatectomy. *J Urol*. 2004 Jun. PMID: 15126787.
1535. **Shariat SF**, Anwuri VA, Lamb DJ, Shah NV, Wheeler TM, Slawin KM. Association of preoperative plasma levels of vascular endothelial growth factor and soluble vascular cell adhesion molecule-1 with lymph node status and biochemical progression after radical prostatectomy. *J Clin Oncol*. 2004 May 1. PMID: 15117988.
1536. Singh H, Canto EI, **Shariat SF**, Kadmon D, Miles BJ, Wheeler TM, Slawin KM. Predictors of prostate cancer after initial negative systematic 12 core biopsy. *J Urol*. 2004 May. PMID: 15076292.
1537. Ohori M, Kattan MW, Koh H, Maru N, Slawin KM, **Shariat S**, Muramoto M, Reuter VE, Wheeler TM, Scardino PT. Predicting the presence and side of extracapsular extension: a nomogram for staging prostate cancer. *J Urol*. 2004 May. PMID: 15076291.

1538. Vazina A, Dugi D, **Shariat SF**, Evans J, Link R, Lerner SP. Stage specific lymph node metastasis mapping in radical cystectomy specimens. *J Urol*. 2004 May. PMID: 15076287.
1539. **Shariat SF**, Kattan MW, Traxel E, Andrews B, Zhu K, Wheeler TM, Slawin KM. Association of pre- and postoperative plasma levels of transforming growth factor beta(1) and interleukin 6 and its soluble receptor with prostate cancer progression. *Clin Cancer Res*. 2004 Mar 15. PMID: 15041717.
1540. **Shariat SF**, Casella R, Wians FH Jr, Ashfaq R, Balko J, Sulser T, Gasser TC, Sagalowsky AI. Risk stratification for bladder tumor recurrence, stage and grade by urinary nuclear matrix protein 22 and cytology. *Eur Urol*. 2004 Mar. PMID: 15036675.
1541. Stephenson AJ, **Shariat SF**, Zelefsky MJ, Kattan MW, Butler EB, Teh BS, Klein EA, Kupelian PA, Roehrborn CG, Pistenmaa DA, Pacholke HD, Liauw SL, Katz MS, Leibel SA, Scardino PT, Slawin KM. Salvage radiotherapy for recurrent prostate cancer after radical prostatectomy. *JAMA*. 2004 Mar 17. PMID: 15026399.
1542. **Shariat SF**, Tokunaga H, Zhou J, Kim J, Ayala GE, Benedict WF, Lerner SP. p53, p21, pRB, and p16 expression predict clinical outcome in cystectomy with bladder cancer. *J Clin Oncol*. 2004 Mar 15; Epub 2004 Feb 23. PMID: 14981102.
1543. **Shariat SF**, Lotan Y, Saboorian H, Khoddami SM, Roehrborn CG, Slawin KM, Ashfaq R. Survivin expression is associated with features of biologically aggressive prostate carcinoma. *Cancer*. 2004 Feb 15. PMID: 14770431.
1544. **Shariat SF**, Khoddami SM, Saboorian H, Koeneman KS, Sagalowsky AI, Cadeddu JA, McConnell JD, Holmes MN, Roehrborn CG. Lymphovascular invasion is a pathological feature of biologically aggressive disease in patients treated with radical prostatectomy. *J Urol*. 2004 Mar. PMID: 14767284.
1545. Singh H, Canto EI, **Shariat SF**, Kadmon D, Miles BJ, Wheeler TM, Slawin KM. Improved detection of clinically significant, curable prostate cancer with systematic 12-core biopsy. *J Urol*. 2004 Mar. PMID: 14767277.
1546. **Shariat SF**, Casella R, Khoddami SM, Hernandez G, Sulser T, Gasser TC, Lerner SP. Urine detection of survivin is a sensitive marker for the noninvasive diagnosis of bladder cancer. *J Urol*. 2004 Feb. PMID: 14713774.
1547. Singh H, Canto EI, **Shariat SF**, Kadmon D, Miles BJ, Wheeler TM, Slawin KM. Six additional systematic lateral cores enhance sextant biopsy prediction of pathological features at radical prostatectomy. *J Urol*. 2004 Jan. PMID: 14665877.
1548. Matsumoto K, **Shariat SF**, Casella R, Wheeler TM, Slawin KM, Lerner SP. Preoperative plasma soluble E-cadherin predicts metastases to lymph nodes and prognosis in patients undergoing radical cystectomy. *J Urol*. 2003 Dec. PMID: 14634390.
1549. **Shariat SF**, Casella R, Monoski MA, Sulser T, Gasser TC, Lerner SP. The addition of urinary urokinase-type plasminogen activator to urinary nuclear matrix protein 22 and cytology improves the detection of bladder cancer. *J Urol*. 2003 Dec. PMID: 14634389.
1550. Kattan MW, Eastham JA, Wheeler TM, Maru N, Scardino PT, Erbersdobler A, Graefen M, Huland H, Koh H, **Shariat SF**, Slawin KM, Ohori M. Counseling men with prostate cancer: a nomogram for predicting the presence of small, moderately differentiated, confined tumors. *J Urol*. 2003 Nov. PMID: 14532778.
1551. **Shariat SF**, Kattan MW, Song W, Bernard D, Gottenger E, Wheeler TM, Slawin KM. Early postoperative peripheral blood reverse transcription PCR assay for prostate-specific antigen is

- associated with prostate cancer progression in patients undergoing radical prostatectomy. *Cancer Res.* 2003 Sep 15. PMID: 14522912.
1552. **Shariat SF**, Matsumoto K, Kim J, Ayala GE, Zhou JH, Jian W, Benedict WF, Lerner SP. Correlation of cyclooxygenase-2 expression with molecular markers, pathological features and clinical outcome of transitional cell carcinoma of the bladder. *J Urol.* 2003 Sep. PMID: 12913755.
1553. Kattan MW, **Shariat SF**, Andrews B, Zhu K, Canto E, Matsumoto K, Muramoto M, Scardino PT, Ohori M, Wheeler TM, Slawin KM. The addition of interleukin-6 soluble receptor and transforming growth factor beta1 improves a preoperative nomogram for predicting biochemical progression in patients with clinically localized prostate cancer. *J Clin Oncol.* 2003 Oct 1; Epub 2003 Aug 11. PMID: 12913106.
1554. **Shariat SF**, Roudier MP, Wilcox GE, Kattan MW, Scardino PT, Vessella RL, Erdamar S, Nguyen C, Wheeler TM, Slawin KM. Comparison of immunohistochemistry with reverse transcription-PCR for the detection of micrometastatic prostate cancer in lymph nodes. *Cancer Res.* 2003 Aug 1. PMID: 12907647.
1555. **Shariat SF**, Kim J, Raptidis G, Ayala GE, Lerner SP. Association of p53 and p21 expression with clinical outcome in patients with carcinoma in situ of the urinary bladder. *Urology.* 2003 Jun. PMID: 12809883.
1556. **Shariat SF**, Monoski MA, Andrews B, Wheeler TM, Lerner SP, Slawin KM. Association of plasma urokinase-type plasminogen activator and its receptor with clinical outcome in patients undergoing radical cystectomy for transitional cell carcinoma of the bladder. *Urology.* 2003 May. PMID: 12736046.
1557. Canto EI, **Shariat SF**, Slawin KM. Biochemical staging of prostate cancer. *Urol Clin North Am.* 2003 May; Review. PMID: 12735503.
1558. **Shariat SF**, Kattan MW, Erdamar S, Nguyen C, Scardino PT, Spencer DM, Wheeler TM, Slawin KM. Detection of clinically significant, occult prostate cancer metastases in lymph nodes using a splice variant-specific rt-PCR assay for human glandular kallikrein. *J Clin Oncol.* 2003 Apr 1. PMID: 12663708.
1559. **Shariat SF**, Kim J, Nguyen C, Wheeler TM, Lerner SP, Slawin KM. Correlation of preoperative levels of IGF-I and IGFBP-3 with pathologic parameters and clinical outcome in patients with bladder cancer. *Urology.* 2003 Feb. PMID: 12597948.
1560. **Shariat SF**, Kim JH, Ayala GE, Kho K, Wheeler TM, Lerner SP. Cyclooxygenase-2 is highly expressed in carcinoma in situ and T1 transitional cell carcinoma of the bladder. *J Urol.* 2003 Mar. PMID: 12576817.
1561. Casella R, **Shariat SF**, Monoski MA, Lerner SP. Urinary levels of urokinase-type plasminogen activator and its receptor in the detection of bladder carcinoma. *Cancer.* 2002 Dec 15. PMID: 12467062.
1562. **Shariat SF**, Gottenger E, Nguyen C, Song W, Kattan MW, Andenoro J, Wheeler TM, Spencer DM, Slawin KM. Preoperative blood reverse transcriptase-PCR assays for prostate-specific antigen and human glandular kallikrein for prediction of prostate cancer progression after radical prostatectomy. *Cancer Res.* 2002 Oct 15. PMID: 12384565.
1563. Andrews B, **Shariat SF**, Kim JH, Wheeler TM, Slawin KM, Lerner SP. Preoperative plasma levels of interleukin-6 and its soluble receptor predict disease recurrence and survival of patients with bladder cancer. *J Urol.* 2002 Mar. PMID: 11832773.

1564. **Shariat SF**, Lamb DJ, Kattan MW, Nguyen C, Kim J, Beck J, Wheeler TM, Slawin KM. Association of preoperative plasma levels of insulin-like growth factor I and insulin-like growth factor binding proteins-2 and -3 with prostate cancer invasion, progression, and metastasis. *J Clin Oncol*. 2002 Feb 1. PMID: 11821468.
1565. **Shariat SF**, Kim JH, Andrews B, Kattan MW, Wheeler TM, Kim IY, Lerner SP, Slawin KM. Preoperative plasma levels of transforming growth factor beta(1) strongly predict clinical outcome in patients with bladder carcinoma. *Cancer*. 2001 Dec 15. PMID: 11753975.
1566. Kim JH, **Shariat SF**, Kim IY, Menesses-Diaz A, Tokunaga H, Wheeler TM, Lerner SP. Predictive value of expression of transforming growth factor-beta(1) and its receptors in transitional cell carcinoma of the urinary bladder. *Cancer*. 2001 Sep 15. PMID: 11745225.
1567. **Shariat SF**, Andrews B, Kattan MW, Kim J, Wheeler TM, Slawin KM. Plasma levels of interleukin-6 and its soluble receptor are associated with prostate cancer progression and metastasis. *Urology*. 2001 Dec. PMID: 11744478.
1568. Tokunaga H, **Shariat SF**, Green AE, Brown RM, Zhou JH, Benedict WF, Lerner SP. Correlation of immunohistochemical molecular staging of bladder biopsies and radical cystectomy specimens. *Int J Radiat Oncol Biol Phys*. 2001 Sep 1. PMID: 11516846.
1569. **Shariat SF**, Shalev M, Menesses-Diaz A, Kim IY, Kattan MW, Wheeler TM, Slawin KM. Preoperative plasma levels of transforming growth factor beta(1)(TGF-beta(1)) strongly predict progression in patients undergoing radical prostatectomy. *J Clin Oncol*. 2001 Jun 1. PMID: 11387358.
1570. Gore JL, **Shariat SF**, Miles BJ, Kadmon D, Jiang N, Wheeler TM, Slawin KM. Optimal combinations of systematic sextant and laterally directed biopsies for the detection of prostate cancer. *J Urol*. 2001 May. PMID: 11342916.
1571. Byrne RR, **Shariat SF**, Brown R, Kattan MW, Morton RA JR, Wheeler TM, Lerner SP. E-cadherin immunostaining of bladder transitional cell carcinoma, carcinoma in situ and lymph node metastases with long-term followup. *J Urol*. 2001 May. PMID: 11342899.
1572. Leventis AK, **Shariat SF**, Slawin KM. Local recurrence after radical prostatectomy: correlation of US features with prostatic fossa biopsy findings. *Radiology*. 2001 May. PMID: 11323468.
1573. **Shariat SF**, Desai S, Song W, Khan T, Zhao J, Nguyen C, Foster BA, Greenberg N, Spencer DM, Slawin KM. Adenovirus-mediated transfer of inducible caspases: a novel "death switch" gene therapeutic approach to prostate cancer. *Cancer Res*. 2001 Mar 15. PMID: 11289132.
1574. Leventis AK, **Shariat SF**, Utsunomiya T, Slawin KM. Characteristics of normal prostate vascular anatomy as displayed by power Doppler. *Prostate*. 2001 Mar 1. PMID: 11241550.
1575. Leventis AK, **Shariat SF**, Kattan MW, Butler EB, Wheeler TM, Slawin KM. Prediction of response to salvage radiation therapy in patients with prostate cancer recurrence after radical prostatectomy. *J Clin Oncol*. 2001 Feb 15; Erratum in: *J Clin Oncol* 2001 Apr 1. PMID: 11181666.
1576. **Shariat SF**, Pahlavan S, Baseman AG, Brown RM, Green AE, Wheeler TM, Lerner SP. E-cadherin expression predicts clinical outcome in carcinoma in situ of the urinary bladder. *Urology*. 2001 Jan. PMID: 11164145.
1577. Slawin KM, **Shariat SF**, Nguyen C, Leventis AK, Song W, Kattan MW, Young CY, Tindall DJ, Wheeler TM. Detection of metastatic prostate cancer using a splice variant-specific reverse transcriptase-polymerase chain reaction assay for human glandular kallikrein. *Cancer Res*. 2000 Dec 15. PMID: 11156423.

1578. **Shariat SF**, Weizer AZ, Green A, Laucirica R, Frolov A, Wheeler TM, Lerner SP. Prognostic value of P53 nuclear accumulation and histopathologic features in T1 transitional cell carcinoma of the urinary bladder. *Urology*. 2000 Nov 1. PMID: 11068290.
1579. **Shariat SF**, Bergamaschi F, Adler HL, Nguyen C, Kattan MW, Wheeler TM, Slawin KM. Correlation of preoperative plasma IGF-I levels with pathologic parameters and progression in patients undergoing radical prostatectomy. *Urology*. 2000 Sep 1. PMID: 10962307.
1580. Djavan B, **Shariat S**, Ghawidel K, Güven-Marberger K, Remzi M, Kovarik J, Hoerl WH, Marberger M. Impact of chronic dialysis on serum PSA, free PSA, and free/total PSA ratio: is prostate cancer detection compromised in patients receiving long-term dialysis? *Urology*. 1999 Jun. PMID: 10367847.
1581. Djavan B, Fakhari M, **Shariat S**, Ghawidel K, Marberger M. A novel intraurethral prostatic bridge catheter for prevention of temporary prostatic obstruction following high energy transurethral microwave thermotherapy in patients with benign prostatic hyperplasia. *J Urol*. 1999 Jan. PMID: 10037387.
1582. Djavan B, Roehrborn CG, **Shariat S**, Ghawidel K, Marberger M. Prospective randomized comparison of high energy transurethral microwave thermotherapy versus alpha-blocker treatment of patients with benign prostatic hyperplasia. *J Urol*. 1999 Jan. PMID: 10037386.
1583. Djavan B, **Shariat S**, Fakhari M, Ghawidel K, Seitz C, Partin AW, Roehrborn CG, Marberger M. Neoadjuvant and adjuvant alpha-blockade improves early results of high-energy transurethral microwave thermotherapy for lower urinary tract symptoms of benign prostatic hyperplasia: a randomized, prospective clinical trial. *Urology*. 1999 Feb. PMID: 9933035.
1584. Djavan B, Lin V, Kaplan EP, Richier JC, **Shariat S**, Marberger M, McConnell JD. Decreased elastin gene expression in noncompliant human bladder tissue: a competitive reverse transcriptase-polymerase chain reaction analysis. *J Urol*. 1998 Nov. PMID: 9783926.
1585. Djavan B, **Shariat S**, Schäfer B, Marberger M. Tolerability of high energy transurethral microwave thermotherapy with topical urethral anesthesia: results of a prospective, randomized, single-blinded clinical trial. *J Urol*. 1998 Sep. PMID: 9720545.
1586. Djavan B, Zlotta AR, Byttebier G, **Shariat S**, Omar M, Schulman CC, Marberger M. Prostate specific antigen density of the transition zone for early detection of prostate cancer. *J Urol*. 1998 Aug. PMID: 9679889.
1587. Djavan B, Susani M, **Shariat S**, Zlotta AR, Silverman DE, Schulman CC, Marberger M. Transperineal radiofrequency interstitial tumor ablation (RITA) of the prostate. *Tech Urol*. 1998 Jun. PMID: 9623628.
1588. Djavan B, Zlotta AR, Susani M, Heinz G, **Shariat S**, Silverman DE, Schulman CC, Marberger M. Transperineal radiofrequency interstitial tumor ablation of the prostate: correlation of magnetic resonance imaging with histopathologic examination. *Urology*. 1997 Dec. PMID: 9426739.

NON-PEER-REVIEWED PUBLICATIONS

1. Mori K, Schmidinger M, Egawa S, Gust KM, **Shariat SF**. Reply to Xiaoshuai Gao, Guo Chen, and Xin Wei's Letter to the Editor re: Keiichiro Mori, Mohammad Abufaraj, Hadi Mostafaei, et al. The Predictive Value of Programmed Death Ligand 1 in Patients with Metastatic Renal Cell Carcinoma

- Treated with Immune-checkpoint Inhibitors: A Systematic Review and Meta-analysis. *Eur Urol* 2021;79:783-92. *Eur Urol*. 2021 Sep 24;S0302-2838(21)02037-6. PMID: 34579998
2. Soria F, D'Andrea D, Gontero P, **Shariat SF**. Reply to Francesco Montorsi Letter to the Editor re: Francesco Soria, Marco Moschini, David D'Andrea, et al. Comparative Effectiveness in Perioperative Outcomes of Robotic versus Open Radical Cystectomy: Results from a Multicenter Contemporary Retrospective Cohort Study. *Eur Urol Focus* 2020;6:1233-9. *Eur Urol Focus*. 2021 Apr 16;S2405-4569(21)00108-5. PMID: 33875390
 3. Wenzel M, Nocera L, Ruvolo CC, Würnschimmel C, Tian Z, **Shariat SF**, Saad F, Briganti A, Tilki D, Graefen M, Kluth LA, Mandel P, Chun FKH, Karakiewicz PI. *J Urol*. 2021 Apr PMID: 33820427
 4. Mori K, Egawa S, **Shariat SF**. Re: Enzalutamide and Survival in Nonmetastatic Castration-Resistant Prostate Cancer. *Eur Urol*. 2020 Dec 20;S0302-2838(20)30935-0. PMID: 33357991
 5. Huebner NA, **Shariat SF**. Re: Enzalutamide with Standard First-line Therapy in Metastatic Prostate Cancer. *Eur Urol*. 2019 Sep 19. PMID: 31542306
 6. **Shariat S.**, Pones M. Urologische Medikamente und männliche Fertilität *CliniCum Urologie* CC *Urologie* 4/18, S. 18-19
 7. **Shariat S.**: BCG Mythen Kommentar: Bladder cancer. *CliniCum Urologie*. CC *Urologie* 4/18, S. 22
 8. **Shariat S.**, Hübner N.: Bedeutsame Risikofaktoren für Prostatakrebs. Rauchen stellt einen der vermeidbarsten Einflussfaktoren dar. *Hausarzt* 11/2018, S. 30-31
 9. **Shariat S.**: Wettbewerb im Gesundheitswesen – Risiken in Lösungen umwandeln. *linik* 1/2018, Gedanken, S. 12-13
 10. **Shariat S.** Empathie – ein Schlüsselement zum Erfolg als Arzt und Führungskraft. *linik* 2/2018, Gedanken, S. 8
 11. Grubmüller B., **Shariat S.**, Remzi M.: Prostataembolisation zur Behandlung von LUTS – Ist der Hype evidenzbasiert? *linik* 3/2018, S. 23-26
 12. **Shariat S.**: Jahresrückblick 2017 Update zum Prostatakarzinom. *krebs:hilfe!* 1-2/2018, S. 16-17
 13. **Shariat S.**: Editorial: Wir orientieren uns an der Klinik. *krebs:hilfe!* 8-9/2018
 14. **Shariat S.**, Gust K. Panorama Perioperative Chemotherapie beim invasiven Urothelkarzinom des oberen Harntraktes. Adjuvant oder jetzt doch neoadjuvant? *SO* 4/2018, S. 106-108
 15. Gust K., **Shariat S.**: „Cisplatin unfit“ – Wahl der Erstlinientherapie beim metastasierten Urothelkarzinom Personalisierte Medizin / Reihe „Molekulares Tumorboard“ *SO* 8/2018, S. 74-77
 16. **Shariat S.**: Herausforderungen im Management der überaktiven Blase. *Spectrum Urologie* 17. *SU* 4/2018, S. 38-39
D'Andrea, Gust K., **Shariat S.**: Drastische Verbesserung der Prognose nach jahrelanger unbefriedigender systemischer Therapie. 25 Jahre Jubiläum. Referat Metastasiertes Urothelkarzinom. *Urologik* 1/2018, S. 20-22
 18. **Shariat S.**, Huebner N.: Prostatakrebs Vorbeugung. Diagnose. Therapie. *Urologik* 1/2018, S. 22
 19. **Shariat S.**, Korn S.: Testosteronsupplementationstherapie und metabolisches Syndrom. *Urologik* 3/2018, S. 30
 20. **Shariat S.**, Remzi M., Resch I.: Organerhaltende Therapie beim Urothelkarzinom des oberen Harntraktes (UTUC). *J Urol Urogynäkol* 2/2018, S. 72-74
 21. **Shariat S.**, Huebner N.: Prostatakrebs Vorbeugung. Diagnose. Therapie. *Urologik* 1/2018, S. 22

22. **Shariat S.**: Prostatakrebs Therapie & Vorsorge. gesund & fit, 12.02.2018, S. 36
23. **Shariat S.**: Weintrinken und Prostatakrebs. gesund & fit, 30.04.2018, S. 23 / top-ärzte
24. **Shariat S.**: Aerzte-Tipp der Woche: Prostatakrebs Vorsorge. gesund & fit, 22.08.2018, S. 23
25. **Shariat S., Hübner N.**: Wichtige Risikofaktoren für Prostatakrebs. gesund.at, 17.10.2018
26. **Shariat S.**: Leben Sprechstunde. Über Harninkontinenz beim Mann. active beauty Nr.4, Juni 2018, S.112
27. **Shariat S.**: Atezolizumab - Wirksamkeit beim Urothelkarzinom, Bewertung und Aussichten. ArzneimittelPROFIL 2018
28. **Shariat S., Rieken M.**: <http://www.krebs-magazin.eu/prostatakrebs-jeder-10-mann-betroffen> Krebsmagazin EU 2018
29. **S.F. Shariat, M. Pones.** Urologische Medikamente und männliche Fertilität. CliniCum Urologie 4/18, S. 18-19
30. **S.F. Shariat**: BCG Mythen Kommentar: Bladder cancer. CliniCum Urologie 4/18, S. 22
31. **S.F. Shariat, N. Hübner** Bedeutsame Risikofaktoren für Prostatakrebs: Rauchen stellt einen der vermeidbarsten Einflussfaktoren dar. Hausarzt 11/2018, S. 30-31
32. **S.F. Shariat** Wettbewerb im Gesundheitswesen – Risiken in Lösungen umwandeln. Klinik 1/2018, Gedanken, S. 12-13
33. **S.F. Shariat** Empathie – ein Schlüsselement zum Erfolg als Arzt und Führungskraft. klinik 2/2018, Gedanken, S. 8
34. B. Grubmüller, **S.F. Shariat, M. Remzi**: Prostataembolisation zur Behandlung von LUTS – Ist der Hype evidenzbasiert? klinik 3/2018 klinik, S. 23-26
35. **S.F. Shariat** Update zum Prostatakarzinom. krebs:hilfe! 1-2/2018, S. 16-17
36. **S.F. Shariat** Editorial: Wir orientieren uns an der Klinik. krebs:hilfe! 8-9/2018
37. **S.F. Shariat, K Gust**: Panorama. Perioperative Chemotherapie beim invasiven Urothelkarzinom des oberen Harntraktes. Adjuvant oder jetzt doch neoadjuvant? Spectrum Onkologie 4/2018, S. 106-108
38. K Gust, **S.F. Shariat**: Personalisierte Medizin / Reihe „Molekulares Tumorboard“. „Cisplatin unfit“ – Wahl der Erstlinientherapie beim metastasierten Urothelkarzinom. Spectrum Onkologie 8/2018, S. 74-77
39. **S.F. Shariat** Herausforderungen im Management der überaktiven Blase. Spectrum Urologie 4/2018, S. 38-39
40. D. D’Andrea, K.M. Gust, **S.F. Shariat** Drastische Verbesserung der Prognose nach jahrelanger unbefriedigender systemischer Therapie. 25 Jahre Jubiläum. Urologik 1/2018, S. 20-22
41. **S.F. Shariat, S. Korn** Testosteronsupplementationstherapie und metabolisches Syndrom Urologik 3/2018, S. 30
42. **S.F. Shariat, M. Remzi, I. Resch** Organerhaltende Therapie beim Urothelkarzinom des oberen Harntraktes (UTUC). J Urol Urogynäkol 2/2018, S. 72-74
43. **S.F. Shariat** Ein TCM-Kraut, das krank macht. derStandard.at Gesundheit, Therapie & Medikamente, 24.11.2018
44. **S.F. Shariat** Mann im Blickfeld: So wird Prostatakrebs behandelt. Heute 13.11.2018, S. 27

45. **S.F. Shariat** Prostatakrebs Autor: Ernst Mauritz Kurier.at
46. **S.F. Shariat** Lexikon #prostata. Experten-Talk: Prostatakrebs Therapie & Vorsorge gesund & fit, 12.02.2018, S. 36
47. **S.F. Shariat** Neuer Ratgeber: Wissen um Erkrankungen der Prostata gesund & fit, 03.04.2018, S. 25
48. **S.F. Shariat** Weintrinken und Prostatakrebs. gesund & fit, 30.04.2018, S. 23
49. **S.F. Shariat** Ärzte-Tipp der Woche: Prostatakrebs Vorsorge. gesund & fit, 22.08.2018, S. 23
50. **S.F. Shariat** Leben Sprechstunde Über Harninkontinenz beim Mann. active beauty Nr.4, Juni 2018, S.112
51. **S.F. Shariat**, N. Hübner Wichtige Risikofaktoren für Prostatakrebs. gesund.at 17.10.2018
52. **S.F. Shariat** Atezolizumab - Wirksamkeit beim Urothelkarzinom, Bewertung und Aussichten ArzneimittelPROFIL 12/2018
53. Gust KM, **Shariat SF**. Re: Pembrolizumab as Neoadjuvant Therapy Before Radical Cystectomy in Patients with Muscle-invasive Urothelial Bladder Carcinoma (PURE-01): An Open-label, Single-arm, Phase II Study. Eur Urol. 2019 Jan 7. PMID: 30630644
54. Moschini M, Zaffuto E, Mattei A, Karakiewicz PI, **Shariat SF**. Reply to Alba Fiorentino, Angelo Errico, and Marcello Scarcia's Letter to the Editor Radiation therapy versus radical prostatectomy: no way out without a randomized trial. Eur Urol. 2018 Nov 30. PMID: 30509762
55. D'Andrea D, **Shariat SF**, Soria F. Re: Docetaxel versus surveillance after radical prostatectomy for high-risk prostate cancer: results from the prospective randomised, open-label phase 3 scandinavian prostate cancer group 12 Trial. Eur Urol. 2018 Jul 30. PMID: 30072209
56. **Shariat S.**, Resch I.: DFP-Literaturstudium: Rauchen und Urologie. Clinicum Urologie. CC 1-2/17
57. **Shariat S.**: Manuela Schmidinger: Young Docs Urologie. Uro-Oncology Academy: Vorwort zur Fortbildungsveranstaltung. Clinicum Urologie.
Shariat S., Garstka N.: Uro-Oncology Academy: 10 Tipps für junge Assistenzärzte. Clinicum Urologie. CC 1-2/17
58. **Shariat S.**, Mun D.: Urothelkarzinom der Blase Therapie der Zukunft. Clinicum Urologie. CC 3/17
59. **Shariat S.**, Schmidinger M.: Uro-Oncology Academy: Vorwort zur Fortbildungsveranstaltung. Clinicum Urologie. CC 3/17
60. **Shariat S.**, Eschlböck J., Veser J.: Uro-Oncology Academy: Wie bereitet man eine hervorragende Journal Club Präsentation vor. Clinicum Urologie. CC 3/17
61. **Shariat S.**, Garstka N.: Active Surveillance bei kleinen Nierentumoren. Clinicum Urologie. CC 5/17
62. **Shariat S.**, Schmidinger M.: Uro-Oncology Academy: Vorwort zur Fortbildungsveranstaltung. Clinicum Urologie. CC 5/17
63. **Shariat S.**, Resch I.:DFP-Literaturstudium: Immuntherapien – ihr Stellenwert beim uro-onkologischen Patienten Clinicum Urologie. CC 5/17
64. **Shariat S.**: Mit RESPECT verständlicher kommunizieren. Management & Karriere.CliniCum Onkologie 11/2017
65. **Shariat S.**: Gelebte Komplexität im Gesundheitswesen. 3/2017 klinik, Seite 26.

66. Gust K., **Shariat S.**: Der große Jahresrückblick. Blasenkarzinom: Immuntherapie-Zulassungen werden erwartet. krebs:hilfe! 1-2/2017, Seite 23.
67. Resch I., **Shariat S.**: ASCO 2017: Die Take Home Messages. Zehn Highlights zum Urothelkarzinom. krebs:hilfe! 7/2017, Seiten 18-21.
68. **Shariat S.** ESMO 2017: Sechs Abstracts zum Urothelkarzinom. krebs:hilfe! 10/2017, Seite 47.
69. Grubmüller B., **Shariat S.**: Systemische Therapie, primäre lokale Therapie, Metastasektomie und darüber hinaus...Die Behandlung des oligometastasierten Prostatakarzinoms. SPECTRUM ONKOLOGIE 2/2017, Seiten 32-34.
70. **Shariat S.**, Garstka N.: Die Rolle der Ärzte bei der Unterstützung der Patienten im Entscheidungsprozess. SPECTRUM ONKOLOGIE 3/2017, Seiten 102-103.
71. **Shariat S.**, Mun D.: Die wachsende Bedeutung der aktiven Überwachung bei kleinen Nierentumoren. SPECTRUM ONKOLOGIE 4/2017, Seiten 82-85.
72. **Shariat S.**: Panorama: Männergesundheit 2017. Das nächste Ziel. SPECTRUM UROLOGIE 1/2017, Seite 32-33.
73. **Shariat S.**: Journal Club. Testosteron-Ersatztherapie bei älteren Männern. Julian Vesper
74. Resch I., **Shariat S.**, Gust K.: Focus: Neue Konzepte in der Urologie/Immunonkologie. Immun-Checkpoint-Inhibitoren in der Therapie des Harnblasenkarzinoms. SPECTRUM UROLOGIE 2/2017, Seite 16-17.
75. **Shariat S.**, Vesper J.: Effektives Mentoring - Goldene Regeln für Mentees. Urologik 1/2017, Seiten 34-35.
76. Irene Resch, **Shariat S.**: EAU 2017: Aktuelle Studien in der Uroonkologie: Neues zum Urothelkarzinom. Urologik 2/2017, Seiten 15-18.
77. Garstka N., **Shariat S.**: ProtecT-Studie für Prostatakrebs. Unsere Interpretation der ersten Ergebnisse. Urologik 2/2017, Seiten 18-20.
78. **Shariat S.**, Maary S.: Ein neuer Standard für das metastasierte Prostatakarzinom? Urologik 3/2017, Seiten 28-29.
79. **Shariat S.**, Remzi M., Resch I.: Organerhaltende Therapie beim Urothelkarzinom des oberen Harntraktes (UTUC) Springer Verlag - Journal für Urologie und Urogynäkologie
80. **Shariat S.**: Gesund-Guide für den Sommer. Die Blase schützen: Gesund&Fit, 29.07.2017
81. D'Andrea D., **Shariat S.**: Benigne Prostatahyperplasie (BPH). Der Hausarzt, 03.10.2017
82. **Shariat S.**: Ich bin 50 und...Gesund&Fit. 15.11.2017
83. **Shariat S.**: Blut im Harn – Was kann das sein? Gesund&Fit, 11.12.2017
84. D'Andrea D, **Shariat SF**. Re: Adjuvant chemotherapy vs observation for patients with adverse pathologic features at radical cystectomy previously treated with neoadjuvant chemotherapy. Eur Urol. 2017 Sep 27. PMID: 28964632
85. D'Andrea D, **Shariat SF**. Re: Radiation with or without antiandrogen therapy in recurrent prostate cancer. Eur Urol. 2017 Jun 20. PMID: 28645490
86. D'Andrea D, **Shariat SF**. Re: Comparative effectiveness of treatment strategies for bladder cancer with clinical evidence of regional lymph node involvement. Words of wisdom. Eur Urol. 2017 PMID: 28599913

87. **Shariat SF.** Electronic cigarettes: a wolf in sheep's clothing. *Eur Urol.* 2017 Jan 24. pii: S0302-2838(17)30021-0. PMID: 28129891
88. **Shariat SF, Gust KM.** Immune therapy meets precision medicine. *Lancet Oncol.* 2017 Mar;18(3):271-273. PMID: 28271858
89. **Shariat SF.** ICUD guidelines for upper tract urothelial carcinoma: a state-of-the-art evidence-based guidance for clinical decisions regarding diagnosis, management and treatment. *World J Urol.* 2017 Mar;35(3):325-326. PMID: 28197726
90. Moschini M, **Shariat SF.** Failure-free survival and radiotherapy in patients with newly diagnosed nonmetastatic prostate cancer: data from patients in the control arm of the STAMPEDE Trial. *Words of wisdom. Eur Urol.* 2016 Aug;70(2):398-9. PMID: 27353963
91. Lucca I, **Shariat SF.** Prostate Cancer Incidence and PSA Testing Patterns in Relation to USPSTF Screening Recommendations. *Eur Urol.* 2016 Jul;70(1):205-6. PMID: 27302292
92. Mathieu R, **Shariat SF.** Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. *Eur Urol.* 2016 Apr;69(4):755-6. PMID: 26972499
93. Rieken M, **Shariat SF.** Letter to the Editor. *Eur Urol.* 2015 Aug 24. PMID: 26314617
94. Mathieu R, **Shariat SF.** Nadir testosterone within first year of androgen-deprivation therapy (adt) predicts for time to castration-resistant progression: a secondary analysis of the PR-7 trial of intermittent versus continuous ADT. *Eur Urol.* 2015 Sep;68(3):537-8. PMID: 26282354
95. **Shariat S., Klatte T.:** Blasenkarzinom. *Österreichische Aerztezeitung* 10:28-36, 2015
96. Maj-Hes A., **Shariat S.:** Active Surveillance bei Prostatakrebs – Entscheidungshilfe. *Spectrum Urologie* 1:44-5, 2015
97. **Shariat S.:** Neue perioperative Konzepte- Verbesserung des outcomes nach radikale Zystektomie. *Spectrum Urologie* 1:53-4, 2015
98. **Shariat S.:** Urology Expert Forum 2014. *Spectrum Urologie* 1: 29, 2015
99. **Shariat S., Krainer M.:** Vorwort zu Forschung beim Prostatakarzinom, *Spectrum Onkologie* 4:10-12, 2014
100. Maj-Hes A., Kramer G., **Shariat S.:** Androgendeprivationstherapie: *Spectrum Onkologie* 4:17-20, 2014
101. DeSantis M., **Shariat S.:** Das Urothelialkarzinom – Fokus auf einen Tumor, der selten im Fokus steht. *Spectrum Urologie* 3, 2013
102. **Shariat S., Loidl W., Dorfinger K.:** Smoking kills. *CliniCum Urologie* 4: 12, 2014
103. Eschelboeck J., **Shariat S.:** Transurethrale Resektion des Blasentumors (TURBT): Room for improvement. *Spectrum Urologie* 3, 2014
104. **Shariat S., Hiess M.:** Die prophylaktische Zirkumzision – weshalb ist die Zirkumzision in den USA so haeufig? *Spectrum Urologie* 3, 2014
105. W. Horninger, K. Pummer, **S. Shariat:** Urologische Forschungslandschaft 2030 in Österreich. *NÖGU* 26-31, 2014
106. Hiess M., **Shariat S.:** Spaete Morbidity bei Hodentumorph Patienten. *Urologik* 5:68, 2014
107. **Shariat S., Maj-Hes A., Loidl W., Dorfinger K.:** Was tun angesichts der BCG-Knappheit? *Spectrum Urologie* 3: 3-4, 2014

108. **Shariat S.**, Loidl W., Dorfinger K.: Schluss mit Rauchen. Urologie 4: 12, 2014
109. Grubmüller B., **Shariat S.**: Nicht muskelinvasives Blasenkarzinom: wie eine „zu späte“ radikale Zystektomie zu verhindern ist. Spectrum Urologie 2‘ 8-11, 2014
110. Maj-Hes A., **Shariat, S.**: Gesundheit der Österreicher auf der Kippe. Urologen vereint gegen den Tabakkonsum. Spectrum Urologie 3: 10-3, 2014
111. **Shariat S.**: Was bedeutet Behinderung? Unsere Sprache beeinflusst unser Denken. Klinik 5: 16-7, 2014
112. Lucca I, Klatte T, **Shariat SF**. Radical prostatectomy or watchful waiting in early prostate cancer. Eur Urol. 2014 Aug;66(2):386-7. PMID: 25305785
113. Catto JW, Cooperberg MR, Cornu JN, Gratzke C, Novara G, **Shariat S**, Vickers A. European Urology: Serving Our Readership Through Systematic Peer Review, Use of Reporting Standards, and Encouragement of Postpublication Review. Eur Urol. 2014 Aug 27. PMID: 25175422
114. **Shariat S.**: Bladder cancer: the curious case of a not so rare disease. Curr Opin Urol. 2014 Sep;24(5):483-6. PMID: 24992244
115. **Rink M., Shariat S.**: Re: global effects of smoking, of quitting, and of taxing tobacco. Eur Urol. 2014 Jul;66(1):176-8. doi: 10.1016/j.eururo.2014.03.039.
116. **Shariat S.**, Swietek N.: Urologische Traumata. Clinicum Urologie 6-11, 1, 2014.
117. **Shariat SF**, Klatte T. Optimal results come from optimal surgery and optimal (neoadjuvant) systemic therapy. BJU Int. 2014 Apr;113(4):516-7. doi: 10.1111/bju.12611. PMID:24629083
118. Klatte T., **Shariat S.**: Impfungen & Immuntherapien: Prostatakarzinom-Impfung: Gegenwart und Zukunft. medonline.at
119. **Shariat S.**, Maddaluno D.: Alte und neue therapiestrategien beim Nichturothelkarzinom. Urologik 5/13: 14-20, 2013
120. **Shariat S.**, Maddaluno D.: Die zytoreduktive nephrektomie bei mRCC: die Frage ist nicht ob, sondern wann. Haematologie & Onkologie 5/13 p. 91-7.
121. Klatte T., **Shariat S.**: Novel Urinary Markers for Detection of Bladder Cancer-Are we Failing? J Urol. 2013 Oct 16. PMID:24139809
122. Xylinas E., Klatte T., Matin S., **Shariat S.**: Prognostic factors, markers and tools in upper tract urothelial carcinoma. Urol List 2013: 11(3):30-39
123. Schubert T., **Shariat S.**, Rieken M.: Alte und neue Marker in Diagnostik and Nachkontrolle. Spectrum Urologie 3:10-12, 2013
124. Mandel P., **Shariat S.**, Tilki D.: Lymphadenektomie bei klinisch nocht metastasietrten Harnblasenkarzinom. Spectrum Urologie 3:28-30, 2013
125. Klatte T., **Shariat S.**: Aktuelle und relevante Studien Juli/August/Spetember 2013 – ausgewaehlt vom Journal Club der urologischen Klinik am AKH Wien. Spectrum Urologie 3:42, 2013
126. **Shariat S.**: Meet the Expert – Prostata und Potenz. Spectrum Urologie Sonderausgabe: 1, 2013
127. Rieken M., **Shariat S.F.**: Biomarkers for screening and early detection of prostate cancer. Hamdan Medical Journal, 2013 Vol 6 Issue 2, p 121-9
128. Xylinas E, **Shariat SF**. Re: Prospective Randomized Phase II Trial of a Single Early Intravesical Instillation of Pirarubicin (THP) in the Prevention of Bladder Recurrence After Nephroureterectomy

- for Upper Urinary Tract Urothelial Carcinoma: The THP Monotherapy Study Group Trial. *Eur Urol.* 2013 Oct;64(4):683-4. PMID:23998501
129. Remzi M, **Shariat SF**. Bladder cancer: Is contrast-enhanced CT necessary for following up NMIBC? *Nat Rev Urol.* 2013 Sep;10(9):500-1. PMID: 23917120
130. Rieken M, **Shariat SF**: Renal Cancer Therapy: Going Forward by Going Backward? *Eur Urol.* 2013 Feb 16. PMID: 23433808
131. Xylinas E, Kluth L, **Shariat SF**: Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castration-resistant prostate cancer: exploratory analysis of data from the COU-AA-301 Randomised Trial. *Eur Urol.* 2013 Jun;63(6):1132-3. PMID: 23608083
132. Kluth LA, Xylinas E, **Shariat SF**: Re: A prospective, randomised EORTC intergroup phase 3 study comparing the oncologic outcome of elective nephron-sparing surgery and radical nephrectomy for low-stage renal cell carcinoma. *Eur Urol.* 2013 Feb;63(2):399-400. PMID: 23272731
133. **Shariat SF**.: Vorwort - Focus Prostatakarzinom. *Spectrum Urologie* 2:11-16, 2012
134. Rink M., **Shariat SF**., Graefen M.: Aktive Ueberwachung: wer, wann und wie? *Spectrum Urologie* 2:18-21, 2012
135. Kluth L., **Shariat SF**.: Akenzeichen XY ungelöst: Chemopraevention. *Spectrum Urologie* 2:22-23, 2012
136. **Shariat SF**: 13 Tipps für eine erfolgreiche urologische Forschung. *Urologik* 5:22-23, 2012
137. Catto JW, **Shariat SF**.The changing face of renal cell carcinoma: the impact of systematic genetic sequencing on our understanding of this tumor's biology. *Eur Urol.* 2012 Sep 26. PMID: 23026395
138. **Shariat SF**, Xylinas E.Biomarkers in personalised treatment of renal-cell carcinoma. *Lancet Oncol.* 2012 Jun 29. . PMID: 22759479
139. Tagawa ST, **Shariat SF**: Is adjunctive systemic chemotherapy after cystectomy for T2N+ disease of therapeutic benefit? *No. J Urol.* 2012 Aug;188(2):359-60. No abstract available. PMID: 22966496
140. Ehdaie B, **Shariat SF**: Magnetic Resonance Imaging-Targeted Prostate Biopsy: Back to the Future. *Eur Urol.* 2012 Jul 4. No abstract available. PMID: 22790287
141. **Shariat SF**: Reply Letter to the Editor. *Eur Urol.* 2012 Jun 28. PMID: 22763080
142. Rink M, Fajkovic H, **Shariat SF**. Das Modell der „klinischen Stadien“: Was es ist und warum wir es benötigen. *SPECTRUM urologie* (1): 8-11. 2012
143. Galsky MD, Tagawa ST, **Shariat SF**: Is adjunctive systemic chemotherapy after cystectomy for t2n+ disease of therapeutic benefit? *J Urol.* 2012 Jun 13. PMID: 22704119
144. Rink M, Cha EK, **Shariat SF**. Recent research will improve outcomes of patients with upper tract urothelial carcinoma. *Eur Urol.* 2011 Nov 3. PMID:22071142
145. Fajkovic H, Chromecki T., Breinl E., Pummer K., Eisenmenger M., **Shariat SF**: Geschlechtsspezifische Charakteristika des Harnblasenkarzinoms: Inzidenz, Staging und Prognose. *Urologik* 4: 4-9, 2011
146. Fajkovic H, **Shariat SF**: Renal cell carcinoma in the era of targeted therapy: the role of cytoreductive nephrectomy. *Urologik* 3: 22-25, 2011

147. Cha EK, **Shariat SF**: Potential role of photodynamic techniques combined with new generation flexible ureterorenoscopes and molecular markers for the management of urothelial carcinoma of the upper urinary tract: adapting new technologies for the diagnosis and management of upper tract urothelial carcinoma. *BJU Int*. 2011 Oct 10. PMID: 21985330
148. Rink M, **Shariat SF**: Can We Apply Nomograms Derived in the United States to European Patients? Yes, We Can! *Eur Urol*. 2011 Aug 27. PMID: 21885183
149. Ramasamy R, **Shariat S**: Book review of Evidence-based Urology. *BJUI*. 2011; 1007:1844
150. Merseburger AS, **Shariat S**: Urothelial carcinoma. *World J Urol*. 2011 Aug;29(4):405-7. Epub 2011 Jul 21. No abstract available. PMID: 21779833
151. Dubin J, Chromecki T., Beltran H., Goldenberg S., Cha E., Karakiewicz P., Zeltser I., Scherr D., Tagawa S., **Shariat S.**: Management of Castration-Resistant Prostate Cancer in 2011. *Annals Of Urology*, 2011
152. SunM., Abdollah F., Schmitges J., Jeldres C., **Shariat S.**, Perrotte P., Karakiewicz P.: Clinical experience and critical evaluation of the role of everolimus in advanced renal cell carcinoma. *Open Access Journal of Urology* 2011;3 43–48
153. Pierre I Karakiewicz, Cha EK, **Shariat S**: The use of 5 α -reductase inhibitors for the prevention and treatment of prostate cancer. *Eur Urol*. 2011 Jan 25. . PMID: 21277077.
154. Ahallal Y, **Shariat S**, Touijer KA: Les biomarqueurs émergents du cancer de la prostate: diagnostic, staging et pronostic. *Clinical Urology* 2010; 6:266-74.
155. **Shariat S**, Chromecki T: Highlights Bladder Cancer AUA 2010. *Debates on Bladder Cancer Yearbook 2010*, page 29-39. **Shariat S**, Tilki D: Bladder cancer: Nomogram aids clinical decision making after radical cystectomy. *Nat Rev Urol*. 2010 Apr;7(4):182-4.
157. **Shariat S**, Hammerich K: Words of wisdom. Re: Timing of androgen deprivation therapy and its impact on survival after radical prostatectomy: a matched cohort study. *J Urol* 2008;179:1830-7; discussion 1837. *Eur Urol*. 2009 Jan;55(1):245-6.
158. **Shariat S**, Karam JA, Karakiewicz PI. Words of wisdom. Re: Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. *N Engl J Med* 2007;356:2271-81. *Eur Urol*. 2009 Jan;55(1):250-2. PMID: 20050019.
159. Godoy G, Chade DC, **Shariat SF**. Words of wisdom. Re: Pathologic stage T2a and T2b prostate cancer in the recent prostate-specific antigen era: implications for unilateral ablative therapy. Polascik TJ, Mayes JM, Sun L, Madden JF, Moul JW, Mouraviev V. *Eur Urol*. 2009 Sep; PMID: 19824127.
160. Karakiewicz PI, Suardi N, **Shariat SF**. The search for better prognostic factors for men treated for localized prostate cancer continues. *Eur Urol*. 2008 Apr; Epub 2007 Dec 17. PMID: 18093722.
161. **Shariat SF**, Hammerich KH. Words of wisdom. Re: Timing of androgen deprivation therapy and its impact on survival after radical prostatectomy: a matched cohort study. Siddiqui SA, Boorjian SA, Inman B, Bagniewski S, Bergstralh EJ, Blute ML. *J Urol* 2008; discussion 1837. *Eur Urol*. 2009 Jan; PMID: 20050015.
162. Sonpavde G, **Shariat SF**: Preoperative chemotherapy for bladder cancer: A standard waits to be optimally deployed. *Cancer*. 2011 PMID: 21732335
163. Lughezzani G, **Shariat S**, Sun M, Karakiewicz P.: Reply to Joan Palou, Oscar Rodríguez and Noel Clarke's Letter to the Editor re: Umberto Capitanio, Shahrokh F. Shariat, Hendrik Isbarn, et al. Comparison of Oncologic Outcomes for Open and Laparoscopic Nephroureterectomy: A Multi-Institutional Analysis of 1249 Cases. *Eur Urol* 2009;56:1-9.

164. Isbarn H, Capitanio U, **Shariat S**, Karakiewicz P: Laparoscopic or open nephroureterectomy? Which is the more efficient way to go? *Eur Urol.* 2009 May 3.
165. Capitanio U., **Shariat S.**, Karakiewicz P.: Reply. *Urology.* 2008 Dec;72(6):1212-3.
166. Svatek R., **Shariat S.:** Words of wisdom. Re: Lymph node density is superior to TNM nodal status in predicting disease-specific survival after radical cystectomy for bladder cancer: analysis of pooled data from MDACC and MSKCC. *Eur Urol.* 2008 Sep;54(3):690-1. PMID: 18792446.
167. **Shariat S.**, Bolenz C., Karakiewicz P.: Words of wisdom. Re: Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Escudier B, Pluzanska A, Koralewski P, et al., for the AVOREN Trial investigators. *Eur Urol.* 2008 Oct;54(4):948-9. PMID: 18953756.
168. **Shariat S**, Karam J., Raman J.: Urine cytology and urine-based markers for bladder urothelial carcinoma detection and monitoring: developments and future prospects. *Biomarkers Med* 2(2): 165-80, 2008.
169. Capitanio U., Briganti A., **Shariat S.**, Karakiewicz P.: The importance of the quantification of the extent of cancer in prostatic biopsies in prediction of biochemical recurrence: a global perspective. *Eur Urol.* 2008 Jul 21.
170. Gupta A., **Shariat S.**, for the Bladder Cancer Research Consortium: Reply by authors. *Urology.* 2008 Oct 7;
171. Svatek R., **Shariat S.:** Editorial Comment on: Potential impact of postoperative early complications on the timing of adjuvant chemotherapy in patients undergoing radical cystectomy: a high-volume tertiary cancer center experience. *Eur Urol.* 2008 Jul 14.
172. **Shariat S.:** Editorial Comment on: Large-scale real-time reverse transcription-PCR approach of angiogenic pathways in human transitional cell carcinoma of the bladder: identification of VEGFA as a major independent prognostic marker. *Eur Urol.* 2008 May 23.
173. **Shariat S.:** Editorial Comment on: Impact of surgical volume on the rate of lymph node metastases in patients undergoing radical prostatectomy and extended pelvic lymph node dissection for clinically localized prostate cancer. *Eur Urol.* 2008 May 21.
174. **Shariat S.**, Skinner E., Montorsi F.: A tribute to John P. Stein (1962-2008): surgeon, scientist, teacher, and humanist. *Eur Urol.* 2008 Aug;54(2):479. 2008
175. **Shariat S.**, Karam J., Raman J.: Urine cytology and urine-based markers for bladder urothelial carcinoma detection and monitoring: developments and future prospects. *Biomarkers in Medicine* 2 (2), 165-180, 2008.
176. Karakiewicz P., Capitanio U., **Shariat S.:** Editorial Comment on: Prostate growth and prevalence of prostate diseases in early onset spinal cord injuries. *Eur Urol.* 2008 Feb 8.
177. **Shariat S.**, Svatek R.: Editorial Comment on: Assessment of pathological prostate cancer characteristics in men with favorable biopsy features on predominantly sextant biopsy. *Eur Urol.* 2008 May 15. (Epub ahead of print)
178. **Shariat S.**, Margulis V., Karakiewicz P.: More nomograms or better evidence of efficacy: what do we need in urologic oncology? *Eur Urol.* 2008; 54:11-12.
179. **Shariat S.**, Karakiewicz P.: Perspectives on prostate cancer biomarkers. *Eur Urol.* 2008 Jul; 54(1):8-10.
180. **Shariat S.**, Karam J., Lotan Y.: Critical evaluation of urinary markers for bladder detection and monitoring. *Abstracts in Hematology & Oncology* 10(2), 2007.

181. **Shariat S.**, Karakiewicz P.: Screening for prostate cancer in 2007: the PSA era and its challenges are not over. *Eur Urol.* 2008 Mar;53(3):457-60.
182. Nielsen M., **Shariat S.**, Lotan Y.; on behalf of the Bladder Cancer Research Consortium (BCRC) Investigators: Reply to Vincent Fradet and Badrinath R. Konety. *BJU Int.* 2008 Jan; 101(2):258-259.
183. **Shariat S.**: Blasenkarzinom: Was der Praktiker wissen sollte! *Avicenna* 2(1): 24-9, 2007.
184. **Shariat S.**, Karam J., Roehrborn C.: Novel biomarkers for prostate cancer. Abstracts in *Hematology & Oncology* 10(3):21-30, 2007.
185. **Shariat S.**: Facing the challenges of T1 bladder cancer. *Issues in Urology*, 19(2): 54-55, 2007.
186. **Shariat S.**: Editorial: Will volume-based referral strategies reduce costs or just save lives? *European Urology*, 50(1): 62–63, 2006.
187. **Shariat S.**, Casella R., Lerner S.: Answer to letter from C. Sier and F. Blasi RE: Urinary level of urokinase-type plasminogen activator and its receptor in the detection of bladder cancer. *Cancer*, 98(9): 1995-6, 2003.
188. **Shariat S.**, Slawin K.: Peripheral blood RT-PCR assays for detection and prognosis of prostate cancer. *Reviews in Urology*, 5(1): 54-58, 2003.
189. Slawin K., **Shariat S.**, Canto E., Kattan M., Wheeler T.: Beyond PSA: new serum markers for improved diagnosis and management of prostate cancer. *Recent Advances and Research Updates* ISSN-0972-4699, 3(2): 175-186, 2002.
190. **Shariat S.**, Lerner S.: Editorial -The use of molecular markers for diagnosis, staging and prognosis in bladder cancer, *Oncology*, November; 15(11): 1479-80, 2001.
191. **Shariat S.**, Sadeghi F., Slawin K.: Vaccine-based immunotherapy for prostate cancer. *Reviews in Urology*, 2(4): 222-7, 2000.
192. **Shariat S.**, Slawin K.: Gene therapy for prostate cancer. *Reviews in Urology*, 2(2): 81-7, 2000.

ABSTRACTS over 2000; available on request

BOOK EDITOR

1. **Shariat S.**, Xylinas E.: *Advances in Bladder Cancer Management*. 220 pages. October, 2015. Future Medicine Ltd. doi: 10.2217/9781780844237 eISBN (PDF): 978-1-78084-423-7
2. **Shariat S.**, Xylinas E.: *Upper Tract Urothelial Carcinoma*. Springer 2014. ISBN: 978-1-4939-1500-2 (Print) 978-1-4939-1501-9 (Online) Downloaded over 3,102x (status 6/12/2017)

BOOK CHAPTERS

1. Kardoust Parizi M., **Shariat S.**: Risk Stratification of Upper Tract Urothelial Carcinoma for Kidney-Sparing Surgery Pages 387-402. . *Bladder Cancer: A Practical Guide*. 2021
Editors: Kamat, Ashish M., Black, Peter (Eds.)

2. Korn S., **Shariat S.**: Gender Differences in Bladder and Kidney Cancers. Editor Marianne J. Legato Principles of Gender-Specific Medicine. 2017
3. D'Andrea D., **Shariat S.**: Urothelial tumors of the upper urinary tract. Textbook of Urology edited by Peter Nyirady. Semmelweis Publishers, Budapest, 2016.
4. **Shariat S.**, Xylinas E.: Advances in Bladder Cancer Management. October 2015, Pages 2-5. Doi: 10.2217/fmeb2013.14.150
5. Xylinas E., Mitra A., Daneshmand S., **Shariat S.**: Molecular markers for screening, detection and prognosis of bladder cancer. In Advances in Bladder Cancer Management. October 2015, Pages 62-88. Doi: 10.2217/fmeb2013.14.157
6. Rieken M., **Shariat S.**, Robinson B.: Nonurothelial cancers of the bladder. In Advances in Bladder Cancer Management. October 2015, Pages 192-204. Doi: 10.2217/fmeb2013.13.314
7. Lee D., **Shariat S.**, Holzbeierlein J.: bladder cancer. Geriatric Urology. Ed T. Griebing. Springer 2014.
8. Xylinas E., Novara G., Remzi M., Karakiewicz P., and **Shariat S.**: Prognostics Factors, Molecular Markers, and Predictive Tools in Upper Tract Urothelial Carcinoma. *Upper Tract Urothelial Carcinoma*, Springer 2014
9. **Shariat S.** and Bochner B.: Urinary diversion. UpToDate. 2009-present
10. Lee R. and **Shariat S.**: Urinary diversion after radical cystectomy for bladder cancer: options, patient selection, and outcomes. In Essentials and Updates in Urologic Oncology (2 Volume Set) 2012. Editor: P.E. Spiess In Essentials and Updates in Urologic Oncology (2 Volume Set) 2012. Editor: P.E. Spiess. ISBN: 978-1-62081-494
https://www.novapublishers.com/catalog/product_info.php?products_id=33161
11. Lee R. and **Shariat S.**: Urinary diversions. In *Textbook of Urologic Oncology*. Spiess P. (eds), 2011.
12. Chromecki T., Margulis V., **Shariat S.**: Upper tract urothelial carcinoma. Editor: P.E. Spiess In Essentials and Updates in Urologic Oncology (2 Volume Set) 2012. Editor: P.E. Spiess. ISBN: 978-1-62081-494 https://www.novapublishers.com/catalog/product_info.php?products_id=33161
13. Bensalah K., **Shariat S.**, Patard J.: Prognostic factors for localized and metastatic renal cell carcinoma. In *Recent Advanced In Renal Cell Carcinoma*. Molins J. (eds), 2008.
14. **Shariat S.** and Roehrborn C.: Prostate cancer detection. In: *Textbook of Prostate Cancer*. Su L. (eds), 2009. **ISBN13**:9781416045755; **ISBN10**:1416045759; Elsevier Science Health Science div
15. **Shariat S.** and Kattan M.: Nomograms for prostate cancers. In: *Textbook of Prostate Cancer*. Thompson I. (eds), 2008.
16. **Shariat S.** and Kattan M.: Risk assessment in prostate cancers. In: *Textbook of Prostate Cancer*. Tewari A. (eds). Springer Verlag, Germany, 2008.
17. **Shariat S.**, Canto E., Slawin K.: Molecular genetics of BPH. In: *Textbook of Benign Prostatic Hyperplasia*. Chapter 9, Vol.2. Kirby R., McConnell J., Fitzpatrick J., Roehrborn C., Boyle P. (eds). Oxford, UK, Isis Medical Media Ltd, 2005.
18. M.Sun, **S.Shariat**, C. Cheng, V. Ficarra, M. Murai, S. Oudard, A.J. Pantuck, R. Zigeuner, P.I. Karakiewicz: Prognostic factors of renal cell carcinoma: A contemporary review. *Kidney Cancer*, (Eds: Z. Kirkali and P. Mulders) 2011 Edition, page 75-98.

